<SEC-DOCUMENT>0001213900-23-025597.txt : 20230331
<SEC-HEADER>0001213900-23-025597.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331170109
ACCESSION NUMBER:		0001213900-23-025597
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		23788940

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2022_actiniumph.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 20:21:21 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:atnm="http://actiniumpharmaceuticals.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> Annual Report Under Section 13 or
15(d) Of The Securities Exchange Act Of 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended<b>&#160;<ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>,
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> Transition Report Under Section 13 or 15(d)
Of The Securities Exchange Act Of 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _____ to _____</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>COMMISSION FILE NUMBER: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">000-52446</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>ACTINIUM PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center; font-size: 10pt">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</p></td> <td style="text-align: center; font-size: 10pt">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">275 Madison Avenue, 7<sup>th</sup> Fl</ix:nonNumeric>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">10016</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices) (Zip Code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(646)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">677-3870</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Securities registered
pursuant to Section&#160;12(b) of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="white-space: nowrap; vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td> <td style="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol</b></span></td> <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="white-space: nowrap; vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NYSE</ix:nonNumeric> American</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Securities registered
pursuant to Section&#160;12(g) of the Act: None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or 15(d) of the Act. Yes&#160;&#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;No
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 15%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the act): Yes&#160;&#9744;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of voting stock held
by nonaffiliates of the registrant as of June&#160;30, 2022, the last business day of the registrant&#8217;s most recently completed second
fiscal quarter, based on the closing price of the common stock on the NYSE American on June 30, 2022 was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd">119,589,361</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">25,729,370</ix:nonFraction> shares of common
stock, $0.001 par value per share, were outstanding.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Table&#160;of Contents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 8%; text-align: justify"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 81%; text-align: justify"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.&#160;</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholders Matters, and Issuer Purchases of Equity Securities</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market&#160;Risk</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></a></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td colspan="3" style="vertical-align: top; text-align: justify"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature Page</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">88</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Annual Report on Form 10-K (this &#8220;Report&#8221;)
contains forward-looking statements that involve risks and uncertainties, principally in the sections entitled &#8220;Description of Business,&#8221;
&#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;
All statements other than statements of historical fact contained in this Report, including statements regarding future events, our future
financial performance, business strategy and plans and objectives of management for future operations, are forward-looking statements.
We have attempted to identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221;
&#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; or &#8220;will&#8221; or the negative of these
terms or other comparable terminology. Although we do not make forward-looking statements unless we believe we have a reasonable basis
for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties
and other factors, including the risks outlined under &#8220;Risk Factors&#8221; or elsewhere in this Report, which may cause our or our
industry&#8217;s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible
for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or
combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements. All
forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation
to update any such forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not place undue reliance on any forward-looking
statement, each of which applies only as of the date of this Report. Before you invest in our securities, you should be aware that the
occurrence of the events described in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Report could negatively affect
our business, operating results, financial condition and stock price. Except as required by law, we undertake no obligation to update
or revise publicly any of the forward-looking statements after the date of this Report to conform our statements to actual results or
changed expectations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1. BUSINESS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Our Business</b></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;) is a biopharmaceutical
company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high
unmet medical needs. Our vision is to build a specialty, hospital focused radiotherapeutics company that develops and markets medicines
for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. We
intend to leverage the clinical data of our lead product candidates, Iomab-B and Actimab-A, to improve outcomes in patients with relapsed
or refractory acute myeloid leukemia (&#8220;r/r AML&#8221;) by launching two radiotherapy drugs in 5 years that address the significant
need for better outcomes from treatment with therapeutics or from undergoing a bone marrow transplant (&#8220;BMT&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also intend during this time frame to further advance Iomab-B outside
of acute myeloid leukemia (&#8220;AML&#8221;) based on promising data as a disease control and conditioning agent for various other blood
cancers. Based on early promising clinical trial results, we are also working on a lower dose next generation conditioning program, Iomab-ACT,
for rapidly growing cell and gene therapies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Our Clinical Pipeline</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AML is an aggressive, heterogeneous disease that is difficult-to-treat.
Most AML patients develop relapsed or refractory disease within one year and have an extremely poor prognosis and dismal survival. Currently,
a BMT is the only curative regimen available for AML patients, however, access is limited to AML patients who are fit enough to withstand
the challenges associated with this treatment. The majority of AML patients are considered not transplantable in routine clinical practice
as they are not fit enough to withstand the rigors of the patient journey which includes: therapy to attain a remission, conditioning
regimens to destroy diseased marrow, challenge of the transplant itself or post-transplant complications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Iomab-B and Actimab-A product candidates fill the major unmet medical
needs in r/r AML in a complementary fashion as they are directed at different parts of the patient journey. Iomab-B is a targeted bridging
therapy that provides both disease control and conditioning in one agent. Results from a phase 3 trial has demonstrated unprecedented
access to a BMT and improved survival in unfit patients who are currently not considered transplantable in routine clinical practice.
Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study
and is poised for advanced development in collaboration with the NCI, or National Cancer Institute. Together, they provide us the opportunity
to transform the treatment of AML, especially in the relapsed and refractory segment which represents over 50% of AML patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 31, 2022, we announced topline results from the pivotal
Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory AML or SIERRA trial, which demonstrated that Iomab-B met the primary endpoint
of durable Complete Remission (&#8220;dCR&#8221;) with a high degree of statistical significance (p&lt;0.0001). On February 18, 2023,
we announced full trial results, demonstrating unprecedented access, improved outcomes and better safety and tolerability with double
1-year and median overall survival (&#8220;OS&#8221;) compared to control arm patients receiving Iomab-B at the 2023 Tandem Meetings aka
the Transplantation &amp; Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (&#8220;ASTCT&#8221;)
and the Center for International Blood &amp; Marrow Transplant Research (&#8220;CIBMTR&#8221;). We believe these results provide the opportunity
to establish Iomab-B as a new standard of care, and if approved, we intend to commercialize the product in the United States (&#8220;U.S.&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 12, 2022, we announced a commercialization
agreement for Iomab-B with Immedica AB (&#8220;Immedica&#8221;) for exclusive rights in Europe, the Middle East and North Africa (&#8220;EUMENA&#8221;).
Actinium received an upfront payment of $35 million USD with the potential for an additional $417 million USD in regulatory and sales
milestones and mid-twenty percent royalties. The market in the EU region is attractive due to the higher incidence of AML and number of
BMT procedures compared to the U.S. with the same unmet patient need, and our partnership with Immedica positions us well to capitalize
on this opportunity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actimab-A is the industry-leading program, leveraging the potent alpha
radiation emitting isotope Actinium-225 (&#8220;Ac-225&#8221;) based on clinical development in approximately 150 patients treated over
6 clinical trials. The potent linear energy transfer emitted by Ac-225 has no known resistance mechanism. Actimab-A is being developed
in combination with other regimens to exploit mechanistic synergies and leverage the mutation-agnostic mechanism of action of Ac-225 with
the objective of establishing it as a backbone therapy in AML, an extremely heterogenous disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2022, we shared the Phase 1 results from the Actimab-A
CLAG-M combination trial at the American Society of Hematology (&#8220;ASH&#8221;) Annual Meeting &amp; Exposition that showed high response
rates and minimal residual disease (&#8220;MRD&#8221;) negativity, translating to a meaningful survival benefit of 53%and 32%at one and
two years in patients who are typically expected to live two to four months. At the same meeting, we shared Phase 1 data showing that
the combination of Actimab-A + venetoclax was well-tolerated with responses, including a Complete Remission (&#8220;CR&#8221;) and a partial
response in early dose escalation cohorts. We believe the promise of these results paved the way for the NCI Cooperative Research and
Development Agreement (&#8220;CRADA&#8221;), announced on February 6, 2023, to develop Actimab-A for the treatment of patients with AML
and other hematologic malignancies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our differentiated R&amp;D is further exemplified by our next-generation
Iomab-ACT conditioning program for rapidly growing cell and gene therapies, as well as our solid tumor and immunotherapy collaborations
with Astellas Pharma Inc. (&#8220;Astellas&#8221;), AVEO Oncology/LG Chem (&#8220;LG Chem&#8221;) and EpicentRx, Inc. (&#8220;EpicentRx&#8221;).
In addition, we have several other programs in solid tumors at the pre-clinical stage with investigational new drug (&#8220;IND&#8221;)
enabling studies ongoing and our extensive intellectual property (&#8220;IP&#8221;) portfolio includes over 200 issued patents and pending
patent applications worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are actively working on launching an early access program (&#8220;EAP&#8221;)
for Iomab-B and intend to file a Biologics License Application (&#8220;BLA&#8221;) by year-end while preparing for a U.S. commercial launch
and working with our partner Immedica to support the Marketing Authorization Application (&#8220;MAA&#8221;) and commercialization in
the EU. Late-stage Actimab-A development is expected to begin in the second half of 2023 under the NCI CRADA and is anticipated to have
a material balance sheet sparing impact over the next several years. We expect to create significant value due to the combination of major
milestones and balance sheet strength with the approximately $100 million cash on hand at year-end 2022 projected to fund operations through
2025 as we continue to drive ahead with realizing our five-year plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market opportunity for Iomab-B and Actimab-A, as depicted in the
diagram below, exists in AML and for cellular therapy conditioning in various blood cancers. We believe that Iomab-B and Actimab-A can
fill the major unmet medical needs in r/r AML in a complementary fashion as they are utilized in different parts of the patient treatment
journey. The incidence of AML is approximately 21,000 patients per year, with a prevalence of approximately 70,000 in the U.S., (approximately
27,500 new patients per year in Europe) and the disease has an outsized economic impact relative to its population size. Over 50% of patients
diagnosed with AML will develop relapsed or refractory disease, with a median age of 68 years at diagnosis. Despite 10 new approved therapies
since 2017, no significant advancements have been made toward a cure and there is a significant unmet need for better therapeutics, which
provide the opportunity for Actimab-A. Actimab-A is a targeted radiotherapy for fit patients that has demonstrated an impressive improvement
in survival in a proof-of-concept study and is poised for advanced development in collaboration with the NCI. Using Actimab-A in combination
with chemotherapy or a targeted therapy, we have the potential opportunity to treat both newly diagnosed or r/r AML patients, with the
potential addressable population comparable to the prevalence of patients with AML.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today, less than 20% of AML patients are able to access a BMT, currently
the only potentially curative option. These patients are usually younger, fit, and able to withstand the challenges associated with this
treatment, leaving the large majority of AML patients ineligible for transplant. This provides an opportunity for Iomab-B, which has demonstrated
the ability to enable unfit patients to benefit from a BMT. Thus Iomab-B can potentially expand the market from the approximately 400
r/r AML patients who are transplanted currently to approximately 8,000 unfit patients that could be eligible for transplant. Iomab-B has
demonstrated the ability to improve BMT access with extended survival and potentially curative outcomes in several other hematological
diseases outside of AML. Several clinical trials in over 300 patients with myelodysplastic syndromes (&#8220;MDS&#8221;), acute lymphocytic
leukemia (&#8220;ALL&#8221;), Hodgkin&#8217;s lymphoma (&#8220;HL&#8221;), Non-Hodgkin lymphoma (&#8220;NHL&#8221;) and multiple myeloma
(&#8220;MM&#8221;) have demonstrated the same value proposition as in AML. This data provides an opportunity to expand the market for
Iomab-B beyond AML via label expansion. In the U.S., there are approximately 185,000 patients diagnosed with blood cancers (e.g., leukemia,
lymphoma, and myeloma) that are treatable with BMT, of which, only approximately 20,000 are transplanted, leaving greater than 165,000
patients who could potentially benefit from transplant. These patients do not receive a BMT today primarily because they are unfit with
active disease and are not considered eligible, as they cannot tolerate the rigors of therapy required to induce a remission and the conditioning
agents required to ablate the marrow prior to a BMT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beyond BMT, the opportunity exists for better conditioning in other
areas of cellular therapy such as CAR-T as well as gene therapies. The pipeline of CAR-T and gene therapies has rapidly expanded, with
the addressable patient population expected to nearly double in the next one to five years and reach approximately 93,000 patients in
the U.S. by 2030 based on the current pipeline. The CAR-T market size in terms of dollars is estimated to grow at a CAGR of approximately
11% over the next 5 plus years. The addressable market for Iomab-ACT is in line with the patient population for cellular therapy as all
patients receive conditioning of some type prior to these treatments. We will continue to develop Iomab-ACT, our lower dose, next generation
conditioning program for rapidly growing cell and gene therapies based on early promising results, ultimately with the value proposition
of improving overall access and outcomes for patients who need cellular or gene therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium&#8217;s strategy is to build a fully-integrated, specialty
radiotherapeutics company focused on the top 100 cancer hospitals using the power of our platform to deliver new treatment options for
patient populations living with high unmet medical needs in hematology and oncology. We believe our focus on relapsed and refractory disease
in cancer indications with high unmet medical need, with limited or no competition, and where the primary delivery of care occurs in a
few large comprehensive cancer care centers, is the appropriate strategy for our company. The cell killing power of linear energy transfer
delivered via radiotherapeutics is unmatched by other technologies and we believe relapsed, refractory disease is an area where radiotherapeutics
can succeed over other approaches. However, radiotherapeutics must be delivered on a just-in-time basis, and commercial and supply chain
barriers are higher than with other types of medicines. The validity of our approach is demonstrated by our product development strategy
as well as the commercial and operating model that we are building for our lead product candidates, Iomab-B and Actimab-A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to transform the treatment of AML with our Iomab-B and Actimab-A
product candidates, each of which has demonstrated impressive extension of survival in the most difficult-to-treat patients who are typically
expected to survive two to four months. The r/r AML segment comprises over 50% of all AML patients. Actimab-A, a therapeutic agent, and
Iomab-B for induction and conditioning, can be used in a complementary fashion as depicted in the diagram below. Based on solid clinical
evidence with these product candidates, we intend to develop and commercialize these two radiotherapy drugs, starting with Iomab-B in
2024 and Actimab-A in 2027, if approved, to improve survival in patients with r/r AML.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Iomab-B and Actimab-A have the potential
to significantly improve r/r AML outcomes in a complementary manner</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operating model required to achieve our vision is attractive for
several reasons, including the concentrated point of care; the top 50 transplant centers account for approximately 75% of BMTs and the
top 100 hospitals treat over 50 percent of r/r AML patients. Further, there is significant overlap in the healthcare providers and ecosystem
required to diagnose, treat and care for r/r AML patients within these hospitals, which will enable us to deploy a relatively small commercial
organization and operate a supply chain without the need for large investments. Our product pipeline is targeting a broader opportunity
in conditioning via label expansion of Iomab-B into BMT for other blood cancers and with Iomab-ACT, our next generation conditioning program
for rapidly growing cell and gene therapies. Further, our solid tumor programs are initially directed at relapsed or refractory cancers,
a stage of disease where treatment is again concentrated in large hospitals, which account for a significant portion of patients. We believe
our strategy will enable us to build a successful company with high operating efficiencies and is feasible to achieve without requiring
a commercial partner.</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our strategic priorities are to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Establish Iomab-B as the standard of care to improve BMT access and survival outcomes in r/r AML patients who are currently not considered transplantable in routine clinical practice: </i></b>We intend to file a BLA in the second half of 2023 based on the strong results from the Pivotal Phase 3 SIERRA trial and leverage our proven operating track record at key cancer centers to build a high impact organization that can effectively commercialize Iomab-B. By virtue of the SIERRA trial, we have established operations at 24 leading BMT centers that represent about 30% of transplant volume in the U.S. and have strong working partnership with Key Opinion Leaders and their teams. The positive SIERRA results demonstrating unprecedented access to BMT and outcomes along with our commitment to operational excellence provides a strong foundation for our commercial team in the U.S. We will also work with our partner Immedica to file the MAA for the EU and support Iomab-B&#8217;s potential approval and launch with our expertise, as well as supply drug product for commercialization.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance Actimab-A in combinations as a backbone therapy for r/r AML:</i></b> We intend to progress late-stage development of Actimab-A to leverage its mutation-agnostic mechanism of action and exploit synergies by combining with other treatments to develop it as an AML backbone therapy. This approach is validated by proof-of-concept data from our Actimab-A + CLAG-M combination trial in r/r AML, which included 57% of patients who had failed venetoclax and live two to four months on average. The results demonstrated high response rates overall and in these venetoclax failed patients median overall survival was 59% at one year and thirty-two percent at two years. Our collaboration with the NCI under the CRADA will provide broad support for late-stage development of Actimab-A + CLAG-M and also other clinical trials to broaden use while preserving our balance sheet. Actimab-A, if approved, would enable us to launch a second product that is complementary to Iomab-B and fulfill our ambition of radically transforming the treatment outcomes of r/r AML and expand our commercial footprint into the remaining top 100 cancer care centers outside of the leading BMT hospitals.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expand the Iomab-B label and revenue stream via life cycle management:</i></b> We intend to leverage data from several clinical trials that demonstrate the ability of Iomab-B to improve BMT access and outcomes in five additional hematologic indications. These data in MDS, ALL, HL, NHL and MM provide the foundation to expand the label for Iomab-B and increase its market potential. In AML, we would seek label expansion into haploidentical transplants, earlier lines of treatment and younger patients below the age of 55, the cutoff in the SIERRA trial. As much as possible, we would seek to use investigator sponsored trials as the primary strategy for label expansion in order to maximize capital utilization.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Further expand our conditioning franchise by developing Iomab-ACT for cell and gene therapies:</i></b> We plan to develop Iomab-ACT to be used for either lymphodepletion or reduced intensity conditioning prior to CAR-T and gene therapies. Similar to BMT, access and outcomes of patients who might benefit from these therapies is limited by sub-optimal chemotherapy-based conditioning agents. The number of patients potentially eligible for Iomab-ACT is growing with increased availability of commercial cell and gene therapy products, as well as the expanding number of indications. We are studying Iomab-ACT in conditioning prior to CAR-T cellular therapy via a National Institutes of Health (&#8220;NIH&#8221;) funded clinical trial with Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;). We expect to present proof-of-concept data from this study in the second half of 2023 and announce further development of this program in the CAR-T space.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage our R&amp;D capabilities and technological prowess to advance our solid tumor programs and partnerships: </i></b>We intend to continue to direct our R&amp;D effort to advance our solid tumor programs into the clinic and support life cycle management for Iomab-B and Actimab-A. Our solid tumor programs and technological capabilities are validated by our partnerships with Astellas, LG Chem, and EpicentRx, which are focused on solid tumors and immunotherapies. Our R&amp;D prowess is demonstrated by our robust patent portfolio with over 200 issued and pending patent applications worldwide which include protection for Iomab-B into 2037. Our IP portfolio also includes several patent families to manufacture Ac-225 in a cyclotron, and valuable know-how.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In keeping with our strategic vision over the next five years, we would
first focus our energies on ensuring an Iomab-B approval and successful launch into core BMT centers to ensure commercial success. We
intend to expand the Iomab-B label and revenue stream in a capital efficient manner while progressing the development of Actimab-A by
leveraging the NCI CRADA and its balance sheet sparing opportunity. We will progress the development of Iomab-ACT to proof-of-concept
and explore partnerships as a means to achieve commercialization. Our solid tumor programs will progress toward the clinic as we continue
to build out our commercial footprint into the top 100 hospitals leaving us well-positioned to develop them in accordance with our vision.
With commercial dynamics aligning favorably for a successful Iomab-B launch and with late-stage development of Actimab-A in collaboration
with the NCI, we plan to deliver on our mission to transform the treatment of AML and patient outcomes, and create a highly differentiated,
specialty radiotherapeutics company focused on the top 100 large hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Product Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have strategically focused our development
efforts in areas where there is a significant unmet medical need. We are developing a portfolio of novel radiotherapeutics that has the
potential to positively impact the outcomes of people living with hard-to-treat diseases such as r/r AML via both a therapeutic and induction/conditioning
agent. Outside of AML, our pipeline development offers the opportunity to enhance the value proposition of cell and gene therapies with
our targeted conditioning programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">AML Focused Programs &#8211; Iomab-B
and Actimab-A</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Iomab-B and Actimab-A product candidates are
focused on addressing the major unmet medical needs in r/r AML in a complementary manner and are directed at different parts of the patient
journey.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Iomab-B &#8211; Targeted Radiotherapeutic
for Induction and Conditioning. A potential new standard of care enabling a curative BMT in currently non-transplantable r/r AML patients
with poor survival prognosis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Opportunity to Change the Current Paradigm
for Accessing a BMT and Improving Outcomes </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current approach in preparing patients
for a BMT is to first induce a remission with therapeutic agents to reduce the disease burden and then suppress or destroy the
patient&#8217;s immune system, including the diseased bone marrow, with conditioning regimens prior to transplanting the healthy
donor hematopoietic stem cells, which are expected to restore normal bone marrow function following engraftment. As this approach
requires patients to withstand multiple challenges from non-targeted therapies, which include chemotherapy agents and/or total body
irradiation that are highly toxic, BMT is typically limited to FIT patients. Iomab-B is a targeted therapy that provides both
disease control and conditioning in one agent and is well-tolerated even by UNFIT patients who typically are not transplanted in
routine practice today. The SIERRA trial was designed to demonstrate that UNFIT patients with active disease could be
administered Iomab-B and proceed directly to a BMT without the need for inducing a remission and that this approach could result in
improved survival and curative outcomes. As seen by the positive results of the SIERRA trial detailed below, Iomab-B represents an
exciting new paradigm in the management of AML patients and establishes a potential new standard of care especially for UNFIT
patients in the relapsed or refractory setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A similar approach has also been tried in the Phase 3 ASAP trial but
with FIT patients. However, to avoid confusion between the potential of the approaches used in the ASAP and SIERRA trials, important distinctions
between these trials are depicted in the graphic below. The ASAP trial sought to demonstrate non-inferiority between two non-novel approaches
and found that outcomes similar to those of current practice could be achieved without first getting a patient into remission before taking
them to BMT by giving them sequential conditioning or treating them twice with non-targeted chemotherapy agents that are typically used
in this setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ASAP approach is limited to only FIT patients as the UNFIT patients
treated in SIERRA could not tolerate ASAP&#8217;s highly toxic sequential conditioning approach. Sequential conditioning is not novel
as a similar trial to ASAP was conducted by the UK National Cancer Research Institute in 2019, which did not show any benefit from this
approach in high-risk AML and MDS patients (Craddock et al. Augmented Reduced Intensity Regimen Does Not Improve Postallogeneic Transplant
Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2021). &#160;The SIERRA trial results therefore can change the paradigm in transplant
because non-transplantable patients in routine clinical practice can benefit from a transplant with Iomab-B and have superior outcomes.
While both approaches in these trials support increased access to BMT, only Iomab-B is applicable to the unfit patients who comprise approximately
80%of r/r AML patients and can potentially expand the market for transplant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Schetelig et al. Results from the Randomized
Phase III ASAP Trial. ASH 2022</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Pivotal Phase 3 SIERRA Trial for Iomab-B (<sup>131</sup>Iodine-apamistamab)
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SIERRA trial was designed to demonstrate the
ability of Iomab-B to overcome challenges related to patient access to curative BMT. Unfortunately, approximately 30% of patients with
AML have primary refractory disease while 50% relapse quickly after achieving initial remission. Getting these patients with primary r/r
AML into remission is very challenging due to characteristics such as age, comorbidities, and disease features such as high-risk mutations
that contribute to lack of response to salvage therapies and limit treatment options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Patients must be able to overcome several challenges related to curative
BMT. The first access challenge is that the patient needs to be in complete remission prior to BMT. The current clinical practice is not
to transplant patients with active AML as outcomes are poor due to high relapse rates. The National Comprehensive Cancer Network (&#8220;NCCN&#8221;)
guidelines also recommend treatment to achieve remission prior to transplant in patients with relapsed AML. The second challenge to access
is tolerance to current conditioning regimens. For older patients, myeloablative regimens are not an option due to intense toxicity and
mortality. The third challenge is the ability to achieve post-BMT remission and successful engraftment. Inadequate conditioning can lead
to graft failure, which is associated with very high mortality. Patients who fail to achieve a CR post-transplant have extremely poor
outcomes and a survival of a few weeks. The fourth challenge relates to BMT tolerability and post-BMT complications. The conditioning
and immunosuppressive regimens given to these patients put them at high risk for infectious complications and toxicity. In the SIERRA
trial, Iomab-B addresses all four of these challenges. Access to BMT is improved as CR is not needed pre-BMT given effective disease control
and targeted myeloablation. With better post-BMT engraftment, CR and lower complications, the SIERRA trial also addressed the challenges
related to improved outcomes through Iomab-B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SIERRA results, presented in the late-breaker session at the 2023
Tandem Meetings: Transplantation &amp; Cellular Therapy Meetings of the ASTCT and the CIBMTR, support Iomab-B&#8217;s value proposition
of enabling both improved access and outcomes of a BMT, thereby providing a significant curative option for r/r patients, a segment that
represents approximately 50% of all AML patients and the majority not transplanted today. The design of the SIERRA trial is provided in
the figure below.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SIERRA: A Novel, Pivotal Phase 3 Study of
Iomab-B in r/r AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><img alt="" src="image_014.jpg"/>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pivotal Phase 3 SIERRA trial is a 153-patient, randomized, multi-center,
controlled trial of Iomab-B in patients aged 55 and above with active r/r AML, who were heavily pre-treated and had high-risk characteristics.
Patients enrolled had blast counts of 5% or greater in the marrow or circulating blasts suggestive of active AML. In this study, Iomab-B
was compared to the control arm that allowed physician&#8217;s choice of over 20 available agents, including chemotherapies and/or targeted
therapies such as venetoclax (BCL-2 inhibitor), FLT3 inhibitors, IDH inhibitors and Mylotarg, reflecting current best treatment practices
attempting to get patients to CR. The control arm included recently approved AML therapies that were added to the SIERRA protocol as they
became available. The crossover arm was designed in SIERRA for an equipoise that offered Iomab-B to patients failing to achieve a CR on
the control arm with an intent to rescue them by taking them to transplant. Of note, SIERRA had highly restrictive optionality for post-transplant
maintenance. Patients with active, r/r AML are not considered eligible for BMT with current approaches and the SIERRA trial was the only
randomized Phase 3 trial to offer BMT as a treatment option for this patient population. These patients would not be offered BMT in standard
practice and therefore have dismal survival outcomes of two to three months. The primary endpoint of the SIERRA trial was dCR of 180 days
and the secondary endpoints are OS and Event-Free Survival (&#8220;EFS&#8221;). The comparison of OS in subjects randomized to the control
arm who crossed over to receive Iomab-B versus all others in the control group was an exploratory efficacy endpoint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As seen in the graphic below, the primary endpoint of 6-month dCR was
met with a high degree of statistical significance (p&lt;0.0001). 75% of patients (44/59) receiving Iomab-B achieved an initial remission
30 days after their BMT compared to 6.3% of patients (4/64) in the control arm. 22% of the patients receiving Iomab-B maintained dCR lasting
180 days or more despite limited optionality for post-transplant maintenance, while none of the patients on the control arm achieved dCR.
The current standard practice is to administer post-transplant maintenance therapy to reduce chances of relapse. The results presented
below are on a per protocol basis, which means that only data that was in strict adherence to the protocol without any deviations was
considered for the analysis. It is important to note that the p-value of the primary endpoint in the intent-to-treat analysis was &lt;0.0001,
the same as the per protocol analysis.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>&#160;</i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SIERRA Results: Iomab-B Meets Primary Endpoint
with High Significance (p&lt;0.0001)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As demonstrated in the OS graph below, patients who achieved 6-month
dCR had 92.3% 1-year survival and 59.9% 2-year survival. Median OS had not been reached in these patients. It is worth noting that two
years in CR is a significant milestone in this patient population, highly indicative of long-term survival and a possible curative outcome.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Overall Survival for Patients who Achieved
6-month dCR with Iomab-B</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OS was one of the secondary endpoints of the
study. The Kaplan-Meier plot in the inset of the graph below shows Intent-to-Treat (&#8220;ITT&#8221;) OS results between the Iomab-B
arm and the control arm. Due to the crossover design, ITT analysis of OS was confounded by the early crossover of patients (within 28
days) from the control arm to the Iomab-B arm (57.1%). The effective rescue of these crossover patients by Iomab-B led to an outsized
contribution of the Iomab-B effect on control arm patients. As a result, median OS in the Iomab-B arm was similar to that in the control
arm and this secondary endpoint was not met in the ITT analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to isolate the true impact of Iomab-B
on OS, one of the exploratory efficacy endpoints was the comparison of OS in subjects randomized to the control arm who crossed over to
receive Iomab-B versus all others in the control arm, as well as the control arm patients who did not crossover versus the Iomab-B arm.
The Kaplan-Meier plot of OS in the graphic below shows that this exploratory analysis demonstrated the clear benefit of Iomab-B over the
control arm. The median OS for the Iomab-B group was 6.4 months which was double the 3.2 months for the non-crossover patients in the
control arm. Patients who crossed over from the control arm to receive Iomab-B had a median OS of 7.1 months demonstrating further the
ability of Iomab-B to treat patients who are non-treatable by conventional means.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A similar pattern favoring the Iomab-B group was seen across the pre-defined
subgroups, where 1-year OS for Iomab-B was 26.1% compared with 13.1% for the non-crossover control arm. The 1-year OS for patients in
the crossover arm was 35.8%. This clearly demonstrates the OS benefit of Iomab-B over the control arm and two to three-fold improvement
in survival outcomes possible with its use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Kaplan-Meier Plot of Overall Survival &#8210;
Iomab-B, Crossover, and Non-Crossover Control Arm	</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_009.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iomab-B produced a significant and clinically meaningful improvement
in the secondary endpoint of EFS, with a 78% reduction in the probability of an event (Hazard Ratio=0.22, p&lt;0.0001 for both per protocol
and ITT basis). EFS at 180 days for the Iomab-B arm was 28% compared to 0.2% for the control arm. In the SIERRA trial, an event is defined
as one of the following: a patient not achieving CR/CRp or crossing over, patient not receiving BMT, a patient relapsing or death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the figure below comparing EFS with Iomab-B
versus the control arm, the initial vertical drop in the curve in the Iomab-B arm represents those patients who did not achieve a remission
after Iomab-B or those who did not proceed to transplant, while the initial vertical drop in the curve in the control arm mainly represents
patients who did not achieve a remission with salvage therapy and either crossed over to Iomab-B or went onto best supportive care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Event-Free Survival with Iomab-B Versus Control
Arm</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_010.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows relevant adverse events
in transplanted Iomab-B patients. In these patients, incidence of sepsis was four times lower in the Iomab-B arm than the control arm
(6.1% vs. 28.6%). In addition, rates of other treatment related adverse events were lower in favor of Iomab-B, including febrile neutropenia
(43.9% vs. 50.0%), mucositis (15.2% vs. 21.4%) and acute graft versus host disease (&#8220;GVHD&#8221;) (26.1% vs. 35.7%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>Grade &#8805;3 Treatment-Emergent Adverse Events
in Transplanted Patients Through Day 100 Post-HCT</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_011.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With current treatment practice, patients who have r/r AML with active
disease, utilizing current conditioning agents have poor outcomes and very low survival rates. Using an Iomab-B led regimen, an unprecedented
number of patients were able to access transplant and were able to do so with active disease, eliminating need for achieving a CR in order
to transplant the patient. Thus, patients are also able to access BMT faster with Iomab-B, in less than half the time compared to conventional
care. Iomab-B represents an exciting new paradigm with the potential to establish a new standard of care in r/r AML setting, making it
possible for most patients to get to a successful transplant with Iomab-B with a portion of these patients having a long-term survival
benefit. As shown below, with an Iomab-B led regimen, the majority of patients who are non-transplantable in routine clinical practice
can be successfully transplanted, administering myeloablative radiation with reduced intensity conditioning tolerability to ultimately
achieve transformative survival outcome, changing the treatment paradigm for r/r AML patients.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Iomab-B &#8211; New Paradigm to Upend BMT
Access and Improve r/r AML Outcomes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_012.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Future Development and Life Cycle Management
for Iomab-B</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of the Pivotal Phase 3 SIERRA trial
validate the value proposition of Iomab-B, and we believe it could establish unprecedented access to transplant (currently the only curative
option) with better safety and tolerability and improved outcomes, all of which could potentially make Iomab-B the new standard of care
for patients with r/r AML. We are actively working to launch an EAP and successfully file a BLA in the second half of 2023, and if approved,
we anticipate the commercial launch for Iomab-B in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to commercialize Iomab-B in the U.S.
The commercial opportunity is supported by favorable dynamics, summarized by the &#8220;Three Ps and Two Cs&#8221;:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Patients</i>: With its promising profile,
Iomab-B provides the opportunity for unprecedented BMT access and better outcomes for patients, with favorable safety and tolerability</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Physicians</i>: Our goal is to help physicians
make BMT an option for a vast majority of r/r AML patients who currently are unable to access transplant without disruption to current
practice. Patients are able to return to their referring physicians for post-BMT follow-up, long-term care</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Payers</i>: Iomab-B potentially unlocks value
through getting patients safely to effective, potentially curative transplants, with improved outcomes and a manageable safety and tolerability
profile</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Competition</i>: While there have been multiple
new product approvals in AML over the last several years, they primarily focus on addressing genetic mutations, with limited competition
in conditioning to increase access to BMT. We do not see direct or indirect visible competition for Iomab-B in the 5-to-10-year horizon
to impair the commercial success of Iomab-B</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Concentrated Call Points</i>: The commercialization
for Iomab-B will benefit from a concentrated market. The top 50 centers perform 75% of BMTs and tend to be concentrated in metropolitan
areas. These factors allow for commercialization delivered by a focused 35&#8211;50-person commercial organization. </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The favorable commercial dynamics for Iomab-B in the U.S. are further
supported by the strong foundation of core competencies developed during the successful execution of the SIERRA trial at leading high-volume
BMT centers. We established and actively managed end-to-end supply chain, never missing a patient dose, and were able to treat 60% more
patients than expected due to the high number of crossover patients. We focused on operational excellence at the point of care, working
in partnership with leading Key Opinion Leaders and their teams to successfully execute SIERRA at a wide array of centers. As a result,
we have broad reach across leading BMT centers that account for 30% of BMT volume, which speaks to the concentration of the BMT market.
The positive SIERRA results of unprecedented access and outcomes along with our commitment to operational excellence provide a strong
foundation for our commercial team.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2022, Actinium licensed the EUMENA commercial
rights for Iomab-B to Immedica, an independent pharmaceutical company headquartered in Sweden. Immedica has significant know-how and experience
in commercializing niche and specialty care products across Europe and the Middle East, with extensive regulatory and commercial expertise
and capabilities. Actinium will continue to be responsible for certain clinical development activities and Iomab-B manufacturing and will
retain commercialization rights in the U.S. and rest of the world. Currently, there an estimated ~7,200 BMTs for AML in EUMENA, two times
that of the U.S., performed in a concentrated of number of centers. The incidence rate of AML in Europe is 3.7 per 100,000, or ~27,500
new patients per year. Actinium received an upfront payment of $35 million USD with the potential for an additional $417 million USD in
regulatory and sales milestones and mid-twenty percent royalties. Iomab-B has been granted Orphan Drug Designation by the EMA and has
received positive Scientific Advice from EMA that the SIERRA trial can support a marketing authorization with filing expected in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background on Iomab-B </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iomab-B is a first in class targeted radiotherapy consisting of apamistamab,
an anti-CD45 mouse antibody conjugated to radioactive iodine 131 (&#8220;I-131&#8221;) designed to deliver targeted myeloablative radiation
to malignant and hematopoietic cells prior to allogeneic BMT. CD45 is uniquely expressed on blood cancer, immune and bone marrow stem
cells at high levels. Targeting CD45 enables delivery of high radiation doses directly to the bone marrow, with a median of 16 gray and
as high as 44.6 gray in the SIERRA trial, while minimizing radiation exposure to vital organs such as lungs, heart and gastrointestinal
tract, thereby producing myeloablative outcomes with an overall better safety profile and the tolerability of a reduced intensity regimen.
I-131 is a beta- and gamma-emitting radioisotope that works on the cell surface and does not need to be internalized. Developed at the
Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;), Iomab-B has been studied in multiple disease indications including leukemias,
lymphomas, MDS, and MM. Over 300 patients received Iomab-B through prior studies, demonstrating the potential for unprecedented access
to BMT, improved survival and tolerability, and we intend to leverage these data as we plan for label expansion of Iomab-B. Iomab-B has
been granted Orphan Drug Designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and has patent protection into 2037.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Actimab-A &#8211; CD33 targeting radiotherapeutic
&#8211; mutation agnostic mechanism of action has potential as combination backbone therapy in highly radiosensitive, mutation rich AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Actimab-A <i>(<sup>225</sup>Ac-lintuzumab
satetraxetan) </i>program is focused on developing combinations with other AML treatment regimens with mechanistic synergies to establish
Actimab-A as a backbone therapy, leveraging the mutation-agnostic mechanism of action of Actimab-A. There is no known resistance mechanism
to targeted radiotherapies, making Actimab-A an attractive candidate for a variety of combinations. The scientific rational is to use
CLAG-M, a powerful chemotherapy regimen routinely used to treat patients with r/r AML, and then use Actimab-A for its precision targeting
ability that produces double-strand-DNA breaks that lead to cancer cell death to clear out residual disease. Actimab-A has demonstrated
clinically significant survival benefit in a proof-of-concept study and is poised for advanced development in collaboration with the NCI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Actimab-A + CLAG-M Phase 1 Study Results </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In collaboration with the Medical College of Wisconsin, the Actimab-A
+ CLAG-M Phase 1 trial was conducted in r/r AML patients. These patients had a median age of 63, failed two or more lines of therapy,
which includes 57% having received prior treatment with venetoclax, a BCL-2 inhibitor. 67% of these patients had adverse cytogenetics,
52% had a TP53 mutation, and 57% had a prior BMT. Median OS is typically two to four months for this patient population, with a median
OS of less than 3 months for patients who relapsed following venetoclax and a median OS less than 2 months for those with a TP53 mutation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These trial results were presented as an oral
presentation at the ASH Annual Meeting on December 10, 2022. In this difficult-to-treat r/r AML population, the results demonstrate its
high potential. We reported 1-year survival of 53% and 2-year survival of 32%, which are as much as double what can be expected with currently
available therapies. The trial showed an Overall Response Rate (&#8220;ORR&#8221;) of 65% across all dose cohorts, 52% complete remission
rate, and a 75% MRD negativity rate. As highlighted in the figure below, the results are highly encouraging and show that the high rates
of responses and MRD negativity are translating to a meaningful survival benefit in these difficult-to-treat patients, who would otherwise
have dismal outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Actimab-A + CLAG-M &#8211; Impressive Response
and Survival Benefit in r/r AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_013.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Actimab-A + CLAG-M Compared to CLAG-M Alone
in r/r AML</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Efficacy of CLAG-M has been reported in older studies (Halpern
and Walter. CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia. Oncotarget 2018 and Mushtaq et al. Comparison
of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. ASH 2018) in patients with r/r AML, however, almost all
of these studies were conducted in the pre-targeted therapy era where no patients enrolled had prior venetoclax-based therapy, thus efficacy
data of CLAG-M in the current era, in patients exposed to prior venetoclax, or with other high-risk features, is limited. When combined
with Actimab-A, the combination has demonstrated a clinically significant survival benefit in a proof-of-concept study irrespective of
prior targeted treatment. Relapsed or refractory AML after failing venetoclax-based therapy is associated with dismal survival outcomes,
with a median OS of less than 3 months. In comparison, the combination trial of Actimab-A + CLAG-M led to 1-year survival of 59% and 2-year
survival of 32% in patients who failed prior venetoclax-based therapy, which compares very favorably to the traditional outcomes in these
patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Actimab-A + venetoclax Phase 1/2 Study Results</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are conducting a Phase 1/2 multi-center trial combining Actimab-A
+ venetoclax in both fit and unfit patients 18 years and older with r/r AML led by UCLA Medical Center. On December 10, 2022, data from
our Actimab-A + venetoclax combination trial was presented at the ASH Annual Meeting. We have demonstrated preclinically that combinations
of Actimab-A and venetoclax have mechanistic synergies. Overexpression of MCL-1, an anti-apoptotic protein, is associated with resistance
to venetoclax in AML. Actimab-A kills tumors cells with DNA double-strand breaks and downregulates MCL-1, which can (re-)sensitize AML
cells or reduce tumor resistance to venetoclax. The Actimab-A + venetoclax combination has been well-tolerated with responses, including
a CR and a partial response in early dose escalation cohorts. In our ongoing clinical trial, we are exploring the optimal dose of Actimab-A,
as well as the dosing regimen of the combination. We expect to present proof-of-concept of this study in the second half of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Advanced Development and Planning for Actimab-A</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2023, we announced that we entered
into a CRADA with the NCI, part of the NIH, to develop Actimab-A for the treatment of patients with AML and other hematologic malignancies.
The NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A, and the CRADA
will provide extensive support for and accelerate the development of Actimab-A alone or in combination with chemotherapy, immunotherapy,
targeted agents and other novel combinations. The CRADA studies will be overseen by the NCI in collaboration with Actinium&#8217;s clinical
development team, where Actinium has the right to review and approval all protocols and has full right to all data. This broad collaboration
may accelerate our Actimab-A development efforts with access to NCI&#8217;s vast network of over 2,000 clinical trial sites and its Myelomatch
program. Later this year, we will provide updates on our progress as we move into late-stage development with Actimab-A + CLAG-M, as well
as other developments with our venetoclax combination trial as part of our backbone development strategy.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background on Actimab-A</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actimab-A is an anti-CD33 antibody linked to the potent alpha-emitting
radioisotope Ac-225. Actimab-A targets CD33, which is expressed in virtually all malignant cells in patients with AML regardless of cytogenetics
or mutations and enables potent alpha radiation to be directed against radiosensitive AML cells. These cells have no known resistance
or repair mechanisms when hit with the alpha particles from the Ac-225 isotope payload that cause double stranded DNA breaks. We believe
Actimab-A is the first radiotherapeutic for r/r AML and has the unique value proposition of broad applicability, a differentiated mechanism
of action, and targeted precision that is well-tolerated with minimal toxicity. Our CD33 development program is driven by data obtained
from approximately 150 AML patients in 6 trials and demonstrated single agent activity with high response rates, but was also associated
with prolonged neutropenia. A combination strategy was considered appropriate given the changing treatment landscape of AML; hence, based
on presumed mechanistic synergies, an investigator initiated trial of Actimab-A + CLAG-M and a company-sponsored Actimab-A + venetoclax
were developed and patients were enrolled into these studies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Conditioning Focused Programs</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-B</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will further expand the Iomab-B franchise by focusing on lifecycle
management for label enhancement and indication expansion. Iomab-B data in five additional hematologic indications (i.e., MDS, ALL, HL,
NHL, and MM) provide the foundation to explore indication expansion opportunities to increase the total addressable market for Iomab-B.
Across early trials at the FHCRC, Iomab-B demonstrated similar improved access to BMT and outcomes. We will leverage these data with strong
results from the pivotal Phase 3 SIERRA trial to execute a comprehensive life cycle management strategy to further expand Iomab-B&#8217;s
role in a variety of malignant and non-malignant hematological disorders, We will continue to develop the Iomab-B franchise to potentially
address a broader market opportunity to address the over 165,000 patients diagnosed with cancers (e.g., leukemia, lymphoma, and myeloma),
who could potentially benefit from transplant, but are unable to access one today.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-ACT</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iomab-ACT is comprised of apamistamab, the same anti-CD45 antibody
as Iomab-B, but utilizes lower, nonmyeloablative levels of I-131 to achieve lymphodepletion for cellular therapies such as CAR-T or reduced
intensity conditioning for gene therapies. We intend to continue to develop the Iomab-ACT program designed specifically for use prior
to CAR-T and gene therapies, ultimately with a value proposition of improving overall access and outcomes for patients who need cellular
or gene therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical data showed a single, low-dose of
Iomab-ACT demonstrated lymphodepletion and as CD45 positive immune cells are implicated in major CAR-T side effects, i.e., cytokine release
syndrome ("CRS") and immune effector cell&#8211;associated neurotoxicity syndrome (&#8220;ICANS"), Iomab-ACT has the potential
to be developed as a conditioning agent for CAR-T therapies. CRS and ICANS remain two most common toxicities of CAR-T therapies with severe
cases (&gt;Grade 3) seen in &gt;20% of patients and fatality rates between 0-10%. Due to its effect on host monocytes/macrophages, we
believe conditioning with Iomab-ACT will potentially reduce the incidence of CRS and ICANS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unlike chemotherapy, Iomab-ACT is targeted in
nature, and we expect it to potentially promote improved CAR-T cell expansion, resulting in responses that are higher and more durable.
We believe our Iomab-ACT program is highly differentiated when compared to fludarabine and cyclophosphamide (&#8220;Flu/Cy&#8221;) or
other chemotherapy-based regimens that are used as standard practice today for lymphodepletion prior to cell therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are studying Iomab-ACT in collaboration with MSKCC, for conditioning
prior to CAR-T therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (&#8220;B-ALL&#8221;) or diffuse large
B-cell lymphoma (&#8220;DLBCL&#8221;). This study funded by a NIH grant is the first-of-its-kind study to use a radiotherapeutic-based
conditioning regimen with CAR-T therapy. We have completed treatment of an initial cohort of three patients and will expand to a second
cohort. This study was presented at the ASH Annual Meeting in December 2022 as a trial-in-progress. We expect to present proof-of-concept
data from this study in 2023 and look forward to sharing more on our Iomab-ACT trial with MSKCC, along with future development plans in
the CAR-T space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">R&amp;D and Preclinical Programs</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our R&amp;D efforts yield differentiated, high-value
programs that demonstrate our experience across multiple validated cancer targets and isotopes and cover broad areas of focus leveraging
our clinical development experience across hematology, targeted conditioning, solid tumors, and next generation radiotherapies. Our programs
also inform the advancement of our Iomab-B, Actimab-A, and Iomab-ACT programs. Our research collaborations with Astellas, LG Chem, formerly
AVEO Oncology, and EpicentRx establish our work with immunotherapies and in solid tumors. We are working on several preclinical programs
which include novel approaches to established targets such as HER2 and HER3, as well as novel targets that show immense potential for
radiotherapeutic approaches. Underpinning our development programs is our expanded patent portfolio of over 200 issued patents and pending
patent applications worldwide.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have utilized our technology platform to develop our clinical portfolio
in hematology &#8211; Iomab-B and Actimab-A, in conditioning for transplant and as a therapeutic, respectively. In addition, our robust
platform been used to develop a pipeline of novel radiotherapeutic assets to drive company growth. Preclinical pharmacology studies with
our targeted radiotherapeutics such as HER3-ARC, HER2-ARC or CD33-ARC have shown dramatic improvement in tumor growth inhibition in various
preclinical tumor models as single agents or in combination with immunotherapy such as magrolimab, an anti-CD47 monoclonal antibody. These
results have prompted the team to spearhead efforts in multiple solid tumor programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium&#8217;s lead solid tumor program is a targeted radiotherapy
against HER3, a pan-cancer target that is overexpressed in several solid tumor indications with high unmet need. In April 2022, we presented
the first HER3-targeted radiotherapeutic agent at the American Association for Cancer Research (&#8220;AACR&#8221;) Annual Meeting showing
potent tumor cell cytotoxicity, enhanced antitumor effects and significantly improved survival with an Ac-225 radiolabeled HER3 antibody
compared to a naked HER3 antibody in a preclinical non-small cell lung cancer (&#8220;NSCLC&#8221;) model. We have also demonstrated the
direct impact of targeted radiotherapy in modulating immune signals such as calreticulin upregulation to enhance tumor cell killing. Further,
we have leveraged the immunomodulatory effect(s) of targeted radiotherapy in combination with CD47 targeting agents such as magrolimab
for sustained tumor growth inhibition in mouse models of AML and NSCLC. These results were presented at the Society for Immunotherapy
of Cancer (&#8220;SITC&#8221;) Annual Meeting held in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our R&amp;D team continues to expand on capabilities
and technologies across therapeutic modalities, linker technologies and in vivo cancer models, and build significant visibility through
presentations at key conferences and publications in journals of high impact. Our R&amp;D efforts are centered on the advancement of our
key programs with a robust &#8220;fast-to-clinic&#8221; approach in niche indications and are backed by an extensive IP estate that comprises
over 200 patents and patent applications including the methods of Ac-225 production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Platform Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our proprietary technology platform is built on
the core competency to produce targeted radiotherapeutics, and coupled with our know-how and IP, establishes our company in the development
of isotope-agnostic, multi-targeted products that may address the treatment of hard-to-treat diseases. In our clinical and preclinical
programs, we have utilized multiple isotopes including Ac-225, I-131 and Lutetium-177 directed at multiple targets in oncology and hematology
such as CD45, CD33, HER3, among others. Our targeted radiotherapies combine the cell-killing ability of radiation via a radioisotope payload
with a targeting agent, such as a monoclonal antibody.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to developing targeted radiotherapies, we also own patents
related to the manufacturing of Ac-225 in a cyclotron. We have expertise in utilizing the alpha emitting isotope Ac-225 including clinical
experience in treating approximately 150 patients with our alpha-emitter-based therapies, &#8220;gold standard&#8221; linker technology
and five issued patents in the U.S. and 49 patents internationally related to the manufacturing or Ac-225 in a cyclotron, which we believe
has the potential to produce higher quantities of highly pure Ac-225 than current methods. When appropriate, we are well-positioned to
leverage this technology to produce Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our proprietary technology platform is supported
by IP, know-how and trade secrets that cover the generation, development, methods of use and manufacture of targeted radiotherapies and
their select components. Our IP covers various methods of use in multiple diseases, including indication, dose and scheduling, radionuclide
warhead, and therapeutic combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 2023, we have expanded our patent
portfolio to over 200 issued patents and pending patent applications worldwide, which we believe constitutes a valuable business asset.
Our IP includes 45 patent families, including key patents that relate primarily to our radiotherapeutic candidates. Our patent portfolio
includes 12 issued patents and 39 pending patent applications in the U.S., and 151 that are issued or pending internationally. The effective
lives of the issued patents in our portfolio, or patents that may issue from the pending applications in our portfolio, ranges from expirations
between 2024 and 2043.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For our Iomab-B product candidate, we have four
issued patents in the U.S. and issued patents in Canada, Europe and Japan that relate to the composition. The basic patent terms of these
patents expire in 2036 and 2037. Related patent applications are also currently pending in the U.S. and internationally. In addition,
we own both U.S. and international pending patent applications that relate to the use of Iomab-B or Iomab-ACT in the treatment of cancers
and non-malignant conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our patents also cover key areas of our business
such as manufacturing key components of our product candidate, Actimab-A, including Ac-225 in a cyclotron. We have expertise in utilizing
the alpha emitting isotope Ac-225 including clinical experience in treating approximately 150 patients with our alpha-emitter-based therapies,
&#8220;gold standard&#8221; linker technology and five issued patents in the U.S. and 49 patents internationally related to the manufacturing
or Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than currently utilized methods. These
patents will expire in the years 2024 through 2027. In addition, we also own U.S. and international patents and pending patent applications
that relate to the manufacturing of Actimab-A and its use in the treatment of cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Strategic Collaborations and Licensing Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fred Hutchinson Cancer Research Center</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 15, 2012, the Company entered into a license
and sponsored research agreement with FHCRC to build upon previous and ongoing clinical trials with Iomab-B. Developed at the FHCRC, a
pioneer in the field of BMT, Iomab-B has been studied in over 400 patients and is supported by data in six disease indications including
leukemias, lymphomas and multiple myeloma.&#160;The Company has been granted exclusive rights to the antibody and related master cell
bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed
antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Immedica AB</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2022, Actinium licensed the EUMENA commercial
rights for Iomab-B to Immedica, an independent pharmaceutical company headquartered in Sweden. Immedica has significant know-how and experience
in commercializing niche and specialty care products across Europe and the Middle East, with extensive expertise and capabilities across
sales and marketing, market access, regulatory and medical affairs, drug safety and quality assurance, among others. Actinium received
an upfront payment of $35 million USD with the potential for an additional $417 million USD in regulatory and sales milestones and mid-twenty
percent royalties. The market potential is extremely compelling in the EU with approximately 50% larger with 15,000 patients with r/r
AML and double the number of BMTs performed than in the US. Iomab-B has been granted Orphan Drug Designation by the EMA and has received
positive Scientific Advice from the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>National Cancer Institute</i></b><i> </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2023, we announced that Actinium entered
into a CRADA with the NCI, part of the NIH, to develop Actimab-A in for the treatment of patients with AML and other hematologic malignancies.
Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to
study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing
additional support as needed. The CRADA will provide broad support for the development of Actimab-A alone or in combination with chemotherapy,
immunotherapy, targeted agents and other novel combinations. The CRADA studies will be overseen by NCI in collaboration with Actinium's
clinical development team.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Astellas, LG Chem, and EpicentRx</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are leveraging our clinical experience, robust
IP and radiotherapy know-how through research collaborations. Our collaborations with Astellas, LG Chem and EpicentRx establish our work
with immunotherapies and in solid tumors. Through our research collaborations, such as with Astellas, we are advancing into solid tumors
indications. With Astellas, we are utilizing a diagnostic agent developed in parallel with a therapeutic agent that shares the same target
to identify patients who would benefit from the treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our platform is being utilized in our ongoing
research collaboration with Astellas to arm select targeting agents owned by Astellas with the alpha-emitting radioisotope Ac-225 for
the development of theranostics for solid tumor indications, which combine the ability of radioisotopes to be used for both diagnostic
and therapeutic purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also exploring novel targeted radiotherapies
in solid tumors and blood cancers such as HER3 expressing solid tumors in collaboration with LG Chem and combinations with immunotherapies
such as CD47 immune checkpoint inhibitors with EpicentRx.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biopharmaceutical industry is extremely competitive
and rapidly evolving, particularly in the field of oncology and hematology drug development. Our competition is likely to come from larger
pharmaceutical companies, biotechnology companies, academia, and other public and private entities that focus on three broad areas relevant
to our pipeline candidates &#8211; AML drugs, conditioning agents and radiopharmaceuticals. In addition, in markets where we are going
after a target, companies with research programs and capabilities in our disease area focus may also be competing with our programs and
pipeline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In AML, the pipeline is crowded with 100+ programs, however, there
are a few Phase 3 assets with limited potential that do not represent an imminent, competitive threat to Iomab-B or Actimab-A. None of
the Phase 2 development programs in AML show the promise of producing high rates or duration of remission, and most patients that relapse
tend to have poor survival outcomes. The Phase 2 assets primarily consist of agents targeting specific AML mutations, immunotherapies,
or cell cycle modulators. Early clinical and preclinical stage assets consist of more cell therapy and immune cell engagers, and the potential
success of these modalities in AML remain uncertain. Our strategy is to develop Actimab-A in combination with other products, and the
agents in the development pipeline have the potential for synergies in combination with Actimab-A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conditioning, agents currently used for
myeloablation prior to a BMT, lymphodepletion prior to CAR-T and other adoptive cell therapies and reduced intensity conditioning
for gene therapy are largely generic, non-targeted chemotherapeutic agents. Recently, Jasper Therapeutics and Magenta Therapeutics
ceased development of their antibody and antibody-drug conjugate or ADC conditioning programs for BMT. Certain companies such as Vertex
Pharmaceuticals (&#8220;Vertex&#8221;), Gilead Sciences (&#8220;Gilead&#8221;) and Allogene Therapeutics (&#8220;Allogene")
have or continue to explore non-chemotherapy conditioning with ADCs and antibodies for their in-house, proprietary cellular therapy
programs. For example, Vertex has in-licensed ImmunoGen Inc.&#8217;s ADC technology, and had a collaboration with Molecular
Templates, Inc. to develop targeted conditioning agents, which was subsequently terminated. Allogene is using its own proprietary
anti-CD52 monoclonal antibody for use as a lymphodepletion agent in conjunction with CAR-T therapies. Telix Pharmaceuticals has
announced plans for a conditioning program based on a CD66 radiotherapeutic approach in systemic amyloid light-chain amyloidosis
(&#8220;SALA&#8221;) via an early stage investigator sponsored trial. Without exception, all these companies have either preclinical
or early-stage programs that are solely focused on their proprietary programs. We believe that we are the only company with a phase
3 completed targeted conditioning asset that has demonstrated clinical benefit with the opportunity to be paradigm-changing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Several companies are focused on developing radiotherapies, including,
but not limited to: Abdera Therapeutics, Aktis Oncology, Bayer AG, Convergent Therapeutics, CuraSight, Fusion Pharmaceuticals, Inc., Lantheus
Holdings, Inc., Mariana Oncology (previously, Curie Therapeutics), Monopar Therapeutics, Novartis AG, Point Biopharma, Inc., RadioMedix,
Inc., Radiopharm Theranostics, Radionetics Oncology, RayzeBio, Inc., Q BioMed, Inc., Telix, and Y-mAbs Therapeutics, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulatory Compliance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development activities are all
subject to stringent regulation, primarily by the FDA in the U.S. under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;)
and its implementing regulations, and the Public Health Service Act (&#8220;PHSA&#8221;) and its implementing regulations, and by comparable
authorities under similar laws and regulations in other countries. This includes research and development, testing, and oversight of suppliers
and contract manufacturers involved in the production of our product candidates we are developing, as well as the design, manufacturing,
safety, efficacy, handling, labeling, storage, record-keeping, advertising, promotion and marketing. If, for any reason, we do not comply
with applicable requirements, such noncompliance can result in adverse consequences, including delays in approval of, or even the refusal
to approve, product licenses or other applications, the suspension or termination of clinical investigations, the revocation of approvals
previously granted, as well as fines, criminal prosecution, recall or seizure of products, injunctions against shipping products and suspension
of production and/or refusals of government contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA Review Process and Product Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates are regulated as biologics
and must be approved by the FDA before they may be marketed in the U.S. This process generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">completion of preclinical studies in accordance with the
FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) requirements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">submission to the FDA of an IND, which must become effective
before human clinical trials may begin and must be updated annually;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">approval by an independent Institutional Review Board (&#8220;IRB&#8221;) ethics committee at each clinical
site before the trial is initiated;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">performance of adequate and well-controlled clinical trials to establish the safety, purity and potency
of the proposed biologic, and its safety and efficacy for each indication, in accordance with good clinical practice (&#8220;GCP&#8221;);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">submission to the FDA of a BLA for a new biologic, after completion of all pivotal clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">satisfactory completion of an FDA pre-approval inspection of the manufacturing
facilities to assess compliance with applicable current Good Manufacturing Practice (&#8220;cGMP&#8221;) regulations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">potential FDA audit of the clinical trial sites that generated the data in support of the BLA; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">FDA review and approval of a BLA for a new biologic, prior to any commercial marketing or sale of the
product in the U.S.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials generally are conducted in three
sequential phases, although they may overlap or be combined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Phase 1 studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions
of the investigational product in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on
effectiveness</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Phase 2 studies are conducted to preliminarily or further evaluate the effectiveness of the investigational
product for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal
dosage, and to identify possible adverse side effects and safety risks associated with the product</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Phase 3 clinical trials generally involve a large number of patients at multiple sites designed to provide
the data required to demonstrate the effectiveness of the product for its intended use, safety and to establish the benefit-risk relationship
of the product and provide an adequate basis for product labeling</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of the preclinical and clinical testing,
along with information regarding the manufacturing of the product and proposed product labeling, are evaluated and, if determined appropriate,
submitted to the FDA through a BLA. Once the BLA submission has been accepted for filing, the FDA&#8217;s standard goal is to review applications
within ten months of the filing date or, if the application relates to a drug that treats a serious condition and would provide a significant
improvement in safety or effectiveness qualifying for Priority Review, six months from the filing date. The review process is often significantly
extended by FDA requests for additional information or clarification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA offers certain programs, such as Breakthrough Designation (&#8220;BTD&#8221;)
and Fast Track designation, designed to expedite the development and review of applications for products intended for the treatment of
a serious or life-threatening disease or condition. For BTD, preliminary clinical evidence of the product indicates that it may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA may initiate review of sections
of a BLA before the application is complete, and the product may be eligible for accelerated approval. However, receipt of BTD or Fast
Track designation does not ensure that a product will be developed or approved on an expedited basis, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA reviews the BLA to determine, among other
things, whether the proposed product is safe, pure and potent, which includes determining whether it is effective for its intended use,
and whether the product is being manufactured in accordance with cGMP, to assure and preserve the product&#8217;s identity, strength,
quality, potency and purity. The FDA may refer an application to an advisory committee for review, evaluation and recommendation as to
whether the application should be approved, and applications for new molecular entities and original BLAs are generally discussed at advisory
committee meetings unless the FDA determines that this type of consultation is not needed under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the FDA evaluates the BLA and conducts inspections of manufacturing
facilities, it may issue an approval letter or a complete response letter (&#8220;CRL&#8221;). An approval letter authorizes commercial
marketing of the biologic with specific prescribing information for specific indications. A CRL indicates that the review cycle of the
application is complete, but the FDA cannot grant approval. A CRL may require additional inspections, and/or other significant, expensive
and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. The FDA could approve the BLA with a
Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to mitigate risks, which could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications,
or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase 4 clinical trials
and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Post-Approval Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any products manufactured or distributed by us
or on our behalf pursuant to FDA approvals are subject to continuing regulation by the FDA and certain state agencies, including requirements
for record-keeping, reporting of adverse experiences with the biologic, submitting biological product deviation reports to notify the
FDA of unanticipated changes in distributed products, establishment registration, compliance with cGMP standards, and certain state licensing
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, any significant change in the approved
product or in how it is manufactured, including changes in formulation or the site of manufacture, generally require prior FDA approval.
The packaging and labeling of all products developed by us are also subject to FDA approval and ongoing regulation. Noncompliance with
any regulatory requirements can result in, among other things, issuance of warning letters, civil and criminal penalties, seizures, and
injunctive action. Accordingly, manufacturers must continue to maintain compliance with cGMP and other aspects of regulatory compliance.
The commercial distribution of prescription drugs is subject to the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;), which regulates
the distribution of the products at the federal level and sets certain standards for federal or state registration and compliance of entities
in the supply chain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DSCSA preempts certain previously enacted
state laws and the pedigree requirements of the Prescription Drug Marketing Act (&#8220;PDMA&#8221;). Trading partners within the drug supply
chain must now ensure certain product tracing requirements are met, and are required to exchange transaction information, transaction
history, and transaction statements. Product identifier information (an aspect of the product tracing scheme) is also now required. The
DSCSA requirements, development of standards, and the system for product tracing have been and will continue to be phased in over a period
of years through 2023. In addition to new legislation, FDA regulations, guidance documents, and policies are often revised or reinterpreted
by the agency in ways that may significantly affect our business and our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drug Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have received Orphan Drug designation for Iomab-B
and Actimab-A for patients with AML. Under the Orphan Drug Act, FDA may grant Orphan Drug designation to drugs intended to treat a rare
disease or condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan
Drug designation must be requested before submitting a BLA. In the U.S., Orphan Drug designation entitles a party to financial incentives
such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. Orphan Drug designation does
not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive
FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug designation is entitled to a seven-year
exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, FDA may not approve
any other applications to market the same drug for the same orphan indication, except in limited circumstances, such as a showing of clinical
superiority to the product with orphan exclusivity or where the manufacturer of the approved product cannot assure sufficient quantities.
As a result, there can be no assurance that our competitors will not receive approval of drugs or biologics that have a different active
ingredient for treatment of the diseases for which our products and product candidates are targeted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pediatric Information</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;),
certain BLAs must contain data to assess the safety and efficacy of the drug or biologic for the claimed indications in all relevant pediatric
subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.
The Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;), amended the FDCA to require that a sponsor who is planning
to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen
or new route of administration submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within 60 days of an end of Phase 2 meeting
or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must
include an outline of the pediatric study or studies that the sponsor plans to conduct or a justification for not including such detailed
information, and any request for a deferral of pediatric assessments or a full or partial waiver. The FDA may grant deferrals for submission
of pediatric data or full or partial waivers. A sponsor can submit amendments to an initial PSP if changes to the pediatric plan need
to be considered based on preclinical data collected, early phase clinical trials as well as other clinical development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to regulations in the U.S., we are
subject to foreign regulations governing clinical trials and commercial sales and distribution of our product candidates, and products
being marketed outside of the U.S. We must obtain approval by the comparable regulatory authorities of foreign countries before we can
commence clinical trials or marketing of our products in those countries. The approval process varies from country to country, and the
time may be longer or shorter than required by the FDA for BLA licensure. The requirements governing the conduct of clinical trials, product
licensing, pricing and reimbursement vary greatly from country to country. As in the U.S., we are subject to post-approval regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Regulatory Considerations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also subject to regulation under the Occupational
Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, The Clean Air Act, and other current
and potential future federal, state, or local regulations. Our research and development activities involve the controlled use of hazardous
materials, chemicals, biological materials and various radioactive compounds. We believe that our procedures comply with the standards
prescribed by state and federal regulations; however, the risk of injury or accidental contamination cannot be completely eliminated.
We may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where
we may market our products and product candidates, if approved. These laws and regulations include, without limitation, state and federal
anti-kickback, fraud and abuse, false claims, data privacy and security, aggregate spend reporting, and product price advertising.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal Anti-Kickback Statute, which prohibits,
among other things, persons and entities including pharmaceutical manufacturers from knowingly and willfully soliciting, receiving, offering
or paying remuneration, directly or indirectly, overtly or covertly, in case or in kind, to induce or reward, or in return for, or either
the referral of an individual for, or the purchase, lease or order or recommendation of an item or service reimbursable, in whole or in
part, under a federal healthcare program, such as the Medicare and Medicaid programs. The failure to meet all of the requirements of a
particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback
Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its
facts and circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Patient Protection and Affordable
Care Act of 2010, as amended (&#8220;ACA&#8221;) codified cash law that a claim including items or services resulting from a violation of
the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (&#8220;FCA&#8221;).
The FCA prohibits individuals or entities from, among other things, knowingly presenting or causing the presentation of a claims payment
to, or approval by, the federal government that are false, fictitious or fraudulent, or knowingly making, using or causing to be made
or used, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money
to the federal government. Our activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting
of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for
our products, and the sale and marketing of our products, are subject to scrutiny under the FCA. State statutes and regulations equivalent
or substantially similar to the federal laws may extend to items and services reimbursed by commercial insurers and/or by patients directly.
State law equivalents to the Anti-Kickback Statute and False Claims Act may not have adopted exceptions and safe harbors available at
the federal level and therefore, may implicate a broader range of activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute,
a scheme to defraud or obtain, by any means of false or fraudulent pretenses, representations or promises, any money or property owned
by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully
falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. The federal physician payment transparency
requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act,&#8221; created under the ACA, and its implementing
regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available
under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program (with certain exceptions) to annually report to the Department
of Health and Human Services (&#8220;HHS&#8221;), information related to certain payments or other transfers of value made or distributed
to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and
teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Under recent
legislation, the Sunshine Act will extend to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level
healthcare providers. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) has the potential to impose penalties for violations
of the Sunshine Act, depending on the circumstances, and payments reported under the Sunshine Act also have the potential to draw scrutiny
on payments to and relationships with physicians and teaching hospitals, which may have implications under the Anti-Kickback Statute and
other healthcare laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also be subject to data privacy and security
regulation by both the federal government and the state governments in which we conduct our business. HIPAA, as amended by the Health
Information Technology and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their respective implementing regulations, imposes, among
other things, obligations, including mandatory contractual terms with respect to safeguarding the privacy, security and transmission of
individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses, known as
covered entities, and business associates. The HHS Office of Civil Rights (&#8220;OCR&#8221;) has increased its focus on compliance and
continues to train state attorneys general for enforcement purposes. Even where HIPAA does not apply, according to the U.S. Federal Trade
Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts
or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act (&#8220;FTCA&#8221;), 15 U.S. Code
&#167;45(a). Medical data is considered sensitive data that merits stronger safeguards. There are numerous other laws and legislative
and regulatory initiatives at the federal and state levels addressing privacy and security concerns, and some state privacy laws apply
in broader circumstances than HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the U.S. Foreign Corrupt Practices
Act (&#8220;FCPA&#8221;), which prohibits corporations and individuals from engaging in certain activities to obtain or retain business
or to influence a person working in an official capacity. Our present and future business has been and will continue to be subject to
various other laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Human Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, we had 49 full-time employees,
17 of whom have Ph.D. or M.D. degrees and 22 of whom are engaged in research and development and clinical development activities. We believe
that we have been successful to date in attracting skilled and experienced personnel despite the competitive hiring marketing in the industry.
Our employees are not covered by a collective bargaining agreement, and we believe that our relationship with our employees is excellent.
We continue to engage external consultants on an as-needed basis to temporarily supplement existing staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated under the laws of the State
of Delaware in 2013. Our principal executive offices are located at 275 Madison Avenue, New York, NY 10016, and our telephone number is
(646) 677-3870. Our website address is www.actiniumpharma.com. The information contained on our website or that can be accessed through
our website is not considered part of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We make available free of charge through our website
our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any such amendments to those reports
as soon as reasonably practicable after we electronically file such material with or furnish such material to the Securities and Exchange
Commission (&#8220;SEC&#8221;). The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements
and other information regarding companies that file electronically with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1A. RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>In analyzing our company,
you should consider carefully the following risk factors, together with all of the other information included in this Annual Report on
Form&#160;10-K. Factors that could cause or contribute to differences in our actual results include those discussed in the following
subsection, as well as those discussed below in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; and elsewhere throughout this Annual Report on Form&#160;10-K. The following are material factors that make an investment
in our company speculative or risky. The risks and uncertainties described below are not the only ones we face. Additional risks not
currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair
our business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are providing the following
summary of the risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor
disclosures. We encourage you to carefully review the full risk factors contained in this Annual Report on Form 10-K in their entirety
for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks
and uncertainties include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical-stage company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to obtain additional financing, we will be unable to continue
or complete our product development or product commercialization and you will likely lose your entire investment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on the success of Iomab-B and the SIERRA trial and we may not be able to complete the necessary clinical development or our development efforts may not result in the data necessary to receive regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not demonstrated that any of our products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary, Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of
the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations;&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently depend on a single third-party manufacturer to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturer, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent position is highly uncertain and involves complex legal and factual questions.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on our key personnel, and the demand for&#160;talent in the biotechnology industry is highly competitive; if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement or execute our business strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical-stage company and have
generated no revenue from commercial sales to date. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product
sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If
we do not address these risks successfully, our business will suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred net losses in every year
since our inception and anticipate that we will continue to incur net losses in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not profitable and
have incurred losses in each period since our inception. As of December 31, 2022 and December 31, 2021, we had an accumulated deficit
of $288.8 million and $255.7 million, respectively. We reported a net loss of $33.0 million and $24.8 million for the years ended December
31, 2022 and 2021, respectively. We expect to continue to operate at a net loss as we continue our research and development efforts, continue
to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that the
products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can be no assurance that
if such products are approved, they will be successfully commercialized, which would have an adverse effect on our business prospects,
financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be more than sufficient to fund our planned operations for more than 12 months following
the date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required
to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred
cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms or indeed on any terms.
In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may cause the generation of
a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability to finance on favorable
terms or indeed on any terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock.
We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal
to or greater than the price per share paid by investors, and investors purchasing shares or other securities in the future could have
rights superior to existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical
studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights
to future product candidates or certain major geographic markets. We may further have to license our technology to others. This could
result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of funding we will
need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope
of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary
to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative,
licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited access to the capital markets
and even if we can raise additional funding, we may be required to do so on unfavorable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited access to
the capital markets to raise funds. The capital markets have been unpredictable in the recent past for radioisotope and other oncology
companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage companies to raise capital
under current market conditions. The amount of capital that a company such as ours is able to raise often depends on variables that are
beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at all. If we are able to consummate
a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds are not available on acceptable
terms, or at all, our business, including our technology licenses, results of operations, financial condition and our continued viability
will be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the success of
Iomab-B and the SIERRA trial and we may not be able to complete the necessary clinical development or our development efforts may not
result in the data necessary to receive regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have completed patient
enrollment in the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML), a 153-patient multi-center randomized
trial that will compare outcomes of patients who receive Iomab-B and a BMT to those patients receiving physician&#8217;s choice of salvage
chemotherapy, defined as conventional care, as no standard of care exists for this patient population. We have announced that Iomab-B
met the primary endpoint of dCR in the SIERRA trial with statistical significance (p&lt;0.0001). The SIERRA trial may be unsuccessful
and fail to demonstrate a safety and efficacy profile that is necessary to receive favorable regulatory approval. Even if Iomab-B receives
favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations.
Any or all of these factors could have a material adverse impact on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to establish sales, marketing
and commercial supply capabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates become approved, we would have to
build and establish these capabilities in order to commercialize our approved product candidates. The process of establishing commercial
capabilities will be expensive and time consuming. Even if we are successful in building sales and marketing capabilities, we may not
be successful in commercializing any of our product candidates. Any delays in commercialization or failure to successfully commercialize
any product candidate may have material adverse impacts on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business could be adversely affected
by the effects of health epidemics, including the global COVID-19 pandemic.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global health crisis caused
by the novel coronavirus COVID-19 pandemic and its resurgences has and may continue to negatively impact global economic activity, which,
despite vaccination efforts, remains uncertain and cannot be predicted with confidence. In addition, highly transmissible new variants
of COVID-19 have spread globally. The full impact of such variants cannot be predicted at this time, and could depend on numerous factors,
including vaccination rates among the population, the effectiveness of COVID-19 vaccines and boosters against the COVID-19 variants and
the response by governmental bodies and regulators. Given the ongoing and dynamic nature of the circumstances, it is difficult to predict
the impact of the COVID-19 pandemic on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many countries around the
world have imposed quarantines and restrictions on travel and mass gatherings and could reinstitute such policies in response to future
COVID-19 outbreaks. In such a scenario, our ability to continue to operate our business may also be limited. Such events may result in
a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect
our business, financial condition and results of operations. In response to COVID-19, we implemented hybrid working for our office-based
staff, while our research staff has been actively working in our laboratory throughout the pandemic and thus far have not experienced
a significant disruption or delay in our operations as it relates to the clinical development, preclinical development of manufacturing
of our drug candidates. Although we are adhering to health and safety protocols, an outbreak of COVID-19 at our facilities could nonetheless
cause shutdowns of facilities and a reduction in our workforce, which could cause a disruption or delay in such operations. New outbreaks
may further divert the attention and efforts of the medical community to coping with COVID-19, and may disrupt the marketplace in which
we operate and may have a material adverse effect on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital,
which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of
COVID-19 could materially affect our business and the value of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our earlier
stage CD33 clinical trials will continue to recruit and enroll patients given the acute nature of relapsed or refractory AML. The
continuation of the pandemic could adversely affect our planned clinical trial operations, including our ability to conduct the
trials on the expected timelines and recruit and retain patients and principal investigators and site staff who, as healthcare
providers, may have heightened exposure to COVID-19 if their geography is impacted by the pandemic. Further, the continuation and/or
resurgence of the COVID-19 pandemic could result in delays in our clinical trials due to prioritization of hospital resources toward
the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials at this time, or the inability of
patients to comply with clinical trial protocols if quarantines or travel restrictions are reinstated that impede patient movement
or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and
other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and
clinical trials, and the pandemic may affect their ability to devote sufficient time and resources to our programs or to travel to
sites to perform work for us, which may result in delays or hinder our ability to collect data from our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19 may
result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&#8217;s
or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to monitor
the impacts of COVID-19 on the global economy and on our business operations. However, the ultimate impact from COVID-19 on our
business operations and financial results during 2023 will depend on, among other things, the ultimate severity and scope of the
pandemic, including the new variants of the virus, and whether governmental and private travel restrictions and public concerns
about public gatherings are reinstated. We are not able to fully quantify the impact that these factors had on our financial
results during 2022 and will have in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to cybersecurity
risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks and
cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility
outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems are maintained,
repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">theft or misappropriation of funds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data or employee data);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption or impairment of our and our business operations and safety procedures;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to our reputation with our potential partners, patients and the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased costs to prevent, respond to or mitigate cybersecurity events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers, and
others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have cybersecurity insurance
coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that it will be sufficient to cover
any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Regulation&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seeking regulatory
approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the effort and expense
incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products from the FDA, we may never
be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution
of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval. The BLA process is costly, lengthy
and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including, but not limited to, technical, preclinical,
clinical trial, chemistry, manufacturing and controls (&#8220;CMC&#8221;) and labeling data, to demonstrate to the FDA&#8217;s satisfaction
the safety and efficacy of the product for its intended use. The lengthy approval process as well as the unpredictability of future clinical
trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm
our business, results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve
any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for
our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate
with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.
Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2012, we acquired
rights to apamistamab, a clinical stage anti-CD45 monoclonal antibody with safety and efficacy data in more than 300 patients in need
of a BMT. Iomab-B is our product candidate that links I-131 to apamistamab that is being studied in the pivotal Phase 3 SIERRA trial.
Product candidates utilizing apamistamab would require BLA approval before they can be marketed in the United States. We are also evaluating
Iomab-ACT, which uses a lower dose I-131 for lymphodepletion prior to CAR-T or adoptive cell therapy. We are currently evaluating clinical
trials that would use our construct for lymphodepletion. Our CD33 Alpha program studying Actimab-A (lintuzumab-Ac-225) product candidate
is also being studied in several Phase 1 trials under our sponsorship and investigator-initiated trials in patients with r/r AML. Product
candidates utilizing the lintuzumab antibody would require BLA approval before they can be marketed in the United States. We are in the
early stages of evaluating other product candidates consisting of conjugates of Ac-225 with human or humanized antibodies for pre-clinical
and clinical development in other types of cancer. The FDA may not approve these products for the indications that are necessary or desirable
for successful commercialization. The FDA may fail to approve any BLA we submit for new product candidates or for new intended uses or
indications for approved products or future product candidates. Failure to obtain FDA approval for our products in the proposed indications
would have a material adverse effect on our business prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other
resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition, even if we
obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA
or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and cash
flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited. Additionally, even
if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications that we
request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful
commercialization or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not demonstrated that any of our
products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development
before any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated biological
product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval, and commercialization
of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval is received. The research,
testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product candidates are, and will remain,
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, as applicable. We
are currently not permitted to market any of our current or future product candidates in the United States until we receive FDA approval
(of each) via the BLA process. To date, we have two product candidates in clinical development and have not-yet submitted a BLA for any
of our candidates and, for many such candidates, do not expect to be in a position to do so for the foreseeable future, as there are numerous
developmental steps that must be completed before we can prepare and submit a BLA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical and biological product candidates under the FDCA and the Public Health Service Act (&#8220;PHSA&#8221;),
as well as their respective implementing regulations. Such products and product candidates are also subject to other federal, state, and
local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal,
state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. The process required
by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical laboratory tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;), which must become effective before human clinical trials in the United States may begin;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with cGMPs and assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval, or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate.
The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND
is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding
the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological
product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical
hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure
that submission of an IND will result in the FDA allowing clinical trials to begin or that, for those that have already commenced under
an active IND, that issues will not arise that suspend or terminate such trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be
conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement that
all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in subjects.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of clinical
trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial
waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept
the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before approving a BLA, the FDA
will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical
trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant
must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and
deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product candidates
or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in
part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed endpoints for
any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also lengthy and
requires substantial time and effort.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2015, the FDA
cleared our IND filing for Iomab-B and we have completed patient enrollment of a randomized, controlled, pivotal Phase 3 clinical trial
under such IND to study Iomab-B in patients 55 years of age or older with relapsed or refractory AML. The Phase 3 SIERRA trial met its
primary endpoint with high statistical significance with positive results for secondary endpoints and exploratory endpoints and it is
expected to form the basis for a BLA for Iomab-B for use in preparing and conditioning AML patients for a BMT. Additionally, there are
physician IND trials at the FHCRC that have been conducted or are currently ongoing at FHCRC with Iomab-B (for other target indications)
and the apamistamab antibody (formerly known as BC8) we licensed. We have other clinical trials ongoing and others that we have planned
but not-yet commenced, for our other drug candidate Actimab-A under our own sponsorship and investigator-initiated trials ongoing. Except
for Iomab-B (for patients with AML), we expect that the clinical trials we need to conduct to be in a position to submit BLAs for our
product candidates currently in-development will take, at least, several years to complete. Moreover, failure can occur at any stage of
the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Also, the results of early preclinical
and clinical testing may not be predictive of the results of subsequent clinical trials. A number of companies in the biopharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier studies. And, preclinical and clinical data are often susceptible to multiple interpretations and analyses.
Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have, nonetheless,
failed to obtain marketing approval of their products. Success in preclinical testing and early clinical trials does not ensure that later
clinical trials, which involve many more subjects, and the results of later clinical trials may not replicate the results of prior clinical
trials and preclinical testing. Any failure or substantial delay in our product development plans may have a material adverse effect on
our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay, suspend,
or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could delay or disrupt
the clinical development of our product candidates and potentially cause our product candidates to fail to receive regulatory approval:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving, or the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients into clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we or they
believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs based on similar technologies,
are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal factors related to toxicity, clinical
efficacy, imbalances in safety and efficacy profiles or for other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result in
perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation of the
study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of clinical
data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for
and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB (Data Safety Monitoring
Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation of data by the FDA or similar foreign regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modifications to our product candidates
may require federal approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United
States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products may require
additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket approvals before
we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.
If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects, financial
condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials necessary to support approval
of our product candidates are time-consuming and expensive. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initiating and completing
clinical trials necessary to support FDA approval of a BLA for Iomab-B, Actimab-A, and other product candidates, is a time-consuming and
expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not necessarily predictive
of future results, and any product candidate we advance into clinical trials may not have favorable results in later clinical trials.
We worked with the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with relapsed or refractory
AML who are age 55 and above prior to a BMT. This trial is designed to support a BLA filing for marketing approval by the FDA. In addition
to clinical data, a BLA filing encompasses preclinical, CMC, labeling and other information. Even if the clinical data from the SIERRA
trial is positive, there can be no assurances that the BLA filing we produce will meet all of the FDA&#8217;s requirements or that they
will not request additional information or studies, which may delay the FDA&#8217;s review or we may not be able to produce. We have also
worked with the FDA to develop a regulatory pathway for lintuzumab-Ac-225 in patients with high-risk MDS that consists of a dose-confirming
Phase 1 trial that can be followed by a randomized, controlled pivotal trial that could support a BLA filing. To date, we have not initiated
this clinical trial and we may never elect or be able to do so. There can be no assurance that the data generated during the trial, or
any trial, will meet our chosen safety and effectiveness endpoints or otherwise produce results that will eventually support the filing
or approval of a BLA. Even if the data from this trial are favorable, the data may not be predictive of the results of any future clinical
trials.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preliminary, Interim, and &#8220;top-line&#8221;
data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject
to audit and verification procedures that could result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;From time to time, we
may publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary analysis of then-available
data, and the results and related findings and conclusions are subject to change as more patient data become available or following a
more comprehensive review of the data related to the particular study or trial. For example, in October 2022 we announced that Iomab-B
met the primary endpoint of dCR in the SIERRA trial with statistical significance (p&lt;0.0001). We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully
evaluate all data. Our clinical trials may be open label studies and certain of our clinical development and or operations staff may review
interim or preliminary safety or efficacy data during routine data collection, cleaning and analysis from time to time. Interim or preliminary
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results once additional data have been received and fully evaluated. Preliminary, interim or top-line data also remain subject to audit
and verification procedures that may result in the final data being materially different from the top-line, interim or preliminary data
we previously published. As a result, top-line, interim and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are
subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data
become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure
of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or
weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the interim, top-line or
preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our clinical trials may fail to demonstrate
adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our clinical trials
are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign
authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure
that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials
and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the
proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, Actimab-A, or any other product candidate for which we
might seek approval, have failed to demonstrate safety and effectiveness, we would not receive FDA approval to market that product candidate
in the United States for the indications sought. In addition, such an outcome could cause us to abandon the product candidate and might
delay development of others. Any delay or termination of our clinical trials will delay or preclude the filing of any submissions with
the FDA and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients
enrolled in clinical trials will experience adverse side effects that are not currently part of a product candidate&#8217;s profile.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intellectual property related to antibodies
we have licensed has expired or likely expired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The key patents related to
the humanized antibody, lintuzumab, which we use in our Actimab-A product candidate have expired. It is generally possible that others
may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patent protection covering
alpha particle drug products comprising Ac-225. Our final drug construct, Actimab A, consists of the lintuzumab antibody labeled with
the isotope Ac-225. We currently own issued and pending patents relating to methods of manufacturing Actimab-A, methods of treatment using
Actimab-A and production of the Ac-225 isotope. In addition, we possess trade secrets and know how related to the manufacturing and use
of isotopes. Any competing product based on the lintuzumab antibody is likely to require several years of development before achieving
our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development by others is nevertheless
a possibility that could negatively impact our business in the future. We own 4 issued U.S. patents, 1 issued Canadian patent, 1 issued
European patent (validated as a national patent in several countries) and 1 issued Japanese patent that relate to the composition of our
Iomab-B product candidate. Patent applications relating to Iomab-B are also pending in the U.S. and internationally. We have and may continue
to file patents related to Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or
such granting thereof will adequately prevent others from seeking to replicate and use the apamistamab antibody or the construct. Our
patent portfolio includes pending applications related to radioimmunoconjugate composition, formulation administration, and methods of
use in treating solid or liquid cancers. This subject matter includes composition, administration, and methods of treatment for our product
candidates Actimab-A and Iomab-B. Any competing product based on the antibody used in Iomab-B is likely to require several years of development
before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development
by others is nevertheless a possibility that could negatively impact our business in the future.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our CD33 program clinical trials are testing
the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CD33 program is comprised
of several clinical trials including investigator-initiated trials in AML that are studying the same drug construct consisting of lintuzumab-Ac-225.
Negative results from any of these trials could negatively impact our ability to enroll or complete our other trials studying lintzumab-Ac-225.
Additionally, negative outcomes including safety concerns, may result in the FDA discontinuing other trials utilizing lintuzumab-Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iodine-131 is a key component
of our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global manufacturers.
Currently, there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131 and for commercialization
of Iomab-B. We continually evaluate I-131 manufacturers and suppliers and intend to have multiple qualified suppliers prior to the commercial
launch of Iomab-B. While we consider I-131 to be commoditized and obtainable through several suppliers, there can be no guarantee that
we will be able to secure I-131 or obtain I-131 on terms that are acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium-225 is a key component
of our Actimab-A product candidate, technology platform, preclinical R&amp;D programs and other drug candidates that we might consider
for development with the Ac-225 payload. There are adequate quantities of Ac-225 available today to meet our current needs via our present
supplier, the Department of Energy (&#8220;DOE&#8221;). The Ac-225 currently supplied to Actinium&#8217;s clinical trials from the DOE
is derived from the natural decay of thorium-229 from so-called &#8216;thorium-cows&#8217; and is able to produce sufficient quantities
that are several multiples of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase.
The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currently
being evaluated by Actinium. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225 does
not impact labelling efficiency and expected distribution. In accordance with representations made by the DOE, the capacity of Ac-225
from this route is expected to be sufficient to supply all of Actinium&#8217;s pipeline and commercial Ac-225 needs and support new program
expansion by not just Actinium but also other companies that are developing Ac-225 based products. Additional routes of Ac-225 production
are being pursued by the DOE including the generation of new thorium cows and production via a cyclotron. The cyclotron production method
for Ac-225 production leverages Actinium&#8217;s proprietary technology and know-how and presents an additional path towards production
of high-quality Ac-225 at a scale that would be able to satisfy commercial needs. In addition, we are aware of at least ten other government
and non-government entities globally including the U.S., Canada, Russia, Belgium, France and Japan that have, or expect to have ability
to supply Ac-225 or equipment for its production within the timeframes relevant to the potential first commercial approval of our Ac-225-based
drug candidate.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract for supply of
this isotope from the DOE must be renewed yearly, and we renewed our contract to extend through the end of 2023. While we expect this
contract will continue to be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities of medical grade
Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates that we
may develop and would materially harm our business.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to conduct clinical
trials to advance our drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other isotopes we may
choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers are subject to regulations
and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these
standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and could result in delays
in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade
secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity compared to the cyclotron
sourced material in the past, this activity was terminated due to operating cost reasons and we currently do not have experience in manufacturing
medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing capabilities in future. Our inability
to build out and establish our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently
do. However, based on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply
to support our current ongoing clinical trials, current and planned preclinical R&amp;D activities and commercialization should our drug
candidates receive regulatory approval.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility criteria defined in the protocol;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials for similar or alternate therapeutic treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&#8217;s and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, refractory patients,
which several of our trials are enrolling, participating in clinical trials are seriously and often terminally ill and therefore may not
complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related or unrelated
to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in our clinical trials, delays
in patient enrollment will result in increased costs or affect the timing of our planned trials, which could adversely affect our ability
to advance the development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product
candidates on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the course of the
clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification is evaluated.
In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or all of the data generated
by the clinical trial is not usable because the same protocol was not used throughout the trial. This might require the enrollment of
additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval of a product candidate. If
the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial while it evaluates
additional information regarding the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required
approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays
or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in
costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or
result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays
in the completion of our Iomab-B clinical trials would adversely affect our business and prospects and could cause us to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have obtained orphan drug designation
from FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the future,
but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have received
or may receive in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received orphan drug
designation for Iomab-B and Actimab-A for treatment of AML in both the United States and the EU. Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects
fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will
be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation neither
shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory
review or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities
for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such candidates
for the applicable indications due to the uncertainties inherent in the development of novel biologic products. And, an orphan drug candidate
may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product
to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product from
competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the FDA or EMA
can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan drug if the later-approved
drug if deemed clinically superior to the orphan drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may
also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our
product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials
that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker
information. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters or holds on clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage and reimbursement may be limited
or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and
reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly
approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products
are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all or part of the
product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as
a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally
does not occur prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In order to
obtain coverage and reimbursement for these products, we or our commercialization partners may have to agree to a net sales price lower
than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain
or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues
particularly susceptible to any cost containment or reduction efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of
the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable Care Act, for
example, substantially changed the way healthcare is financed by both governmental and private insurers. The Affordable Care Act contains
a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval to commercialize one of our
product candidates in the United States, if ever, and may also affect our operations in ways we cannot currently predict. Affordable Care
Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare programs, reimbursement
changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion of state
Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and fraud and abuse enforcement.
Such changes may impact existing government healthcare programs, industry competition, formulary composition, and may result in the development
of new programs, including Medicare payment for performance initiatives, health technology assessments, and improvements to the physician
quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been significant
judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act since its
enactment. For example, former President Trump issued several Executive Orders and other directives designed to delay the implementation
of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the
Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part of the Affordable Care Act.
While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation the Affordable Care Act have
been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision requiring individuals to purchase
and maintain health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty to zero, beginning in 2019.
In December 2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the Affordable
Care Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded
the case back to the lower court to reassess whether and how such holding affects the validity of the rest of the Affordable Care Act.
The Fifth Circuit&#8217;s decision on the individual mandate was appealed to the U.S. Supreme Court. On June 17, 2021, the Supreme Court
held that the plaintiffs (comprised of the state of Texas, as well as numerous other states and certain individuals) did not have standing
to challenge the constitutionality of the Affordable Care Act&#8217;s individual mandate and, accordingly, vacated the Fifth Circuit&#8217;s
decision and instructed the district court to dismiss the case. As a result, the Affordable Care Act will remain in-effect in its current
form for the foreseeable future; however, we cannot predict what additional challenges may arise in the future, the outcome thereof,
or the impact any such actions may have on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Affordable Care Act, there have been numerous other
Congressional initiatives and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drug products. Pharmaceutical product prices have been the focus of increased scrutiny by the government, including
certain state attorneys general, members of Congress and the United States Department of Justice. State or federal healthcare reform measures
or other social or political pressure to lower the cost of pharmaceutical products could have a material adverse impact on our business,
results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biden administration
also introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory
Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple
source drugs, beginning January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021,
HHS released a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and
sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take
to advance these principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most recently, on August 16, 2022, President Biden signed into law
the&#160;Inflation&#160;Reduction&#160;Act&#160;of 2022 (the &#8220;IRA&#8221;), which, among other provisions, included several measures
intended to lower the cost of prescription drugs and related healthcare reforms. Specifically, the IRA authorizes and directs the Department
of Health and Human Services (the &#8220;DHHS&#8221;) to set drug price caps for certain high-cost Medicare Part B and Part D qualified
drugs, with the initial list of drugs to be selected by September 1, 2023, and the first year of maximum price applicability to begin
in 2026. The IRA further authorizes the DHHS to penalize pharmaceutical manufacturers that increase the price of certain Medicare Part
B and Part D drugs faster than the rate of inflation. Finally, the IRA creates significant changes to the Medicare Part D benefit design
by capping Part D beneficiaries&#8217; annual out-of-pocket spending at $2,000 beginning in 2025. We cannot be sure whether additional
or related legislation or rulemaking will be issued or enacted, or what impact, if any, such changes will have on the profitability of
any of our drug candidates, if approved for commercial use, in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our relationships with customers, health
care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including
administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs
such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and
earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare professionals and
third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any products for which we obtain marketing approval. Federal and state
healthcare laws and regulations that may affect our operations, directly or indirectly, include the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal false claims laws, including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of the covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state laws and regulations, including (among others) state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to comply with applicable
healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under these laws and regulations
are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight (if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws), and the curtailment or restructuring
of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities
with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party payors may not adequately reimburse
customers for any product candidates that we may commercialize or promote, and may impose coverage restrictions or limitations such as
prior authorizations and step edits that affect their use.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products
and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other
third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring
that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage
and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement
may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may
not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining reimbursement approval
for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consuming and
costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products. Moreover,
eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a product that we may commercialize
or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements, or may simply deny coverage altogether.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be
based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change product descriptors, coverage
policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party payors often rely upon Medicare
coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain and maintain coverage
and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our
overall financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with
regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract research organizations,
medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on these third parties for
clinical development activities results in reduced control over these activities. Moreover, the FDA requires us to comply with regulations
and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our
reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable
foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties, meet
expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number
of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative
third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned clinical trials and delayed
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we
cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry
out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory
approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results
and prospects would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The antibodies we use in our targeted radiotherapy
product candidates may be subject to generic competition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any existing
or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our targeted radiotherapy product
candidates. Our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these products pursuant
to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval
of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review
and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity
to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after
the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As
a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the
antibodies that we use, the final constructs of our drug candidates consist of an antibody, radioisotope and in some cases a linker. Therefore,
we do not believe that the final drug product of our candidates can be subject to competition from a biosimilar as outlined in BPCIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may never achieve
market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B, Actimab-A
product and future product candidates that we may develop may never gain market acceptance among physicians, patients and the
medical community. The degree of market acceptance of any of our products will depend on a number of factors, including the actual
and perceived effectiveness and reliability of the product; the results of any long-term clinical trials relating to use of the
product; the availability, relative cost and perceived advantages and disadvantages of alternative technologies; the degree to which
treatments using the product are approved for reimbursement by public and private insurers; the strength of our marketing and
distribution infrastructure; and the level of education and awareness among physicians and hospitals concerning the product.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific
cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with
sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the use of each product candidate
from influential physicians will be essential for widespread market acceptance. Our product candidates are still in the development stage
and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be
obtained. If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use
or continue to use, and hospitals may not purchase or continue to purchase, them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of Iomab-B, Actimab-A
or any of our other product candidates to significantly penetrate current or new markets would negatively impact our business financial
condition and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our third-party
service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial
cost and be a distraction to our management and employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently depend on single third-party
manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party
manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to continue
to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory approval of our product
candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual commercial supply
may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances that might occur
at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing contracts or
new contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity we are
evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners,
however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity and support
our growth plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates require
precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we may engage in
the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals,
delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers
may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing
periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and
other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may elect to build or purchase
a manufacturing facility or facilities in the future to operate for the purposes of manufacturing our own products. We have never built,
owned or operated a manufacturing facility. There can be no assurances that we will be able to successfully accomplish this and in doing
so we may experience delays, cost overruns, or other problems that could seriously hurt our business. Even if we successfully build or
purchase a manufacturing facility, we may not realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on vendors with
specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered into manufacturing
and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the exclusive manufacturer and
supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply with required regulations
or breach their contractual obligations it may be difficult, or we may be unable to identify suitable alternative third-party manufacturers.
While we identify and evaluate third-party manufacturers from time to time, even if we do identify suitable alternative third-parties,
we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there can be no assurance that we can successfully
complete technology transfer and development work necessary or complete the necessary work in a timely manner. Any of which could prevent
us from commencing manufacturing with third-parties which could cause delays or suspension of our clinical trials and pre-clinical work
that may have a negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or
any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either
ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers
to consistently supply quality product when required would have a material adverse effect on our ability to develop or commercialize our
products. We have faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such
delays and risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company,
including delays in clinical trials.&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other regulatory
agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party
specialized manufacturers to produce commercial quantities of approved products. These manufacturers may not be able to successfully increase
the manufacturing capacity for any approved product in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. Scale-up for commercial product may require financial commitment
or investment by us, which we may not have sufficient capital for or may elect not to undertake. If third party manufacturers are unable
to successfully increase the manufacturing capacity for a product candidate, or we are unable to establish our own manufacturing capabilities,
the commercial launch of any approved products may be delayed or there may be a shortage in supply, which in turn could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure
and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for
or market our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have conflicts with
our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation
of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during
our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our best interests.
Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization
of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner to pay us milestone
payments or royalties we believe are due under a collaboration; uncertainty regarding ownership of intellectual property rights arising
from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the partner to
cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the
part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure
of the results of those activities; initiating litigation or alternative dispute resolution options by either party to resolve the dispute;
or attempts by either party to terminate the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we are unable to establish
U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates,
we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval.
In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with
technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming
and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the commercialization
of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with
third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution
systems or in lieu of our own sales force and distribution systems. In particular, we have and expect to continue to partner with third
parties to commercialize Iomab-B outside the United States. In April&#160;2022, we entered into a licensing agreement with Immedica, in
which Immedica acquired the product rights for commercialization of Iomab-B for certain territories outside the U.S. If we are unable
to enter into or maintain such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize
any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If
we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties,
our future product revenue will suffer and we may incur significant additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other
biotechnology and pharmaceutical companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates face,
and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic and research
institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii)
emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with
our product candidates and technologies. Because several competing companies and institutions have greater financial resources than us,
they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D,
and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially
greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing
and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our product candidates
receives marketing approval, as greater numbers of patients use a product following its approval, an increase in the incidence of side
effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result
in a number of potentially significant negative consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw their approval of the product;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may elect, or we may be required, to recall or withdraw product from the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or could harm or
prevent sales of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon securing and protecting critical
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of
development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial
versions of these product candidates will incorporate proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our patent position is highly uncertain
and involves complex legal and factual questions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our licensors might
not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors
might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative
technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially
viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and,
we may not develop additional proprietary technologies that are patentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, our owned and
licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection for the
full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors have
applied for and will continue to apply for patents for certain products and methods. Such applications may not result in the issuance of any
patents, and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore,
it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred
competitive position because of such patents, such preferred position would be lost. If we are unable to secure or to continue to
maintain a preferred position, we could become subject to competition from the sale of generic products. Failure to receive,
inability to protect, or expiration of our patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies
that we license from third parties, or subsequent related filings, would adversely affect our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such enforcement
is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further, such litigation
can go on for years and the time demands could interfere with our normal operations. There has been substantial litigation and other proceedings
regarding patent and other intellectual property rights in the pharmaceutical industry. We may become a party to patent litigation and
other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial. Some of our competitors
may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources.
Litigation may also absorb significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although
we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of
confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may
not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access
to, the same or similar information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may
be terminated, and we may be unable to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found to be infringing on patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the
development or sale of our products, and/or pay damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others,
or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases
that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other
persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the
affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.
Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved
in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to infringement
or other intellectual property claims against us, we may become a party to other patent litigation or proceedings before regulatory agencies,
including post-grant review, inter parties review, interference or re-examination proceedings filed with the U.S. Patent and Trademark
Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our patent rights or the patent rights
of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings
can be substantial and the outcome can be uncertain. An adverse determination in these proceedings could weaken or invalidate the patent
claims that cover our technology, which adverse determination could harm our business significantly and dissuade companies from collaborating
with us or permit third parties to directly compete with the same technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to protect and enforce our patents
does not guarantee that we will secure the right to commercialize our patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.
This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using its invention.
While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention where other permissions
may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriate authorization from the
FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented itself, cannot be commercialized
if it infringes the valid patent rights of another party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on confidentiality agreements to
protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our
competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets that
we seek to protect through numerous measures, including non-compete and confidentiality agreements with our employees and other parties.
If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. Any remedies
that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we
may have to expend resources to protect our interests from possible infringement by others. For instance, we learned that a former employee,
Qing Liang, Ph.D., who was employed by Actinium in the position of Vice President, Head of Radiation Sciences, violated the non-compete
provision of her employment agreement by working for a direct competitor. Dr. Liang, who had access to materials containing proprietary
information and trade secrets, is no longer employed by the direct competitor (who terminated her employment after learning of her actions).
With the assistance of outside counsel and a forensic investigator, we also identified that Dr. Liang downloaded confidential information
prior to the end of her employment with Actinium. We petitioned for and were granted a Stipulated Preliminary Injunction by the Supreme
Court of the State of New York, New York County (Index No. 656841/2022) that ordered that Dr. Liang be enjoined from destroying or deleting
any Actinium documents or information, enjoined from using, transmitting or transferring any Actinium Information (as defined in the injunction)
other than to her counsel or Actinium&#8217;s counsel, ordered to return all Actinium information within 5 days of the Stipulated Preliminary
Injunction, ordered to disclose to Actinium, under oath, all persons and devices to whom she transferred or disclosed Actinium Information,
and ordered to allow a qualified forensic examiner selected by Actinium to remove and permanently delete all Actinium Information from
any electronic devices, systems, email accounts, or other electronic or physical storage sites belonging to Dr. Liang. We also filed an
arbitration proceeding against Dr. Liang and we intend to enforce the terms of her employment agreement, especially the non-compete and
confidentiality provisions, to the fullest extent of our ability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to expand our development and
regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to experience significant
growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory
affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that are potentially able to obtain
regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales,
distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we
may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales or
marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be
expensive and time consuming and will require significant attention of our executive officers to manage. We will also have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of
any of our product candidates that we obtain approval to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To manage our anticipated
future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may
divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans
or disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us
to liability for claims arising from the use or misuse of these materials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials,
such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among
other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the
risk of contamination or injury from these materials and we could be held liable for any damages that result, which could exceed our financial
resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future claims
may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs
of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of waste
disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our research,
development, production and commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not have any
international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves
inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in
regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to experience any
of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition
may suffer and cause us to reduce or discontinue our international development and registration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future operations and
successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon
to manage our business. If any member of our current senior management terminates his or her employment with us and we are unable to find
a suitable replacement quickly, the departure could have a material adverse effect on our business. An overall tightening and increasingly
competitive labor market has been observed in the U.S. employment market generally, especially in response to the COVID-19 pandemic. Specific
to the biotechnology industry in which we operate, there is significant demand and competition for highly specialized talent that we require.
A sustained labor shortage or increased turnover rates within our employee base, caused by the COVID-19 pandemic, as a result of general
macroeconomic factors, or due to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract
and retain employees, and could negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development
and potential regulatory and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level,
or if mitigation measures we may take to respond to a decrease in labor availability, have unintended negative effects, our business could
be adversely affected. An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, caused by the COVID-19
pandemic, general macroeconomic factors or as a result of biotechnology industry dynamics could have a material adverse impact on our
operations, results of operations, liquidity or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. This activity is likely to create additional demands on the time and attention of our senior management personnel as they identify,
hire, and train external and internal candidates to fill the sizable number of positions required to execute our business plans, including
submitting a BLA and building a commercial organization. The market for talent in our industry is very competitive. Many of the other
biopharmaceutical companies we compete against for qualified personnel have greater financial and other resources, more favorable risk
profiles and a longer operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities
and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have
to offer. There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing
professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on us. Failure to establish
and maintain an effective management team and workforce could adversely affect our ability to operate, grow and manage our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Managing our growth as we expand operations
may strain our resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to need to grow
rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates as well
as potential commercial operations, which will place a significant strain on our financial, managerial and operational resources. In order
to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.
Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our
expenses and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm
our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expand our business through the acquisition
of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
ownership interests in our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so. Acquisitions
involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt
and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business
concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key
employees of the acquired companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired products,
businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business
or companies may require a substantial capital investment by us. We may not have these necessary funds, or they might not be available
to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute
each current stockholder&#8217;s ownership interest in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional capital
through the sales of stock and warrants in order to expand our level of operations to continue our research and development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any sale of common stock by
us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional shares
of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing strategic relationships
with targeted customers and vendors. In order to do so, or to finance the cost of our other activities, we may issue additional equity
securities that could dilute our stockholders&#8217; stock ownership. We may also assume additional debt and incur impairment losses related
to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our common stock is subject to price volatility
which could lead to losses by stockholders and potential costly security litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading volume of our
common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to fluctuate
substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating
results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and
the financial markets or other developments affecting our competitors or us. This volatility has had a significant effect on the market
price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of our common
stock may be highly volatile and could fluctuate in response to factors such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our operating results;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of developments by us or our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions regarding our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting standards affecting our industry;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products by us or our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock or other securities in the open market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">inaccurate or unfavorable reports from securities or industry analysts; and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market is subject
to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities
class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful, could
result in substantial costs and diversion of our management&#8217;s attention and our resources, which could harm our business and financial
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock, so any returns will be determined by the value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. As a result, the
success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common
stock will appreciate in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain provisions of our Certificate of
Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to
complete, even if such a transaction were in our stockholders&#8217; interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our
stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock.
Among other things, the certificate of incorporation and bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that the authorized number of directors may be changed by resolution of the board of directors; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide the board of directors into three classes; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&#8217;s notice; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own,
15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with the reporting requirements
of federal securities laws can be expensive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the
preparation of registration statements and related documents with respect any offerings of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to utilize our
federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code.&#160;The limitations apply if we experience an &#8220;ownership change&#8221;, generally defined as a greater
than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period.&#160;Similar
provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred.&#160;If we
have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize
our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership,
which may be outside of our control, may trigger an ownership change and, consequently, the limitations under Sections 382 and 383 of
the Code.&#160;As a result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards
and other tax attributes to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal
controls requirements for publicly traded companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we operate
in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary
for us to produce reliable financial reports and are important to help prevent financial fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. We complied
with Section 404 at December 31, 2022 and 2021 and while our testing did not reveal any material weaknesses in our internal controls,
any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner so as to be able to
comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner
each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities which would require
additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose
confidence in our reported financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Multiple
securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish inaccurate or
unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause the price of our common
stock and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated&#160;bylaws, as
amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated&#160;bylaws,
as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities
Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing or otherwise acquiring
any interest in our security shall be deemed to have notice of and to have consented to such provision. Such choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits, if successful, might benefit our stockholders. Stockholders who do bring
a claim in the federal district courts of the United States of America could face additional litigation costs in pursuing any such claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>
</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1B. UNRESOLVED STAFF COMMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. PROPERTIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not own any real property.
We have leased offices at 275 Madison Avenue, New York, NY for seven years and our long-term lease for this space expired in 2022. We
entered into a short-term lease for the same space until April 2023 with a monthly rate of $53 thousand. We are also responsible for certain
other costs, such as insurance and maintenance. We issued a letter of credit of $391 thousand in connection with the lease and maintain
a $391 thousand certified deposit as collateral for the letter of credit.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a lease for
corporate office space at 100 Park Avenue, New York, NY effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration
date in 2027, and a current annual rate of $599 thousand. We are also responsible for certain other costs, such as insurance, taxes, utilities
and maintenance. We issued a letter of credit of $299 thousand in connection with the lease and maintain a $299 thousand certified deposit
as collateral for the letter of credit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease lab space and office
space at Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY. The lease has a term of twelve months, expiring August
31, 2023, with a current annual rate of $136 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. LEGAL PROCEEDINGS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. We are currently not
aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business,
financial condition or operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON
EQUITY, RELATED STOCKHOLDERS MATTERS, AND ISSUER PURCHASE OF EQUITY SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
for quotation on the NYSE American under the symbol &#8220;ATNM&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2023, there
were 25,729,370 shares of common stock issued and outstanding, which were held by approximately 100 holders of record. There are no shares
of preferred stock outstanding.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have never declared or paid
any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. The decision to
pay dividends is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, capital
requirements, and other factors that our Board of Directors deems relevant.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Authorized for Issuance under Equity
Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have three equity
compensation plans defined as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s 2019 Amended
and Restated Stock Plan has an expiration date of October 18, 2029 and the number of shares of our common stock authorized under the plan
for grant to employees, directors and consultants is 9,333,333 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s 2013 Amended
and Restated Stock Plan has an expiration date of September 9, 2023 and after a number of amendments approved by stockholders, the number
of shares of our common stock authorized under the plan for grant to employees, directors and consultants is 758,333 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s 2013 Equity
Incentive Plan has an expiration date of September 9, 2023 and the number of shares of our common stock authorized under the plan for
grant to employees, directors and consultants under the plan is 33,333 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table indicates
shares of common stock authorized for issuance under our equity compensation plans as of December 31, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Plan category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> securities&#160;to<br/> be&#160;issued<br/> upon&#160;exercise<br/> of&#160;outstanding<br/> options and restricted stock units<br/>
(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> exercise<br/> price&#160;of<br/> outstanding<br/> options and restricted <br/>
stock units<br/>
 (2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> securities<br/> remaining<br/> available<br/> for&#160;future<br/> issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,721,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,383,638</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,721,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,383,638</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes shares issuable upon the conversion of outstanding restricted stock units (&#8220;RSUs&#8221;).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left">(2)</td><td style="text-align: justify">The Weighted Average Exercise Price column does not include an
amount for outstanding RSUs.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. RESERVED.</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The information and financial
data discussed below is derived from the audited consolidated financial statements of Actinium Pharmaceuticals, Inc. for its fiscal years
ended December 31, 2022 and 2021.&#160;The consolidated financial statements of Actinium Pharmaceuticals, Inc. were prepared and presented
in accordance with generally accepted accounting principles in the United States. The information and financial data discussed below is
only a summary and should be read in conjunction with the historical financial statements and related notes of Actinium Pharmaceuticals,
Inc. contained elsewhere in this&#160;Report. The financial statements contained elsewhere in this Report fully represent Actinium Pharmaceuticals,
Inc.&#8217;s financial condition and operations; however, they are not indicative of the Company&#8217;s future performance. See &#8220;Cautionary
Note Regarding Forward-Looking Statements&#8221; above for a discussion of forward-looking statements and the significance of such statements
in the context of this Report.&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals,
Inc. is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and clinical experience to develop novel
targeted radiotherapies for patients with unmet needs. Our targeted radiotherapies combine the cell-killing ability of radiation via a
radioisotope payload with a targeting agent, such as a monoclonal antibody, to deliver radiation in a precise manner inside the body to
specific, targeted cells such as cancer cells, to potentially achieve greater efficacy with lower toxicity than with cytotoxic chemotherapy
or external beam radiation. Targeted radiotherapies also enable broader application of radiation than external beam radiation as they
can be used in the treatment of both solid tumors and blood cancers, which generally cannot be treated with external radiation given their
diffuse nature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations &#8211; Year Ended December
31, 2022 Compared to the Year Ended December 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>(amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,030</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,144</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(114</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,030</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,144</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(114</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,104</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,999</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,077</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,922</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,134</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,026</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,087</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">897</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,087</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">897</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(33,017</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(24,774</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(8,243</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenues for the years ended December 31, 2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We determined that certain
collaborations with a third-party are within the scope of Topic ASC 606, <i>Revenue Recognition from Contracts with Customers, </i>or
ASC 606. The collaboration agreement is made up of multiple modules related to various research activities. While the third party has
the option to terminate the agreement at the conclusion of any module, we identified a single performance obligation to provide research
services within each module for which we receive monetary consideration. The consideration is recognized as revenue over each module and
revenue of $0.9 million was recognized during each of the years ended December 31, 2022 and December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Institutes of
Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration with Memorial Sloan
Kettering Cancer Center, or MSK, to study Iomab-ACT, our CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve
lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. We recognized other revenue during the
years ended December 31, 2022 and 2021 of $0.1 million and $0.2 million, respectively, from this grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, we entered
into a license and supply agreement with Immedica Pharma AB, or Immedica, pursuant to which Immedica licensed the exclusive product rights
for commercialization of Iomab-B in the European Economic Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain,
Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia,
Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, we were entitled
to an upfront payment of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible
to receive regulatory and commercial milestone payments and are entitled to receive royalties in the mid-20 percent range on net sales
of the product in certain countries that may result from the License Agreement. We will continue to be responsible for certain clinical
development activities and the manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our contract liabilities are
recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in our condensed consolidated balance
sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract liabilities primarily consist of
advanced payments from licensees. There was no Other revenue deferred-current liability at December 31, 2022, Other revenue deferred &#8211;
current liability was $1.0 million at December 31, 2021. Long-term license revenue deferred was $35.0 million at December 31, 2022, resulting
from the receipt from Immedica; there was no Long-term license revenue deferred at December 31, 2021. This deferred revenue will be recognized
upon European Union regulatory approval of Iomab B.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses increased by $5.1 million to $23.1
million for the year ended December 31, 2022 compared to $18.0 million for the year ended December 31, 2021. Higher expenses were primarily
due to increased CMC activity related to Iomab-B, as well as increased compensation of $1.0 million resulting from increased headcount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General and Administrative Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses increased by $3.9 million to $12.0 million for the year ended December 31, 2022 compared to $8.1 million for the year ended December
31, 2021. Higher expenses were primarily due to increased compensation of $0.9 million, increased non-cash equity compensation of $1.0
million, higher professional fees and consulting fees including recruitment costs, and higher legal fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. Other income of $1.1 million for the year ended December 31, 2022 increased from $0.2
million for the year ended December 31, 2021 due to a higher average balance and higher interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss increased by $8.2 million to $33.0 million for the year ended
December 31, 2022 compared to $24.8 million for the year ended December 31, 2021, primarily due to higher research and development expenses
and general and administrative expenses, partially offset by other income.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have financed
our operations primarily through sales of our common stock and common stock equivalents. The following tables sets forth selected cash
flow information for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>(amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash provided by/used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,644</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(20,866</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,387</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by operating
activities for the year ended December 31, 2022 of $8.6 million increased by $29.5 million from a use of funds of $20.9 million for the
year ended December 31, 2021. This increase was due to the receipt of the $35.0 million up-front payment from Immedica.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $0.4 million and $0.1 million for the years ended December 31, 2022 and December 31, 2021, respectively, primarily due
to the purchase of equipment for our laboratory space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020 we entered
into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which we
would be able to sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. On June
28, 2022, we entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement, or the Amended Sales Agreement, with JonesTrading
and B. Riley Securities, Inc. The Amended Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement to include B.
Riley as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration statement on Form S-3
filed with the SEC on August 7, 2020. For the year ended December 31, 2022, we sold 3.5 million shares of common stock, resulting in gross
proceeds of $23.9 million and net proceeds of $23.2 million. For the year ended December 31, 2021, we sold 4.6 million shares of common
stock, resulting in gross proceeds of $36.5 million and net proceeds of $35.3 million. As of December 31, 2022, we have sold 10.2 million
shares of common stock, resulting in gross proceeds of $83.0 million and net proceeds of $80.2 million relating to the Sales Agreement,
as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a lease for
corporate office space effective June 1, 2022 and paid a security deposit to the landlord. The lease has a term of 5 years 2 months, with
an expiration date in 2027, and current annual rent of $0.6 million. We are also responsible for certain other costs, such as insurance,
utilities and maintenance. In July 2022, a certificate of deposit was provided as collateral for a letter of credit and the security deposit
was returned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will require additional
funds to conduct clinical and non-clinical trials, achieve regulatory approvals, and, subject to such approvals, commercially launch our
product candidates, and will need to secure additional financing in the future to support our operations. As of the date of filing this
report, we expect that our existing resources will be more than sufficient to fund our planned operations for more than 12 months following
the date of this report. We base this belief on assumptions that are subject to change, and we may be required to use our available cash
and cash equivalent resources sooner than we currently expect. Our actual future capital requirements will depend on many factors, including
the progress and results of our ongoing clinical trials, the duration and cost of discovery and preclinical development, laboratory testing
and clinical trials for our pipeline candidates, the timing and outcome of regulatory review of our product candidates, the costs involved
in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the number
and development requirements of other pipeline candidates that we pursue, and the costs of commercialization activities, including product
marketing, sales, and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to operate
at a net loss as we continue our research and development efforts, continue to conduct clinical trials and develop manufacturing, sales,
marketing and distribution capabilities. There can be no assurance that the products under development by us will be approved for sale
in the United States or elsewhere. Our ability to obtain additional capital may depend on prevailing economic conditions and financial,
business, and other factors beyond our control. Current economic conditions have been, and continue to be, volatile. Continued instability
in these market conditions may limit our ability to access the capital necessary to fund and grow our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any off-balance
sheet arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion
and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of
contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored and
analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our
estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may
differ materially from these estimates under different assumptions or conditions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurement </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the
price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants.
A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for
identical assets or liabilities and the lowest priority to unobservable inputs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize revenue in accordance
with ASC 606. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects
the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements
within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue as we satisfy a performance obligation. We only apply
the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the
goods or services we transfer to the customer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, we assess whether the promised goods or services promised within each contract
are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not to be distinct
are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods or services are
distinct, we evaluate certain criteria, including whether (i)&#160;the customer can benefit from the good or service either on its own
or together with other resources that are readily available to the customer (capable of being distinct) and (ii)&#160;the good or service
is separately identifiable from other goods or services in the contract (distinct in the context of the contract).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires us to allocate
the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction
price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling
price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer.
We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation as each performance
obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input
method.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We follow the accounting guidance
for collaboration agreements, which requires that certain transactions between us and collaborators be recorded in our consolidated statements
of operations on either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced
disclosure of collaborative relationships. We evaluate our collaboration agreements for proper classification in our consolidated statements
of operations based on the nature of the underlying activity. When we conclude that we have a customer relationship with one of our collaborators,
we follow the guidance of ASC 606<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Grant Revenue </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had a grant from a government-sponsored
entity for research and development related activities that provided for payments for reimbursed costs, which included overhead and general
and administrative costs as well as an administrative fee. We recognized revenue from the grant as we performed services under this arrangement.
Associated expenses were recognized when incurred as research and development expense. Revenue and related expenses are presented gross
in the consolidated statements of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Revenue </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a product
licensing agreement whereby we allowed a third party to commercialize a certain product in specified territories using our trademarks.
The terms of this arrangement includes payment to us for a combination of one or more of the following: upfront license fees; development,
regulatory and sales-based milestone payments; and royalties on net sales of licensed products. We use judgment to determine whether milestones
or other variable consideration should be included in the transaction price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement,
we will recognize revenue from upfront license fees allocated to the license when the license is transferred to the licensee and the licensee
is able to use and benefit from the license. For licenses that are bundled with other promises, we determine whether the combined performance
obligation is satisfied over time or at a point in time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, we evaluate whether the milestones are considered probable of being achieved
and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant
revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not
within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until regulatory
approval is received. At the end of each subsequent reporting period, we will re-evaluate the probability of achieving such development
and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such
adjustments are recorded on a cumulative catch-up basis and recorded as part of license revenues during the period of adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, we
will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and if
such is the case, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation
to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements or when it is
probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with
any variable consideration is subsequently resolved. Amounts payable to us are recorded as accounts receivable when our right to consideration
is unconditional.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Costs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are expensed as incurred. These costs include the costs of manufacturing drug components and final drug product, the costs of clinical
trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and equipment. Research
and development reimbursements are recorded by us as a reduction of research and development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Payments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate the fair value
of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the
cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the
award. We account for forfeitures of stock options as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Income Taxes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use the asset and liability
method to calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income
tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
We review deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will
be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon our assessment as to their
realization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize tax when the
positions meet a &#8220;more-likely-than-not&#8221; recognition threshold. There were no tax positions for which it is considered reasonably
possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year. We recognize
interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounting Standards Recently Adopted </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, the Financial
Accounting Standards Board, or FASB, issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s
Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. We adopted this standard effective January 1, 2022 and the standard did not have a material effect
on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB
issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. We adopted this standard effective January 1, 2022 and the standard
did not have a material impact on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Accounting Standards Recently Issued</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In October 2021, FASB
issued ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with
Customers</i>, which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination
in accordance with ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for
the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets
and contract liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The
amendments of ASU 2021-08 are effective January 1, 2023, including interim periods. Early adoption is permitted, including adoption
in an interim period. We will evaluate the impact of ASU 2021-08 on any future business combinations that we may enter in the
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Subsequent Event</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Since December 31, 2022, we
have sold 0.1 million shares of common stock under our Amended Sales Agreement, resulting in net proceeds of $0.8 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i>We are not currently
exposed to significant market risk related to changes in interest rates. As of December 31, 2022, our cash equivalents consisted primarily
of short-term money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the
general level of U.S. interest rates. Due to the short-term nature of the cash equivalents in our portfolio and the low risk profile of
our cash equivalents, an immediate 10% change in interest rates would not have a material effect on the fair market value of our financial
position or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently exposed
to significant market risk related to changes in foreign currency exchange rates. Our operations may be subject to fluctuations in foreign
currency exchange rates in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial
condition, or results of operations during the years ended December 31, 2022 and 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Stockholders and Board of Directors of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actinium Pharmaceuticals, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated
statements of operations, changes in stockholders&#8217; equity and cash flows for each of the two years in the period ended December
31, 2022 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its
operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles
generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical audit matters are matters arising from
the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and
that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <span style="font-variant: small-caps">llp</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorName">Marcum <span style="font-variant: small-caps">llp</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2012<b>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">Houston, Texas</ix:nonNumeric><br/>
March 31, 2023</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.<br/>
Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(amounts in thousands, except share and per share
data)&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">108,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">77,829</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">110,942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">79,749</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">487</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">335</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">604</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted cash &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">2,341</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">241</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">114,192</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">80,388</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">10,130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">5,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other revenue deferred &#8211; current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd">998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">10,628</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">6,840</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="atnm:LongtermOperatingLeaseObligationsNoncurrent" scale="3" unitRef="usd">2,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Long-term finance lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">47,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">6,843</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">25,674,823</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">355,220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">329,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">288,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">255,748</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">66,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">73,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">114,192</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">80,388</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.<br/>
Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other Revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">1,030</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">1,144</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">1,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">1,144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">23,135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">18,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">11,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">8,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">35,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">26,108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">34,104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">24,964</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Interest income - net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">1,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">1,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">33,017</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">24,774</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12">Net loss per common share - basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.37</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.20</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-15; -sec-ix-hidden: hidden-fact-14">Weighted average common shares outstanding - basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">24,141,545</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">20,568,373</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.<br/>
Consolidated Statements of Changes in Stockholders&#8217; Equity<br/>
For the Years Ended December 31, 2022 and 2021<br/>
</b>(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January 1, 2021</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">17,532,893</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">292,275</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">230,974</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">61,319</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares">21,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">1,694</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">1,694</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">4,588,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">35,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">35,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">24,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">24,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, December 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">329,271</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">255,748</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">73,545</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares">19,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">2,795</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">2,795</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">3,511,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">23,154</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">23,158</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">33,017</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">33,017</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,674,823</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">355,220</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">288,765</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd">66,481</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.<br/>
Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">33,017</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">24,774</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">2,795</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">1,694</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Depreciation and amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">158</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">161</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">4,595</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">1,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Other revenue deferred &#8211; current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">998</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd">998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" sign="-" unitRef="usd">272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" sign="-" unitRef="usd">342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Net Cash Provided By/Used In Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" unitRef="usd">8,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">20,866</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows Used in Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">366</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Net Cash Used In Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">366</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">49</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">85</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from sales of shares of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" scale="3" unitRef="usd">23,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" scale="3" unitRef="usd">35,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from the exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Net Cash Provided By Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">23,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">35,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net change in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">31,387</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">14,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash, cash equivalents and restricted cash at beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">78,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">63,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash, cash equivalents and restricted cash at end of year</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">109,608</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">78,221</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Cash paid for taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Right-of-use assets obtained in exchange for lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:RightofuseAssetsObtainedInExchangeForLeaseLiabilities" scale="3" unitRef="usd">2,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Equipment obtained in exchange for security deposit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:AcquisitionOfEquipmentFinancedBySecurityDeposit" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.<br/>
Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:NatureOfBusinessPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business - </b>Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular
level precision to treat patients with high unmet medical needs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.
All significant intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in Financial
Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash and Cash Equivalents
and Restricted Cash-</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
cash, cash equivalents and restricted cash at December 31, 2022 and December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">108,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">77,829</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssetsCurrent" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">109,608</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">78,221</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases of corporate office
spaces.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Property and Equipment
-</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to five
years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years.
When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is
reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets are recorded at the
lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful life of the related property
or term of the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term. The Company entered into a lease for corporate office space effective June 1, 2022 and paid a security deposit
to the landlord. A certificate of deposit was provided as collateral for a letter of credit issued with this office space during 2022
and at that time, the security deposit was returned to the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:GrantRevenuePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenueTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_2" id="atnm_LicenseRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_3" id="atnm_LicenseRevenueTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation continuedAt="atnm_LicenseRevenueTextBlock-c0_cont_4" id="atnm_LicenseRevenueTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="atnm_LicenseRevenueTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Income Taxes -</b> The
Company accounts for income taxes in accordance with ASC 740 <i>Income Taxes</i>, which requires the asset and liability method to calculate
deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income tax bases of assets
and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be
fully realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 740 prescribes guidance
for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meet a &#8220;more-likely-than-not&#8221;
recognition threshold to be recognized. There were no tax positions for which it is considered reasonably possible that the total amounts
of unrecognized tax benefits will significantly increase or decrease within the next year. The Company recognizes interest related to
unrecognized tax benefits in interest expense and penalties in operating expenses</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly to basic
loss per share because the impact of all potential dilutive common shares is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">For the years ended December 31, 2022 and 2021,
the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units and warrants,
have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_29" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">3,396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">1,362</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">1,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,112</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">5,164</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">3,474</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_30" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Subsequent Events </b>-
The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent
event disclosure consideration.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_31" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" continuedAt="atnm_Accountingstandardsrecentlyissuedpolicytextblock-c0_cont_1" escape="true" name="atnm:Accountingstandardsrecentlyissuedpolicytextblock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s
Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard did not have a material
effect on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_32" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation id="atnm_Accountingstandardsrecentlyissuedpolicytextblock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB
issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022,
and the standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Issued Accounting
Pronouncements &#8211; </b>In October 2021, FASB issued ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets
and Contract Liabilities from Contracts with Customers</i>, which provides guidance on accounting for contract assets and contract liabilities
acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606
to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring
the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial
statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods. Early adoption is permitted, including
adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future business combinations the Company may
enter in the future.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Prepaid Expenses and Other Current
Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2" id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and other
current assets consisted of the following at December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd">684</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd">874</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="atnm:PrepaidClinicalTrialExpenses" scale="3" unitRef="usd">887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="atnm:PrepaidClinicalTrialExpenses" scale="3" unitRef="usd">543</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">61</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,636</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,478</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment consisted
of the following at December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lives</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c28" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">476</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office equipment&#160;and furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c31" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c32" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">315</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="3" unitRef="usd">487</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="3" unitRef="usd">335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">604</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">340</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense consisted
of the following for the years ended December 31, 2022 and 2021, respectively:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">88</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">152</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">105</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_LeasesTextBlock-c0_cont_1" escape="true" name="atnm:LeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 - Leases </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_2" id="atnm_LeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines
if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the
right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed
to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_3" id="atnm_LeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_4" id="atnm_LeasesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_5" id="atnm_LeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company entered into a lease
for corporate office space, effective June 1, 2022. The lease has a term of <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription">5 years 2 months</ix:nonNumeric>, with an expiration date on July 30, 2027
and current annual rent of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="6" unitRef="usd">0.6</ix:nonFraction> million. The Company is also responsible for certain other costs, such as insurance, utilities and maintenance.
At December 31, 2022, for capitalization purposes under ASC842, the Company has this operating lease and a finance lease for office equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_6" id="atnm_LeasesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2021, for
capitalization purposes under ASC842, the Company had an operating lease for corporate office space that expired in 2022 and finance leases
for office equipment and furniture located in the corporate office space. In addition, the Company has auxiliary corporate office space
that it rents on a month-to-month basis; this rental was accounted for as an operating lease with the same term as the Company&#8217;s
office space.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_7" id="atnm_LeasesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_8" id="atnm_LeasesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">584</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">372</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">57</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">90</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_9" id="atnm_LeasesTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_10" id="atnm_LeasesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flow information:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">352</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">377</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">49</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">85</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">2,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_11" id="atnm_LeasesTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_12" id="atnm_LeasesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOrDescriptionOfWeightedAverageTerm"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.6</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">1.0</ix:nonNumeric> years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_13" id="atnm_LeasesTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflect the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_14" id="atnm_LeasesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOfWeightedAverageDiscountRate"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">8.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_15" id="atnm_LeasesTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Maturities
of lease liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="atnm_LeasesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" escape="true" name="atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" unitRef="usd">606</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="3" unitRef="usd">618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="3" unitRef="usd">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="3" unitRef="usd">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="3" unitRef="usd">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">2,877</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="atnm:PaymentWithImputedInterestPremium" scale="3" sign="-" unitRef="usd">300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">2,577</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_OtherRevenueTextBlock-c0_cont_1" escape="true" name="atnm:OtherRevenueTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Other revenue</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="atnm_OtherRevenueTextBlock-c0_cont_2" id="atnm_OtherRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s ability to terminate
the module. The consideration is recognized to revenue over each module and revenue of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RecognitionOfDeferredRevenue1" scale="6" unitRef="usd"><ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RecognitionOfDeferredRevenue1" scale="6" unitRef="usd">0.9</ix:nonFraction></ix:nonFraction> million was recognized during each of the
years ended December 31, 2022 and December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_OtherRevenueTextBlock-c0_cont_3" id="atnm_OtherRevenueTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had a grant from
a government-sponsored entity for research and development related activities that provide for payments for reimbursed costs, which included
overhead and general and administrative costs as well as an administrative fee. The Company recognized revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Other revenue recognized
from this grant during the years ended December 31, 2022 and 2021 was $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RevenueRecognized" scale="6" unitRef="usd">0.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RevenueRecognized" scale="6" unitRef="usd">0.2</ix:nonFraction> million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="atnm_OtherRevenueTextBlock-c0_cont_4" id="atnm_OtherRevenueTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $<ix:nonFraction contextRef="c41" decimals="-6" format="ixt:num-dot-decimal" name="atnm:UpfrontPayment" scale="6" unitRef="usd">35</ix:nonFraction> million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="atnm_OtherRevenueTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#8211; current liability at December
31, 2022 and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="6" unitRef="usd">1.0</ix:nonFraction> million at December 31, 2021. Long-term license revenue deferred was $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="atnm:LongtermLicenseRevenueDeferred" scale="6" unitRef="usd">35.0</ix:nonFraction> million at December 31, 2022; there was <span style="-sec-ix-hidden: hidden-fact-46">no</span>
Long-term license revenue deferred at December 31, 2021. This deferred revenue will be recognized upon European Union regulatory approval
of Iomab B.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $<ix:nonFraction contextRef="c42" decimals="-6" format="ixt:num-dot-decimal" name="atnm:MilestonePayment" scale="6" unitRef="usd">1</ix:nonFraction> million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed antibody. <ix:nonNumeric contextRef="c42" name="atnm:DescriptionOfRoyaltyPaymentToRelatedParty">Upon commercial sale
of the drug, royalty payments of 2% of net sales will be due to FHCRC.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 - Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company entered
into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which the
Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c43" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd">200</ix:nonFraction> million of its common stock. Shares of common
stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. For the year ended December
31, 2022, the Company sold <ix:nonFraction contextRef="c44" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares">3.5</ix:nonFraction> million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c44" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">23.9</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c44" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd">23.2</ix:nonFraction>
million. For the year ended December 31, 2021, the Company sold <ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="6" unitRef="shares">4.6</ix:nonFraction> million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c45" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">36.5</ix:nonFraction>
million and net proceeds of $<ix:nonFraction contextRef="c45" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd">35.3</ix:nonFraction> million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2022, the Company
entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;) with JonesTrading
and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies the original Capital on Demand&#8482;
Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2019 Amended and Restated Stock Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the Company&#8217;s
2019 Stock Plan was established. The expiration date of the plan is October 18, 2029 and the total number of shares of the Company&#8217;s
common stock available for grant to employees, directors and consultants of the Company was <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">333,333</ix:nonFraction> shares. After a number of amendments
approved by stockholders, the number of shares authorized under the plan was <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">5,833,333</ix:nonFraction> shares. At the Company&#8217;s Annual Meeting of
Stockholders held on December 30, 2022, its stockholders authorized an increase in the number of shares authorized under the plan, resulting
in the number of shares authorized in the plan to be <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">9,333,333</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2013 Amended and Restated Stock Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013, the Company&#8217;s
2013 Stock Plan was established. The expiration date of the plan is September 9, 2023 and at the time of approval, the total number of
shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan was
<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">91,666</ix:nonFraction> shares. After a number of amendments approved by stockholders, the number of shares authorized under the plan is <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">758,333</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>2013 Equity Incentive Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013, the Company&#8217;s
2013 Equity Incentive Plan was established. The expiration date of the plan is September 9, 2023 and the total number of shares of the
Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan was <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">15,000</ix:nonFraction> shares.
In December 2013, the shareholders of the Company approved the plan and increased the number of shares authorized under the plan to <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares">33,333</ix:nonFraction>
shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
stock option activity for the years ended December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">21.53</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.51</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares">881</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" unitRef="shares">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">18.78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">12.45</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">8.69</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares">2,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">60</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">12.90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">3,396</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.00</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">8.85</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">15,204</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">804</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">15.30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted">7.58</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" unitRef="usd">2,432</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2022, the Company granted
its employees and members of the Board of Directors options to purchase <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:GrantOfStockOptionsPurchaseShares" scale="6" unitRef="shares">2.1</ix:nonFraction> million shares of common stock with an exercise price ranging
from $<ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" scale="0" unitRef="usdPershares">4.96</ix:nonFraction> to $<ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" scale="0" unitRef="usdPershares">13.54</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:StockOptionTerm">10</ix:nonNumeric> years, and a vesting period from <ix:nonNumeric contextRef="c54" format="ixt-sec:duryear" name="atnm:VestingPeriodOfStockOption">4</ix:nonNumeric> to <ix:nonNumeric contextRef="c55" format="ixt-sec:duryear" name="atnm:VestingPeriodOfStockOption">4.2</ix:nonNumeric> years.&#160;The options have an aggregated fair
value of $<ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="atnm:AggregateFairValue" scale="6" unitRef="usd">7.7</ix:nonFraction> million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from <ix:nonFraction contextRef="c54" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure">1.5</ix:nonFraction>% to <ix:nonFraction contextRef="c55" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure">4.3</ix:nonFraction>% (2) expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric> years, (3) expected volatility range from <ix:nonFraction contextRef="c54" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">78.8</ix:nonFraction>% to <ix:nonFraction contextRef="c55" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">81.1</ix:nonFraction>%,
and (4) <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:Dividends" scale="0" unitRef="usd">zero</ix:nonFraction> expected dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2021, the Company granted
its employees and members of the Board of Directors options to purchase <ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="atnm:GrantOfStockOptionsPurchaseShares" scale="3" unitRef="shares">881</ix:nonFraction> thousand shares of common stock with an exercise price ranging
from $<ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" scale="0" unitRef="usdPershares">6.02</ix:nonFraction> to $<ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" scale="0" unitRef="usdPershares">9.25</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="atnm:StockOptionTerm">10</ix:nonNumeric> years, and a vesting period from <ix:nonNumeric contextRef="c59" format="ixt-sec:duryear" name="atnm:VestingPeriodOfStockOption">4</ix:nonNumeric> to <ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="atnm:VestingPeriodOfStockOption">4.2</ix:nonNumeric> years. The options have an aggregated fair value
of $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="atnm:AggregateFairValue" scale="6" unitRef="usd">3.9</ix:nonFraction> million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from <ix:nonFraction contextRef="c59" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure">0.65</ix:nonFraction>% to <ix:nonFraction contextRef="c60" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure">1.28</ix:nonFraction>% (2) expected life of <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric> years, (3) expected volatility range from <ix:nonFraction contextRef="c59" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">79.8</ix:nonFraction>% to <ix:nonFraction contextRef="c60" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">85.1</ix:nonFraction>%,
and (4) <ix:nonFraction contextRef="c5" decimals="0" format="ixt:fixed-zero" name="us-gaap:Dividends" scale="0" unitRef="usd">zero</ix:nonFraction> expected dividends.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2022 and 2021, options to purchase <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" unitRef="shares">60</ix:nonFraction> thousand and <ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" unitRef="shares">333</ix:nonFraction> thousand common shares were cancelled, respectively, upon the termination of
employment. During 2021, <ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="atnm:StockOptionsExercisedSharesOfCommonStock" scale="3" unitRef="shares">1</ix:nonFraction> thousand options were exercised for shares of common stock. There were no exercises of options during 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31,
2022 was $<ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnrecognizedCompensationExpense" scale="6" unitRef="usd">10.0</ix:nonFraction> million related to unvested options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:WeightedAverageTerm">3.3</ix:nonNumeric> years. During 2022
and 2021, the Company recorded total option expense of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">2.5</ix:nonFraction> million and $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">1.5</ix:nonFraction> million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company issued <ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" unitRef="shares">325</ix:nonFraction> thousand
restricted stock units (&#8220;RSUs&#8221;) to employees during 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares">325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c70" decimals="INF" format="ixt:num-dot-decimal" name="atnm:RSUsOutstandingEndingBalance" scale="3" unitRef="shares">325</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.96</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestmentsAtFairValue" scale="6" unitRef="usd">1.9</ix:nonFraction> million, was determined based on the stock
prices on the dates of the grants and is being recognized over <ix:nonNumeric contextRef="c64" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">three years</ix:nonNumeric>. The unrecognized compensation expense at December 31, 2022
of $<ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnrecognizedCompensationExpense" scale="6" unitRef="usd">1.7</ix:nonFraction> million is expected to be expensed over <ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">2.4</ix:nonNumeric> years. During 2022, the Company recorded compensation expense related to RSUs of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToRSUs" scale="6" unitRef="usd">0.2</ix:nonFraction>
million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activities for the years ended December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="0" unitRef="shares">2,113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">20.55</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.76</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">362</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" sign="-" unitRef="shares">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="atnm:WeightedAverageExercisePriceCancelled" scale="0" unitRef="usdPershares">50.17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="0" unitRef="shares">2,112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">20.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">1.76</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" sign="-" unitRef="shares">669</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="atnm:WeightedAverageExercisePriceCancelled" scale="0" unitRef="usdPershares">29.01</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="0" unitRef="shares">1,443</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">16.58</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c74" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">1.33</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,440</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">15.95</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c74" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.33</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2022, warrants
to purchase an aggregate of <ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="atnm:ClassOfWarrantsSharesExpired" scale="6" unitRef="shares">0.6</ix:nonFraction> million shares of common stock expired. These warrants were issued on August 2, 2017, when the Company
completed an underwritten offering of <ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnderwrittenOfferingShares" scale="6" unitRef="shares">0.7</ix:nonFraction> million shares of common stock and warrants to purchase <ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="atnm:warrantsToPurchaseSharesOfCommonStock" scale="6" unitRef="shares">0.6</ix:nonFraction> million shares of common stock at
a price of $<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">22.50</ix:nonFraction> per share and related warrant. The warrants were exercisable for a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:ExercisablePeriodYears">5</ix:nonNumeric> years at an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">31.50</ix:nonFraction>
per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2022 and 2021, the Company recorded stock-based compensation expense related to warrants of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">6</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">16</ix:nonFraction> thousand, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Note 8 - Income Taxes </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income taxes reflect
the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December
31, 2022 and 2021 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">44,233</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">36,405</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd">1,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd">17,247</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd">14,536</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Capitalized research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd">13,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd">10,426</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd">69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">76,093</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">62,599</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>


</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has recorded a
valuation allowance of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="atnm:DeferredTaxAssetsValuationAllowances" scale="6" unitRef="usd">76.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="atnm:DeferredTaxAssetsValuationAllowances" scale="6" unitRef="usd">62.6</ix:nonFraction> million against its deferred tax assets at December 31, 2022 and 2021 respectively, because
management determined that it is not more-likely-than not that those assets will be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For federal income tax purposes,
the Company has $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxContingenciesForeign" scale="6" unitRef="usd">178.6</ix:nonFraction> million of unused net operating losses (&#8220;NOLs&#8221;) at December 31, 2022 available for carry forward to
future years. <ix:nonNumeric contextRef="c0" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse">NOLs of $118.4 million generated prior to 2018 will begin to expire if unused in 2023. NOLs generated in 2018 and later
years of $60.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1,
2023.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For state income tax purposes,
the Company has $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal" scale="6" unitRef="usd">271.1</ix:nonFraction> million of unused NOLs at December 31, 2022 available for carry forward to future years. These NOLs will begin
to expire in 2034 if unused.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has federal research
and development tax credits of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" scale="6" unitRef="usd">3.4</ix:nonFraction> million at December 31, 2022 which will begin to expire in 2034 if unused and orphan drug credits
of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" unitRef="usd">13.8</ix:nonFraction> million which will begin to expire in 2028 if unused.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Federal and state tax laws
impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership change for tax purposes,
as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize these carryforwards may be
limited as a result of an ownership change which may have already happened or may happen in the future. Such an ownership change could
result in a limitation in the use of the net operating losses in future years and possibly a reduction of the net operating losses available.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2022 and 2021 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd">6,943</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd">5,202</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd">4,863</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure">14.7</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd">373</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure">1.5</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd">89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps" scale="-2" unitRef="pure">0.3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd">562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps" scale="-2" unitRef="pure">2.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development/orphan drug tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" unitRef="usd">2,711</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" sign="-" unitRef="pure">8.2</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" unitRef="usd">1,898</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" sign="-" unitRef="pure">7.7</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">934</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure">2.8</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure">2.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">13,494</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">40.8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">6,425</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">25.9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; "><b>Note 9 - Subsequent Event</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Since December 31, 2022, the
Company has sold <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DividendsCommonStockStock" scale="6" unitRef="usd">0.1</ix:nonFraction> million shares of common stock under its A&amp;R Sales Agreement, resulting in net proceeds of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">0.8</ix:nonFraction> million.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9A. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Disclosure controls
and procedures.</i></b> The Company, under the supervision and with the participation of its management, including the Company&#8217;s
principal executive officer and principal financial and accounting officer, evaluated the effectiveness of the Company&#8217;s &#8220;disclosure
controls and procedures,&#8221; as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Securities Act of 1934, as amended (the
&#8220;Exchange Act&#8221;), as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, the Company&#8217;s
principal executive officer and principal financial and accounting officer have concluded that the Company&#8217;s disclosure controls
and procedures are effective as of December 31, 2022 to ensure that information required to be disclosed by the Company in reports that
it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities
and Exchange Commission rules and forms, and includes controls and procedures designed to ensure that information required to be disclosed
by the Company in such reports is accumulated and communicated to the Company&#8217;s management, including the Company&#8217;s principal
executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Management&#8217;s Annual
Report on Internal Control Over Financial Reporting.</i>&#160;</b>The Company&#8217;s management is responsible for establishing and maintaining
adequate internal control over financial reporting. The Company&#8217;s internal control over financial reporting is a process designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s internal
control over financial reporting includes policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect transactions and dispositions of assets; (2)&#160;provide reasonable assurances that transactions
are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and
that receipts and expenditures are being made only in accordance with authorizations of management and the directors of the Company; and
(3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the
Company&#8217;s assets that could have a material effect on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assessed the effectiveness
of the Company&#8217;s internal control over financial reporting as of December 31, 2022. In making this assessment, management used the
criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework
(2013). Based on its assessment and those criteria, management concluded that as of December 31, 2022, the Company&#8217;s internal control
over financial reporting was effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K does not include an attestation report from our registered public accounting firm regarding internal control over financial reporting.
Our internal control over financial reporting was not subject to such attestation as we are a non-accelerated filer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Changes in internal
controls over financial reporting</i>.</b> There were no changes in the Company&#8217;s internal controls over financial reporting that
occurred during the fourth quarter of the fiscal year covered by this Annual Report on Form 10-K that have materially affected, or are
reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9B. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>ITEM
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Options: NewSection; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors and Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The names, positions and ages
of our directors and executive officers as of March 31, 2023, are as follows:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 30%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 60%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lead Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors hold office for a term consistent with classified board provisions
of our Charter. For further information, see the section titled &#8220;&#8212;Corporate Governance&#8212;Term of Office&#8221; below. Officers serve at the discretion of the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no other&#160;arrangements
or understanding between any of our directors and any other persons pursuant to which they were selected as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background of Executive Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal occupations
for the past five years (and, in some instances, for prior years) of each of our directors and executive officers are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sandesh Seth, Chairman and Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Mr. Sandesh Seth has been our Chief Executive Officer
since June 2017. Mr. Seth has been a Director since March 2012, our Chairman of the Board since October 2013, and served as Executive
Chairman from August 2014 to June 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Mr. Seth has 25+ years of experience in investment
banking (Laidlaw&amp; Co (UK) Ltd., Cowen &amp; Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry
(Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&amp;D project management). Mr. Seth was chairman
of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Mr. Seth has an MBA in
Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in
Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research
Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals
Society which signifies proficiency with U.S. FDA regulations. He has several patents related to use of radiopharmaceuticals as conditioning
agents for adoptive cell therapies and as therapeutic combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">That Mr. Seth has served in various business executive-level
positions over the course of his career, has significant investment banking experience, has developed significant management, operational
and leadership skills and is well accustomed to interfacing with investors, analysts, auditors, C-level executives, and outside advisors,
led us to conclude that Mr. Seth should serve as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Steve O&#8217;Loughlin, Chief Financial Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Steve O&#8217;Loughlin has been our Chief Financial
Officer since August 2020. Mr. O&#8217;Loughlin served as our Principal Financial Officer from May 2017 to August 2020. Mr. O&#8217;Loughlin
joined Actinium in October 2015 as Vice President, Finance and Corporate Development, with almost a decade of life sciences industry experience
gained from previous positions in investment banking and publicly traded life sciences companies. Prior to Actinium, from June 2015 to
October 2015, Mr. O&#8217;Loughlin worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Mr. O&#8217;Loughlin
held the position of vice president, corporate finance and development and was a corporate officer at Protea Biosciences, Inc., a publicly
traded life sciences tools company. Previously, From June 2010 to June 2012, Mr. O&#8217;Loughlin held corporate development positions
with Caliber I.D., a publicly traded diagnostics company. Mr. O&#8217;Loughlin previously worked in investment banking at Jesup &amp;
Lamont where he focused on the biotechnology and life sciences industries. Mr. O&#8217;Loughlin has a B.S. in Business Administration
with a concentration in finance from Ramapo College of New Jersey.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Jeffrey W. Chell, M.D., Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Chell has been a Director of the Company since
April 2018. Dr. Chell is also a member of our Audit Committee and Compensation Committee. He has been the chief executive officer emeritus
of the National Marrow Donor Program (&#8220;NMDP&#8221;) since 2017 having served as its chief executive officer since 2000. Dr. Chell
has led the NMDP through transformational growth as its Be The Match Registry tripled to more than 12 million donors, the number of transplants
facilitated has grown fivefold to over 6,400 annually, and revenue more than tripled to nearly $400 million per year. He is also the co-founder
and has served as executive director of the Center For International Blood &amp; Marrow Transplant Research since 2004, a leading research
program in the field contributing over 70 research publications per year in peer-reviewed journals. Dr. Chell also currently serves as
chair of CLR Insurance, a captive insurance company domiciled in the Cayman Islands. From 2014 to 2016, Dr. Chell served as co-chair of
Bone Marrow Donors Worldwide during its IT transformation project, improving revenues and reducing costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to joining the NMDP, he served as president,
Allina Medical Clinics, a 450 physician multi-specialty medical group from 1994 to 1999. Prior to that he practiced Internal Medicine
in Minneapolis and in the U.S. Air Force Medical Corps.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Chell received his M.D. from the University
of Minnesota and his training in Internal Medicine at the University of Wisconsin, Madison. Dr. Chell is a diplomate of the American Board
of Internal Medicine, a member of the American Society of Hematology and a member of the American Society of Blood and Marrow Transplantation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">He has received multiple honors including the 2018
Public Service award of the American Society For Blood and Marrow Transplantation, 2017 Most Admired CEO by the Minneapolis/St. Paul Business
Journal, 2010 Healthcare Executive of the Year by the Minneapolis/St, Paul Business Journal, and the 2017 Bone Marrow Foundation Service
Award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">That Dr. Chell brings many years of experience
with patient donor programs, knowledge of challenges related to bone marrow transplants, leadership of organizations and experience working
in medical groups to our Board, led us to conclude that Dr. Chell should serve as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>David Nicholson, Ph.D., Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">David Nicholson has been a Director of the Company
since 2008. Dr. Nicholson is also a member of our Compensation Committee and our Nominating and Corporate Governance Committee. Since
March 2015, Dr. Nicholson served as Executive Vice President and Chief R&amp;D Officer of Allergan, which was acquired by Abbvie in May
2020. In August 2014, Dr. Nicholson joined Allergan (previously known as Actavis plc and Forest Laboratories, Inc.) as senior vice president,
Actavis Global Brands R&amp;D. From March 2012 to August 2014, Dr. Nicholson was on the executive committee of Bayer CropScience as head
of research &amp; development responsible for the integration of the company&#8217;s R&amp;D activities into one global organization.
Dr. Nicholson graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University
of Wales (1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-W&#252;lfing
in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular
drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From 1988-2007, Dr. Nicholson held various positions
of increasing seniority in the UK, the Netherlands and the U.S. with Organon, a business unit of Akzo Nobel. Ultimately, he became executive
vice president, research &amp; development, and member of the Organon Executive Management Committee. He implemented change programs,
leading to maximizing effectiveness in research &amp; development, ensuring customer focus and the establishment of a competitive pipeline
of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth, New Jersey as senior vice president, responsible
for Global Project Management and Drug Safety. From 2009 to December 2011, he was vice president licensing and knowledge management at
Merck in Rahway, New Jersey, reporting to the president of Merck R&amp;D. As an integration team member, Dr. Nicholson played a role in
the strategic mergers of Organon BioSciences, the human and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough
in 2007 as well as of Schering-Plough and Merck in 2009.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">That Dr. Nicholson brings over 25 years of pharmaceutical
experience to our Board, having served in various pharmaceutical research and development executive-level positions over the course of
his career, and that Dr. Nicholson has developed significant management and leadership skills relating to the pharmaceutical industry
and is well accustomed to interfacing with investors, analysts, auditors, outside advisors and governmental officials, led us to conclude
that Dr. Nicholson should serve as a director.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Ajit S. Shetty, Ph.D., Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Shetty has been a
Director of the Company since March 2017. Dr. Shetty is also a member of our Audit Committee, Compensation Committee, and Chairman
of our Nominating and Corporate Governance Committee. Dr. Shetty joined Janssen Pharmaceutical, Inc. (&#8220;Janssen&#8221;) in 1976
ultimately rising to the position of president in 1986 where he led the establishment of Janssen&#8217;s business in the U.S. From
1999 to 2008 he was managing director of Janssen, during this time the Janssen Group of companies&#8217; global sales grew from $1
billion to $8 billion, and from 2004 until 2012 he was chairman of the board of directors. In Dr. Shetty&#8217;s most recent role at
Johnson &amp; Johnson he was head of Enterprise Supply Chain, where he reported to the chief executive officer and was responsible
for the transformation and optimization of Johnson &amp; Johnson&#8217;s supply chain. Dr. Shetty earned a Ph.D. in Metallurgy and
B.A. Natural Sciences from Trinity College, Cambridge University and a Master of Business Administration from Carnegie Mellon
University. Dr. Shetty has served as a member of Agile Therapeutics, Inc.&#8217;s board of directors since February 2016. In 2007,
Dr. Shetty was bestowed the title of Baron by King Albert II of Belgium for his exceptional merits. He is a member of the Board of
Trustees of Carnegie Mellon University, serves on the Board of Governors for GS1 (Global Standards) in Belgium and formerly served
on the Corporate Advisory Board of the John Hopkins Carey Business School. In 2016, Dr. Shetty was named as chairperson of the
Vlaams Instituut voor Biotechnologie (VIB), a Belgium based life sciences research institute focused on translating scientific
results into pharmaceutical, agricultural and industrial applications. In addition, he was elected Manager of the Year in 2004 in
Flanders and received a Life-Time Achievement Award in India in 2010. We believe Dr. Shetty&#8217;s qualifications to sit on our
Board include his extensive pharmaceutical experience leading commercial and supply chain operations and his significant education
background.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">That Dr. Shetty has more than 30 years of leadership
and executive experience in the pharmaceutical industry, that he has significant supply chain knowledge and that he has experience conducting
business in the U.S. and Europe, led us to conclude that Dr. Shetty should serve as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Richard I. Steinhart, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Steinhart has served as our Director and Chairman
of the Audit Committee since November 2013. Mr. Steinhart is also a member of our Nominating and Corporate Governance Committee. Since
October 2017 Mr. Steinhart has been the senior vice president and chief financial officer of BioXcel Therapeutics, Inc. Since March 2014,
Mr. Steinhart has been a member of the board of directors of Atossa Genetics, Inc. where he is chairman of the audit committee and a member
of the compensation committee. From October 2015 to April 2017, Mr. Steinhart was vice president and chief financial officer at Remedy
Pharmaceuticals, a privately-held, clinical stage pharmaceutical company. From January 2014 through September 2015 Mr. Steinhart worked
as a financial and strategic consultant to the biotechnology and medical device industries. From April 2006 through December 2013, Mr.
Steinhart was employed by MELA Sciences, Inc., as its vice president, finance and chief financial officer, treasurer and secretary. In
April 2012, Mr. Steinhart received a promotion to senior vice president, finance and chief financial officer. From May 1992 until joining
MELA Sciences, Mr. Steinhart was a managing director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital,
and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was vice
president and chief financial officer of Emisphere Technologies, Inc. Mr. Steinhart&#8217;s other experience includes seven years at CW
Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a general partner and
chief financial officer. Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds BBA and MBA
degrees from Pace University and is a Certified Public Accountant (inactive).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">That Mr. Steinhart brings more than 30 years of financial experience
to our Board, having served in various executive-level financial positions over the course of his career, and that Mr. Steinhart is a
certified public accountant (inactive), led us to conclude that Mr. Steinhart should serve as a director and chair the Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors oversees
our business affairs and monitors the performance of management. In accordance with our corporate governance principles, our Board of
Directors does not involve itself in day-to-day operations. The Directors keep themselves informed through discussions with the Chairman
and Chief Executive Officer and other key executives and by reading the reports and other materials that we send them and by participating
in Board of Directors and committee meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Term of Office</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors are divided
into three classes, designated Class I, Class II and Class III. Class I shall consists of two directors, Class II shall consist of one
director, and Class III consists of one director. The term of office for each Class I director expires at 2023 Annual Meeting of Stockholders;
the term of office for each Class II director expires at the 2024 Annual Meeting of stockholders; and the term of office for each Class
III director expires at the 2025 Annual Meeting of stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of each director
is set forth below or until their successors are duly elected:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 32%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term (from 2022 Annual Meeting)</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Steinhart </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit Shetty</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class III</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
each director shall serve until his successor is duly elected and qualified, or until his retirement, death, resignation or removal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Director Independence</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use the definition of &#8220;independence&#8221;
of the NYSE American stock exchange to make this determination. We are listed on the NYSE American under the symbol &#8220;ATNM&#8221;.
NYSE MKT corporate governance rule Sec. 803(A)(2) provides that an &#8220;independent director&#8221; means a person other than an executive
officer or employee of the company. No director qualifies as independent unless the issuer&#8217;s board of directors affirmatively determines
that the director does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director. Under the NYSE American director independence rules, Jeffrey W. Chell, David Nicholson, Ajit S. Shetty, and Richard I.
Steinhart are independent directors of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Chief Executive Officer Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2020, we and
Mr. Seth entered into an employment agreement whereby Mr. Seth will serve as Chairman and Chief Executive Officer until February 24, 2024,
unless terminated earlier as set forth in the employment agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the employment
agreement, Mr. Seth is entitled to (i) a base salary, which will be determined by the Board and adjusted to be competitively aligned to
a range between the 25th and 75th percentile of the relevant market data of chief executive officer positions of similarly situated publicly
companies, (ii) a performance bonus with a target of 50% of his annual base salary as well as other multipliers as determined by the Board
and (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2021, Mr. Seth&#8217;s annual base salary
was set at $615,000, and for 2022, his annual base salary was set at $665,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When and if granted, options
will have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of the approval, and 2% of the
grant will vest each month from the grant date until fully vested, in accordance with the 2013 Stock Plan and 2019 Plan. The options will
expire 10 years from the grant date, subject to Mr. Seth&#8217;s continuing service with the Company. Mr. Seth also receives the standard
benefits available to other similarly situated employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Mr. Seth&#8217;s employment
as Chief Executive Officer or Chairman is terminated due to death or disability, Mr. Seth will be entitled to earned, but unpaid, salary,
benefits and the Pro-Rated Bonus (as defined below) for the year of termination. Upon termination of his employment for Cause (as defined
in the employment agreement), or his resignation without Good Reason (as defined in the employment agreement), Mr. Seth will receive any
accrued and unpaid base salary, the Pro-Rated Bonus and benefits through the date of termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we terminate Mr. Seth&#8217;s
employment without Cause, or if Mr. Seth resigns for Good Reason other than in connection with a Change in Control, Mr. Seth will be entitled
to (i) a single lump sum payment equal to 24 months of his compensation, (ii) continued health benefits for 24 months, (iii) immediate
vesting of all outstanding equity awards granted to Mr. Seth, and (iv) a single lump sum payment equal to his annual bonus subject to
the achievement of the applicable goals, pro-rated based on the number of days in the Company&#8217;s fiscal year through the date of
termination (the &#8220;Pro-Rated Bonus&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we terminate
Mr. Seth&#8217;s employment without Cause or if Mr. Seth resigns for Good Reason, or if we fail to renew his position as Chief Executive
Officer and Chairman on February 24, 2024, in any case, within the 12-month period beginning on the date of a Change in Control (as defined
in the 2013 Stock Plan and 2019 Plan), Mr. Seth will be entitled to (i) a single lump sum payment equal to 30 months of his compensation,
(ii) continued health benefits for 30 months, (iii) immediate vesting of all outstanding equity awards granted to Mr. Seth, and (iv) a
single lump sum payment equal to the Pro-Rated Bonus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Chief Financial Officer Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2020, we entered
into an employment agreement with Mr. O&#8217;Loughlin, pursuant to which he serves as Chief Financial Officer of the Company. Under the
terms of the employment agreement, Mr. O&#8217;Loughlin is entitled to (i) a base salary, which shall be determined by the Board, (ii)
a performance bonus, which may be up to 30% of the annual base salary based upon the achievement of certain objectives such as the Board
shall determine and (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2021, Mr. O&#8217;Loughlin&#8217;s
annual base salary was set at $370,000, and for 2022, his annual base salary was set at $400,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When and if granted, options
will have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of the approval, and 2% of the
grant will vest each month from the grant date until fully vested, in accordance with the 2013 Stock Plan and 2019 Plan. The options will
expire 10 years from the grant date, subject to Mr. O&#8217;Loughlin&#8217;s continuing service with the Company. Mr. Loughlin will also
receive the standard benefits available to other similarly situated employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we terminate
Mr. O&#8217;Loughlin&#8217;s employment without Cause (as defined in the employment agreement) or if Mr. O&#8217;Loughlin resigns for
Good Reason (as defined in the employment agreement), in either case, within the 12-month period beginning on the date of a Change in
Control, Mr. O&#8217;Loughlin will be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued health
benefits for 12 months, and (iii) immediate vesting of all outstanding equity awards granted to Mr. O&#8217;Loughlin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors Meetings and Attendance
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2022, our Board of
Directors held five meetings and acted by unanimous written consent on three occasions. Each director attended all of the meetings of
our Board during the year ended December&#160;31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
formed three standing committees: Audit, Compensation and Nominating and Corporate Governance. Actions taken by our committees are reported
to the full board. Each of our committees has a charter and each charter is posted on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="width: 32%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit Committee</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation&#160;Committee</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating and Corporate<br/>
Governance Committee</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty*</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>*</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
committee chair</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee, which
currently consists of three independent directors, provides assistance to our Board in fulfilling its legal and fiduciary obligations
with respect to matters involving the accounting, financial reporting, internal control and compliance functions of the Company. The Board
has determined that Mr.&#160;Steinhart is an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii) of Regulation
S-K. Our Audit Committee employs an independent registered public accounting firm to audit the financial statements of the Company and
perform other assigned duties. Further, our Audit Committee provides general oversight with respect to the accounting principles employed
in financial reporting and the adequacy of our internal controls. In discharging its responsibilities, our Audit Committee may rely on
the reports, findings and representations of the Company&#8217;s auditors, legal counsel, and responsible officers. Our Board has determined
that all members of the Audit Committee are financially literate within the meaning of SEC rules and under the current listing standards
of the NYSE American. The Audit Committee met four times during 2022. Each member of the Audit Committee was present at all of the Audit
Committee meetings held during 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee,
which currently consists of three directors, establishes executive compensation policies consistent with the Company&#8217;s objectives
and stockholder interests. The Compensation Committee met two times and acted by unanimous written consent on one occasion during 2022.
Each member of the Compensation Committee was present at all committee meetings held in 2022. Our Compensation Committee also reviews
the performance of our executive officers and establishes, adjusts and awards compensation, including incentive-based compensation, as
more fully discussed below. In addition, our Compensation Committee generally is responsible for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and periodically reviewing our compensation philosophy and the adequacy of compensation plans and programs for our directors, executive officers and other employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our compensation plans, including the establishment of performance goals under the Company&#8217;s incentive compensation arrangements and the review of performance against those goals in determining incentive award payouts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our executive employment contracts, special retirement benefits, severance, change in control arrangements and/or similar plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acting as administrator of any company stock option plans; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing outside compensation consultants when engaged.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee
periodically reviews the compensation paid to our non-employee directors and the principles upon which their compensation is determined.
The Compensation Committee also periodically reports to the Board on how our non-employee director compensation practices compare with
those of other similarly situated public corporations and, if the Compensation Committee deems it appropriate, recommends changes to our
director compensation practices to our Board for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside consulting firms retained
by our Compensation Committee and management also will, if requested, provide assistance to the Compensation Committee in making its compensation-related
decisions. The Compensation Committee engaged StreeterWyatt Analytics LLC, or Streeter Wyatt and paid consultant fees of $22,000 during
the year ended December 31, 2022. Streeter Wyatt was instructed to provide support and analysis to the Compensation Committee and their
services included developing a peer group regarding executive and director compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating and Corporate Governance Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Nominating and Corporate
Governance Committee, which currently consists of three directors, is charged with the responsibility of reviewing our corporate governance
policies and proposing potential director nominees to the Board for consideration. Our Board has determined that each member of our Nominating
and Corporate Governance Committee qualifies as an &#8220;independent&#8221; member of the Board as defined by the rules and regulations
of the SEC and the NYSE American. The Nominating and Corporate Governance Committee held no meetings and acted by unanimous written consent
on one occasion during 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Nominating and Corporate
Governance Committee&#8217;s primary responsibilities and obligations include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the administration of our Code of Business Ethics and Conduct and related policies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leading the search for and recommending individuals qualified to become members of the Board, and selecting director nominees to be presented for election by the shareholders at each annual meeting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring, in cooperation with the Compensation Committee, that no agreements or arrangements are made with directors or relatives of directors for providing professional or consulting services to us or our affiliate or individual officer or one of their affiliated, without appropriate review and evaluation for conflicts of interest;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing the independence of directors annually and report to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the Board for its approval, the leadership structure of the Board, including whether the Board should have an executive or non-executive Chairman, whether the roles of Chairman and Chief Executive Officer should be combined, and whether a Lead Director of the Board should be appointed; provided that such structure shall be subject to the bylaws of the Company then in effect;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring that Board members do not serve on more than six other for-profit public company boards that have a class of securities registered under the Exchange Act in addition to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the Board&#8217;s committee structure and to recommend to the Board for its approval directors to serve as members of each committee as well as recommendations for committee chairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending changes to procedures whereby shareholders may communicate with the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing recommendations received from shareholders for persons to be considered for nomination to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with our corporate governance guidelines;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and implementing an annual self-evaluation of the Board, both individually and as a Board, and of its committees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in; text-align: justify; text-indent: -0.9in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Nominating and Corporate Governance Committee
considers all qualified candidates identified by members of the Board, by senior management and by stockholders. The Committee follows
the same process and uses the same criteria for evaluating candidates proposed by stockholders, members of the Board and members of senior
management. When evaluating a candidate to serve on our Board, the members of our Nominating and Corporate Governance Committee consider
items such as experience in the biotechnology sector, experience with public companies, executive managerial experience, operations and
commercial experience, fundraising experience and contacts in the investment banking industry, personal and skill set compatibility with
current Board members, industry reputation, knowledge of our company generally, and independence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Bylaws,
as amended (the &#8220;Bylaws&#8221;) contains provisions that address the process by which a stockholder may nominate an individual to
stand for election to the Board at our annual meetings. To recommend a nominee for election to the Board, a stockholder must submit his
or her recommendation to our Secretary at our corporate offices at 275 Madison Avenue, 7th Floor, New York, New York 10016. Such nomination
must satisfy the notice, information and consent requirements set forth in our Bylaws and must be received by us prior to the date set
forth under &#8220;Submission of Future Stockholder Proposals&#8221; below. A stockholder&#8217;s recommendation must be accompanied by
the information with respect to stockholder nominees as specified in our Bylaws, including among other things, the name, age, address
and occupation of the recommended person, the proposing stockholder&#8217;s name and address, the ownership interests of the proposing
stockholder and any beneficial owner on whose behalf the nomination is being made (including the number of shares beneficially owned,
any hedging, derivative, short or other economic interests and any rights to vote any shares) and any material monetary or other relationships
between the recommended person and the proposing stockholder and/or the beneficial owners, if any, on whose behalf the nomination is being
made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our approach toward Board
diversity takes into consideration the overall composition and diversity of the Board and areas of expertise that director nominees may
be able to offer, including business experience, knowledge, abilities, customer relationships and appropriate perspectives on environmental,
social and governance matters. Generally, we strive to assemble and maintain a Board that brings to us a variety of perspectives and skills
derived from business and professional experience as we may deem are in our and our stockholders&#8217; best interests. In doing so, we
also consider candidates with appropriate non-business backgrounds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Lead Director</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In September 2017, our Board
of Directors created the position of Lead Director and designated David Nicholson, an existing independent director, as our Lead Director.
Pursuant to the charter of the Lead Director, the Lead Director shall be an independent,&#160;non-employee&#160;director designated by
our Board of Directors who shall serve in a lead capacity to coordinate the activities of the other&#160;non-employee&#160;directors,
interface with and advise management, and perform such other duties as are specified in the charter or as our Board of Directors may determine.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among any of our officers or directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, none of
our current directors or executive officers has, during the past ten years:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our directors or executive
officers has been involved in any transactions with us or any of our directors, executive officers, affiliates or associates which are
required to be disclosed pursuant to the rules and regulations of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has adopted a
code of ethics, a copy of which is attached as Exhibit 14.1 to the Form 8-K filed on January 2, 2013.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Discussion and Analysis</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee of
our Board of Directors has the responsibility to review, determine and approve the compensation for our executive officers. Further, our
Compensation Committee oversees our overall compensation strategy, including compensation policies, plans and programs that cover all
employees. At our 2022 Annual Meeting of Stockholders, our Stockholders voted on an advisory basis to approve the compensation of named
executive officers. Of the votes cast (excluding abstentions and broker non-votes), 79.3% were cast in support of the results of our compensation
program. In light of this, in reviewing the executive compensation program for 2021 and 2022, our Compensation Committee decided to retain
the general overall program design, which ties a significant portion of the executives&#8217; pay closely with our performance. In the
future, our Compensation Committee will continue to consider the executive compensation program in light of changing circumstances and
stockholder feedback.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently employ two executive
officers: (1) Sandesh Seth, our Chairman and Chief Executive Officer (who we refer to in this Compensation Discussion and Analysis as
our CEO) and (2) Steve O&#8217;Loughlin, our Chief Financial Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Compensation
Discussion and Analysis sets forth a discussion of the compensation for our Named Executive Officers, or NEOs, as well as a
discussion of our philosophies underlying the compensation for our NEOs and our employees generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Objectives of Our Compensation Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee&#8217;s
philosophy seeks to align the interests of our stockholders, officers and employees by tying compensation to individual and company performance,
both directly in the form of salary or annual cash incentive payments, and indirectly in the form of equity awards. The objectives of
our compensation program enhance our ability to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and retain qualified and talented individuals; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable and appropriate incentives and rewards to our team for building long-term value within our company, in each case in a manner comparable to companies similar to ours.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we strive to
be competitive with other similarly situated companies in our industry. The process of developing pharmaceutical products and bringing
those products to market is a long-term proposition and outcomes may not be measurable for several years. Therefore, in order to build
long-term value for our company and its stockholders, and in order to achieve our business objectives, we believe that we must compensate
our officers and employees in a competitive and fair manner that reflects current company activities but also reflects contributions to
building long-term value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We utilize the services of
StreeterWyatt Analytics LLC to review compensation programs of peer companies in order to assist the Compensation Committee in determining
the compensation levels for our NEOs, as well as for other employees of our company. StreeterWyatt is a recognized independent consulting
company and services clients throughout the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Elements of Our Compensation Program and Why
We Chose Each</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Main Compensation Components</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company-wide compensation
program, including for our NEOs, is broken down into three main components: base salary, performance cash bonuses and potential long-term
compensation in the form of stock options or restricted stock unit awards. We believe these three components constitute the minimum essential
elements of a competitive compensation package in our industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Salary</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Base salary is used to recognize
the experience, skills, knowledge and responsibilities required of our NEOs as well as recognizing the competitive nature of the biopharmaceutical
industry. This is determined partially by evaluating our peer companies as well as the degree of responsibility and experience levels
of our NEOs and their overall contributions to our company. Base salary is one component of the compensation package for NEOs; the other
components being cash bonuses, annual equity grants, and company benefit programs. Base salary is determined in advance whereas the other
components of compensation are awarded in varying degrees following an assessment of the performance of a NEO. This approach to compensation
reflects the philosophy of our Board of Directors and its Compensation Committee to emphasize and reward, on an annual basis, performance
levels achieved by our NEOs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Performance Bonus Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have a performance bonus
plan under which bonuses are paid to our NEOs based on achievement of company performance goals and objectives established by the Compensation
Committee and/or our Board of Directors as well as on individual performance. The bonus program is discretionary and is intended to: (i)
strengthen the connection between individual compensation and our company&#8217;s achievements; (ii) encourage teamwork among all disciplines
within our company; (iii) reinforce our pay-for-performance philosophy by awarding higher bonuses to higher performing employees; and
(iv) help ensure that our cash compensation is competitive. Depending on the cash position of the company, the Compensation Committee
and our Board of Directors have the discretion to not pay cash bonuses in order that we may conserve cash and support ongoing development
programs and commercialization efforts. Regardless of our cash position, we consistently grant annual merit-based stock options to continue
incentivizing both our senior management and our employees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on their employment
agreements, each NEO is assigned a target payout under the performance bonus plan, expressed as a percentage of base salary for the year.
Actual payouts under the performance bonus plan are based on the achievement of corporate performance goals and an assessment of individual
performance, each of which is separately weighted as a component of such officer&#8217;s target payout. For the NEOs, the corporate goals
receive the highest weighting in order to ensure that the bonus system for our management team is closely tied to our corporate performance.
Each employee also has specific individual goals and objectives as well that are tied to the overall corporate goals. For employees, mid-year
and end-of-year progress is reviewed with the employees&#8217; managers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Equity Incentive Compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We view long-term compensation,
currently in the form of stock options generally vesting in annual increments over four years, as a tool to align the interests of our
NEOs and employees generally with the creation of stockholder value, to motivate our employees to achieve and exceed corporate and individual
objectives and to encourage them to remain employed by the company. While cash compensation is a significant component of employees&#8217;
overall compensation, the Compensation Committee and our Board of Directors (as well as our NEOs) believe that the driving force of any
employee working in a small biotechnology company should be strong equity participation. We believe that this not only creates the potential
for substantial longer-term corporate value but also serves to motivate employees and retain their loyalty and commitment with appropriate
personal compensation.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Other Compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the main components
of compensation outlined above, we also have provided contractual severance and/or change in control benefits to several employees including
our CEO. The change in control benefits for all applicable persons have a &#8220;double trigger.&#8221; A double-trigger means that the
executive officers will receive the change in control benefits described in the agreements only if there is both (1) a Change in Control
of our company (as defined in the agreements) and (2) a termination by us of the applicable person&#8217;s employment &#8220;without cause&#8221;
or a resignation by the applicable persons for &#8220;good reason&#8221; (as defined in the agreements) within a specified time period
prior to or following the Change in Control. We believe this double trigger requirement creates the potential to maximize stockholder
value because it prevents an unintended windfall to management as no benefits are triggered solely in the event of a Change in Control
while providing appropriate incentives to act in furtherance of a change in control that may be in the best interests of the stockholders.
We believe these severances or change in control benefits are important elements of our compensation program that assist us in retaining
talented individuals at the executive and senior managerial levels and that these arrangements help to promote stability and continuity
of our executives and senior management team. Further, we believe that the interests of our stockholders will be best served if the interests
of these members of our management are aligned with theirs. We believe that providing change in control benefits lessens or eliminates
any potential reluctance of members of our management to pursue potential change in control transactions that may be in the best interests
of the stockholders. We also believe that it is important to provide severance benefits to members of our management, to promote stability
and focus on the job at hand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also provide benefits to
the executive officers that are generally available to all regular full-time employees of our company, including our medical and dental
insurance, and a 401(k) plan. Further, we do not have deferred compensation plans, pension arrangements or post-retirement health coverage
for our executive officers or employees. All of our employees not specifically under contract are &#8220;at-will&#8221; employees, which
means that their employment can be terminated at any time for any reason by either us or the employee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Determination of Compensation
Amounts</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of factors impact
the determination of compensation amounts for our NEOs, including the individual&#8217;s role in the company and individual performance,
length of service with the company, competition for talent, individual compensation package, assessments of internal pay equity and industry
data. Stock price performance has generally not been a factor in determining annual compensation because the price of our common stock
is subject to a variety of factors outside of our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Industry Survey Data</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In collaboration with StreeterWyatt,
we establish and maintain a list of peer companies to best assure ourselves that we are compensating our executives on a fair and reasonable
basis, as set forth above under the heading &#8220;Objectives of our Compensation Program.&#8221; We also utilize StreeterWyatt-prepared
data for below-executive level personnel, which data focuses on biotechnology companies that can be considered peers in terms of numerous
variables including phase of development, size, therapeutic and technological focus among others. The availability of peer data is used
by the Compensation Committee strictly as a guide in determining compensation levels with regard to salaries, cash bonuses and performance
related annual equity grants to all employees. However, the availability of this data does not imply that the Compensation Committee is
under any obligation to exactly follow peer companies in compensation matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Determination of Base Salaries</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a guideline for NEO base
salary, we perform formal benchmarks against respective comparable positions in our established peer group. We adjust salaries based on
our assessment of our NEOs&#8217; levels of responsibility, experience, overall compensation structure and individual performance. The
Compensation Committee is not obliged to raise salaries purely on the availability of data. Merit-based increases to salaries of executive
officers are based on our assessment of individual performance and the relationship to applicable salary ranges. Cost of living adjustments
may also be a part of that assessment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Performance Bonus Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Concurrently with the beginning
of each calendar year, preliminary corporate goals that reflect our business priorities for the coming year are prepared by the CEO with
input from the other executive officers. These goals are weighted by relative importance. The draft goals and proposed weightings are
presented to the Compensation Committee and the Board and discussed, revised as necessary, and then approved by our Board of Directors.
The Compensation Committee then reviews the final goals and their weightings to determine and confirm their appropriateness for use as
performance measurements for purposes of the bonus program. The goals and/or weightings may be re-visited during the year and potentially
restated in the event of significant changes in corporate strategy or the occurrence of significant corporate events. Following the agreement
of our Board on the corporate objectives, the goals are then shared with all employees in formal meetings and are reviewed periodically
throughout the year.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Determination of Equity
Incentive Compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To assist us in assessing
the reasonableness of our equity grant amounts, we have reviewed StreeterWyatt supplied information. Such information included equity
data from a cross-section of similar companies in our industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Equity Grant Practices</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All stock options and/or restricted
stock units granted to the NEOs and other executives are approved by the Compensation Committee. Exercise prices for options are set at
the closing price of our common stock on the date of grant. Grants are generally made: (i) on the employee&#8217;s start date and (ii)
at board of director meetings held once each year and following annual performance reviews. However, grants have been made at other times
during the year. The size of year-end grants for each NEO is assessed against our internal equity guidelines. Current market conditions
for grants for comparable positions and internal equity may also be assessed. Also, grants may be made in connection with promotions or
job-related changes in responsibilities. In addition, on occasion, the Compensation Committee may make additional special awards for extraordinary
individual or company performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Compensation Setting Process</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Annually, at a meeting of
our Board of Directors and the Compensation Committee, overall corporate performance and relative achievement of the corporate goals for
the prior year are assessed. The relative achievement of each goal is assessed and quantified and the summation of the individual components
results in a corporate goal rating, expressed as percentages. The Compensation Committee then approves the final disbursement of salary
increases, cash bonuses and option or restricted stock unit grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Compensation Committee
looks to the CEO&#8217;s performance assessments of the other NEOs and his recommendations regarding a performance rating for each, as
well as input from the other members of our Board of Directors. These recommendations may be adjusted by the Compensation Committee prior
to finalization. For the CEO, the Compensation Committee evaluates his performance, taking into consideration input from the other members
of our Board of Directors, and considers the achievement of overall corporate objectives by both the CEO specifically and the company
generally. The CEO is not present during the Compensation Committee&#8217;s deliberations regarding his compensation.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
has the authority to directly engage, at our company&#8217;s expense, any compensation consultants or other advisors (such as StreeterWyatt)
that it deems necessary to determine the amount and form of employee, executive and director compensation. In determining the amount and
form of employee, executive and director compensation, the Compensation Committee has reviewed and discussed historical salary information
as well as salaries for similar positions at comparable companies. However, the availability of this data does not imply that the Compensation
Committee is under any obligation to exactly follow peer companies&#8217; compensation practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We paid consultant fees to
StreeterWyatt of $22,000 during the year ended December 31, 2022. NEOs may have indirect input in the compensation results for other executive
officers by virtue of their participation in the performance review and feedback process for the other executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding the compensation earned during the years ended December 31, 2022 and 2021 for our named executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name/Position</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus&#160;(1)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
Awards&#160;(2)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other &#160;<br/>
Compensation</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 28%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">665,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">480,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,875,167</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,020,167</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman and Chief Executive Officer(3)</i></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">615,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">430,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,290,323</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,335,323</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">185,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">891,144</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,476,144</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Financial Officer</i></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">370,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">447,034</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">967,034</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify">The bonus disclosed in this column relates to performance in
the prior year, but was contingent upon board approval, and was paid in the year disclosed.</td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify">The dollar amounts in this column represent the aggregate grant
date fair value of all option awards granted during the indicated year. These amounts have been calculated in accordance with FASB ASC
Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions, see Note 6 to our financial statements.
These amounts do not necessarily correspond to the actual value that may be recognized from the option awards by the NEOs.</td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify">In addition to the foregoing, on August 17, 2022, Mr. Seth was granted
an award of 300,000 restricted stock units, or RSUs, which were granted in exchange for warrants that Mr. Seth received for services provided
to the Company prior to becoming employed by Actinium. These warrants were granted on December 17, 2012 and vested and became exercisable
on the 12-month anniversary of the grant date. The warrants were in the money for their entire existence since vesting. Mr. Seth was appointed
Chairman of the Board in October 2013, became Executive Chairman in August 2014 and Chief Executive Officer in June 2017. Mr. Seth refrained
from exercising the warrants in order to be aligned with the long-term interests of the Company and shareholders. In November 2018, the
Board extended the expiration of Mr. Seth&#8217;s warrants to February 2022. In February 2022, the Company requested that Mr. Seth not
exercise the warrants to maintain alignment with the long-term interests of the Company. In exchange for refraining from exercising these
warrants, the Board determined to grant Mr. Seth 300,000 RSUs based on the average fair value of the warrants during their vested life
based on the Black-Scholes option-pricing model to continue to align Mr. Seth with the long-term interest of the Company and shareholders.
The RSU grant was detailed on Form 4 filed with the SEC on August 19, 2022.</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Narrative Disclosure to Summary Compensation
Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a discussion of the material
terms of each named executive officer&#8217;s employment agreement or arrangement, refer to the sections above titled &#8220;Directors,
Executive Officers and Corporate Governance&#8212;Chief Executive Officer Compensation&#8221; and &#8220;Directors, Executive Officers
and Corporate Governance&#8212;Chief Financial Officer/Principal Financial Officer Compensation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 17, 2022, Mr. Seth
was issued 300,000 restricted stock units, or RSUs, in exchange for warrants issued to him for services provided to the Company prior
to being employed by Actinium. These RSUs vest at the earliest of a change of control event, the termination of the recipient&#8217;s
continuous service status for any reason other than by the Company for cause and the third anniversary of the date of the grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 1, 2022, Mr. Seth
was granted an option to purchase 827,366 shares of common stock and Mr. O&#8217;Loughlin was granted an option to purchase 256,438 shares
of common stock. The options have an exercise price of $4.96 per share and expire on July 1, 2032. Pursuant to the terms of the Company&#8217;s
Amended and Restated 2019 Stock Plan, 2% of the options will vest each month from the respective dates of grants until fully vested.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 1, 2021, Mr.
Seth was granted an option to purchase 310,182 shares of common stock and Mr. O&#8217;Loughlin was granted an option to purchase 107,463
shares of common stock. The options have an exercise price of $6.07 per share and will expire on September 1, 2031. Pursuant to the terms
of the Company&#8217;s Amended and Restated 2019 Stock Plan, 2% of the options will vest each month from the respective dates of grants
until fully vested.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the compensation of our non-employee directors for the year ended December 31, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees <br/> Earned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/> Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Awards&#160;(1)(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other <br/> Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Jeffrey W. Chell</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">51,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,748</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301,748</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">David Nicholson</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">63,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">313,748</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ajit J. Shetty</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">309,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Richard Steinhart</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">63,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">313,748</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dollar amounts in this column represent the aggregate grant date fair value of all option awards granted during the indicated year. These amounts have been calculated in accordance with FASB ASC Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions, see Note 6 to our financial statements. These amounts do not necessarily correspond to the actual value that may be recognized from the option awards by the Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, the aggregate number of option awards outstanding
for each director was as follows: (i) for Dr. Chell, 112,423, (ii) for Dr. Nicholson, 115,506, (iii) for Dr. Shetty, 112,173, and (iv)
for Mr. Steinhart, 117,171.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our non-employee directors
are paid an annual fee of $40,000 and receive annual option grants. Dr. Nicholson as Lead Director receives an additional annual fee of
$10,000. Board committee members receive the following compensation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">BOD Committee</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Chairman</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Member</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Audit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nominating and Corporate Governance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
- 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The following table sets forth
all unexercised stock options and unvested restricted stock units that have been awarded to our named executives by the Company that were
outstanding as of December 31, 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name <br/>
(a)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/>
Securities<br/>
Underlying<br/>
Unexercised<br/>
Options<br/>
(#)<br/>
(Exercisable)&#160;(b)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/>
Securities<br/>
Underlying<br/>
Unexercised<br/>
Options<br/>
(#)<br/>
(Unexercisable)&#160;(c)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
Incentive<br/>
Plan<br/>
Awards:<br/>
Number of<br/>
Securities<br/>
Underlying<br/>
Unexercised<br/>
Unearned<br/>
Options&#160;<br/>
(#)(d)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
Exercise<br/>
Price<br/>
($) (e)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
Expiration<br/>
Date<br/>
(f)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number&#160;of <br/>
Shares&#160;or<br/>
Units&#160;of<br/>
Stock&#160;That <br/>
Have&#160;Not<br/>
Vested <br/>
(#) (g)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market<br/>
Value of<br/>
Shares or<br/>
Units of<br/>
Stock<br/>
That <br/>
Have&#160;Not<br/>
Vested <br/>
($) (h)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
Incentive<br/>
Plan<br/>
Awards:<br/>
Number<br/>
of<br/>
Unearned<br/>
Shares,<br/>
Units or<br/>
Other<br/>
Rights<br/>
That<br/>
Have&#160;Not<br/>
Vested&#160;<br/>
(#) (i)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Equity<br/>
    Incentive<br/>
    Plan<br/>
    Awards:<br/>
    Market</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>or<br/>
    Payout</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Value of<br/>
    Unearned<br/>
    Shares,<br/>
    Units or</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Other<br/>
    Rights<br/>
    That<br/>
    Have Not<br/>
    Vested&#160;<br/>
    ($) (j)</b></p></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,333</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">183.90</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/23/2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.40</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/15/2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,666</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.70</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2026</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,998</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.70</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/14/2027</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,333</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.487</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/13/2028</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.96</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/12/2029</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,868</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,194</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.55</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/12/2030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,054</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">217,128</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.07</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/01/2031</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,736</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">744,630</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.96</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/01/3032</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,195,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,333</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53.70</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,666</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.70</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2026</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,333</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.70</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/14/2027</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,833</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.487</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/13/2028</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,933</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,400</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.96</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/12/2029</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,068</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,998</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.55</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/12/2030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,338</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,225</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.07</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/01/2031</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,643</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,795</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.96</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/01/2032</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully vested.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Company&#8217;s 2013 Stock Plan or 2019 Stock Plan, 2% of these options vest each month from the date of grant.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 102(b)(7) of the Delaware
General Corporation Law allows a corporation to provide in its certificate of incorporation that a director of the corporation will not
be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where
the directors breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law,
authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal
benefit. Our certificate of incorporation provides for this limitation of liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the General
Corporation Law of the State of Delaware provides that a Delaware corporation may indemnify any person who was, is or is threatened to
be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director,
employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer employee or agent
of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person
acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with
respect to any criminal action or proceeding, had no reasonable cause to believe that his conduct was illegal. A Delaware corporation
may indemnify any persons who are, or were, a party to any threatened, pending or completed action or suit by or in the right of the corporation
by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity
may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense
or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to be in or not
opposed to the corporation&#8217;s best interests, provided that no indemnification is permitted without judicial approval if the officer,
director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise
in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or directors
has actually and reasonably incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 further authorizes
a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise,
against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or
not the corporation would otherwise have the power to indemnify him under Section 145.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide that we
will indemnify our directors and officers to the fullest extent authorized by the General Corporation Law of the State of Delaware.&#160;&#160;Expenses
(including attorneys&#8217; fees) incurred by an officer or director of the Corporation in defending any civil, criminal, administrative
or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding
upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that
such person is not entitled to be indemnified by the Company as authorized under Delaware law.&#160;&#160;Such expenses (including attorneys&#8217;
fees) incurred by former directors and officers or other employees and agents of the Company or by persons serving at the request of the
Company as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may
be so paid upon such terms and conditions, if any, as the Company deems appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indemnification rights
set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any bylaw, agreement,
vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity and as to action
in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or
agent and shall inure to the benefit of the heirs, executors, and administrators of such person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a general liability
insurance policy that covers liabilities of directors and officers of our corporation arising out of claims based on acts or omissions
in their capacities as directors or officers. We have also entered into Indemnification Agreements with our executive officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the present time, there
is no pending litigation or proceeding involving a director, officer, employee, or other agent of ours in which indemnification would
be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table shows the
beneficial ownership of our Common Stock as of March 31, 2023 held by (i) each person known to us to be the beneficial owner of more than
five percent (5%) of any class of our shares; (ii) each director; (iii) each Named Executive Officer; and (iv) all directors and executive
officers as a group.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined
in accordance with the rules of the SEC, and generally includes voting power and/or investment power with respect to the securities held.&#160;&#160;Shares
of Common Stock subject to options and warrants currently exercisable or which may become exercisable within 60 days of March 31, 2023,
are deemed outstanding and beneficially owned by the person holding such options or warrants for purposes of computing the number of shares
and percentage beneficially owned by such person, but are not deemed outstanding for purposes of computing the percentage beneficially
owned by any other person.&#160;&#160;Except as indicated in the footnotes to this table, the persons or entities named have sole voting
and investment power with respect to all shares of our Common Stock shown as beneficially owned by them.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
the principal address of each of the persons below is c/o Actinium Pharmaceuticals, Inc., 275 Madison Ave, 7th floor, New York, NY 10016.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> Shares of <br/> Common <br/> Stock <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Percentage</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ownership<sup>(a)</sup></b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Beneficial Owners of 5% or More of Our Common Stock</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Michael Bigger</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,691,667</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.6</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Name Executive Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sandesh Seth</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">522,029</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Steve O&#8217;Loughlin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,859</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jeffrey W. Chell, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,915</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Nicholson, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,581</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Ajit S. Shetty, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,672</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Richard I. Steinhart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,229</td><td style="text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">All Directors and Officers as a Group (6 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">855,285</td><td style="text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.2</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">less
than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">Based&#160;on 25,729,370 shares of common stock outstanding as of March
31, 2023</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    address of record is 2250 Red Springs Drive, Las Vegas, NV 89135. Based on the beneficial owner&#8217;s Schedule 13G filed February
    6, 2023, shares beneficially owned consist of 416,000 shares of Common Stock owned by Bigger Capital Fund, LP (&#8220;Bigger
    Capital&#8221;), 708,167 shares of Common Stock owned by District 2 Capital Fund LP (&#8220;District 2 CF&#8221;), 172,500 shares of
    Common Stock held by Mr. Bigger through an IRA and another account, 135,000 shares of Common Stock through an IRA held by Patricia
    Winter, the spouse of Mr. Bigger, and an aggregate of 260,000 shares of Common Stock through an IRA held by the sons of Mr. Bigger.
    Mr. Bigger is also the beneficial owner of 66,406 shares of Common Stock issuable upon exercise of Warrants owned by Bigger Capital
    and 96,666 shares of Common Stock issuable upon exercise of Warrants owned by District 2 CF. The warrants are subject to a 4.99%
    beneficial ownership limit. The number of shares and percentage set forth above assume the no exercise of the warrants due to the
    beneficial ownership limit. Mr. Bigger disclaims beneficial ownership of these securities.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On September 23, 2014, Mr. Seth was granted an option to purchase
                                                                                                                                                                   9,333 shares of common stock with an exercise price of $183.90 per share. On February 18, 2015, Mr. Seth was granted an option to
                                                                                                                                                                   purchase 5,000 shares of common stock with an exercise price of $107.40 per share. On April 15, 2016, Mr. Seth was granted an option
                                                                                                                                                                   to purchase 16,666 shares of common stock at an exercise price of $59.70 per share. On March 14, 2017, Mr. Seth was granted options
                                                                                                                                                                   to purchase an aggregate of 24,998 shares of common stock at an exercise price of $41.70 per share. On July 13, 2018, Mr. Seth was
                                                                                                                                                                   granted an option to purchase 33,333 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Mr. Seth
                                                                                                                                                                   was granted an option to purchase 50,000 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Mr.
                                                                                                                                                                   Seth was granted an option to purchase 139,062 shares of common stock at an exercise price of $9.55 per share. On September 1, 2021,
                                                                                                                                                                   Mr. Seth was granted an option to purchase 310,182 shares of common stock at an exercise price of $6.07 per share. On July 1, 2022,
                                                                                                                                                                   Mr. Seth was granted an option to purchase 827,366 shares of common stock at an exercise price of $4.96 per share. All options are
                                                                                                                                                                   subject to vesting. Within 60 days of March 31, 2023, options to purchase an aggregate of 516,648 shares of common stock will have
                                                                                                                                                                   vested. Includes 5,381 shares of common stock.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On October 1, 2015, Mr. O&#8217;Loughlin was granted options to purchase
3,333 shares of common stock with an exercise price of $53.70 per share. On April 15, 2016, Mr. O&#8217;Loughlin was granted options to
purchase of 1,666 shares of common stock at an exercise price of $59.70 per share. On March 14, 2017, Mr. O&#8217;Loughlin was granted
options to purchase 3,333 shares of common stock at an exercise price of $41.70 per share. On July 13, 2018, Mr. O&#8217;Loughlin was
granted an option to purchase 8,833 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Mr. O&#8217;Loughlin
was granted an option to purchase 13,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Mr. O&#8217;Loughlin
was granted an option to purchase 59,066 shares of common stock at an exercise price of $9.55 per share. On September 1, 2021, Mr. O&#8217;Loughlin
was granted an option to purchase 107,463 shares of common stock at an exercise price of $6.07 per share. On July 1, 2022, Mr. O&#8217;Loughlin
was granted an option to purchase 256,438 shares of common stock at an exercise price of $4.96 per share. Within 60 days of March 31,
2023, options to purchase an aggregate of 162,676 shares of common stock will have vested. Includes 1,183 shares of common stock.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On April 27, 2018, Dr. Chell was granted an option to purchase 2,500 shares
of common stock with an exercise price of $10.41 per share. On July 13, 2018, Dr. Chell was granted an option to purchase 2,500 shares
of common stock at an exercise price of $23.487 per share. On July 12, 2019, Dr. Chell was granted an option to purchase 8,333 shares
of common stock at an exercise price of $6.96 per share. On August 12, 2020, Dr. Chell was granted an option to purchase 8,333 shares
of common stock at an exercise price of $9.55 per share. On September 1, 2021, Dr. Chell was granted an option to purchase 18,351 shares
of common stock at an exercise price of $6.07 per share. On July 1, 2022, Dr. Chell was granted an option to purchase 72,156 shares of
common stock at an exercise price of $4.96 per share. All options are subject to vesting. Within 60 days of March 31, 2023, options to
purchase an aggregate of 39,915 shares of common stock will have vested.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On February 18, 2015, Dr. Nicholson was granted an option to purchase 833
shares of common stock with an exercise price of $107.40 per share. On April 15, 2016, Dr. Nicholson was granted an option to purchase
2,500 shares of common stock at an exercise price of $59.70 per share. On March 14, 2017, Dr. Nicholson was granted an option to purchase
2,500 shares of common stock at an exercise price of $41.70 per share. On July 13, 2018, Dr. Nicholson was granted an option to purchase
2,500 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Dr. Nicholson was granted an option to purchase
8,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Dr. Nicholson was granted an option to purchase
8,333 shares of common stock at an exercise price of $9.55 per share. On September 1, 2021, Dr. Nicholson was granted an option to purchase
18,351 shares of common stock at an exercise price of $6.07 per share. On July 1, 2022, Dr. Nicholson was granted an option to purchase
72,156 shares at an exercise price of $4.96 per share. All options are subject to vesting. Within 60 days of March 31, 2023, options to
purchase an aggregate of 43,248 shares of common stock will have vested. Includes 333 shares of common stock.</p></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On March 28, 2017, Dr. Shetty was granted an option to purchase 2,500 shares
of common stock with an exercise price of $47.40 per share. On July 13, 2018, Dr. Shetty was granted an option to purchase 2,500 shares
of common stock at an exercise price of $23.487 per share. On July 12, 2019, Dr. Shetty was granted an option to purchase 8,333 shares
of common stock at an exercise price of $6.96 per share. On August 12, 2020, Dr. Shetty was granted an option to purchase 8,333 shares
of common stock at an exercise price of $9.55 per share. On September 1, 2021, Dr. Shetty was granted an option to purchase 18,351 shares
of common stock at an exercise price of $6.07 per share. On July 1, 2022, Dr. Shetty was granted an option to purchase 72,156 shares at
an exercise price of $4.96 per share. All options are subject to vesting. Within 60 days of March 31, 2023, options to purchase an aggregate
of 39,915 shares of common stock will have vested. Includes 757 shares of common stock.</p></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On December 16, 2013 Mr. Steinhart was granted an option to purchase 1,665
shares of common stock at an exercise price of $201.00 per share. On February 18, 2015, Mr. Steinhart was granted an option to purchase
833 shares of common stock at an exercise price of $107.40 per share. On April 15, 2016, Mr. Steinhart was granted an option to purchase
2,500 shares of common stock at an exercise price of $59.70 per share. On March 14, 2017, Mr. Steinhart was granted an option to purchase
2,500 shares of common stock at an exercise price of $41.70 per share. On July 13, 2018, Mr. Steinhart was granted an option to purchase
2,500 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Mr. Steinhart was granted an option to purchase
8,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Mr. Steinhart was granted an option to purchase
8,333 shares of common stock at an exercise price of $9.55 per share. On September 1, 2021, Mr. Steinhart was granted an option to purchase
18,351 shares of common stock at an exercise price of $6.07 per share. On July 1, 2022, Mr. Steinhart was granted an option to purchase
72,156 shares at an exercise price of $4.96 per share. All options are subject to vesting. Within 60 days of March 31, 2023, options to
purchase an aggregate of 44,913 shares of common stock will have vested. Includes 316 shares of common stock.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">Includes options to purchase 847,315 shares of common stock and 7,970 shares
of common stock.</p></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transactions with Related Persons</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For disclosures regarding
our policies relating to director independence, refer to the section above titled &#8220;Directors, Executive Officers and Corporate Governance&#8212;Corporate
Governance&#8212;Director Independence.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-Competition Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers have
signed non-competition agreements, which provide that all inventions become the immediate property of us and require invention assignments.
The agreements provide that the executive officers will hold proprietary information in the strictest confidence and not use the confidential
information for any purpose not expressly authorized by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below shows the
aggregate fees billed for professional services for the audits and audit-related fees of the Company&#8217;s annual financial statements
included in Form 10-K for the years ending December 31, 2022 and 2021, respectively, by Marcum LLP (PCAOB ID Number <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">688</ix:nonNumeric>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit Fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">178,793</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">128,400</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Audit &#8211; Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All Other Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">208,333</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">149,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Audit Fees.</i> This
category includes the audit of our annual consolidated financial statements, reviews of our financial statements included in our
Form 10-K and Form 10-Qs and services that are normally provided by our independent registered public accounting firm in connection
with its engagements for those years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Audit-Related Fees. </i>This
category consists of assurance and related services by our independent registered public accounting firm that are reasonably related to
the performance of the audit or review of our financial statements and are not reported above under &#8220;Audit Fees.&#8221; The services
for the fees disclosed under this category include consents regarding equity issuances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Approval Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2015, the Audit Committee
adopted policies and procedures for the pre-approval of audit and non-audit services performed by the independent registered public accountants
pursuant to which the Audit Committee generally is required to pre-approve the audit and permissible non-audit services performed by the
independent registered public accountants in order to ensure that the provision of such services does not impair the registered accountants&#8217;
independence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the services rendered
by Marcum in 2022 were pre-approved by the Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br/>
Number</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020020895/ea125182ex1-2_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital on Demand&#8482; Sales Agreement, dated August 7, 2020, by and between Actinium Pharmaceuticals, Inc. and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit 1.2 to Registration Statement on Form S-3 filed on August 7, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390022035693/ea161465ex1-1_actinium.htm">Amended and Restated Capital on Demand&#8482; Sales Agreement, by and between Actinium Pharmaceuticals, Inc., JonesTrading Institutional Services LLC, and B. Riley Securities, Inc., dated June 28, 2022 (incorporated by reference to Exhibit 1.1 to Form 8 K filed on June 29, 2022).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm">Certificate of Amendment to Certificate of Incorporation filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm">Certificate of Amendment to Certificate of Incorporation filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February&#160;7, 2014).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm">Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm">Certificate of Amendment to Actinium&#8217;s Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</a></span></td></tr>

<tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm">Certificate of Amendment to Actinium&#8217;s Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm">Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm">Amendment to the Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex4viii_actinium.htm">Form of Common Stock Warrant, dated December 27, 2013 and January 10, 2014&#160;(incorporated by reference to Exhibit 4.8 to Form S-1 filed on January&#160;31, 2014).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390019006723/f8k041819ex4-1_actinium.htm">Form of Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on April 18, 2019).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390021019297/f10k2020ex4-15_actinium.htm">Description of Securities (incorporated by reference to Exhibit 4.15 to Form 10 K filed on March 31, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390015001800/f10k2014ex10xlii_actinium.htm">Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan (incorporated by reference to Exhibit 10.42 to Form 10-K filed on March 16, 2015).</a> </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390015005829/f10q0615ex10i_actinium.htm">First Amendment to Amended and Restated 2013 Stock Plan, effective August 6, 2015 (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 7, 2015).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390015009512/f8k121515ex10i_actiniumpha.htm">Second Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 15, 2015 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 16, 2015).</a></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390016011534/f10k2015ex10xxxxxvi_actinium.htm">Third Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 22, 2015 (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 11, 2016).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390016019421/f8k121316ex1i_actiniumpharma.htm">Fourth Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 13, 2016 (incorporated by reference to Exhibit 1.1 to Form 8-K filed on December 14, 2016).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lix_actinium.htm">Fifth Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.59 to Form 10-K filed on March 16, 2017).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10i_actinium.htm">Director Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on March 28, 2017).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10ii_actinium.htm">Indemnity Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Form 8-K filed on March 28, 2017).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10iii_actinium.htm">Confidential Information and Invention Assignment Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to Form 8-K filed on March 28, 2017).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390017004962/f8k050517ex10i_actinium.htm">Amendment to Amended and Restated Consulting Agreement, dated May 5, 2017, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 11, 2017).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10ii_actinium.htm">Employment Agreement, dated September 17, 2015, between Steve O&#8217;Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Form 10-Q filed on May 15, 2017).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10iii_actinium.htm">Indemnification Agreement, dated May 15, 2017, between Steve O&#8217;Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on May 15, 2017).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-56_actinium.htm">Sixth Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 16, 2018).</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-1_actinium.htm">Director Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 1, 2018).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-2_actinium.htm">Indemnity Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.2 to Form 8-K filed on May 1, 2018).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-3_actinium.htm">Confidential Information and Invention Assignment Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.3 to Form 8-K filed on May 1, 2018).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-1_actinium.htm">Employment Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 9, 2018).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-2_actinium.htm">Employment Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Steve O&#8217;Loughlin (incorporated by reference to Exhibit 10.2 to Form 10-Q filed on August 9, 2018).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex10-39_actinium.htm">Seventh Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.39 to Form 10-K filed on March 15, 2019).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189ex10-1_actinium.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 18, 2020).</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-3_actinium.htm">Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on August 14, 2020).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-4_actinium.htm">Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Steve O&#8217;Loughlin (incorporated by reference to Exhibit 10.4 to Form 10-Q filed on August 14, 2020).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390020038523/ea130223ex10-1_actiniumpharm.htm">Actinium Pharmaceuticals, Inc. 2019 Stock Plan (incorporated by reference to Exhibit&#160;10.1 to Form 8-K filed on November&#160;20, 2020).</a></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390020038523/ea130223ex10-2_actiniumpharm.htm">First
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan (incorporated by reference to Exhibit&#160;10.2 to Form 8-K filed on November&#160;20,
    2020).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390021057769/ea150278ex10-1_actiniumph.htm">Second
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan (incorporated by reference to Exhibit&#160;10.1 to Form 8-K filed on November&#160;9,
    2021).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26+&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390022047496/f10q0622ex10-1_actinium.htm">Exclusive
    License and Supply Agreement, dated April 7, 2022, between Immedica Pharma AB and Actinium Pharmaceuticals, Inc. (incorporated by
    reference to Exhibit&#160;10.1 to Form 10-Q filed on August&#160;12, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390022047496/f10q0622ex10-2_actinium.htm">Sublease
    Agreement, dated April 28, 2022, between ABN AMRO HOLDINGS USA LLC and Actinium Pharmaceuticals, Inc. (incorporated by reference
    to Exhibit&#160;10.2 to Form 10-Q filed on August&#160;12, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390022049740/ea156670ex99-4_actiniumpha.htm">Third
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Stock Plan (incorporated by reference to Exhibit 99.4 to the Registration Statement
    on Form S-8 filed on August 19, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/ea171085ex10-1_actinium.htm">Fourth
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Stock Plan (incorporated by reference to Exhibit&#160;10.1 to Form 8-K filed
    on December&#160;30, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000107878212003323/f8k122112_ex14z1.htm">Code
    of Ethics (incorporated by reference to Exhibit 14.1 to Form 8-K filed on January 2, 2013).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390015001800/f10k2014ex21i_actinium.htm">List
    of Subsidiaries (incorporated by reference to Exhibit 21.1 to Form 10-K filed on March 16, 2015).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="f10k2022ex23-1_actinium.htm"><span style="font-size: 10pt">Consent
    of Marcum LLP.</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="f10k2022ex31-1_actinium.htm"><span style="font-size: 10pt">Certification
    of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
    2002.</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="f10k2022ex31-2_actinium.htm"><span style="font-size: 10pt">Certification
    of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="f10k2022ex32-1_actinium.htm"><span style="font-size: 10pt">Certification
    of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
    2002.</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><a href="f10k2022ex32-2_actinium.htm">Certification
                                    of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant
                                    to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></p>
</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS&#160;&#160;**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH&#160;**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Schema
    Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL&#160;**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Calculation
    Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF&#160;**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Definition
    Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB **</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Label
    Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE **</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Presentation
    Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates a management contract or compensatory plan or arrangement.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of the schedules (and similar attachments) to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5) of Regulation S-K under the Securities Act of 1933, as amended, because they do not contain information material to an investment or voting decision and that information is not otherwise disclosed in the Exhibit or the disclosure document. The registrant hereby agrees to furnish a copy of all omitted schedules (or similar attachments) to the SEC upon its request.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because they are both (i) not material and (ii) the type that the registrant treats as private or confidential. A copy of the omitted portions will be furnished to the SEC upon its request.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>Dated: March 31, 2023</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 60%">&#160;</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 36%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer (Duly&#160;Authorized Officer,<br/>
Principal Executive Officer) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer <br/>
(Duly Authorized Officer, <br/>
Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Registrant and in the
capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer) </span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey Chell</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Chell</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Nicholson</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Richard I. Steinhart</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ajit J. Shetty</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit J. Shetty</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 107; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>
</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:SecurityDeposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:RestrictedCashNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:DeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="atnm:LongtermOperatingLeaseObligationsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-11" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.20</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.37</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-14" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">20568373</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-15" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">24141545</ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-21" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-27" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-28" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-29" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-30" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-31" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-32" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-33" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-34" name="atnm:RightofuseAssetsObtainedInExchangeForLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-35" name="atnm:AcquisitionOfEquipmentFinancedBySecurityDeposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-36" name="us-gaap:OtherRestrictedAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-37" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-38" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-40" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-41" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-42" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-43" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-44" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-45" name="atnm:PaymentWithImputedInterestPremium" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-46" name="atnm:LongtermLicenseRevenueDeferred" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-47" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-49" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-50" name="atnm:RSUsOutstandingBeginningBalance" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c69" id="hidden-fact-52" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c69" id="hidden-fact-53" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-55" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-57" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-59" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-60" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-61" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-62" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-64" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-65" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001388320</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah3T1Ki2MCKemJQOnFITo819XV2SZHEI0EiEoEUPiTVdpo53/UPf4KPbGQfg8/dyhoreC4upaSg/wmtLLQQWzYYSy386a+zde19o0mZ+MfUY4O+0PtDOcp+vogPUqDYU7nDBNPaVkLXMQ==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-05-16</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-03</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:EquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:EquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-08-01</xbrli:startDate>
    <xbrli:endDate>2017-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>f10k2022ex23-1_actinium.htm
<DESCRIPTION>CONSENT OF MARCUM LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in the
Registration Statement of Actinium Pharmaceuticals, Inc. on Form S-3 (File No. 333-242322) and on Form S-8 (File No. 333-266996, 333-231391,
333-223741, 333-216746, 333-197283), of our report dated March 31, 2023, with respect to our audits of the consolidated financial statements
of Actinium Pharmaceuticals, Inc. as of December 31, 2022 and 2021 and for each of the two years in the period ended December 31, 2022,
which report is included in this Annual Report on Form 10-K of Actinium Pharmaceuticals, Inc. for the year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 31, 2023</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U></U></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10k2022ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO 18U.S.C SECTION 1350 AS ADOPTED<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXELY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. I have reviewed this report
on Form 10-K of Actinium Pharmaceuticals, Inc. for the fiscal year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a. Designed such
disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b. Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c. Evaluated the
effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d. Disclosed in
this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a. All significant
deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b. Any fraud, whether
or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 31, 2023</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer,<BR>
Principal Executive Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>f10k2022ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING
OFFICER<BR>
PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXELY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. I have reviewed this report
on Form 10-K of Actinium Pharmaceuticals, Inc. for the fiscal year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a. Designed such
disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b. Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c. Evaluated the
effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d. Disclosed in
this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a. All significant
deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b. Any fraud, whether
or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 31, 2023</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer,<BR>
Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>f10k2022ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER,<BR>
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Actinium
Pharmaceuticals, Inc. a Delaware corporation (the &ldquo;Company&rdquo;), on Form 10-K for the period ended December 31, 2022 as filed
with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chief Executive Officer of the Company, certify,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 31, 2023</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer,<BR>
Principal Executive Officer)</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>f10k2022ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING
OFFICER,<BR>
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Actinium
Pharmaceuticals, Inc. a Delaware corporation (the &ldquo;Company&rdquo;), on Form 10-K for the period ended December 31, 2022 as filed
with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin, Chief Financial Officer of the Company,
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 31, 2023</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 36%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer,<BR>
Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %W U(# 2(  A$! Q$!_\0
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MX,>,OB[XC_9+;XR6WP9M_AY^T'HGPR^'WQ,\,?&/QUK/Q>N?!_QUVZ5>^/\
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M6-4#_@H]^T/M/;X6\#H/^+/^ 1P/88S@X&<X!Z^(?L'^#_@[\4/VDO ?P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG^/.:?O7U_0_X5^<P^./_!18# _8;\#@#I_QD=X(YSU_Y;>OK1_PO+_@HO\
M]&-^"/\ Q([P/_\ 'J^87AYG/_0YX"\[>(G!MK];+^TM#] _XC1PXM/]5?%[
M9?\ -E_$K;_PSK\EZ'Z,[U]?T/\ A1O7U_0_X5^<W_"\O^"B_P#T8WX(_P#$
MCO __P >H_X7E_P47_Z,;\$?^)'>!_\ X]1_Q#S.?^ASP'_XL3@W_P">0?\
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M&_!'_B1W@?\ ^/4?\0\SC_H<\!?^+$X-_P#GD'_$:>'/^B5\7O\ Q2WB5_\
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M (I?Q*_^=!^C.]?7]#_A1O7U_0_X5^<W_"\O^"B__1C?@C_Q([P/_P#'J/\
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M_H?\*_.;_A>7_!1?_HQOP1_XD=X'_P#CU'_"\O\ @HO_ -&-^"/_ !([P/\
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M)'^"/_CM+_PO+_@HO_T8WX(_\2.\#_\ QZE_Q#S.?^ASP%_XL7@W_P">0_\
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M.>.2,9XXSC]*7R_?]/\ Z]?BU^SY_P %C/AAXH^"/[+_ (E^.7A3Q)8?&?\
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ME'VE[57&-N)93ER4(\DW"$5&%.5>M*G"-Z#E:+=DY_5Z7M'=N=G?=GXHZO\
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M\)SJRF#RK+VXOV=K*LG:<O?]O.I5GSWA-RY*M3GH:P]A*%/V5E3@E^#?@O\
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MS_A1==PYH_S+^OD345#YR_YS_A1YR_YS_A1==PYH_P R_KY$U%0^<O\ G/\
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MN]2U>YTO38WAME^\B#M.#GAA[]..G<'W'Y\U'YP]OU]>>WIT_6E\Y?\ .?\
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M?:JNDV][KVJ:!IXM?#ECT?PF_P"":_[3]GIW[%?P ^/'QY^#OC']DG_@GO\
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M\!^&M>^)_P ._$?B66T\-:+K'@33=>N[SQ)JOA_0GL(M7\2^'++5OR6\5?\
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MVU?7ZHM^NW9:6-%X39!TXB\45_WEWQ"79?\ 0PT^_P#4^"!\$?VY@,?\-G^
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MS'&8;+,HR;*L*ZE-8K-,WS;'8' 8&BZE*FJF(G6Q-:A@L%C\3A_0_C3^UE\
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M^US^U:/^[E/C2.G'?QT?3U_0TO\ PU]^U_V_:Z_:O'KG]I7XT?\ S<C-?/.
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MCR2BI*IS1]FZG/#G2JXMWM5Q3M)P=JF*E:2^).U1I.%FYW:5-)NHX)-KV_\
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M_P".1_\ Q5'R_P!W_P <C_\ BJ/84/\ H'PW_A-AO_F4/;U_^?U7_P &U?\
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M/^BT_&?_ ,.Y\0/_ )IJ/^%P_&C_ *+3\9__  [GQ _^::O//E_N_P#CD?\
M\51\O]W_ ,<C_P#BJ/84/^@?#?\ A-AO_F4/;U_^?U7_ ,&U?_EAZ'_PN'XT
M?]%I^,__ (=SX@?_ #34?\+A^-'_ $6GXS_^'<^('_S35YY\O]W_ ,<C_P#B
MJ/E_N_\ CD?_ ,51["A_T#X;_P )L-_\RA[>O_S^J_\ @VK_ /+#T/\ X7#\
M:/\ HM/QG_\ #N?$#_YIJ/\ A</QH_Z+3\9__#N?$#_YIJ\\^7^[_P".1_\
MQ5'R_P!W_P <C_\ BJ/84/\ H'PW_A-AO_F4/;U_^?U7_P &U?\ Y8>A_P#"
MX?C1_P!%I^,__AW/B!_\TU'_  N'XT?]%I^,_P#X=SX@?_--7GGR_P!W_P <
MC_\ BJ/E_N_^.1__ !5'L*'_ $#X;_PFPW_S*'MZ_P#S^J_^#:O_ ,L/0_\
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MI:4YX:;DU:VC:;V6KE96:2I>#_\ D5O"_P#V+NB_^F^SKID^Z/Q_F:YGP?\
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M\'LY]NTDG5^J>)^2O#*HU9SC0EB\2Z49\ZIO$5N1Q52<6S_@H2<?L#_MO?\
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M.1__ !5+FC_-'_P*/_R0??\ <_\ (,^[?]\1?XT9]V_[XB_QH^7^[_XY'_\
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MY3F^=1IRM3I37LZ<DI1YY+F/U5_X)T^/O@O^S[XT^%_[14W[9&D?!CQ#X?\
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M,91?Q1E]5FW&7FN;[FO,I>#_ /D5O"__ &+NB_\ IOLZZ9/NC\?YFN9\'_\
M(K>%_P#L7=%_]-]G73)]T?C_ #-?/S_BU?\ KY4_]/53U:7P4O\ KU#_ -(I
MCJ***1J(0#P:38G]T<=..G)/]3^!(Z4ZB@#XR_X*#_M52?L-?L8_M"?M;6W@
M.'XG2_ CP%<>.%\ 3^*'\%Q>*/(U/2]-;36\41Z!XI?1ODU!IUN5T#4]SPK
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M%MKXHU'2H)K72[_Q';^!M T*+6[W3;6XGMK"ZU-+J>SMYI8;>2..1U;V^B@
MHHHH 0]/Q _,C]1V]ZXB[&?'FGY"G_BCM=R."-O]M^'">N>O8''4GBNW;D8]
M<#\R*XB\4GQ[IH).#X0USMD9&M^&2,G@=0.N.XSS5T[-U4^N'K*UDV_=CHKM
M+F?1-I/5/0PKZ*F^GMJ-_)7J)OS].MVKH_C3_P""^GP ^+_BO]O?POXF\._#
MOQQKVB?$/X,_#7PKX)U#PQX;U;7K?Q/XJT'6?&UGJOA?39-)M+K?XEL)-3T^
M1]%)6^^Q:K87\:26MT)(OS._:(_X)H?M??LL7G@73/BE\.];U)OB=HFDZEX>
MOOAS:ZIXXLEU34H;:[OOACK-QX?TV;R_B-X?O7MK+6]"A;4-/U>^MTN?"&H^
M)-,A341_I#[!N))?#\8!95*@L-I .3@9[8&2!ZA3'&@)4LH;@A69"<GIA2HS
MR>F,$LW7D_IN5>*>895@LER^&48#$X;*L+/"5U6JXASQR;JRHR3BTL)&G*K>
MI2I1Q-.LU)3<4H*'\\<2?1VRSB/-N*\[GQ5FV#Q_$&94LPP$J67Y;5IY'-RB
M\?1BZB57'0Q;]I&G.=;!5,-"25\3%U:=3_.@\??L#?M_?L(:U\$?B_K'A[Q9
MX,\9:ZVE>-/AYXR^$TFI>*=4^'?C$75S'9_#WQA/I6DW4&F_$<:=Y UKPS-;
MZYX1\2Z1KLOAFSU+Q2J>+]-L_P"@G]J;Q]^T.+%_BYXMLO%7PM_:-N/^"*$'
MB+QC+X'&N>&M<\&?%G5OC_\ !J^\5Z?HEQI,HU+P[JMMJ-SJZ3:':W\EYH]O
M]HTMKR^@@DNY/Z55502%)!) .QF!(.,\C&<!@>,%?X2,DFR(E& "X'7[[ @X
M SP>21G))).3G.<CP>(.-,1Q)1P"Q^69?2QN"^LPJYAAXSC6QE'$3@U0J1G*
M;I4X>SAS0C4J1=6,JT/93JUH2^XX#\+<+P!F.>U\JS[-,3D^;PRUX?(L72PL
M</EN*P-*-.ICHUJ"I_6<5BHQC#VE3#4)T\/+V-2IC%3HU*?\[_QK^%'CKP3X
ML_;@\,>&/VC/VT8]'^!G[&'@S]I3X3M)^TE\8[^XM/CGJ]C\2H=5UBYU>;79
M-0\5:7>S?#S3;B;X7:O>:C\.[&7Q'K9TWP981SZ FA\%\5M;^-_BSP3^V]^T
M'#\</VF/#'Q"^$GB7]B*Y^%>E^"OBM\1_#G@#1)?BI\-?@)_PM!K3X6V%\O@
M;7K'79_%^N2WNEZMX<UK2-%U*!]1TVQTW49=7EO/Z7?*!.2SY!)&&8#GN0"!
MN.2,^G X)!7RA_>D_P"_C?X\>_KWKY98KE5O84V[4US-)MJ#A?2ROSJ%I=;2
MEKJC]0]BKK71.32N_M7MUTY;Z6^9_-U^T)KO[1WP%U7]L7X,?"'XH?'S7?@Y
M\/\ XI?L+ZUXE\0>-/BI\6?%WCGX>?![XK>%OBA=?'?4='^-QT;XI?&3PGX8
MU'Q%X/\  S^)]<\':3XPU?X<Z)JGB+5?"GANV69K9N5T#XG?'I/@/XLU^V^/
M_BR^_9 U/]JWX'^'_B'XV^"GQ>_:A^.7Q(^"7P9N/#^NS_&MO#?[0OQF^"7P
M[^+NM?#W4O%"?"Z6?Q3X-U+QMJ7@>QU?QGI=OK]I"M_'<_TW>2O'S/QDC#D
M$G.0!TZD#V)7H<4C1#!;+EERRY=B <8'?.,=>><GUJ5B+12]A%[7>B<K12YG
M=-W5N9-.S>ZLQNFV_B:79-VM>]K7LUTUUL?R]^'O%UIIO[0GQSUW]GWXJ?'C
MQ)\,->_:?_X(L>%?#WQ#\2>(OB=>>(O%7PQU3XV?%K3O&?AY/'_BG[-X[^)'
MPODM;[5]&N-=\7ZAKT>O:%)/:WFL:[X=32[^Y^C/A)\28M2\8>+X_C#\</VD
M]*_X*26_Q5^/]KX-_9R?QS\<-'^"]S%I.J?$*'X#>&-.^%.B6Z?!/5/@=J_@
MBS\ Z_/\1M:@C&J:W<SS:]X]@%[-IES^UVKZ%XQU?5=7-MXDNM&TEC8#3(H'
M9IE>(Z+<R3!X-LB!)[35H'B>22.\CU!X[M?L\-O'0?#GC>1]3:7QJ8H[A[J3
M3UM++RQ9LVF36EL7$PFW)#<M#?RVH(@DN8&94AMYS9Q$L1S14732Y5%<UU%O
MEY4DVTTT^7WK*-[NW02I--OFWO=:VN^;5*^ZYG;?YG\^GP+^+%M?^,/^">47
M@S]HW]L3QG\;/%GQC\/6'[;_ (&^)7B_XTW'A70_&MQ\)_'E_KWA7QIX4\3Q
M6G@KX:3Z;XYM[W3O"GP]\&Q:1X=\1>&].DUO5=$\0R>'=$\16']*L&?+'IVQ
MTQ@9P1P1NSR./3C KSRS\.^,+>\TIG\7RW5A::G=W6HV]S;F:XU&PFTW3K2#
M3#<%8T6.&YAOKTR&$3M+=VY6<&&XCNO1UX4#TZ].O<< # Z# Z5G4FJDE+EY
M+<VFC^*3ET26E^6-E\*5];EPBXK67->W2UK*WF[]7W;N.HHHJ"PHHHH 8_\
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MO$/BF\LCJ6I'2+2_O#I'AZ#4+W3_  SIFC:9,;.O>-WQ*Y/D>!.?^G[Q)_\
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M]H-_Q+_Y]_ ?_@9XB_\ D&D\SXE#K!X"'_;YXB_^0:/]<>,/^BOS'_P\U_\
MYG'_ &3DW_0DI?\ ANI?_)GXP?\ $.+_ ,$K/^B4?%;_ ,2)^-7_ ,UU'_$.
M+_P2L_Z)1\5O_$B?C5_\UU?M!YGQ*/2#P$?^WSQ%_P#(-&_XE_\ /OX#_P#
MSQ%_\@T?ZX\8_P#17YC_ .'FO_\ ,X?V3DW_ $)*7_ANI?\ R9^+_P#Q#B_\
M$K/^B4?%;_Q(GXU?_-=1_P 0XO\ P2L_Z)1\5O\ Q(GXU?\ S75^T&_XE_\
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MX)?_ ,L._HK@/,^)G_/#P)_X&^(__D&CS/B9_P \/ G_ (&^(_\ Y!H]DO\
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M ,#?$?\ \@T>9\3/^>'@3_P-\1__ "#1[)?\_P#"_P#@]?\ RD/K/_3C$?\
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M&H82.'JY[&O%QJ</PQU>HXY(N2%/#4J^'J8B5#%X:DU3F]?_ (B%?VP\D_\
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M_P"_QUGZGH_[:6B6C:AK/[3'['ND6"/'$]]JO[)'Q5TZS269@D,;W5Y^W1#
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M  E^S5X M_A+X<USXMWW@'1]%\6Z/XK\27^BZ?\ $#PQIG]F8/KE3_GQ@/\
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MZ,;L7T_4_P"-&Q?3]3_C3J*+?U=_Y@-"J#D  GO6-XC_ .0!KW'71M5!_P#
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M$O@7]K73OAC\./A[XC\%^$OB%\)DTOX>ZWXBN-9M]-);^KO_ # _I?T7XO\
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M*\$7>@:[X6:PU30OO/X-_P#!(/\ :.\$?M'GXY:U\(?A6GB&_P#^#A?]K/\
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MA"P\$7GQ)^&\OQ6O8_AQX TRU>32_!VJ^-O"@GM_!_@G3K.T,^G>'M4U?3]
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MVOP\\/?&/1/"^M2Z'?00ZMX8U+6K35+BT_)[PS^TS^T?X*UB3Q!X,^/?Q?\
M"&MR>!_#/PUEU/PQX^\1Z!<S^ O!EK)8^#/"D_\ 9E[;1S:3X.M)[JW\*++&
M]SX=COM1.D7-HVHW[SWM _:M_:A\*^)M3\9>&?VC/C;H/BS7=%T#P]XA\0:9
M\2O%5IJ7B?2/"-BVF>%;;Q7,NI!?%<_AK37EL-!U3Q)'JNL:1:3W5M97\%O=
MW44O'5R;B*HYN.=QII82%&#IXK,HRJ2IRHSC5J**J1BW3IU82KT84I8CVDHU
MZDJCJUI]U'B?@RDHREPO)S>-K8IQE@LDG"C2K4<30G0H1E4HSFG[:A4CA\3[
M7#85T82PL4^2E3_3C1_V(OV=O@YIFBV_[1_A)_\ A(_B1^U7\4_@SJ'A^_\
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M<_!_0/@G>?"*R_9RO[C4F\'1>.+;QY'KWAT6-GJ.O^(/[1_M3ROS@UO]HO\
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M^+5U\2=&^*^H_&W4/@_\,-$\;GXM0ZQ=3Z1X_E\>W&A6FK1>.KOQ#KEY=?\
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MBQKMY:)8>"_C)XW\<1Z!=>(_@UXN^&^G^))_"=OIEUXX%M:K(NB?;]:LLO\
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MK\:_&'H,? ']H 'WX_X5KD^YQ@=R!1_P_#_X)L_]%J\89'0_\,__ +0''/\
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M_P"5' ?:OB-_T!?!'_A5Z_\ _,?1]J^(W_0%\$?^%7K_ /\ ,?7?[%]/U/\
MC1L7T_4_XT>U7_/FA_X!/_Y<'L/^G^)_\&Q_^5' ?:OB-_T!?!'_ (5>O_\
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M&_V#?^CO_P!G7_PZ'A;_ .6-/_77Q#_Z!*W_ (C^)_\ E(?\0L\'/^AA0_\
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M!G_1W_[.G_AT?"W_ ,L:/]=?$+_H$J_^(_B?_E(_^(6>#O\ T,*'_B98/?\
M\'[G\U'_ !#[_MS_ /0_?LF<?]5+^+W7C_JWGC&./\X/^(??]N;/'CW]DWKD
MG_A9GQ>'\OV>QD9ZY]Z_I8_X>.?L&#K^U_\ LZ#_ +JCX6_^6-)_P\<_8,_Z
M._\ V=/_  Z/A;_Y8T?ZZ^(2_P"82K_XC^)_^4B_XA9X.?\ 0PH/_N\<&_\
MW.?S4#_@WW_;F[^/OV3"?^RF?%_Z_P#1O7'/;\>N<@_X-]_VY\$?\)]^R;C&
M!GXF?%\_3_FWK'/7OZ8QP/Z6/^'C?[!O_1W_ .SK_P"'1\+?_+&C_AXW^P;_
M -'??LZ_^'0\+?\ RQH_UV\0O^@2K_XC^)_^4_J'_$+/!S_H84/_ !,L'_\
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MX;:QXBTZSN/M=IIVM:KX0_9PTB_U+3[6[S<V]E=W$MM!<LUU%"MQ^\JQ\/\
MX/\ BGX3_%+Q9\<?A;_P27_8X^&_QH\>?VM_PFOQ:\"?%WX6>$OB3XK'B"_A
MU;Q NO\ C;0?V;K#Q'J:^(=6MK?5?$ NM1D_MS5+:#4M5^UWL23K^K_EP^@_
M[Y'_ ,31Y</H/^^1_P#$T/&89_\ ,LP7_F0_^>/D/^S,=_T4&;?^"<H\_P#J
M4^;^]GYO^%K;X]>!K+XCZ9X+_P"";_[.OA33/C%XR\4_$7XM:=X>_:-\':18
M?$WQ]XYL++2_&GC/Q_9V7P AM_%_BCQ9IFEZ9IWB36]?BO\ 4-:L;"SM-0N+
MFWMH8U\6\(?LRV?P^\)^./ ?@+_@C5^PKX'\$_$S6_"/B3XB>$?"'Q%^#_AO
MPWXYU[P!K;>)? >J>+-&T;]FBRT_7[OP/XBDEUSP=)J=O<_\(SJLT]_HBV-S
M/+(_[$^7#Z#_ +Y'_P 31LBQ]Q2/4C')[<+[?K2>,PW_ $*\"_5Y@OQ>8O\
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M\31]<PO_ $*\%]^9?_/,7]F8[_HH,U_\$9/_ /.@^*?^%N?ML?\ 1F7PX_\
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M55[6K^YHO][5U<9WUJU?^GP4J3=.FG6K_P .GM4BO^7=+_IUY'!?:OB-_P!
M7P1_X5>O_P#S'T?:OB-_T!?!'_A5Z_\ _,?7?[%]/U/^-&Q?3]3_ (TO:K_G
MS0_\ G_\N+]A_P!/\3_X-C_\J. ^U?$;_H"^"/\ PJ]?_P#F/H^U?$;_ * O
M@C_PJ]?_ /F/KO\ 8OI^I_QHV+Z?J?\ &CVJ_P"?-#_P"?\ \N#V'_3_ !/_
M (-C_P#*C@/M7Q&_Z O@C_PJ]?\ _F/H^U?$;_H"^"/_  J]?_\ F/KO]B^G
MZG_&C8OI^I_QH]JO^?-#_P  G_\ +@]A_P!/\3_X-C_\J. ^U?$;_H"^"/\
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MR1NPNXN<<?Z+?[:O_)FW[6O_ &;1\>__ %57BNO\Z6,YC4<#"+UY'3Z<$'D
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MB_&G]E_4OA-\/;[XOZ-\6O@I\8/AKHGQ0N?@WXVUOX4>*/$^J-\,OB+]AO\
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M?V=_C)\??AO\,OC?\7_^"@?AE_AA\+?$NI2:7XK\;1^/_P!D_P#8S\ ^#9=
MTQ;$+<IXD\<:=JWARP=&2.35[*\A80JF]_ZK%;<,X(.2"#V(/3W]\9&<C)Q2
M>S]'^3 ;+]P_C_(U^7__  40O+RP_P""67QZFL;NZLIIO@GI&G2RV=Q+:S2Z
M?JVL^&],U6Q>6!XW>SU+3;NZTZ_MF)AO+&YN+2Y62WGEC;]0)?N'\?Y&ORV_
MX*-_\HK_ (Z_]D>\,_\ J3^$J]?(DI9AEJDE)//,I3C))IIUK------:----
M:--:'S'%;<<CX@E%N,H\,9^XRC)QE&2P&(M*,HN,HR3U4HR4D]4T]3^%< (
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MPA7G&<:4\)FV+IQYL3A<'AJE:=/)LPM3I9AB)T94Z2Q5/"4\11KK\E"Y[''
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ML.@Z]3<>O7)['(/'4<<#'(ZDCGIS7Z<K^PYX#UKX[_\ !0_X.Z'XQN] T_\
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MX4_MC:38:CJ7@GPUH^H_!_\ :)T_2K2]O]0@^$OB?5++6-"\?Q65FL\D]O\
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MU)THT\L>;8"G*C_9:Q6=58XRE"I1O2YCQ5^P3XD\->"O''B"U^.OP7\4^-/
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M1ZC\Q1D>H_,5)K==U]Z_S%HI,CU'YBC(]1^8H"Z[K[U_F! /J/<'!_/K2!
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M]O4_DPO_ (1T ^JK_G[B?_"NM_D<%_9/Q#_Z'/PS_P"$1<__ #7T?V3\0_\
MH<_#/_A$7/\ \U]=[@>@_(48'H/R%'MZG\F%_P#".@'U5?\ /W$_^%=;_(X+
M^R?B'_T.?AG_ ,(BY_\ FOH_LGXA_P#0Y^&?_"(N?_FOKO<#T'Y"C ]!^0H]
MO4_DPO\ X1T ^JK_ )^XG_PKK?Y'!?V3\0_^AS\,_P#A$7/_ ,U]']D_$/\
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M)_=7_OD?X4?7,7_S\I_^$]/_ .6!_9>!_P"?$?NA_P#*#PK_ (4[;?\ 0/\
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MH_LGXA_]#GX9_P#"(N?_ )KZ[W ]!^0HP/0?D*/;U/Y,+_X1T ^JK_G[B?\
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M_(48'H/R%'MZG\F%_P#".@'U5?\ /W$_^%=;_(X+^R?B'_T.?AG_ ,(BY_\
MFOH_LGXA_P#0Y^&?_"(N?_FOKO<#T'Y"C ]!^0H]O4_DPO\ X1X</JJ_Y^XG
M_P *ZW^1P7]D_$+_ *'/PS_X1%S^G_%8#GTY%<S-I_C8^,=/BD\4: ]\?"^K
MNEVOA&Y$"6HUCP^)[9[-O%#F1Y)'@D6X%R@A6%XS;RF4/'[$0,=!U';W'MWZ
M5Q5R<^/],(& ?!VM@<8.#KGAHGVP<D'UP0.E:4\1-.I[F'TH5GIA*";LH:)I
M7_3N9U<-%*G^\Q#O6I+7%UW\3J+LNQ772_B%CCQEX:Y)SGP1=8R 0<?\5?QS
MR,].<]12_P!D_$/_ *'/PS_X1%S_ /-?7=J!G&!]U<<=1ZX_+\J=@>@_(5DJ
M\^D,-U_YA*#ZM]?4T^K1>JJ8E?\ <W7Z)+L^W]7."_LGXA_]#GX9_P#"(N?_
M )KZ/[)^(?\ T.?AG_PB+G_YKZ[W ]!^0HP/0?D*?MZG\F%_\(Z ?55_S]Q/
M_A76_P C@O[)^(?_ $.?AG_PB+G_ .:^C^R?B'_T.?AG_P (BY_^:^N]P/0?
MD*,#T'Y"CV]3^3"_^$= /JJ_Y^XG_P *ZW^1P7]D_$/_ *'/PS_X1%S_ /-?
M1_9/Q#_Z'/PS_P"$1<__ #7UWN!Z#\A1@>@_(4>WJ?R87_PCH!]57_/W$_\
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MJ_;;3_GXA_[^Q_\ Q='VVT_Y^(?^_L?_ ,71KVE_X!4_^5ASQ_FC_P"!1_\
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M_ *G_P K#GC_ #1_\"C_ /)EJBJOVVT_Y^(?^_L?_P 71]MM/^?B'_O['_\
M%T:]I?\ @%3_ .5ASQ_FC_X%'_Y,M455^VVG_/Q#_P!_8_\ XNC[;:?\_$/_
M ']C_P#BZ->TO_ *G_RL.>/\T?\ P*/_ ,F6J*J_;;3_ )^(?^_L?_Q='VVT
M_P"?B'_O['_\70[V>DMG]B?9_P#3L.>/\T?_  */_P F32_</X_R-<3\,O\
MD0/!_P#V+ND_^DD==9)=V[1D"> G!ZS1@'@C^]GGUZ8RV<"N+^&US;Q> ?!R
MM-$"/#>D@AI(U8$6D9((W$\9(/!YX!.":U@I+#57RR_WBC]F?6AB?^G9RRE%
MXND^>'\"K]N#_P"7M#M,]"HJK]MM?^?B'_O]'_\ %4?;;3_GXA_[^Q__ !=9
M:]I?^ 3_ /E9U<\?YH_^!1_^3+5%5?MMI_S\0_\ ?V/_ .+H^VVG_/Q#_P!_
M8_\ XNC7M+_P"I_\K#GC_-'_ ,"C_P#)EJBJOVVT_P"?B'_O['_\71]MM/\
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M7M+_ , J?_*PYX_S1_\  H__ "9:HJK]MM/^?B'_ +^Q_P#Q='VVT_Y^(?\
MO['_ /%T:]I?^ 5/_E8<\?YH_P#@4?\ Y,M455^VVG_/Q#_W]C_^+H^VVG_/
MQ#_W]C_^+HU[2_\  *G_ ,K#GC_-'_P*/_R9:HJK]MM/^?B'_O['_P#%T?;;
M3_GXA_[^Q_\ Q=&O:7_@%3_Y6'/'^:/_ (%'_P"3+5%5?MMI_P _$/\ W]C_
M /BZ/MMI_P _$/\ W]C_ /BZ->TO_ *G_P K#GC_ #1_\"C_ /)EJBJOVVT_
MY^(?^_L?_P 71]MM/^?B'_O['_\ %T:]I?\ @%3_ .5ASQ_FC_X%'_Y,M455
M^VVG_/Q#_P!_8_\ XNC[;:?\_$/_ ']C_P#BZ->TO_ *G_RL.>/\T?\ P*/_
M ,F6J*J_;;3_ )^(?^_L?_Q='VVT_P"?B'_O['_\71KVE_X!4_\ E8<\?YH_
M^!1_^3+5%5?MMI_S\0_]_8__ (NC[;:?\_$/_?V/_P"+HU[2_P# *G_RL.>/
M\T?_  */_P F6J*J_;;3_GXA_P"_L?\ \71]MM/^?B'_ +^Q_P#Q=&O:7_@%
M3_Y6'/'^:/\ X%'_ .3+58GB+_D :]_V!M5_](9*T?MMI_S\0_\ ?V/_ .+K
M&\075L^A:X%GA);1]4 _>(>38S#LQ/Y>P[U5._M:7NR_BT_L3_Y^0_Z=F5:4
M72J+FC_#J;R@O^753^_YD7@__D5O"_\ V+NB_P#IOLZZ9/NC\?YFN2\(W%NG
MA?PSOFA1E\/:+N4RQ@AO[-M<A@6&W!^4G'4$=JZ-;RU&?](@Y)/$L?Y8W?U]
MO>BHI*M5O&7\2I]B?_/VJ_\ GV%*<.2E[T?X4/M0OK"GTY[ERBJOVVT_Y^(?
M^_L?_P 71]MM/^?B'_O['_\ %U.O:7_@%3_Y6:\\?YH_^!1_^3+5%5?MMI_S
M\0_]_8__ (NC[;:?\_$/_?V/_P"+HU[2_P# *G_RL.>/\T?_  */_P F6J*J
M_;;3_GXA_P"_L?\ \71]MM/^?B'_ +^Q_P#Q=&O:7_@%3_Y6'/'^:/\ X%'_
M .3+5%5?MMI_S\0_]_8__BZ/MMI_S\0_]_8__BZ->TO_  "I_P#*PYX_S1_\
M"C_\F6J*J_;;3_GXA_[^Q_\ Q='VVT_Y^(?^_L?_ ,71KVE_X!4_^5ASQ_FC
M_P"!1_\ DRU157[;:?\ /Q#_ -_8_P#XNC[;:?\ /Q#_ -_8_P#XNC7M+_P"
MI_\ *PYX_P T?_ H_P#R99/3\5_F*XJZ 'C[3 .@\':T/RUWPX*ZLWMJ>//B
M/TFB_3Y^H[<=:XZYN(3X[TV02Q;/^$0UL%C*FT.=;\.%5W [1E48G)X"L<85
MJNFFW5M&7^[UOLS_ )8=X&-:</W?OQ_CT?M0[U/[YW*]1_N#^=/JG]LMA_RW
MAZ=?.CX' X^;@'J#W/7'0.^VV@_Y>(1_VUC_ /BZRBFDTXRW_DG_ /*S6,X6
M^./RE!]NTWV+5%5?MMI_S\0_]_8__BZ/MMI_S\0_]_8__BZK7M+_ , J?_*Q
M\\?YH_\ @4?_ ),M455^VVG_ #\0_P#?V/\ ^+H^VVG_ #\0_P#?V/\ ^+HU
M[2_\ J?_ "L.>/\ -'_P*/\ \F6J*J_;;3_GXA_[^Q__ !='VVT_Y^(?^_L?
M_P 71KVE_P" 5/\ Y6'/'^:/_@4?_DRU157[;:?\_$/_ ']C_P#BZ/MMI_S\
M0_\ ?V/_ .+HU[2_\ J?_*PYX_S1_P# H_\ R9:HJK]MM3_R\0^O^MC[<G^.
MG)<PR$B*2*0@C(65"<$@ D+D\G '8GC(P:/E+YQDOQ<$OQ!2BW92BWVYHW^Y
M2;_ L444AX' S[4%"T5"92"?E_5OZ(1^1-%3SQ_F7WCL^S^YA*<*,]B-Q&.N
MT]SC' YQS@C'7C\WOVBM/;]IG]I3P1^R1<7]S!\)O!O@^'XY_M!V%G/+:MXT
MMQK]GI7PV^&=Y>6I@N[6PU+4(K_7=?AMKI9+O2!;3+-IVI6>D74GZ03'Y>!D
M[N,C('# D^P"D\GDA1GD ?#7PG53^W9^V-*ZJS1_"W]E7RG8?ZLO:?%YI",\
MHLAAC,A&-WEJ&SM7;]IP57>75N(\^H)PS'A_A3,,PR>K:,I87-<7F&2Y#ALP
MI\W,H8K*Z.>YACLOJVOA\R6%Q5->WPF%J4?RCQ4PRSBAP1PEB)?\(_&/B!DN
M3<1X=.<?[2R# Y9Q+Q3C<DJNG*'-@<ZQ/#&4X'-J,Y*GC,G^OY=5YL-F.,HU
M_LW3M,L=*L++2]+L;/3=,TVTMK#3-.L;>*ST_3[*SA2WL[.RL[18K:TM+6")
M88(+>.*&**-(HXXXE5%O"-0 1SN'S$#&XX! &=Q!..A/LK#D'XK_ ."B?[3O
MBK]CS]CSXN?M"> ]+\(Z_P"._!C?#_2_!'AKQRNM'P[XI\5^/OB=X,^'NA^&
M;H:#=:?J-O=ZY=^*%T[2[R2_TW2=-U:>SU+Q%J6G>'+35;V#\=/CO_P4F_X+
M*_LM^-OA[X/^-7[)G["L=]\1?AO\9OBSX2T[PU\7_B;(OB[2?V=? TGQ4^,/
MP[T[Q!+)?Q^&_B1I/PZM+S6],O=>\/R_#Z^,$L6G>*]7U.$:+/Y&6\.9EG5)
M8O"ULOBZE;%48+&YGAL/B\15PU.CB,7.A3KQJ5*\81Q=&K6JRK1CSSJWO.%>
MM#]"Q&/P>7\N'G"K&G3I44HX;"-X:A3G)T,/3G*BZ=&C!*C[.G3C245"E'EA
M&,(J/ZH?MJ^$;CX23:/^V_\ #2P-I\1/@H]E_P +.L["+GXJ? B[N(+'QKX2
MUN"$1I?:CH%L]MXC\.ZK?2&/2!HS2SF1]/T.;2?T&TK5;+5K"TU+3YEN=/U&
MUM+ZQNXQF.[LKZ!+BTN8B.#'<6\L<R$@,5< X(P/B7XD_%;1?C[_ ,$Z/%'Q
MT\/:;?Z7X>^-/['5W\7/#^E:N8)-3TC1OB-\&_\ A,M*T_4#:O-:RZA9V.LQ
M6EV;:62W:[AD>%WCV&OHSX  #X%?!8*%51\)?AH%4=@/!NB#;CJ H"@=1CCZ
M>QFU2MC>"LDK8Y3EF'#_ !)G'"E+$59N==Y1#*,'G>%RVK4;E*=')LQEFE'+
MX2G46&PV/Q.%HSIX2GA:%/\ .<AP]')O%?BW+\KY:.4\4<'Y!QYB\%3BH89<
M3KB+,>$\QSC#4HQA3IXG/\JHY)6SF<:<)8W'91A,;55;%RQ>*K>P75M#=P26
MUQ%'/!,CQ303(DD4T4B-')%+'(&22.1&*.C JZDJP*D@\[_PA?A+&!X4\-#W
M_L+2?_D3'Z5U)(P#D<D <]<G'%-#J1E2#R!USUQWSUZ_B*^,4Y0YN6I.%_BY
M9SCWLVHSBKVVNKM'ZO*G">LH0E;;FIPE;YRA)_)NWD<Q_P (7X3_ .A5\-_^
M"+2/_D.C_A"_"?\ T*OAO_P1:1_\B5U5%+V]3_G_ %__  95_P#DR?8TO^?5
M'_P32_\ E9RO_"%^$_\ H5?#?_@BTC_Y$H_X0OPG_P!"KX;_ /!%I'_R)754
M4>WJ?]!%?_P94_\ DP]C2_Y]4?\ P32_^5G*_P#"%^$_^A5\-_\ @BTC_P"1
M*/\ A"_"?_0J^&__  1:1_\ (E=511[>I_T$5_\ P94_^3#V-+_GU1_\$TO_
M )6<K_PA?A/_ *%7PW_X(M(_^1*/^$+\)_\ 0J^&_P#P1:1_\B5U5(3CMG\_
M;C@&G[>I_P!!%?\ \&5/_DP]C2_Y]4O_  32_P#E9RP\%^$_^A5\-_CH6D_T
MLZ#X,\)#_F5?#66' _L+2L]O^G/Z9Z@'M75?Y_SV_"J[R+N'*G:2N,C[Q9<*
M<GJ0"0.IZ8[T*K5=FJU=Z]:M1=&U]M>7^0.C2L[4J7RHT^Z[4WV\CRK2/"_A
MJ;QCXQMI/#V@O;6MEX4>WMY-(T]X('N+;5&G:"%K9HX7E95,[1HK2[$W[MHV
M]G_PA?A/_H5?#?\ X(M(_P#D2LK0_P#D=_&_J+#P@?\ R6U;K^OOW-=\.@SZ
M"MJM2K>G:M65\-A6[5:F_P!7I]ZC[&-"E3<9WITG_M&)U=*D]/K%3_IW?J<M
M_P (7X3_ .A5\-_^"+2/_D2C_A"_"?\ T*OAO_P1:1_\B5U72DR,9R,>N>*S
M]I6_Y_U__!L__DS;V-+_ )]4?_!-+_Y6<M_PA?A/_H5?#?\ X(M(_P#D2C_A
M"_"?_0J^&_\ P1:1_P#(E=5SZ?G_ /6S1D=,\^E'M*W_ #_K_P#@V?\ \F'L
M:7_/JC_X)I?_ "LY7_A"_"?_ $*OAO\ \$6D?_(E'_"%^$_^A5\-_P#@BTC_
M .1*ZD$$D Y(Z_K_ ('\J"P&22,#J<C@^GUZ?F*/:5O^?]?_ ,&S_P#DP]C2
M_P"?5'_P32_^5G+?\(7X3_Z%7PW_ ."+2/\ Y$H_X0OPG_T*OAO_ ,$6D?\
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M?]"OX:_\$.E?_(5?F/\ \/P?^"4W_1Y7@+_PFOB?_P#,-1_P_!_X)3?]'E>
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M?PU_X(=*_P#D*C_A#?"'_0K^&O\ P0Z5_P#(5?F/_P /P?\ @E-_T>5X"_\
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M,D]G&48-23[IM'*_\(7X3_Z%7PW_ ."+2/\ Y$H_X0OPG_T*OAO_ ,$6D?\
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MI'?ZG'\__P!6.U+7-[2M_P _ZW_@VI_\F'L:7_/JE_X)I?\ RLY7_A"_"?\
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M$9QJ2G3A3G.4FH+VN*LW[3$KXDFYUDN:GS>TCO=NGRR]I96I\K]HH)-GHO\
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MX?!'BG7];\6>++RW^'W@Z[UQ;&ZELO#/A[2[CQ#J-AX0\(2WVD>(>"?VNO\
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M&>W/.:LUGJ;ZK%<I=;;(!=\0DDV8"LKQ_9_FC8NS%A(6!7@<!>00:D=6\X3
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MC*?L8-1/VH_:]_Y-7_:,![?!+XG?^H9K(&,XXX)YY/![G';_  !_Y(3\%/\
MLDOPW_\ 4.T*N(_:^!7]EC]HQ<YQ\$_B?@DYX_X0S6N_4D=#TZ#CFNW^ /\
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MP.@QT' X!Y*@]]JC Q_RT.,]<90^N>"/IC&/#_U$RQSIU)5:SJ4ZGMHUEA\
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M)_9O^*7B7Q!X^U;XM?LH67PX\9^(?#&H^+_'FD^"O#]_I/QN\2>*;'5/&?\
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MKJI*S3:L:N%]3_Y$_P *,+ZG_P B?X5E?VYHG_09T?\ \&4/_P ?H_MS1/\
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M-M*W70L^S\KQNKZ[IIIK5W5NK/L3]J/]JK7/VE(?@II<>C^(/ OA?X1_LL?
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M8L_9UT;X8?#[X3:M\5;71M#UOXY0>./&'Q*UW]I'5M2O?A)XKLH+^[\>^/\
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MHW-Y+X=UV?QYH%]JWA;5?(?V;O\ @EK^U-\._&_[)WB?QU^QEJ>J3_"35O\
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M_%#6O*M/"/A>YU(W.EV?!_%K_@GC\,_C[^W58_M/_'?P1\$OC3\+M*_9*C^
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M9>F^X?J*^&_A+C_ANC]LG)_YI9^RF1]19?&3&< DCCTYZ5]R3?</U%?#7PE
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M]>^8/^"?'PX_9J@_;5^#?BK3?V+_ /@O#HGQ'T2V^*D?PZ^+7_!0+0O%^I?
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MM7_^'1\4?_(=!_X-T?\ @F*>O@G]J[C_ *JAXG_^0J_>[_A:GPM_Z*/\/O\
MPLO#O_RSH_X6I\+?^BC_  ^_\++P[_\ +.C_ %TXQ_Z&^>?^%V+_ /F4?]B9
M3_T#X'_PEPW_ ,T'X(_\0Z7_  3&_P"A)_:O_P##H^*/_D.C_B'1_P""8O\
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M[5Z^)O:C1DO]XJJ]VT]DM+:=W>YR@\7Q@#/A[Q:??^P;CGG_ *Z4O_"81?\
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MO\RKO\*?]$^O_P#PB8/_ (U1O\*?]$^O_P#PB8/_ (U5K_A:GPM_Z*/\/O\
MPLO#O_RSH_X6I\+?^BC_  ^_\++P[_\ +.B];_H'Q/\ X49A_F'LX_\ /ZA_
MX38+_,J[_"G_ $3Z_P#_  B8/_C5&_PI_P!$^O\ _P (F#_XU5K_ (6I\+?^
MBC_#[_PLO#O_ ,LZ/^%J?"W_ **/\/O_  LO#O\ \LZ+UO\ H'Q/_A1F'^8>
MSC_S^H?^$V"_S*N_PI_T3Z__ /")@_\ C5&_PI_T3Z__ /")@_\ C56O^%J?
M"W_HH_P^_P#"R\.__+.C_A:GPM_Z*/\ #[_PLO#O_P LZ+UO^@?$_P#A1F'^
M8>SC_P _J'_A-@O\RKO\*?\ 1/K_ /\ ")@_^-4;_"G_ $3Z_P#_  B8/_C5
M6O\ A:GPM_Z*/\/O_"R\._\ RSH_X6I\+?\ HH_P^_\ "R\._P#RSHO6_P"@
M?$_^%&8?YA[./_/ZA_X38+_,J[_"G_1/K_\ \(F#_P"-4>9X4_Z)]?\ _A$V
M_P#\:JU_PM3X6_\ 11_A]_X67AW_ .6='_"U/A;_ -%'^'W_ (67AW_Y9T[U
M_P#GQB?_  IS#_,/9Q_Y_4/_  FP7^96\SPI_P!$^O\ _P (FW[?]L?S]>])
MO\*?]$]OO7_D2;?_ .,_Y''<U:_X6I\+?^BC_#[_ ,++P[_\LZ/^%J?"W_HH
M_P /O_"R\.__ "SHO7_Y\8G_ ,*<P_S#V4/^?U#_ ,)L%_F5=_A3_HGM]Z<>
M";<<>G$5&_PI_P!$^O\ _P (FW_^->_XU:_X6I\+?^BC_#[_ ,++P[_\LZ/^
M%J?"W_HH_P /O_"R\.__ "SHO7_Y\8G_ ,*<Q_S#V4/^?U#_ ,)L%_F5=_A3
M_HGU_P#^$3!_\:HW^%/^B>WW_A$6_KGIY..M6O\ A:GPM_Z*/\/O_"R\._\
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M^+?_  0S_P#Q==9Y:?W11Y:?W11[2'_0-'_P?6#EK?\ 01+_ ,)Z7_R1R?\
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M==9Y:?W11Y:?W11[2'_0-'_P?6#EK?\ 01+_ ,)Z7_R1R?\ PF$7_0N^+?\
MP0S_ /Q='_"81?\ 0N^+?_!#/_\ %UUGEI_=%'EI_=%'M(?] T?_  ?6#EK?
M]!$O_">E_P#)')_\)A%_T+OBW_P0S_\ Q=96N>*8YM%UF,:#XJC,VDZE&'ET
M*X2)"UG,H:1]Q"H.K-CA02> :]!\M/[HK%\1*HT#7<*!C1M5Z<'_ (\9N_T.
M/;DU=.I#VE/_ &>*_>4_^7];_GY3,ZT:OLJEZ[?[NI_S#T5_R[J=>8X[PQXG
M2#PYX>A.A>*)3!H6D0F6#0KB6!VCT^W0R12JP62)M@=)%&UD=3\IZ;X\7QC
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M%WQ;_P""&?\ ^+KK/+3^Z*/+3^Z*/:0_Z!H_^#ZP<M;_ *")?^$]+_Y(Y/\
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M4)<L5"4IVDXU>1>].3BG;63W=K?GY^R/^R=X?_9;N[_63J'CCQ]XCN_ NC>
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MAW0?AGJ\FD>/?"OQ'@\&^);OQ3>Z?9W/AW5OW!_X*6_'3XO?LT_L1_';XT?
MSPUX:\2?$;P?I'AJ/3$\8:3K&O\ A'PSHOB3QQX9\(^,?B'XIT'0(Y=7UGPY
M\-/"&N:WX\URPM(I@=)T"ZN+NVN[&"ZLY_@#]@KX:?M"_#?XY>"GE_X*'?\
M!-[XH_"CQ.FOZCXV^#?[+_[./P3^%_CGXJJG@'Q1/X7O]*\1?#SQ5/=7(\-:
MW-I?C.\NUTF]CN?#VCZQ SVMC>33P^ME..G_ *GXQ8E8-JA#-\'A)2I8*4\5
M%X+"3=&O*CPOC\72G@:E>IB,#B99QE\L54K3IXC$0PV%E-_48K#O^V</*D\1
M>3PM:NU/$^SIN%6H[TE+-:&'<<2J/LL1'ZEB7&G'FA"$JB;_ %<_:]_Y-6_:
M,XP1\$OBA[CY?!>M8].HP<'D9QR0:[GX!#'P*^"H]/A+\-Q_Y9VAUP_[7PQ^
MRM^T:.?^2(?% =_X?!&M+SDD\X[Y)ZGT'<? /_DA?P5_[)-\./\ U#]#KR'_
M ,F_P^R_XSO&Z*UE?@K+W96]VR325DE9::'RU+_D\V.M_P!&DRZS_P"\G9M_
M7].]']IWQAKOP\_9N_:!^('AB>.T\2^!/@E\6/&?AVYF1Y8;?7?"_@'Q#K>C
MW$L<4D,CQP:A8VTSI'/#(P0JDL;$,/\ .0NT_M>\O=8UF2;6M8UB[N-4UC6=
M8D;5-7UG5M1E>[U'5=5U&\,MWJ&IZA>2S7=_?W<LT]W=.\\S/,Q>O]$G]M3_
M ),Y_:RZ\?LT?'@_^8K\6?Y_*O\ .W5BEN)  =EN' .1DK'NP200 <8)P< D
ME3D@_H/A+&'U3/)J$?:_7,!!3LN=TUAJDU2YU>7(ZLE4<(\JE-1<G9-KU>+Y
M<M7 IR:BJ5:?+=<O,ZL8<TKRBK0@I-/1:[JUU7_L[3^?] L^W/V6W'H!UBXX
MQWP!CGGD_L[3^]A9CZVL _\ :/U^N#C-?9GBO]BKXQ6WCSP?\/OA1I'B/XY:
MOXG_ &>/A!^T3K-UX:\'Q>%M.\#:)\7?#ESX@LM#\2ZIJOBO5/#]A%I+6TFE
M6?B;6_$'AV+Q;J,<T&DZ!9WD?V*7S_1/V4OVF/$?C3QS\.=$^!/Q(O\ QW\+
M[O1[3XC^%/[#6SU?P*?$*SRZ)J'BF/4+FSATGP_JEI;RZG;>*KF9?"S:*UMK
MC:PFBWMC?77Z;3S?+YP<UC\-&$:2K3YZU.E*G0]K4HQK3IU:E&I"G4G2<:4I
M4U&I)I)^]2]M\Q+#8F+2=#$?$X)PH5*L9RC!5)*E.G*4*C4'=-3Y7::4DX,^
M<_[.T_\ Y\+/'_7K;G@=3Q#V_P \9-']G:?S_H%GP<?\>MOU^IA _P#U5]%^
M//V4_P!IKX6>$-;\??$SX!?%7P%X,\-:_;>&/$'B+Q9X3O='L]'U6^O1INF/
M?17.R^A\/ZUJC#2/#WC,69\$^)-8DAT;P_XBU/5)X+.7O-*_8;_:7A\3_!K2
MOB5\*/'WPA\)?&+XP?!SX0Q>/_%/A:.]@\%ZA\:?%^@^%O#VJ>*O"4.NZ9KV
MBW,4.N+J=GX=\7OX+O-;GMUT&+4-+U&]ADIRS? 1IJJ\QPDJ<E6Y)T\10J*J
M\/2]M6A2C3Q,YU*M.G:<J,(3K*G*G4</WM.$Q87$N7(J.(YKPT="NHKGDJ:O
M)Q2BE5ER.<W&*2<F[19\<?V=I^<?V?:=O^76W'7_ +8_K1_9UAQ_Q+[/GI_H
MMO[?],??_(KZ@^/_ .R9\>/V<-2UZ;XA?#CQUIO@&R^)7B_X<>&/B=K/A&X\
M.Z%XPN?#.JZG:Z/J4VG#4=<G\%W?C?P[IT?C3PQX:\1Z@-0U3PW=K?Z+>^)-
M)M/[7D;^R[^SM_PTCX\U[P[JOQ)TKX,^ / _@K4?'OQ(^+6N>%I_&VF>#-"M
M]5T;PSHP/A:S\3>$;K7;[7_%GB70M$M;:TU^Q>SM+R^UIUO(M&FL+L>;8+ZC
M/,8XNG4P<*<JDJM&2KNT52?)&%"=6I*JW7HPC14/;^WG["5%58RB'U;$>VAA
M^2<:TYNG&$XNDG+DE-)SJSA&*Y8RDYM^RC&,VZGN2/F'^SM/Y_XE]G^%I <^
MXQ#2#3M.)S_9]D<?].L'?MQ#P<__ %NM?6GA?]E+Q-J'QP^-7P@^(/C#0_A'
MH7[-R_$'5/CG\4_%&CZQJ6B^#O"/P^\56?A!M=TGPKI3'Q!XVU;QOKFK>'+/
MX;>#M!G;5O&X\1V TVZ>US>&+Q+\&?V=]"M/A[XKL/VR+'Q/\-?&$?C"S\3:
MEI?P$NH/C=\+O$_A2WM[VTT[Q;^S;?\ QPBO[CPIXNM+M%\.?$G1OBG<^&Y;
MB.^L)H([VP2RO$\VP;G&G"M4KNI3I58/#X7%XF$H8C#2Q>&7M*5"5)5<1AHN
MM1P[G&O4A9TXN3A2J5]5KVE*25*,)RA+VU2A2<73K0I59<L\2IN%)S2G4490
MYVJ<;N\H?*7]G:>/^8?9?3[+!SD=,"(=><^^?H?UM_X(B:_K?AS_ (*!?#[P
M_H.K7^C:%XY\(?$G2O&6BZ=</:Z3XHLM$\#Z[XBT:+6M/B*VE[)I&MZ?:ZEI
M=U)%]KTZ<72VEQ%!J&H177RK^UG^S;\._P!F+QC+\.-'^/\ KGQ?^(&GQ^"]
M4U[1I_V>[GX3^']+\-^.O .F?$'1M5M/%MQ\;?B6=:U..QUW0;.[T%/#VF&&
M>XU&X;6<:0(+WZ3_ ."+W_*1KX*9YQX=^+HQQGCX7>*A]W&/4#D]?>O'SW$8
M?,N$\XQ-%NMA:N4XVK1G4PE2E&3C24J56$,5"%6*4N6I3J^QIO2]*:DKOIP5
M.KALVPE*?N588O#QJ1AR-I2JJ+3JT>:.NTX2J-M>[)2UO_:IH6?^$Y\;]"#8
M^$2>F<_9]5Y&!TSR>3DXXQR.^K@M!_Y'CQOR1_H'A'OCK:ZL/YGC\*[PD 9Z
M ?3C^G'UQ7\R5?BI_P#8+A$EV2H0LKO>RLO-*]S].P[]V>K?[_$[VTMB*BMH
MDK+IUMO=ZBT4S>..&&3CE2.>W;N>!2LP SS@9R0,X"C)S[$<9]ZS-S\\?^"B
M'[6'Q6_9I\+?L\^#/@!X0\">+?V@/VN?VF_!'[+GPCN/BK<:W'\*_ .K^)?"
MOCGQ_P"(OBA\1=/\-WNC>(_%'AKP5X-^'6OW7_"&>&O$/AWQ#XIUB[TK3-.U
MG3T-U=0>"_%7]L;]LS]BG]B3]O#]H']M[P1^SEJ7B_\ 9JL-:N/V=?'/P-N?
M&&@_#+]I6X\5:3I.F?!33-?^%'B[QGXY^(7PBUW4OBOXJ\)_##Q;H5W\2O%4
MNI:I>7>I^#;^XTI='O\ 5_M3]L3]CWX9?MK?#+0OAS\1];^(?@?5? GQ(\(_
M&?X1?%;X1^)H_!_Q7^#/QB\"C4H_"OQ)^'>O7>FZYI%MXBTW3M:\0:)-;^(=
M \0:!J>AZ_K6GZCI%W!= Q?"\_\ P1&_9M\2_#/Q?\-?C'\8/VFOV@O^%S?M
M3?##]J?]IWQK\:?'WACQ+XM_:CU7X.0K'\-O@O\ %N#2_ F@>#(_V?/#$=CH
M5KI_PR\$>$O"-I9:;X<T;2]/O[&QLK>.  ^-/B!_P6&_:G^%O_!/+XQ_%GXF
MZ-^S1\.OVS/V7O\ @H+X6_8@_:0DU7P#\3?%G[._A?1_&/Q8\*6NB?&3P[\.
M_"7QOO/BEJ?A^7X$?$CP=XRCTZ+XH7^J:AXKTSQ3IEO9JJ6^EV?U9_P2]_X*
M,?%C]L#Q9^T[_P +!\6?L^?%[]G3X3K\)[?X5?MF? GX0?'7]FOX0?$3QOXM
MM?$Y^)7P@_X1G]H_Q]\0;WQ!XP^%MUI&ASZ[X@\%>-=1T"SA\5Z7HNMV6E^(
M7>P3?M_^"%O[$?A76/B)+\%K'QS^SSX&^)OQ*_8Z^,&O_"/X-W'@_0/AI8?$
MO]BGXCZE\1/AQXM\,:+JO@W6KSP_?>,9=4D\/_%!+34&@\3:98Z7?V*:/K]D
M=9N/?(/^"6?[)$OQM_:8^*?B'P#HOQ$^'W[7&H^"_'/QJ_95^*?@[X=?$C]E
MO5?COX'A:PM?VD- ^%/B_P &:M8^&?C3XHT4C3?B)XETR]CM_'M[#:>*/$-E
M=>+8'UN< ^3?%7[37_!2^#_@J5X:_8A\+?$C]@G_ (5/X]_9]^(O[7_A?Q7J
M?[,O[06K>-],^#WA'X]^$OAIIGPRU35],_;)TWPQK_Q!O?"?C*TU*;XFZ?X9
MT?PM+KFGW,]M\.+?3K^"RA_=,9QS^'<X[9]_7''IFOCK3?V(O@[H7[67PW_:
MY\,_VQX2\4_"7]E#7/V.? _PT\+0>%]"^$&C?"+5_'7A'QY;1:?X4T[PW!>:
M3J/A^Z\%:/H7AVUT?6=/\.:9X=5]/3097CM9[;[$9@N"<GG& ,\GI^O'ID@=
M: '4AZ'Z&FE\<[7. . I/4GTST R?3IRQ H+ @XSSD#Z\#&>F<GIUR".H-"W
M!;KU7YC9>%P/1CS]/IZG_P"MTKY"^,_QO'[-W[&'C7XYII<>NWOPX^#\NO:-
MHTZS&SU7Q0;"'3O"NFZDUO-;W,.D7OB._P!+MM8NK>03VFEM=W,"O+"D9^NI
MCE?^V;G\P*_+_P#X*)G/_!++XY'J/^%0>&./^YF\*$_D?;WY->CE5&GB<3@<
M-7BYT<5G&68>M&]G*E6J.G4C?5KFIRFKV;7,]#S<74E2E6J0=I0R[&5(-I2M
M*'LG'1Z.S2=GIIJ?Q3_%GXI_$7X]>.]9^)OQH\7:I\1/'>OW$L^H:YK[Q3Q6
MT<BQ1KIF@:5&@TGPUH-K!;P6]AH.@VEAIEI!;Q(UL\HG>7S8Z?I_;3[//I]D
M@R.GK$?SX^GK?/WN<G..3WX;K^'';\A2XY/^?7\?PZ>G>OZSI4J>'A"CAZ<*
M%*DG"G3I0C"G3A&4U&G"G"-.G3A",8J,81LWS2<G*;/RN4IS?M)SE.I4O*52
M5W*5YRW_ 'FEM4DDE9[=3/\ [.L/^@?:?^ MO_\ &:/[.L/^@?:?^ MO_P#&
M:T:*UO+^9_=_P2=?YOP?_P L,[^SK#_H'VG_ ("V_P#\9H_LZP_Z!]I_X"V_
M_P 9K1HHO+^9_=_P0U_F_!__ "PSO[.L/^@?:?\ @+;_ /QFC^SK#_H'VG_@
M+;__ !FM&BB\OYG]W_!#7^;\'_\ +#._LZP_Z!]I_P" MO\ _&:/[.L/^@?:
M?^ MO_\ &:T:*+R_F?W?\$-?YOP?_P L,[^SK#_H'VG_ ("V_P#\9H_LZP_Z
M!]I_X"V__P 9K1HHO+^9_=_P0U_F_!__ "PSO[.L/^@?:?\ @+;_ /QFC^SK
M#_H'VG_@+;__ !FM&BB\OYG]W_!#7^;\'_\ +#._LZP_Z!]H/^W6W_\ C-']
MG:?_ ,^%GUQ_QZVY_E#V[XYX-:![<9.<C_.1_P#KQ3&.$;CHK<#N0I.W S^1
M('4]J7-/I)]EH]6[I):VWLE>R>V]DVK_ ,SW2VD]VEK:;Y>NLN6.FLDVKTSI
MVGC_ )<+/TS]E@Z^G$)[Y_+Z4G]GZ?\ \^%E[_Z+;\?CY./\.<X )K],O#G[
M WPZ\2>/?@%\%(_VNQI7Q_\ VD/@7X+^-7PX^'6J_LQZ^?!LMQX\\%Z_XST;
MP1K/Q;T7XWZS<Z9*D?AC7+.Y\67'PN.FK%:1WLVD6EQ?6VEQ^/WG[#GQYO?A
M)\)OB]\.O"'C/XK:)\1?AEXH^)?B6R\+>!GA'PUB\*>-_%/@R\\-)J,?B;5Y
M/B3JY@\(WWB:YA\'Z/::IIFE7$ N/#]S:FUU>\\>'$.5SE"/UZ-)U)*--XFC
MB,+"IS2Q$82A4Q%*C%TYO!XN,:JYJ<ZN'J4*<IU72C6ZW@<6E)JE*?*DY>RE
M3K<K:I-P<:->I452/MZ4IP]G>%.<:DFDT?%O]G:?C/V"SP>/^/6WZ_\ ?G_.
M#1_9^G_\^%GSW^RV_M_TQSW';Z5]!^%_V7OVCO&_PRN?C-X1^"?Q!\1?"RTL
M==U;_A--,TB)]/OM)\+.(?$VLZ%8374.N>)]$\/3B:WUG6O#.DZOI&F75GJ=
MK=WD4^CZO%8'B;]F#]HSP=\+;3XV^*_@MX]\/_"6]T[PWJ\?CK4=,MX]+MM&
M\9W L_"&M:O8I>2:]X=T;Q1>/#:>']6\1:1I6G:O<WNGP65U++J6GK<]G]I8
M/VGLEC\(ZGUAX3V?UK#JI]:C9O#J$L0I3Q"B[JA&/M97Y8Q<E*,<?85VN?V6
M(Y.3VBF\-B;>RLG[1-0E[EG>,GRWCJU$^?/[.T__ )\+//I]EM__ (S_ )R/
M6C^S]/QG[!9_^ D'X?\ +'G(QCZU[[X\_9F_:(^%O@G2/B3\1_@I\1O!/@/7
M%TH6/B?Q!X?FM+"W?7(8KC0[?Q!"LDNH^#[S6HIXSHMGXRL?#]WJSN(M/AN9
M@4KT?]G/]D+Q+^T+X(^,7Q$7XA>"/AWX7^$WPZ^*?C*PAUN[TC6_&GQ*\1?"
MGP3I_CW7O!?@KX?Q^*-!\23V%KH.LZ)<>)?B"\-SX<\)C7-)06/B/4I[O2[7
M.IFV!HX:6,J8[#O"QJPHNO2JPQ$/:U)PIQI+ZM.O>LJE2,)TD[Q;]HY*C&=6
M-0PV(G5C05.K[64934)4JE.T8J4G*3JRIQ45RN-[MN:<5%M2M\=_V=I__0/L
MR._^BP>N,<PC/T_^OA#IFFN&1].L'1N"LEG;LK ')# Q;6&1G!RI^Z0037UG
M\,/V<?#GC+P%\/OB/\0OCUX1^!GAGQ]XY^,GAJVO_&OAB\U"UA\(_ SX?^"_
M%OC'Q=HES'XFT6?QUXHU/Q'\0/#?PZ\$?"30;'_A(/&7B*YU*YM-?LAHMS8'
MGOCW\"=/^#MG\'?%'A7XD1_%;X:?';X=2_$3X>>,I_ >I?"WQ%)::9XCU+PG
MXBT7Q/\ #G5_$OC"\\/ZCHNOZ7<6]G?6_BG7-%\1:=)!J>BWWD>=:V9'-<++
M%QP:KS^L>VK4HKZOBO9.MA)<U:DL1+#_ %6=2"ISG*G"K-N%.K>W)),>'K1I
M.LTN1*G--5::J1C4DE"JZ<:RKQI\ZC'VBA95'"&J;G']V?\ @A-^V3\4/%/C
MSQ7^R?\ $CQ-KWCKPU:>"+OXA?"S5?$>H7&MZQX.;PYJ6D:3XC\'G6=1GEU*
MX\,ZA:ZYIVJZ'87,MTFA7UEJ,%D\-EJ,5I9?T_U_%_\ \$&^/V\9@>#_ ,*"
M^)(_ >(_ 6<_H??K7]H%?S[XAX/#8+B?$1PM"%".(P>"Q=:--*,9XBM3K*K5
MY5&*4JOLJ<ZC22E5]I-*/.XK]"X;KU:^5TW5G*HZ5:M1A*;<I>S@Z<J<7)ZR
MY54:3?33H%%%%?$GO!1110 4444 %%%% !1110 4444 %%%% !1110 5B>(@
M/[!UX_\ 4&U3_P!(9?\ $UMUB>(O^0!KW_8&U7_TADJJ?\6C_P!?J7_IR!E7
M_A5/^O=3_P!-52EX/_Y%;PO_ -B[HO\ Z;[.NG&",CO_ /J_I7,>#_\ D5O"
M_P#V+NB_^F^SKID^Z/Q_F:4_XU7_ *^5/_3U4*7P4U_TZA_Z13'4444C4**:
MW0=\L,\@<9YZ]?H.37\6W_!/3]L#_@IU\3/&OP;^,GA36_\ @HE^TAH.F_$S
M]MF\_:VT+XO?!7X3V/["VJ_ #X0^+_C5X:\ Z+^RM\4/#?A'PW\5_%G[1,GB
M+PA\.O!F@>%O#DOCZ?4/'EQXTL=;L-$\(>&-5@U0 _M+HK^5#X;?M&_MM>"_
M@'_P2P_X*0^)?^"A9^-+_P#!0;]I[]D+X6?&;]E+4/ ?P3TS]F32/!W[9WB:
M'PW+\+OV=+3PGH-C\9?#'Q9_9;AU6^BOM1UKXO?$#7O%.M?#+Q)<_$C298++
MQ/IUQWW['/QV_:L_:0^&?P"_X*4_%+_@I?I7[+6E_%?]M+XC_!C7OV)OC+\/
MO@UIW[-UC\+_  Y\<OB9\#]!_9?T-M0A\$?&RV_:T\2)X"L_'F@?$S5OBK<Z
MFWB/4#X<D^%EWX1$EA? ']./I[T=*_#3_@H[KGQZ\:_\%$_^"7G[(GPP_:F^
M.W[+_P -_P!HGP)^WIXD^*VM?L_2_#*R\::YJ'P3\$?!CQ+\/LZG\4/AE\4=
M'M;33-2US5[:X2+0(Y+JRU:\@2XM[AK*YM?@K2/^"V'[0_[,W[)?Q)3XK6/@
M7]J+X]_LQ?M*_P#!2/X&^)/%/BC3OBK\//'?[2WPQ_X)_P"MI=/\7_"'PK_9
MD_9T^.6@>#[+7?#^M6'AKXA_%3QM=_#G]G_X1>(?#L^H^-?&RPZ[*^D@']8'
M^?\ .:*_EI^#'_!9']H_5_BC_P %&/BAXYLO@7IGP.^'GA+_ ()B0_LM_"GQ
MIXV^(MEK^D>.?VX/A!\/_BCH'@V"W^$'[._Q7^)_QI\;>(] ^*7B#7];\->
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MLKG4]7UG]GCXVZ7I6FV<9EN]0U+4/AEXHM;*QM8E!,ES=W,L<$$8Y>615')
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M&\.^*W\&7]ZDNEW>LW$5V(Q-=,MW[%8_MD?L9>!V\>V_P\U3Q4FG?$#]J/\
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MAG]JS]GGPQ^S[\6O!UQ^RQ\/M6\5?M"_$+P)I_Q%^%7A;QG^T/\ #KX9Z/\
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M7WK_ #):*BWGT'Z_XT;SZ#]?\:+KS^Y_Y!\U]Z_S):*BWGT'Z_XT;SZ#]?\
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M1:>]E_1';?LO_"[0AJUEX6C^+TD_A7P[JMEX3T+3?BMJ]K+9Q:;HQTFW\/\
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M3I4:L=4[V56G42>U[)=-[:?F9_P[(_8AX_XP;^''_@_E./;G6Z/^'9/[$/\
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MG/\ T,\R_P##KFG_ ,UA_9F$_P"?%'_PCP?_ ,SGYF?\.R?V(?\ HQOX<?\
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M&P\0ZJL<,%M;C6]8T673+_739VUM#;6#:S/?O8VR""T>&-G5O+?^'9'[$/\
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MCS_^%%I/_P 57;[?]W_OG_Z]&W_=_P"^?_KT<Z_Y\T__  .K_F')/_G[5_\
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M(F^53BL5*%2%)U;35)J,=E.2=&4G%6=TI:M-1U:ORQ\2^(S ;AO!<CPGJ_\
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MFZT*S3I4(-U^7F3GA93IKD5-K]XJMN>49)7L<W8>+-8OIITLO!<C2Q@22?\
M$\TF(L"2-SGRP=^\LI5SG+'&[Y]K+'Q?K%Y<S6]IX,?[0JRR2G^W-(C+^1,(
M69Y"JEB)6*?,S$<\+E0W2Z-K&FW]Q>1V]N\+QLTTCM"B?:5\SRA.VPEC\RMQ
M-B10<D9+5#I.MZ;?:C?VUK;F.9=\C3>3&HO$AD6W>7=&6D+(\D?RSC=MD#
M^;&E3A%/$WP52/LJ-.3O6J-48OD7M:EY-SC)NRA;2Z?1-94ZTI+ O^TL+)5Z
M^(IKV>'26)G!S7LL,^1.%2'(O:5)>ZY*48R?NQJ<_;>,-5N+^>QMO!DAOU,@
ME7^W=*1F^SNR2B21D4D(PVKEBKJ?E)*X%W2/%4E_KDVDWOAYM*O )4,YN[&]
M+RP*))8G:!%=(_*"L)RTD3-L1MIDC+:&G:]I5UK=[80VK)=KYH>[\F)/M;VF
M!.H9<SDQY&TS$+*.47U;;:[I<WB*XTN*U:._S+;->M;Q!9VM5,LD'F*6G81(
MNY6F41DQ84[9(\U*G%.LOJ%:/+@XU%^_DW1<N7]_.\DY4)7O"FE*23C>"::C
M$,2Y?5G_ &KA)<^9SP]UAH>SKM.;^JTO=O#$I)2G7]V,Y<T5*2LY(OB:R?Q(
M=#%G(ET 8#?>7&#YJVYO#&4/[W[.85R)@Y1FVL$VMOJ*?Q1I\/B:#0WLI)+D
MB.$7@2'=$\Z^:D:J1YTD!4_O9E=54M)M1Q'(]/'B#21XE_LH6T@U'#VYO3#$
M SK"+O[-YF1<,GE*27&Z(L N,$$,G\1:1%XEM](EM)'U!BMLNH?9XBL3RH&6
MU$N5GVR+(%=T3R4!*$N"<.-"\DOJ.(E_PG.LE&O)-V4H_76[/]S%V_<72:3<
MJ=S*>+]QO^U<!%QSJ-!REA8OECSTW_9RC>SQ<[I_6&K4E*ZJP=^;K"QR>HYZ
M;!Q[<J3Q[DFBHR[@D+$" 2 <MR.QZCM[45YON?S5/_)?\CZ!\U]J?S>'O\[U
M;W[WUOOK<T^>Y]?_ *WY=/>F2(71P<#Y3M/4@XX(Z8(Z@AAC]:**'U?E^6O]
M:>MUH6U?3\M/N:U7E;8^</BY^RC^S]\<]0BUOXE_"[PQK_B6T-DUMXPMH;SP
M[XTB33PXL(3XP\-W6D>))[6T61Q;65SJ4UI;LYDAABE <>7:3_P3S_9'L-7L
M=;O?A%8^)KO2WE>PM_&WB3QCXZTF RB(S;]#\8^(M:T6X67RH5EAN;"XMY@@
M$T#A4VE%?08;C'B_+L''+\#Q5Q)@\#1H2I8?"X;/,TH4,-1K3Y*M#"PIXQ/"
MT)J<VZ.%K82CS2DU2@I24OA,Q\,?#C.,UGG.:\ \&YCFM;$4Z^(S#&\,9)B<
M5BJ]&/MJ5?%U*N7-8RO"I2IS5;&T,?5<HQ<ZE5QCR_95CIMGIMK;:?IMK:V%
MAI\,-I8V5E;Q6EG8VMO&L<%K:6D$<<%O;01(L<-O D<484*JJ@ &K&!\WIP,
M8&,@L/Z#VQC'.:**\&3;DVVY.34I2DW*4I-:RE*3E*4FVVVVVVVVVVV_M:48
MP480C&$(0C&$81C&,(QA",81C&,(QA""C"G",(PA"*C",4K$M%%%(V"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *IWETEHBR/O(+!0J $L2,Y.2  -
MI[_S%%%73BI3C%[-V?0RK3<*<I1M=6M?7=]BK<75I]D2:1#)'-LV(8PQ;(!
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M$S1><A>"W-T3YP+(>L:/$H8*SH=Q!15QP5)SI+GK+FR6IBW:K)/VD5*T$_\
MGSWI?"^QE/,J\:562IX;W.**.7I/#TVO8SQ$*;J/2\L3&,FXXAMU5+WKMG6%
J5R?NCGI@\?D#_,T445Y"BFD^Z3V75)_J?3NO43:7+9-I>ZMDVE^"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $\ C,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YK3_ !K8ZC<7.VTO(;&V>5'U&<1I;YC;:V&WYZ@@9%=&X9HV
M"-M8@@'&<&N(A^&6F6>A6EK9F"/4X)8IY+]K8$W,B-O_ 'BYRREN<9]/2@#J
MUUG2V-L%U*T)NAFW F7][SCY>?F_"L*X^(.CVVHW=B8[MYK:0Q-LC!#-NC3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %>_N&M-.N;E(VE>*)I%C09+$ G '<FO'["R\7:((
MXEM[N<V%J=0AF=&DQ)<[%D7;_$8\S,%ZX(KVBB@#SO3;GQ)J'B+0UO;C4(]/
M2>[D64VWE_:HU"B+S5"_(3F0@'&0 <9J"_\ $?C";7]1M=,L[R& _N(&N;,%
M8Y#,D8<$#E=I=SDGC'2O2Z* ."U"^\0?\*W\023K<SWS27%O9E+8K*8R_EJ^
MQ1]6X'3%<W9OJF@>'XW\/VCK-+/MF-OI4\4DRHG"CSMX#DMG) 4\C(ZU[#10
M!Y/JEQXC_M;4I_*U*Z\J\,T-M);G9&L-OF/;@8.^9_4_=JZ-7\:6%R[7#7=]
M! \ZND5@H:18X%RR].LK?+ZA3UKTNB@#R5=5\;W(M;HI?--;+?RP0-;;%NF0
M*L2RX4=<NP^[D 8YK>L-7\6_\(-JE_)%]HU!)<6F;9@_E_*&8IM7=C+D  9
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M 'W]#MMZ[0VX8/0YZU%/<K#;23*IE\L<JG)/M7'R0&33;P6Z2BP>ZC-NI!!
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M6MZ;S97RWD(_Y8W/WOP/_P!<5/;^)X5E$&I026,__30?*?H:3P\GK!\WIO\
M=O\ F4L7%.U5.+\]OOV_(W:*:CI(@>-E93R&4Y!IU<YV!1110 4444 %%%%
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M!_G\>E=U;W$-U;I/;RI+%(-R.AR&'M652FX:[KN1*+1)11161(4444 %%%%
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MS=ZI(T&D9B@!P]VPZ^RC_/X46>EVUD=Z@R3G[TTG+$_TJVB+&BHBA448"@8
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M;9#&I=W/15 R3^5*C+)$DJ'<DBAD8=&!&0: %HK-7Q!I+7QLA?Q_:!*82I#
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MLC[I%BCCB7+R.QPJ@>I/KQ6;/XJLK>,,]IJ&4A,]PGD?-;1ABI:0$],@],Y
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M8YQ(K#KTQ46J:K+JYOM8\R2**31KF*./<5"F-HO,./7S&<9_V:BZ*LSM=/\
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M>NO&36WB Z<E@MQ&99(%:"4L_F+&SX/R[ 3M(QNR.XJ]X:\0'7K>=I8(K>:
MKOB61BR9&<.K*K*1R.1@XX-2R>%-&EOC>2V&Z7S6FPTC[ [J5=@F=H+ D'CF
MI;+2M,T-9#!$T?G;(F:61Y68#A$RQ)VC) '09HU&9>@^+3K6L26#6D:*;<W,
M4T4C.K*'"D9*@$\@Y4D>]0IXBU&TU;5/M=M'+I46J)9K/YH5XMZ1XPN.5#-R
M2<_-Z"MC3_#.E:1=K=6=H\4RPFW5FE=ML60=@#$@*". .E5O[(\.R>))ODB?
M56Q>2P&9CGC8LICSM[8!Q0!CP>/GFG>W&FQO+(L1M3',WER&241@%V0# )!+
M+N&.E.N_%E_9>)=/L+BU1)KR!HEMA*&B6<3!=[2@<+MS@$9)(&,U8CTGP9%I
M,^I+) ;!8_LSW+7;LL:HXP@8M\FUP,8Q@]*O0^'_  ]<PSVT5O'*L:M:S 2,
M6!+"4[CG._=M;=US@YI:B,>+Q=>Z9%>76K6HDTY=1NK:*XCD'F#R][*-F,8P
MA7.<YY-69?%NHVT\%E/H\(O[A[?RHUN\IY<Q< EMO!4H<C'/:M6+POHT-Y)=
MK9!I9'DD<22,Z%W&';83MW$$@G'0T6OAC1[/88;0[HY8Y49Y7=E* A!DDG:H
M8X7H,T]0,&;Q])'M@72M]]&LS7$*N[@>5(8R(RJ$DL0<;@H]:[*&43P1S!74
M2('"N,,,C.".QK+F\,:/.<M:LK%Y&+13.C-YC;G!*D$J3R5/%:RJ%4*H 51@
M =A0,6BBBF 4444 %%%% !1110 J_?7ZURWPY!:WURX_AEU24@^HXKH[JX6T
MLY[ECA88VD/X FL3X;6[P^#+>63[]S)),?Q;'\A6JTI2?I^K+^P_D=;1117,
M9!1110!SKC[#XR["._A_-U__ %?K6U69XGM9)-/2\@_U]FXF7Z#K_C^%7;6Y
MCO+2*YB^Y*H8>WJ*ZI^]",_D_E_P#@I>Y5G3_P"WEZ/?[G^9-1163X=@URWT
MQD\0WEK=7WG.1);1[%\O/RC'K_GGK6!U&C<75O9P^==7$4$6<;Y7"+GTR:5K
MB!(DE>:-8W*A'+@!B>F#WSV]:YG6Q#:^+K+4-5@:72ULI(HW,)E2&<N"2P .
M"R\!L=B._.#J.GS>(XK;2-(T5K73K>.:Z"73M %D=F6%U^5L$'?(%XQE>G2E
M<=COKK4]/L9!'>7]K;N1D+-,J$CUP34LUU;V]O\ :)[B**#C][(X5>>G)XKS
MV-->UV_DO[:VM(M1&C11RQ7]F71IUDE#("2,<@\\\$'I71^%(C_8&EV<=CG2
MDM@NZ];$ZN#RK1%<#!R.#CCCBBX6-NUU"ROM_P!CO+:YV8W>3*K[<],X/%6:
MYWP-:+:>$-/4VRP2E&W@Q["?G;&>,US-OJ.KMICLUWK?VHF+^ULP_+:@RXD\
MGC((7LN1M&[KU+A8](IA,5O&,F.*/.!T49)Z?4D_K7GL)UC4+CR5U'5TT](+
MV2UF!*23*IB\HN2,G!+XSRP'.:IW=UJ6HI9C5)=3%Z]SILD%M'"WDO%F)I'8
M 8R'WY)(*X'0=2X['I9N;9H]QGA,9XSO!!R=O\^/KQ4P&!@# '85Y7;_ -HQ
MW@O':_%[/;6R*&5MK!;YPXQC PA7\#FI)]0\0-ILWV:\U;^T&MW_ +15HSMM
M9O-0((LC X+X"Y!49/K1<+'IS2(CHC.JLY(12<%B!GCUXIU>=:O+KEA<ZA:6
MESJ,T=O+.;>5P9'P;(N,-CD"3I[\>U/N)=6TZ<VLFHZHVGN+*2YN&):6,.)/
M,V$#(R5CR%^Z"2,47%8]"HKG/!-W->:+<R2W5S<A-0N8HI+H8D,:R$*#P.WM
M71TQ&'XKB8Z5'=("7M9ED&/3I_A4B.LB+(IRK@,/H:U+B!+JVEMY/N2H4/XU
MS.B2.+5[.;B:T<Q,/;M77!\U+T?X/_@G%+W,1Y27XK_@/\#3HHHJ#<*0@'&0
M#@Y&1T-+10 THA8,44L.A(&108XR,&-",$8*CH>M.HH CB@A@SY,,46>OEH%
MS^52444 %%%% !7#^.H?LFK:/JP&$+-:RGV/(_K7<5E>)-)_MKP_=V0'[UEW
MQ'T=>1_A^-:4I*,TWL:4VE+78Y2BJ6DWAO=.BD;B5?DE!ZAAP:NUT-6=F1*+
MBVF8<'_(ZWGO:)_,5N5AP_\ ([77_7FO\Q6Y53Z>B,J?7U85JZ!;?:-3A!&0
M&W'Z#FLKKP*[#PM9^7%)<L/]A?YG^E9R?+%R"2YI1AW?X+4Z*BBBO./1"BBB
M@ HHHH Y_P 7:>;^PT\_99;D6VI6T[I%DL$5_F( Y. :Y9- URQTJ%])BO(-
M1N(M16;,K;02Y:+@G"G^Z1CK7I-%*P'GNFZ+?3W=A'*NI?V:;X/)#)');J@$
M#Y.#(S%2^S.3@L.,\UB7\>NVMGJ=[-;:G:))82B<*SKMF\^/:!(SG<VW=AP%
M'.!7KM1SP0W,+0SQ)+$_WD=<J>_(HL(\\U&+5=.MKC4M)@OK>W6[CALK2ZD8
M.WG)Y4AVL2<!V1P#W1B.M=9JMC<V^BZ;9V+3RM;W=HKLK$LT:NN\L>XP"36O
M+;P3R1230QR/"V^)G4$HV,9'H<=ZDHL,XOPKI.H:==:-+,EZIFL9QJ!GE9QY
MN]3'N!) (!;&.U58=.\0+J\/B@VL0D?4"\EJ$;[2+5L1!#SCA0LF/4&N^HHL
M!Y2WAS6O^$:N-(&FS_9YX);YU _Y>%+JL>/5LQO_ ,!-=CHUQ)I^K:O;7%AJ
M -SJ'FQ2K;,T14QQC)<< 94_E72T46 ****8!1110 4444 %%%% !1110 44
M44 <SX]O6MO"LUO%S<7SK:Q+ZECS^@/YUU&E6*Z;I-I8IC$$*Q\=\#%<>X_X
M2+XCP6Z_-9:(GF2'L9VZ#\./^^37=UI5]V$8?/[]OP*GHD@HHHKG,PHHHH 1
ME#*58 @C!![US6F9T?5IM'E/[B4F6U8^_5?\^GO735F:WI?]IV8\L[+J$[X7
MSC#>E;T9I7A+9_AV?]=#EQ-.32J0^*/XKJOGT\[%NBL[2-3_ +1MF$J[+N$[
M)XSP0?7Z&M&IG%PDXLJG.-2*E'9E.YU?3[&62.YO(H7C$9<.V,"1MB?FPP/>
MLR_\8Z787(A>42YN([8^42Q61W9#D8X *GGV(J'Q+X4.OZA:W*W*PK'#)'*C
M)N\PXS$?^ /\U48_!5W;I:O#?0M/ EH69T.)98IGED8XZ!BY^E0::&QHOBO3
M-=;R89PEV#*#;.?F'EN4)!Z'H#@=,C-33^(+.UU"_MKQ_(2SAAE>=S\K>86"
MJ!USE>G?(Q5#3?#$MC)HS-<Q-_9\EV[X0C?YS$C'IC/-)JOAFXO=7GU*"ZB2
M8-:RVZ2(2N^$R</CL1)CCD8S0&A=F\6:!!##/+JUNL<Z,\;$GE5.UCTXVG@Y
MZ=\4Y?%.B/;R3IJ<+1Q2+&=NXG<PRH  R<C)& <@&L5/!MR?M\LM[ 9[ZSO(
MI=L9"+).RG*C^Z H'J>M+>>$;^2Y\ZVOXE4I;1O"=Z+*(D=2"R$,!EPPQ_=P
M>M ]"^_C;1(]1CMI+V-8IK9+F*YW91PSLGX8*\DX S6GJ^IKH^DW%\\;R^6!
MLBC/S2N2 J#W9B!^-<?:>!M5L; V4.HV!CFT]M/G9K=LA&ED<L@SUQ)C!XR,
MYK9O?"273V4*W]Z+*&83S(US(79D4B/8<_( QW''7 H#0G_X2J&33=,GM+::
MXNM3R(+0,%8,H)D#L>%"8()]>!UJOJ'BG4-/TQ[V3P_<#R)!%,CW"KM)954H
M<8=3N'(QW[BJL/@^ZTZY^T:;?INM[N2YLUNMTF%E4":-SG)!8;@1R#ZU?O-$
MU/4]!O+2^U")[FYFCD79&1% J.C;%'4_=/)[GL.* T-JTEN);9'N;?[-,<[H
MA('V\_WAC-1ZAIUIJEL+>]A\V-7$B_,5*,.C*P(((]0:MDY)-)3)(+*RMM.M
M$M;2%8H$SM1?4G)))Y)))))Y-3T44 %<UK<1TS5HM54?N)L17..Q[-_GT]ZZ
M6HKFVBO+:2WG7='(NUA_6M:4^25WMU]#"O2=2%ENM5Z_UH_4S>",@Y'8T5EV
M+RZ?=MI%X<NG-O)VD2M2MIQY78SI5%4C?9]5V?8****@U"BBB@ HHHH ****
M "BBB@#SKQ!9?\(_XG^TJ-NGZHV2>T<W?\^OX^U2UV6LZ3;ZWI4]A<\+(/E?
M'*,.C#Z5Y[82W%O<3:3J(VWUK\IS_P M%[,/7BNN,N>-^J_JYM+WX\W5;_YE
M.+_D=KCWLU_G6Y6''_R.\_O9K_.MY$+M@?C5RU:]$<D&DFWW98L;9[FX1$&6
M8X4>]>AVUNEK;1P)]U!C/J>YK(\/Z7]FA%S*N)'&$!_A7U_&MRN.O.[Y%T_,
MWP\'K4EUV]/^#N%%%%<QUA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !63XDUM/#^BS7I :<_N[>/N\AZ#'MU_"M22
M1(8GEE=4C12SNQP% ZDUR&B0R>,O$8U^XC*Z18L4T^)Q_K'SS(1_GMZ&M:<5
M\4ME_5OF7%+=[(W/!FA/H>AJ+D[K^Z8SW3GJ7;M^'\\UT5%%83DYR<GU,VVW
M=A1114B"BBB@ HHHH PM9TV>.Y75M-&+N,?O(^TR^A]ZM:=J,&IVHGA)!'#Q
MGJA]#6G6#J>DSP71U/2<+<_\M8?X9A_C75"2J)0F[-;/]'^CZ>APU*<J,G4I
MJZ>Z_5>?==?7?6HJCIFJP:G$=@,<Z?ZR%_O(?\*O5E*+B[2W-H3C.*E%W044
M45)84444 %%%% !1110 4444 %%%% !1110!GZOI4>JVP0MY<\9W0RCJA_PK
M(L;Z0S-8WR^5?1\$'I(/45T]4-4TFWU6 +)E)DYCF7[R'_"NBG45N2>WY?\
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MN=M?+^NXJ-)5U[3[-WI_GY?TS>HHHKRSO"BBB@ HHHH **** "BBB@ HHHH
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M;6-I9KMM;6&!?2.,+_*IZ**R;ON0%%%%( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *&M:<=7T:[L!,8&GC*K*%W%#V;'?!P:YM_ "&">.
M/4&7S))'3=%G8&0J%Z\@%I"?4N>E=G69K\VH1:3(FE1;[^<B&%B/EB+<>8W^
MRHR?PQWH JZ?X=CM=1AOFN%E=&N9#M3 :25P2W7LJ[1[52G\'QW$,]O)?#]_
MYS,!$.6EDW2,1GD[,(/09]:P[.PUK3(+?27@U&&UCGFV-ICYW.Q1D+.X^Y\S
MDDC!.0>P+;'3M<%P /[5ACEF>2XE/WQEY794)Z A(E&..>* .MUGPY#KES;?
M:[B9;2V5BD$#M&?,(V[RRD'A2P _VC60? JN4#ZF6=85B;]U]Y%C54!YZ;DW
MGUZ5CRQ^*K/3-C2:M<-+%;B9\Y99-CLX4*,@9V(<8YY)ZT_2H/$KZS;W,D=^
MFH>5 D[3*$MI(UA);<1G+>8Y''(QGIF@#I=*T*]T;4':'4+9K*7RU,3VY\S"
M1*@ ??C^'/W>YJE+X&634KB]&HN&EDGD5?*&%W@;1UY"ON?W)]JIZM:^(]2U
M>RO);&#R-+GB.Q)'R\A9?,DC&/F4(2HW8_C]JDUFX\1_\)G!]BM[W['"Z@JG
M^JECV,S'/W<EL+SD@@'@&@"X_@UX;F.ZT_4%MYXE6*(O;B18XQ%Y> ,CG[Q!
M_P!HC!%6KGPRZVNDQ:;??9'TV)H8WDA$ORLH4G&0 V!P>G)X(-8FG2^((/">
MJR,-4FNC(JPO.NV3!P&=4()&,GY1D$K\O!%$5MK-YX)AMM1743)+J*AMFX3)
M;B;(SSNY5>^3AN: +5QX(>YAN(!J:"WW3/;J+895Y#\Y<@_.,97 V\'V%./@
MJX-R;YM65[_SQ.LCVV4#[L\KNY&T(HYR-H.:PFLO%&GZ<%MGOQ'.L4MT A=D
M>1I'D$87YAC**2.><^]7)HO%$>G22S2ZC)*B6]L!%\O4;I)=JY+'D)P<@@D>
MM &]:^%%@LM,MI;UI/L;32.ZQA#)+(&RXQ]TC>Q'UK,L/ #Z9! UGJ$,=Y;L
MOE3&V+*$",@!5G.3\Y.00 >V.*QM,N_$]W+! SZG_:%LD V' @5BS.XF/.3Y
M91<9R<@]>19TJ?Q3;VR7-_\ VG.KW41GC2W.\$*[.%!/W"VQ.,+W'<T :$O@
M"$WEY,=04?:MV&:+YP[($8\,%^Z#@!0?F/.!4U[X#BNUO3]M^:6Z6XMU>,[(
M0#N*8# D%LL2"#T]*Y]+/Q,))KTQZC]N=5DEWJ'5%$>0(U/!8&5\ =XZ[OPZ
MDJ:4#(=0(9V:,:@P,P7/&<<^^#R,X- $^CZ9'H^E06,1#",'+!<;F)))QD]2
M2>M7J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0DEMBY R8_+Z _W/E^E0:EX8L;S3I+:WCCMY"'"2%-X7>X=^,CJ5'((([$4
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &; D,# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK+"X:=#"RJSE*=5X;GE*3DF%%%%<QZP4444 %%%% !1110 4444 -89!_/\
M*HW4_-C@C)QG&02QZ\X.2.2K<\%<\B1^@^O'UY].G^1U-0R;@I"@D\YZ=3TX
M]P.V>IY%1)N[LWRQCSRCRZ22YM%/NVHJR=U=7W0FM8]Y245Y7LI/Y)79\._
MG]I[Q?\ %3]J7]J7X&:QX>\/:?X<^!,WA>/P]J^G/J?]L:U'K\$[RG6%N;NY
MLPUNT02,VD-L&!):,YQ5;Q[^U-XP\)_MW_!/]E6Q\.^'KKP=\3?AWK'C'5O$
M=RVJ+XDL+W3-.^*=[#::='!=+I;6;R> M,C=;FV:3R[Z^QE_*V_.?[)$\&F?
M\%(/^"A&DW\D=CJFHP_#K5M-TN]<6FH:CI<%I')-J5C93[+F[TZ)-7TAY;Z"
M*2UCCU;3'>95U"S:;(^+T\-S_P %C_V5(;62*>:P^!7B?[?%%());-I?#W[0
MLR+>1+O:U+)?VDJBY$0,5S;2 [9X#)^LU>'\HAQ+C<%# QE@Z7A?B.(:2<Y^
MSCF,>%,#CJ6.C4O[.?-C9XAP4:C@ZD9T4G*,J:_)(Y_FD^'\%BOKLJ6*J^).
M%R.MRJ,JKP4^),5A:V%J0^.">%]@W>"Y:;A-M1DI'ZH7GQ5^&&GV6OZA?_$;
MP'86'A+4X-#\4WEUXPT&VL_#&M3S);PZ-KUS/?1V^CZG+<RQP06&H&TNYG>.
M%("Y5:X?XS_'OP5\)/@GXI^-;:MX;\0Z)I'A#6O$_A.UC\6:/I=A\0]1L_#^
MHZ_HWAOPUX@D:[LKS4/$D6FRIIG]FPZI/-#YEQ:V-X(C&WY#?LW?LW_"+]H/
M]M;_ (*#K\7?"\7C;2?!7Q%T]=#\.ZC>7T6C0ZCXYUCQ_:ZGXA:TM+RU<>([
M*R\'PV&E:O#/#/IMOJ6J&T\F::.XA\I^!?P[\)ZG^P[_ ,%$_ NNZ3'XA\._
M WXG?&?Q)\+[77I3=2>$?$_A?X>ZW9:'XKL)UCM7.MB',YNF$D=UJ$]W. 6N
M9&;6GP#D$*ZIU<]S.O4RW&\"5,YPBRRG0H5\#QC7RU1P^ S".-]JL3A*N-I4
ML4Z^&H4ZF%JUUA*L\5AX^V4^.<_KT*KI9/EN'CC<!QO'*<3+'SJ5J6,X5P^,
M<J^,P<L)[&>"Q<,-4E35+%U*JQ$*$:E*G2KS:^W?A%^VG^TA\5O@;\3_ (O0
M>#OV8]';1M*\'ZO\/8;WXRVUGIUBVO>+_P"Q]4TKXL_;=3MKGPE<2:$EQ<^&
MKZ_NM#.KZO:?91IC-=K!:>N?M _MQ1?L\_ [X2^,?$6E>"O$OQ;^*,'PVL3X
M1\.^.-);PQH]YXPT2ZU#7/'4.II/?:QJOPPT*72M5BTG7;"RO;?Q!>MHND/K
M&DVVJ7&OZ5^>U[\-/ ?A#_@C5XG\:^&_"^F:-XJ^)_A3X5W_ ([UVSMVBO?%
M%_HGQSTJWT>?5"TS+)+80:A=QVTA9"D=Q/(Q5-@&/^VC\/\ P;=_L2_\$]_B
M#<>&=,?QI?6O[,7PPN?$;(4U2X^']U\&_$VOW/A&XN$DDVZ3-K AU%H?),QN
M!)F40LF?H%PMPGF'$V IO /"9-BO$;B/A*G@\OPM:E6DLFX4QN94J%;%8G-L
M3_L57$82O*=6%'ZVY4</B/9J.8XC 8?PGQ)Q/@L@Q*^NSK9K'@;(<_J8K%XB
ME7P\:F<<08/!SK4:.'RVARXR.&K453P]1^PC"MB*+J*>7X?%3_H2\,>(] \6
M:5:>(/"VOZ/XET#4%G_L_6= U*QU;2;S[)<R65W]CO\ 3I9K2?[+>V]Q9W C
ME<P7$$D#A)HY4KHZX+X;?#WP3\*_".E>!/AUX:TSPCX.T3^T'TC0='@^S:;8
MG5=4O-:U VT DD$1O=3U"\OYQE=]S<RMM7I7>U^$XA4(XC$+"NK+"JO46'E7
MITZ5>5!2M2E6IT92I0JNFH^TC3G.$97C"3C&-OW'!SK5,+AYXE4EB94:;Q"H
M3G5H1K<D?:1HU*E.E4G24K\DYP4YI\TKRDY2****R.D**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **1F"XSGDD< GH"W. <# /)P.W4@&
M,S1J-S,54=258 =3DY7@  DDX [FCMYWMYV5W;T2;?H'6W6S=NME>[]%9_<R
M6BHQ*C $$D,2!\K Y&<C!&0?E/4#D8ZD4\,"< \CV/\ 6AZ.ST;NTGNTK7=N
MRNKOS0+5*2UBU=26S7>_86BD!!SCMUI: "BBB@ HHHH **** "BBB@!",X]C
MG^=,:,,N .001R?4'!PRY&!@C< 1P<@D&2BI:ONKJZ<EW<=8_<Q/HU\23Y7V
MOO\ >?+_ (._99\$^"OVEOBG^U%I^O\ C&[\<_%OPYI/ACQ#H.H7V@2^#=,T
M_1M(\$Z1;S:%9VGAJQUZWNY8O NFSW3ZEXCU:%KJ\U-X+>WAFM+>P]\\4Z!:
M^*O#>O\ AJ]DN(++Q'HFJZ%>7%DT27D%KK%A=Z=<2VCSQSP)<117!>W>:">)
M)55I(9%#*>B.<G"]1UR,'CIC/^?6FD-C[N0 , 8 SW[CU/<#ZUUUL;C,36H5
M\37G5JX:EA:&&G*7,Z&'P7*L)2@[+EA0Y%R1U4/,XL/@<'A:->AAZ"IT:]7$
MU\1!1LJU7%J?UJ37VG6<VV]>:Q\-Z;^P5\([']DZX_8\NM8\:ZO\-[BZO[^+
M7M6O?"[^.;#4[SQ8_C.&_L]0M?"5IX;2XTW6&1;,7'A6[AEL-]C?PWD4LID]
MK_9^^!NE_L]^!CX$TOQM\1OB%"^KWVL7GBGXJ^)(_%7BZ\GN;;3].M;%]1M]
M.T>TATG2-)TK3=)T;3[/3+>WL=.L;>%%WK(\GO)4L>5 '?(!_P#K_CP>33MH
MX&,\Y^;D#V'.1[<'_#HQ>>YSCL-B<)C<QQE?"XK,GF^*P\I0J0KY@U&+Q49R
MA[2%648P]LX3IJMR+FA/E37%A<@RG XC"XS"9=AJ6+P>6+*,+B4JD:E+ WYO
M83A&2IU(QU5)RA)TU*23C?44 'U(&">?;'MT[^WUPZBBO-5_M6O=[*RLVVM.
M]GKYGM)626NFFNNVGZ?UT****8PHHHH **** "BBB@"*494>Q8_^0Y/2O&OC
MM+\(K?X6>+I_CJGAV7X3I::<?&*>+K5K[PZ;?^UM.&F#4;-8+EIX_P"V3IAA
M586*7/DR9Q'S[-*2J@@D<GIDD_(W0 $G!^;&#]VOBO\ X*#>%_$OC;]C_P"-
M7A?P?X=UGQ9XBUC1_#T.F>']!TB]UK5M2*>-?#-Q=)9Z5IT%S>W;0V4%S/*D
M5N[1012S-MCB9U]')Z-+$YQE6'KXF6#HU<RP5.>-A-4ZF#5;$4:4L13JMQA1
MG1A.=7GJ3C&/+"3DHZKP.*:]3!\-<0XRA@:&95\-DV:8JAEV(P];%4,PQ&'R
MW%3HX&MAZ"G5KPQ4J<*,J4(2E5A6=.$93FK_ $G\*Y/ TG@'P/)\,?[)'PWD
M\%^&'^'ZZ$K0Z*O@@Z+8/X272+=E1HM.709+$6B&. QVAMHS&VT/7HM?.'[)
M&B:SX;_9H_9XT#Q%I6H:%KVB? ;X1Z3K>BZM;366JZ3JVG^ O#UEJ.F:I87"
M0W%AJ&G7UM=6=Y9W%O;SP7$,L4D2/&Z)]'URXN"IXS&PC4]K&..QT85.92=2
M$,9BJ=.I*47*,IU:=*G6J2BVI5*U22;4KOMR:O4Q.493B*V'AA*M?*LJK5,)
M3@Z5/"5*^5Y;7JX2G2DHRI4\)5K5<+3I3C&=*&&C3FE.G)(HHHK ](**** "
MBBB@ HHHH **** $..,^O'UZU%(I<?*0.1DD]",]^0""1@E6! (*D&I6!XP,
MX.?T./3OBH_GP 5ZYSRI_'/Y8ZX_(5-FY)IJUG&:>EU)-IQOHVM4_-I;V%=J
M2Y5[UG*+:]U-=&^C?3OT/B;X\?L(?!_X[>/-.^*\FN?$CX3_ !;L+(::?B=\
M%O%P\#>,=1T];*32UCU2[.F:I875P-)FFT9M2&G)J\^C&#1+F_FT>TL;&UN_
ML\_L2?"O]G+Q%XE\=:-K7Q"^)/Q.\56QL-9^*'Q?\41>+O',VE&6*Y?2(-3M
M]+T:TM;.YO88KO4YH=/74-5>"VBU*]N[>TM8;?[+,9(&,Y&0.G((."3G/4Y]
M20..,TC(Q4 =?ESPI/ Y'+ 9/U]\BO:?$G$']F5,E_MK'O+*F$6"JX3G4:5?
M!PKK$1P=6M"C]:E@W5BN;!K%>PE=R5))<C\%<-9%',(YQ'*</_:4*DL33Q*C
M>I1QE1.G+$4Z=2I]7^LJ$Y3AB)47*#O[_/9KYF^#G[+O@GX)_$[XZ_%CPQKW
MB_4_$/[0FNZ-XA\8Z?XBO="N=!T>\T2Z\37EK;>%+32O#VD:A964TGBO45N4
MUC5=>F*6UAY<\<B7$MQP?@S]A[X9>"/AM^T9\+])\5_$2ZT+]IS5_&^K^.;[
M4]0\*R:QH<WCK2KO2-7A\'2V?A"ST^SM[6VO)7TT:]IOB.5)4C-U)>=*^U=K
MG'R$  \$KP<'G[QY/Y=^U."MD=0/^ G''3KGKG!&<&I_UASUU*]6>:XZ4\9/
M*)8E.JIJI/(I4<3DU2<W3YI?V56PN'EA+VY'1I4W&?*D5_JUD<:5*E'*\)&.
M&690H^[+W89S2G1S96C-IO,H5:D*\EM*<Y^[HSX]U/\ 8T^'6K_LHVO[(-QX
MD\=K\/8-)T724\2QWOAA?'SQZ)XOM/&]O/+J$_A2Z\-/<3ZO8QVUZW_")LKZ
M=/,($BO]E^C?B?\ L5_#+XL?L\_#O]G/Q+K/C2U\-_"VS^'<'@SQAHNIZ'9^
M/-*O?ASHJ^'-*UH:A<>&KSP\VJW^@R7MCJC+X52S8:C>3:7:Z1=#3[FP^Q&4
MX&%R1G!.... ,'UP<Y]3S0%<GYNFT YP<G'(P#V.1^9H7$.?1JT\1#-L='$4
M,WK\04JWM(JK3SK%PG0Q69TI**A];K8>I4I5I<OOTYN'+9-%3X=R2K"M0GE>
M$]C6RFEDU2#C/DJ95AJE*IA\%4O+F<:%6E"=%Q:E'E<E*[N>8_!KX76'P:^'
MN@_#O3?$_C7QE;:$VM3OXH^(NOR>*?&VNW^O:]J/B/5-3\0Z_+!:OJ-[=:EJ
MUVZN+:WB@M_)MH8EBA0#U.HU4@Y.0 ",<<\@@\$^_'^3)7F5:M2O6K8BM+GK
MXBK.M6G[JYZM1WG/EA&$(\UD^6$(0BVU&,4DEZN'HT<-0HX>A#V="C2A2I4T
MY-4Z<%RQ@G-RFU%+1RDY.]VWN%%%%0;!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% $<AV@'G&[G'T)'U^;  '))%?FO\8OV^K_ , _\% /
MV;?V"OAY\%_$WQ:\2?%3P=K_ ,5OC5XV\/ZMI"67P'^$5K;>(]%\->+]8TEI
MD)LM1\?Z59:?XAU'Q'JOAJPTO1M1TJR\%1?$/QQXIT3P>OZ33E0JY(&&)!X!
M&U2>,^OW3[,1STK\#_V]?@Q^VU\!_P!NSP#_ ,%,/V)/@IHW[3L@_9WO_P!F
M7]H#X%3>*M+\)^++KP'IGC.X^*%AXB\'7&MRJ\[3:C8:?IK1>%+?Q'XSLM<M
MM(?3_ GC31=9UR/1_9R'"X/&XW$87&/"_OLKS..!AC<4L!A:N:_5Z4<OHUL=
M*=&EAJ;=3$U%4Q%:GA77A0IUZD(SN>?F-:M0PZJT?:VIUZ#Q/L*3Q%=8:4K5
M'2H1NY/W8KFTG&]3V<9M-'UEXH_X*">)/A?_ ,%'O!_[%'Q<^"/B'P1\+OCG
MX4LY/V;/VC;^_P!*'A+XE?$C0/"^H^*OB!X'?[!J^L6]DUE&^D^&_#\>M_\
M")^+;OQA;W=BWA2]\.^(_AYXI\6?IZA#!BC!O4@@_,#\P)7"AL\L !@]OF%?
MS;_"SPC_ ,%$_P#@HU^V_P#LD?M$?M3_ +)%G^Q/^S9^QEJWQ!\=^'_"FO\
MCZP\5_$GXE?$WQ)X9;PS806_E6.A^)-,TS1M4M-$UN1]7\%>&/#<OAI-6TVP
MU?QCJ^JVMYX:_I"A #+M.1C[QZME@V5)RS1C<P3)PN6P6# BL_P&$R]Y7A,/
M#"T\;#*H4\[6#QT<PP]/'4JM:.'E#%4L5C,-+$XG#?5YXNEA<14PU*K3A[%_
MO:B)R[$5<3]:JRG6EAW6F\-/$4)8>?L9<KA!PJ1A-J,O:1ISE&,JD;-Q2BF[
M0X8CZD>X)'\L4^DXSGN1[]/Y?UI:\-;7ZO5^K2O;[CT@HHHI@%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRCAGC*V$RZA6JPJXW$TL(GBJE##0JU88=.O*"I+G/8:*C\V/^\#UX&23CJ
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MTKV4G)M+3\U_AI^T9_P3W^-__!5__@G2?^"4/P \)Z!J6E7/Q<TW]HR_\*_
M?2?A)\/KOX7W_@_4[VUFNO"TUMX96Q\:> Y-+U+Q5IWQ)M=#T'4DN+KP7X)L
M?$7CI=3N/AW!_9!&BX8XY()^Z5^\V"0K99 0 -A(V[5RN:_F@_9._;N^-O@G
M5O\ @CM>>*_AK\,]7^&'_!1CX'Z_X?\ BE\0/!?AKP3X#\>2_M :-#_;WA77
M;KPCX1\+>%M!LO"6D:1<VEC-9V%W=6NH:?XN\5:O'IOAW5/ 6BZ3\2_Z7H%W
M9;'S-G< "O(;Y22W.XH5!+89U5"$C V#IXQ]I&OE%*6'JQP^'RVO0P6*Q.<2
MS?%9A]6SC&4,5]<Q,H494IX'%1J8>C1GAL-)4G3<J;=5<O/D23I8FHW3]K4Q
M.'K3C2PL,'%1J86$H26'A5JJ*FKM5'+W[-\JY=;2]3]!^& /YY/Y4^F+P<8Y
MQUSV&!_/.,\@<>U/KY&.VV[;\W=[O:S?;R7<]X****H HHHH **** "BBB@
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MVT6F"&*.32]$U_0/#VKVN^:&-!>)>^(QXJ>!YF>XMX84M!ML8;!I/$/V;OV
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M%?QWXOU^TT[4KOPW\-/@S\$_ ?Q%^*GC[Q*=..CP6'ABRT>^U7P\WB2'5K(
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MD-@'KN Z@X8$,>>"0,D;OEW*>,\%?%#X<?$_3KS5?AIX[\%?$;2]/O?[-O\
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M8MNEKMI)623;:5FD[ZMNZWD^B1JK+1=';>3V2O[TM9:WM+:UDM(G;D@=>/\
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MI&I:!;?&N?QU;_M+Z?\ M5:EXYBU231F\/6>O:Q\4;.6XNI;'1;8V6GW<O\
M8WV"[@LY+?TG0?\ @E[\#?"7@[_@G;\*_">N^--#^$'_  3A\7K\1OAQX!B_
MX1:-?BA\3--^&/C+X=^&_B)\4_%.F>'],\37/B/2]3^(7C?XCZW!X4O?"WAS
MQ[XY\5:K>>.?#^NZ6]OI-H ?+WP:\)Z?\1_^"XWQQUGPN4TSX7?\$Y?^"=WP
M'_9.\/>&+?38-/T72OBK^TUXTU?XV:W-X:?PW;V.CVL>B?!;X>_"/0]9\):P
M89-(@UCPOJNA:'IVG:BM_J'YJ_MD>/?AE\3=8_X.6_VM_BMI'PT^(/PN_9F_
M9,^$G_!.[X&7OB_09O&W@I_BAX$\'^+/C7XL\#ZUH.C:=/X;UCQ)H?[7GQF^
M$=IHNM:A>W_C/X9^-M&A?4;SP+IFEVDT_P"R/Q6_X)0Z1XZ_:B^,G[3?PW_;
M._;9_9JNOVF8_ ,7[2GPW^ ?Q.\'>%_!_P 49?AC\/\ 3_A?X3U32=7UKX?>
M(_'WPE\1-X$TJP\.:QXM^%7BSPSXJFM[6QU'P_JOA7Q%IMCK]OQ6D_\ !$']
ME;P_^P'^UA_P3Q\/Z[\2O#_PF_:]^+GC[XV^/_$FB7_AVW\5Z!XR\7>)O!'B
M#1+?PE#=Z+>^'-.T3P98?#'X?^%[+3FT-SK6D:%<7NM7<_B36]5\02@'R%\?
MOV5?V3OV%?\ @FE\$OV$O"'[./Q%_P"%R?MF:1^SY^S-XT^$_P"PI??!GX1?
MM0_M@>*?A5\.CXL^,EM\5/C"^C^';76/AS=^ _!GQ%7]H;XHW\FDV)\(^.?$
MVG3:_P"$(?B;=:E7YP?%?X''X5_M6?\ !)3PE\)_^"+_ ,)O^"9OB76_VW/V
M>-,^#_[0OP^_:B^%^I?M3:_\,O!GARW\7_M+>"?B;\(O@!X<U+QA\0O">K?!
MWP_XK\"?%7QO\0?BQ\0= M[/Q)%?_$K6K.Y^)NMQ3?T7?'7_ ()>>'/VE/@/
M\ /AO\7OVF?VE]4^//[,/C.[^)WP:_;6\+>)O!W@7]HSPW\1KN36XI]:G?PU
MX-L_AMJ.C7VAZK;^$]=\)3> X]&UKPUI=G:3LFH2SZLGCGPJ_P""+/@SP3^V
M7^S_ /M]?%+]L+]L?]IW]I3]G]OB5:Z+KOQS\>>"]5\'7WAGXA?"CQ?\(6\(
MZ#\._"O@?PCX0^'6EZ=HOBR3Q'>#P18:3-XF\<VTOB;Q%>7UWJ^KFY /SV_9
MR^'W[+_PC@_X+P_\%?=5_9\^! ^*WP0_:V_;!G^!WBW2OAO\.].F\-6G[('P
M!TWP/J>N_#2\\1Z7?>*/!7Q4^,_QJ?XK6WQ<U.;6+&P^+GQ NU\4V/AZ+2?$
MVGWNM^'_  J_8NC^+7P1_P"")?\ P1,\>ZEXO^''[-%[^QGXV_X*$?MU_#7P
MYX@\9>%?$?QYU#2_&?PZ\3Z+\ ]1\2^=I7B_PYX/UC]H?XZ^)_&GQ9\(WFE:
M#?6>F:+HFE_#_P 0^#/&7A;PWK^A_L+?_P#!&3P-J/P:_;U_9VOOVG_VB-0^
M"'[?/Q>UCXP^+/ &I)\*+RP^$6L^//C3>_&7XQZ5\*K]/AW#JEOIOQ4FOY/!
MNHWOB:XU_7]!\/VVGZAX?U?3?%5DOB";Z0_;=_X)S_#C]M;5/@3\0W^)OQJ_
M9S_:&_9B\1:MX@^ ?[1W[/GBVT\+?$WP%;>*[/3].\=>#K^+7M.\3>$O&WP_
M\>Z9I&DZ;XT\(^+?#^K6FLV%K<:8;G^P]:\2:1K8!^9/Q5_9<_9:_8U_X+%_
M\$JF_8C^&_@3]FCXD?M Z;^UYX/_ &B_A1\ M'T3X;_#SXK?LT>!?@KJ7C.T
MU_XC_#GPWI&G^#8KOP/\9O\ A!)?!_B&RBT+Q/KU[=W]A);^*[3PA:/X%\!_
MX)L_L&?LG?MD^%?VQ?\ @J]^W'X.\.?M"^$?VBOVLOVQ?BW\!? /QEU?1_$7
MP%^#/[.G@KQ7J'P<L_',/PKN;+3/@J?BYXS\&_!O1H/%?QFOKGQPFJ>!OAY\
M*-:\.>,O#NH3>,KW5OV+_9H_X)A?#K]FGQ3\9_CI_P +F^./QL_;0^./@"?X
M:^*/VU/CIK/A3QQ\8?#_ (+ACMYO#/@[P!X8A\*:5\(O!7@CPKKNG:/XK'A'
M2?  TCQ9K^D:;/X['B>UT[3+2P['PI_P3R^&G@+_ ()O+_P3/\ ^+_&OA;X7
M_P##-'B']FJ3Q]')I>M>/)M'\9^%]2\/>.?&9'BFQUO08O$7BF[\0>(=;EL;
M72O^$=T"\U8V7AS3-+T?3=%TVQ /Q&_X);?MWR_L(?\ !*O]@+X;VG[#O_!1
M[]K>Q\>?#/XO?&+PQKW[&W[..I?'7P=\/_AK\0_VF?C3XF^%?@'QQXY\3^/O
M!]M8>/-$\!:EHNGZAX-TO5?%$^@P:7;>;JTFAWOAW5-<]=_;R^/?PO\ V^A^
MQ7\!O%O[ /\ P4&^.WC7Q1X?\4?ME>._^";6L^)/@7^S9/8?"SPOXLU'X0?#
M'QE^W1:>*OB7!&ND77Q(G/C7X.?![1OBU86>LZIH>L:G\9=$GE\$?\(.O]"/
MP5^#W@[X!?!OX3? GX>VMU9^ /@K\,O 7PD\"VE]J%UJ6HVG@[X;>%-+\'>%
M[:[U2\>2]O[V'1M&L4NK^[GEN[J='GN;B=Y&(^%/VO?^"87A+]IC]H7X>?M=
M_#K]HK]I+]D']J?X>_##4_@C_P +A_9S\8:!9MX[^"NH:SJGBB+X7?$GP#\0
MO#7CCX?>+/#FB^,-=UGQ?H1F\/6U[9^)KNRUJ]NM3O/#?@]_#@!_/]\&M/U;
M]GS_ (*_>&/B!I?_  3/^$G_  2TA_9G_P"";?[8_P"U!^T!\+OV;OC[X%^(
M5A^UM\!;/6/#?A7X0Z%XU\!_!KP1\//A3X \5^'/B/9>*O$OAR]\2CQ!_P )
M1<:3>0/XCO!\-O#1C]W^$O\ P3L_8W\>?\$D_B1_P4G_ &_M&C^)O[6/[5?[
M,$W_  4 ^-'[9VG3W\OQ\^#VJ:EX%N?CO\$[7]ECQ#XJ\5V'_"E=0_9]\)3^
M ?A]\-_"/@+Q/X&\'^)5\ ^'?!WB4:AX&6RT"Q_1'X._\$MO W_!/'QE^U?^
MW'\.?$_[5G[<_P"T5\2_V6M4\(?$+P1\>?B=X<\>>-OVEO%?@>?5O%F@V9\3
MZOX;TZPT?7/$ND:;X6^#?A7PW:Z?:?#_ ,+^#=$T#2=.\,R2K=-<_P TWC'X
M*_LL?MP? O3_ /@F#_P3Q_:-_P""FWCB3Q]\:_A=9:_^P1X_\!?$7PE\!_\
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M&/\ P6,^+5[^P+KG_!-[]I_X>_\ !/WQ)9_M+_\ !-/Q]I'@CXB_L%?%K2M
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MM5\.:.GB?Q/<Z5X6N8_%6J:I)\L?M@?LM? /]F74?BG^S=_P3J^.,'P T_\
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M+\(/A3K.FZ/!JGA'7X/%L.KV33GQY-X0\'_"_3/!/YS^#8/B-^V%_P $P/\
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M._#^O>)+"#2+.SU_4+ZU^'?PP\.?#C1?"^NZSK/@#1-&3^U=)\-6?B9$UV,
M_&7QC^Q-^Q!^QQ_P5]_X(Z>#/V3?@[\+?@-XE\%?#S_@H'\4/C%JV@W<]MXQ
M\:?!FQ^ W_""Z3<?%SQ9J^N:WX]^)FM'XF>/++7_  ]XK^+UYKDS6'A;Q[=Z
M=XR%]H\^E:E^?W[1_P"S#X.^%>D?ME_M5?M1_L$_ /\ X*Z?\$_?VROB[\5/
MVC9/^"D7[-_CFS\:?MM_LM?LY^.M+LX+$V.C_$'3O$NJ^(? '[/?AK2]#\-_
M#'4?@!\6-!\ _#3X;?#S6/&OBS3]&T^]U3PY:_U=V?[''@-?VY=<_;UU'7O$
MVJ_%.]_9<TO]DG0?#MU_9-OX0\*?#%?B=+\6_%#Z=#::9;:EK.K^+_%L6A2W
M]WXFO-4_LNWT%;;PZFD6^K:PM[^<\G_!"#X4V>D>+O@KX4_;#_;E\$?L*^/_
M !%JFL^+_P!@;PK\7M"TSX$OX<\2:L==\6_!WP;XE7PD?C3\-O@3XNU RP^)
M/AGX%^)N@VUYI.M>---M=6M4\6W\M 'ZI?LGZ5X(T/\ 9<_9WTOX9_$OQK\9
M/AKI_P #_A=;?#CXM?$J\BU+X@?$7X?#P3HK>"O&GC?44\-^"VU#Q-XC\+OI
M6JZU>W?A?0+ZZOKF6ZU/3;?4);G/\W?Q'\.?#/\ ;1_;!_:I_:?^%7_!(7XF
M?\%7KSP[XCN_V8_A[\4?VQ/CM^SAX$_8N\+M^S_KVA>#?BSX)_9=\(?$W2/$
M>IV?A)?B,GBS5KOXIM\*_B5=>/?B/:>.]/\ #'C?1?#&I^(;:R_JF\*>$_#O
M@7PKX<\$^#/#VC>$O"'@SP_H_A7PCX5\-Z99:-X=\,^&O#NG0:1H/A_0-(TZ
M.UT_2]&T;2K2TTW2].M+:VL;&SM;6WM;2WA@2-?Q=U?_ ((>>"[+Q'\:K#X*
M_MS_ +?_ .S%\ /VAO'WB'XI_%+]FOX"_&CPUX7\$2?$'QAJ,^M>-=4\ ^,=
M:\!>)OB?\+]%\<:XEGJ'BKP[X1\86UEJUK)JOAYFMO"^I1Z'IP!^&O[*?P'\
M2?M=?\$Y/VP?V5/@QJ_P$_8LU?X]_P#!47XAZ?\ LG?L/_%3]H+XC_$G]G'Q
M[X3_ &3M-^%OB3]I[X!>!/B)\/W\+>*?B3^SOX^\5^%?BCXQ\;:G\"/#M[X>
M:P&N06<6G+++XATC[I_X)\_#+X'^%_\ @IC\.--^+/\ P3AU?_@D/^WA\//@
M;\6['PSH7[*^J?#Z\_8@_P""@?P+N(_#-E\1+V]UGP3\-=,T#4]2^%WCG6_"
M?Q,TOP:9/#7Q'\(&X^'=OX\\:^,++1;'PMI?Z(:/_P $2?V:/#O[!GPH_8-\
M,?$;]H/P%H7[/7Q3\??&+]G#X_?##XE77PZ_:+^!'COQSXT^)7B@:MX%\?\
MAR&))8]-T'XK^+OAW<VGB+2];M]?\*7GVG5TG\46FD^(K#V+]EW_ ()F>$/@
M1\>-0_:N^+7[0/[1'[9'[3[_  ^OOA/X3^+G[1_B3PK,GPM^&.LZM8:WX@\(
M?"SX??#;PIX%^'?A&3Q+JNEV5]XD\41^';WQ=?A;C3;77K/1-5UO2M0 />/V
M[?CUX$_9C_9 ^/OQE^(OB+XF^%]!\-^ -1T:UU/X(V&F:I\:I/&?Q FMOAY\
M.=(^#.E^(-+U[P_=_%OQ'X^\4^&M!^&5MXDTC4O#2^,]0T5/$<$OAZ/45/\
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MN)4DGD]$J-(PC,1GYR2<G/0Y&.><DLQ+98EL$A55%DH **** "BBB@ HHHH
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M$GQ7XNU;[3:6_AOPQH>F7>@:4U^PO)Y_$/B?P[IUII]R;NXDM/Q-\/?L3?\
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M.M_$/1CK%U=:S?1Q^1XQ^[?%_@K]J/\ X)K_ +2O[!7Q U?]NCXU_M0_#_\
M;+_:ITC]C3]H'X ?$[PQ\-?"WP2\,ZK\0?A#\3O&'PI\??LF>$_!?A^SN?V;
M/#GPIUSX7W>DWOPMFUGXFM\1?"7B"RTK5_%VG:[X6M_$FI ']#>Y<@;AD]!G
MDXSG'KC!_(^AHWJ02"" 2"1R 5)##([@@J?1@5/S#%?SO>&K']K_ /X*P_M*
M?M?76C?MG_&_]C#_ ()Y_LR_&;Q#^RG\)O#G[)Z^!/AY^T?\=OV@?@K-ING?
M&KXL^-_C#XY^'OQ.N-+^$NB^,=0\4_#[PAX3\'K:Z?\ $"+1[75?$&D>&-2\
M%SW/CCYE^(G[<_[8G[,__!/'_@LK\ /C%\5==_:#_:<_8<\5>%OV7?V</VCO
M &GW?@#XW?%-_P!M#X=_#A?V9->U'1_!FA7:7'QX^%VH_&31TN-8\%Z'IS^.
M[WPWI=@M[_PE U?XJ>* #^KL.I. 03QQW(;."/4'#$$9&%8YP#@W+ZXZ<'(/
MS,57@X/S,"!QSVK^5O\ :<^$7_!1C]COP3^Q!^T_\7/^"HGQD\>?M4>(/VP/
MV./V=/$G[-/PTT[P7I'[&GQ$\(?%3QC:^$/B-\(?!/PC\0^%+GXJ?&#QKI?A
M74O'?B:3XW>-?$NK_$WQ+H'A6^\7KX-\#7?A[0;_ , ^5_M)_P#!3WPC^T9^
MV)^UC\$?B1_P4!_:[_8?_97_ &6OBU=_L_>$]!_86_98^,?BWX[?'+XO?#_3
M]);XO^-_'/[2&@?LY?'[PUX \'> ?B7_ &[\-O#7PQ\&0Z?J_C/3=*O?$7CB
M&RT^;P]_: !_7QN'8@\XZ\9R5P#@@D%2".H(YQ7@WQZ_:1^$G[-UC\,+SXM>
M)3X?/QH^.?PH_9P^&-C;6%_JFI>+OBY\9O$L?AOP9X:TZRL(9)=H":IX@US4
M)6@LM$\+>']?UR_GCM--E#?EC_P1?_:^\=?M$)^UK\&=<^)'Q6_:0^&'[+OQ
M.^'NB?LY_M=?&SX,^+O@1\5_C=\&/B=\/X_%&F>%OBAX*\7>!/A]=^(?B=\"
MO$&E>(/A?XM^,EKX;\*CXSPZ=H?CK4O!>B7]]<:GXG^>O^"G7[+_ (R_;2_X
M*\?\$X/@=HG[5'[4GP \&> /V=_VH_VFO&9^!WC#PCX'E\.:CX#N_"?PA\ ^
M-_@_KEU\-/&][I_Q9UO5OCIJ?A;XEW_CL7W@Z/X16-EIOP_B\.>+->\2W/B0
M _:OQG^UC\+?!?[4_P &/V.;B#Q=K?QF^.'PX^*7Q:T2S\*^&[G7O#O@KX=?
M">7P_I^J^+/BCK=A+YG@+0?$VM^)=/\ "?@?6]2LVTG7?%\4WAN._AU>XTBR
MU;Z=0J"QW#'<'8I4D\G 4$%R0S;C]]C\JGBOY;]9^"'[27[:'_!9;]J7PS\"
MOVD?'7[,WP/_ &*?V+?V;/V&_B[^T'HD%S\0/VE?B'JWQ2OM>_:'\;>#O@+X
M[\?^%K[X6?"SQUKWA_4? $OQZ^+<^E_$;XJ^&=5\$_!G4_#=G#<>.;J?P3Y%
MI_\ P4_^/?[$/[$W[>VGWO[07B[]IOQ)\'?^"K-Y_P $U?V*/CO^T=\/-7\9
M^-Y]8GTWP9<?$2+XQZ+\'O#.G>./C)<_L]6]I\:O$,7B#0? \^N?%C4_!MGI
MWARTN]&UC1_#NB ']>.]0"<CC@@<G/7&!D[O1<9/84@DC)P'4G)7J.2,9 ]<
M;E!QT) ZG%?Q,:U_P4,L?V=I?!W[0?[/O_!43_@I9^WI^TM'\2/A-I?QA_9:
M^/W[$OQ=^'_[+O[1OPX\6^./#GA'XP:%\*/"$7[(GPXT']DGQIH'A_47^*OP
M\\=6/Q!\4PZ/+X"OO 6H^&?'-MX]U33[G]-O&=G^V'^V]_P5T_;H_9Y^'G[7
MOQ;_ &9/V2?V8_V;?V6_A1\2[_X(ZFNC_$2/XI?%8:K^T%'_ ,*R/C?2_$O@
MWPM\4M;\'ZSH5EXJ^.VG:%K:^'_A=8:9\,M/\&WWC#Q7+\0?A^ ?T9;UXYY;
M[H[G@'('4@ C)' [XP:0NG(+ 8&XG.!MQDG=P, $$\\!E)QN7/\ *-^U-^T'
M\+?#W[0GCW]E?XX_\%P_C_\ !7X7_LS?#/X-^#?!/P._8<T[7_BM^W;XU\;>
M'O#>FV?C7XS_ +7/QIT3]F/XT^*]5\::_K'B:YL?$?PL^'NDV7@N"Q'A3QWX
MIB\.Z];WME=<%\/_ /@IO\8O"/\ P1V_X+!_&RS_ &EOBO\ M">#OV0_&_BK
M]F+]C?\ :Q\>_"<?#+]H;5-9\1?#OX1^!_"DWQ5\-ZUIOP]U6;QU\'/C#\7-
M'TKQ%\0?%W@/P[XNU$:3J/C3Q+:>(M<:ZL4 /Z]MZ<#<.F1SU'&2/4 $$GL"
M&. 02-+&N=SA< D[C@@+M+-@\[5#*7;[J@Y8@<U_*'^TE\.?^"BW_!+O]B3X
M"_\ !0_XM?\ !2']HG]H3X[?LV7G[)GA/]K']G?Q-?\ PRM/V5_BO\)_&_Q6
M\&_!_P ;_#SPIH5O\,[[QC#\7;5OB'X?CO/VI?&OC3Q=XU\8:OX>\5^.)M%T
M<>)]%\$^$_O_ ,,_M:O^S?\ \%$?^"O5M^TK\<-6LOV;OA;^S=^QO^UOX'TO
MQKK-U!HGP>\&2^ _B5\-?BGI'PR\.WMW<C7M(\5^+_A9IGB'49/#5M;MJ/Q)
M\8?\(HFGZCX@U.UFO0#]O]P)(SR.QX/U&>HZ\CC@C.0:6OS'_P""5Z_M'>/O
MV>+S]JG]J;Q-XXC^)O[97BV__:&T+X(^(=:^V^%OV7O@MXGC6'X"? KP;HT.
MDZ!!I&H:%\(X/"6L_$^[O-$L/$6L_%+7/%LOB,W6HVK7,GZ<4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1RJ63
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MC:5PJMM*\A"H; 0D%<< @DC^;W]EW_@L[_P3@^.W[17P?^#7PK_8H^-7P_\
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M\5[F3_A'='UO4O$3ZA\,1XKT(^"W.BZ;XT35&\-:KXE\.:9J=UJ]I^8_B?\
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M/&APS$'T".3Z]E/0=?3O32;T2OUT[=Q-I6OI>]O.R;=N]DFW;HF^A_+-=_\
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M4K2XL;ZTD9U2YL[N"2WN;60QR(=CQR-&S*0QB(48>-7KYJ_9*_8D_95_85\
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M?^^6_P *+Q_FC_X%'_Y(+KO^?_R(^BF>8OJ?^^6_PH\Q?4_]\M_A1>/\T?\
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MQ5?K%]D]C^:?_&Z/LGL?S3_XW1]9X1_Z$?%/_B797_\ 06'U7BO_ *'.1?\
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MQ_-/_C='UGA'_H1\4_\ B797_P#06'U7BO\ Z'.1?^([FG_T2'Y._P##[_\
MX)I?]%T\:_\ B+G[6G_SBJ/^'W__  32_P"BZ>-?_$7/VM/_ )Q5?K%]D]C^
M:?\ QNC[)['\T_\ C='UGA'_ *$?%/\ XEV5_P#T%A]5XK_Z'.1?^([FG_T2
M'Y._\/O_ /@FE_T73QK_ .(N?M:?_.*H_P"'W_\ P32_Z+IXU_\ $7/VM/\
MYQ5?K%]D]C^:?_&Z/LGL?S3_ .-T?6>$?^A'Q3_XEV5__06'U7BO_H<Y%_XC
MN:?_ $2'Y._\/O\ _@FE_P!%T\:_^(N?M:?_ #BJ/^'W_P#P32_Z+IXU_P#$
M7/VM/_G%5^L7V3V/YI_\;H^R>Q_-/_C='UGA'_H1\4_^)=E?_P!!8?5>*_\
MH<Y%_P"([FG_ -$A^3O_  ^__P"":7_1=/&O_B+G[6G_ ,XJC_A]_P#\$TO^
MBZ>-?_$7/VM/_G%5^L7V3V/YI_\ &Z/LGL?S3_XW1]9X1_Z$?%/_ (EV5_\
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MR7MU@98)5GS-^U51-MIM_D[_ ,/O_P#@FE_T73QK_P"(N?M:?_.*H_X??_\
M!-+_ *+IXU_\1<_:T_\ G%5^L7V3V/YI_P#&Z/LGL?S3_P"-UR?6>$?^A'Q3
M_P")=E?_ -!9Z/U7BO\ Z'.1?^([FG_T2'Y._P##[_\ X)I?]%T\:_\ B+G[
M6G_SBJ/^'W__  32_P"BZ>-?_$7/VM/_ )Q5?K%]D]C^:?\ QNC[)['\T_\
MC='UGA'_ *$?%/\ XEV5_P#T%A]5XK_Z'.1?^([FG_T2'Y._\/O_ /@FE_T7
M3QK_ .(N?M:?_.*H_P"'W_\ P32_Z+IXU_\ $7/VM/\ YQ5?K%]D]C^:?_&Z
M/LGL?S3_ .-T?6>$?^A'Q3_XEV5__06'U7BO_H<Y%_XCN:?_ $2'Y._\/O\
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ML?S3_P"-T?6>$?\ H1\4_P#B797_ /06'U7BO_H<Y%_XCN:?_1(?D[_P^_\
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M:T_^<57ZQ?9/8_FG_P ;H^R>Q_-/_C='UGA'_H1\4_\ B797_P#06'U7BO\
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M2E*4J;;****P/0"BBB@ HHHH **** "BD) ZG'_U@3_($TA=1W_F>V>P]/\
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MB@ HHHH **** "BBB@ HHHH **** "D) ZG'8>Y]!ZGVI&8*,G/X DG )Q@
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MC:% <9)Y);@<-5FH$)W MD<%,#INRHQM'?"[@P&-F3DK\U2[@!DY XZJP//
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M"</AN'PW?Z7-XUN-#@\*:KX@O_"UWK7F6'C3^D;X(?#V7X0?!GX1_"B?6O\
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MJ,%@.#CHP. PSSP"2<4/3?3??RW^X2E%I----733O=>5M_E?_)SG!8YRP&X
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MHO\ \%3?VP4_:E^.'BSP3\:OA9_P4:^'_CF[^$?BOX&>#/@S\3/BAXR^*WP
M\=_%3X"?L_-X9\0?#2^L-&U06/P[U:]G\4:;?Z)!?Z5K?AC2=+T#7@#^Q_>O
MKVSGG '.<GH,8^;/W<C.,C)O7!.X #N3@?=W9R>"-OS9!QC)[''\8'[:GQ[^
M(^D_ME?M)^'/^"DG[>?_  5#_P""6&B6WQMU_P '_P#!.SXS?LX^'M-\-_\
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MMOJ/Q3MO%-A=^--%\(>-OC1\'O$Y\*KJ?AJTEN@#]0;O]O'X1>&? ?@?Q_\
M$SPK\9/@MI_Q4_:ST#]C?X1>&?C%\,M2\ ?$'XI?$SQ9\59OA/X.\0^%_ &J
MW(\46WP[\7O9:K\1=#USQ/I?AG57^$NA:EX^O= LM+-I;778^._VN?AI\/\
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M7-=U9O;GJ.3E*SM=WT;:5P G8 "3NC_]"4\^@]SQVZD5<CZY]3'CCG[[=1U
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M$9*<8V?,V[16KE9PORJ+ES?''X>;XEO?3?0'>W'_ "R;]02/K^'3O5Q/N_\
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MU::YM]*L[FZAM[K4Y[.UEO;J'3K>9TFOI+>RAFO9DM4E9+.*2Z8"!&D%XR(
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M6_MX? 7QWXX@UCQ5^SUK>N_&/X??"?XDW7PY\5^$]"'ACXY:CH"_%KX:^+?
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MGZAKGB#59+;2='L;S4+N&VD_!SQI_P %+_\ @JU\/_@9KW[:GCC_ ()/^#/
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M?'GP+XC^(&F?"K3O$/Q N=:\&?&WXFZ=I:S:W!=ZAKA\,Z18>.X9[6SUG2Y
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ME^-WQK\"ZEI][\-;*Z\,:#KEI<Z%\0[^TN/>/C+_ ,%)/VG/"_QB^#?[#WP
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M[:'QIF_86_;?\>?M-_%'1_VBM4_X)Z_M&?MC?!73?VE]1M- ^$FB?M+?"_\
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M-9UK0IM$:^URU\&? SP;XKO[30I;Z;7?#UI'XATM[;6;/2+R\DO[>VNK*_\
MH7]K;]M7]F[]AWP!HOQ&_:1\?R>$-(\8>,-+^'?@+0]$\*^+_B'X]^(OQ#UU
M+F31/ O@#X>^ -"\1^-/%7B+4UMYGBLM+TBY@L8FDGU6[T[3D-RH!\Q^)?\
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MDCQE/@QH /&JZZ<#.1/IP/IU&EH>_J?IGD3+\&]!7/\ Q,]=;/9KBP(SZ_\
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M.!W[$"D /<-]=W/\P*3Q^->GMIV\Y/\ RN6LDRF/P8&E%?RQYTO-ZRZ_=V.
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M$_C'5K6QT)[KQE\0O^"FGB_P[X3M+K7=3<>"M/#:+I'[0OA[P?IVKZU=3?\
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M9\/_ !OXN^,-UI'C0>(?%GA:T\*V=MI,GA?P[XTO;?\ H!$;*JJN %7:NT
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M6-\VR>]L+:X6RO+RWL[VYMY;FQM)8?7;3X2?"ZQ^&J_!FR^&O@&R^#P\(R^
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M:I_;$^,_[6<EO<>%X?# \"3_ !>N],NY? D,D?B'7CXDM]#;30D?B.5-%EU
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MQ+P[Q--N4I2AB(2<FY791117.>F%%%% !1@=<<^M%(2 ,DX'.2>@ &22>@
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MD9I=E]+'FLN9Q<FHWY;\J?)3YE&^O+SJ;A?[#@%%%%(H**** "BBB@ HHHH
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MLPW4^EV9TWQ'HNL3?;8K)7N3%-!IDEN&B4[99(V8>6&(^C[@D*H )W/M.%)
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %W U(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^C3_@K'_P
M66\._P#!-+Q%\,/AMI'PAU'XQ_%3XE:!JGC==.N/$,?A3PKX;\%Z1JL6ARWN
MH:LMEJ=]>:QJ>JRO%INF6E@(DM;:ZO+RZC401S?C=>_\'8WC#35234?V./!6
MGQ2,$B>^^.%Q:I))C<%C:;PI&LC!3O*J6*@;L#K7C7_!TLV/VU/V=&5]F/V:
M-9R VQACXD3NI8!2<#:<$G@C( .<_G[^P!\0?$?A3X2_$'2/V<OVC/V:OV4_
MVLM0^-GP_O\ 7_BK^T/_ ,(%HEQKW[,%GHM]!K/A/P3X]^*'A?Q=X7@TK2_'
M[V'B;XE?#?3;*Q\2?$30HK.VTM[C[*RQ_ON0<'<)1X(RC/,?DCS/&XVFJF(K
MXC,,RP]*$JV.QE!U:LL)&M'#X+"0P]&,G0P>(JIXBC>$E4<Z/YQF.=YN\\QF
M!P^-6%H4':$84,-.3Y<-1JJ$(XB='VU:M*K4Y$Z].RHS3O=-_K?_ ,177C\@
M-_PQ;X4*A1@K\9[XH0 &!##PD5(P<@J2",')4AB\_P#!UK\01N#?L4^&.&((
M_P"%QWYP58J00?"'#*5SAAD97!R0!^3VI^"_V#=>^#/QK\9:EXK^ &I^+=1N
MOVTO$GB?Q_\ #G6?''P:\3>&OC9I7Q>UU?V+O!/[(W[)T^JQZ)#^RS\8O ,N
MG:QXLM-7T#QE<^"-/U/4++5O&/@R3PMH=EJOT!X]^%O_  2\U/QS\3K+P1H_
M[.FA7/@#]IK]K7X6_ KPY<?M(?$)?A?\=_"6@_LH_#WXC?LZZY\8O%MW\1;J
MZT3X?ZS\?]?\8^!M(\>^$O$?PY\*WEIH%EX!UGQ"VIZ=>>)7Z7DWAU&\9<$9
MR^64HUZD7FCITI*G3YFI2Q%-RCS-_'2ISIX>5'%XBG"E6A2IY?7^(7K'.\OV
MA**<L-S.+J5(R:C&G=R<53E&-U&555:%.<O9NM4^U1_P=D>+VRH_8Z\$[E64
MD?\ "[IPP2&Y:SF.W_A% 5$=U&;9R0 )\0GY\*9D_P"#KSQQ<!S'^Q?X2F\F
M9X)?+^,][((Y[=MDL$FWPDP2>$L#)$VV1"Z[@"PKPS1/BM^RKHWQVUZYUCQ1
M^S'XET=_BQ^QQX,\+>!=>^.6M>*/V?K#2]*_X(U^'OA7+K=E>V_C/2AJFB^
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M]3_C5BB@++LON17R_P#SR_4_XT9?_GE^I_QJQ10%EV7W(KY?_GE^I_QHR_\
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MH:_XACO^";H&!JW[3@!&T@?%C11\K-EAQ\/N <EFQP23GYJ4_P#!LA_P3?.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HI 0>E+0 4444 %%%% '\D_\ P<"_#GXD>(/VCO@3
MXE\,_#;XB^+= ?X-:YHC:SX+\">+/&5C#K%KXS^V3:9>R>%](U@Z==?8[B*Y
MBCO4@%Q YDA<F-E'X4:3\/OC'HNMZ#KT'P/^.%S/X>\0:!XC@M9O@A\78[>\
MG\-ZU8ZY;VDSQ^#&E2"ZGT^*WG>(-+%%-(\0:0*#_I2M#S\LC)\_\+%26(X#
M8X/!XP!QTP,BD,4@P#,XZ -O?DG. 1GD]<GC/&:_1LG\1\3E&48/*7E&&Q5/
M!X>>&5:>.Q5%UH3G6FW*E3HRA3ERUI4WR5)2<8I\Z^%?AG$O@EA.(>(LPXAC
MQ'CL#6Q^)IXIX>GEN Q$*-6G1P5/]W5K8NE4:Y\%2JQ<J:E&=MU'WOX&O#'[
M0O[2?A?XM^/_ (OVO[*WQ*O=8^(7[77AS]L.^T>Z^%7QV72M,\7^')/BI/;^
M#;&:+P%]KG\/7+_%C5'FU2X U"(Z1IZV]EMN;@1=OX/_ &Q?VM?"/A'X$>%!
M^S7\<M6C^ >A> O!N@"33OVN-)\(Z]X*^%W@_P 0^!?!.BZQ\*-/T1_AY'K5
MEX:UG3;+6/%\FEZM<ZQ/X;LM9L])T+Q)J>M:W<_W7F&0#/G2<$'[S=!UR>_/
M.-O08I!'(K &9R54MRS%2,D#(ZGC!QGJ"><@#"KQQE^)E&=;@_*ZCC%07-F&
M82:A"G1H1BFH0<>6GA\/"+5VE0II/W6YZT/"7.L+&<<-XC9]1C4J2JU%'*<D
MM.I/$XG%.;4:L%S>WQF,J2;]V3Q>(4Z<XU91/X*/@W\>?C1\,OA/X&^ J_LC
M_$W3O!UIKWAZU\?^/-"^&O[3UEKGB/PU#^T/X5^.%YXIU3X=V?A]_ASXB^(O
MAV'1)?#>E^+K_0KWQ3JGA.RTSPM::AH]E:06\OL6N_MG?'7P?\5?B=>? C]D
M;XH^#OA)XY^('[27BGQ%8Z%X#_:S\,>,_BCJ?Q_\<>!_$&L_$R?QIK.D^(_%
MOP=U^ZL/A-\-I[+P+X%\OPAX?DM]<TDZ9<Z-JD>C:3_;KY3X.)G'\.2\APVX
M[CC=]=O0 ;<< [D$;\YF;H1G=)G:K%=V-V <=6_B)R0  !G4XSR^KB*V(J\*
M8*HZ_.ZU*>;9G*A4K2JPKO$2A*$INO3J03H2=6U&\W3A%RNMJ/A5G&&P^&P^
M&\0,WHQP:IQPU2GD601K4:%/#/!K!QJ1G'EP<Z;E+$THI5,7S<N*Q-2FE _@
MZUS]J']HWQ%X3U70=8_8]^)&J>()?#O[1G@?PW\0=8\/?MB>(O$WASP+^TO\
M1M.^+'C#P_J,7BBWUJV^(&J:+XRL(!H?C+QI<7GB(^&_+\/SO%<P_P!M'/US
M]HOX[:Y>>*A<?L4^.(_#7Q,^(WQQ^(OQ=\&2> _VGKG3/B%>?M'?"?X;_"OX
MKZ';:S%X8LO%'@/3]2'PTL/&'AV\\+:PDWA36M0ETNR@N?#]E]BOO[U<,H)\
MQS@DD[V/ )Y.22!G/ QQ@8.,'GM;\1:7X<TZZUC7M8LM%TBQC9[S5=6OX-.T
MZT0,41[F^NY8;6'>Y"A9)$9BP5<MM4Z0XUR]NG1I<'X&<G*,*-*GF.<U9RJ.
M;="G1HTXU*CG2JRE4P]*A2E)5YR=&FZC:7+6\+<SP]*KB<3XE9O1I4Z%5XC$
MULHX=P\(T5%RKU<5B:V(I0]FZ7[K%U\574:V%A2I8S$2HPIM_P"<?XM\!?$/
M7O$NKZSX:_9<^+?PUT#4)XFTKP+X>^%G[1?BC2O#MI;VT%M%:P>(O'VDZ]XI
MU>XE$!NM0O=1U!;>:^N+DZ9IFBZ=]ETFS_H=_P"#=_P-X\\,>(/VP-5\5^ /
M'O@[3-3T?X"Z9IE[XU\$^*?!L>IZAI5[\7[K4[73$\4:1I$VHO86NKZ7/>/:
M1SP6PO[6-Y \I6OV1UG_ (*,_L:Z%<3VMY^T)X%O)K6[:PN(-!N]5UZ:"YCC
M:203MI=E<PK&@4*\BRN%>6)"%:6,UC#_ (*;_L4,.?CAI#@GH=$\4,".?[VD
MD@#KQP2 3G"U]=F=7Q XAR'$971\-.(Z.&Q,*-'ZU'*N(ZU51P]>G62<<9EF
M'G4E.4$G.LVVFY*<FW(_.^'J/@]P?Q3A,]Q'C9P=B,9@:F,K/ U<YX-PE&<L
M=AJN'TEE^>8F%&$(SG*%.BI13CRN$$D??T3DXSC[W/!X 0^W4D@D #.2>QS8
MWKZ_H?\ "OSZ'_!3?]B@ C_A=ND'!SDZ)XI')X.3_9!.>.>>23WI?^'G/[%'
M_1;='_\ !-XI_P#E/7P"\/?$!)?\8/Q;M_T3^:/O_P!0WF?LR\:O""VGBCX?
M6\^+<C\NV/\ (_03>OK^A_PHWKZ_H?\ "OS[_P"'G/[%'_1;='_\$WBG_P"4
M]'_#SG]BC_HMNC_^";Q3_P#*>C_B'OB!_P!$/Q;_ .(]FG_S,/\ XC5X0_\
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M#[_Q+<C_ /F\_0/>OK^A_P *-Z^OZ'_"OS\_X><?L4<_\7MTCC_J">*>OO\
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M_HZ7A]_XEN1__-Q^@F]?7]#_ (4;U]?T/^%?GW_P\Y_8H_Z+;H__ ()O%/\
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M_L4GI\;=((/<:'XGZ>W_ !)^<XY[>G2G_P 0\\0-;\$<6Z;_ /&.YIIJX_\
M0,NJMK^JN/QK\(/^CH^'_P#XEV1]E+=8Y]&G\_N_0/>OK^A_PHWKZ_H?\*_/
MW_AYS^Q3R/\ A=NCD^G]B>*.Q]M'SSU/Z<&D_P"'G'[%/?XVZ/Z?\@7Q3_\
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M/T"WKZ_H?\*-Z^OZ'_"OS\_X><_L4XX^-NCD#/\ S!/%!_,G1S_];CMFE/\
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M=?\ \(7X1!!/A7PT>#@_V#IF/0X'V<X_PZD]X+M%'Q%T0#I_PB>O''&/^/\
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M_:<5H\+;_:L7HW7JWU^N];6=[Z;:ZF,\HRU5Z"679:DU7O\ \)N7ZVHT[?\
M,JZ)NVJUWNM"Q_PA7A'OX4\,_CH6EY_6WSU]:/\ A"O"'_0J>&/_  1:5_\
M(]=SY4?]Q?RH\J+^XOY5"KXFR_VG%:I?\Q>*[?\ 89YFW]BY9_T+LL_\-N _
M^=9PW_"%>$/^A4\,?^"+2O\ Y'H_X0KPA_T*GAC_ ,$6E?\ R/7<^5%_<7\J
M/*B_N+^5/V^)_P"@G%?^%>*_^; _L7+/^A=EG_AMP'_SL.&_X0KPA_T*GAC_
M ,$6E?\ R/1_PA7A#_H5/#'_ ((M*_\ D>NY\J+^XOY4>5%_<7\J/;XG_H)Q
M7_A7BO\ YL#^Q<L_Z%V6?^&W ?\ SL.&_P"$*\(?]"IX8_\ !%I7_P CT?\
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M^S'^5)_PA7A$?\RKX:YSC.@Z7_\ (O\ ]:NY:.)5)\L' Z #/X9XK\Y/C?\
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MJ/\ A"O"'_0J>&/_  1:5_\ (]=SY47]Q?RH\J+^XOY4_;XG_H)Q7_A7BO\
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M/;K;YSV Z>U+_P (7X2('_%*^&^V?^)#I?\ %T!_T;_/>O"/A'^UY\(/C/\
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M5UMEC6O357M=71C_ /"%>$/^A4\,?^"+2O\ Y'H_X0KPA_T*GAC_ ,$6E?\
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M_:'^&G[//BO1="^*7Q&33_VB/ MIXEAT&'4_&PN?$MYIGB/1?@A/XIMH-?\
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MQ8R^%/V4O'7PF^+,,_B7X@_$'X@KH,.O65WI&M#7O&T>C#36_JT 7.X$ [0
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M_P#%"]^$G@"]\+6VK:!%8^+-9\)W*:+;2Z,+[PG-;Z/_ &8G W,#AR&&Y<9
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M'<K!I5C,2;&!;AB/C.P_X*%?LN7^J^']&MO%WB5M1\3?M?ZQ^PMI$3_#KQS
ML_[1^@>%M=\9ZKX7::70XT@\.P:!X<U>ZB\=RL?",[PK;PZQ)++&LG\\>L_
M;XMRP^,_":?LV_M:3_\ !8JZ_;=G\4^!OVSG\'_$>;X+6?PD_P"%YVOB'2OB
M%:_M((6^#V@?LV67[-:WWP^U;X*70'BB?Q>]YX73X>:G/J-IXMN_:]*^"GQL
MM_'_ ,)]0M_@M\5'MM*_X.-/BK\:)B_@/Q-:V\7PFN_V=?C)IFE_$NZN)-,\
MC3?ASJFMZCIFCV7CR[:'PLU_J-E:MJ7FS11O["X<RZA&HL3F"JRE%.C:I@:2
MJ<M'%UI8FBEF&*E5P.*?U:."G6^K8A>RQ4:N'IOV:?(\RQ4W'V>#E!)_O'*&
M+ERJ56$%"5L'&/MJ<54=51<HZTI0J3BYN/\ 3)KOC'P_X<TWQ#J>I:O L/A;
M0M4\1Z[:VTWV_5K'1M'LY-0U"[.DV;SZE(T=HH\J.&U:6:26"./=)+&C<1\#
M?CG\.?VBOA7X!^,WPGUBYU?P'\3/".C^.?"UQJ&EZGX;UJ?PYX@B:72+[4_#
M.N6]AK^B/=)'(4@U33[:<[3E"4Q7\D_PI^''Q>UO]JS]F'XM:7^R7\:_@9XW
MU3XK?M?:+^T_:)^R_P#M0Z7<:-8_%+]F7]I"'P=X(^-'[6_QE^+7B[3_ -JB
M'Q'X]T[P'>>$KSX6_"_PW\)]#UJYT"VNM2\,ZG=_#'0_$F=^R)^SS\:H?"G[
M"GAK]CK]E?\ :R_9._;1\ ? #]I#2OVMOC=\;?AU\1OA;\+M5M-?_99^*'A;
MX)Z3XP\9>+;RZ\&_%6'5?VC-6^$'B3X;^&_"-CXE\3?#?3_#VIZ[K'A?PN=#
MU6R7:7"6#I8*I*IF<:6+I\LKSEE53#8>$,'BI5YXR-#/*C6&J8JC2CA<3AOK
M=>-*M3C4PKDU.:_M7$2KP2PE25!QG:U/&1J59?6*<(.DYX*'[Q4>?GP]5T(M
MKG51*2:_LWCU.QNGO;:&\L[B:PDCBU&W@O(;B:Q=P6":A&LF^T<QHS#[0J-A
M. 0IQ%_;FDFUFU ZOIC6-J8FN;T:G9BUMA<+$;<37/V@V\!N%GA,(EE0SB9?
M+)5E+_RN?LI?!G4+/XG?L0M^S3^R3^V'^SS\5?AW\)/B];?\%/\ QW\<O _Q
M0\%Z+\4=,U#X"ZWX=N? 7BGQQXVNK_PQ^T]\5/&'[1=SX*^(?PT\0_#'5_%D
M&A^&=-U/69-7T:PEET:WX/PU^SM=?!G_ ()O_P#!-+P%XF_8Z^(NN6GQ1U37
MOBA^UYXE\;?!;]K+]I=_AQ\4?#7POU71_ =Y\;OV1?@GX]^'WQ.^*\_BN2YM
M?"?@^#Q'KVG^"OA=J6AZ/XEOM$DU%=,O]/Y:G#.%A)1682G5EB(TJ>&E#+*6
M)]E&AFN(KUI-Y]/#4U4HY;"IEU/VTYXVGC*"K1H5XJCB-EF565G]4<5[-R<D
M\7*FI^TPU*$/=R[F;C4Q$HU':\/8SJ4W4I<U6G_49XO_ &A_A!X!^(_P;^$?
MBKQOIFF_$3X_W7BJW^$?AM5N]0F\6?\ "%^'I/$_B*ZBO+"WN=/TVPM-+11#
MJ.K7>GV6I:E<V6E:=/<:G>6]K)ZTFI64MU<V45Y:3WMH(WN[&*ZMY;NSCEPT
M)N+6)FN(%F4KL::.,,&#;AQC^-K]GO\ 9<\?6'B3_@G#XZ^)G[+WQN-[\-OV
MNOVUO .@:AXU^ 7CRXU7X'_\))K>B^)_V'=4\<^!/"]]\2D^%GP@\!?%O5-)
M\;6%^/$7BCX;_#:QTS67U/QA?Z'H-Y>/ZY^Q_P# _P"(6F>)O^">>C^!?V7_
M -KSX3?\%#OAM\;-.UC_ (*1?M)_%7PG\2-!^&WCGX;:?;>(A^T"/&WQUUVY
MN_AC^T+I/QNU";2S^S]X:^'U[XSO/#TATF^F3P18:!>WL/57X4P%*,E1S>,I
M4:6)>)J2_L[ZM"KA\1FB^L>TAF\JL,"J6"PN&FXPQ-?^T<RH4Z5&>$<ZYA2S
M7%5&G+ 5(QG.')!1Q<:T:<J>$O']Y@>25;GK5JMW*C2="A-J7M+4W_659:II
MM\2UC?6-\JK&7-G>VUXJ"5W6)G:W>0A9?)F,3.%WF&0 L4<+?D/R$Y!^4("#
MT(8Y.1GD[01QQTZFOQH_X(9?LX+\"OV%?"GB'Q7\-O%_PZ^.'Q9\:?%S6OC%
M#\1(?%5AXXU%?#/QR^+&@?#%=5T;Q?.M]HFFV'PY_L67P_86UCIUI-I>HIJL
M<,IU#[3)^QUPZJAZ=01@X/ R <L@Y;'0D$=<DBOELRP]+ 9ECL#A\1]<IX/$
M8C"QKQC3C&N\/4=%U(0HUL7&,9RC-P<)U8SA&-12:FF>IAZTJV%HUZT'0E5H
MTZLJ<FU[/VD5/DG*K3PT>:/-%2<G3M*Z:35G7N5?R9 %!_=X')P3LQ@GV.,Y
M&3G@$XQ\!_L=7MMXB^.'[?OC#3"DVA7_ .TGI_@VUO8Y(6^T:_\ #3X>Z!X7
M\76B+&Q=4TW59(XA-(J+(\DD:YEAF(]:_:G_ &B[/X"> 5N-+@/B?XL>-KQ?
M"/P9^'MD+>XUCQAX[U8K8:,$T_[;93/H>CWEQ!J7B*]-U:16UG$T,EW:S7$4
MB:7[)?P-O/@#\$O!_@36[NVU7QM*FH>+/B9KT%R]ZNN?$SQI>'Q#XXU"*^FM
M;*>^L(M9NI=(TB]O+:&\GT;2M->Z47#R ?48+#RRG@K/,RQ4/92XLQ&4Y!D=
M.J^2>+PF29K//.(,TA2TF\%A<11RO)H8MQ="KFN)Q6$P]2K6P>*^J_E6:8JG
MQ'XK<)93EDO;P\/,%Q)Q+Q7B*:YZ67X_BGAZ/#'"_#]2K&ZCFF88:MG7$-;"
M*<<5ALDP6#QV(HT:&8X'ZW],F-F)(V@$DX) (SSR.WT[45;\@'DD$GDDJ<DG
MJ3\PY]:*^)Y5_/\ ^2/_ "/V)3T6^RZ+LBQ1102 "3T R?H*V("BC/3WX'Y$
M_P @:3(P#D8.,'Z]* %J*1 W)[#CUR Q!'TR?K]<9ESU]N#^6?Y$4A&01Z@C
M\Q2=K:ZK\_Z]5MN!DWVG6E]:W-I=VT=W:W<$EK=6MQ&EQ;W=K<+Y4]O<P3*T
M,L$\3-%-#*&22,E7#)R?SKN/V7OCC^SUJ^IZW^QCXQ\.#P'JVH7.LZQ^S5\7
MI=4E^'L-_<37<]Y-\,?&.G+?ZY\/FNFF$BZ"UE=Z UPD -[86=N+67])'"X.
M&4# 4\X.5.!CGC&<=?\ Z]<KM!VL,@MD@9#<$,%&1C!.#GL,CBO8RCB',,C^
MMT<,\+BL!F$:,,TR7-,)1S+)LSA1=25!XO+\2G!8NA*=1X+,<+4P.9X!U:DL
M%CZ:J3HR^/XHX)R7BQX'$XW^T,NSC*)5YY)Q-D&85\FXDR6>(4(XF. S7"J<
M_J>*5.@LPRK'4,SR?,HT:<,?ELI4X8B'P#%^U5^TGX=\NR^)'[!'QIM=0DMO
M.AN/A)X^^$GQ8T>Z>&YD@FWWK^(O"4NE1R1"WGM8-00:C(99XWM%AMX[RYG/
M[8OQ,()/["_[8 R1P=#^#Y.,'!.WXK,,XZX& ??%?>@BCW9W+D,3E1D9. >>
M@X"]"<_-[U$85/=...6Y_4Y[#KG&,>]=\\[X=JRYWP%EE.32;CAN)^/L+072
MU.A]>Q2IK_N8J/1;))'A1X0XRIKV<?%KB*I&'+&,\7P=X8XO$NT4FZV(_L?!
M*O.37-*?U6C)RE)N+NY2^$/^&QOB;C_DQC]K_P#'0_A#TZ=!\4\=#Z'WX'!_
MPV+\3.?^,&/VO\' _P"0#\(CTX_Z*L.GZBON[RE]5]1SS_G\:/*7U7_OHU/]
ML<.?]$)@_P#Q+^/7?[ZW3M]]RO\ 5+C3_H[&<O\ [L7PQ_3 GPB/VQ/B4/\
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MGK_Q(_A"<_G\4S7WCY _NG\S_P#$T>0/[I_,_P#Q-']L<-_]$'@__$RX[_\
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M?.?_ !!O##_YB/A+_AL7XF_]&,?M?_\ @E^$/_SU:/\ AL7XF_\ 1C'[7_\
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M_:_^HT7X0_\ SU/Z4?\ #8GQ-_Z,8_:__P#!+\(>?_,J_P J^[?+7T;\C_\
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M\5*^[O*7T/U*GC]21[XZT[R4)X4#!P/EP#GKCJV3QCC]12><<-K_ )H3#?\
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M_P!$'@__ !,N._\ YI!\)<:O_F[&=?\ B!^&7_S ?!W_  V+\3?^C&/VP?\
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M?^+JL!C'3 & .Y-!_;#^)G)'[#7[8>X\9&A_"-21Z%O^%K,<>W.#TSU'WGY
M_NG\S_\ $T>0/[I_,_\ Q-']K\-VM_J%@EZ<8\=?E]82_+U71_ZI<:?]'7SG
MO_R0GAI_\Q/\;^FKO\'#]L/XE<@?L,_MA#("Y_L/X1#"@GY?^2J] "2!DCMW
MR$;]L'XE, K?L,_M@L!V.B?"' SG.!_PM;@\G/)!]LYK[S\A?[K?K_A2B!1V
M;UQ@D9'3/J.N1_/-#SCAO_HA,&K6M_QEW';M;L_K'^5NG1I?ZH\::_\ &U\Y
ML[Z?ZB^&?75[X+6]EO>]EMU^#A^V'\32&)_8:_; /RXS_8GPAW$XVAVS\5,$
M<<KU"\8]<'4OC-^W=\4+?[!\*?V3='^#MCJ OUL?B)^T3\4/#;/8+!<75O;W
M%Y\,O $/B#Q';7DL4$$\<=VNJ6(N)\)%?Z9%#J%]^AY@4G '0#/WNV,#&W.#
MM'4\C/.>:=' >[*IR!MP0, @Y R222<9)R ,>]:4>(,BPLI5L/P)D,JJ5Z?]
MJ9QQCG6%IS7O0F\MQV:X3!8KEE[TJ.+=7"U8IPKT903YHJ\#\4XVE/#8WQ9X
MRAAZJ4:_]AY'X?<.8^K3<DZE*GG&6Y!CLSP"JTU.E+$9>J.-I>T]I0Q%*K&G
M*/QQ\#?V3++P%XSF^,GQ<\8ZG\<?VA-4@FMKOXD^(K./3M+\+V<S2K-H/PS\
M&Q7=[IO@C06C9HI/LDUU?W,819+M8E$"?9Q@ 3 R,!1@ G !^Z,<D#IWZ$\=
M*58"N#D-AR^.G]X[?Q)Y/I].;/?\#_3_ .O7BYKG.99]C'CLVQ+Q.)5&CAJ=
MJ5'#X;#87#QY,/@LOP6%HX?!X#+\-3?L\/@L'AJ&&IIN2A.I4JUZOUW#/"N1
M\(98LHR# QP>$=>MC,14G4KXO'YCF&*:GC,TS?-,;6Q.8YOFN.J_O,9F68XK
M$8NO)1BY4:-.AAJ$&U?]L>VUSCVR"0<>H)'O14]%>?9>?WO_ #/H1A< <[A]
M1@G! R<\8.1R>H/KQ4(G#8!!P<[AC)&<@*V.C*?E8<Y;@=\+(<HP8C!4#J#@
MAL'(R3N!(Z#''<C%>9?%GXJ>#?@M\//%?Q0^(&J+HOA#P9IDNJZU>K;O<SK&
MLL<,%K9VT(+SW]]=S0V=E;AD1KF=&N)(+=99TTP]#%8O$8?"8/#UL7B\7B*.
M%PN&P]*=:OB,3B*D*-##T*5-.I6JU:M2,*=.FG.=245I!3E'CQV/P>68/%YC
MF.+P^!R[ 83$8['8W%UJ>'PN#P>$I3Q&*Q>)KU7&G1H8>A2G4JU)RY80C)M-
MNG&?H,U[&#@A@=@;:/F=<%N2J!F'RL"3C !!)QR*::Q;2-Y"D.6QC:6?! X
M"QD_W<=P1@G.<?FKX7^%7[0W[7UC;^/OC_XR\:_ ;X5>(D@U'P;^SE\-M2N/
M#/C$^&KF-9]+NOC%X[@M8=;C\07]ND.I'PSI+Z;)H\.H/8:U;Z?J*SZ/IWH,
M_P#P3A_9GCTBUM=(TGXC^&]9M+:UBA\7Z%\7OB18^*A/;1+$+\WYUZ>WDN[I
M_P#2;N4Z?&MQ.7+1Q*Q2OK,3D'#F5U7@<XXNJ/-*51TL;0X;R"/$>79?B(R<
M*V$KYS4SC*<-F.+P593I8N/#]''X.G5P^)H4LPQM2C*M4_+<-QQQ[G]%YKPK
MX=X=\/U*<*^68OC3BU<'YSG6%J)5*..PO#M'AS/<9E& QE%TZV75.**^6YAB
M,/BL)B<7E66T:\:5+[\BNU?. 3M)4DXY" CGIM)/S<@<,!ZXG20,QVCKCDD#
M(!() R26 VY&!@8R0?E'Y;W7C'XV?L.:OHS_ !7\=ZO\=?V5M8U:ST.]^)'B
M6WMT^*GP/O=39;73+SQK=6IMK/Q;\/I;^06=UKYMQJ7AZ!;5]15_,>XF_3>P
MN8+F&&YMYHY[:X@CF@N('CE@G@GC62&>&5&9)89HF$L4L3,LJ%3&65DSY>><
M/ULEC@L72QN#SC),UCB7E.=Y=]8C@\9/!SA#'8.OAL;3I8W+,VP$ZU".891F
M%.&,PJQ&&Q-*>.R[$X;'2^HX1XUP_$\\QR[$Y;F'#O$V1RPT<]X8S=X.>89?
M#'1K3R['X?%9?6KY?G.0YK3H8B64Y_E56>7XR6%Q>%K0R[,\)B\MIZ+G 8D<
M D@#G.>.W.X$$C@]@,GBOYM/^"FG_!P=X#_8[^+NM?LY_L\_#;3/CY\6? DQ
MLOBQXHU_7KS0?A9\/O$LD)F'P^M)],ADUCQUXWTJ)[6X\91Z3/IOAGP=-=0^
M&[C7]2\:6GBKP[X0_I+?.T8/(P>3D?* 1N(P3\V.XR#U%?Y%?Q>UO5/$OQ?^
M+_B77+LZAK>O_%3XCZSJ]\P16O-2U+QGK=U>W#("2IFG=GD&<*>Y#9/V'A9P
MKE?%&:9E4SB#KX7*\+AY1P:JU*,<56Q=:O2@ZLZ5JJHT84)U)TU5INHY1BY)
M73ZN*\YQ658;#0P35.MBIU4ZSC&7LX4H1?+'F?*IU:M2G%3<9*"C*36J<?Z#
MC_P=(?MS#K\"/V4R/FX_L_XJ_*>HR3X^ *[=H)X);MSPX?\ !TE^W,1G_A1/
M[*O7'_'A\5!Z$]/'QZ @GT!&<<U_-;@>P'/&8^._&#D\]QD9[@AJE:VN$MXK
MQ[2\2RN+B>VM[][61+"XN[95>YM;>^>-;6:ZMHW5[FUBG>>!)8WFB0.N[]Z?
MAYP(FK\,Y0N>5H\T*RYG9M*%\?%RF^5M03FW:3Y7ROE_/O\ 6+/'_P S3&*R
M;=ZB:2TN[^QLM=.9VCMJKJ_])W_$4E^W)_T0G]E3_P  ?BK_ /-[1_Q%)?MR
M_P#1"?V5>_\ RX_%3M]?'O/X?XU_-85P.F<$ _=.,].Q)[#/3D'@=$QGH!WS
M\T? "DGG(SM )*KD@*QQDC+_ .(=<#MK_C%\K6R;]EB$DVD[?[UH[23L^C3L
ME),7^L6=VN\VQ25D]:L%9-V3;<%9-V2;23NK7;L?TJ?\127[<O\ T0G]E7_P
M!^*O\O\ A/<Y_P ^E'_$4C^W+T_X43^RIG_KQ^*OKC_H??R]:_FL(QSM.T]R
M <<X &T$DD\;0N<\D 9J66VN+8QB[M+RR,]O%=VZWUI/9M<6DP)@N[9;J&-I
M[6<!C#<PB2"4*3&[8-+_ (AUP-=+_5C*KOF<5[.O>2@DY./^VKFC%:RE%24$
MU*I.$;.5+B'/6F_[2QEDTG+G5E)_9?[KW7T2ERR=KI/5K^D[_B*2_;E_Z(3^
MRIW_ .7#XJGH,]O'M _X.D?VY3P/@3^RIG&>;'XJ@=<=3X]Q[GG@<]"*_FTL
M["_U&=;33=-U+5+MHWG6STG3KO5KUH8V42S)::9;W5T88MZB241>6F] S#>H
M+[W3M3TFXBM-8TC6=%NI8FN(K76M)U#1KJ>V#F-IX;?4[2UGDA23$+31(T8E
M(C+;_EJ7X?\  ,:BHOAW)%6Y93]BY3C6<(IN4XT)9HJK@DN9S5&4(I-RFE>S
M_P!8,^Y7/^TL;R)I.=WR)M)Q3G]6<+OFC9>T3?-'1\T;_P!)*_\ !TE^W%O1
MY/@-^RK)&KHTBK9_%1'DB5U:9 Q\>.86>-71)2DGENZN8Y NQOVO_P""7'_!
M>3X>?MW?$R+]GKXN?#NV^!GQZUJ#5=1^'D>F:\^O?#WXF6FC6DFIZMHFBZIJ
M"6FKZ/XXTS2H[K5X_#U_;WEMK6D6.H7^EZF9;&ZL(?\ /]&!Z<8Q@QXYR/E]
MNQ( X[XR1]=?\$^+FZL_V_/V'[FRN9[2Z3]K+X$0QW%K.\%PL5]X]TC3[R)9
MH'5O+O+"[NM/O(RVRXLKJZM9 \,\B-X_$'AGPA6RG,'@\HH97C,/@\9B,-C,
M#[>+A5P]"OB(K$49UZU.O2YL,Z=2,XPDHU>:,X2@=F6\49O2Q="-;%U<70K8
MBC2JTJSC/FC5J0I/V<U&$J<HNI&6CLW'5-71_J,W(_XN+H?7'_")ZZ2.V?MF
MF9'//MWP!@$&O0PF0.V0.HY!XP.O '/'OSTKS^\&/B1HV,\^%M?'(/7^T-.X
M&>><CH>>*]#R ,YX]>PR< ?AT]N^*_E:27)AE;_F&IO973=2NFF^5:JSOILT
MS]8HJ\L1JW?%57O*Z]VBK:RU]597V0WR_?\ 3_Z]'E^_Z?\ UZ=O4 DE1@X/
MS#CYMN221CW'8\<FC>IQAAR<#D=>?4\YP<8SGJ..:SY5_5O_ )$VLO/_ ,"E
M_P#)#?+]_P!/_KT>7[_I_P#7K*M_$?AZ\OX-*M->T:ZU.ZTO^V[;3;;5+*>_
MN=&^T&T_M>"SBG>YFTS[6#:_;XXVM?M \CS?-^6M8R*!D,&YQ@$$\<D?7';N
M<#J11RK^K?\ R(67G_X%+_Y(3R_?]/\ Z]'E^_Z?_7IV]<@;ER>  03GG/\
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M" 0<'T/I3Y5V_!?_ "(67G_X%+_Y(@90N!QU&..N0>H]@I(Z9..>PX#P*?\
M0_$@S@GQEXD')& 3.F[)_A7&2S=%49P3U] D^\OIE?SVR\_D,8]Z^?/$K/'\
M&_CJ\;/'(FE_%UTDC=HI8Y%T#42CQ2(RO'(I 9'1E96^92"H8;4*?M%5IW4?
M:U<#34N6+Y74Q<J7-:VO+[12MU<6NIRUGRUZ#U:5/%3M>6KA0A*U^:RORVN^
M^EM3^5G]NC_@YC\<:%\7_$OP\_86\#?#O7/AUX'UJ^T"Z^-7Q/L]9U<_$;5M
M'N;K3]8O/ OABPU+1H=/\#IJ,$L>B>(M3FOKSQ=:PPZUIUKI^CWEE<7WQ%_Q
M$Q?\%'STT/\ 9N'7_FG^OX/<#GQ?P5X)ZCG@\9K^<WP;\W@[PBWS$MX6\..S
M,4,C,='M"SNS,69FP26.2<[L$].D (R"<8.#S$!V'3.1@ #I[<U_7V \.N#<
M%@Z&'>0X#%SITH>TQ>.PWML3BJG+%U*U2K*O3OS5.;EIQIPITHV5.%KR?Y%B
M.)<[JU:E18^M2C-WA2I/DITD^:*A%>\].6_,Y2;;UUNS^A#_ (B8O^"CG_0#
M_9N_\-_K_P#\V%'_ !$Q?\%'/^@'^S=_X;_7_P#YL*_GP_'_ ,>C_P :/^!?
M^/1?XUV?ZB\%_P#1,Y-_X0K_ .:CG_UASO\ Z&>+_P#!G_VI_0?_ ,1,7_!1
MS_H!_LW?^&_U_P#^;"C_ (B8O^"CG_0#_9N_\-_K_P#\V%?SX?\  O\ QZ+_
M !H_X%_X]%_C1_J+P9_T3.3?^$*_^:@_UASO_H9XO_P9_P#:G]!__$3%_P %
M'/\ H!_LW?\ AO\ 7_\ YL*/^(F+_@HY_P! /]F[_P -_K__ ,V%?SX?\"_\
M>B_QH_X%_P"/1?XT?ZB\&?\ 1,Y-_P"$*_\ FH/]8<[_ .AGB_\ P9_]J?T'
M_P#$3%_P4<_Z ?[-W_AO]?\ _FPH_P"(F+_@HY_T _V;O_#?Z_\ _-A7\^'_
M  +_ ,>B_P :/^!?^/1?XT?ZB\&?]$SDW_A"O_FH/]8<[_Z&>+_\&?\ VI_0
M?_Q$Q?\ !1S_ * ?[-W_ (;_ %__ .;"C_B)B_X*.?\ 0#_9N_\ #?Z__P#-
MA7\^'_ O_'HO\:/^!?\ CT7^-'^HO!G_ $3.3?\ A"O_ )J#_6'._P#H9XO_
M ,&?_:G]!_\ Q$Q?\%'/^@'^S=_X;_7_ /YL*/\ B)B_X*.?] /]F[_PW^O_
M /S85_/A_P "_P#'HO\ &C_@7_CT7^-'^HO!G_1,Y-_X0K_YJ#_6'._^AGB_
M_!G_ -J?T'_\1,7_  4<_P"@'^S=_P"&_P!?_P#FPH_XB8O^"CG_ $ _V;O_
M  W^O_\ S85_/A_P+_QZ+_&C_@7_ (]%_C1_J+P9_P!$SDW_ (0K_P":@_UA
MSO\ Z&>+_P#!G_VI_0?_ ,1,7_!1S_H!_LW?^&_U_P#^;"C_ (B8O^"CG_0#
M_9N_\-_K_P#\V%?SX?\  O\ QZ+_ !H_X%_X]%_C1_J+P9_T3.3?^$*_^:@_
MUASO_H9XO_P9_P#:G]!__$3%_P %'/\ H!_LW?\ AO\ 7_\ YL*/^(F+_@HY
M_P! /]F[_P -_K__ ,V%?SX?\"_\>B_QH_X%_P"/1?XT?ZB\&?\ 1,Y-_P"$
M*_\ FH/]8<[_ .AGB_\ P9_]J?T'_P#$3%_P4<_Z ?[-W_AO]?\ _FPH_P"(
MF+_@HY_T _V;O_#?Z_\ _-A7\^'_  +_ ,>B_P :/^!?^/1?XT?ZB\&?]$SD
MW_A"O_FH/]8<[_Z&>+_\&?\ VI_0?_Q$Q?\ !1S_ * ?[-W_ (;_ %__ .;"
MC_B)B_X*.?\ 0#_9N_\ #?Z__P#-A7\^'_ O_'HO\:/^!?\ CT7^-'^HO!G_
M $3.3?\ A"O_ )J#_6'._P#H9XO_ ,&?_:G]!_\ Q$Q?\%'/^@'^S=_X;_7_
M /YL*/\ B)B_X*.?] /]F[_PW^O_ /S85_/A_P "_P#'HO\ &C_@7_CT7^-'
M^HO!G_1,Y-_X0K_YJ#_6'._^AGB__!G_ -J?T'_\1,7_  4<_P"@'^S=_P"&
M_P!?_P#FPI/^(F+_ (*/?] /]FW_ ,(#7_\ YKZ_GQ_X%_X]%_C1SZ_^/1?X
MY_PYI?ZB\&.UN&<F_P#"%?\ S4'^L.=_]#/%_P#@S_[4_H._XB8O^"CO_0#_
M &;NH_YI_P"(._\ W-_'X_I1_P 1,7_!1[_H!?LV_P#A :_Q]1_PE^?\_6OP
MF\"_##XI_%34K_1OA/\ "GXL?%W6]*T]=6U;1/A#\+?'_P 6-=TC29+N*P35
MM6T3X<^&_$^IZ7I+WL\-BNJ:E:VM@][+%9I<-=2QPMF>+O!GC?X>Z_>>$OB)
MX%\>_#;Q;IT=O/J'A#XE>!_%/PZ\7:?!>1F6SN-0\*^.-'T#Q%8V][$/-LIK
MS388KV$&:UDFC!-9?ZF<#.J\.N'^'_K"CS_5_98=XB,&DU)X=8]UW&S34_8.
M+6J;33>G]NY]R>U^OX_V7-R^TO)4W+^55/9\G-IJG-.^W\J_>S_B)B_X*._]
M /\ 9N_\-_K_ *\?\S?_ )Y., D'_$3%_P %'?\ H!_LV_\ AO\ 7_7_ +&_
MT_SWK^>\D@XR?48*'=R%//( !X.2"3@*">*U=/\ #WB;5]+\2:YHWA?Q3KF@
M^"K+2]3\;:_HOAG7-9\/>!M+US5H= T'5?'.OZ7IUWHW@K2M>U^XM_#VA:IX
MLOM&L-9\1W%KH&EW%UJUQ'9MI/@;@RFG.?#.2PA>,>>>"4(<\IPIQAS3Q$(\
MTYSA",.=2<YP@H*<XQG,<_SN3Y8YGBY-IM)5+OE47*3LDW91BY-I-1C%MR24
MK?OW_P 1,?\ P4=_Z ?[-W7'_)/]?'KC_F;^YXXR.>M'_$3%_P %'?\ H!_L
MW?\ AO\ 7^?I_P 5?^OKZ5^!UEX0\::EINNZQIG@GQSJ.C^%/#^F^*_%.M:;
MX(\5:CHOA+PEK=_%I.A^+_%NKV6CW&F^%O!^NZI/!I.A^*_$-SIOA[6-5FBT
MW2]2N[^2.V?!SC@$CCY0S)NP.6)QP HW$Y(("_-CD@CP/P5._L^&\CGRM*2A
MA(3:<H*I&+Y,5+E<J;52/,]8?O(WIOV@WG^=QMS9EC(IIM-U'%-*R;5X+12?
M*V[)2]VZ=HR_H/\ ^(F/_@H[_P! +]F[\?A_KX_]V\Y_#OQ1_P 1,7_!1W_H
M!_LW?^&_U_T_[&__ ".?:OY[R2 2=V <'&P[C]W QDD<\9Q@\#YCBO7/#'[/
M7[1GCGPTGC;P+^S7^TOX]\$/'?RQ>._ /[.GQK\=>!9HM+>6/59HO&_A'P%K
M7A*6'1WMYX]6ECUEDTJ6&>/4C:O!*J16X*X&P\%4Q'#V08>#=N?$4*.'CS/5
M14J^-P\7*R;2O=K51DDY#AGN?5'RT\PQU1J/,U3<JC45O)J$)RY=E>UM4G9N
MQ^VG_$3%_P %'<X_L/\ 9NZ_]$_U_P#^:_\ _5TSS1_Q$Q?\%'?^@'^S;W_Y
MI_K_ /3Q>?UQ[9K\!/\ A'_$9\-:?XV;PSXHC\#:OJ]YH.C^.I?#.MQ> ]9\
M1Z;9V^H:EX=T?QQ+IZ^$M5\1Z;I]U9ZEJ7AS3=:NM:T[3[RUO;NQ@L[J"63*
M ((R3D' ^YVSCG)VD'')VD9 _BXTCP+P9.[APSDDDI2@^3!J=I0TG%N&(J>]
M%M*4-9P;C&<(-ZR^(,[BTI9GC(MI-)U.6ZE%N+5U%\KY9.+LN91E9RY9*/\
M0A_Q$Q?\%'>/^)'^S;_X;_7_ .?_  E_\\4?\1,7_!1W_H!_LW=?^B?Z_P#_
M #7_ /UNV:_GO))&0<9X&&B/UZ$GGOC(&">@S2_/ZCH"?FCSSQUS@<LAZ'@C
M!)8"C_43@ZU_]6,FMU?U&Z2LG=M5;6LT^:_+M:IKI*XASK5?VIBTTM4ZJ3]7
M'ENK?RVUUTTN?T'_ /$3%_P4=Z?V%^S<#GO\/_$'X_\ ,W]<=.G/!QS6YX8_
MX.=/^"@&E:]INH>*/A]^SAXP\/07"MJGAN/P[XJ\+W&J6AXE@M=>LO$FHW&E
M7BJ0;:[.FZC##-AI["\B5X&_G]\&^!/B#\1]7F\._#/X=_$;XH>(K?3+S6;C
MPY\+_A]XQ^)?B*UT33T5]0UNZT#P)H7B'6+71-.1T>_UF>RBTNQCDC>[O( Z
MYY0$,'7D,KR1RHP5)(Y8I'@FCD1PKQRQRQRPRQMMDBEC>*15D1E7*? W ]7V
MM#_5S(G*-->VITJ<%B*<*L)<LI*GCI5L.Y).5*;I4[M<\'+EN]?[>SZ'+-YC
MC(P<DHSES<CDI15N:5+V<FI2@I)2:]ZSM>Q_JB?L%_MP?"#_ (*"?L[^&_VA
M/A$][I]K<ZE>>#_B!X#UF6UN/$_PJ^)^B66EW_B3X?>)VLW-M+>V5EK6C:]H
M^J6ZI:>(_!^O^&?%5C''I^O6P'VCMY&1W3T.#O8?F,>X_D?Y)?\ @U&O+P_"
MO]MK2S=W+:;!\8_A'JMOIWG,;&#4]1^&]]8ZCJ$-ON,4=W?V6A:-:7ERBB2>
MWTC3H)"T=G$%_K;'\/UB_P#0WK^4N+LGH9!Q-G63X64IX3!8MQP_/RRG&E6P
M]#%4Z<I\D74E1CB50E.48N;I*5DY._ZODV.GF.68'&U8\E;$4(RJI.2C[2-2
MI1FXI3:2E*E*7+K922UM<\_^&HSX4MSUSJ'B,GL<#Q!?DCZ$=AT/->@B,_-R
M/O']0#V_EVKS_P"&G_(IV_\ U_>)?_3_ ']>BCJWU_H*\:NE]9Q&B_BU.B[P
M_NG;AU^XH;_PX_:EVE_>&>6>Y_K_ (4>7[_I_P#7J2BL[)Z_Y?\ R)M9>?\
MX%+_ .2(7 12Q)(! X&3EB%'?U(R20 ,DD $U&751DB0>QC8$\XP!W8@$JHR
MS8P!DJ#YA\>[^]TKX&?&?5-.O+G3M1TWX3_$:_T_4+.XDM;RPOK/P?K-S:7M
MI<Q,DMO<VLT23P3Q.LD,L:2HRL@8?P]?\$J_B5^U)X4^*'_!);QO\0_B-^TO
MX;\(?M=? 3]JG0O$_B+Q;^W</VMM&_:G\9Z1^SEK_CKP8FL_ 'Q5KFB^-/V6
M],\ 7_AR_P#'MS\0_"NG?$.31O$-OX,^'_C&]T;2O&M[XDTU<J_JW_R(67G_
M .!2_P#DC^]4L@)&3D#)&WD=.""01@$'D8P003D9&*KU+=&)RISQ[=2.#DKG
M P3P0:_"/_@G+^VEH_PG_P""$'P0_:J^,WQ(O/B=XM^#W["_B3X\_$/^W_'5
MIXC^)GB^/X=Z)XBUJ:VOK[Q%KBZKJFOZ_?V>F>%M/FUG4$FO==U/2M+FO!>7
M<>[XB_X(#?M1?%Q?CW\1/V:_VB/BU^T=\3/'G[0/[,7PE_;ITZX_:5^'7Q\^
M'=[X<^,'BK5=5T_]J+X6_!RP^.'@7P6E[\(?AUK'BOX=P^'K_P #G6_ EZUW
M=W'A/7;W3_W-J<J_JW_R(67G_P"!2_\ DC^KG(VDD2 @$[3&V>!TR,K^.<?A
M2@@G WY[ QL,\$CEL $XZ$@@88@+\U?R<_LS> _VD/CM_P %:_VS/&$_AW]I
MOXF_"'X$?\%';30U\<Z1_P %'/%GPI^%?P=\.^'/AC\._%MIX2O/V/4T?4M+
M^*?A7^U;M;C5='76M)L/$,.O364MDL.GW4MY^:6G_M__ !X\1_LAZO\ '<^(
M]8LC+_P1K_:]^(;_  QL_BI\:7\ S^-O"O\ P4GOOA5I?BQ[[_A92_$$>(H?
M#<'D6VNVGC*SUJQ@D_L;3M4L=$VV2G*OZM_\B%EY_P#@4O\ Y(_OU50RA@3@
M],HRGDXY5L,/?(&.]+M SEL8]1[9SUY'N/<=0:_FC\=?\%1_VS/!7[7GQ%\-
M6R_ O4OV<?A9_P %7/V9?^"=;>!#X*\6/\6O%WA_]IGX9^"M?3Q>GCY?&,ND
MZ?K/P^U?77N-%TZW\)7\GB][NYTO4KFS%C97-]S7[ W_  5V_:[_ &HOCM_P
M3W?Q]/\ LXZ5\*O^"@FG?ME^/$^#/A30-?3XS_L[:!^S1XGU_P  >&?!OB?Q
M-?\ C&\A\67.NW^AG5?%'B6\\$^$)M/\5IJWA.QTM;*P$K'*OZM_\B%EY_\
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M'_?<7^-%GV?W/_(!,>R_]]Q?X48]E_[[B_PI=P_OC_ON+_&C</[X_P"^XO\
M&BS[/[G_ ) )CV7_ +[B_P *,>R_]]Q?X4NX?WQ_WW%_C1N']\?]]Q?XT6?9
M_<_\@$Q[+_WW%_A1CV7_ +[B_P *7</[X_[[B_QHW#^^/^^XO\:+/L_N?^0"
M8]E_[[B_PHQ[+_WW%_A2[A_?'_?<7^-&X?WQ_P!]Q?XT6?9_<_\ (!,>R_\
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MX?V&G>,+?]I'P-X0L_$7BNQURZC@U72-1T^]N^<U_P#8[_92TC]FGP!I=A\
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M-\)0H8>K1Q#P^*AA,)A(T:6)>'Q.%PV-G4>+<,3@YTG7M_GU?";]L/\ :O\
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M^J?F57^IJ63[J_A_[+W[?6HK;'ED'')3@_[J_P! ?RI)9,84#/"X^]C^+()
M(!)7''^%?,SE%2FKZN4U:ZON]EOMKTTUZ,_48KW*7E"FW\DG^CTZO1%>0C@=
MQ)&/_2<_UK\[O^"98/\ PH/Q@?\ JXKX_'CC&/',X[>X_I7Z(.6(&0!^\CQR
M2"-T S^.,CV(K\[_ /@F6?\ BP?C#/'_ !D7\??QSXZGSC(]\5]CDZ?^I''*
M2_YFG G;?^T>*K]-NU^_3<_)>)?^3N^$;_ZDOBR].E^'^!OZ=O-7/T=E ,;
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M_P (%QVS[9'0FD'_  ;+_P#!1X9_XGW[,N1RI/Q$\4YQWY/@+WQG_$U_>/\
M\+ T?_H$^+<],?\ "(Z]T_\  'OG'O0?B!HXQMTSQ;D],>$/$!YP?^G'J!G!
M/'.201RO^(I\?:+FR];M7RC W>EF[_6.9W7:5FMQKA?AVVD\3II;Z[7M>S6R
MP]KZVVYNY_!N/^#9C_@H\ -VO_LRC!P!_P +%\4\$G/'_%!'G'3C@9!R*_9'
M_@D[_P $";S]D#XM>&_VH/VHO'7A7Q_\9/!,>LM\-/A]X(M+F[\!^ =8U6SN
MM%?QA?>(=9M[/4?$GBR#1+R_MM'^S:7IFFZ-'JMS(J7>H+%<Q?T:MX^T<G/]
MF^+?F4@G_A$/$'3OQ]CP<DD]NYSG& >/=' &--\6Y&#N'A#Q 2.J@DFS.,%N
M"23@=^,<6:>(7'&;X.ME^*Q%&GAL4E2Q"P>7X;"5:M&5XU:,JT,1*2I5%:$X
MTU3E.,I0G-QE*+Z<+D/#^#K0Q-*,Y5:;<X.MB:U6,*B3:DH.E&GS1W3E'1VD
ME=)C;M0/B-H1!.#X3UTC+9(Q?:: ,YR<#C).,\X)S7HJ=,<G'&3UX)_IC\Z\
M/N?&6F'QOI%^-/\ $HAM_#VL6CQ-X7UM;IGGO;%D:*S:T$\L"B-A+.BM%&Y5
M9&!<$]>/B!I.!G3O%XZ8'_"(>(1QM&/^7,>_(X/X5\+/#8GV>&M1G98:FE=1
M=OWF(:3:K).UV[JZ:=MT>Y2Q-!2Q%ZT/]YJM:O9QHZ/]UH[ZVMI??4]#HKSX
M?$+20,?V?XM_'P?KY/YFSS2_\+#TG_H'>+/_  C]?_\ D.L_JV+_ .?+^Y?_
M "\V^MX?_G[#[Y?_ "H] P#U /!'X'J/H>]%>?\ _"P])_Z!WBS_ ,(_7_\
MY#H_X6'I/_0.\6?^$?K_ /\ (='U;%_\^7]R_P#EXOK>'_Y^T_\ P*7_ ,J/
M0**\_P#^%AZ3_P! [Q9_X1^O_P#R'1_PL/2?^@=XL_\ "/U__P"0Z/JV+_Y\
MO[E_\O#ZWA_^?M/_ ,"E_P#*CT"CITKS_P#X6'I/_0.\6?\ A'Z__P#(='_"
MP])_Z!WBS_PC]?\ _D.CZMB_^?+^Y?\ R\/K>'_Y^T__  *7_P J/0**\_\
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M^V;_ -',_LS?^$U\3_\ XBO[:O\ A/M$_P"@3XM_\([Q!_\ (E'_  G^B?\
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M@^&/B<1@=!@QXP.WIVK^VS_A/=$Z?V7XKYZ?\4?X@Y]O^//K[=:0^/=$&/\
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MLOBJ+PJVD'Q'+I4=E8WTDL>CGQ!HZWI<1^4;^W(#B3*QRQ[+^OF=-WW?WO\
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M/^BH>+/_  V?B_MV_P"//\/SQ7\0F0!SG!P<@  ENPSC. .PR1R"0U)U)'0
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MF"XPNDL!PZV]DL-C6WI?1+,'?37TUVLW_;Y_P_"_X)Z_]%0\6<_]4S\8>_\
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MU6HZDZD*5.$)_(W_  UIJPZ?LH?M>>O_ "3'PCWY_P"BD#\>WIQ2']K75O\
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MHIIJ6;:=I5JFIZ=8"G6PW3"-_P#<]C5_[C%]0S'_ *&UO^Z/E;Z_]?C]8?\
MAK35O^C3_P!K_P#\-AX4_P#GD4?\-::O_P!&G_M?>W_%L?"G_P \CZ?AS]?S
M:^+G_!=GP%X-BUS5?@_^R!^T=^T;X2\-?L0_ C_@H=XB\4>!;CX;^&XM!_9D
M^..FZWKMMX@U/3/&?B;1[]?%7AC1=+BU*^\&64=]J^K6SZM+IX\K0-0F.[^T
M#_P6_P# GPA\4^/M#^&W[*/Q[_:-T;X:?LA_!K]NGQ7XL^'-_P##K1--T[]F
MOXLG6YKKQ<]AXV\1Z'J4FM^$M+TJTU.3PI9P7.KZ];WMZUBD*Z+>2E>VP_\
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MLVJ:N+8NL4<3%_??V'_V;O!/BBY_:0\$_M/_  >UK1=<\0^"O@O\-?@YJWQ
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MH^,?P;)UG4M(/@[XZ>#(O ?C<"P:,+J::)#JNLQG2+T2%M/N_MA-PJ2 QH4
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M9\0:?XQT/0-1O=/U_06%_P"&/%6E0W>E:S;V[EVMY'B#]QX8_;5\1>%_B_\
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M+Z)XKTB;4M<U;1M3O;._M-3T_P"Q745I%^D=Q_P7O^!%M\?[_P"'[_"S4_\
MA0UI^U>O[%<'[03?&7X-0Z[-\;T\30_#^ZU0_LX3^*HOC</@Q#\299?!,7Q7
ML_#U_ISS6LNOOID'AJ/^TH@#/^(?_!"+3K_Q_H?Q+^"/[4TGP:\6^)O@U^SM
M\&OVC[KQ/^RO^SI^TA:?%B+]FKP!H_PM\$?%'X:67QZ\.^,$_9\^+MW\/-.?
MP9K&O>'W\7>%;_1HM!N+SP3=^(/#UMKUQ!\9/^"$=[XST[]H+X4_!?\ ;H^*
M_P"SO^R=^TS\1O#7Q\^*G[,WA7X-_!?5M$U3]HS2)O!,OB7QKI_CFUT;POXE
M\.?#7XHS_#[PQXB^(GP5\*1Z!H-YXO@O[GPUKOA?P9JVI^ KKV[P-_P6$\&>
M*_#W[+\VL?!;7_!?C_XU?&/]L_X9?&7X;:QXY\/76M_LNZ%^P/J'C_3_ -H[
MQ[XYNM/LKB'Q)!X5D\,^$;BV\.:+;1:SJ5O\2?#GV)KJZ\FUN?AW6?\ @X4\
M*?%?X1>+(_ GP[UK]GWQ+\=OV;?VEOB3^Q#\5-3^+'[.GQ8UG6_%?P=^&&O>
M/M$MOBG\&_#WB3QCK_P7\6^)] L+?Q9X!\+_ !+\,ZSI7B>&*ZTC4VM]2MY]
M.< _4+]M7_@E]\)_V_?B;^RIJ7[27B*]\9?L_?LRV/Q/U:Z_9O6U\0Z)H7Q3
M^*7C'P[X>\*>#/B3XE\9^%_'/A_6=,E^%.DV/B1O#&B:?IMPUQJ'B_4+BXUJ
M"VA:QO/D.[_X-^/V=/"J?M&>'OV>/B5XP_9S^'/QA\1?LM_''X3^%/"6G77C
M74?V7_VQ?V5-4\53^%_VC?A;K'Q+\6>*M%U&/XBZ%K]AX9^,/@?Q-X/OM2\;
M:9I=S$?B%IUIJ4%AI3?AQ_P5O^+%_P"!/A]\._AG^RW\5?VXOCO\)?V*/V</
MVF_VVO%G@GQ5\(?A#H?P\D^-WPMMO'WAS1[&#Q/<>&M%\6_%CQ[H%CK7CG1O
MAUX-TG2=%30XQ%:ZC:7V-(M]35/^"W=G\0/B1X&^'O[&W['WQ6_:[;Q[^PQX
M(_X*":3K6C?$3X:_"2UTSX+:]X[^(/P[\6Z/XAMOB5J.G7%M\1_"_B?P=H^B
MZ?X1TT:K+XEU;6]8B-WI-CX;;4=7 /3O@I_P2*N/#B_\% ]2_:B_:J\<?M@>
M-/\ @H_\'O@Q\+_CCXD\5_#CP?\ "NQT2X^#GA3XL>#]/U+X>>&_AG?:=8^&
M/#LFG?$NPFT'PQ%<2ZOX<OO"JZC<^-/$.HZU<7MEP/C+_@B-HNO?L#?L\?L=
MZ'^T[XMMOB+^SU^T)8_M3K^T%\2_A9X)^.UC\9?C=<7?CR7QKK_QU^"WQ2O]
M;\._$?1/%MO\2?$T\6D:GXHCU#0O$%IX6UVWUZ\_L&33]3\G\4?\'!OA"73?
M&/C/X-_L:_'3XT?"OX9_LA?!O]NGXJ>.K#QC\+O!$_@+]G[XG6/BJ7Q)]OT#
MQ?KME/J/Q5\#:CX;ETZV^'^D7MW'XLM]/\8:E9>(]/@\/V0\0^F3_P#!=#X?
M>!_ 7[6OC;X\_LO_ !F^"UY^S1\+?V9?C/X8\(:AXI^%OBS6OC3\._VP?%5U
M\/\ X!SZ3?Z!XJ;P[X#\3Z[XU2STWQ;H/C'6+5/!.G7IUG4M4N+72=:73@!_
MP3_X(C6OP?\ %'P]\5WG[5?B7Q_J/@S_ (*,)_P44U6^U;X+?#KP=>>*/%5S
M^S*/V>M:^&T>F?#&Z\%> O"GARXO))O%VC7WACP'80:'HXM?!A\/ZE<6\GB^
MYLZY_P $6=3TSQSK?Q]^!W[8WC7X%?M8Z9^U-^T7^T5\*/CAH?P?\!^,-'\-
M>#_VHK#P)HWQ7_9^^*'PO\9:GJ.C_&;X=7>E^"8+[P[=7.N^"]4\*>-+F'QO
MX?\ [/U:RE2^X&Z_X+^?#3PQ\(?VH?&'C_\ 9Z\0Z=\7/V3M3_9>NO'_ ,&?
MAO\ '+X(?&^V\6_#S]J+XP>%_A!X<\;_  P^*WPU\2ZMX$\2WGAC7M?FL_$G
MA+5[OP[J%AKD&E:/J%Q8V.NVNM0>3_MI_P#!93]J7PW^R?\ MB?\*A_91\7?
M ']KS]E/]H3]D?X1_$CPWXZ^(OP1\;Z?X(^'?[47CSPO8^#?B=X<UZ*3Q-\/
MO&NJ^+K+5+;X;)X>2#5H? WB3QI:^.-8_MOPSX0U..Y /H/XJ_\ !$"]\<6G
MPH^(>B?MM?%36?VN/ /@CQQ\//&7[1O[47PA^#/[9&@_%7PE\3/' ^)WB71=
M1^ WQ@T(> _ &G>#O'OF:A\#=/\ AA>^$K+X2^')I_!"6_BCPQ>ZC8WK_$'_
M  1+\0V,'B&U^!G[?7QN^ (^//P$M_V?OVTM0\&_!?\ 9K@U']HWP]I6D^)-
M)T/QQX5L/#_PW\(>"?V>_BM8:9XNUCPC<^//AYX+N]4O_ OV&V M?B)I>F_$
M^U_;WP/J_B+7O!_AG6O%_A.7P%XIU30],OO$/@BXUS2_$L_A/6;FUCFU#0)?
M$.BO)I&MOIER[VC:GIKM97AA\^W/ER+7597U'YB@#YX_9)^ %K^RM^S!^S]^
MS79^)YO&EE\!OA!\/OA-9^+;C1XO#]QXCMO /ARP\.V^M3Z);ZAJD&E2ZA%8
M)<R:?%J-[%:NYB2YF55:OHBDR/4?F*,CU'YB@"D?]8G_ %V7^25^>7_!*P_\
M84^ /^RK?M7]R/\ F[GXY#IT[ ^^.>M?H;G]X@ZXE!Z^H!'\QCGD\'CK^>'_
M  2M/_&%/@ ]3_PM;]K# Z9(_:Y^.7'/J0<8STZ5T0L\MQEUOCLKU\G3S2_7
MMK?L>'B-<]RNW_0JSUZ?]A'#Y^C:< _[S_\ H1'X<=AQG\Z=35Z'_>;]23Q]
M,X_"G$@=2!]:YDUT_3_/[_F>X%%)D>H_,49'J/S%,!:A;[W_  */_P!&/4N1
MZC\Q43?>[<F,CW_>,>/P)/X#IFHGLOG_ .DL3W7JOS1Y_P##3_D4[?\ Z_O$
MO_I_OZ]#8D*Y&,CIGIT'IG^5>=_#7(\*VXQ_S$/$8]SG7[_\,\C R<\],5Z"
MQ)#@>^3DC&>F",9X'/3J"01G.U=KZSB/^OM3JN\-]3'#N]"@U_S[CW72?='Y
M0_%;_@L+^SW\)_%'[3FC:C\'?VM/&'A;]CC7;G0?VD_BO\.O@9>^+/A?\+9M
M.\&:/\0]9O=8\06^N6^H7>GZ%X'UW3O%.L3Z/H^H26.D3BY:(DJA^[O#_P"T
M;^S[XZU[PAX%T#XT?";7/&GQ'\":9\2O!7PY7QSX:7Q_XN^'.O:,FNZ;XOTW
MX>WE]%XNO/#5[HDZZBVH?V(UJ+)96G9$64+_ #G_ +2?_!#7XG?';X@?\%'O
MVA8+W3+'XW>/_P!J?X<_'[]E7PIKWQ,\::U^SA^T'\.?AY\*O .FZ]^SA^V!
M\![3Q+HGP_UWX:?%OQ/X>USP_KNMRZ=:?$7P^W_",:U;^+-3\':1JWP^\3\]
M9?\ !'S]J#7/VZ-8_:!^(6F>(]&^'7CG]I+X;_MB:9/\./VJ/ _A#0OV=O$W
MAK]GQ_AIJ/PYF^']M^RQX]^+'Q9N?A_=KJG@7P7HW@CXU_#?X5_$/X6^)VTK
M5='^'FJ:)%<ZI!N?T?Z/^TE^RV\_CC3?#WQ\_9_%Q\-]/\:>(OB7I^C?%3X<
MF7P#I/PWATM_B)KOCRUT_70_A?3O 46K:&?&FI:^ME:^&(M5TPZY+91WEF6\
MM^-_[;W[+/[//A71=5U_QKX<\36GB3Q_\ ?A\WAOX4W?AOQMK-E=_M7>+8?!
MWP=\5^(O#>B:F)].\#^/-3FN+C3/%5["--UW3[2_NM*?51;R(O\ (O\ L+_L
MP?$7XW>,=<_8W\%^#_A'X;U/P]_P;T_MH_L%R_&KPGHWQ-TWPCJOQ3^)WQA\
M">&O WBKXZ3ZY\'_  9K'P_\0^(X[K4O$-Q\.KRS\8_$*RM]'\;:_/;W,=Y9
MVR?:GA/_ ().?M^>(KJX\1>._AU\'O UUG_@A[X6L?#VC_&B'Q9=/X:_X)M_
M%#4IOC+XBU34H?"F@V5C?>(/#,=IXK\(Z%ITFJ>;9WD&AS:K_;=E.A /Z-/B
MC^V/^Q_\*_#/QS\1^.OCU\%GB_95\(:U\2/C7X:TOQKX0\3^._A1H7A*SBNI
MKK6O .C:CJ'BO1=;D>;3M,\/:4='M]7UC7=4T70]'MKG5-4TZUF9\.OVQ/V2
M/BO\+/@)\4](^,WPCTOPE^UOX7T+Q=\%]+\;>-/!'AGQ!\34U[2K*_?0=-\-
MZMK*77B'QCH;W46B^*O#=E'JFK^']<M+O1]2CAO[.2-/YS!_P2$_X*)>/?C/
M^V%XW^*^I?"N^N?CK^Q'_P %2_V0_".OVOCGP/HGPVTW4_VJ/%<7BC]GW7?#
M/PM^''P2\&:E\/?AT$FDF^)DGB.^^+?Q7N_B9<>)?&VL:YK\&JV1CL>,/^"0
MW[:7B+X#:W\,Q\'_ -G;QQK'[2'_  3"_97_ & /$L/Q9^)*?V9^QE\1/V:H
M9=&N_C7X2.@^&_$4?COPWXDN+B'XQ^#X?!<6F>,]&^*_A7P<FOVDVG+<ZAI0
M!^^'BG3?V$]1_;"\&?'/Q-\7_A%'^U#\-_ >L_LM>'/#MY\;O"UE>Z?I?Q5\
M>^#=1/@6\^&#>(4%UXPUWQQIO@_3=!M;S2FUQM1NM/TK3('NKVUC?WOXB_'#
MX-?#SX=_'SXHZMK^A>(]&_9P\+^*O'GQHTWP?-I7BSQ5X47P#X(E^(=_IFK:
M#IUU-?V?C >$;>'4M%T;4?L6IW%M>:=-:JD%W;2M_.K\?O\ @F]I/P5_8R_X
M+8>-OVC=5T72O%7QT\::/\6?V>?VCM.BN?$_QLO/%?P/^$GPKN_V?_%?B6]\
M%>$=6\6V?BS6?VC_ (9V?B?7?"OA#1S<ZWJ'B'6X=(M8;C7( GW[^Q%^Q_X\
M\3_\$M_C3X0^+MM8?"[]HS_@IEX=_:>_:,_:#CM='\1>1\,OBM^W9I?B/6(O
M"+^'_%%_<^((E^!G@WQ3X.^&LGA^_P!0::'_ (0*6S^TR2.]U, ?3^@_\%"_
MV4O%-_\ LH:-/>:GHVG_ +:_[,WB/]L?X8:UXP\-6.B>$;#X/>$? _@GXD^(
M/$7Q/UO4KL:3X/U;3?"WCC1+^[&IRR16OD:@UQ?QQ6/F'Z6\.?'3]G?QYI_C
M[6?"7QD^"?C33/AY;6U[\4]4\/?$3P%XCL? EE%I9\06-W\0+_3-6N[?PU:0
MZ-'+KEI<>(IK*./2T.HPN+5#./Y=/%O[!G_!0"R_9ETR_P#VDOA1\$/ASX2_
MX)Q_\$4OVSOV,/ ;_"+XP^)?CAXP_:=UWQ/^RYI/PST?Q79>$)/A;X+D^'5D
MVD_"^SU/_A&+G4/%NN7^K>(8=-M;AA')$GD_P>_X)-?M7_M7?L/?!#Q#X7\!
M? 3]FK3Y/^"07['?P.\)^$]-\8ZS;VW[77BZWU_X5_M&ZI)^TSH^A_#/PW<>
M&-!U"QT_6O"/BG2?%=AXZU2R^)?Q#^)%VJ>(O#,C^(O%8!_29\-_^"D?[#OQ
M-\=?M0Z/X=^-'PUTS2_V4+KX&VWQ7^-_B#Q5X%T;X*ZDO[0?P]3Q]\-+KPA\
M8YM?/A7Q39W6AN-)NY(=5MQ9ZQ"VC1QR@Q>9Z!IG[?O[)&K?M*:!^R3HWQO\
M!:Q\9O$O[/Z?M-Z%IFE>)-%O] U/X/7=[9PZ/K^G^*+?4&T;5+S7M)NW\::/
MI6F7%Y=W?P_L;SQPZQ>'&L]1N_Y_M>_X)I?\%%-5^+7[77QU\!?"#X$_ +1/
MVK?VG_V)?B_J_P #_AG\3?A)=>./#'P_^!O[/_Q-^#?Q!M_ 7QA\:?L^>-/
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MT_/=_EG$FOB[X1/_ *DOBP_+_DG^!>_;N_F?HS(Q 8,"!\H)49.U@%) YS@
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M/+;7EI)#=1.$D&(/^%/_ !CX_P"+._%X#T/PN\=YP3SQ_P (_GU&/IG=BO\
M2D5I> '=R .<.<G/(PK8SM!SD[=W0J 33QN)&6E''\6\ X'7[V/YC/J.*_38
M^+>/:2>28*>BYFL9B4I-0C%.W+=*48OW-E=M[W/P%_1TREN2CQ1FBBY-Q3RS
M+Y2L[V4I0JTG.33UJ<L$U\$(7DY?YJX^#WQB P/@[\7LC)R/A=X\/7H"5\/C
MWY&#D ],BE_X4]\8@>?@[\7<8'7X7>/!P.!T\/<'&!D_+D9Z'%?Z5!W=S,/^
M!,/ZTG/9IOH"Y/7T!]NO;/UJUXN9BK/^P\'I=I_6\1IJWI>+6K;;\];K8G_B
M73*G?_C*LT:;<K?V5@;7[_[RKOL[-K9-:\W^:O\ \*>^,6.?@Y\7<D$_\DM\
M>D ]SSX>''0XR5]N1A3\'_C!W^#OQ>&<DX^%WCS)W<]?^$?SQC@]ONGC(;_2
MGR>>9L#T+_\ Q1XY_P#KYS1\PQEI<'OE_P">X^OI_*E_Q%O,-GD>#[V^N8K5
MVM?5/5627HK:;-?1SROIQ5FFUO\ D58+75.R7UFVCBFM+K=..Q_FKGX/?&$]
M?@]\7AV'_%KO'@XYR3MT!0<C&#P!C*GKE1\'_C#SGX.?%[DGI\+_ !YCO]W_
M (I_DDD].1D 9QD_Z4_.!S-]<N,_FW4=_P :!GUF/_ G'\F'/\J'XMX]_P#,
MCP>FUL77TU>UJ:LM9;63N[IN]S_B7/*NO%69]/\ F4X"WNNZT]NXZ-MJZ=FV
MU9ZK_-8_X4]\8<9'P=^+V><G_A5WCSIV! \/YYP02V1C& O)+3\'_C'G/_"G
M?B\<#/'PM\> XP 1D^'B,'&/N@ C.#GC_2J))_YZ_@S_ /Q7\J3YCT:7@^KY
MZ#/<9&?Z]>M'_$6\PV_L+!I/_J+Q"MK?9044KZ_#:[>U[ OHYY6O^:JS-=;_
M -E8'?1WUQ+UNENGLNJN?YK ^#_QAP/^+.?%[<.>/A;X\P3R!Q_PC_/<YY/7
M.1D4O_"G_C"!E?@[\7AZ$_"[QX #]X8QX?/)QSQU/;H?]*;YO[TW'!_UG!]_
MF/&.#C&,?FOS'O-QUY?CW)R??CK]!BC_ (BYF"7_ "(\&VNOUO$OJFM7'FWV
MM)<K^#DO=B^CGE:_YJK-.NG]EX&UGJU9XB2]Y-Z--/9QDK1/\U<?!_XPCK\'
M/B]ENY^%WCS/)!/_ #+YSTZC.., 4G_"G_C#C'_"G?BZ#GD_\*N\>@@\J"H_
ML$\XS]"0>V#_ *5&23P9O<9?],GCWQ^@I<-_TW_-O\:3\6\>TT\BP=FG=?7,
M3O*W-?W7J^5)ZMM)>]OS+_B73*MGQ5FCOWRG WM>ZO\ [0G9-)JS5K>ZXKW5
M_FK?\*?^,(('_"G?B\!P0#\+O'IQCD\?\(_DC/?/0D8QBKNG? 7X]>)=0LO#
MOA_X&_&35M<URYBTO1],@^&7C.&6^U"\(@MK=)KS0[>UA$LKC=)/<6\,2CS'
ME5%8'_2<PWK,!W^^?;C![9SZ>M0RAC@;Y54 [R7D "\JVXDX[_*"6 ')R>0_
M^(N8^W_(DP2E9I2>,Q37-RM1NFGS:OX;ZJZ?DX_1TREOWN*\ULVN?ERS J4H
M)N\5*5:HHR:<U&HXU'!U'-1NDS\F/CQX+\867_!.+X9_"KPSX>U;QY\5?@!H
MO[$7CZ\\!>'--O9+_P ;ZE^R)\8_@/\ &3QMX+\)WD]O!9W6M^(M-^%&O:'X
M9D-PT5UJUSI_DQ7/F)#+]%:-_P %&_V+]:TRQUF+X[:#ID>HP)=KIOB#0/&/
MA_7=/\X%VL]8T35_#=KJ>D:G;.QAO=/O[:&ZMIXY(IHU=2J_;H1I.1(Z !BI
M&22#DC:2W!'7C#$C&\ \U&T+39':1[&T>21FE=Y+*V8N[DN[.6C=F9F;YF)+
M9)RS$YK\WEB\-7A*&*P^(<EB\5BXU*&*I4W[3%RISK4YPJX:K"=)3I1G3<?9
MS4N>$G.FXV_;%E6882M"KEV,P<*:R_!9=5H8W!UZR=/+X3AA:].O0QU"M"M[
M&K4HUHU(U*=1J%:,858OG^0A_P %"?V-,#'[0G@D\#_EAXBZ]\?\20\>G3'0
M #BE_P"'A/[&O_1P?@G_ ,!_$7_RCKZ\&@Z4./[.LN..+"VP??B,9S1_8.E?
M] ^S_P# &V_^(K+VN6K3V.866G^\87II_P! /D;\G$#U>(R.[W_V+-%KUT_M
M73TZ;=#Y#_X>$_L:_P#1P?@G_P !_$7_ ,HZH:K^WS^QAJ^EZGI,W[1'@V"+
M5-.OM.EFAM]>,T,=]:RVKS0B707B,L2RF2-9$:-G4*ZE217V7_8.E?\ 0/L_
M_ &V_P#B*/[!TL]-/LA];"U/\T_R,CH31[7+GI[',%_W,87_ .8@5/B#IB,C
M_P#"+-/_ )ZO\C^6/X _L=_L+_"?X5_L_P#[-WQ%_P""L_QH^.O[(G[,_CSP
MM\4?AA^RWK?@[X,?#SP'>^.?!'C>_P#B1X3G^(OC?X>_ 72?C/X^\+:'X]U.
MX\8P^#]5^)$6EWFOV>BG56O]'TJ/1I?6]%^ G_!/SP1\;M1^(/PH_P""E7Q5
M^%'P<\2?M"ZQ^U-XK_9K\'Z-\)O^$9U+XO\ B?Q39^,O%]AH_P 8M:^ &K?M
M"^&O@WXY\3V;:UXN^"]C\3IO"=U=ZIK-MHA\/Z1>6VFV/](7]@:7P#867;G[
M!9YX&.OEDC/?GGJ<]:3_ (1[2N,6-A^.GVA_]I#]<T*>6M_P,?Z_6<*E\V\'
M_78?)Q$M\5DGK]0S)?\ O2T_/S/P-^'7PQ_X)1_#[]L']K+]KL?M(6_B&Z_:
MT\*>(?#/B#X+:G<:W;?!_P  W?Q2\/?#GP_^T9XK\":%I>@6=SI_B[]HZ+X0
M?#+4/BAXEEN'UW4;_P , IJ9M;E+:T^:?AQ^R-^P)\,O!6I?!S2/^"J_QMU;
M]GS3/@C\4/@9\+_@YJ_ACX&V%IX-\.?$_P !:KX#>Z\;>/O!?[.7A#XB_'1_
MAS;ZU=:C\)[/XH^)-6A\&W-KI*&34A9SO??U$?\ "/:7S_H.G\Y_YAUIW]/W
M?Y>E'_"/Z4#S8V!Z_P#,.M>X/?RCZ_A^%5?+O^?.._\ "O"?_,:OY:A;B'_H
M*R3_ ,(<R?R_Y&1_-!J7[./["N@ZI;>)/V?/^"JOQP_9=\5^+OV8O@I^R1^T
M;K'PJTSX6:O:?M&?#'X#^#+[P#X&\3^)-$^)WP)\=6?@;XS:/X0U";PWH7Q/
M\!/I&H>&]":2RT?38+B]U.^O_DC4/V??@'X=_P""A_AS_AE[]LSQY^Q=^R%\
M,/\ @DG\-?V/O _Q?^$%SX \8WVO:[I7[1WCKQ!XU^$7C'P[\:_A=\2GU_5-
M;\ >)9_&B^/[72-%\3^'O&<NE^)=,\3/G5O#VI_V*_V!I9SC3[#@]386O.23
MWA'//X=.0!2CP_I1Y.GV Z#'V"T[>_E#.?T.0#@TN?+7I]7S#3J\5A%UZ6P:
MOY??KH#AQ#H_K>1N]]L!F7;SS)]?7Y'\RNF_LA?\$IO"W@;]I/X9^!/VS]=\
M,>!/VB/V!_AI_P $_I-(N(4\0:AX*^'OPTTSQC86?CVSUJ_\'QWGB#QUX@F\
M9:EJNMG4TAT8ZC-<M86-I9M8V>G=A\2_V<_^"5_QCD_: LOB1^V5XFU+0/V@
MOV:?V2/V<M8L_#\EMX<USP8_[&OC"]\??"GXK>#M>_X0#4[9?'$'C!M+\07.
MG:]H>M^$+BXTV;2]3T'5_#NI76BG^CL^'M*Y_P! L,]LV%IQCI_RRZ=N_'TI
MO_"/:9_SX:=_X 6O_P :H4LNZT,?_P"%6$_^8WO_ ,"P6XA_Z"LC7_<AF3Z?
M]C,_FB\6?L^_L4?$_P" /Q]^!_QH_P""JOQ-^*UQ\??&'[/GB&\\77_P^^"7
MP^TWX?:5^SM\8=*^,?A_2/AY\+O@U\!?AO\ #?2=9\::QI<=I\1O%]_H>IZG
MXF6UT2[>UMCH_P!GO>V^/_P5_P""<7[0!_;YN-6_;L\0^$=1_;QUW]E/QAJ^
MH^&M'T*XD^$?C#]C_7?#GBOX9:KX0M?$/P\UG3O$=AJGB7PKHUQXPT;QA::C
M!J>E?;M-T^?2;BX@U.T_HI'A_2^]AIY]O[/M/_C5!\/Z5_SX6/T%A9X'YQ=_
M:ASRU:.AC^FJQ&%EZ:K!_P!=^R4.)'MBLC]5@,RWZ[YF?#'@;]NO]D[PMX-\
M+^'/$?[7.C_$GQ#HFAZ=INN_$#Q1I$6E>(?&>L6MM''J7B76-*\%>!_#/A#2
M[[6+L2WLNF^&?#NB:%I_G"TTO3+2SABB7JO^'A/[&O\ T<'X)_\  ?Q%_P#*
M.OKS^P=+'73[(D^EA:#\]J<_C1_8.E?] ^S_ / &V_\ B*7M<M6U+,/EB,+;
M_P!00]GQ#UQ&1W_[ LT_^>I\A_\ #PG]C3_HX3P2/<6_B'^NAT?\/"?V,\?\
MG">">P'^C^(1DG&,G^Q"!DGT/T[5]>_V!I?_ $#['\;*UQ^/R$X]<@GV[4PZ
M#I9_YAMB, ?\N%KSZ_\ +$Y QP3CV%+GRW?V.8OR6(PBO]^":7F[:]@Y.(%O
MB,C75?[%FG_SUO8^*M>_X*/_ +&.@Z3J.MGXX:3KW]FVTETNB^%?#OC+Q-XF
MU>6-,V^FZ#X?TCPW<ZEJ^L7\@6TT^PLX9)[FZFBBC4R2*:Y;_@GK;:Q\(/V1
M/A3X/^)^AZOX.\=7E]\4?B)K_@R[TO4;O5O!@^,?Q@^('Q?TGPIXAFLK.:Q3
MQ1X;T3QSINC>*;>TGN;6R\0V6I6<,\Z6ZR2?H NA:=&P>*RM(Y8V#1R1V5LC
MQNIW+(CK&I#*0"A7:X8 @C 9=+R70LPD=BWN5'W@ ",GG:0"PP>&8$9 6IXG
M!1H3PU#"XF*J5J.(J5*V+IU)MX>-:G2A"%#"TJ<(KZS5J3E+FG-\L=(1M(H8
M#,IXV&.QV,P4G0PN(P>'HX3!5Z=.,<75PM7$5:L\3BZ]2=6^#P]*E&+A1IP]
MK-JI5G%0X0?$CPS@?Z5JAQC)_L+60#[@FP!_,'UXZ4'XD^&/^>^IG'3.A:T>
MOKBQX/3T]QTKOA$PX$KX[9))]N<CM^O-+Y3_ //5OU_^*KC52@M/957_ -Q9
M*^OEA_N2T6RTL>MRU]/WU*RV_P!G=[^;]LFUZW=O,\__ .%D>&/^>VI?^"'6
M_P#Y!H_X61X8_P">VI?^"'6__D&O0/*?_GJWZ_\ Q5'E/_SU;]?_ (JJ]K0_
MY\U?_!T__F<.7$?\_J7_ (3O_P"7'G__  LCPQ_SVU+_ ,$.M_\ R#0/B5X6
M#*&N-3QD')T'6B  0<<6' '.,Y/&#R":] \I_P#GJWZ__%4S#!\;V.TI_$>=
MQ7.?;/;/3KFDZE!K^#55M?XS72VG-0\UHM?E=H4:_6M2Z;8=[W7_ $^Z:GB?
M@7QSX=TWPY;VUS-?+*-0UJ4I'I&JW*".XUF]G7,MO9/&3Y4D1*JVY'9E=5V-
MCK_^%D>&,\W&J9P<C^PM:(/.#Q]A'!&.Y/'WL$BF_#<LWA6W^>0!=2\0\;R>
MFO:B1CH0/GP>.FT \$UZ"(FQQ*PQU&2<''(SN&1DG [=.U;8B=%8C$7I5+^U
MF[>WOIS1[4'=VMT_&YAAHUGAZ-JM-?NJ=_W#NWRROHZVFM_Z9Y]_PL;PM_SW
MU0G! SH6M].01_QY=.3P.A- ^(WA8$$2:B""#D:#K8/ (&<6/.,]\\@'J!7H
M7E/_ ,]6_7_XJCRG_P">K?K_ /%5C[6A_P ^:KOK_&E^F'-^6OTK4OGAW_\
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M]?\ XJCVM#_GS5U_Z?2_6@E^0*->_P#&I+S^K7_#VQY^/B1X8486?4@,\_\
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M'[0O[.%S^SW^V3\// _[1?AGXG-\6-$_9O?X/0:[XH_:B\9_&#Q%8_";XJ^
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MVEGJNE:]H%W=WEG=W7A_Q'H&I:5KNC74]I:W+V&HPK=6]O>)<01^^?\ !/\
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M^&O[3WQJ_P""E_A3XV^)OC%\2?A?>?%F\T[]C7QSJG@O[)H]_P#"?]F+X->
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MM[B?2;.XOX;>X:+$BV\TELL<S1DR"-F\O:Y!7V9^GX'^:UX#JO\ R2?XS_\
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MES8-J,-A)?K=O8K?6;7:0^0MU;-)YR?CIX8_X(P/X9\6_"GX@VG[0T=KXI\
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MZ+X"N8?MEA=_15E^P-=6?CW3/&3_ !'T2>WT[]O/Q+^V8NG-X!D$_P#9&N_
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M)XG+\13>!HUL7.."P5..!Q+I0Y8YCB(U,;=0/R/+>'^$\RP> G5SJCE^,QV
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M:80>.O3CG\*]!4YP>Q!.#U^]_P#7KSZ])_X63HN<$?\ "+:]Z?\ /_IO!Y/
MZ\@=^#7H8(X .<#^7?\ S_0U_*\GI07_ %#P>C[U<1?[K+YG^@5#XL1YXBI_
MZ117Z)^C7J>1_'GX$_"G]IKX0^/_ (#_ !O\'Z=X]^%7Q/\ #UUX7\:^%-4:
MXCMM4TJY9)D:*YM)K>]T_4=/O8+74M(U73[FVU'2=3M+34+"YM[NWAE7X%T;
M_@C1^PSIOPN^._PKU?P?\3O'MC^TCX2\$_#WXL>.OB=\=?BQ\1_C#K'P[^&^
MHZ1J_@CX?:1\6/%GBG4_''AGP3H&J:+9ZE:^&] UBPTZ>^-Q=7L-Q<7$DE?J
MO14FY^>OB/\ X)A_LB>*_BK\0/C/K?@?Q+<>/_B;\;/V6/V@O%^I0?$3QK9V
M5]\4/V-?!0\ ? 35X-)M-6AT^ST_PWX:)MM9T>WA33/%EP%NO$4%_<1Q>7G^
M"/\ @E=^Q[\-M8_9U\1>!O!WC+P[X@_98^+7QZ^,OP<US3_BEX]BU31O%/[3
MFLOKWQRTO6KG^VL^*?!/C_4/LC:OX-UU;W1?(TZRMH;>.&-DD_1JB@#XF^*7
M_!/[]FKXR?$WXQ_%SQUX6\1W?CCX]? OPA^S?\3]0TSQWXKT2TU[X1>"/&NH
M^/=&\-PZ;I>IV]IIKS:[J5[%J^I6,,-_JVCWESHUY-)83SPR>C?"S]E'X+?!
MWXX_M%?M$^ ?#-[HWQ1_:G_X4]_PN359-?UF^TG6X_@3X+O/A_\ #2WT7PU>
M7LVA^%+;0O"E_<Z?-;^'[+3X]2D:.YOUN)X8Y!])T4 ?FEXE_P""1?[ ?C+P
M=^T=X3\8? +0?%=Q^U7\2?&'Q9^+WCOQ-?:AKGQ8E\<>,TT,:AJG@SXK:C-<
M^._AY;:4WAG1'\+:3X+UO1M*\,/9E]&L[-[JZ,O?ZC_P3E_9/UWQ9HOCG7_
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M7Q2\/_"[XLZ#KVJ:5I?C?P%X,L_BEI6O6VN64^J"$:D_XY?M,?$V/QA^TO\
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M/OM2O_%'C2*[^(<_A2.V<?#EM'A\/3PF"XTO4+G\]"" ,%>!G/\ =)QG:._
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MQ<Z7J5U%#>VDL5S:2,L]O*DR(R^;^"/V:O@YX&_9L\.?LCV/@ZVUO]G[PO\
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MH-Q/H-E);Z1+):R?IS1@>E #$ 550;B%X!([?,!^  QD^H/4YI]%% !1110
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M^M+]G3T'Y?\ UZ]5<4YWI;,,T5FFN7.<T37Q:Z5M+\TMFMW;=W\3_4/A-_\
M-/</_9?_ "3V3[Q<91_Y<='"+5]G&+M=)K\:!_P2&_X)\CD?LI?$S) !_P"*
MRU3!& .?^*][<C@8Y)]*4?\ !(;_ ()\C/\ QBE\3#R,$^,M4)&#N&/^*]P,
M$9[DDD$X)K]EOLZ>@_+_ .O1]G3T'Y?_ %Z7^L^<Z_[?FFJ:?_"QFFS7*_\
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MCRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\
M\ _#O_S24?\ ":ZC_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'
M3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\ \ _#O_S24?\ ":ZC
M_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T
M%3_\)L-_\D>?GQMJ0_YD#Q__ . ?AW^GB,TG_";ZE_T3_P ?_P#@'X?_ /FB
MKT Q#LS#\2:7RAQRV?<D_IFDZM+_ * X>BQ6)_\ D;_B'LZW_05+_P )L/\
M_)GGQ\:Z@>OP_P#'V25'-EH''S 9!'B(XVY)Y ''4#)'&>%O$4RV/B&TE\#^
M+M5@N_$OB)[B.*PT6:V,5U*(YM.O8KG6HE,BQLT-U"4FB8.RH\JFO<'C YR3
MR.,<')P<]>@Y&.G;'-<#X#'^B>(@<\>,?$IY]3<(>#UR<8[[@23G)K2G4HJC
M7MA5&TL*[+$XG_G_ %6G=I.Z:NK-;+5-:<]6G5]M13Q#;E'$JSP^&=U[&DFM
M6TDT[---23LTUH_Q?\5?\$4_V'O$7B/5-<TOX5?M&>";+5;N:]C\+>$O&6F6
MGAG1GN)I)9;70K"]UF^ETS34+[+;3(KE[2SB18[,)#L08'_#CG]B\8 \*_M6
M@CT\;^'^<8Q_R_'IC!^N#7[^B!3W(P,?= W X8DCZGIC@@C I_EGNYZ<G QQ
MU_+%>W3XSX@I0C3IYCF"C!1C&+S/&MJ-ERIMTZEWIOS2OWN?(S\,^":E6K6G
MPYDLJE:HZE22RK"P4IRT<N6G5A"+>ND(0BKNT4Y._P#/_P#\..?V,/\ H5OV
MKO\ PMO#_&/3_3?\:/\ AQS^QA_T*W[5O_A;>'__ )._E7] 'EG^^?R'^%'E
MG^^?R'^%:_ZZ\1?]#',/_#EC/_E!/_$,>"/^B:R;_P -M#_YH/Y__P#AQS^Q
MA_T*W[5W7_H=O#WY?\?O_P!?WH_X<<_L8?\ 0K?M7'Z^-O#W_P FC_.*_H \
ML_WS^0_PH\L_WS^0_P *7^NO$/\ T,<P_P##EC/_ )0'_$,>"/\ HFLF_P##
M;0_^:#^?_P#X<<_L8=O"W[5P^GC;P_\ _)U'_#CG]C#G_BEOVKL=A_PF_A[C
M_P G?\Y/%?T >6?[Y_(?X4>6?[Y_(?X4?ZZ\0_\ 0QS!^N98S_YG\@_XACP1
M_P!$UDW_ (;:'_S0?S__ /#CG]C#_H5OVK?K_P )MX>S]?\ C]H_X<<_L8=_
M"W[5QYY_XK;P_P#_ ";7] 'EG^^?R'^%'EG^^?R'^%'^NO$/_0QS#_PY8S_Y
M0'_$,>"/^B:R;_PVT/\ YH/Y_P#_ (<<_L8]_"_[5Q^OC;P]_P#)M'_#CG]C
M#_H5OVK3_P!SMX?_ /DZOZ /+/\ ?/Y#_"CRS_?/Y#_"G_KKQ%_T,<P_\.6-
M_P#E ?\ $,>"/^B:R;_PVT/_ )>?S_\ _#CG]C#_ *%7]JW_ ,+;P_\ _)U'
M_#CG]C#_ *%7]JW_ ,+;P_\ _)U?T >6?[Y_(?X4>6?[Y_(?X4O]=.(?^ACC
M_P#PXXS_ .4!_P 0QX(_Z)K)O_#;0_\ F@_G_P#^''/[%_0^%?VK3G/!\;^'
M\'WP+[J/7T)Z=:VO#?\ P1-_8AT/Q!HNM:A\-?VDO%EIH^I66IS>&O$GC32Y
M_#VN"QNH+I=-UZSL]6LYM1T6\,1AU735NXTU*QDN+*</#,Z']Y3%G&7/!R.!
MU_+WH$9ZDY/(Z#&,YXYZC'4X/7ITJ*G&?$$H3IRS+'J%2,H32S/&IN%1.,E[
MM*#7-%M73B[;/=E0\-."J<X5:?#F31J4IPJ0E_9>&G:<)*<&XSJSIRY9)2Y:
MD)Q;23A)>Z>9Z=XC_LBPL=+TKX9>,]-T[2[*VT_3M.L=)\-VEE86%E%':VEC
M8VL&O);VMK9VT4<%K;VX6**&....-8U45=_X374@/^2?^/\ _P !/#QY[]/$
M9]^?Y5WH@3[W\6""V "0>2...3SD?3M3_*'8G\SR?P(QGZ5\\JM+?ZHG>[;E
MBL2I-MMMM6=VVVVV^9MMO5GVBHU8I6Q,DE%12CA<,DE&*BDDI1245%)**BDD
MDHI))<#_ ,)KJ/\ T('C_P#\ _#O_P TE'_":ZC_ -"!X_\ _ /P[_\ -)7?
M^4O<M_WT:/*7U;_OHU7MJ7_0'3_\*L5_\B5[.M_T%3_\)L-_\D<!_P )KJ/_
M $('C_\ \ _#O_S24?\ ":ZC_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z
M-'MJ7_0'3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\ \ _#O_S2
M4?\ ":ZC_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?
M_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\ \ _#O_S24?\ ":ZC_P!"!X__
M / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T%3_\)L-_
M\D<!_P )KJ/_ $('C_\ \ _#O_S24?\ ":ZC_P!"!X__ / /P[_\TE=_Y2^K
M?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('
MC_\ \ _#O_S24?\ ":ZC_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ
M7_0'3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\ \ _#O_S24?\
M":ZC_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?_(A[
M.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\ \ _#O_S24?\ ":ZC_P!"!X__ / /
MP[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T%3_\)L-_\D<!
M_P )KJ/_ $('C_\ \ _#O_S24?\ ":ZC_P!"!X__ / /P[_\TE=_Y2^K?]]&
MCRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\
M\ _#O_S24?\ ":ZC_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'
M3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )KJ/_ $('C_\ \ _#O_S24?\ ":ZC
M_P!"!X__ / /P[_\TE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T
M%3_\)L-_\D<!_P )KJ/_ $('C_\ \ _#O_S24?\ ":ZC_P!"!X__ / /P[_\
MTE=_Y2^K?]]&CRE]6_[Z-'MJ7_0'3_\ "K%?_(A[.M_T%3_\)L-_\D<!_P )
MKJ/_ $('C_\ \ _#O_S24#QK?Y&?A_X^ZKS]B\/'D-Q_S,F ,8YZ8SZ9/?\
ME+ZM_P!]&F%-K#D\%#@GKER![DKG^53*K1:5\'#=Z+%8J[T>FR]1.G6_Z"I[
MK_F&PW?_ !/^OQ\1\#>*;NR\.6\$/@WQIJ"+J&M2"YLK/1FMF$NLWKM#NN-;
M@D9X-YCDQ%M$\<JH\H"LW8?\)KJ"D[?A]X^Y'_/EX?YZ_P#4Q=<D_0_E3?AL
M#_PBEN.K'4?$1Y[?\3_4 1VQ]\@YZ'@\')]!"9_B( !7Z8.>N>AZGGTZ8Q6F
M(JT?K%=?58RE[6;_ -YQ-E[T>RN]._YF.'IU?8T;8AK]W!?P,/=Z2UUE^"T[
M' _\)MJ.1_Q;_P ?^F?L7A_^OB(=?PZ<TO\ PFNH_P#0@>/_ /P#\.__ #25
MWWE#.=S$>@./U_KW[TOE+ZM_WT:A5:2_YA*;U_Z"L5_\B;^RK?\ 05/_ ,)L
M/_\ )' ?\)KJ/_0@>/\ _P  _#O_ ,TE'_":ZC_T('C_ /\  /P[_P#-)7?^
M4OJW_?1H\I?5O^^C3]M2_P"@.G_X58K_ .1#V=;_ *"I_P#A-AO_ )(X#_A-
M=1_Z$#Q__P" ?AW_ .:2C_A-=1_Z$#Q__P" ?AW_ .:2N_\ *7U;_OHT>4OJ
MW_?1H]M2_P"@.G_X58K_ .1#V=;_ *"I_P#A-AO_ )(X#_A-=1_Z$#Q__P"
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MGA>$^,.%<VXQCD>'DJ>6Y+Q)D^?Y/E^98S(\-3?L,!@>)<%Q)A\=FN7X.%'
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MO_XBC^P_$/\ T.-]_P""+2__ (BNZHH]I5_Z<_\ @BA_\SA["EVJ?^#\1_\
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M /RYHX;^P_$/_0XWW_@BTO\ ^(H_L/Q#_P!#C??^"+2__B*[JBG[2K_TY_\
M!%#_ .9P]A2[3_\ !]?_ .7'"_V'XA_Z'&^_\$6E_P#Q%']A^(?^AQOO_!%I
M?_Q%=U11[2K_ -.?_!%#_P"9Q>PI=JG_ (/Q'_RXX7^P_$/_ $.-]_X(M+_^
M(H_L/Q#_ -#C??\ @BTO_P"(KNJ*/:5?^G/_ ((H?_,X>PI=JG_@_$?_ "XX
M7^P_$/\ T.-]_P""+2__ (BC^P_$/_0XWW_@BTO_ .(KNJ*/:5?^G/\ X(H?
M_,X>PI=JG_@_$?\ RXX7^P_$/_0XWW_@BTO_ .(H_L/Q#_T.-]_X(M+_ /B*
M[JBCVE7_ *<_^"*'_P SA["EVJ?^#\1_\N.%_L/Q#_T.-]_X(M+_ /B*/[#\
M0_\ 0XWW_@BTO_XBNZHH]I5_Z<_^"*'_ ,SA["EVJ?\ @_$?_+CA?[#\0_\
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ME_\ Q%=U13]I5_Z<_P#@BA_\SA["EVJ?^#\1_P#+CA?[#\0_]#C??^"+2_\
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M8R#3A3=23C%I.5_BFHK1='+1>BM?4*M2-&'/)3:6EH1<GK9+1&P(XV 8DY8
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MES./:Z:2G_15_P 10?\ P4!ZCX2_LM'G QX=^)6<@9S_ ,CQZ=/>D_XB@_\
M@H#Q_P 6D_9:R?\ J7?B3[<<^..#@^_4>]?SAL ",!\<,"!+QDD<Y?@8W8(7
M)QQP30$'/7/)!!DSSCG&[+9STSR<8R.*I^'G!*M_QC&7Z[?N,0^;WHQT2QS:
MU=US<MTG+X4I,7$6>2NEF6(=E?11MU6K^KV7-KRN;BFTDFFTC^CW_B*$_P""
M@(SGX2_LM#COX>^)(S_Y?'.>,#U]>P?^#H/_ (* Y/\ Q:7]EH]>?^$=^)/K
MUS_PG'XGKU'/K_."=F"=K, ,DYD5< #)W,W "\N3@%<DXZUI:GH6MZ&UA'K^
M@:_X=EU/3+/6]*7Q!H>L:%)JNAZD"^GZWI46J6ME)J.B:E&KMINLV"7&F7ZJ
M[6MU.$9@GX?<#QDE+AO*[R3E%.G.+FHJ\Y0B\PC*4(W7-)0Y8N4'+W91FU_K
M#GJ3;S'%I+E6J3WNM.3#R6K26LHZVLIM\J_HL_XBA/\ @H%@#_A4O[+9],^'
MOB3]./\ BN/Y4G_$4)_P4!SS\)?V6NG_ $+OQ*XQ[_\ ";]-N#Z=0":_G@\.
M>$_%?C358] \%>#_ !CXX\02VUQ>1^'_  -X3\3>-/$,]C:!6O+J+0?#&GZK
MJ\EG:B2/[7>16C6ML9H3/+'YJ*UGQ;X&\<^ -0M-)^(GP_\ '_P[U;4+62_T
M[2/B)X&\8^ M3U*RAF6*:^TS3O%^DZ+>ZA8PRGRWO;*WN+:.5DCDE1V4&'P#
MP)[3V+X?RGVSCSQI-2A6E"*3E)4IYDJG+!7YI.$8JTDGHF[6?Y_9OZ_C7%.*
M<G#W;RT2YG04(R>BY)SC+WHZ:I/^A9O^#H7_ (* */\ DDG[+7(R"?#_ ,2@
M#A21D?\ ";YQD<\9]*_53_@F)_P<+S_M7_&[PA^S+^U!\*_#?PQ\?_$R[N-&
M^&?Q)^'NKZ@_@+Q#XJMM.GU"W\(:_H?B5Y=6\,:QKL-E>Q^';VVU35M/OM1%
MMHSB"_O+0S_PX;>1@,<XQ@2GDYR?O;@>Q.<<D8Y)KZS_ & 55OV]/V(E=>#^
MUM^SZ2I5\9/Q,\/==Q*DJQR."%(4 ;<BO-SSPXX-J9/F7U?)J.7XJA@<;B:&
M+P<J].M0Q&'P^(Q%-JG+%5Z4X*>'C&I&M!J5.I4BDJBC)=& XESF&-PKJ8ZK
MB*4J^'ISHUE3<*E.K6A2D],/":?[Q-6DFI13NE%Q?^I'=\_$;0@W)_X177MV
M .#]OTS.,=<9ROJ.I))QZ(I[8P<<X& ,'&!].@]A^%>>WI ^)&B8ZCPMKQ![
M\7VF9SZC(!]\G//3T)<X!/4@'IT)Y/Z]O:OY0G;EH=O802]54K:.RL^KTMO;
M2VOZW1^+$=%]8J:;:^SH[]];N[O>Z[(4G ].O/IP>3[5^1W_  56_;B^._[$
MMM^R?K?P9\*^!?%NC_$?]H1_#OQQM/&&F^(-2U+3?@1X;\">(/&7C_6O! T+
M6=,^Q^+M$L--76([K4;;5M+CTJPU$7&G[0+J#]<OZU\I_M)_LB?##]JB]^'D
MWQ/F\0R:=\.&^+:6FB:/<Z3%IOB&Q^-/P/\ '7P%\8:;XBAU32-5:XMX_!_Q
M"UJ]TK[&UG+;:[!IUY+)<6\$EI/!N?SQ?&;_ (+7?MRR?M0?M'?!?X%>#OV:
M=#\#Q_M"? ?X,_LI^-/BCH7C_P 2KK&A>(_VG_B1^Q9\7/'WQ#/@SQEISZOH
M:?M ? 7XTP^#$\/66DW=MH>DV"7<.LHL.JZG[AXS_P""K/[?_P '/A]^WM\&
M?''P*^$?Q6_;._8D^(W[*&G^(/'/P*\)?&+Q-\!(O@)^UQH-SKFE?M :Q\*=
M-E\1_'#5+;X*V_ASQC+\3O!?A>6\OY[2'2+_ $>\ET^/4KY/IOQ#_P $)/V:
MM1TGX46?A7XW_M._#O7/@K\'OV7OA!X"\9^'/$'P=UGQ1:R?LH?&/XF?';P/
M\2];_P"$]^"_B[P]XC^)'BOXA?%CQ5JWQ$N]8\/W?A37O/@CL_"6E.+I[GTB
MR_X(\?!@>'OC#?>(/V@/VK_%7[2'QK^./PV_:)\3?MIWGQ \ >'/VEM&^(OP
M9T:Z\.?"&T\*/X!^%OA'X-:=\-?AUX?U;Q5H/A_X2WWPAU7X=R:1XU\5Z=JO
MAW4+2]LHM/ /1?\ @EC^V!XV_;0_9QU3XI^/O'_[,'Q4U+0OBCXJ\!:?\3?V
M3?$GBN_^&GC;1=*TSP_K.E:GK/@;X@VEM\1/@OX^@@\0_P!G^(_A5XXDO]9T
MV.VTWQ';:A<:1XEL%3YH_P""MO\ P4K^/G[&GB_X5> ?V6/ ?PV^*/BS1/A)
M\</VT?VJ--\;3:S>WO@/]BS]G0^$="\8ZIX>T;P[J6G:E;>-?'GBWQ]:Z?\
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M;II-*H[-IJ_+=6WXZ[<:]&2M>-+&25TVKPPT9J_2S<(W2U:NG=,_SM_VVO\
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M*_\ $O?VF_\ YZM'_#57[7/_ $>-^V5_XE[^TW_\]6O#,#W_ #F_^+HP/?\
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MVJOVN@/^3QOVRP,9S_PU]^TX..N>/BM@#COV&<XZ'_#57[71_P";Q?VR\?\
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M?Q1XDT#]E?X6?'_XAQ/X5\;^/?"U]8^$]>^#/BSPU\5XHM.\'>*_#5GXBO\
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M\>Z_'_Y$FS[/[G_D&6]%_*;_ .+HRWHOY3?_ !=&1Z-^4_\ \71D>C?E/_\
M%T<\>Z_'_P"1"S[/[G_D&6]%_*;_ .+HRWHOY3?_ !=&1Z-^4_\ \71D>C?E
M/_\ %T<\>Z_'_P"1"S[/[G_D&6]%_*;_ .+HRWHOY3?_ !=&1Z-^4_\ \71D
M>C?E/_\ %T<\>Z_'_P"1"S[/[G_D&6]%_*;_ .+HRWHOY3?_ !=&1Z-^4_\
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M4DN519][P-&2RO$SM)0J8Z4H-II24:,(-Q;5I)27+=-JZL]="6BF[U]?T/\
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M=:#K<NBZ_P"'I-0MX+J>RE=M'\4:5HNN686ZMYHO*OM,MF<@/&C1E'/Y>_\
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M]AF+TU_[!_G_ ,&Q_">/^#7O]O4?\UQ_8OS_ -CU\9<#'3 /P0P#T.>>:/\
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M#._\$Q/^?S]HS_Q(C5O_ )4T?\0SO_!,3_G\_:,_\2(U;_Y4U^_?_"%>%/\
MH :1_P""^R_^-T?\(5X4_P"@!I'_ (+[+_XW1_KQQ7_T5?$G_A;#_P"5A_86
M6?\ 0JRK_P %5_\ ,_ 3_B&=_P""8G_/Y^T9_P")$:M_\J:/^(9W_@F)_P _
MG[1G_B1&K?\ RIK]^_\ A"O"G_0 TC_P7V7_ ,;H_P"$*\*?] #2/_!?9?\
MQNC_ %XXK_Z*OB3_ ,+8?_*P_L++/^A5E7_@JO\ YGX"?\0SO_!,3_G\_:,_
M\2(U;_Y4T?\ $,[_ ,$Q/^?S]HS_ ,2(U;_Y4U^_?_"%>%/^@!I'_@OLO_C=
M'_"%>%/^@!I'_@OLO_C='^O'%?\ T5?$G_A;#_Y6']A99_T*LJ_\%5_\S\!/
M^(9W_@F)_P _G[1G_B1&K?\ RIH_XAG?^"8G_/Y^T9_XD1JW_P J:_?O_A"O
M"G_0 TC_ ,%]E_\ &Z/^$*\*?] #2/\ P7V7_P ;H_UXXK_Z*OB3_P +8?\
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M/_;(:];/W/+]0_L'+/\ H4Y3_P""J]_S[MGX"?\ $,[_ ,$Q/^?S]HW&.O\
MPT1JQXSD@ Z5U],\#L0>0J?\&SW_  3!21'DN?VC)HDDC>2%_P!HG6A'/''(
MKO;RF'3H9A%.JF*5H9X;A8Y&,$\4H21/WZ_X0KPGT_L#2/\ P767\_*Q3?\
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M]_ . W0?/D\Y)/<G 'KB?\(1X4_Z%_1__!=:_P#QNHQX+\*AQ_Q3^D?>&/\
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MR_Y_+7_P(B_^+H^W67_/Y:_^!$7_ ,77/_\ "$>%/^A?T?\ \%UK_P#&Z/\
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MJ7+-I>G1W=S)!IVC:=:0HDO]JK9V<<DKD]\GY?\ /IZU_FC^,L-XU\9@=/\
MA-/%P .[D?\ "1ZED9W A@0#GD9(/)^5OJO#'*\NS'%9Q4S'!8;&RPV&P<:$
M<32C7ITE6KUO;SC2FU!U9T\/"$:D[JFG)I:MOZ7BC%XC#TL'&A6J4(SJ3E4=
M.<H3FH*')3YHIM)SFKM-:7NFE8_0/_A[[_P47'_-QESUQG_A7?PK(S@=CX*)
MZD=P#SSQBE/_  5]_P""BX&1^T;<'CD?\*Z^%/7O_P R6,8ZX/4X'>O@'7/
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MRNN6#;U_1#_A[Y_P47Y_XR-N.&QC_A7?PI!/3_J2C@<C)QZX&<4@_P""OO\
MP47(S_PT;<<-@?\ %N_A4,@]_P#D2L<9YY.<<#)P/@KQ=\./'_@/Q]?_  J\
M7^"_$.A?$O3-<TWPW>>!;O39W\31Z]K"V,FCZ5#I=N+B>]O=534M..G6]A]I
MDO5O(5M!),5B/JWC#]D;]IWP%>>$+'QK\"OB!X8N?'WBFT\#^$VU?28(;/5/
M&M\H>S\(2ZBMZ^G:5XEN$R4T;6KG3;W9'.[QQBWG,>,LJX3A[)3R_((/$4_:
MX?GIX%?6*/)[3VU!*;E5I*%Y2G3A-)*37-RSY:CC,VG[3DQ&83=*3C44:N,O
M":Y5[.?[FT*C<FE3DXR;A4;Y8QYI?3__  ]]_P""C!)4?M&W/5@/^+<_"H\@
M<#/_  A8(// ;&2 #@C=7U)^QA_P5Y_;7UG]IOX+_#_XI>.=$^+/@+XI_$CP
MI\-]>T37/!_A?P_J>E1>,-6M]#MO$?A?7_"&E:%<66IZ/>W-O?M::M!K6DZK
MIT=]I,UC:WEW9Z[IOY@?$+]D3]IKX4>$KKQY\2/@MXN\'^"[-;66?Q#J\N@)
M8&*_U"'2K6X@-IJ]Y/<V[ZC<16@GM;:>)9VVR21'FG_L:8/[8G[)I&#C]I#X
M-GT_YGC1R3TP.#D^F>^,UQ8K)>%L9E>85,+EN1UH1P>,:K8*&'FZ=6CA*]6+
MC7PDFZ=6$H4YPC&MSK3FBX2FI:TL=FM'%485<3BZ<G5IWA6JU?>A*K2IR:IU
MU&-2$U*4;^SLKMQC=*9_H%W8/_"R-"7.6_X177E+#C[M_IHR!D!0Q&2!T(*Y
MZ&O0UQ]TCGOGG/3DG')]??./6O/[TC_A9.AC@$^%M> /_;_IN20?0Y).>??-
M>@+P!GJ ,GWYR/H"#^%?S5-7AAM'986FE=ZM*KB=]$F];:6T2ZWO^E4?BQ&W
M^\57HK6O&CO>[;[V:6JLAV!Z#\A2X Z "F[EP"",$XSV_'T]/J0.]+GOD8SS
MGL,8P#_O>OJ1Z5GR1_E7]?,W/)?CO\=/A1^S1\(?B!\=OCCXTTKX>?"GX8^'
M+WQ1XT\8:R9C9Z3I5F H\JWM8;B]U+4KVYD@L-)T?3;:[U35]3NK/3=-M+J^
MN[>WD^8OV7_^"B'P+_:I^(7C'X1^'/#OQU^$7Q:\&^ ?#_Q<G^&G[2/P5\;?
M SQCX@^#OBG4KO0]$^+/A+3O&=A;QZ_X$F\06-]X?N;ZVN!J&C:U;-9ZYING
MFZT]KB?_ (*3?LDZ]^V_^R#\4/V>_!WC'1_ ?CK6KGP1XT^'WB;Q-I=[K7A&
M'Q]\+?&^@_$;P?IGC+2],N['5+CP=KFO>&K'1?$TVF3RW]CI.I75_9V.IW%F
MFFW?PCXWT#_@M'\<_AO^V'J7B+X8_LK?L_ZEXK_92F_9U_9Y^!GA+XJ)\8-;
MU[XU>*]5FC\5?M)>+_V@[SX>?"NY\#?#/P[X1UVYTOPO\'[3P]XGUW4M:L]1
MUJ:;0KK3-,NO&QRQ71?<!]$_"K_@L9^Q-\9/@#^UA^TAX*\5?$)OA]^Q?II\
M0?&RQUSX=ZYH/CBW\%WGA$^.?"OQ!\+^#M3\C5M>\$?$'PQ%?ZIX!\0+%:P>
M)8-+U"6T18+4O)U/P _X*B_ ;X__ !D\$? 8?#O]I[X%?$CXL_#KQ/\ %+X.
MZ9^TO\ _%WP7T_XO^$O Z^';CQB_PTUCQ$9;#Q1JGAO2O%FAZ_J^D6LJ7]OH
M-Z-56%K2WN'C_#Z[_P"")W_!0/X(?#CXZ?!SP)^T-\/?VJ/ W[3'_!*OQ-^P
M?K-E=?#/P+^RKIWPG\6_ +0U;]C[7-7M_#NN^,W^-SWMGXY^+?PRU7Q;JMAH
M7B;PWIFI6.O:YK7B"S>#2-.^J_V<?^"2?QM_8W_:8\+>-?@/XIU1_ 'QI_8I
M3X&^./B9\0?B,GQR^.'_  3X^/7AW1=$OKKQG^ROJ/[05OX^TOQU\$OC/KUI
M;)X[^#GB/3-0MM'\7^&-(\6Z5JL7@B.W^%H?+'LON _0S]IK_@J-\)/V4OC-
MX=^!WC[X"_MJ>*_%?CS6;+PW\,M:^$W[-'B[XB>"?BKXIF\$7?Q#OO"OPW\3
MZ3=?8_%7B/0_"VEZY?\ B#2;11=:4/#VN>>KPZ9/+7Z,^%]=3Q1X;\/^)(]*
MUW0X]?T;3-971?$^ESZ'XDT==3L8;U=-\0:+=DW6DZU8B86VIZ;<$SV5Y'-;
MR$M&37Y0_'3]C3]I+QG\5/\ @E-XCO/BA/\ M"7'[(_[47Q!^*GQU^+?Q#LO
MAS\,_%FK^$?$GP,^*_@C1K^R\%_#/PGX8\&7E_9ZQXKT71X]-\.:'I\ILX8M
M0OPY?4+Z+]=XL; 2 IQ@C(QD?B>><$^OMBERQ[("7 /49I,#T'Y"C</4'\1_
M4TN1ZT<D?Y5_7S CD P, 9R/RSD_Y_QKSKP/(D=EXF>218H_^$O\2N\LC[$A
M19TDDD=SM5$2-69G9@HQDX7->B2'HOJ5R/3&Y@?_ !P@^QKP74R1\*_C)U!^
MS_%/GH01HU]@C!.#C&,=/KS6]"'/"K3OR^TJX*":M=*>*E!RLVKN//>*>C:W
MM<Y*SY*]&35W&EC)I=/<PT9V>^DG!*]KVN?S$?M??\%SOC[XK^)'B7PQ^R??
M>&OAM\)/#FKWNBZ-X^NO#=AXL^('Q&;2M0DMYO%=O+XA:Z\-^&O!^L?9\^'=
M&MM N]=O-*DCUB]\36[ZI'H^E_'@_P""OG_!1CI_PT=<9'<_#KX5'/ Q_P R
M4O./9<]<+R!^7?A=O^*9\+X_Z%[02S#('S:79[LYSP<+U(YY&0<UO^6#U([X
M!P<$XXX(SC'3O^)S_3^#X1X;P.&HX:GD^ J^RA&$JV(PT*]>LU&FG5JUJTJM
M2I4J2YZDE)QA33]E2BHQ3/S:KF^8UZLZL\7B(<TYVA2K3ITJ<8S:C&$(T_DW
M)N]M-;L_2C_A[W_P47_Z.-N/_#=_"K_YB:/^'O?_  47_P"CC;C_ ,-W\*O_
M )B:_-?RO=?^^/\ [*CRO=?^^/\ [*NK_5S(/^A)E7_A#A__ )$Q_M''?]!V
M+_\ "JO_ /('Z4?\/>_^"B__ $<;<?\ AN_A5_\ ,31_P][_ ."B_P#T<;<?
M^&[^%7_S$U^:_E>Z_P#?'_V5'E>Z_P#?'_V5'^KF0?\ 0DRK_P (</\ _(A_
M:.._Z#L7_P"%5?\ ^0/TH_X>]_\ !1?_ *.-N/\ PW?PJ_\ F)H_X>]_\%%_
M^CC;C_PW?PJ_^8FOS7\KW7_OC_[*CRO=?^^/_LJ/]7,@_P"A)E7_ (0X?_Y$
M/[1QW_0=B_\ PJK_ /R!^E'_  ][_P""B_\ T<;<?^&[^%7_ ,Q-'_#WO_@H
MO_T<;<?^&[^%7_S$U^:_E>Z_]\?_ &5'E>Z_]\?_ &5'^KF0?]"3*O\ PAP_
M_P B']HX[_H.Q?\ X55__D#]*/\ A[W_ ,%%_P#HXVX_\-W\*O\ YB:/^'O?
M_!1?_HXVX_\ #=_"K_YB:_-?RO=?^^/_ +*CRO=?^^/_ +*C_5S(/^A)E7_A
M#A__ )$/[1QW_0=B_P#PJK__ "!^E'_#WO\ X*+_ /1QMQ_X;OX5?_,31_P]
M[_X*+_\ 1QMQ_P"&[^%7_P Q-?FOY7NO_?'_ -E1Y7NO_?'_ -E1_JYD'_0D
MRK_PAP__ ,B']HX[_H.Q?_A57_\ D#])S_P5\_X*+CG_ (:-N3[#X=?"K/M_
MS)0^GU(H_P"'OG_!1@$C_AHVX//!'PZ^%6,>I/\ PA?3L"0.>@/?\US&1V5O
M4 !?H3DGISTP><\]*3 X7&2<%3MX!&#C&02,9 P/4X(!R?ZN</\ _0DRK_PA
MP_K_ "-_))M[)/8/[2Q][?7\5LK7Q557L]5>2BKNZZZNR2EL?I1_P]]_X*+_
M /1QESQP?^+=_"GT.<#_ (0HG@C&/4CJ*/\ A[]_P47Y/_#1EUP<#'PZ^%7/
M0?\ 0D@=2<<]B>Q%?,7P[_9$_:;^+7A71_&_PU^"7C+QEX2\07NI:=H6NZ4N
ME-:ZSJ&DW/V/4[32XKK4[6[U&>RNB+>>*R@EE$I\N-)I-J/Y)K/P^\=>'/":
M^./$7A#7/#WA(^-]>^&C:WK=D=+M8/B)X8@AN?$?@R[BO7BN;3Q!H<%S ]_I
M]Q#')$)0H<R;D')#*N$ZE2I2I9?D%2K3J*E.C"G@)5E5E=0I>RA.I456HX5(
MTZ3@JLY4JL8TW*#B:2Q>;0BISQ./A!Q<U*=7&1C*"?O34W15/EC=7?M$O>BE
M=M7^^!_P5]_X*,?]'&W/! S_ ,*Z^%7S<')'_%%8 '!R2>N,9Q2C_@KY_P %
M&"#C]HRYZ?\ 1._A3UP3V\%]/4_EG!K\T);FWM]@N+B"#S,)'YTT<1D(XVH9
M70.0<*2%)#8R!E33GN;=)1;M/;)<ORMNTT0F(.=I2$OYK@XR"$'0_2NK_5W(
MD[?V'E7HL!1DUU5^2G+2SYN9.4>5.47.-I/+^TL=_P!##$W3U2QTG9VYFG=I
M7BK.5FTKI.5[I?I9_P /??\ @HOS_P 9&77'&/\ A77PJX.3@$_\(2>PYY]"
M/<_X>^_\%%^O_#1MP!D\_P#"NOA2!CG;U\%DC/IR1WQUK\T_/MQ+]F\Z$7!4
M.;<S()RO/[P1@^9L8?,&"D!2<L2!77^!/ GC3XG^+]!^'OPZ\*ZUXX\;>);E
M[;0O"_ARP?4-6U.2*![FY>.WB(CBMK2WCEGN[R>2&UM8H_,FF1*B?#_#U.#J
MU,FR>G2C'GE4J8.A2@J76K*=6%.$::L^:<G%12O)1BXN5QS#,)N,(XW%2E-I
M0C'%U)RFY7LHQA&4FY?9LFGUE'1/[\_X>_?\%%\9'[1ER<=O^%=_"DY[XR/!
M8'3CKU(Z]WI_P5^_X*,(\;G]HN9VCD238?AS\*GC;RW5]DD8\&9DC<KAT5P6
MC8J>&R/@;P[\.?'OB]=>?PKX+\1>)#X4O-%L/$2:/I\M_+IFI>)/$47A/P]I
M4T%J&FFU/6O$4Z:-IUA;*]U=W7F/%$(HI0G7?%G]G_XW? G_ (1\_&+X6>,O
MAS'XJ.J1^'[GQ-I8M;35[K0VMTUO3[>\MI[FT&KZ-)<P1ZOHLUQ!JNF.X6XL
MPNV5\GE'"JK0PSRS(5B*E_9T)T<![>=H4J_N4/:JM)2HU(5$U3LZ4_:+W;-O
MZYFW)*I]8QZIP2YJJJXF4(MRY(Q<_9NFI.:<5[244I0FI.*C>?\ 35_P2[_X
M*Z>.OVD/B+:_LX?M)Z7X8C^(6M66HZA\-/BCX0L&\,Z=XM;1]/M+G4/!_C+P
MK)>ZC8V7C&2WAU37--\3>&I=,\.:U#N\/GP=H&HZ3:ZIXL_H548 &<]>?49.
M/TZ^_2O\_7_@F^-W[??[(Y8@%?C#II YR2-'U? Y)^8%W!('.6R2 ,?Z!2?=
M'^>YK\2\0\ER_*,]I1R_#QPV'QV!^N2PL%:A1K+%5L//ZM3YY^QHU%%35%2E
M&G)/E?+-*/V_#F.Q&-P51XFI[6K0Q$J7M6DIS@Z<*L7-148N2YG&Z2NEK?HZ
MBBBOA>2'\J^[_@GT 4444<D?Y5_7S ****.2/\J_KY@%%%%')'^5?U\P"BBB
MCDC_ "K^OF 4444<D?Y5_7S ****.2/\J_KY@%%%%')'^5?U\P"HB/G/7K$<
M=C\Y'\^>><Y_"6H6/S?\"C'Y2/\ X5,HQ5K*U[WMUM%ON%]O-K\_^&//_AIQ
MX6MSZ:CXC/O@:_?=0>^.,<<>W7T->I)]<#CH<MV^A4$]3CGI7GGPU_Y%.W'K
M?^)&/U_M^_Y_2O11_%]?Z"ML0D\5B+I?Q9K\86ZZ?+1G/ADU0H:_\NH^FTO)
M"X'7'/K1116?)'^5?C_F= 44UR0,CMG/3T/KUP<$C(. <9Z'^<OXZ?\ !>;Q
MS\!/C!^TSIOB/]B_PUKO[-?[)G[5WPU_9=^*_P 7/#G[77AF3X[W5Q\3$^'P
MTOQU\/\ ]DG5?@[I?B'X@VEC=_$KP[9WGAKPW\3+K5)B-4N[*YGT_1=;O-,.
M2/\ *OZ^8']&U%?A+\3O^"R7Q)\)1?'7XX?#O]A3QA\6?V OV6/B_P",?A!^
MT)^U;I_QS\#>&O'VC7'PCUW4_#'QX^('PO\ V8]0\,WWB+XF_#?X.^(=-;3=
M<U6\^(/@C7O$<::GJW@WPYKNA:3<:LW2_$O_ (*T_%Z;XE_&W2_V0?V OB?^
MVK\%/V5?$/@#PW^TE\3OAS\5_!W@[XCP:MXS\->'?B#JFC?LW? +Q!X=U'7_
M -H7Q%X-^&_B?1_$FI:1>>+?A9'K.J7UKX9\-ZCJMV;VZL#DC_*OZ^8'[:T5
M^=?_  4._;?\<?L7?#/X >*OAA\"-/\ VA?'W[1W[5/P7_94\"_#_P 2_%6;
MX!:=;^)OC=;^)?\ A'M>UOQ=?_#/XDW6EV^GZCH5I9:CI-YX3ANXDU&>9KB*
MYT];"]\B^ O_  5;T'Q%:_M'>#OVM?@AXL_97_:'_96^+/@#X4?$WX+>#]6U
M7]K!?%-S\9=&D\5_!3Q%\#]=^#_@.W\7_%;3/B#X/C?6;FPM_A?H7B'P9>66
MN:1XFT:UDT2]ND.2/\J_KY@?KC17X_\ @K_@M9^QY\3?C_\ "GX2?#+6?$/C
MKX:_%;]D7Q]^V-IG[2.C^%/&\GPJT_X>?#_Q1XC\+ZYIU]-#X.N;K3M4T6^\
M"_$"T\9'Q'-X<'@SQ!X7'@S48;CQ=J=OH\?VI^S3^VC^SS^UR?B-;_ SQKJ>
MO:W\(M:\/Z!\3_!_BSP!\0OA;X[\"ZCXO\/V_BOPDOB7P-\3O"_A+Q9IMIXF
M\-W,6MZ!J4VD"PUBP+S6,THBE,9R1_E7]?,#ZLHH_3_/M11R1_E7]?,!KCY6
MQZ$\=<]?S_SS7"^*/^0SX$P,?\5-<J?;;X<\1*3]"5!Q_A7=MT/T/\JX3Q/Q
MK?@4# _XJ29L?]RUKY)/KDD\8Y/.>U7225562^"I;_P55OMKT,:VE-_XJ7_I
MZG;H]C"^)WQ0T_X;Z?I@CT/7_&GB[Q-?SZ/X*\ ^$H].D\3>+M6AMVN[F*Q;
M5K[2]'TW3-+L]]]KWB#6]2T[1="L(Y+F_NE+P1R>#77Q7_;1T?.LZI^RC\(=
M>\-VZVUUJ/ACX<?M8ZCKWQJMM-N6PG]F^$O&_P"SU\-_A7J^NQJL[SZ3/\;-
M&TUFM;B'2/$.MRB$3^I>%[)_$'QH^*_C&[ABN3X&L/#/PD\)K)+*8K W&@Z=
M\2/&MY"5#&WF\1WGBKPCI>LRPV\Q>V\&:6J%I(KF ?$OP5^$?Q:TC]HWQE\1
MY/CSH_BGXIWVO^ ]1^.6EO>:FWPA\>> ?&FGZ[IUQ\./AOX6CU.];P9??!'3
MO"7A/4OA1KWV>^UC4[V+X@67CHRW'QB\0>*M&SBDXJZO9+5ZZ\L;FVFK^[3S
M>FZ[GZ$_"+XK>$OC-X0M_&?@]]8BM!?:EHFM:'XFT:]\->+O"'BC1ITM-<\(
M^,/#.IQPZEX?\3Z'=JT&I:9>Q!D+17%M)<6=S;W,WI^U<DXY((/N#U%?,VC:
M4G@O]J3Q&NF)#;:;\<OA*GC34[*)WCBF\=_!;Q%X?\&ZSXFFBRZKJ/B#P=\2
MOA[HE],L48FLO NDC;(\,TE>#>$?^"E7P.U>_P!9T[QEIOC#X>7VD)963:==
M:/-X[U6Z\20:IKVE>+]#ATKX9P^++VVB\&WECX>L-2UW44M-*O=8\8:+HVGR
M3:B)8)&U%;I+\/U&DWLFWY*[_ _1,*HZ ?\ ZOK1@>@_(5\.W/\ P4)_9LET
M^.[T'Q7K^KW4D>H7!LY_AK\6-,AT^TT2=(_$5UXCO#\/[UO#,'A]&<:G-K%K
M;16MXL.GW+037<3)QOB7_@HM\./#Z^#]2@\/7>I>$/&'COQ-X5LO&D^LIH6B
M6^C^#UT.[UO6)TU?2(-23Q(NBZAK_B"T^',UE;^)K_1? WB_4M/-Y8>']>NM
M(7[O^Z_O?Z@HRO91?W;_ "_K\#]$F4$$;01Q\N.O//\ 3\JK"T@61YHX(EED
M5@[*J@L3U#D<G&<GLW3'<?':_MY_L[ZI_:NG^$_$NM>)_$UC9>,3;>'AX(\<
M: L^M>"_!>J^-=1\/ZGKVO>&['0_#%]-8Z3<V$,OB&\L(/[:']B*TFK8LFXC
MPS_P4;^"NNVOA"&6P\6R>(_%D'@Z^?P]X4T'4O&@\,:7XZ\4^'?"7AZ\\4:]
M9V.FZ+IMV]_X@%UJVAQW%SKF@:;IFHW&KZ?:SFSM+EIQC=)I)W32;2:[-)VE
M\^X<C=GR-V=TW%NSVNM'9]VM?,^^5L+=;@W*Q1"8_>E"*LCG'(9@O 8]2.2I
M ["LN9]-AU6**2)5U&XC=HY1%C<J!_E\[(P2J,3GY@BL 237Q?:_\%'?V6KU
M-&U>V\9>()/!?B!M!M-*\6R?##XO6]E?:AXFBN[_ $EK6*?X>1P2^'UT2QNM
M9U;Q6+]=)T.S6WEU9K6WNX+AOIKP#\1/!?Q0T#P_XY\-G4I-/\0PZS)HD^M:
M)JF@7UQ9Z;JVIZ--<G3-5@@N[6"]GTNXNK 74$%Q=:=+!>K&D4ZK6M.3DY*\
MY?NIWY).ZA%<UY*]_91^TGHE9VUTYJ\'3C3<51IWQ%*_M:<4I.4[-0]Q?OGO
M2=TW+1NS2.P>;2GUA;?[,9-22-2LZVK2B+,9(62=5/E;E+;03'E2=S*",+=G
M2UU6T2>QFDOB(_(N4LI9T@+*P0/.4PF7#$G)P"2Y0GC\+/\ @L':_&3QQ\:?
MV,_@C\&/BU>?"?7/B9=?%EKK5W\8:_X)\*+-X9\*QZ__ &AXOUCPW;7M]'96
M.DZ9J445T]E=1V,DZ7,RQ6XGD3\/?#'@']M_Q)IFK:C??M">//!VM>&_'OB_
MX8^(O"OB_P"*/Q,M?$WA_P 7> _B9\&?A/KUC?C3K;5-+,$?B7XW^&IK6ZM=
M1GANM%T?7=1BEE!T1-8Z(QBE3;E7C?#\MN>2?,[I2C;:EHDH)6DDU:[.=PJS
MC42>"DUC.=/V+E'DC)/EDM6\7:Z]LVU&3322C8_N.U2?18=2L%O["22]9X1:
M3?89)TA,CA(E\\*R1;I4)"JQ*E=Y4=:IZY?^'+>\LH]8A2:Y8J]LSVAG,&V1
M4$K':#&BRJ ?1P[$80X_B-\,>)/VD/A'J/Q:U_XZ_&CXMI\(?!GQ:U#]D+XN
MW)\9?%%/$D$?CB;QYHLOQL^$ U33(1K,'PLU7X=/\1-'N8;C3-;URVLM.\-6
MMD8?%%XUG_2I_P $ZOVE[WXU_!RY^''[0=[:ZE^TS^RYXDM/@E\7M7607]O\
M118:78WWPW_:!T2[LFGMM1\&_';P2^C^.;#Q!;I#HNHZQ=ZO/I$::+/I+7'?
M0RUU<%/'4I8FLL!.G1Q>$P[FL3'#XV%=8;'8:\FGA/KL%@,9&G%U,+6K86M.
M:H8N-O*S#%U,/B98:HLOHK&RC5PF*Q5*+P_-A9X=XG!XIM1<\?+"5%C<')R:
ME1A6IQ2JTFU^HA=,G !&3@D$DC/!.$QS[<>E%-).3\A/)Y'0^_#8YZ\<>E%?
M.MZO]]16KT=*[6NS?+JULWU:;ZGTZYK+]S6>BU4Z23T6JO4O9[KR:'R?<?\
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M?7EY)V\-U<+3RK.*>)Q$:"Q"K5(0K4\-*,84,MQBJ8W"1Q>29I+&8BG7JX;
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M\5? B*R@5YV2)9+Z[TE[>(NPB5XV,DBHH+?G'+^TEX0\):-J&J>(?V8/A_\
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M>$SXP3P[IO[0&C7>CF2[M+*[;QS\.KGP0(;K4;;3=42"XMK3Q)-JD5O+:/\
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MT/\ SRA_[\Q__$T?\1 XJV_MFO\ ^$>4;]_]TW>[\Q?ZN9;I_L\--5^^Q?\
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M\*'2_P#Y+KL_LT7]R/\ []K1]FB_N1_]^UHO2_EJ_)T%^0[5>]'[JIQH\?\
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M'_P=C/\ YH/Y6/\ APAX1_Z/N\+?^&TT'_YZ-'_#A#PC_P!'W>%O_#::#_\
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MQG_"?>!/^AT\)?\ A0Z7_P#)='_"?>!/^AT\)?\ A0Z7_P#)==G]FB_N1_\
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M'!IGE)C&/Q'7_/K117G1^RWJW'7\#WOZ_K]"09YR<\_D/2BBBCEC_+'[E_D
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9S@]7%7>KWW>O<]J-^6/O26BTOMHO[I__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$ U(# 2(  A$! Q$!_\0
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIKMM4MZ#//\
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M>&KQ:(_A6U3R-)U.:&QO->M]2N8K"[DM[.5()67ZG!) )QD@$X.1DCL>X]Z
M%HHH_P _Y_,4 %%%% !1110 4444 %%%% !1110 4444 %%%>??%/XG^"/@K
M\-_B#\7OB?X@M?"7PU^%G@SQ+\0_'_BN]M]0N[3PUX*\'Z->Z_XEUVZM-)M+
M_4[F#2=(T^\OIH=/LKN\>*!A;V\TI2-@#T&BOQ'B_P"#CC_@BG*\4:_M]?#,
M-,\4:F3P5\9H$#32*BF26;X;)'!&"P,LL[1Q0(&EF9(U=E^UOCE_P4E_8?\
MV;/@5\-?VF?C1^T;X#\)_ 7XPW&D6OPR^*=BGB'QEX3\:3:]H]QKVDMHEYX'
MT7Q'-/;W>E6EU=+=RP0VT0@DAGEAN%,- 'W%1_G_ #^1KXF^+/\ P42_8V^!
M7[,_PW_;)^+?QT\.^"?V9OB]IOP^U?X;_%;4=$\:W.E^*-.^*OAU?%O@"XMM
M#TSPU?>*K#^W_#F=3$6K:%83Z:JR0ZK'87$<D*^3_$K_ (+#_P#!-OX/_!/X
M(?M%_$O]JCP=X2^"W[25MK=[\$/'5]X8^)4UGX_M/#TS6^MSV.EV'@J[U_2A
MIURK07 U[2M+;SMJ1AWD16 /TQHR..1R,CW'J/;D?G7XLZ+_ ,'$'_!&3Q'K
M6C^'-#_;O^'-_K?B#5M,T+1[&/P5\8T>]U76+V#3M.M5EF^',5O%]HO+F"(S
M3RQ6T&\RW$T4,;R+^Q.L>(M(\/Z-J?B+7=4TS0]!T32KW7=:US6M0M=+T;1]
M$TVTDO\ 4M8U74[Z6"STW2M/LH+B\OM0O9H+2TM(9+B>6.)&< &[17X37/\
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M!M/U&PN+D [FBC_/Y]** "BBB@ HHI,@]#G@'\#G!_'!H 6BBC/3WX_0G^E
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M:IJ_Q%7XBZ;IMC9+HVNVO@VWL=";2Y+%Y+HW]E>+<I(BP+!M- ']>_@SX?>
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MB8_#SIC_ )$OPWTXX_Y!O3@<>P]*/^%1?"C_ *)A\//_  BO#?\ \K:]#HH
M\\_X5'\*#U^&/P\/_<E^&_\ Y6T?\*B^%'_1,/AYSU_XHKPW_P#*VO0Z* //
M/^%1?"C_ *)A\//_  BO#?\ \K.]*/A'\* ,#X8_#T#T'@OPV!_Z;:]"HH \
M\_X5%\*/^B8?#S_PBO#?_P K:!\(_A0.1\,?AX#ZCP7X;_\ E;7H=% 'GO\
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MI?\ @N__ .)XZ#_\Y.C_ (<3ZO\ ])I?^"[_ /XGCH/_ ,Y.@#][:*_ >_\
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MR.75/#C>%HM 'VJ\NWF$%N5LC]Z_\';TMY;?\$MO!5QI]DNHZA;_ +8_[/\
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MC]3@?J: %X_ ?T_PHK\]OVN_^"I_["7["7Q*^%'PB_:G^.VD?"SQ[\:1:R^
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MT\JNJ:'K%E.L.HZ%XATF22&+5-"UBTL=4L7EC^T6J+)$S^^T %%%% !1110
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M3WGPS^SW^TRGQG^%NEZ9\'?V@-$_X*V:3_P5WU?XH?&+]J^X\,^-!\*_&G[
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M9+232?&VLZMHVJWOA;Q!+9:+J.AK=7$QLZW[/W_!8/X#_&C_ ()[?'7_ (*
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MK_@[6-7\'0>);BU4ZU!&^MQ744\^CE)/#$5KH5E]A:9_P2*^"/AG]O?]E?\
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MTC#->).&@C[[PI_P6_\ V8?%W[4'[!?[*-A\,/VAK7QY_P %#_V;?AY^T_\
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M]1\2?\&]_P"WW\;O@S\+/V+_ -J__@L_XY^+?[#/PPU+PU'<?"_PK^S/X?\
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MWQ0TW7_B!KNH+IK2Z=XLL_AMX$\ :5=W3W.H>&M9TL_8?L?Z,?LB_L<_ /\
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M]5OX;CX:_$74HH/"V;'6;O3-8 /Z!1[]\=\@'@8'3C\.3]:^=_VF?VJ_V?\
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M1XMU?7?!\4^O7'B"Z\/^#K6QE2&_ /TZ^#'_  5[_P""<7[07Q2\'?!_X/\
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M&/V<?&7C?X<Z1<Z;92WU\_BWPKHNM:-I_AN1X],U&^O5L;A[6&\FE7#^ _Q
M_9S_ &S=1_X)#?LY:+^VK^W3\<_CA\(/&/@KQ/\ #K]G[]G?]A']D/X5>)_V
M'?&'PGC\':9XQ'QN^(Y7X2>)_#OPKE^T:K>ZMK>D>*/B)#XFLO"USXL\46=S
MXKM?#D6J@'];WQ-_X+E?\$QOA)\1/$WPB\8?M(V[?%7P=\<K#]G;Q'\-O#OP
M]^)?BGQQ9_$R_AN9#!!X9\/^%-1U?4_"NG36Z:;K7CC2;74/".D:SJ&CZ-?Z
MS!J>KZ=:77$?\$Q?VR?$GQ,^%_[<OQ._:._;=^ 7[0OA+]GO]J+XI^%I?B)X
M'^'_ (F^"O@[X!_#?P5X5T#6KWX?_$*^\>?#?X76^KZQX.BN+[4==\96,OC#
M0Y([LPQ>+KU[>2RL_P P?^"(7@#P%XD_X+1_\'#WQ UCPCX;UCQIX5_:-^%6
M@^%?$VH:5;ZAJ?A[0/%/C#XWZSXDTS1+R\CWZ?;:SJG@GPC?7P@@CEN+GPYH
MTPE0V$0/X^_L^_ SX_\ [1?_  0X_P""]WPW_9RT_5_$7CD?\%0?B/XU\0>"
MO#]Q=P^)O'GPX^'>J_"GQSX^\*>'+>RM[B^UG6KW0M N+ZV\,V@%[XH73)?#
MNGPZC?ZI;Z1J(!_7#\"/^"\G_!+3]HWXO^'_ ('_  R_:;L3XW\:ZS>^'OAQ
M<>-OA_\ $OX;^#?BIKMCK!T.;2_ACX]\=^$] \(>-KZ?4WMX-.MM%UFYDU5K
MJT33/M4EU$IU_P!H#_@N1_P3'_9C\>_$7X5?&']I&VT;XG_"KXA>&?AAXU^'
M6C?#[XE^+/&UCXI\4:%+XFLWT_P[X7\)ZKJ6OZ!INB0"]\1>)]!M]1T#P]-?
M:/IFJ:A;ZOK6CV&H?RK_ /!0;]K#]DC_ (*0_P#!.3_@G#_P3[_X)Z_!_P 1
M^*_VUM'^+/[/&FZ-\(O#/PU\1^"O%G[&5QX+\(ZGIOQ%U;QEXGO?"FA^'=,M
M]2U8"SE/_"4^'-(UW3VO_B?JNM6G_"%?9[C]&_\ @EE\-O".N?\ !Q7_ ,%K
M=0\=^'_#/COQ=X)\ ? WP]8>+=?\/6-W?Q2ZOI/A*#Q;>:7%?_VC_9"^++[P
M]I=]J=O#=3RDVMK:O>7*0R22 'V;8?\ !4^Y_9[\>?\ !9/XJ_'[]K?X2?'?
MX/\ [$UM\.M;^'G[-_@?X2?$OP!\2?@7J'CRZUOP[X(^&?Q3\=W'P9M+77M6
M^*/C:^\*>#HM<T2Y^)UIX%N6U#7/$TVF:;:W4"U?^";O_!PO^RK^U'\ /V>?
M%?[1OQ*\,_#/]H?]H7X\R_ K3/ACX.^&_P 7)?!GASXG>+_&4.E_"KX8#QI?
M:!K.CW>KW_A;6?"E[JGBO4?$%KHU_J%WKVJ"+P]INGSZ3HOYC?LL>'=0\9?M
MN?\ !WSX8T?19O$NMZ_\*I=+T'0K6Q_M.]U;7[KX7?M&1:%9:?8>7*UUJ4VK
MFR73HHXVF-]]G,($P0CYC_9O^'?PJ_X*$?\ !K7XQ_9R^"%[<ZK^V!^P/#J7
MQ[U+P_HWA7Q#H?C?P/\ %KX:^/\ QYXYT_2[/4)]*TLZUXK\3?":3QGX=T%-
M%U#4M0@U#4[.T1$OK>UMJ /[9/$7[:'[.WA7]JGP#^Q/JWCUC^TS\2O NL_$
MWPQ\-=-\->*-8G7P)H,>IR:GXCU_7])TF\\,^%=.C;2+NVM9/$FL:8]_=O9V
MMC'=7-]:13?4J$D;B00>F!CCH,<G@\G!R?F SQS_ "<_\$"_&.J?\%(_VPOV
MWO\ @LKXW\):CI*>+/"OP>_9(^ \>KV[20Z%H7@;P!X4U_XX0^&;M;:S5M*U
MGXD+;WRP-;F:P@N8;&:2YN5N+BX_K%C0HH7HH'"GDKSD D$CCT&0.@) % $E
M%%% !1110 4444 %8?B+4+K2M#U75++39M9O=/TK4K^ST:WE:*XU:\M+*:YM
M=,MY$@N95FU">-+*)H[6XE5YU9+>5AY9W*:R*WWE!^O/;'\N* /Y%+O]L'_@
MZ6_9YU32?VDOC)^P5^SW^TO\"OB9';ZQK/[)'P"UV*+XW_LVZ8;E;"Q\-SZS
MI=UK'B/6O$VHV-LNN:QJ%A;?'O0;)]1F2^F\#O'_ ,(_HWZ(>!CIG_!1G]AO
MXD?&/_@N)^P[\._V7OA-X%^+_BGXI?#7X1?&;Q;/?77PX^!7@[X=>#X=+^)7
MQ5UU-2T.[L/&U_XLO/BO;3Z?J?AKP1?1^&FT.S7P=*MQ;:YXA_=DQJ 2HPP&
M <X.!VW=1D<9[9R*_'[_ (+*_P#!-;XO?\%4?V:-!_9A\ ?M2Q_LP>#+KQU8
M^+_BI<_\*SU/XBS_ !(TK0[.5O#_ (2N8-/^(WP_CL]$LM?EB\17]I>OJJ7^
MI:9I$B1VHLL2 'XG?LOCXC_\%TO^"QWP._X*5^"?A1XH^#W_  3?_P"">F@:
M[X)_9U^)OB[1(- \5_M/>.K;5?$MH=8T6"^TA=;E\)G5]1:ZNM)EN[O3O!>C
M^&K:SNKS1_'OC7Q+H-C\\_\ !"[2-)\;?LS_ /!ROXS\>Z7I_B/QSXR^)7[0
M=GX[UGQ':V]]K.MVD'@7X]:_';:Z;Y))S;Q^(-8UW4Q]IBA1M3N;F;>]Q 1#
M^G7[#G_!#O\ X*)_LA?&+]F[Q%XD_P""S_Q1^+?[/'[/U[X<LC^S#%\'/$/@
MOP%XA\ ^%] GT'2_ =I#;_''7-&TK2K>WDMGB\SP[?Q/<6YOKBVGO7EF/BW[
M6G_!NS^UA=?M%?M9^/\ _@G'^W;8?LM? G_@H]/J$_[;?PA\;>&=:UV9-1U;
MQ+J'B#7-6^&-YH=I<_VK8:S<>+_B!<6'AF^U'X?77A&U\0ZWX5TSQE?^%O%0
ML?"8!\>?\$7/V$_B;^WE_P $5O\ @G]XV\!_%;1_A;\=?V"_V[/BU\;/V8=?
M^)G@O6/''PJOM+L?'<^L^)_ 7B_PMH6O^#M:U?PCXB\4ZMK.I2:MH?B"WUO3
M=9L;S3["^MX9[R.VT_B-^RKX1_9JUSPG_P $T_B_\>++Q]\)?A_\0OC#_P %
MX_\ @M)\3_#OA1O#?@O4M)L]9\,Z=\$/V??!'AJ3QMK&M:4OC+Q)X#TEKSPE
MK>M6FMS:3HGA/XF0QW=IK,V@VO\ 6E^PQ^Q]X(_8!_8\^"'[(?PDGN]>\,_!
M#P9<Z-8ZQKH.G7?C'Q5K6LZQXQ\8^*M46W;4TT2;QEXZ\0:_XBNK.T&H6NA+
MJSV-C'=6UI"E?F=\(_\ @D3\2O%/[*G_  4V\/\ [7'Q \$:A^V/_P %2]6^
M)+_%WXJ?"N[\2^(O!_PZ\!QZ%=^$OV>/A+X+O_&GAWP_K%_X,^$_AZ62[GBG
M\+V%Q)J/B/7M)M[K4K+2M"O@ ?07_!/O_@L-^S[^WU\4?$GP+\)_!K]I/]F_
MXIZ#\$/A]^TAX/\ A[^TUX#\&>!=4^*'[/7Q"N!IV@?$[X;1>"/B#\0K2[\,
M:5<WOAJUUI=5ET22#_A+?#PT1=;\KQ!_87E/_!QY\3_B1\&?^".?[6_Q(^$G
MCWQ;\,_B#X;D^!4F@^-? VNZAX:\3Z0NJ?M"?"[1]2AL=8TN>"\MH[_2;^_T
MR\6&9/M%C>7%O(2)&+>/?\$O_P#@E;^V5\"?VR;S]M']N_X@?LW^(O'WP\_8
M9^$_[ OP.T#]F"Z^),_A[5_AWX$UC3=3UOXE_%/_ (6'X1\)2Z?X]U(>%/#L
M%AI?A;[=X8E'B#Q.[Z=I;:/H<L_Z,?\ !4_]AG4?^"D7[#'QK_8TT_XEV_P>
MNOBZ_P .W7XB7G@VX\>VNA1^!/B;X0^(<\3>%[?Q-X/FU(ZI'X7;2(&77K/[
M#->C47BO([;[%< '\Q'[,_PM_:9_8U_X)@_';_@MO^U+_P %"OB9^T1XR^,/
M_!+G6/ /@CX/^,QXCM/ ?@+Q;\4M5\!:#\"91JP\8!?%?BI=4C\->$I]9/A?
MP_JEMJOB?7+N#4-9%TMP/@O_ (*+Z1^U/_P3E_X)W_\ !NU\ _V9OCAXO_9^
M^)'Q<M/B]KWQ#U+X>>./%&G^'?$GQ%^*VL_LV>-=+U7QC&\-O/K5KH>I?$*Z
M:;3;W2Y;*Q^TZO:VUC<1S;YOZH?VA_\ @CAXT^.G_!+7]DO_ ()DVW[4-MX.
M\,? S7?V?Q\9/'EM\)KS4H?CGX"^",-[J$O@NV\('XBVH\'1>(/%\'A;Q/!=
M:AK?BZ'3+KPQ9(UIJ#-O1W_!73_@C-??\%.?&/[!7B#PQ\>-(^ .E?L1^./%
MGBZWT*Z^$]Q\0HO&]KKVI_!>\TO1;*?3_'_@B+PG!HMM\)I+20M9ZTE['KMO
M+!'8IH\T-Z ?2'_!+C_@GS\2O^">WP_^,GA_XN_M??$O]L[Q_P#&?XK3_%37
M?B)\1K+4M#;1K[4-#L+;5M!\/^'+_P 9^,;'2=*GU]-8UH?V=?V$#_VFD!L(
M$L8E/\Q'_!Q9^VQ^S'\1_P#@K=_P3U_8G_:?^)&G> /V/?V6_&.A_M'?M9:U
M>^&?&WC*PU#7KVPG\6Z3\/+O0/AKH/B'QG?S>)O!WAW3_ -O/H-E=MH]_P#%
MBYO=4&F6&DWNHP_W=%7+AMIY/ (/3()##HI()4MDKR6SG;&WX,?L:?\ !#SP
ME\%?VROVW?VV/VK?'GPZ_;*^)/[7/B1+_P .Z+XT^!.E6OA_X.^%_P#A(]2U
MB3P[ID/BSQ'X\M=<NSIT?@_0(]9@TWP]/!IWA3;#;HNJ740 /Q6_X->_VS/@
M'X3_ &[?^"B/_!/?X ?$BU\?_LP^.?B!XN_:;_8W\0)H7B[P?:R^%H-6L[/Q
M)X-T_P -?$'3].\8V5SI'A'6O"ENT&LV]I?7C>!_$.NBP$-W+,GX6?'WPEXB
M\/\ BW_@L3^VK\-M+T^;XP?\$]?^"V/@7X^^#=7O;>XN+;3M*UKX^?%W1[PZ
MFFG00ZI>:='\0M"^$TLEI%K6@V\5F=6F^WK?_85;^X+]H[_@B-X=\9_\%&OV
M*O\ @HC^RE\1O ?[(OB?]F"[L['XD?#;P-\#-$31/CSX'_M]SK_A6[U3PUKG
MABQ\(7OBGX?:_P"-OAYJ/B.Z\+^,+BQL=9TS5K'3Q<Z#''/Y!X&_X( ?V!X5
M_P""SGA+Q=^TA8^*M+_X*P:[X]\3:";+X/W6CS_ 3Q!XC\7^/O''@V^U3[3\
M0]8C^)$'A'Q'XG\.75Y;V4?@F;5T\.W8M[O1WU6"?2@#^4'_ (+!>.O#W[='
MCO\ X+,_MY:"MAXE^&GP?T_]@[]F+X!^*VAAEE7P_P"--2TKQKKUQ87%DVIZ
M,RZK<:7J5^)X-5355L-2MHY[6 RWT0^Y/@J"?^"RO_!KIZ_\.BOV8B<^W[&_
MQ1)_&OU1\%_\&P*>"/\ @DY\8_\ @FYI_P"UGI+>-/C3^T;X2^.GB;]H(_ G
M4_LSZ5X)M-'M="\'M\.?^%MM/)<VB6%_Y>N#QHD)74!&=(+0[Y-+]HC_ (-R
M?V@OB1\0OV _B]\!?^"CC_LU?%/]@S]BGX(_LF>$_'?AW]GN]\1^(=9UGX3^
M ]0^'VN?$;3+A_C+I$'AZU\9Z-J=]#'X:DM-9FTBUN[BVEUO5'F62  _K"SQ
MGI]>,?7TI<_J,Y[=N_X\?C7\_G[%G_!,+_@J3^SS^TAX"^+G[1/_  6F^*'[
M6OPC\+KXC'BGX#>(O@M/X2TGQH-4\/ZCIFE^?K8^+/B2.T?1]6N;'683)HMZ
MKM9&%!%YQG3^@)1@ <]!U]@!_3\Z %HHHH **** "BBB@ H_S^5%!X!/IZ=:
M /YV?^#@.)/@A%_P37_X*/+IGB#4=+_8(_;\^%VI_%ZXTO\ X1FZMO#_ .S3
M^T&A^&'Q:UP:%K\EC>:YXD/B.V^&'AOPM#H^L6DEA<^)KW4+RU:&V77O#G]"
M]I>V]W;V]S8S07=E<0QW%K=VTJSVUS:S1+/;SV\\;21SPSPLDD4\3O%(DB.C
M$-@?//[7W[-'@3]LC]F;XZ_LN?$NVFD\%_'/X;>(_ &JWEO':M>:'=:I9LV@
M^*-):]M+ZVBUKPEX@@TSQ1H=U/97<=GK.D6-S]FF*"-_RC_X(4?M6^-=<^$O
MC3_@G/\ M2WCZ1^W%_P3DNH?@O\ $K1;Z"^M1\1O@WH\J:;\&/C=X-N=4=;O
MQ)X1\2>%AI>FS:L;/2[JVN8=,GU#2+"#7]'EOP#]\?KSU_GQ^0X]Z,9_#FD5
ME;.T@X.#CL:6@!,?SS_CZ=03^//-+@=<<GJ?7'2BB@!,>O/.1D#CZ?Y]J6BB
M@ I" >>>W0^F?\3FEHH **** "BBB@!C@%6SG& <# /!SP>.3P.3C]:_$KX'
M:QHW@W_@O%^WOX+\=1HGCCXZ?L)_L4?%/X 7EQIZW/F_"'X,^-/CI\/?C7HN
MG:[/%&UA-;?$_P <>!M5U/P[833_ &^*2PUR]4?8(%3]N" 1@\@U^:W_  43
M_8?\5?M1Z)\*_B]^SO\ $,? K]N#]E37?$GCO]ECXTO$]UX>MM5\1:/'I?C3
MX._%C2DM+YO$/P.^,NGVFF:/\0=*ALYM1M_[-TC6=,69K"ZTK5@#])(\;%8
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M4_#]Q,^H2>(8]+MKB\C_ "@TW_@@U^TCXC^#?_!.'X(>//BI\%_#VA_LV?\
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M*@^#>HX\3:1\0O%]KXH;X(Q$_$P_V1J6FK'<V*?$)VU*UN&GANSX-46TD%P
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MI110  8&!T' I,#]<_C_ /7R:6B@!-HX]CD?@,#\A_C2X&<]P"/P.,_R%%%
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M?!?_ .+H_P"'N_\ P41_Z0$?MM?^':^"_P#\70!_0-17\_/_  ]W_P""B/\
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M_1Y;H3V%WX?O/'GB+0O /[.?@S4+>!5N;/Q7X2T?XF26URVR&WCF@$Z^6?\
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MH ]P^)W_  1T\!>'O&>H?&+_ ()\_'KXF_\ !-+XPZM>3ZIXEC^ 5AH_B/\
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M[^T-*_X,^_&D=V(9+</>7'[/FJQ".5HV<BVU5;VU$F8DV3B$31C>L4B++*'
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M=8-EJ)N8;W]F#X -\:OB=JD%I>PVB:?=W/C+0DU&2XMXKRRL+*XN+ZP9>?\
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M* "BBB@ HHHH **** "BBB@ HHH)P"?2@ HHI,@Y]O\ ZW^- "T444 %%%%
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M<#+M?BG*%^#Q.I^B/G+Z/_WPW^%'G+Z/_P!\-_A7YW?\/0?V$_\ HY+X>_\
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M_P#?#?X5^=W_  ]!_83_ .CDOA[_ -_-6_\ E?1_P]!_83_Z.2^'O_?S5O\
MY7T?ZB<<_P#1&\5_^(]FO_S('_$8/"G_ *.9P-_XE.3_ /S4?HCYR^C_ /?#
M?X4><OH__?#?X5^=W_#T']A/_HY+X>_]_-6_^5]'_#T']A/_ *.2^'O_ '\U
M;_Y7T?ZB<<_]$;Q7_P"(]FO_ ,R!_P 1@\*?^CF<#?\ B4Y/_P#-1^B/G+Z/
M_P!\-_A1YR^C_P#?#?X5^=W_  ]!_83_ .CDOA[_ -_-6_\ E?1_P]!_83_Z
M.2^'O_?S5O\ Y7T?ZB<<_P#1&\5_^(]FO_S('_$8/"G_ *.9P-_XE.3_ /S4
M?HCYR^C_ /?#?X4><OH__?#?X5^=W_#T']A/_HY+X>_]_-6_^5]'_#T']A/_
M *.2^'O_ '\U;_Y7T?ZB<<_]$;Q7_P"(]FO_ ,R!_P 1@\*?^CF<#?\ B4Y/
M_P#-1^B/G+Z/_P!\-_A1YR^C_P#?#?X5^=W_  ]!_83_ .CDOA[_ -_-6_\
ME?1_P]!_83_Z.2^'O_?S5O\ Y7T?ZB<<_P#1&\5_^(]FO_S('_$8/"G_ *.9
MP-_XE.3_ /S4?HCYR^C_ /?#?X4><OH__?#?X5^=W_#T']A/_HY+X>_]_-6_
M^5]'_#T']A/_ *.2^'O_ '\U;_Y7T?ZB<<_]$;Q7_P"(]FO_ ,R!_P 1@\*?
M^CF<#?\ B4Y/_P#-1^B/G+Z/_P!\-_A1YR^C_P#?#?X5^=W_  ]!_83_ .CD
MOA[_ -_-6_\ E?1_P]!_83_Z.2^'O_?S5O\ Y7T?ZB<<_P#1&\5_^(]FO_S(
M'_$8/"G_ *.9P-_XE.3_ /S4?HCYR^C_ /?#?X4><OH__?#?X5^=W_#T']A/
M_HY+X>_]_-6_^5]'_#T']A/_ *.2^'O_ '\U;_Y7T?ZB<<_]$;Q7_P"(]FO_
M ,R!_P 1@\*?^CF<#?\ B4Y/_P#-1^B/G+Z/_P!\-_A1YR^C_P#?#?X5^=W_
M  ]!_83_ .CDOA[_ -_-6_\ E?1_P]!_83_Z.2^'O_?S5O\ Y7T?ZB<<_P#1
M&\5_^(]FO_S('_$8/"G_ *.9P-_XE.3_ /S4?HCYR^C_ /?#?X4><OH__?#?
MX5^=W_#T']A/_HY+X>_]_-6_^5]'_#T']A/_ *.2^'O_ '\U;_Y7T?ZB<<_]
M$;Q7_P"(]FO_ ,R!_P 1@\*?^CF<#?\ B4Y/_P#-1^B/G+Z/_P!\-_A1YR^C
M_P#?#?X5^=W_  ]!_83_ .CDOA[_ -_-6_\ E?1_P]!_83_Z.2^'O_?S5O\
MY7T?ZB<<_P#1&\5_^(]FO_S('_$8/"G_ *.9P-_XE.3_ /S4?HCYR^C_ /?#
M?X4><OH__?#?X5^=W_#T']A/_HY+X>_]_-6_^5]'_#T']A/_ *.2^'O_ '\U
M;_Y7T?ZB<<_]$;Q7_P"(]FO_ ,R!_P 1@\*?^CF<#?\ B4Y/_P#-1^B/G+Z/
M_P!\-_A094/!#\_[##^E?G=_P]!_83_Z.2^'O_?S5O\ Y7TH_P""H7["8/\
MR<E\/#]9-6_^5]'^HG'/_1&\5_\ B/9K_P#,@_\ B,'A1_T<S@7_ ,2G)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUY9W$UO/%(^]YJ9*C)(P,;3W;;Z=-W&3@9R 258#^0[_ (>3?M<?L>_LZ?\
M!MY^RS^RA\*_@W\4O$?[<O[!GPI\&FR^+5[X@T.UT7Q;X1_9]_9MMO"'B)O$
MFB:E&++PQX<A\9^(?$'BO2O[%U+4_$%II=OIFCWND74IFFW?"O\ P4=_X*ZZ
M9^UA^WK_ ,$NOB[:?L@>./VEOAQ^R=/^T/\  #X\^"M+^(WPU^&%S8W^D>$-
M5U;1O$GA^+Q%JWBJ!(-%\3^(--T#68;S2-9T;QAX5MKB[76] UB+5K0 _HQU
M+]N?]B;1K[Q_IFL?MB?LLZ7J?PHLKW4OBEINH_M!?":RO_AKIVG:M8Z#J%_X
M^L[GQ;%<^#[.QUS5=+T6\N?$,6G06NK:C8:=-(EY>6\,GT/8^*O#6JZ+HWB3
M2O$&B:GX<\10:1=^'_$&GZK87NAZ[::_]F_L*YT;5K>>33]4AULWEHNCR6-Q
M.NI_:8/L)G\U,_YFW[ G@S_A3?\ P03_ &Y?VQ_BG^Q?^P-\<?"<GBZ_\*^%
M?&WQ \)^/M4_:'\:>,-4^-WP]T'Q]X2^)/Q$T/Q)X7\::/\ ";2M+L]"U+P9
MX8^'GCKPK:7FN6;:MKMA<ZGJNN7^I_I#_P %5?B+^WA??M6_\&Y&A_ FP_9[
M\'_#+QI%X#\??LI?":]UOXJV'PYG^/GA[P1\ (]=M_COX>MM:OEO? OPY/C#
M2-'^#6LZ5)J'CC1?#_BGXC6T^K&XUB22Z /[N-2U;2]'T^_U?5M1L=+TK2[.
MZU+5-3U&ZALM/TW3K&WDN[V_O[VY>*VL[*TM(9KFYN[F2*W@@B>6618T9A\A
M:3_P4<_X)Z:_>Z5INA?MX?L9ZUJ.NW5C9:)I^D_M0?!'4;[6+W4Y8H--L]+M
M+3QQ-<:A=:A//!#8V]I'+-=RS11P)(\B*>X^,8\3R?LD_%=O&ZZ.OC(_LY^/
M&\8Q:")WT >*'^&>K#7ET3[:SW3:,NJF^731=EIGLS&;C,I9C_F(?LD^)_\
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M6']DY?\ ]"[+/_#=EW_SG.>_LK3O^?&Q_P# "P_^1J/[*T[_ )\;'_P L/\
MY&KH?LZ^I_-O_BJ3R$'5CC. 2QY_\>QG.11S5O\ G]6_\'U__FP?]DY?_P!"
M_*__  W9=_\ .<Y_^RM._P"?&Q_\ +#_ .1J/[*T[_GQL?\ P L/_D:M\Q("
M <X/?<W7./[WKCO_ "I3 HYR1VY+=>W\7^?PHYZW_/ZMO;^/7WV_Z#!+*<O?
M_,NRS_PVY=_\YSG_ .RM._Y\;'_P L/_ )&H_LK3O^?&Q_\  "P_^1JW_(4Y
M )R#@$LW. ,DX/')P0,=.,4WRAR,DD'U;+<$] W';'M@DX-+GJZKVU:ZW7MZ
M_P!_^][=V/\ LG+_ /H797_X;LN_^<YA?V5IW_/C8_\ @!8?_(U']E:=_P ^
M-C_X 6'_ ,C5O^2ISU&3@ LV>A'/S="1]<]..*3R5X!+#KW;('OD@<GOCVZY
MI\]7_G]6U_Z?U_G_ ,Q?0/[)R_\ Z%^5_P#ANR[_ .<_]?)F#_96G?\ /C8_
M^ %A_P#(U']E:=_SXV/_ ( 6'_R-70?9UQU.?JWX9^;\\?A2B!/4]3W;L?\
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M.'*>>+BWA[+L?'"8C <.\09_D]#)<WQT:4*=?#TL3@:E;]=V<% !)L#8RQ?
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M8"M]1Q53+\-E_"6$P6*S"6.Q-#"8F-"I6>+E3P]*,9RC/!8RIB9T*,L$L?\
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ME_5\72HXVK6P>(3HXBC3GH_FN!O$G@CQ(PF/QG!7$&%SRGE6)IX3-*%.AF&
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M+NYOM(U75A;*I"..8_X+W_\ !+3]IW]J_P 3?\$A]'_8Y^%]CXO\ ?L8^/\
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MJ%[=7]O=WRW72_$/X_Z]\8/V'?AM^SUX%^&,_P -_B3XX^)&D_ 7QOX"\.^
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MQ.>Q&788!Q_@,TOED/\ >;/4'+8P"#]T-M)./[N<YY!K"OXK8C%5<11QW#>
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M&@\M1G(!W9Y.02YSG'49(^J^F!4K#Y<!MN.<\=O7((Y[\<\CO0F  H_VL8]
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MBACO-*@N+G2;TV=RZ2P[X9/T&G "LP*KDJ">Y(=3SGC@GH>H..N"/C3]L?\
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MRVCT3^PM-OK86MCJCV-_!%;:,VE6UK;7$8U6#Q)=RZM+?\;\;?VLOC/\3?\
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MVGIHZJ^^U-+]?,TAY0XWD="Q# 9. !UX(P"<'KGG-)B,GAA@8'# G / SUX
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MO+0UV<'TZC/S#H,]./?O2!AGG;C/ R,_CQ_];H,5D_;$_O?^@?XT?;$_O?\
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M/^!Y!S_W9?=4_P#E/_!\S5+#;CY#@D\X(^]GI]>3WSG!YJ/:@!YR>G+9R ,
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M,*6VGV%C$-JJB!=SS.R/-=74IENKV>:6YN;B:>:9V[987!4;B0,G)P%&=A
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M_P!?^*?^@G*__$1X*_\ H*'_ ,0AX"6V#S__ ,6!XE?_ $QC\Y?^&+_V@O\
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MR_8?]]/_ (T>7[#_ +Z?_&C_ %_XI_Z"<K_\1'@K_P"@H/\ B$7 ?_0)G_\
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M^"KPO_\ $T?\,7_M!?\ 20K]HO\ \%7A?_XFOT:\OV'_ 'T_^-'E^P_[Z?\
MQH_U_P"*?^@G*_\ Q$>"O_H*#_B$7 ?_ $"9_P#^+ \2O_IBGYR_\,7_ +07
M_20K]HO_ ,%7A?\ ^)H_X8O_ &@O^DA7[1?_ (*O"_\ \37Z->7[#_OI_P#&
MCR_8?]]/_C1_K_Q3_P!!.5_^(CP5_P#04'_$(N _^@3/_P#Q8'B5_P#3%/SE
M_P"&+_V@O^DA7[1?_@J\+_\ Q-'_  Q?^T%_TD*_:+_\%7A?_P")K]&O+]A_
MWT_^-'E^P_[Z?_&C_7_BG_H)RO\ \1'@K_Z"@_XA#P$]\'G_ /XL#Q*_^F*?
MG+_PQ?\ M!?])"OVB_\ P5>%_P#XFC_AB_\ :"_Z2%?M%_\ @J\+_P#Q-?HU
MY?L/^^G_ ,:/+]A_WT_^-'^O_%/_ $$Y7_XB/!7_ -!0+PAX"6V#S_\ \6!X
ME?\ TQ3\Y?\ AB_]H+_I(5^T7_X*O"__ ,31_P ,7_M!?])"OVB__!5X7_\
MB:_1KR_8?]]/_C1Y?L/^^G_QH_U_XI_Z"<K_ /$1X*_^@H/^(1<!_P#0)G__
M (L#Q*_^F*?G+_PQ?^T%_P!)"OVB_P#P5>%__B:/^&+_ -H+_I(5^T7_ ."K
MPO\ _$U^C7E^P_[Z?_&CR_8?]]/_ (T?Z_\ %/\ T$Y7_P"(CP5_]!0?\0BX
M#_Z!,_\ _%@>)7_TQ3\Y?^&+_P!H+_I(5^T7_P""KPO_ /$T?\,7_M!?])"O
MVB__  5>%_\ XFOT:\OV'_?3_P"-'E^P_P"^G_QH_P!?^*?^@G*__$1X*_\
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MKCWHHHLNR^X!:***8!@<^_6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $] U(# 2(  A$! Q$!_\0
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M1['A&_\ O?%-_P#L6Y%_\]A<^;_\^,J_\*,R_P#F4^R?^&UOV.O^CM?V9/\
MP_WPI_\ FLH_X;6_8Z_Z.U_9D_\ #_?"G_YK*^-?^'%'_!(S_HQ;X2?^!'C?
M_P":V@_\$*/^"1HZ_L+?"0?]O'C?O_W-M/V/"6_USBFW?^S,A_\ GJ+GS?\
MY\99_P"%&8__ #*?97_#:W['7_1VO[,G_A_OA3_\UE'_  VM^QU_T=K^S)_X
M?[X4_P#S65\:_P##BG_@D9_T8O\ "3T_X^/&_7T_Y&VD_P"'%/\ P2,_Z,7^
M$?\ X$^-O_FMH]EPE_T&\4?^&S(O_GJ/GS?_ *!\L_\ "G,/_F0^R_\ AM;]
MCK_H[7]F3_P_WPI_^:RC_AM;]CK_ *.U_9D_\/\ ?"G_ .:ROC7_ (<4_P#!
M(P]/V%_A&?\ MX\;_P#S6T?\.*/^"1O_ $8M\)/_  (\;_\ S6T>QX2>V-XI
M_P##9D7_ ,]1<^;_ //C+/\ PIS#_P"9#[*_X;6_8Z_Z.U_9D_\ #_?"G_YK
M*/\ AM;]CK_H[7]F3_P_WPI_^:ROC7_AQ1_P2-Z_\,+?"3'K]H\;_7_H;?3F
MC_AQ1_P2-SC_ (86^$F?3[1XWSUQ_P!#;Z\?7BCV7"7_ $&<4_\ ALR']<U#
MGS?_ )\99_X4YC_\RGV5_P -K?L=?]':_LR?^'^^%/\ \UE'_#:W['7_ $=K
M^S)_X?[X4_\ S65\:_\ #BC_ ()&_P#1B_PDXX_X^/&Y_P#=MH_X<4?\$C?^
MC%OA)_X$>-__ )K:/8\)/;&<4_\ ALR+],U'SYO_ - ^6?\ A3F/_P RGV7_
M ,-K_L=#_F[7]F/_ ,/[\*#_ #\64?\ #:_['?\ T=I^S'_X?WX3_P#S5U\:
M?\.*?^"1G_1BWPD_\"/&_P#\UOY>M'_#BC_@D;_T8M\)/_ CQO\ _-;2='A+
M_H+XI_\ #9D7_P ]@Y\W_P"?&5_^%.8__,A]E_\ #:_['?\ T=I^S'_X?WX3
M_P#S5T?\-K_L=?\ 1VG[,?\ X?WX3_\ S5U\:?\ #BC_ ()&#_FQ?X1],_\
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MRKN^DN[[2M]QV<TOY8?^3?\ R)=HHHK<U"BBB@ HHHH **** "BBB@ HHHH
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M+#&>HQGCGBODK2/V[?V.->^".N_M(:-^TU\$-2^ ?A?64\-^(_BU;?$+0)/
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M4^%^C3^$$T.]\/6^O66M?VKJ7B^^T/\ M'1_[)U3PM_:T%X7'->'_P#@M/\
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M/ZTTZU:I'#R24JN)IT9.I5IQDE2C&RAK\YZ9^RQ^W=^S]\5OV%_C7\*_V?/
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M5X2G)5%5JTVJ:M:M3C"/LGA*E:3YDVTUE]!55*<H*$'_  _B/YG?@Q_P3O\
M^"@_[.WPZ_X)[ZKH7[/GPY^*?Q&_9%_;%_;I^,_CWP-KGQZT.WTSQ%X%^,]W
MJD7@34_"/Q)\2K?ZAJ/BW7['53?^']:\3Z3#J5EJENDWC^VT>\O;RXB]C\'_
M /!/K]L?Q'^T3X9_:]\>?";PK\/_ !A\8_\ @JA\(?VI_BC\%M%^*GA'Q38_
M GX!?!#]G#QQ\%_#NLWWB>W@TS3?''Q3\8ZUXIO=>\;6/@^?5K#[+)X96P2.
M>PUHR_L[^SI^V_\ L[_M+_LY:#^U1X0\<Z/X7^$GB"ZU*V;5/B-KWA?PC>>&
MI;37+K3--M?&4%YKCV_@_5]?TU-*\2Z=X<\07EIK\.B>(-&;4]-LKR[:TC^C
M%^('@)?!T7Q"_P"$W\(?\*^FTN'7(/'A\2Z+_P (;-I%S@P:M#XJ.H#0)-,F
M5E,-Y'?_ &656Q'*W)K;&\3YS]8Q5/%Y?AJ6+Y\9@L1*>$Q].M%UL9BL97P;
M;Q4Z4*M'&XNO4C3IP>(7+3HSGB,-SJI-/*L"Z=-TJ]6=)+#5Z7)5IW:I4L/2
MIUVU3A5<70H4X.JY1ISC*3M%KW?Y=O@Y_P $M_VKOA_I?P^_9-^)_P "?B!\
M8O@UX(_:0F^(=O\ &;2_^"C>M_";]G]O".G_ !JU?XR^$OB5_P ,X:)X7U_Q
M_:?&;0]0N;-M6\,Z5I]MX6\3^*+9M:N/%>FVNLZG;6'ZT?\ !4/]C37?VVI?
MV%_!7_" V'Q%^%?PY_;A\+?%+]H70M0\5MX.6+X+V_P.^.G@76]1MKRUUK0]
M>U"[AUWQSX;BCTKPS??VW.MP]Q%$;2WO#'^C6F_$GX>:UX2D^(FC^/?!.J>
M+>VNK^Y\>:9XIT"_\'1V%F ]U=3>*+749]"BM+4$_:+F2_2.WQF9E7!/SI^T
MG^V[\%_V=/V5_B'^UVM\_P :OA?\.H[ Z@/@IK?@CQ?>ZO->>(=+\,O9Z+JD
M_B73/"LEW87VL6\NH0WGB"T>WB27*F9HX9.2>=9SF.9X+$0PR>84\57CAZ=#
M#XNFJV/S&E]4D_9SG"C0QF(3ART:4\*^>$&Z;<+QWC@\%A\-5I.4%AY0O/FE
M2<50HR=6-G!>_37/*\DG3<4Z;Y6FY_"?[5O_  2"^"H_8;^-O[/_ .PA\)O
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MV]OV@O\ @IEX5^(_P%T_X,?#?X:_L7_!(V?PT\=?M3?#+X@?$SX6_$GXP_M
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M')!)'HED)(9$=0\,B.C))&Z!E9<, Q(7OU#?Q$'Z<?AC'J3SG^%?5J_+(?\
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M?!VHZ)X5\"_!ZSB^(<=CX0L_#VF>'_%&M>(TU[QO<>H:U^R1\$M+_P""2O\
MP4H\::'\&XQK_P ./^"G7QI\/:7?VA\77=SX9^%'P:_:?L?"_AKR[)M1F,NB
M>#_A]XC\1V<FJ+:SW4^EWL]]J5[>W$"7L7[H#_@NE_P2R\R[E/BCXTF2_N[2
M_P!0E/["/[7YDO[ZP<2V%[?.?@$7N[RRE02VMU=&:XMY0)()(FY$B_\ !=K_
M ()>+;7MBGB[XWI9:E+<W.H62_L*?MA+:7]Q>-NO+B^M1\!?)O)[MB'N9;E)
M'N&&Z5G8 B'QG.C]66"R^K0CA\7@\2^;,74JS6%Q^(Q[HSJK"T7*/)BJN#HR
MDI.G34)V]ZI!U_8CJ^W>)Q3J.M&M"-J24::K86EAG*FI5)V?[B$VGISMJ.B4
MC\,OC[\)?@!XK\,_\%I?C5\%[?Q-<^#OV4OV,_\ @GK\4_V$-7\*>-?BMH_A
M?P%?R_LW:\_A[XA>!='@U_38=6UZ*T\'Z-;:;K^L6VI:BFD3WT)=[/Q%J'V[
MW7XC^ _C-^S/^T?^V7\*OV'M4^*T7C3XB_\ !!+X=?M(WME+XR\:^-?%/Q"_
M:>U']HCXA>"O$_QLNKO6]:FEOOC?J?P_T=[2WU'37TZ:]OH!+!IDDC212?JB
M/^"Y_P#P2Q6"[M1XF^,WV34+2UT_4+0?L'?M>BVO].LH3:V5A>6X^ 0ANK2P
MMLVUE;SI)#:V^884$9*U:7_@N]_P3 BO#J47C3XYPZE]ACTT:@G[#/[8JWPT
MZ&=[F+3UO$^ RW(L(YY))XK)95MDGD>9(PTC[N:7%U=NC#ZFZF&HQ4?JM>O2
MG1K<F"RJA1CB.7 QYU3KY=5Q=22]Z=;&U*OOU5*I5WAE%.,:G[QQJ5)3:JP4
MH5*<9XBK5?LVJDE%J-54U))/E@D].51_G6\"Q:7:?#3]HFZ_9R^)7P<\*>'A
M_P $U/VFKG]HGX,?!?QG^WE\5]>^(=T/!EF_@OQ_\9I?CW\*]$\$?"/]HKP?
M\2[2T@O[UO%VD>._&6@ZIXC\,K8:OI.FZ/"OZ*? G]G/P!\.OVOO^"9&@^%[
M'X@W>F?MQ_\ !-#]HFU_:\L_$_C_ .(OB^V^/%WX:^&WPOU+PU>>/HO$.N7]
MI#XCLM0\4ZPMKK&FQ:-K/V9=.TR"<6>F06\?Z&)_P72_X);(-45?%GQJ5-;9
MI-95/V$/VOE&JR/YF]M5"_ +&IEC+-N-^+EF,\I9B9":L+_P7;_X)?1RV-PO
MC+XXK<:; ]KIEPG["_[8:7&G6DZQK<6MA.OP%62SMIUBB22WMGBB9$171PHQ
MM5XRJSI8NE3RZ,8XFCC:3YZV'Y_]JP&+P=)U)4L#3]N\%6Q,,;A:M5RK*>'H
M)U5.E0=#.ED_*Z<IXB<Y4G2<-)-+V6*IUTH<U5N//"$H33T?M*KU4W$\N_X-
MU=!^$?A;]B[QEX9\':3;Z!\7?#OQY^,&B?M!:&]KKUGKFD:SI?Q(\:6?PPTO
MQ#:ZU&MO;7UE\*8/#'V2'3B7_LJ2QN=1$MU=K-)_0%'N Y[L>X[J#CITSGIC
M&%P-I('XJ67_  7C_P""8.G&Y:R\:?'2T:\N9+R[-G^PU^V):?:KR5%26ZNO
ML_P&C^T7$H2/?/-OF81H&D(45]L_LB?\%!/V9?VXI?B);_LZ^(/B!K\OPLB\
M'S>,5\<_!'XS?!H6L?CN3Q7'X=?2V^+W@7P6/$7VA_!FO"]'A_\ M,Z0T-G_
M &K]C&J:=]I^8S7'3S3-,=F3I2HO'8FKBITZE6%:<*E:TIKVL*5%."J<_LX\
MBY:4H0DY3C*<O3P>&6$PN'PRESK#T845)0Y.90ND^52DDVK7U=VF]+V7VQ36
MZ$=<@\>HXS[YQT&1G/4=0H.0#Z@'\QFOB#]K+]O'X<_L?:UX,T'QS\(/VJ/B
M=<^-]+U75;"[_9X_9S^(GQPTS2H-'N;:VN(?$M]X(T^]AT&]N'N4ELK2\*RW
M4"2RQC8@+<4E==K:JSMT?^?S[HZ3[+N(G-O)$LC1-+'+$DPS^X9X)E25=JAS
ML8C'*E0.I(R?Y@OV7/VQ=#_X)W_L'ZI^P-\>_P!G3XT?&G]LOX-7WQ9^%FA_
ML^^'_A)XXUW0?VU]<^)/Q'\3ZGX)\4^&_B9<>"O$GPZ/@7XMV_C6TO?&FO>)
MM0UW5?"^E1>(CJ/A_P 3:_:67AK6?O@_\%M?@$<Y_90_X*;\G/\ RC]^/WTX
MQH/4#'/IG.2:8?\ @MC\ CD#]E3_ (*<HI4@!?V /C\O!Q@C_B0D \ < <$C
M !X[\OQM'#4<3AL;@)8[#XC$8+&.%+'5<!5CBLO6(C0J?6*=+$5%0G3Q56C7
MH4XTJCNL1AJ^'Q-.C7ARXBA4JSIU*554JE.G7I^]3A5C.%?EE*/).2@I*4(N
M,Y<T%\-2G4A*47\B_$W]GK]H_P#:#_X*=?M%#X*_&WXO?L+?$FQ_X)P_LVW_
M (:\0>!- \'>*/ +?$)_&'Q -E\,_B/<Z_X)UG1?%_A'P-J+[-0TWX;:QX1U
MV2VO+N^MM2AM6LK9_KW_ ((H/X5L/V6?''@V;X=?$+X9_M'>$_V@_BW:_MHZ
M;\3_ !)K_CGQ3XL_:BN_$5T_C[XI6OCW6=+T6U\9^$OB1]EMO$7A/5O#^E:=
MH$6G3BRM;:ZDMYM7U6(?\%L/@"%"G]E/_@IN0 00/^"?W[0 !)W<@?V&0I!.
M2<Y)SAL8 /\ A]C\ 0>/V4_^"G' P%;_ ()_?'YE53VP=!SP/ER"#C(&,G/H
M8[B"KCLL>5RP=*G2C0RJC2K49J%9?V93QU.2Q%3V7M,;A\4L6JE/#XJK4^H8
MJC'$T*LW7Q,9<^'RZ&'Q'UB,Y2FZF+J-3YI1OBYPDU"$JLX47!P2E*E&*JTY
M2I.,(<L8_"W[./[$_P ?_P!J#QS_ ,%5_"-O^VC^T'^RU\!/B!_P43_:/\)_
M$/X0?#GX,_ Z.\^*?A#Q%I7@ZWU_Q)X8^,?Q/^&GB7XB:#+XMT&2;PS#J/AJ
M^N_"=G%9220:5J1OM7@N>0^-GP?_ &1OV>?VT_'G@+_@HK\(?B!XW_8O\!_L
M>?L^?!?_ ()WPR^ /C+\9?A-X+\!_#OP5/X/^)7@:SA^'VC:UJ5I^T?/J^G?
M;CXLN[>7Q5J'A2[\)II7B>*YM[33K']&?^'V'P R,_LH_P#!3<X/R@_\$_OC
M]A<X&U0=" 4 <8 &.HP.I_P^P^ .<C]E7_@IRO X7]@#X_ 9VA5)4:#@X R1
MC#$@$'!4]*XIQD\56JUJ+6&K8:.&]A@JU/ 8FE4CALHPJQV'Q]'#5*T,9*CE
M%*C4Q%>G7K/"5J^#IRA1:Y\%DU"$*:IR;J4ZRJJK64Z\9Q]MBZ_L:E*K6Y?9
M0J8VK5A3I2A!5H0J-3<8Q7\_?Q0^$GQ:T;]F[_@G3?\ [8&N^*=$\>>"_@G^
MT?H_@'P5^WC^RO\ %C]KC]FZZ^$?BOXI3+\$?!G[1OB7]G7Q#X<^(/PT_:[\
M-?!-?"=C%XB\.^&O$)AT^Q>TBN?#FLVUQ'+[OX=\(>"M4^('_! WX\_M.?L6
MW/P0\)R^ ?BY\$]7\&_\(K\9OC!;>&M4\ _$;1M._8E&O:YXSM/%'Q9M[;6+
M*WA^,'@6\^*U_<:OX,LO%.HQ^*-:EETJ[N6_8M?^"U_P!4OL_95_X*<*6RW_
M "C_ /C^!N_B)#:'SD@<#  !!R,X7_A]C\ \Y/[*O_!3KG&0/^"?_P ?5)QT
M+%=!#,20!U(_A "D"NJ?&5>:C)Y<J=1?VO%NAC9T8QH9M1S.C/#4(4J%.G3I
MTYYC&NI5H8F=2K0E:="&*JTJ&;R6-YI5N:,I8.:]I1A.2J8.IAJM.I*4ZLG-
MVPWLK1]FK5%4:<Z:G/Y"_P""KT_[=^M_LB^-(/VK/!7[//@SX7:=^T1^S3JG
M@[Q7^QS\1_CW\4/C3I5IIGQ[\/3ZGXFUKP_XN_9_\.V'AV?PYX BU#Q):ZOX
M>?QB^G>+=/L[=]'U'2]UR?*/V9]2\$:[_P %/OV._&'[*W[0O[9O[=T-OX$^
M/G@[XZ>*/VS_  9X@UC2/V<OA7JNA:1JVG^*_AA\1-=^#GP<3P+XV\<>-=.T
M;PMJ.CV</B.7QWX=MY]/NS8II-LTOZ*_\/LO@!D%?V4O^"FZX7&%_P""?_Q\
M7@XR3C0LD'@@$G&!@9!RA_X+8? )L_\ &*G_  4YY/0_L _M $#D_*5.B8Z]
M..@ ))Z\N$XFEALL>7_V?23=+-Z*6'JPH8#DS?"X3"U'5PCPV(Q#J8=X.&)A
M/#9IA55KO]_2E2=2C4VJY9*>+^M1KO66$FXS3G-?5)XB48TZCJPI4XU%7<9\
M^$K.,4W"49J$X_B7^R3^S_\ %J;0_P#@G]X"TWP/XQ7X=_\ !033K'P9^TD9
MO#%_HZ>!(_\ @G#^W#\<?CYH]QXJO=3%E=6*_&CX._$K7OA_;PZA9Z='+;^!
M-%O-);5]5UEHI?JCQ3X9\5G_ (-F%\,OX5\6-XH/AY$;PM'X;UYO%"N_[6ES
M>+$OAQ; ZUE;4+=*/L(S9A;HC[/AZ_0S_A]?^S_\V?V4O^"G#;B&<_\ #O\
M^/\ \Y557)/]A#(^53CDX "D9)*?\/K_ (  DG]E3_@IR6YPY_8 _: # $EM
MI*Z$I*^H 4':N>AR3XFD\5@L3#+J=-X3-L-FTXO&8FJ\36PN(QE6G"I*5^5+
M#5L+@54BN>%#!4K)N<XP*>4QITJL/K%1NKAWA4U&$/9P=&%&]/E?N+G57$.*
MUE5Q$Y2;:2C^N'A-)$\,^&]P*R#PYH2,LB,K _V=:;E=7PR,IWAT(5@3R-RU
MUR !5 Q@ =.GX>WI[5^,@_X+9?  8_XQ1_X*:]<\_P#!/SX^\MDC/_("ZD%@
M<GJ W8AON+]DG]LCP+^V#H'C'7O _P ,?VBOAG;>!_$&G^'-1LOVB?@=XV^!
MVLZK=:EI$>LPWOAK2O&UG9W>NZ3!!*MO=ZC9H;>WO0UJS&0+N^6<>:<IM).4
MG*R=[<TZD[*6[2=1JS6NKW9ZT5:*5V[*UV[Z)12ZOI&]NEVO(^NZ***L84C=
M#]#_ "I:1NA^A_E0)[/T?Y,_!'_@H;_RE]_X(I_]CC^T]_ZI_6*_>.+K%_UT
ME_\ 0*_!S_@H;_RE]_X(I_\ 8X_M/?\ JG]8K]XXNL7_ %TE_P#0*^GS_P#Y
M%/!W_8@QW_J_S@\G!?[UF_\ V'T/_5?@RY14;R!" 0><<Y  R<<YYXZGC[N3
MVP?S!N_^"I?A:SO+RS/[#W_!4*Y-G=W5I]IM/V#/C)<6ES]EGD@^TV=PMGMG
MM+CR_.M9P%$UO)')M7=M'S!ZY^H55I!L;?P<.C'^\ 2 W '(5<D #<QP"3DY
M_+[_ (>I^%?^C&/^"I7_ (@/\9O_ )#_ ,]JC;_@J?X3;I^PQ_P5*5LYW?\
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M'5O$,7P:6P\.QZ==>')[FS\"7_V=H[/3KA/Z !_P5,\+;=I_8<_X*F'G)/\
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M?AKP_P#$37=,U_2=.N]+UFX\1Z'I]Y!XLGTU;K^UO-#_ ,%3?"N#_P 8.?\
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M55,C<C<.>X^F01P,="&!!//')&0RGH./3(Y(R,$D_=]1G)'<8Y!=]G]TO_D
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M_P"5KY2_^0\[>OSM'.N\?O7X:Z^7?I<LT56\T^H_7_XFCS3ZC]?_ (FCG?\
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M?/ITZEC/0'@G/^<T#IUST_D/_P!?XU"93G@9] ._!R".HXY'N.E'F,,_+W[
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M'_@H;_RE]_X(I_\ 8X_M/?\ JG]8K]XXNL7_ %TE_P#0*_!S_@H;_P I??\
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MO*GU_P"XWW=>ZL6]P]1^8HR.>0?Q'Z<U1R>Q)Z?Q*#[@_-VXQSZ\#J3+>_\
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MU\5C*6$R;!9+E.6<.XRKFF8X[&X:GA95,-R4ZJK1I3:?^"JG[:G7_A/?"H#
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M&9<78JGE^&Q=?-H9=5R_,,?/$Y;AL#B\MPDL5C<THXQ4ZV E@*N"J86K7Q6
MQN(_2,Z\0/IA9?A\UQ>6^.N09]1RJKC)5:>7<#8*>8XO 87(:V;T,TRC*Z&7
MYQB<VR_-L53PF7Y+BL"Z^%S&CF-''PQ=*A0S' Y?]1_\/MO&)_YMX\)<]O\
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MNK+1:]%;>]GW7R7G?_6^+O?U=FMFDVD]WNDFNFKMHT24AZ$<YQCH>_OTIAD
MZA_^^309 %W=O0G#8'4XQT R?]WFGS1[KRU2&WILW?M_5S\%?^"AH_XV^_\
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MR[W[ZZ+RN[V5MVMSU.9+?Y6W:WTOV6NWR9%),0\8!?+_ "@$,5WYPI'!&=V
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MJ?2ADTGXO9[TVP'#W==N'[OTZ[=5?]E!_P %H/C:W3X0?#/A3G_B9^,<9XP
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M>H(1KE2X)Z\#  ;.2!2_\/H/C6%W_P#"H_A=G.TH=7\8*0^5P%Q=/ORH.X[
M%.,YYKPSPWX>^ GQ$^',GPR^&9\!W.N^,IO'GAGP7H6KV.H+^T,WQ?U;XSZ!
M-\*?%Z:E]@GLK+X+Z%\#8O%5QXJOKSQ39V%E$+:#6=%;5([U+3PG]J#X>ZMX
M>UO3/%VD?#.\\$_!:]&G> ?AMKSV6C61\7#PKI(/]O:Y:6>I7VKZ?XB\<1VF
MK>,;2'Q-::7=:MHXDN-(2ZT_3)I(=>&N!_H^<0<0+AK$>$$N'<QEB\QP]&EQ
M/F&8Y9B\32PF&P<\)*AA:F;TZE;&8[%5L7@Y8##?6GA5EF*KU,97ITY4UQ<8
M^*_TM.$^%7Q=A?I$0XORR&"RO$8BOPAEV5YQA,+6Q6,S2AF%+$X[#Y!4P>&P
M6787"X'&QS'$_5UCXYSEU"G@<'-QJU?N@?\ !:'XV'_FD/PN_P#!QXR'(ZY_
M?_SYQZBE_P"'T'QL_P"B0_"[_P '/C'_ ./U^-7 Q\S#'&"%^8;?EVXR22.I
M(W'@=3R\@]F/X@'^@K]=7T:_ VW_ ";O*E?7_?\ .UOMI_:SL[6NKZ/0_ I?
M34^E#'3_ (B_GCMVP'#KOZ/_ %?LUV?56VV/V1_X?0_&S./^%0_"[_P;^,L?
MGY^._P#/C@TG_#Z/XV<#_A4?PO&XD '5O&//4_>^T JN"<D8/.#@,6'XVD'^
M]W&> /I^.<#WR*C5L#\-I/<*3EMH.!D*<-V /!P,4+Z-?@9?_DW>4OUS#.[7
M>B>N;:<M^:RU:BTM6A+Z:GTH96OXO9ZM5_S+^'M/.T<@NTFE===OM,_HM_9=
M_P""MD7Q-^)_A[X:?&;P)H_@<>-=8TWP[X2\7^%M4U*_T=?$^M7D&G>']"\0
MZ;JL;7EE#X@U*Y@TK3M:MKN:WAU2YM+?4;:UM;DWUO\ M?'(& PI&<DAU8-D
MCE2" RLN,$''88QT_@XTJYGLM3TZ]M'D@N;&^TN_M9HWQ+!=V6JV=Q:3HP!*
M2P7$44Z. VQXUV@@ 5_>#%_K'.2<-,>3QEFD)'L.GL/PK^(OI2^%W"GAKGW"
ME3A#!/*\#Q#EF:3Q65QQ.)Q6$P^,R?'X3#?6,'/%SJ5Z=/&4,?!UJ'M:E*->
MC*K2]G&I*E'_ %)^@;X[>('C-PCQS0\1,SAGV:<(9UD5+ Y[+"8;"8_%X#B#
M+,RQKPV80P5'#X6M4P.(RR?U;%0H4JSH8GV%7G]C3J&C2'I^*_S%(K;L\$8.
M"",'H#T_&E/3\5_F*_EM[/T?Y,_O=[,@;[P_W?Z+7X*_\$?O^3L_^"W7_:1+
M6/\ U'KNOWJ;[P_W?Z+7X*_\$?O^3L_^"W7_ &D2UC_U'KNO=R?_ )$'&/\
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MFJZQK6I:CIUYJ;R73:61Y4<'*>%OVK?AG8^&O@CI?BOX&ZAXLUS]GV'Q5?\
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M*=0T*XM]&TQ+ 3^-?'4'ARXOO#.AV\M[/%9P9U"W\Z[L8KCHSY^#%&MAJ_\
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M>TT(Z]#$_A.7XI7FC7D5[/?_ -D.FK_V.^E3+-:Q6=B]^UQNCFMC&=]WP/\
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M VYR>1^(#*2/7/&[CKACTS2G Z<9(SCZC^>?RS]"FTN0 3GG !RVX MD #G
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M'/< GH>W.01W'.,<@FOT#373^GWZ=O3L?D=^EOZUW5VG_700@XXXS@=.@!R
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M<IPM6GF. A1>=912Q&,QF+R+'8I9=/)<SI9LJ>+I8AM\M\0OC=8>(_A]X?\
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M[>#=;P<9P#_Q,^G)]LGUXKZ3_B9WP1O_ ,ES2]?[%XEOI_W1=[^:]5NOB_\
MB1GZ3_7POQ%G=Z\0<)6_]:#>^UG\['X?F,*,DIR000>3@?/&""2 ,\DXSQCI
MFOZ)/^"*43+\)_CO(R%8G^,>F>5*(W6.4P_#/PLLGE.PVR"%FV.T;,%8,C8:
MO)+/_@BIXE%W;+JOQWT1-,,RM>_V9X)U"2_,(&[_ $.._P!56S>;*J0MT1$<
M?,<+BOV>^ 7P(\#?LZ?#31/AA\/[26/2=+,UWJ&IZBL#ZSXBUJ^<2ZKK^N7-
MM##'/J5_,V"L<:06UK';6=LH@M8P/Y]^DEX\^'/&OA_+A'A'-*V?X_,,ZR?&
MUL3'+L?@L-@<-E-2KC:CK5<RPV%=:MB:TH4:&'P]"<J?).M6JQHQC"K_ %Y]
M"_Z)OC%X;>+\/$'Q!R.APME61\/Y_@,-AJN:93F&99OCL_P=' 4H8:AE&-QL
M</AL'0C5Q.)Q6+K48RDJ6&PU.I5J3E#V63Y=N Y!;9E3D)D%OFZG+; N 2P8
M@C&":_ ;_@M5H6KG6_@-XF33YFT+^R_&?AC^TS'(;5/$,E]HVOQZ6\H3RH[R
MYT;3[_4[:!I!+<VNEZC)#%(EE=-%^_V&;=VQD,V<\;7PK#G:W.0W;.>PKB/B
M#\.O!'Q2\)ZIX)^(7A;0?&7A/5Q#]NT'Q!IT.HZ?<2V<T=U8W:1S+YMMJ.G7
M<45]IFJ63V^I:5?PP7NGW=M=1)*/Y(\*^.*?AQQ]D/&53+Y9GALKEBJ.+P5&
M=+#U\3@\QR[$Y=B9X3$54Z,<52HXF-?#0KKZM4E0=#$2IJK[6C_H9X]^%E;Q
MG\*.+/#JAFU/),;G<,#7P&95J%?%X.CF.3YKALYR^./P]&I'$RP&(KX183&/
M!\N*A1Q"Q.&56I1]E5_AEE!<EE#%2/E;RW()!XVG;VVD $@\$G!R*C8*.&W(
M<'Y=K9P>C '!],GV/2OZQY?^"5_[%[N[_P#"O-?C$DTLBQ1?$+QDL,9FD=]D
M2'56VQQ;C%$I+LD2*A9MNXL'_!*S]C X \ >)3G.W_BXGC#G\M3P,X'0GWXZ
M_P!\KZ:/ABXJ^1\:QD]7?!Y'9?#=+_A6O;S6B?Q+6+/\F'^S1\<5)M<3>&LK
M*RMFW$$6EK9\SR"5KKI97W6S/Y/#C(X<<G^%A@'!!ZD9Z<_7CCER"/.T[@=P
MR>0,'*YYS@'/)! P3G (K^L/_AU7^QAT_P"$ \2]<8_X6%XRZCCI_:7Y>O:D
M/_!*O]C 9SX!\28Z$GXA^,2 ,9(/_$S.05R",'C((I_\3H^&2U>2<:I1:=_J
M>1Z6MJ_^%6ST3=GI)*SLG(7_ !31\<?^BD\-D^ELYS_OH]>'K/7IL]+NSL?S
MD^&OCC+X,^$'@3PIX734]+^(?@'X]7_QET;Q5)$KZ%$%\-Z+I>G6D\4<RWUP
MTMYI4RZK;!!#<:;=S6Z2%YB![+\7_P!KK19?&'@SQ+^S5X<U/X3:=I?@?Q)X
M?UCP]XBTCPMX@T^PG\7^.KOQ]JVG>%[:[L]1L;3PWIVJZC=V.BK!9V,MMID=
MI916=O:PQ0)^YP_X)7_L7@?\B!XERB[5!^(?C' W9_=Y&I@@#G*@=N<]2B_\
M$JOV,-KC_A7WB/8[E67_ (6'XO"LP/0@ZE\W(XR6Z9ZG)_-\5X]?1ZQV;T,[
MQG!_'.*QE+$<0UZL*]/*JF#Q,>*)Y=4S2&,HPSBA'%4(5\LP^(RVA.K2^I5Z
MF+='$\M>M3J?K.%^B!]+3 <.5>%\'QYX787+:N&X5PM)T,3FJQN _P!3HYK1
MRW$8#&5N'L4Z.+KX3.<1A,VJ+#UJ69X:E@:=;#TI8'#8B'\^VB?MI_''2?&.
MD^-M0U/PAXGU+1= \3^$[2R\0>!?#YT230_&-O!8Z[;7VF:+9:1%J:75I +1
MDU"62$PO*KQM'(Y;V3Q+_P % M=&B? :;P'\,_A7X:\3?#'PI\0= \2Q+\,=
M!L/!U[:>-]2U*RET3PMH^FW8:T\)W?AV^2YUS09C;VNH>(FEU">WF)=Y/VF7
M_@E;^QBH7;X \2+\Q  ^(GC%,D Y#*-3 ..H )7&#@+@%@_X)6_L8!0#\/\
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M9 NI&<$_VF"0,$@-D$8YYX!_P2K_ &,%QCP!XC VCD?$/QBO ]AJ?  P>W/
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M1V:TTTTMT"]]G)V724O)-?%NKJZZ73/P6_X*% #_ (*]_P#!%%<\+XP_:@R
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M+=?]I$M8_P#4>NZ_>IOO#_=_HM?@K_P1^_Y.S_X+=?\ :1+6/_4>NZ]W)_\
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M*F']%_[[?_"C#^B_]]O_ (5<HH"S_N_^ _\ !*>']$^NYL_@<9'?\SZT8?\
MNQCZ%@?S JY10.S[KMMT[;[>13VOZ)Z\LY_I1A_1?^^G_P *N44>?7OU^\5G
M_=_\!_X)3P_HG?HS#KUZ#OW]:,/Z+_WT_P#A5RBBR[+[D.SWTOWY=?OO<IX?
MT7_OM_\ "C#^B_\ ?3_X5<HH%9_W?_ ?^"5XQG!9<MG@CG Y R2<]R"/1CD8
M.*G  Z #Z#%+14J*3;5]>E[I7=]+^?3;LAKY?)6# ]/3].1^1Y%(0#P0"/0@
M?3^7%+15#*KAU8A NW ."3P?0 =!TP.E-Q(>R_\ ?;_SZ_3)_K5RB@FS_N_^
M E/#^B_]]O\ X48?T7_OM_\ "KE% 6?]W_P'_@E/#^B_]]O_ (48?T7_ +[?
M_"KE% 6?]W_P'_@E/#^B_P#?;_X48?T7_OM_\*N44!9_W?\ P'_@E/#^B_\
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MK72+26XN$U70[6_EU'3)-T2VSM>V\207$\,=QY;RH&_/WX._LZ_%GX?>-9?
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M/3\5_F*6D/3\5_F*3V?H_P F#V9 WWA_N_T6OP5_X(_?\G9_\%NO^TB6L?\
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MD?ZB'_#^#_@DQGG]L_X? G YT'Q[SRP Q_PB?7J#WZ ]J/\ A_#_ ,$E^/\
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MX+N?\$E0?E_;.^'JDGD_V#X^YP2>WA,=<GGW(/I3A_P7A_X)+D#_ (S0^'_
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MLGH_CP>EDDF_]G=GY-77WD_\1NSV_P#R*,J_\&8W_P"3[:]S_5*^&W_!9/\
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M()?!6G?$74EB;3_AQJ'C>/3V\.6WC6\AFBD@T.2],Z[Q#(8[D&WKG-&_;?\
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MH\'C3X>>$K:>[USQG\.+C4M.LT\;>'K2&W+)?:-),TZ36ES"K6][;W$GQ?\
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M:09]3T%I(4M-76SG47</E.Q\?O\ ]@?XQ2>%?@[I/AWXQZ#X&\1?##]A6/\
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MQ9\0^+['1/%EK>V=M8V]C?>$KV]GT71HM#M/LW]C32_V:/@QX<^-?[&^@?\
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M:226262266X>XEFEGN92&GN+FYF>>XFF<!=TDTTC2N0 N7*JJK\M,!"^N/4
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M:?#Y$</BGB3]@_1_&%A^T=%XB^+?CF_UC]ICP]^S]HGC+7X/#_@K3;G2M0^
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M#(Z9]?7'M[]..]5$BR1N4$!OFW  $_*#@#UR23T).T8 YNGH?\_U'\Q]:0
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M8/,=2$4%?5?Q#_X*=_ .ZT+]MGQ3\'/V=_C)X%^/7[;OQW_97_:A\;Z_X_\
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MK\6?U<%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7*=*OAZL(8K!XA3H8NE2K0BJG+E?A-D6;4)U*>=YK0Q&&JSP^.P.)P."IXO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW\C_ /BJ//B_OI_WVGUY^;C\: ):*B\^+_GHG_?R/_XJCSHO[Z?]]Q__ !5
M$M%1>=%_?3_ON/\ ^*H\Z+^^G_?<?_Q5 $M%1>=%_?3_ +[C_P#BJ/.B_OI_
MWW'_ /%4 2T5 \Z8^4HQ)4;0RL6!8*5 #?>(.1GCG)Z$4]'++EAM.<8Y_/D
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M>S(&^\/]W^BU^"O_  1^_P"3L_\ @MU_VD2UC_U'KNOWJ;[P_P!W^BU^"O\
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M>6:1WDE9G=B3?=_\_P#J_P#X.-7_ /DVG(047!!PH!QV.!Q]:?0!%ON_^?\
MU?\ \'&K_P#R;1ON_P#G_P!7_P#!QJ__ ,FU+10!4N+F6"&26?4]4CB1&9V;
M6-98  #(V1W<DKNVX*D4<;RRL1'$K2.@/U[)^PO^U;9_$[X9_!OQ!X-?P/\
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M]XDRI53UW%OP9TQ^/'_UZ_!__@H4-W_!7W_@BGT^7QA^U&PYYR?@WK"G('.
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MR-AUG5]V0,GC[: , ]![8X(S^^<W@+1OBWX/O?A1X_\  ?C*;XEZ[\'O@?\
MM1_&;]E_]FB35;CXKI\//#'B;X:?LS?L6? S3Y]2M?'7C/4_"_[.'P@\:Z_^
MT)\9[#6?#FJ:P/%/CKX=^)]4UO0M%U"&34OQ3^,G@2P^%OQA^*_PQTCQ!;^*
M]+^'GQ(\:>"M-\3VS6QAU[3_  SK]SI=IJ2FRGN;1WGAB1;G[-/)$MSYNW:#
MM4 \XWW?_/\ ZO\ ^#C5_P#Y-HWW?_/_ *O_ .#C5_\ Y-J6B@"+?=_\_P#J
M_P#X.-7_ /DVC?=_\_VK_P#@XU?_ .3:EHH ^POV'_VQ?BU^Q_\ 'CX>>+_"
M_CS7+7X;ZMXZ\&:)\8O!&N:_K.H>!]>^'>M^)]'TOQGJEUHUY=W=CIGB'P]X
M<N+_ %W1?$^GV2ZE:7>G1PW)O=,:[L9O]#M"!E,DE<YSU()SG/?.>3U]<$U_
ME]2##*P!RMQ:'<>O_'S$1L/\)4C((_B"L02JX_U TYDE) R"%_  'K[\<=CT
MZT 2TAZ?BO\ ,4M(>GXK_,4GL_1_DQ/9D#?>'T(_(+_G\Z_!7_@C_P ?M9_\
M%NO^TB6K_KX>NN?PSD_CC-?O6W7/'(!^F "?SW#\J_!;_@CYG_AK3_@MUCO_
M ,%$M8_+_A'[HG] :]W)_P#D0<8]O[.R#_UHG8\O&J^-RM=ZV._#+_\ AS][
M8_\ 5Q_[B_\ H(HIL8&Q.7^XOKZ#V/\ .BO"6R]%^2/5):***8!1110 4444
M %%%% !1110 4444 (1GOQR"/7/OU'X5'(N%Y('S)CIQAE)P#QD\G'>I::Z[
MEQEAR,[3@XS@@^V,Y]JEQ36UM+73L[;V3MIJD'SM\KV^1YY\2/AQX+^+?@CQ
M'\.OB#H%EXF\'>*M.ETW7-&O%;RYHS(L]M=VEQ$R76FZMIEW%!J>B:SI\UMJ
M>CZM:6>IZ;<V][:03)_&?_P5S^ OQ5_9GG^!7PB\1>,QXW^"6C:C\3-1^ -]
M?S1GQ-H6BZC_ ,([-K_A/5X(HXDAM=%E^P?9%A5M-EDFN+C2X-/CN);"+^W
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M(TDS101^3;Q///)';1!$46]I')(T=K J11H(K=8T8(FY21F@#^@_]GG]H/\
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MZBC/V;4FY1E+F2LDEHES;7;NDOYK=T0V,%[$\SW#LROT7>)BSC9NDVL 5"8
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M[4LR_P"?67_^%&,WMTOA/Z[:V/U[_P"%D_#S_HH7@K_PK]!_^3J/^%D_#O\
MZ*%X*_\ "OT'_P"3J_(;_B'0_P""/G_1KOC+_P 2[_;7_P#HBZ/^(=#_ ((^
M?]&N^,O_ !+O]M?_ .B+I?5N$_\ H8<3?^&;)_\ Y\BYLR_Y]9?_ .#\9_\
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M9W0TR?4;>ZN[:QUR]M!-::%JLEOW4OQ9^&T%EH>HS?$'P:MCXDU&YTCP_?\
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M9Z%JWAC0_%\,NL:(UY+<Z9/9^'_$6CW^IPRM*MK;7D4PN&@(N& /8*,_7O\
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MU[?='(Y& 1S0!YA\$_AY_P *D^#_ ,*?A4NIRZTOPS^&O@#X>_VO,$6?5?\
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M%<6GCB'06TG5(]0?7TMM4\+ZKXITV[\W1K7Q>FA-:6EA^A Z=<^_K[T>G/\
M]?@\?U_"@#\])_V5M?\ $OBKXHZ7J$YTKPA%X(^%VC>!]1\4Z5HWB'1?$'Q/
ML_#/AS1/B-\2K'PWX<\667B?3M$G\)?#[X4^#=*34?$7@_Q?IOB;1_B!JV@K
M:Z7=Z3XC\1OU']C#Q/J&G:?/=?%71=0\7V.@VFC0ZWK?@3Q3=V]@L7BSXL^(
M7;1[[2?BOH?Q"MX;+3_BFV@6$M[\0-0U;5;/1;D>,]2\2VWB&\M;3] _)3CK
MP2>O<]?Y"I ,$\D_4].G^?QH ^/_ (E_!CQ%XDO?V;]!CN?$7B:'P9J<VG?$
MKQ]>/X2L[?7? %AH.GW&M>&_%VG)?:;K-Q+\0?&'A_P=JVGQ^"-(FMM,U;PW
M#<ZW=6&F0M!J_$6_[%OE>/D\7S^.M.U+3;R]T?6-9TK4/".MF_M=4\+^*/&/
MB?PT_A.\T[Q]IN@:?8PS>+&EU2U\3^%/%\IUFWU/6M!N=#F\1W-O:_>;1(QW
M'.>.<XZ8QG\0#]0/05(!CN3[$Y% 'P*O[%MX8H='?XD:9%X:-_I_B+49;+X<
MPKX^N/%$7P7NO@E?G3?'5UXINH=(\(SZ,;'Q):>'X_#ESJUOX@BO;&7Q/-X6
MOY= 6GI?[%>K:-H$":=X]\$P^,M^NZ1J.L7OPKUWQ%X5U'PAXA\ Z1\.[Q7\
M*^*OBIK6H1>.K72_#FB7>E>*1XG&BZ7!'JOA>S\(IX<U_5[6Y_0>B@#Y#^(W
M[-5_XYTGP!HEGXOTG3K+PO\ !GQ_\$O$+ZMX,.N7.O\ A_QKI7@!HM6TF2#Q
M#I5KH6I:=XB^&VAS7EI?6&OZ=J?AS5?$.BPP6%[<6>K6O#?$']BRW\:^(M0U
MNV\8Z79Z;X@D\<Z;K_AW5/"6L7FE+X3\<ZYH_B"]M] @\.^._",=GXEAGTF2
MTNK_ ,11>)_"VL6[Z5+J'A![C18VN_O6C'\L8[4 ?*_Q=_9]U;XC>./!GC30
M?&UGX'NM!T_2='U#4H/#&H7_ (OFTK1]?;74M-)UFQ\5Z#H4L=VTD\+:7X_\
M+>/O#&GZ@UMX@TS08=2MI?MGG/@#]C[5?#/B#3/$?C'XCZ3XUNM/\6?#_P 1
MO;_\(%=:?97D?PX\,_$3PUI/^AZQXT\31:?JFHQ^.X]8O)-,^Q>'='U'2##X
M7\-Z-IUQ;6NG?=N!Z>_]*,=,\X&/K[X_SU- 'P%K'[%+2Z9X#A\/>.='TK5/
MA_HWAS2[ 7'@G4X/#NMWFD6WQ&TR\O\ 7;+P?XY\&>(F^TZ?\1)VTLZ5XHTR
MYTS5-*@FN;G5-+OK[2INW\5? 3Q)I7A_]G'P9\-6\))!\(K_ %O=K7C#P?:^
M*O">G1S_  X\3>'+6:\\"GQ=X7UBYT^YU/6Q#I]MX=\50:QHI^Q&YU*_TJ/5
MK;4_L?\ S^72F-&K;2V3MSCD]\9SV/0'GC- 'QMK'['WAN^^%_@SX<6?COQS
M:1^%?#_A/P8=6N]0DUI-0\$:9X17X?\ COPU!X?O9X]*\/6WQ(\&7&I0:I_8
M(LK73?$8T/6UL-0L]%_L._P?B+^R1XB^(7C_ %CQ;<?%*RL=&NIM5?0M!'@F
M_:ZT2VUG1?#^CW>G3W5IXTL_#VHV]A+X:MKC2;VW\):1K<L%]-9Z]JNL1:=8
M%?NC;C;@XVC Z'CC^@Q^)I<>_<GTZYX_#/Z9- 'PIXJ_9#\0>*KGQ2MU\4M-
MMM)N]5\5ZUX)TZU\ 7=I=Z3>^+?C7;_'.\@\9ZO;>.H;KQ9IL7B!;S0%@\.I
MX"OET%[*Z&H#Q!9_VG)U]G^S->:/\+?"_A/0O%'AZP\7^&?B???&*'5+KP7J
MFL> +_QAJNH:W?ZC;ZCX+U7QM>>*+K1;AM<N[E)9OB))XF&O11>(+C7IYI+B
MSF^O:3'&,]L9Z?CQP* /F[X*_ *#X21:U'+KUKXED\2:%;Z=J[P^'+;PW:1Z
ME=>/?BM\1O$S:186=]>_V7X3GUOXJZCHW@_PG]JNI?"'A#0= T2XUOQ#=6TV
MJSY^L_LX6VE6\5Y\*/%$W@K6M)\5:5XU\.:?XFL[SQS\/].UVT@U>ROS/X;_
M +7\/:^UKK=CKFI0Z@-/\8:;.;MK"^60M8Q0M]1?Y_/K10!\DVWP \:Z'X:\
M)6GACXB^'8/&?@7Q?XJ^)NB^*-?\ :IJNCZI\1?BCK'Q'UOXP7>O>%K'Q_I4
MW_")>)KWXCZF?!^@:3K^GZGX(BB2&;7_ !&D< 3@K3]C?4;33_$_@J3XG17?
MPT^*&J:!XT^,&F?\(7+;^.?$/Q*T?P7H'@75=>\$^+(_%KZ#X(\+>)M(\'>#
M&NO"5QX)\17.C3:5K<NC>(HY/$43:%]X[><Y/Y\?3Z4[T]OU'I^>#^% 'Q]'
M^S9XNU?PC\1M'\;?$K1=6\1^,OA[X!^%6D:[X;\!7OAG2-$\$_#K4-?U;1Y]
M0T"^\<>)KK6_%FJZCXJUV;Q!JD&O:/HC62Z'8:1X=TR2PU6^UWM/CK\ [7XX
M#38;[Q'<^'+6U\(?$WPM(]CI5K?Z@W_"P])T;3$OK>YO)A;6PTIM($]U8R6M
MQ%J\$[6;2VN/M%?1O;!YXY]__P!=% 'RE\//V>-9\-_$NR^*_BWQ5X4USQ-Y
M'Q(75--\(_#D^"_"L5UXWTOX(:%IUSX9T[4/%?B_5M#?2M)^"MN^K37NMZUJ
M&O:MXGU"6+4-)T?3[+1ER=<_9@D\0>*_&&O:AXKT*32?$%S\4[_1]*D\">??
M:+J'Q7\">&_!FJ76HZG<^(Y;36)M&E\._;=,FL](T.=M/U&^TB[DD=_M\GV'
M1@?Y]\_XF@#XL^'/[)=OX"^+.G_$B\\66_B.UT35?$?B30+:?0];@\3V7B3Q
MCX8@\*>(([G6IO&=_P"%Y/"ZZ>UV^G:?I?@72O$2'^R(-5\5:E:Z/<#4.-T+
M]DWQ)KUQK>J>,]8\.Z)$OBGQ=-X9T2Q\%:?<Z@^B^(?CY\./C!JTWC+7;+Q;
M<Z;XN76(?A5H&F>'8CH>AW_AN'6-9N=<D\0WDEO#9_H(RAA@YZ@\'!X.>OOT
M/J,CO2*@0;5Z?F>W4GDD]230!\8ZW^R38ZYK7CC6+OQ/I\S>,_&/A/Q.D-YX
M*L[UM*L_#GQF\,?%B\T(RSZLWVVTUN'PVGANZ.+>V*S1:G/8W<=J+&3G_%?[
M'VM:_P")K;4;+XFV&E>%X/C)X'^,S>&4\#7BW,.I^ OC9X,^,EIH.GZEI?C+
M3-)2QUR3PG)X;U/4-?\ "OB:[TV+4Y]6\.0:?-Y]I=?>%!&01ZC% 'PWI/[-
MM[H'Q ^ &GVMO<W?@_X8^&O$6H>-_$<=KX>T[P]XUUW3/$$VM_"W1;KP^FNW
M'B5=7\(^)]:U[QS#=1Z6-$>^2TN[[5KS68K"'3=#QW^R3_PF7Q;UWXBR>-+-
M=,U^2SUI]&U/PWK.J:OH?BC2/!.L^"M(OO#NKVGC;1_#MOI,<.L-J5Y9ZMX-
MU?7#*E]9:5XBTRUU680?:"Q*I!!8X&!DYP.^?7)YYZ')[FI!Q^OY=A^ XH ^
M&Q^R'<Z/=:5J'@[QGX4TB\TKP9X"\"PVFN_"BP\3>&3I'ACP+K/@/7K_ /X1
MO_A)=(MO[>U;3M1M+KP_=S37%CH:V$^CZQI7B;2-3EM8?)_#O[#WB'4M-\5>
M O%WC*ST?P-8:CX1LO#NKZ1X/T:7Q[XJF\)?LG?"CX$V'C*W\1W/B75]/T7P
MS<:GI7BM]:^&OBOPGKC:M-I>GQOJ*>'[JZCU[].RH/TY/XY!!SUR,<?_ %A3
M?+7.>>"" #@#  Q[CY10!\%ZS^QUKWC6[O==\=?$'P;)XCUF;2(=8L/!?PH?
MPO\ #YM$T#3;+3=/TZP\*:CXX\3:BMY?P+JR>(=7UCQ%K,^J:;<Z!H,4-II/
MA2QCN^Q/[/\ XH\'_%'6OBW\/];\)7M]K6K>*EF\#^(O!\T&DPZ%X[N_@<FK
M1Z=K&F>)+)-,U71U^%%_KB7<NEWUKK>H:^$EL+6]@FOK[[&Z5$T8!+$DEG4\
MG@<JN /;DCODGMQ0!\I_&7]GGQ!\6/'.A>(H/B';^'O#FDIX)FNO#LOA6]U&
M_N=2\"^.%\8VEU8ZUI_BW0K'R-<0+I&J0>*/#WBY])%G;:GX2ET&ZO=;CU6?
MX=?L[7_P]^&WCKP%9^._M%YXP\-^"="M/$:>%;51HDW@SX/>!_A5'?-HM]J6
MH6NJI?R>#1KLED\]HT$6I-ID=T)K:/4F^J1SSGH6Z=#R0,_YZTM 'P!X;_8H
METZ#Q;/XD\?:3XDU7QA??$G6+B<^"=2-AH^M?$3X&_"KX+23:5%XD\:^+-=9
M=)@^&(\2&YU/Q#?7VIR>)=0TB.72K&RM#(S7/V,O$GB/Q#<:KJ/Q=LVL(--\
M5Z3H5M%X%U&*\LK'Q=HFF:==1ZEGQU)X=NSIEWHVG2V$VC^&?#M_J=F9Y/%U
M_P"(]92TU6#] 2/P^GTQ_GZ"C'!&3R,=>>F/_K_6@#\^++]E?7_%?AGX@3:E
M/%X*\0ZM\6Y-:^'=GXOTN'Q,? WPT\':CXM_X0KPW;2?#/X@^';K3GN=;\<^
M/_'6AZ[X;\:Z3XITO3_%^E^&O$\FHVVDWVBSTK']A27[=K#>(OB-IOC.TU2'
MQ#JWV[Q1X#U#5-?B\9>)O M[X"U&>ZMIO'K^!M0\$V^EWUU%IV@7'@O_ (2N
M'219>'I_'D]M;/>77Z)+&JYVY&0 ?H.!^..,]<?04X#'O[GK0!\C:5^SQXWT
MOX*^)_AK%\5+-O$6K>)-)\2Z-KDGA?Q'>^&_#]OHVK>'=37PM#IVM_$36?B'
M<:-J<>A3VFH:M_PM*V\9::^MW5]X3\0^'KK3])-GP6E?L30V_@WXE>%-1^)$
MUU/\1/AW/X(&O6'A-;"]T26?XC^/?B/<7UN;OQ!J=Y=Z/=7GC2+1=0T&;5$N
M-3TS26EO-<>]U$W5K][T4 ?#NN_LW>(M)^ GBGP#X>N?#>N>,_&?Q4^''CS5
M[JS\/SP>%UN-'^*GP]UW6;]O#WQ \:^*K[5K/3/#_AJYU#4--UKQK=W^O_99
M=/L+NSN;BSCBY^__ &*&UC7K+7]9\<Z!>MK%S'=_$72;7P-K^DZ%<SP>/+CX
M@)<?#'1['XEI:>#)5U&>* +XV7XGV:7=I9>(8;:+55N'O/O]HU?[P/3'!QZ_
MKR>?>E"@ @=\\G!QGK_^J@#Y)^(WP0UIOV;=;^$7A@V.NZUJFO:?J?VI=*T/
M3K21=2^,&G>-M9O[C2=>NY]"O_[*TVXO;B;3]:N;FS\1-IS6=U;7(U%[%^&O
M?V-)]:B\<:CKWQ!TH>+/'$.EZE<W_AOX<P:-X4T[QAX:^)_AWXFZ!<6W@W4_
M%.O37/@#4+[P?X=TGXA> =1\37=UX^TZ;Q1!=>+-.36[4:5]WLH88/3T_P ]
MO:D08&.P+ #Z,W.>N3QGZ<4 ? ^N?L>^)?%$NJ:SJ_Q(\'VWB3Q3J,/B#Q,=
M&^$[V_A$>(/#OB[X:^.O \>A>&KOQQ=72^$9/$7PLT.+XK>'O$&NZYJ?Q'\/
M:SXITG3/$O@B2^TJ_P!(Z?1/V8?%FD^-8_B&?B#X-E\1^(]2U&[^(]HGP?L'
M\/36-YKWA[7[>+X7Z7J/BJ]F\$ZQ#/X8TR/5=<\477C_ /MG4;K4?$AL+#5$
MTR/3?M/'_P!;VXQ@?K^>.E!'''&!P?3C'^<T ?"?@C]CW4O"1^'-C=?$C3M2
MT3X.V_@[P]\/A:_#Y-*\3ZGX+\&ZM%J5HGQ4\2MXJU$>.?'UY#:65O>>,-+L
M/"6E7FIR:[XBN/")O]<$.F]=\1OV:-5^('Q,\0>-U\=Z9H.A^*-%^']G>:;%
M\/['5O&>C:S\-8_B$V@ZQX;\9:GKLFE6L$][X]%SJFD:SX-URTO+31VTPA;/
M7-623Z_HH _.;_AB+Q=<V6IWE]\5O"UUXPU+5O"VIKK+_#OQH=/T=_#7A?Q)
MX.6X\/2I\:(?'VCWFHZ7KT=W>0P?$$Z([V]QX<NM'O?"5VFDVO3/^Q[KT&J>
M'-7TKXL06>K:;XE\4:SK7B27P1=IXMU"Q\3_ !/N_B7<V5G?Z%XWT#07EN[R
MX?3M4MO%_AOQCX6,LIUS0/#F@ZDDQO/O(CW(^AQWSGZTN/\ /^/\_K0!\L^/
M?V<+7QU\7-4^*%]K]BL.H^"? ?A)?#UWX7AU>.WE\$:3^TWID&K+?SZG%&\M
MT?VC%NH;?^SDDL&\)2I'<S'7UETORT_L::JEW';6WQ&T&'PV/[4U>>"?X:K=
M^++GQ7K?P$N/@/JDH\6GQ>HB\')IPT[Q+I?AC^QGU*SO8+K1'\1W/A\:78Z7
M][X^HZ]..V/T[4N.G?'KR?S]: /BM/V8?&%AI'BGPYH?Q.\-:9H]]-XCUCPK
M=R?";3KSQ;8:_P",=5T[6O$*>+O%D?B:UU#7?#B7-E=:?H%MX43P)XILM#ET
M6RU3Q=K%_P"&;+4KOA9/V(]9/AW^P(_B?HD@GL?% U6]NO 6O2RSZCJ/QNN/
MCOX;73YXOB7'K5KX>L/$-[=^'?%6FW^NZQKWB;PU]GFTWQ7X6UTW5_/^AU)C
MWXYX&/3&/YGZGV% 'P1#^QG=Z?80V.C^-O"6G#7ET.Z^($]Q\,]1UN>XU3PY
M\8-9^,5E-\,[O6OB'>ZEX(@U36?%&OZ7XG?Q)??$+4M2M4\.ZKIVI:/KFD7]
M]J_H7Q2_9RU7XB>,O$VLV7C/1]$\-?$;2/ ^B>/[#4O D'B3QC9V'@/5M0U/
M3)OA5XT.NZ6G@/5-234YX;^[U?0O&4>CZE;6?B7PK;:)KGVRZN_K7'  [8Y]
MN,C\<8I: /ANV_9"G;39;;5?&VB3:D/$WP!U?2M9T;P"=)N=-T?X#_M"2?'"
M/28OM?BG5)X[SQ=9SR^%+^_M+RUL+*>2374T>Y@;^QJR_AG^Q7!X$UCP3J&J
M>+]"\2GP+XE\+W>GNW@K5(;S7O"?@_P5\7/"^CZ1XFG\0>.O%=G)XB>]^*;Z
MY>ZQX?L- \.?:]"-QIG@_3+_ %:XO+7[ME9BY7. I &!@@&,L>?<@?D*P--6
M1)[QC,[B/:-K<[GDD<^8Q))RJY0 8&T@= 0;C!3C.7-;V=G:SU^[MIOHS*=7
MDJ4J?+?VSE%.]E%Q2>O6SO;2[VTLVU\6I^P[H\%])+%\0M2:Q\CQ_''83Z%)
M+%*;_0-:\+_!.RU$2:\UK=Z!\ =!\7>+[?PMI:V-N;N\?P9J-E>:#<>#HDU/
M'OOV(M7N;?6K*T^+%GI&DRKX3U+1M!TKP1KUEHU]XJ\(>-_!WCS3M8\>6:_$
ME[>_LY[[PC/IFI6OPVA^%6JW]AX@U34[O6I?$UOI6K67W)"DI\0.AN'P"9#V
M#1[!B$KG;L]2 &/J*CU59?[3L&6=U$ODX49Q&=X#8^;#!P"&#*<AB,XK54G*
MI%*JUS48S4N6]O=O[-QV<=US77==#F>)4:4Y>Q;<<3[/EYTE)N7*JFS2;W<>
MBMW:/._A3\'[3X9>!+/PBFH6EQ=MK&N>(M6N]*T[4=/TFYU?Q)?M?ZF^G:?K
M.N>)M7@@+D,LFK>(]:U">Y:YO+F^W7'DP^M7NG075FEJ)'3RPC1NRARK)E09
M%8@2*5.2"0P !0[@<8_B;S&CMW65T0S/ 8E)"DMN"REE*MN0J" , X[5-K\4
MBZ,Q,\A,/V8RG[K7"CAU=E(*AR0QQD#!&"":N-.HE@K5^7GK2C!*G_#;O>5[
M]7;;FMNE=MK"O4I<V8\V$C4=/#0E5YJB_P!H6B5*3MI%)\R=DKW7F[R:5$--
M?3?,E,;1N)'^19"78.2FWY0-R@%/E7'&>3AFF:3'IT$L!G>=IWS)(%$2X\OR
MQY:AGV8^Z%5BQ(SN4G)HP0S/X>:/[5('DLII!,1N9 5,JQC+;BBI&8LE]Q5V
M8,K!<0>%4=K"1FF=@\S>6I+-Y)5'#E"S-_K&P^, *0,9ZT2C55+%KZPG&.+C
MSP]FDISNKU;V;;O9ZV;LM!*I25?!IX;WJF JSA5=2[I4TDO86W:J)^\]4K*[
M>M[>DZ%%IDUS,+AYGE&V,&(*HB+B0*RAL/*6WC>Y * 91<9J*W\.P0:Q+JB7
M$K RR3+!M;<LEQD/NEW[I(R2-D;H@0 @EU"M65X5CF%SJK274LJQRR0,CDD2
M2(X<3L69PK?,R!45?E(!8XJ"T2=?&%\K74KA!+.^20)(C'MCM]N[8JQ; 0^U
MBV3P&^:MY0KNIBW]97,L-%RG[/6I'W?<:>MK.U[KK\N2$L,Z&7)8&T99A*%.
M'MUS8:HV^;$*I;]ZWHG3TTNNFOH)+Y.&CQGCY!T[?P'^9^M%0EI%)&Y3@D9*
<#)QQD^YHKRO;/^6+\^5?_)'T&OE_X!#_ "/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Z U(# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@_Q$YVG(Z%N1][IQC:<=J1IPHX )49R2HSDE1Z 9!QR#R ,$D&OE+XJ?M9>
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M&0!R,<YZ5&6Z*7<*P+$,6W'YL</E2H4C:RCC&<@G)KXX\8>*/V]+3Q5XBM_
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M73VGGKO%JTWV<2(DGD[U#'Y)_P""@P5/V%OVO5W$_P#&.?Q:<DYZ/X,U8?,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_#K2?AW!IWAK0+G25BOOL=LOB:_T?4K36@^HI<:21.L2I&7_ &KC +# .1D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "JLV\KPH.45L$D#*G+#C/9AC(/..O2
MK6>GOP/R)_D#43@%", ;<!2QPO\ "<_0'MSG'KQ2>VEF]+7U5[Z7VZ_UT#?J
MUYIV?WK7_ARD3SS*5/=0&(4]U!!P0.@QQ12D*Q)R!GG'EL<9YZ\9^N!GKBBB
MZ_O?^ __ &QE>MTH4[>B_P#D#1HHHIFH4444 %%%% !3-@&?[N/NX''X@;CW
MX]\4[(Y]OQ/3.,#G..<=::[ +RVTG@$X]0-W7&.02>V1W(% "A5'('. ,]SC
M'7\A7Y\?\%0OBQ\+_AA^P_\ M(V?Q+^)7P_^'<GCWX+_ !4\&>!H_'7C+P_X
M1F\9^,KSP%KM]:^%/"RZ]?V#Z_XBN;*TO+N#1-&2_P!2EM;6>X%N(H':OT#\
MQ"P(<G).!@[>!C'3U(QW)X%?$?\ P4@\.^'M=_8=_:IGU[0-"UZ31/@)\6M7
MT9M;T?3=8_LG58O NL6T6J:8-1M;D6&HQ6]Q<0Q7MKY5RD<SA90&X /H_P"!
MBLGP3^#JNI5T^%GP^5E((*LOA+2%92" 00<@@@$'J :]3KRSX&$GX)_!TDDY
M^%GP].6)+$GPEI!)8DDDGN222<DFO4Z "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 09QSGOUZ]>,_A1[<]^?K_ (=N*6B@"-V8,H 7;_$QZ@'^
MZ!SG@\].F1SD5;B81DY;&%!'?(WJ&QZ\#/;U]:LR, 0""20<8!//;)' '7D\
M<^U9=ZK;R0C$",98 ' \U"6VD#. "?FP,=^,@23OLM[MO1JTG?2[O?HK77I=
MQ-M+1-W:6W]ZGMIO[S6KMKKI<^ /B]^T=IWPP_:X^$OA?Q-\4]'\'_#L? 7]
MH#XC?$'2=6N[/3]*BM/!U_X$CTGQ7K%W=(OV.ST5+O6(A<?:8(8Q-.)U;,>W
M[*^'OQ*\&?%#PEH/COX>^)=%\8^#_$^GG4M \1>'[R/4-(U>P:6>U%WI][$P
MCGB-S;3PLRD@2QR1AV:-@O\ *+_P4,_9,_;RO/CAXONK[XO?$'XWV]S^QW^T
M?=V^L^%_V>"EB/"$VM:?<W'[/J-X8M]3MK[Q%XVLWMUTF_GDC\1ZJ-+FFT_3
MY9%E0_1G[(_@/]N#]FC]AKX&?&35OVC_ !#X9\):5/\ "[1M*_9F\4_ G0O#
MVH>'=,\9_''3O"FL>'_$^L^(X8?%JRS:5K.I:G;BXL--U&R-]!<Q-("%/YU@
M>+<T?$F<Y9B^&<UI9=AXYGCXYA)X22H+"5,JPM.G[66+>#E0J4ZE2I*&'JSQ
M$*]:+A1>'6*G3_LWB;Z.G *\%/#3CC(/'/@'-.-,WJ\(<+_ZKX7#Y_"CFM?.
M\M\0<_J5I4:>0KB.AG/UW X#*J6,SW X/)Z&6X>JLTQM''O(\-BOZ<?-."2P
M'+=0QR!G)X.-HQE2>Q#8YP98F+*I;J1TP1@\G)!/L>F>O7%9Z'+, H55)3"L
MH *D*5P2N"/F&<!<#<".M7XB JX^[R0P!.2"P*G.6&#D#/)(P/2OT+F]YKE:
M=VFFV_A<8NS24;7ET;<K)_"?QE!\RO=M-NUX\MDI3M?NVHJTD[6=E=.ZGHHZ
M]**LL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *@FQY8+Y'0,.V6QP2.P('0\]L]#/5>=OD8$$=\GI@$\@@@9/ VDCKD\<U,[
MM-)VOHK)-WOIOITV=D[[K<3V?IW:_%*37R3?9,ARYY"*0>02HR0>A/SCK]!1
M4/F(."4!'4&4@@]P0&P"#P0. >E%3>I_*O\ PGG_ )O\S#VM'^>7W?\  -2B
MBBM#H"BBB@ HHHH :^,'/ PQ)ZD #!( YSSV^G>OP%_X*K_'W]KKPI\;=)^'
M/[*5_P#%O6Q\-/V3OB#^T3\1_#OP3\0?"'P1?_#2^B\<V>B_#GXN?&?5_C2T
M=G\4/A$]AX7^)5I+\$OA3YOQ+UNY\-:Q>O$+>?0$N/W[90P(P,E2O(!X/4'/
M4' R.AQS7RI^T!^Q3^S/^U'JWA+7_CM\*],\<ZSX*M-0TK1M536_%7AK4;CP
MWK%U9WNL>"O$ESX1UO0I?&7@'5KVPM+S4_ ?BQM9\)7]S;)/=:1([2LX!^/O
MP]_:@^/?B^?X(_MGZ/\ M/:UXY\%_%7_ (*(> _V18O@%I>AZ+I/P9U[X)^.
M+A?AS;^)M%T'4-(@^(.D>/()+J+]H.#5=2U9-3M= M7\/:QHZ:-'=3+]-?\
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M1EJXQY(\OO6;3)0,?Y]L?ATI:**?9?UIZ:+^K&H4444P"BBB@ HHHH ****
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M^(M:5+ZZ_33]BGPO\8;OX-?#?XC_ +67@WPM'^UG/HGC3PKXG\<-X2\#Z/\
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M@+SDXY!/OCO@^F< @9J(2,S@,2.W.X#D >G'U)]/6OFSXQ_%/XK>"->T73?
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MH'(!]:*T.7?4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ J.7=L8J<8!]N<C'."<=<XZU)5:Y*[
M1]TMD#YC@8+# )'(YP1TR0<5,MMTNK;2:23O=W:5O5B>SOV?6WXNR_%$0EP
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MU/4#\<TCLJJI)'U/< @=_<CCGC(Q@U\R_P##8G[)^"Y_:7^ >Q=I+'XL>!P
M?X?^8RP(R!G&.F-RYR?1O%_QJ^#_ ('\/^'O$_C/XI_#WPEX:\5);/X9U[Q+
MXOT'1M$\1+<6JW]NVB:GJ-];V>II=6+I>1-933+):,LZEH6W4+$8:2DX8K#S
MC&SJ2C7HR5.+M:4Y1KRC!.^DI2BGHDV[()Y+G=*=&C6R7.:%7$RE3PU*KE&:
M4JN*J0A[2=/#4ZF6TJF(J0IKVDH4*5:<8?O)1C#WUZ?O )RV=S\ #@<D!6Z]
M2P!88(P2,8J)YV#$!NFUB=O)YR$4MN]>>-P##!)Z_,LO[9'[)R1R2M^TQ\!D
M2-9'ED?XL>!F\I41G+DC6"2D<8>1S&I**'+LH4X^3=!_X*F_L[ZM^U1XW^!=
MY\0_A%IGP[\*_"KPKX_T;XSS?%?PNOAS7_$/B#6)]-U'P3:"1Q9/?Z':QIJ,
M\UMJLDI@E5&MAE6?DQ><91@I8>GB<RP=&>+KPPN'YL3AFI5JD,1.,7_M-XP<
M,+6O5DHTZ<E!SJ1<H*7T.2^''B#Q%1SC$9-P7Q-CJ/#N3U\_SF5/(LYA]7RO
M"XG+<+6J4^;)6\5B%5S; \F PRJX[$4JF(JT,-4I8/%U</\ J6LC,"I<@@D$
M@*=Q7@G_ %:J,\DE4&23P0!5S*@@%CGEL'J 3D_3!],'! %?-^E_M8?LPZSJ
M.FZ3I'[17P/U+5=7O;;3],TVP^)W@R[O=2U&[E6&VM+"T@U9Y[F\NIF"06T<
M;S22,$1=V .L\=_'[X'?#36(="^(OQA^&/@+7+FP&IP:/XQ\<>&_#NISZ>\\
ML"7\5CJ^H6EQ):/-'+#'<*C0M+"T0?>CJ.F.)PS@ZL<10]FE%RD\30E"#<;+
MGJJMR+G2NHRE'52Y5*S9\\\DSN%>&$J9-F\<75A5J4L/+*,TIXBM1H5%&M6I
M86>7K$5*=&4XPK5:="I3IN<%4J4W.$'[*&4E2&![9QU(XZGGKQW_ %H9AG&_
M!&,CZYZ\CT_PKY_\,?M0?LW^,=>TKPSX2^/?P;\3^(]9G%MH_A_0/B/X1U;6
M-5N?+>;[-INFV.J3WUY<E(I9!!;Q._EQ.^PA6Q<\9?M(_L^^ ?$5[X5\=?&_
MX2^#/$^G6UI<ZAX=\5?$'PKH6N65MJ%NMW937.EZGJ=M>V\5[;2QW5H\L*I/
M#(DL9:)U)KZSAE#VGUG#>SNH^T^L4'3<I?#'VGMN3F=](\_,UM%JP/)L[5=8
M1Y)G*QCI.NL&\HS/ZV\/&:IO$+"O+EB7AU5<:;Q"P_L54E&FZJG*,'[H&4L?
MFYP/EX_Q^O7UXH+)R">1GKC..Y'MGU/MTXKP_P $?M%? /XB^((O#'@'XU_"
MCQMXDFM);Z#0/"GCWPOK^LSV=JGFW%U%I^EZE=7LMO;Q,LDTJ1-'#'EI"J<U
ME>(?VI/V:O"VO:OX<\2_M ?!?0/$6AW<VG:WH6M?$GP?IVL:1?6YVW-AJ>GW
M>JPW5C>P,2ES:74<4T3Y5HT(I/$851C-XG#^S<G!5/K%!4W46]-3]NH.2^U!
M2<E]J"'')L[==X3^Q<Y^N1HK$3P:RC-'BXX><N2&(EA?[-^LQH3FN6%9X=49
MS3A&M*2Y3Z%5ES]X$=!TZY ('.1R0,8 %-)0#!()]AT& >>1G\>>:\@\ ?'G
MX*?$_4;[2?AO\7?AGX_U73+%-3U#3/!OC3P[XEO['3VF%N-0N[/1K^[N+:T:
M>1(!<S1K"9W6(-YCA3QM]^UI^RWIU]>:=J'[1OP-L;^QNKBRO;&[^*/@J&ZM
M+JVE:*ZMKN";5UF@N8)8VBGAD5)(Y%*LJLI%-XG#*,9O$X90DY*,WB,.H3<-
M)J$W74)2A]I1E)QL^;EL*.39W.M5PL,DSFIBJ$*=2OA891FDL3AZ=6[HU*^&
MCEDL11IU5&;I5*U"E"JHR=.=11E;Z/)8@_,I(')P/EY .,@@G!;.1CD=A@56
MD(8GS'#':#C:&SDGYCL.%8 C*H.0H#*<&O*/"7QV^#OQ T[Q%J7P]^*7P\\=
M6?A6WCN_$EWX0\8:%XAM] MIEN)8+G6I-'OKI=,@N(;#4)('O&B\U+&\>,R+
M!,4^#= _X*E_L]:S^U=XO^ 4_P 0/A'8> -#^$/A7Q]H_P 9)/BKX:?0/$7B
MW7O$3Z)<?#RTC,GV*35M-ME.I.T.I3S^4P62TRV3QXS-<LP#PGUS'X7#+'8F
MGA<%.>(H\F(Q$X59J-_;1C[*,:4U4K.2I4YRHPG4A.K3A/W<A\/^.N*7Q%'A
M_A3/LSJ<)9'B>).(Z5#*\RC6RK*<+4P%&I5JTGE52K+%SEF6&JX7+8TEF.-P
MT<3BL)A,1A<!C:V'_5*-LCY]W<*V ,#:.FU%ZYSR.H'H,3K]U?H,=N.V1ZXQ
MGWJE:SQL"P*X/IC!;Y1@8 R3D=.#D8 !%7@01D=.?T./Z5Z-_>DK-)6LWU[_
M *->31\C%IQ5GS;J^BU3DFM.S3C?JXMV5[):***904444 %%%% !_6H)B=HV
MGW!&/O @#DA@.I/0DD8Z9J>J]R5$1!P!D<8)[\#"\\GCCU]:3O;2]]+62;O=
M:V;2=M[-KU0?>_):M^25U=O9*Z]5N43,,G*N#GD;EX/?^"B@)!@;F&[ SQ#U
M[]4SU]>?6BMO84'K[*.O_7S_ #.5UK-JV$T;6M7$)[O=<SL^ZN[.ZN]WK=*C
M?<=@5@N6!R<YX!( '0Y[Y(XR!R01)33C'S8. <D]>,9.,?GC&./PR.H_F4_X
M*K?"?]EC]G/QQ\*_%]Q\*O\ @DYX_P##FE?#[6="\(_L8_M+?L]W4_QP\57&
MH?$/QE\2?$NH_LY^/?A/X:^)OCNR;QEXO\9ZY?7W@_4?@1XL\*77C"_UCQ$=
M:T[4=8UF<?L3_P $Z]2\*ZS^QU\$=9\%_LA:Q^P;X9U;3?&.HV/[)FO^%M"\
M%:K\);B]^(OBZXU9)?#WANUT_2;.V\;ZT]_\2-/N(M/T^ZU73_&%KJVIZ=8Z
MG?75G!^57_!0KX[>./V._P#@H5=?&3X;?'3_ ()F^$/$'Q3_ &8/AMX4U'PM
M^W9XK^.F@_$KPO:_#WQ]\4[BQUSX07OPA^''B>TT7P/XL7QMJ%MXT@U34Y[[
M6]>\.Z-)!#IEMILIU']</V#?CMXG_:7_ &6?A7\;O&7C;]G+XB^(_&\WQ :]
M\9_LE>)/&_BW]GW6;?PW\3O&O@_26\ ^(?B+H^@>,-3DL=&\/6&E^,)=5TFU
M@A\<V7B>VTG[1H\6G7<X!]D]:*** $(R&!QR"!]"._3OGH>G>OSS_:N_85US
M]H3QW/\ $KX;?M >(?V>_&/B[X*ZS^S/\8;_ $CX<_#_ .)UK\2_@'K>N:AK
M\GA>.Q\>6,R>$?%FBZAK?B9_#?C#39+VTM(_$^KQ:YX7\1B+2#I?Z&T@ '0=
M?\2?YDG\: /R6^'_ /P2JT;X:^.OAKI/AW]H'X@-^R+\)?C+X<_:*\"_LF7_
M (5\(7%GIWQH\)>&H](\-ZI??&(0IX[U'X?Z+XGB3XK6?@&6".63XE0VM_>>
M)[KPW$WA:3U3_@HO\$_@[J_[(7[7?C[7/A)\+M7\<I^S]\3[Q/&FJ?#_ ,):
MCXJCNM-\%ZG_ &;<+X@OM)GU4W%@8D-E<-=^9:F.+R"GEH!^BI ((/>OSA_X
M*L_&#2?A5^Q%\?K/5_!?Q9\7CXA_"?XH^"K"3X5_"[Q?\2X_#=Y=_#WQ'?)K
MOCN7PKI][%X*\'0K9_9[KQ9X@DL=%MKVZM+2:[269-P!]F? PEO@E\'68EF;
MX6?#XLS'<S$^$M()+-@9)/).!D\XKU.O+?@:I3X*?!]"48I\+?A\A,;!T)7P
MEI )1U^5T/577A@01P:]2H 0YP=I /8GG%+1_G_/YU7>5@Q!"JH*\DG<>0>,
M+C[O4=O6ID]'NM>EME9O5V27?=K7Y%[6\]%Y_AY>7J2LQ!V@#D8[]3C&>F .
M2><GC'-*'!/T[]LXR1^ []#SCI6'-KFF03-#/J>FP31X62*:^MHIXG ! EC>
M=64E2K88!B'484@,4_X2#1L?\A?1ST.3JED#T!S_ *[COG(Z]^:E\UMIWUUA
M"I):]5>DE9]TY)[\QDZD4VN:.FZYHZ>MJET^EFD[K5&]N'J/SHR/4?F*P?[?
MT7_H,:1_X-+'^LP/Y@&C^WM%_P"@QI'_ (-+'_X_2]_^2K]U3_Y63[>'\T?O
M7_RPWLCU'YBC(]1^8K!_M[1?^@QI'_@TL?\ X_1_;^B_]!C2/_!I9?TF/^?3
MK1[_ /)5^ZI_\K'[>'\T?O7_ ,L-[(]1^8HR/4?F*P/[?T7_ *#&D?CJEE_2
M4_KCZT?\)!H@_P"8OHY_[BEI_P#'1S_G-*\^D:J?G&H_P=*W]=P]M#^:/WQ_
M^6,WRP&,GKTIAD&<8...<'_#M6'_ ,)!HI^[J^D#OD:I9@X[]9B#].?7M2_V
M]H_&-9TK!R>=5L1QU)_UOU_STTBY/_EW4]>22U_\ 5BO:PZRC_X$O_EAO9'J
M.>>>*-P]1^=8)U[1?^@QH^>,XU2R]@<_O1@]^@!)QGGA/[?T7_H+Z1_X-++\
M/^6N.>?;C&>14MSO\%1+I[LU^*@[D^VA_-'SU7_RQ&_D>H_,49'J/S%8/]OZ
M+G_D,:1_X-++_P".X_44?V]HO_08TC_P:6/_ ,?I7G_)5^ZI_P#*P]O#^:/W
MK_Y8;V1ZC\Q1D>H_,5@_V]HO_08TC_P:6/\ \?H_M[1?^@QI'_@TL?\ X_1[
M_P#)5^ZI_P#*Q>WA_-'[U_\ +#>R/4?F*0M@]01C(ZYSS[$8/Z8[YXP_[?T4
M#_D+Z.>?^@I99_#$_/TI#X@T7MK&C+TSC5+/D$'C)G]<< 'ZGH2//S:QJ+2V
ML9NVM[ZTWKHUMMW*]M!_:C\Y17_N0V]Y)&,#D YR2<G''0#\:<6'&,'UY''^
M-8 \0Z1G_D+Z0!DYSJEB.01V^T/SU/)/( )!IW_"0:)R/[6TG /&=3LNX'/$
MY(SQU_"M+R5KPEJK_#/]*0O:QUM./SE#3T_>+\>EC>W+ZC\Z RGH:P?[>T7M
MK&C_ (ZK9#'7TF/M^?M2C7]%'_,8T8_]Q6R/Y?O!_,5F^>]U&JEY0G;_ --+
M\0]M#^:'RE'_ .6F[N &<\=/7^5-+@8QSGZ_SQ6)_;^B_P#06T?M_P Q6SZG
M_MO^6,YIO]OZ..NM:2 !_P!!6Q)_,RBKBYM:TZCMUY7K\N6_Z#]M"_Q1^]?_
M "S^D;P8$9Z=N>.?QQ2Y'J/S%8)U_1L'.L:0<=_[5LB?TE_IZTG]OZ-WU?2,
M'./^)I9GI_VT]?KZU,G._P $TNW+*]_50>GZ>6H>VATE'_P*/_RS<W\CU'YB
MC(]1^8K _M_13_S&-)_\&=E_\>_+U/'ID_M_1?\ H+Z1^.J60'3U,O7KQZ#-
M*\_Y*OW5/_E0O;0_FC]Z_P#EAOY'J/S%&1ZC\Q6!_;^C?]!?2.^?^)K98_\
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M7/$4?BC6_AWX%UGQ'%/97">(=3\*Z!?:U'<63*;*==3NM.GOEFLF13:.+G?
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M37PL,DIE?>?A_P"$,ON9BY=O[")WN26+-NR3R0>3[3Y&<9(!R#QDCCC'.,
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M'@OPW\$S\)/#RZ+X5\9:!KDVIZIX]LH'MFT*"]URQ:'3FCLM+@N;81><MP2
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MCX;\/:KXN^+-WJ.@Z5?W;_%KQ1$UW?6<=Q.T<6@^$1'$9) S".,MA$7Y0"V
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M/U6P:;[#JVG6.K6)N(C#=?9-3LX+ZU2Y@<!X;E()D2Y@;!BD50 #(0UI=S'
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M** "BBB@ HHHI));)+?\=7][ 3 XXZ=/:EHHI@%(!C/.<DGH!CVXZ_4\TM%
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M+N/CO?Z=XG\8V5A\8-3^"&O_  \U+XA>%[;7)%\&^*+S5/"3:7X=.AMX?TL
M_1X?YQSSWHH'3ICU'OWHH ,=?7&,_GC^=<#XM^&7P^\?S^';CQUX$\$^-;CP
MAK$7B'PE/XO\*:%XGN/"WB& (8-=\/S:UI]\^B:S$L<8CU/3'MKR,(FR?*K7
M?4?UZT <,OPV\ )XXE^)R^!?!@^),NCCPW+\04\+:&GCJ;PZLD<BZ%-XO^P#
MQ!)HXEB23^S&U V.Y5<0%T0U\V_\%!!L_85_:]&2@_X9U^+;$'.03X+U4J5P
M"% Y#(N=I*G@$9^RZ_-G_@JYX9^,/B+]B?X\2?"7XKZ%\+;?0_A9\3]9^(\&
MN_#73_B,?B!X!@^'GB&WU#P;I37NNZ./"&H7=]<65U%XGB34+FV^RO!'8,LQ
MN(0#[2^!7'P1^#G_ &2OX>_^HCI'L/Y#Z5ZI7EOP.9&^"GP?9$:)'^%WP_9(
MV;>T:GPEI!5&<9#%%PI;HQ&1U%>I4 -;.5^O/\_TQ567YQ*HZX(P,=-Z<GZ;
M6);[H'7%67 (P<C)&"#C'(']>G?I59NCGIC<><CY>6P?0'^\?4CIS6<UHVUH
M_=3TT34[N_R=^NVM@6COYPMZ\T;?J?$5A_R,_P 5..GQA\6GJ <?V%X1!/./
ME7(Z%B><# )K;)( .WHQ'!Y. 1G!]2<]PK<DU<\,_#74?%'B+XM7T'C74-$A
M_P"%O>)1'90:/HU[$LCZ'X4#L);J&28Y"98.^ 2<A>#79'X&ZOR?^%EZKD8_
MYEOPV"<CD<P9!.!Z 8&,$''UM/'X"E3I0J5^6<:5%37LJ\K-4<.K+DA):6LV
MVFVKI<KBW^<U<ES*M5KUJ>&YXSQ6-G%NK0A>$L9B7'2I4B]8M-:-='9WMP8D
M']UO_'>__ J/,']UO_'?_BJ[W_A1FK=_B9J>>_\ Q3GAOK_WY'\A]*/^%&:J
M.?\ A9FI\<_\BYX;_P#C-/\ M/+O^@K_ ,M\3_\ *@>1YI_T!1_\*<-_\N."
M\P?W6_\ '?\ XJD,F0<*W3V[>F">G7..,5WW_"C=6_Z*9JGJ?^*<\.<#.2<^
M0<>^<>IQ@4G_  H[5A@_\+-U7)/_ $+GAT@D\C/[CG'3GH,BC^T\OMIB;^E#
M$Z]=/W6[7H+^Q,T_Z DM_P#F)PO3I_&W?S[WT. R3N(W8')&/8+UW$8(]R<Y
MR.<'YT_:V_9H\&?MC?L[_$S]F?XB:UXG\.^#/BEINFZ;KFM>#9K&#Q)8IIFL
MV>LH^DRZG:7MBLDUQ90K.T]G,&B=T*IMB"?9?_"C]6R0?B7JJY.?^1;\.'T[
MB#('0<@'MCM2?\*-U<$D?$S5>V/^*;\.8 X./^/< ''3U&/2KIYO@Z-2E6IX
MQPJ4*L*]"<:&(YJ=>DVZ=2*="4>>FVY0<H346W[K:N)Y'FDE)?5/BBXZ8C![
M2Y=5^\DT_=T>MM;=$?"/QM_9!^'WQZ\9?LP>-?%7B+QCI6H_LI:]XE\0^ K?
M0+C2X+77;OQ3\.&^&=[%XJ%W974LT%OH\CWUHNFR6DB:@2[.8V>&O#_"7_!,
M3X*>#O@[^Q9\%--\;_%"?PW^PQ\=M6^/WPPU.\N] ;6_$WBS5]>\4^(9]*\;
M/'I(MKGP['>>+=1@ABTJWTZ\^S0VP>9F\PM^KY^!VK'_ )J9JN!C'_%-^'3P
MN3_SP&3G=CC/)[]3_A1VK'K\2]4))+'/AOP[U!"C_EW&<$D8/0DC'IUT^)E0
MI0HT,SG2I4]84J>'Q$8IJ6/DYI>PE[S>9YBW/OC*UHI33IG]A9I>[PB=N]?!
M:?!JO?ZJG35GJK76K9^4GC'_ ()@?L]^/;S]K#5/$>N_$U];_:O^.WPQ_:5N
MO$.CZ[I^C>(_@M\8_@]I>K:3X$\6_!O5[33#/I-UIL6M:@URNM#54O;>ZOM-
MG+:?=SPGZ?\ @)\#]:^"=CX[_P"$B_:!^/W[0WB'XA^*X/%FM>)/CMXPM?$!
MT>>QTN'1;'2O ?AK2--T?PSX&T-=*M;1-2M-#L8_[:O;.UOKYC<0C?\ 7O\
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M%?\ RHW>1YGK;!K3K]9PJZM;>UZ=4]MF<"DCI(CHS1NDBRQR)GS(YD97C=6
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M?P]Z=,?\(CI&,?I^%>J5Y;\#7,GP4^#[L%!?X6_#YR% 506\)Z22%4 !5!/
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M]A',VHP7T\FGQP?IE_P2K^!O[:OP%^$7Q*\,?M@?$G7_ !?9:C\4;[4OV?\
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MUTXAVJTG96^IX/96;?U>&EM'Z(QPWP5-;_[3BO\ T]V_KU=R6BBBH.@****
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M>Y4C9W[1O?:5E9<5*E)T_=KUH^]5=HQHVUK5GKSTYR=DU%--744VN:[?F/\
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MF.G.[/4US<].^F&H[_SXC_Y??\#I]E/_ *"J]_3#_P#RD\O_ .$P^(G_ $3
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M4]0#<J1M.74\ CG*\G PW)SU&3D \''\W*_ G]GWX ?\%T/@K\-? 'P_\#^
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M#_;3^%[/X>>)+*SFO?$7AE]$;3M0U_6?$WB*X4ZQXCU:[NO3/&GC+P7\)/\
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MM$VGZ> A;3[/+Y(C:VMU;C!.T; QV[EW[<H#V'"KI.1N!P?E()&,D@$G:O\
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M<W/-<+S1C3IU:LG7CA=80HPES5UAZE5.<9.4:4W2=TE=5$XJ>O+_ %XI8V#
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M+1A<646I:%KPM+F6_P#UP:%RQ(D<+D\%Y.C88\!QD*P&PC:RY*[C'E'^/?\
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M/'+VCG?_ %PX(:4U4Y^9OZW>_M'S\W_/SWGJKGW3H'_!*/\ 9*\-_!7]G7X
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MDEO9P_J0+N,<[\GG'SQ8!QG)P 3R>.>HY&VOYVS_ ,$E/VK%$;#X_P#A ;6
M8MXG^*064<C&"Y (('W2O&,]!EQ_X)*_M7G'_%__  CSD#_BJ/BJ1M_!E XY
MP> >1SS6%7PS\.:ZA[;Z1?!];DE4<(SX:XNDZ;J5.:HTY8&]ZU1>V<Y.I-\U
MN=)*$:I^//CI3O['Z'GB!3YT_:<O&7 \7)QG.,92Y<7%-NFHM64$E:*3MSS_
M *(S>+_ST;IV>''\A[]A2?;%_P">C?\ ?<-?SN?\.E/VL.?^+_\ @\_]S/\
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M*_%M[XDU+P9X.\?:%J%U'K&NZAH]]?:=_8JQW=O#K-S)-Y*I,P@,L2RIN<C
M)%?TB0%@@!)Y;)ZX.,KD=?NHH. 0,@GO@_&>)W __$/N(\)D4,ZP_$%+$\-Y
M#GF&S/"X.O@Z&(P6:82M/!\E+%SEB%:C0A5_><C4<3",H1G&:C^I> WBS+QB
MX.Q_$M;A;'<'XK <8\4<+XS(\;F>%S6OAL;D.,PV'QLJF)PM&C1B_K>)K4)0
MI\]/FPDY4ZDJ;IRGJ+TY&#DY'XGG\>M+4<62@R<G)!Z<8)P. .!^/UJ2OSY[
MG[:G=)VM=)V[72=OQ"BBB@84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 '^?\_7_]55Y5.PDD]>H/.>%!
MZ  \#)Z EL=05L>GM_@1S^?YU#(=JD@D[<9R3C!(ZX!ZYZ@$@=N*B;2A)MQ2
M46VYWY+6UYK:\O=K5;K8/ZTW*@+X&%7&!CYD_J ?S HHV \^>ZYYV^9]W/;K
MVZ452<;+T6TW;9;:[=O*Q%E_+A__  '$?I-K\31HHHIEA1110 4444 '^?\
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MHJS5Z,US1<FX7ZQ?NRT0_:032]K%)RC=<U-*T;MIW=_>;2^5M-&OY?/V.O\
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M#WC"U^ =K%I6O^&H?#^@^!O#]KXEGO?"S6QTK^G'S4))''.>@&.<C.'SUQT
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M$8Y].N+?_!2K]D;]F+Q=^S!^UW\9O%WP"^%?B'XK1? /XB:G'\0-6\):5?\
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MLJ<Z.(E'VN)Q$ZD[U9)R]Y6;DE_.M_P\-_X*(8R?@;;X]_@%\5.__;_BD/\
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M:]_YU&_X*'?\%#@<I\#[7;D[2/@#\4Q@DG. VH8 _0Y.,+BE/_!0W_@H@/\
MFAUK\S'>!\ ?BJ 6&.3NU'DX^\1T89&0:_HJ\G(_UTG3&?/D!^O#=?>D\CI^
M^EX_Z;R<_7YO\]JG_B+_  +T^CKX6Z:V_M#BA*^KT7UNRU=[ZV:C;X8M"^CA
MXL=?IA>-][6_Y%G!FMGS)O\ V+?FZJS=ULD?SK'_ (*&_P#!1$ 8^!UI@YW8
M^ /Q3X]"O_$P_B. ,@8QTP>0?\%#/^"B&/F^!UJB]R?@%\42?X2.!J)S][@\
M#.<@\5_15Y/_ $VD_P"_\G_Q5 AQ_P MI#]9Y#_6C_B+W MGR_1V\+HMWU68
M<3Z7OI%/%M1BKOEBO=5V[-N3DG]&_P 6'>_TPO&^[3U66\&IZMMVM@K)ZZ-;
M626R/YU?^'AW_!1 X;_A1UJS XP/@%\4@A'#9).H#&,\8SSG.1R4_P"'AW_!
M1#_HAUKSW_X4#\4L$CD@ :AD8//)R"2#SU_HK\G_ *;2?]_Y/;K\WM_.CR>O
M[V3GG_7R_P#Q7'T'%"\7^!5M]';PM6EO]_XHTUT24<9'X5I'LKK7<?\ Q+AX
ML:_\=A>-VKO_ ,BO@OLE_P! 2LK13LDE=R>\FS^=8?\ !0S_ (*(?]$-MC]/
M@%\5.O/_ $_^_P#/UI?^'AG_  41_P"B&V__ (8+XJ?_ "?7]%'D_P#363_O
M_+_\51Y/_363_O\ R_\ Q55_Q&#@3K]';PN_\+^*/_FW^OR7_$M_BS_TF%XW
M?^&S@W_YC/YU6_X*%_\ !1$]?@;;8P<C_A0/Q3Y'<9-_P.!Z?7T3_AX7_P %
M#7RLGP-L@I5B0WP!^*A5N"?+8+J09D."#M*L <JP8BOZ*_)'_/:7Z">3^KC^
M='DC/^NF '.?.<<COD/G'MG_ (#P2)EXP<"<KB_H[>%Z4DXW6-XIEHU)27+]
M=M*ZD_=>CO9OH"^CCXLIJWTPO&Y-6DG_ &7P8[.+4HOWL$TTG%:-:[;+7^=/
M_@G]9_&3Q+^W)XK^+GQ*^''BOPS>^-O!_CS5=6OKGP+XH\,>'(M9U%M'*6MK
M-K-FD4'G_9R(+>6[EN'*N0\G%?T5PCY!M;(W$YXZ$'CJ2/?'3EL>L)MU#%C)
M)ZLKRNW3G=M9^/EY *D ]>>*N6X4)G@'>Q894X. > I/\*\*=IVMDJ.!7P?B
M/QY5\1N(L-GM7)<OX>AAN'\HX?PV595B<7B<%A\)DL,11PLJ=3'VQ$9>PQ$*
M3HQC.%&.'HVJRUO^N^"/A%1\&.$L9PO3XGS?B^IF'%7$'%>-SO.\%E^!S#$Y
MAQ%6PN*QRJTLLG+"S3Q.'JXCVRC&K*KB*W-3I14(NU']P<8QD8SG&"13Z:@P
MN/=O?'S'C\.A]Z=7PV^I^QI6279)?<DOT"BBB@84444 %%%% !1110 4444
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M #/T[V)_=7_OD?X4;$_NK_WR/\*_-/\ X;G_ &GO^D2/[=7_ (<+_@G_ /\
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M;J_\.%_P3_\ _HTZ0_MS?M/,-I_X))?MU -A21\0O^"?^1DXS_R>E@#U.?\
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M\B@#_@DC^W7CT;XA_P#!/TL#P2#M_;58<$XR"0>2":=_PW/^T]_TB1_;J_\
M#A?\$_\ _P"C3HLNR^Y?Y!9=OQ?^9^EFQ/[J_P#?(_PI"L8ZJ@^H4= 2>OH
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M^6C:TZ;WOI^EB JH![$_B,G!^I')]Z=7YH_\-S_M/?\ 2)']NK_PX7_!/_\
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MO^"?_P#]&G1_PW/^T]_TB1_;J_'XA?\ !/\ 'Z_\-IF@#]+<C.,C/IGGOV_
M_D?0TM?DEIO_  4O^,.L?$?Q;\)-+_X)9_MV7?Q(\ ^&/!WCCQ;X8;QG^P=
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M:/\ PW/^T]_TB1_;J_\ #A?\$_\ _P"C3H_X;G_:>_Z1(_MU?^'"_P""?_\
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M8HK\T?\ AN?]I[_I$C^W5_X<+_@G_P#_ $:='_#<_P"T]_TB1_;J_P##A?\
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M1O@?\4],T^+Q]\)_"+:M=^'_  EX&UW1?#O@J>7P3IOAZ1P#]/** <^H^O\
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MQBXFMK.6\NYK2"65XK5[NZ,*IY\I?4'?/K_08Q_7WS2T4 %%%% $<SJB$L2
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MG:HP>?F//4%CGG/\7K@AP0 K@8"@!>?8C!'? /&>F3C&33Z* "BBB@ HHHH
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M%O$WAG3/$7C/PY\7([6Y_P"%9:GX6TO5X?&MQ;SV.CM<W<$MN@!]^Y&<=_\
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M>@_(44M% K+LON7^04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9@2&YM(A92?9KDRJB[^H?\$^/VK_ !U\-?VSO[>\-_#WPAXP_:0_X(]? _\
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0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %I U(# 2(  A$! Q$!_\0
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MO^"AW_ASO@Y_\XJ@#](J*_-W_AWWXX_Z2-?\%#O_  YWP<_^<51_P[[\<?\
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M'H#Z4[.!D_YYP/Q/8>IQ1&5TM%TVU6NS\OZ>VH"T4458!1110 4444 %%%%
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M\/%WQ$XZ\'_BY/4>O.:D_P"'>G[1 Q_QL1_:0YR<'Q=\1,],\'_A9'( !SU
MR#D4O]2^!+V_XC1PWY_\8)XE?_,6K^2[["_XB?XJ_P#2.'''G_QLOP<TZ_\
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M9)[##9SVZ]Z^./!5K\,OV&/@=\&_@M+J7BSQA?01S>$_#L&C:!)KWQ'^+?Q
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M,.LV_@G7OAE>ZU?WIM&MX[ZUN/%-OXUTQE%_YDC6\L>CL;(R*'BN0#7Y[_L
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M]>M5J24*=.E1R+/:M2I.3VC"$)2;MHDW?O\ %W_!)!=W[&?@K.,_\)+XH7
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M"BJ&%%%% !1110 4444 %%%% !1110 445\V?M _M=_L]?LLKX2?X]?$2W\
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MFTA/#BVUI925^P<Y(1W#*"%(Y*1H2J,Q9WQMC! Y<[DC!W%3@$?*OPE^-WQ
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MM1US3;/PL-+^'4=GJ UVZG6/2UL[Y?#=L]I<M< &WG2XMG5T4^85S7KY-DF
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MN(5C*.6 /0/[+TG&3INGY)&1]CMB020N/]7_ 'CSGO\ E2_V5I/_ $#=._\
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M_P 4+[5-=GT*?[#XC\4>+M2U'Q#JEO\ Z<VO67@_PQI)OK4OYEMQ<S[1_P#
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M- \+>$-!U?Q-XFUW4I##I^BZ!H%C<ZGK&JWLN&V6FGV%K<W5S(JL4AA9MI.
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M^&-:\+>&]7\,01V\4?AS5M#TO4M 2&T4+:10:1>6DNG(EHN8[=4M46)-HBV
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MG'3ZFI.>._KV_''/?MFBBFE;^NVWW?CU 3'&,]\Y_P"!9Q_3Z4O?/U^G./\
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MUR:KX9\6']G[7O@AX!7PK;OX)@UCQK82ZUXS\=VE[<?#R#Q3:0)%IFMZFO\
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M]HO_ (.-+_\ DRC_ (2OPW_T'M%_\'&E_P#R90!T%%<__P )7X;_ .@]HO\
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MVA^*M#;4K:6V.K>'=86*8Z9K-AO$^GWR0RO:W$<4GEM@ ]54<HRC8&3M('+
MC<,9#(0ZX!^\A##J#D4 ?R]Z1=?'*.&]\5_#']L#]LF#]GO]I']N'X8?\$]?
MA-XS^)'Q?T_XA^+5\"^!/''BW3/VA?VEO!6L:QH<R^!?%GQ4^+'@_P 1_L[_
M  B9]/N%TWP-X,LOBK91W6I?%/3[+P]^DG[&OQM^)7P]^%__  4 \,^-];^,
M_P"UI!^Q%^UQ\0/A!\-;_2-.T7QY^T)\3?A];_ ;]GWXYZ9X/F99_"6F>/\
MXB>$]?\ C3XD^',>I7UWI-QJL7A2Q75[Q-2@O6K[#U?]CS]FO7/V?++]E35O
M@YX:NOV?M-BLUTOX;B75X+#1[NP\1/XLL-4TC6+75(?$NDZ[8>)9#K^G>)-,
MUJWUNSUDOJ$&HVUPN\=W\"_@!\'OV:_ $'PQ^"7@33/A_P""K76=:\12:78S
MZGJ5[J?B+Q'>OJ?B#Q+XAU_7;_5O$'B?Q)K=]*]QJGB#7M6U/5KYA&EQ>2+!
M$B 'Y&_#W]I:]_:2_P""MG[)FI7O[-7[5/[.1\)?L*?M[6T,/[3OPOT+X;-X
MR_MWXS?L#R2GP*VA^._&O]M2^&_[(C_X2V&^321I,>O^%Y;634_[6G73OW8K
M\P?BOL/_  5__8;93E?^&"_^"BI4_7XU_P#!/#.. >I.>.,C/49_3Z@ K\R_
MV_Y$'QN_X))M+)'&H_X*9F-'D<1J[O\ \$]/^"@4:(I(8-)+(XCA0$%Y&1 =
MQP?TTK\K?^"O?AG0->_94\%:SJ^BV&I:UX _;._82\7^!M4FA:34O"'BN?\
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ME"NW.OPWP/PKD^(FX.#EG/%=7&\>YYB8RY;36)>+RB->*E*4,1&K"IRIW=^
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M%OH&BP7^NZM'IMB91;KJ7B?7M3\4:_=[I7DD:;5=?UG5-4NB7.ZXO9BH1&5
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MT?\ !.M))40DJLDB1Q)(Z@,Z1QJQ*HH'Z;U^'_A;QM^T5XV_X*V_LC2_M$?
M/PG\"+[3_P!A']OJ/PI;^%?C-8?&!?%45W\:OV"SKQOWL_!_A-O#:Z"MMHC6
MF_\ M)=8;7;E4:R;2I([C]P* "BBB@ K\\?^"IW@#XA_$K]B'XK>&/A3X \1
M?%'QW'XQ_9W\8Z7X!\(-I"^*?%&G_#;]I/X0_$7Q+IV@_P!O:GHND2ZJGA;P
MIKEY9VU]JUC#<RVX@$Z/(*_0ZD(SCDC!!X]NQ]C0!\[?LP?M*>#/VL/A18?%
M[P'H/C?PKHT_BSX@>!]1\,_$;1+3P[XS\/>+/ACXTUSP%XOT37=+L-5UO3X;
MG3/$OAW4[026&KZC:3I"LL-S)&^1]%5^ 7[#'[<?P)_99^%OQ3^$'QNL/C]X
M1^(.D?MA?MJZS?:/#^R9^U#XEM'T?Q9^U#\3_%'AK5M,\0^%?A'K?AS6M(U[
MP_J^FZMI6IZ-JU_9W=I=12++D[3]\_#_ /X*=?L??%#XE_#OX0>'/%OQ,TSQ
MW\6?$&I^%/AWI_C_ /9P_:*^&>D>*?$^C^#O$WC^]T"Q\4?$3X6>&?"\>K1^
M$/!WB77(K&ZU>"XN;31[L6L<LJK&P!^@E07&/+Y7<-P.!U.,D8]2",CW (P<
M$2J2R@D8)SQWZGJ.Q]1VJ.7.T<'(;MC(.UN1GKC/.,YYX(J)?"^;;6Z2;O'6
MZM9MWC?:+WVWN?U_P>FVY^?_ .V=X<^#'PA\(^)OV\/&?@F?6->_8\\ ?%OX
MZ7-GX3M_#VBZW\0;7P]\*];T_4M#\4:U=:9+/?6R>'H;BVTJ74KLV>F%OM$^
MZSB>*NK^%/[8_AWQ;\,/AMXN\0?#;XVZ5KGBSP#X-\4:KI7ASX!_&77]!TV_
M\1>&]/U>XL=#URS\&S6FL:39O?-!I^IVDDEM?6J0W43;)E4?9&,2J,%,NH)+
ME3L/ Q@C.[< 023D\C)%?.7['WQ/^*'Q?_9K^$'Q+^-?@B7X:_%#QAX6;5/&
MO@=],U;0V\-:K'K&J62V1TK6B=5L5:RM+6X$-X?-,<HD_P!6RUZTIU\9P]2Q
M6,E4Q-7(,VP>34L=B<VYIT<MSS 9GF&#R; Y+6]I7EA,-G&49QFM;-*&)EAL
M%+'8?**N%P\*N ,TN6KRQ7+&<)2Y%!M2E3E"'M95-N:5*4(J%KRDJDW*4HR;
M]Y\*>)K'Q?X?T/Q/ID.KVNFZ]IT&JV5MK^BZIX<UF*VN(M\<>HZ#K=K9:QI5
MXH)\^QU"TM[N!QMFAC8A:Z>OE;X"?'7Q%XU\5?$+X0?%;2O"'A3XV?"E?#US
MXET+POXI&O6/B#P[XETN#5-(\9:+9W5K9ZK8:/*EW!IMS'=Q3FVUF"[MC=RQ
M^2[_ %)YR\DG & 0<9!P6/?H%P1WQ\WW2"?,ZV_K5)KJ]TTUY=C0EHI 01D?
M_7&1GGT."*6@ HHHH *:3UZ<9QC&> #_ #X(^GUIU1< 'CN-O7/4#COR<#UH
MTZJ_1^FO]>C$_P"M;>B7J]/3S/*_C#XFMO!/PR\>^,K^;R+7PMX1\3^(+AR<
M!5T[1;ZX!!!!!$R1<'H6XQBOC3P!X<NK?Q3^Q3\-+S+W?PW^$GC+XV>*[)DW
MR6?B?5_#^F>$/#[W)SNCEN-6\;>.9;4R'>\FER!LN"1[3^UYG4/A3:> (&>.
M[^,'Q(^&/PHB5)-D@L?%?C32Y?$DD9()+VWA/3==N&!QE4920"35;X26I\3_
M !^_:)\>6[RMI^E/X#^#ND,<!?LW@K2M2\2:NL(VY$:>(_&%_"50["8(3@,.
M/L<IC]2X:QN+TISJQSJO2BX2G>K/!8#A++Y>TZ2E6X@XAJTW>U*KEU[>TJ0E
M#\0XJY\V\1,JRV,)3A0?"F!JN%:*Y:$,WS;Q)SA>RDFJB6#X1X0PV(MK##YW
M"4XMQ49?5422*I))5AN."2!L Y4KGJ.",\@YP0"<[(SQGI@#\?6J$44BH0V[
M^,\GH I 5AT'8]"!C'O6AUKXN+3YFD[-[.VG>SZ][[=(G[;3BXQ47?1*.KYM
M$GZ6UE*[^TU?J(,D<C![TM%%66%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'S3^U[:W%W^S9\;H;9+J5W^'VM^9%:W,=H6MQ;G[7YS32V\%W:1VI
MEDOM-FNK:/4[,2Z>]Q MQY@[7X%S6$_P4^$<FEQQ)IS_  O\ 26,<&A_\(W
MEBWA73#;(OATO*="187&S1C+*=/C46XDE$9->4?MQ06Q_9H^)>H7GA#4_'=G
MH=C8ZY<^$M&\0ZKX:U+7HM-O8I9+""^T>SU"]NO.0F.32%L;N'58F>SGA,<I
MQZO\"9].N?@E\'[G2-,U'1-+G^&'@.;3M%UFYO[[5]&L9O"^F/::7J=WJL4&
MJ75_96SI9W4^HPPWLTT4CW,,<LCB@#!\7?#SX%7_ ,3M(\6^*M%\#7'Q9U'1
M6T3PT-=U:VM==U[3K.+4;A-'L]&N+Q6UJQB?[1=LD>GWT<;6BWJ*);)736_9
MUM!8_ [X6VBV-OI@M/!FCV8TRSP+335M86B6PM5$4 6WL@OV6%!!#LBB5?+C
MQM',>+?A+^SUX@^+<7C[Q%X<\#:C\:KGPM8>%(9]0UF*T\2:]X9ME\1:SHGA
MJ_T<WP_MC14O7U[5-.MKC2[J..YM-0U"'>]A*8][]G6T&G? OX6:=#IMMHZ6
M/@C0+"/2+(!;32XK6*6VCT^T"QPJ+:S2);:W(AB#11J0BY"@ ]P9=RD9(Z<C
MV.?Q!Z$'M5>5%7 P3E>AY4A,DAE P<@]^_3O5JDQG.>_]#D?B.N?7FH<8WO)
M+5)-]]&E?32UW9^;>Z30?$7P^6?]FWXF3?!Z;0%3X0?%37/B=\2/AQXOT2S\
M0ZBGA;Q1=:MI/B+Q7X#\:Q6UA=:5X:TJ2/Q!K6N>%=<FO[;35T?0-;7439?V
M?YC?:$;EB&!#9PX*88NI7DJW0IR"&0LK CGG ^>_CO\ LG_L]_M*WWA/5OC;
M\*?#'CW7OA_IWCG3/A[XIU6U9?$_@"'XC:1:Z#XPO/!NN02Q7NAZEJNFV=@A
MO[1TN;:73K.[M9(;BVBDKS?X.?$'XE>";GQU\%_B;H?B_P ?>,/AA!K_ (D\
M.>+[*#11/\0_A1/=7UQ\/[BP2;5;:[U[Q2EK;#P;XAD%M $\36L37LD<6H07
M3]U6%/'TE6I0I4<=0=.EB:-U2ABZ?*J2QM*52O"$:W*J-/%THR2<K8JC!^TK
MTJ,ZIV;;3=XN]WS=G_=WM?LE?1'VPK!AGH><@]0 3C(_SFG @C(((]1R*YCP
M[XBTWQ!H]GK5@TXMM1ABE^SWMM+9:C9O)&IEL=2L)T2XL-1LY&\B]L;A5EM9
M$9'  #'=29$54(/&[ P<XSP,>I)'TZ'FN"7-2FZ=6+I3A.5.5.5TXRC\49<V
M\HO>,6Y)-2LX.,I4M5=:KH^_IW+5%1+*K-M&>G7!]0 ._<G/3C%2U:DGMZ-=
M4^S71]T[-:::JX%%%%, HHHH ****/O **** "BBB@ HHHH **** "BBB@ H
MHHH *\9^-7_(O>'O^RH?#'_U+M'KV:O&?C5_R+WA[_LJ'PQ_]2[1Z /B[_@I
MY_R+W[$__:1O]D[_ -/GB.OTWK\R/^"GG_(O?L3_ /:1O]D[_P!/GB.OTWH
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MG/4]:'_;\_848 #]M/\ 9)))''_#2/P<Y/0+C_A,N23@#WQP:V?^&'OV*_\
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M6TFL8[/P1H=LEA<7DVH3V:6\+P+:S7]Q/<SWLT"1K#+=37$\MP\9E>61G+D
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M'4;\Z>-06UNS8-=B%;TV=X+8R-:7(B_7"OQJ?X!_ KX#_P#!7?\ 8YL_@?\
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MX8[2&'W2PVEB-Z]":^$/V@/^"='PM_: ^,S_ !\D^,_[6_P1^)5[\/\ P_\
M#+7M2_9K_:5^(?P3TWQ1X3\*:WK_ (A\-VWB;1/"MZNF:Q>Z-J/B;7#9ZC/
M+M;?4)[9Y'@(C'E'_!-K3/%/@;Q[_P %!/@?K'QE^.OQF\)_!']J[PUX4^'.
MM?M"?%/6/C!X\T'PYK_[,_P+\>ZKH2^-O$<2ZY>:*/%GB?Q!JNFV&HS7DFFC
M47M8;EX8HR(G%25G^2;U]UM7C)II2;35GT4EJ&JV=O3?_+[SZON/V7_"4GQ_
M'[0LGQ(_:53Q*C6)'@"W_:A^.]M^S^HM=$AT$+_PSS;^.8_@^8I;6);RYB?P
MA(ESK;2ZY.KZI-)=-8_9AU/X\3>!/$.G?M+6VB6?Q1L/B]\<QHL>AW?AZ6'5
MO@P/C'XR_P"%%Z_'8^'RBV8F^%$GA'3-0%_%_:AU?3[]M5D>_GE9_I2XC#*N
M"P)(P4(!!^8CG#=,C@YY"\5^?W[1'A2[_9^\;_'O_@H9I<.L?$74O /[&,O@
M*/X)Z>(=+G\06WPW\<^*_BW=:A8>(7%X8]4U6WUBXT6WT\Z5,"]E"T<S-.(D
M];"XO&YO3QF59AB*6+Q57 82EP]4Q=+"_6:>,R_$T:.4<+X+%X?"Y91R[ YP
M\YQE+&X_,WCJ-*&38*>,Q]Y4:RF7+&THM12<G5LI-M25YSY;R=2:45)1C:[<
MHI*S/>?BYI_P#\)^*_AY\9_B7H4%GXR\-ZU)I/@WQUI/A/6=6\3QM>:!KUK_
M &#J6I^%='U'6[CPTUGJ^MW$6D:N[: FJ2PWGDK?I:R#USX>_$;P9\4_#5OX
MN\!ZY'X@\/7-]K&F1ZA':7]@R:EX>U6YT36]/N;+4[6QU"TO-,U>RN["\M[J
MUADCN()$92!DV_".M+XD\*^&?$JVD]@GB#0-$UY;&[&;FPCUC3K3419SDJI,
M]HMQY,V57,B-\BY"KY=^S[X-\1^!O#_CO2O%-I;6-]JWQQ^/?C73([;4K:_6
M?POX_P#BSXI\7>&-0E%N0+:6]T?5+9Y[.X!N+.X6>"1BX:O(;G3G4I3ARRHS
MJ4I1NI>_1JUJ,TFE*]G0=[.2U;4G'EDZTZ/[]'T>U]-U=='IJ>__ .?7^=%,
M+#<O(YSGUX&1SV_KTK*FUK3H-1L]*N-0T^'4]0CN;C3M,FO;6+4;Z"R"F[GL
MK)Y1=7<-DLL1O)8(G6W#+YFT.*I2N[6:NKK?7Y<J_,#3DDVIDHQ!)! '..G8
M@\]L?C6;/<Q^40RE59@"Q7HI>(<98X #,QY &W('2K5R0T8RH."6*L.B[3C)
MZ_>V_4GVX\E^*/Q T+P+X.\6ZSJ6IZ;9W>D^$]>UR"VGU"TM[R8:=IT\T9BL
MY9DN)\RK&8_*BD1WB)((4XTHT*N*Q%+"T:<ZE;$5*5&%.$*LY-UZM/#Q?+3I
MU&HQE6O.>D()-U)PC>9Y^9YA0RO!XK,,56I4,-@L/B,55G6E&$&L+AL3BW&+
MG4IIRE'#**BFYSDXPIPJ2DHGP+X0AC\=>.OAJ#;M+'\5_P!JOXG?'34HW^:2
M3PO\!M'N?#7AA9R5V26J>)G\'/#YJLJFUC$+H\:@_JA:"0*QD Y /3!^ZYX
MX&<[N,=?>OSE_9,\.WMS\0HKDK(D'PE_9^\ > 96DR%A\=?$_5)?B[X^6(,2
MRW$MC+X-BO20) ]N4)5)"A_1J)6C7:6W$%2IY^4[]O3OPQ!Q@!><$#CZCC/$
M0J9IA\+2J3E3P6$4(\U.--WQ=>K6I1:NY2=#+\!E%*,Y6M2Y*<4XQYI_F/@_
M@ITLBQV85:3A5S/,H<THN,J-99=@*&'Q.(HN[?+B<[S3B6K.GS>Y7C57*G&2
M+R=/Q_H*?6)IVMZ=JT#7>DZAINIVJSW%L]SIM_:WUN+JU=X[FU,UK++&+BWD
M1DEC+AXI%>*1$85M9!Z$'\:^5/UY"T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !3)!E&'(XSQ[<_7\B#Z$'FGTA'MG@C'8Y[$=/S_J: /"O
M&GP,\ >,/'FB?$S6-/U0>,/#EC#8Z==:-J\^BR:A;6%EX@-A9/-:M%>Q75E)
MX@U2>SU#2;_2]3A\TP&^&G&]M;B;]G2-+3X&?"J 6UW:"'P1HD$=G>75QJ%Y
M:I%;NBV]Y?7,]W=7MS$H6*YNKN[NKFYG4S7%Q/.[2ON>//A7X<\?:WX(U[7;
MC6X;SP!J>J:IHG]CZM-I(EEU?2I=(NH[BXM$34K5HX)(Y8+S1K[2M44QR6WV
M\V-W?VEWX+\)_A7X&NKWXD^%[&#]HSP]I'@+QK#X7T2WUWX^?'*UT9M*L?#>
MBPP+X.-K\0H)I?#S26\FIJ;^;4+TS:J\S:@;6>#3[( ^R!,O?=TSPC<=!CIU
MYSCKC/&!FCSESC#@$8^XPSN*J"".1C=SZ#)[5XO<? +P7-)9RKXD^-L7V.=K
M@Q0?M'?'^.*]#6L]J(+T'XDNTENGGBZ6.-HC]J@@D9F561ZFL?!GP7I>EZG?
MIJGQQO6L=-O[Y;/3OVAOC]<:A>-9VTMP+6QBF^)A22\F,8AM8R522:14D^7H
M >YK,G )))[XXS^';GCV'K0)XR=H)SSQCGC'.!S@]CWP:^6OA-\,_"7C/X;>
M"_%-W<_M&:/<ZWHMM=SZ7XS_ &@?CM:^*[&60R%K?7K:Q^(MM91ZA&5VS"W@
M2'[H0,GS'O$^ /@M;V:[_P"$D^-I66UM[86K_M'_ !_-I&8);F4W$4'_  LD
M,ES/]I,=Q(96$D4%L@11$"0#VEIXQC.[/55VG<3TPON>@Y') SD@&/*J9&VG
M<?E!*@< GDN!DCG)8DY R<]3\@_'#P7X5^&W@Q?$5J?VD=:2#4H;F\;P=^T!
M\<KN_L;30K.^\52+?PWOC_4L:/K[^'X_"-])::?=7L?_  D49MOLKDWD'J>E
M?!?P9J.EZ=?R:C\:["2^L;*[DL+C]HSX_/<V3WEM%.]K.\?Q/=&FMFE,4K1R
M,F^-FC8C::F4>:UWI=W6EFFK6>FW71IW ]L1T)#!"">/NMP1@,.?NG! YP3@
M=0*>95YP/GQ@#!!(.3P0-W !)QTP2!7BUM\ _!EI%,#XE^-UUYES<W8:Z_:,
M^/LDD0F=I!:Q%/B1'MM8 =D$;!VC0*K22$9KP_Q[X;\.^$OBG\+_  Q%I/[5
M.LZ;XLU)_#\^L^&_CW\;;SP9ILFM6M]=)K'C">X^(\FHVL>@OX?2"W-K+!$W
M]ORR3QW,$!$0H)*UOOUMY*Z;MY7?J!]JEEPV0VT\@!7+<MW7&>A/ Z#*X*YJ
M-GWJO! )5 0C'*G &-@^ZQZ=% .20OWO'+CX#>#+ZSGMU\0_&RU-W;RV[75K
M^T=\?X;NV\^,I]HM7;XDO'%<1;S)"_E$1R*I$>.!,/@5X*BC1#K_ ,9V(0(S
MO^T9^T 6<@("[/\ \++P'(!)9%1=Q;&W<")]FE\+:=[JU].[2YK7>TGU738#
MUJ0KEN6#'CR\$X9%Y&,%><9';&"!@DU(=OR@9'&T [@&88(()'/RC&<@D9]2
M:^(OAOI7A#QE\3/B3X1_L_\ :JT^T\,WM];V_B'7OCG\>X/A_</X<U$>&I[/
MPIK7_"PK:[O[_4)Q+JFH6=^+ORRGVFRNYK66#'O5Q\ O!,[63#Q)\;;<6]TM
MUMA_:0_:"B%P%BD7[/=*WQ+?SK9MX9X<IET1M_RD-'U>FI.?)#F:BF^2',U&
M7-%-^SNU&5Y1YI2LW=6?O#N[6N[+S[GJ5QI>FW<Z7%W96=S+#!-;QR7-E;W,
MD=O<X2:&.6:!YHHIE5%N+=)%AG#$2QL2Q-:/0=%B%D8M&TN(:>[O8B'2=/5;
M1YG-Q(UKBT7[.99F::4VYB9Y3(SLS$&O*/$7PD\&>'= UO78M0^-&IR:-I.H
MZLFG0?M%?'\SW[Z=:37BV,&?B1/B6Z:'R8SY3@.ZAE,>5KR/]GSPKX6^*/PV
MT[Q)J%I^U%X5NH;Z\TF2Q^)7Q_\ CIIWBVX^SI;W?VS4K;3/B%8V22*]ZVG3
M""UB2&[T^[MHS-' LTFD5.,>15JZ@KVA&OB(QBFVVHQAB(1BGS35HPBDISC&
M,8U*JJK_ ('X;?UN?6"^'M"$,5HNBZ.MO%=KJ"6XT>P2%+P*%^V11"S\H701
M0#<*OG#"J) "%$DF@Z*YO!+H^DN-2<2WX?2K!A>NI8[KL/:D73@RR%6N#*^T
MM@AFD9_,E^ 7@PW_ -L;Q-\;0GV,6?V(_M(?'XV61<-=?:UB'Q(63[8Q?R6F
M\XH+9%@$>U<UXO\ M#>&O"WPE^'-YXKTS3_VH?&EU'J>FV2Z)\-/C_\ '34?
M&$BRSF=YM-LM5^(E[87$"K;&'41-$&CL)KB>&19(D-/]]=OZSB+O5MU\2]4T
MU)7Q3M)2C&:DK2]I"%5R=:G2JTSU_K\^I]#:3\*?AMH/A1O _AWP!X/\->#7
MTZ]T=?#?A;PYI7AO2(=-U&1YK^TL[/1+*QCLX;NXD:>86JQ-)<YGW&0!JK)\
M/=:AT^_TVU^*GQ&M8[B[L9K"XCB\%R7.@V5@MS&-'TUI?"$B26%ZD\/VI]1B
MO;\_V7:^3=6YDN?M>!H'P@\%:[HNE:S]N^.&G#5M,L-3-AJ'[0W[0<%]8MJ%
MI#=&RNX&^)H>&YM?.\J=/E"2(P48X%NW^ 7@VU6XW^)/C;<B>ZN+H&Y_:/\
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MY]2<$ \XXP !00&!!&0>"#2T4 ,"+@J1D?EU[<=2 !\QRQYY[4X#' )_3V[
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M8D#J<9XY_/\ I28YW9';&0. <=",'G!ZYYQCH05=7M?7M_GY ?B=^T%^T/\
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MW _+_/.:^=(_VNOV3T!S^T_^SKAB&&/C9\-\#(4' /B4X!(9AAB,GW)J6/\
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M//B# CW5[,D%O&\TWAF.&!6E=0\L[QQ1#+2NB@D?22Q@*07=0#@;78#Y6))
M!R,LQR/[H49(Y+]BJ,F1]N ,ER3P1CG/L0>I.3D\4.25WVMU26J7RZ@>1?$7
MX\?#;X4ZCIFE>.-4U73KW6+&XU&QCT_PKXI\01R6MM<K:2O)<Z!H^I6]N_G,
MH6&XDBF=<R(C1@L.)T_]KOX%ZI?V.FV7B'Q%)>:E>6MA9I)\/?B!;QRW5Y,L
M$"-//X9CAA0RL \LTB11+\\CJG-?2 C48(D<<[3@XR01\Q XZ<9Q]TCG %.\
MLG/SR#[VT[LX^Z.1T.3DK[>F<4<R\NE]=-=4U??=:I=0/(OB+\>?AK\*=4L-
M'\;ZIJNG7^IV,FI64=AX5\4Z_%+9QW+VC227.@Z/J-O;R^>CJ+:>5+@J/,$>
MPACQFF?M<_ S6-2T_2-/\0^(9K_5+VVT^RBD^'OQ MHY+J\GCMH%DN+CPS%;
MP(TTJ*\T\L<42MOD=4!8?1_EA2"'?!XSOPHZ<D<C).3D  G ;CFE9>V]\$X+
M>801R.F",$G(S@C"E>-V0<RNUK]W;>[Z+M>U^EP/(?B'\>OAI\+-5L=&\;:K
MJ^G:CJ&GR:G:PV'A7Q3K\+VD=RUJ7>ZT'1M1MHI?.C95MY98YROSB,H0U<?I
M7[6WP.UK5-,T;3O$/B"34-7U"RTRPCF^'WC^UBDN[^YBM;=);FY\-0V]M&\T
MJ*]Q<2QPPJ3)*ZHK$?2'ECG#, <$!6(QU_/).23UP!T&*#'_ --).AZMQGL>
MW3ZT<RLV^F]M?^#VT[Z >,?$C]H+X8?"?48])\<ZOJVF7\FER:TB6/A+Q7K\
M']G123(\K76A:-J-JDG^CR_Z.\R7&T!_*"LI/YPV_P#P5<^#O_#1NK:=<>/=
M._X9M3X/V.KZ5K$7PQ\>OXOD^*<FO,E[ITSB#[:=&7P_MD53X:2W-Z1&-6/S
M(O[""-0-H9AT_C)Z$'D$D'H%.1RO!R":^=(/V<O!]G^T9JO[1BZCJ;ZYJOPI
ML?A*_A![+03X/@TRQ\0'Q''K<$0TH:LNL&<M;2&34)+06A8+;YP16X&]XU_:
M+^%/P\OM-TWQ7K.L65YK&D6NO6"67A#Q=K<4FF7FX6\SW.BZ'?V\$C[&+6TT
MJ7$?5XP"I.#HG[5_P2\1ZUI'A_1]?\07&JZ]J5EHVF02^ ?'EG%+J&H3I;6B
M2WM[X<@L[.-YI5$ES=S0VT*_O)I8XT9J^B1"%P%9P%"@*&. ,X  R% "Y  4
M8&.N *4Q'IO=E.<JSD9&#QD>_!X^Z?4<@'C?Q _:#^%WPPUR+P[XSU?5]/U:
M>QCU**&R\)>+-<A:SFEDAC<WNB:+J%FDA>*0&!YQ,H7+( 03S>@_M7?!/Q+K
M>C^'='\0:]/JVN:A;Z7I\,W@'QY90RWER2L4<MY>^';>SM(V(P;B[N(H(NLD
M@'-?1/ED\[W4D8*ARPX(Y&<<D Y.,_-STQ2^7P?G?IW.1^(XR/49&1QF@#Q7
MQ_\ M#?"WX8ZXGASQEJ^L6&K/8PZDL%CX0\6Z[";2X:1(7^VZ'HNH60D9HGS
M"9_-4 %D"NK'"\._M5_!3Q3KFD>'-&\0:[<:OKE]#ING0S^ _'5A#-=S%E19
M;R_\.V]G:1DH0TUU<10IE=\@# GZ%$1!(#N$P, 'H1D8'4@8 R.A))&#FE,?
M'#R?B=P()Y!''&#V(QVZ4 >&_$?]I+X1_";5+C1_'VOZEHMY9Z.NOWAB\)^+
M-6LK72&69C=W&J:1HU]IT2PI;3RW"O<+)!$F^5$3#M[/I.J6&N:7INM:7<QW
MNF:O86>IZ=>0Y\F\L-0MHKNSNH2P#&*XMYHY8R0#M<9 .17(?%+P_J7BCX:?
M$+POHOE_VOXD\#>+/#^DK/<?9X#J>LZ%J-A8K-,R.L$1NKF(/.5?RDRP1@N#
M<^'6C7_AOP!X'\.ZJD::IH'@_P ,:+J2PR":%;_2M#L+&\$,ZJBSQ"X@D6.8
M(@D4!@B_= !V=%,9PG4$DG  !);Z8!SCO]*4-GLPZ]01T^OZ>O:@!U%,+[2H
M())'4<C/?L,GJ< 9]N: _'W7'K\I_P G\* 'T5$TN,C!!Z+N# ,<XR" <@#!
M..><=:>I)&6ZDGL5P,G P23P._?KB@!U%1F3!P0PR0!\C?C[<8Z\#D  GK)0
M 45&\@0X*L>F, X.>,#U.2!@<\].*>&SV8?4$?SH 6BHV?:0"&.>00,]^G'/
M QT!)X]:>#D X(XS@]1[?6@!:*:SA<9SR2!@$_3\3Z?SH#9[$?4$'MV(Y'7)
MSQCI0 ZBH6<J0#P"^!\C%B.,*.@Y(89&?EV_Q9-2!LG&&'!Y(P.W'Z_H: '4
M5&\@4A<-N(XPI/8].#D\>AQUQ3P<]B/3/T'Y=<8//!H 6BHC* P7#@L1CY3S
M@@'KVQW&>,D=,U)G(R,CZ@YX]CR0?;G'0@T +17C#?''P@GQ\A_9Q:+7C\0Y
MOA._QG61-*)\-+X-3Q6_@S:^LF0;-8;68R!IWDG%NXG^T,/W8]E4MD@G( '.
MTJ2><GGC&-O3ONSP10 ZBF;\<$'=C@8Y; R<#GOD=3TZD<T;NAP_N-ISW&,=
M?0\?XT /HJ(R@,%VMDC(X.> 2>.O;\>?3F0'(!Y_$$'\N3]!S0 M%1B3U5AD
MG'RMDC /0JI!]0,@8ZGFGJ21R#Z<C!/ YQVH 6BF;_GVD8X/7.2<\$<8VXR2
M<Y]N.5)((&"V2>0. ,\9^@./?% #J*\3\8?'?P=X)^+?PJ^"NL0:\?&?QBM/
M%=[X1>RTA[O0TA\&6$>HZT-9U07$8TV0VTJ&T7R;CS6)5E4#<?9T=R<,A''7
M).3D#GY$'J<CCCI0!+13-XP.&Y. -IR<#/3TI<Y' (SD<C!''7!H =149D&0
M,'/7!4[L9[+UQUY[''!S0\FU2VUB!VP1U(QS^)['\,<@$E%(K!@&'0C(I: "
MBBB@ HHHH **** "BBB@ HHHH _,C_@IY_R+W[$__:1O]D[_ -/GB.OTWK\R
M/^"GG_(O?L3_ /:1O]D[_P!/GB.OTWH **** (Y< *2< 2(3V[\<X. #@GIP
M#R*_FR_X)-_M6?LC_L?? OXV?L^_ME?&3X/?L_?MT?#S]HC]I/Q-^VM-\:_$
M&A?#SQ+\8/%GC+XQ>-/&7ASXZZ1KOB^;3)/B9\-O&GPRUOP>?!GB'2Y+K3;3
M2+-?#Z6UF^FF.7^DZ0$J0 "3Q@]QWYR,$=0><8Z$UY!\0?V?O@=\6=4TO6OB
MI\&?A-\3-7T-0FBZK\0?AQX/\8ZCI*(6=4TZ_P#$&DW]W91>9)(XBMY5C$C&
M145@" #\H?\ @BKIT.J>'/V[/C#\+O#6L>"?V.?V@?VZ_B;\4OV-/#>KZ9>>
M'K+5OAO<^'/".A>//BMX$\+WL%G)X7^%/QI^+VB^-_B'\-]+%CI?F^'M7BU@
M:)IJ:I' W[@?Y_S^59UKIT%E#;V=K#!:V=K!#;6EK:P16]M:VMM&D,%M;P0H
MD,$$$2)%!#%&D<:(H15"[3H 8SSGDG_ZWX?_ %Z  @]CC'^!'/3C)SU[5Q7C
M_P ,ZKXQ\$^,?"6C>+M?\ :MXH\,Z[X?TSQWX2&FCQ1X-O=9TZZL;?Q/X<76
M+'5-+&N:'+<IJ.E/J%A>V::A DMQ:R1 1'MJ* /QI^'O_!(=/!'PDG^#M_\
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ML<9 .&;!..@!I_4^!4K_ .LG$-N_^J6$_P#HA#VF9?\ 0OP?_A:__F8_=O\
MX7A\&O\ HL'PJ_\ #B>$_P#Y<T?\+P^#7_18/A5_X<3PG_\ +FOPE_XA7?\
M@CIG:/@U\32P&<#XU^.21VY7[7T!(SNP!N7W(0?\&KW_  1S);'P9^)Y*YRJ
M_&KQTW0X/'VK.002 /O 9&6.TGU/@5_\U)Q%V_Y)+";]O^2A#VF9?]"_"?\
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MWSX]O7\<GTZ?_KK\6O\ @F=_P6$^!G[<6G7WA?Q9\3_@)X6^/VH?&3XU>"O
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M5I)I'_ _$\H\*?!_PGX)\,^(?"6A2^*WTCQ.;S^TY-9\;^+=?U.,W5B-/?\
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M+&\-ZXE^-0;4/'7B[4?$ &HB,3&Q\4WNJ7/B'3F78C1-::A";0*RVL:EV>N
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M/BMI">'/M_PZ9M+@NI]:\902^*_#MC'X?\/0ZOJ-SJVJQ:1;03:K%-91^F_
MWX]_"#]I'X?V7Q3^"'C[1?B+X$U'4M5TB'6]'^V6[66LZ%=MI^MZ!K6DZK::
M=K?A_P 0:+?Q26NJZ#KNG:?K&GS;5O+.$N@/X$V_[+'Q6^"?@GX\^)_ ?[,G
MC2?X>_ __@MYH7[6?A?X&?#3PEH=GK_Q%_9O\,?!;X&^&+SQ?\%_!<E]H^E^
M,KG0O$4>N>+]$T6RN+76_$^N>#=8MM&CO?%;VD5[]X?L/?#CXS^*/AM^WO\
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ML5EX';XO'PEJ&KVFE^/[9H=0MM0TW5]0E\20V"6$FJ(T<EI=7?IW_!0?5/\
M@KK\,/CM\)_C%^PC\-OA;^V%^SHOA+7O"'QK_8K\8>*_AO\ !GQIJ'BJ]::?
MPS\4_"?Q>^(<5EH\VG:3(EF-5T"]U^"2-+26ULM!UB36FU7PQ^>'[$7['?\
MP5@_X)P?L6?'3X@_!OX(?L[_ !1_;4_;#_;AN_V@_'G[+MS\1K'PY\$OV??A
MAX^?59/$FB>&/%1U[PWX?U'Q#X;=-*AN[+PUJ%_ID-A*J:--XOFTB*.^=UW7
MWK_,#YT_X.D_C]_P5$\$_ ;XE-\'[?1/V:OV(_AUXH^"%EK/QV\/_$S4=/\
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M$NX+JTMAM+=K>VZW[;[@?KI-_JS]5_(L,G\!S7X8_P#!R "?^"-W[9 !R/\
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MS^(SXG_81\+ZA%JN@MH5W$NGV"67Q.NIX+L73!S(MO([K)&T9;R6M;K\E_\
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M("'Y0$KX,_X9\_X*1_\ 21WP#_X@_P""_P"GQ4_'_P"M1_PSY_P4DS_RD=\
M].3_ ,,/^#.?S^*OIQU_ U\\E75E]:Q-N7V5GBL<T\-O]4:>8.,L*G?_ &62
MEAKO_<K(UT>O*D[;I13\VFH:/LU9J^MS[T7P3X.B\02>*HO"GAJ'Q+*C"7Q+
M'H6E)XAE#0+;DR:W'9+J4FZ!! 6-WN\E(XL%!MKXVOO$OP6_9O\ VEO&_P!A
M^&/[1VM_$3]K'6_AYX@\:>*?A_\  KXI_$CX56FI^%]"@^&WA^XUGQUX2\,7
MWA#P0\&D:?#)KYUW5(IHX/+U6]:.TVN.5_X9\_X*29X_X*.> C@=1^P_X,.,
M]!Q\5,]_P'7O7!>"?%O[9OP9_;=_9^^!'QL_:4\#_'_X>?'#X6_'GQ+<VNE_
ML^Z+\(-:\-:_\*?^$'GTFZL]6T;QGXA.H6M\OB.]AOK&ZMHU)2.6*4*N']'
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M_@WIYU6&>>%]>^+^D>'[KP!H4%LD#C4I=4UJV73I'ABO&AEGA63Z::/@!1@
M=!CWR.>,<Y_,XS@%/*'3HNTX';+ @@X].".,<XQQ2A/*OW3J9-6FU@ITJ]L_
MS&FZ^:._L<V7+@)?5Z5&ZOD]/VF#K<G[S&0<G9N,NDTO?;U@G[KO>"3J=4_C
MTL]H[6^7?%W[3OA/P?\ &?2?@A?_  Z_:'U/7M8LX;N+QGX9_9\^*7B/X/6:
M7.EZAK"1:O\ %_2= N/ &CR);Z=/;W0U'6[>.ROYK2QNYX+J]MDE_G7\5?\
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ML-"NS#<6\=OJ0MK.X0ZA,5KT;4?VD](TOX\V/P ;X1?M(7FK:A%8RI\3],^
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MIL ;B,!1SDD;>A]-P).#CT/4##\+$A))(!))/4EB?0=23C@4[<,9)'H<'(!
M)(R/0 TQR&XR,J=P(9<@K@\J2.GS9!/1>>N* /S"^*EQ!<?\%?\ ]B'RIH)3
M#^P?_P %%89UAFBE>!_^%T_\$\B$FC1FDB=A&^T2(H8I*H8M&PK]-9#QN*DM
M\@VG'  D;<<XX)X)Y(!& >_X\ZI\#?A-\)?^"T7[-'B_X=> M"\(>*?C+^Q3
M_P %!O$OQ2US2C?'4/&VMZ7\;/V!Y-,OM8%U>W-N#8R:_K<UO]B@M=TVK79F
M#J(EB_8IE4ON^<'S/FR&P1M88! (Z@,,=\ @9)K*ITVLU.[?1<DTO_)I1_JX
M:]'9V=GU79KIH]=>Q_$/HW[9?Q5_X)G_ /!93_@K3\6]3_8-_:\_:+\)?M"^
M)_AEH7@S5_@U\-?$<^C(G@2VU74=2U(ZS?\ AR32]9T_4!XEAM[*YT2\N_*N
M-.O8IX66:&=/N(?\'+7BW.X_\$=/^"D*D9R#\.[P=1M( /AD'/!XPIZ9 Z#^
MI1L@X!D(5?O+(<'ID?>&3P #@XRW0 FG R'A=QP0""RDKP""3OYW9Y.<\'OT
M^WQ/%60Y@\+7S/A"&*QE# 8' 5<1#B+.,-[>. PE'!TJCH4</*E1;IT8N4*<
MIJ][/4\M8'&4^>-',?9TY5)U(4_J=";IJI-SE'GG4O+WG)IM)ZVLK(_EJ_XB
M7?%P_P"<.?\ P4@_\-S>?_,S33_P<M>+">?^".?_  4A[<?\*ZO,9'0@?\(S
M@''&1@XK^IG$W<'\P?\ V<48E]_S'_Q=<_\ ;?":VX&BO^[JS[_YF']4S'_H
M:?\ ECAO_DS^64_\'+/BT_\ .'7_ (*1=C_R3J\ZC'KX9(YQ@YZ@_3 W_!RU
MXM88/_!'3_@I%C!&/^%=W@&">>GAGJ>_K^6/ZFL2^_YC_P"+HQ+[_F/_ (NE
M_;G":_YH>/\ XE6??_,P?5<Q_P"AI_Y8X?\ ^3/Y9A_P<M^+0?\ E#G_ ,%(
M3CIGX=7O)R3DX\,\'G''&/6D/_!RUXM(P?\ @CI_P4A."2#_ ,*ZO,\]O^18
MX [8K^IK$OO^8_\ BZ,2^_YC_P"+H_MSA.__ "0Z_P#$JSW_ .90^JYC_P!#
M3_RQPW_R9_+*/^#EGQ:!C_ASK_P4BZ$9_P"%=7?0GH?^*9QCVQC'!X-/'_!R
MWXN48'_!'7_@I"1C)S\.KL]R?^A9YY. !T&.  2/ZE\2^_YC'_H?Y?C1B7T/
MYC_XOZ4_[;X3Z\#1W_Z*K/OR^K6[!]5S'_H:?^6.&_\ DS^6<_\ !RYXN/!_
MX(Z?\%(!Z$?#J['/(XQX:]#]!U/0X_/W_@J1_P %E_B;^WI^PK\>OV5?"?\
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M 0J&&",CKS3?+3^Z*?10 SRT_NBCRT_NBGT4 ( %X  ^E?F=\;_^4H'[!/\
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MZ\>V6VO;:27]-3%Y88AG)^\3O*[BH4*&;/?D=,'\.?FS]GGX 7'P0\6?M/\
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M +<7_BK'_@IY_P#0?UB:]_P5]_8I\)QZ')XJ_P"&Q/#:>)_%?A[P'X:EU_\
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MIY_]!_1_P]2_93_Z%_\ ;B_\58_\%//_ *#^OT@HH _-_P#X>I?LI_\ 0O\
M[<7_ (JQ_P""GG_T']8%]_P5^_8JTSQ+X9\%ZB_[8.G^,?&FG^*]6\'>$[[_
M ()E_P#!2VT\3>+-*\"1Z'+XXU/PUH,_[)":IKVG^#8O%'AJ3Q7>Z5:W5MX=
M3Q%H;ZO)9KJVGFX_3_&?_P!9'\J\_P!:^&/@;Q#\0O!/Q2UGPOI>H?$'X<:'
MXW\-^!/%\ZR'6/"^A?$EO"S^.M,TN02"-+;Q*_@KPHVI"6*5G.A6!B:(QN9
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MSZ9Y&,=#SSSR: /SB_X>I?LI_P#0O_MQ?^*L?^"GG_T']?$WQ1_;I^"OB?\
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MSHQ)3SBBS $L/WO#M6O_ )]/YT ?F_\ \/4OV4_^A?\ VXO_ !5C_P %//\
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M#PSXQ\,^/_#]IJZ220Z1XR\':BFK>%_$5H(I(RFH:)J2+>64A+*DJJ61PH
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M@Q^%;CXO)\*1KH^&P^*MQX;BBT6X\?#PQ_PDDUJD<\U])?C[4?L",84 @ @
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M'>'-%M;+Q+X;T >/T^.WPIT_5O%WASX00OX!\/\ B/5=.^(>HZCI,/[11$E
M2&!R1AA@\$CI@8'' (!]:^(OV8_^"?G[/W[(-QH0^!S_ !=T'0/"G@^Y\ ^$
M_ 7B#XZ?%?QK\-O#'AF\OH-2DL] ^'_BKQ3JOA72[A+^.6YBU&VTQ+];F_U.
MX:Y:;4KZ2;[>C4HH4GIG'T)R,^I'0GOSUS0 ^BBB@ HHHH *1L[3@X.#SQQ^
M? ^IX%+37!*LHZLK $C(!QQN]OPYH _GQ_X+>_\ !41?V3O 7B3]GOX,_M _
M!WX&?M-:K\']8^.>H^-/B?XT\+^'=4\)?##PQKEC8VGAKX4>&?%$L7_"R/CC
M\:-6BU+P9X'\.Z):ZK)X0T"T\5_$/Q!:VL>E>'K77/+_ !'^V-^TIJ/[:UG\
M5O!'Q5^).K_L=Q_MT_ 3]G2R^+OA^?X6:M^PT_P<^*G@GPQ877A#4M(ABG^+
MOB+XH^*_BEXO\,>&?"7Q\\.W5U\)=-\3^,/"-A<:Y%H+ZA#<?T'?&#X0>!/C
MQ\+O'/P9^*NAQ^*/AQ\1]!O/"_C#P_+=W5C'JVA:CA;JP:ZLIH+R!9PJ(7MY
MXI0N0C*QR? -7_8!_98UKXZQ?M$:C\.+F?XA)XYT+XKSV"^-?'$'PSU'XQ>&
M+&'2O#'Q@U7X21>(H_AMJ?Q3\/V%M:P:-XWO?#$VN64]K9:G%<_VO96E]" ?
M9T0PBCNN5/U!(/YXI],C7:BC.[@9/8G')';!Z\8'/04^@ HHHH /\_G1110
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MP S(5VKSP57"D@G.,#"DD X (/9EK^5+]I_QS\3/'W[4?[0?P;U#X\?'_0?
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,<+=^Y4W?_+Z?<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %< U(# 2(  A$! Q$!_\0
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M')SC\\<?44;AG!R.O7V[_3T^AHNOZ3 6BC/?U_K11>X!1113 **** "BBB@
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M?M9VVD>(O"$MQ:V\>I> ;UK#5;K2M9CU*PYQF3XQ_P""2'CQ]$\0> ?AA8_
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M/FWMIZ;,=W??I;MV_"WF0")3@[%QT!R> 00<?-W!P1WX]!AQC7& JA1DX^Z
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M&'PX^*UMXQ^&?P2\=:;\7]&T#P)\+I?AYX\\1^#(/!VI_$KP]IWB'5Q]:_M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;RTG6:SO;>*[MIXV8QSV]W&L\<J%B&998Y4=2ZJ[9RZ+A17X^_!K_@G'\1?
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MN<U%)SLYR46I22=HMM*3EJVHOEMV74F:!'W*P+<@_,S'#  9ZY!VMZY("C<
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MX?DLP#$L/F)7;M+'C.WG&1G#>U3T4526BOTMWZ*W?HK+=[>EF%%%%4 4444
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M!9/XL^"^I1"72?[3MM2N]#^*/A;QY\.? _C>Q>SU'PM\-O&5JMKXYTO^E8G
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MT^,/PIU3]F7P'\*?#_Q"\,>'=4TK7/V=Y?BL_P 4O&FG:1H%WJ>A7_A/P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _*W_ (* ?\G5_P#!(C_L]SQU_P"L
M>_M'5^J5?E;_ ,% /^3J_P#@D1_V>YXZ_P#6/?VCJ_5*@ HHHH **** "OYG
M?V]/C7^T3^R9^V_X5_:"^)'[37_!+?X9:CJG@CXB_"?]GOP1\2/@#^UE\4_C
M-J/P;\1?$WPG?:9K&L)\*O$6M^(M"UZ'Q(/#7A+6M<\)Z;H'@;Q;XCUNPT.:
MVO-4/AFRT[^F+/3KR<?3@GGVXQ]2*_#/_@IWX3O?&OQG\/>#?@WX7_:V^)O[
M1WCC]F'QGH\/@3]FJS^ >A:5X/\ !OA;XS?#;XC_  Y^.OBWXI?M*>,_A=\/
M/#^M_#_XU^%-#C\-^!](^(-SXF^(NGZAXBM)O"HT73+GQ#I ![E_P1FUKPSX
MJ_8DTKQGX4^(OP>^*FG>-/C7^T9XHN_&7[/GPN^*/P7^"%SKFJ?&7Q8?$&D_
M#3X:_%C2]'U[P[HGAW68;S0=0;2K-O#VM>)M.U[Q!;7^JZGJNK:G=_JU7YO_
M /!*Z8WO[*%IK6L>-_%'C;XF>)OB_P#'KQ1\>AXQ^%-G\"->\%_'_7?BQXFU
M#XN_#J\^#&F>)?&^D?#^3P;XOGO=-FAT/QWX^T'QC=?:?B3H?CWQMI7C6T\4
MZM^D% !3)"P1RN2VT[< $Y[8!(S_ #],GBGT4 ? O[6W[1W[37[/VJ^$9?AC
M\"?@S\8O#GCWQ-X!^&W@;1]9^/7Q"\"?%OQ?\4O&6J:E%?Z!I_A'1OV;OB#X
M'TKPMX;\-64GC'5/'/B+XG:1IUAH.E>);K6++2H]+L9=6\J^&W_!0GXC^(OB
MG\ K+XD?L[Z!\/\ ]GC]KKXJ_&;X._LR_&/1?C;_ ,)KXWU[Q9\-/#_C+QSX
M#N_BI\'[OX9^$3\/-"^._P -_A5\6O&/@R[\/>.?B-=>$/\ A&O#/AWXD6?A
MGQ#XXM[#1_L#X@_L[:7\1/VD?V=?VA-9\4Z^@_9P\,_'2R\*_#ZW8#PMJOC7
MXS:7X$\+P_$75U#[W\0^!_ VA_$#P?X< BD TSXK^*CYD).R?Y>^&_\ P3PF
M\&_&/X7>+_%7Q]\;_$7X+_LX^/OBC\4/V7/V?M7\)^#=*T7X0^//BMI?CCPU
M<:IJWCC2K$>*_B+IOPX\#_$OX@>"/A/INOSP#PWH?BRZDUJX\2:QH_A[4M+
M/(O^"J'Q[^!?B3]G[3/AOH'QI^$FM_$6#]K3]C?3I_ &D_$KP7J/C:+4-)_:
MP^$DNIZ>WA6SUN;73J&G1VUQ+?6"V/VNVBM[AIH8UAE*_L8".<>I!QSSGG]3
MSZ<YZ5^*?_!4+]EK]F/P7\#['XQ^$OV;_@!X9^+=U^UK^QWJ4WQ5\/\ P8^&
M^D?$F74=>_:P^$D&N:I_PG-CX:A\3QZIK,%U=6^IZG'J8O[ZVO+RWNIYH;JX
M23]K ,9&>Y/YG./S_2@!'&489QP>?2O@S_@H5*++X#^ [@J9-_[<W_!+RT*
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M(-XT^+&M^'M33QC;?"WQ9>^,O ?@BQ\&^)[72QX&\-7VE:I!XE_=A8&RN=H
M'/0X.YFXSG(Y P1SCKZ((FR<[,GL,G( 7)P,G*L#CJ<@C/(!ZXYMC(I<L,/:
M":@O9U+1C%MQ2<\1*I-QE.I^\DY3J0G[*JJE*-.-/"6!H3NVZC;M=\VGNJT;
M)12BE9.R2BI>\DI.3E^-'@_]@+QF^F_#32?&OPS^!+6_PC_9H_;\^!NBRE])
MU^RUCQM^T!\4_P!FOQ3\+/B=I>G2^ K6/PY_PD7A[X4^*#XV,ZR:[X6O;;0]
M/6[\517LFH6/ZO?##0-3\,?#KP%X9UN:&?6/#7@KPKH6M3VUS->6TVJZ/H.G
MZ?>R6U[/%#/=P-<V\S1W4T44DR!)'BCW #NQ$W/RJ02",YR.G Z$ GYB,#GT
MIP1P1@*,[0P]0K$]>OH"/3'H<\-?$U\1!4ZB4H0GSKDYN9R]BJ$_>E*4Y<T9
M2EK.SJ7<KR2:WITH4U[BM[O*F^BO=:*RT>VFBTT)AG@XQQCKGO\ AU !.>>@
M[&G4@SCY@ ?0<C\Z6IBDKI=-/1]ONM\K&H44450!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y6_\% /^
M3J_^"1'_ &>YXZ_]8]_:.K]4J_*W_@H!_P G5_\ !(C_ +/<\=?^L>_M'5^J
M5 !1110 4444 (??V/Y'/].:_FH_;?\ V6?C-;?MP>'==_9S^(7_  4>^-_[
M1?B[P+\4/B1%IO@G]LGX%_LQ_!CX#_ W7?'NCVMYX$BUGQM\'_']]XKTJ[\:
M3:9;>"O =QX'\:2:-8Z-<ZQ=^)-%DMXFU/\ I7;H>,\'@=3QT_'I7X,_\%1O
M /BCQC^T1\*=3T?]BG]IC]IG3-#^"OBW3+3XG_L4?M"^&OV;OVBOA'XFU'QS
MX>O[GPQJ?C.7X[_!OQ)K'PW\<:!!!>7_ (:N+?7=%35]*L-3BA6_9IK< ^M/
M^"2OA_0_"/['FB>$;*Q^.^B^,?#'Q2^-VD?&?PS^TM\1O"?QD^-'A;XY1_$S
M7KGXHZ'XK^,G@CS/#/Q9LHO$EU/?>#_'^G7,KZ[X)O\ PZU_9^'-1AN_">@?
MIG7Q9^P#H6B^&/V9?!6@>'/V4?'?[%NCZ=K'CQXO@/\ $WQ'X<\8^/-,O=3\
M:ZUK6L>,O%/B_P -^.?B1%XHUOXC:WJ6I>-=4\0:UXSUWQ+K&H:Q=7^O7T^H
MSS2O]IT %%%-9@JL3GY1N. >GUZ=N>>!R< B@!20.X'U_,_H#^I[5&1L5@C9
M<\ ,P/(.< $@9^;ZGC/:OSV^/G[>^E_"S]H+2_V;OA]\)M9^-WQ)M/#_ ,,_
M%/Q TS1/BI\%OAI-X/TSXS>*/&?AGX4:+H<'Q?\ &W@__A97C_QK;?"_XN>*
M;/P'X,EN]7T[PO\ #ZYU'6FT]_$W@VWUW$^&_P#P4,TSQK\8_AAX%U[X#?$[
MX=?"O]H'Q_\ %[X7_LU_M">)-5\"W/@KXR>.?@_IGB3Q/=:7#X9TG7[KQKX)
MM/B5X,\!_$GQQ\)M4\4Z3;V_C#P]X"U4W8T75-3\-:9K(!Y5_P %@=5^+$7P
M/^&6E>'?!O@/5/A9J'[37[(C_$;QAKGC_7=#\;^%M1M_VL/@P_ANU\&> [/P
M#K6C^-(]5F\V+4IM6\=>$#I*".:"#50^(_U]4YSG&<MT.>-Q _0?GD=J_,W_
M (*T+)+^R1I86)R5_:E_8G<@#?A1^UM\'"S80DD <'..3QGBOTQ!!)]1D$]>
M,G R..V=N<J",@9&0!) "C G (P3G& >^3P/J:^$/^"A9EA^ O@-[6-IIC^W
M1_P2\B=%C:4BWE_X*8_LDQW4I5.0L%L\T[2_<B5&E?"(V/N^12R,HZD8&1G]
M*_.;_@IW-XPT_P#9:TR\\ 6WA6Z\<_\ #8W_  36M_!EMXUGU6T\)S>*[K_@
MI#^R?;>'D\3W.BPW&L6VB'59;7^T)]*M;K4([7<]G:74ZQV\JH0]KF66TG*A
MAXU<;A*<L=BJT</A\#&I4Q,)8NOB)QJ4Z-##*4:M>M4I584:-6I5E3J1@H-.
M_+.SVBWRK>6D?=2W;;Z)K5;H_0VWDC(W(RG (;Y@?O8QG!)'*C)(  W$X S4
MAN5YPR$<X^=<9'''7G((QSSGBOD;]G*]_;0O[GQD/VHO#'[->@6D6GZ:W@(_
M WQ/\3M=N;S46EO3K*>*T\=:)I45K8HB:9]ADTDW%Q(TMXDPC"1/)\WOKW_!
M7E6F"?#G_@GGY8FF\LO\0?VA\F'?($=]G@\J'9-ID0,=K;U#$ &KHY:FWAUQ
M/X=T(X>-)+&XGQ!R'"9/C/:1DU')\TJY=4PF:NAR2CC(X2E2>!DX0Q#FYPY5
MSZ.3H8MOFMR1PM652/O25YTE-3A%V3A*3:FFW%)+7]3!.I4D.AQZL!Z  D'@
M]?7I3U<'.6 (.><  9Z<_ES[$5_/7^U=_P %A-9_83^'<7AK]HKQ7^Q'<_M<
M'XX?"#PUJOP+^'_Q7\:RGPS\#OB)K%E;ZQ\4/$-CXFT[3O%%G=^&]%:]U^8_
M91HT.F);W5W.L<RK)^MG[/G[9W[)W[5$OB"T_9J_:5^!GQWO_"L4%UXFT?X5
M?%'P?XWU_P ,V%]>W5AIVH>)- T35;O6]"T_4+FTN(M.U'5-.M;#47@G%E<7
M/EOM^DSC@'C7A_AW(^,,TR#%QX4XCQ69X').)\#[;,N'LSQ&52RR.)J87-\-
ME^&P<\'76:X.668ZHZ.%SB$,QGE<L1#*L?4IYPQ6&JUJN'IU8.M14)5:,I*%
M6'.I-*5-RE)2BX252.KI248U&I3BG]5C!'![8.#G!'N._//X4N!C'48QSW'O
M52)AN!"MWR -P)/&2P^7)^\"3@AB3UJY7RE.:J14K-)N\4U*+MLKQ>J>^CU2
MMS).Z-@_S^='^?SHHK6P!1110 4@&/U_7DTM%%@"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /RM_X* ?\G5_\$B/^SW/'7_K'O[1U?JE7Y6_\% /^3J_^"1'_ &>Y
MXZ_]8]_:.K]4J "BBB@ HHHH .G6OY!?$?PAUCX<?M17_P =_P#AVW^UOXE_
M:M\&?\%AOBY\<O$?[5/PY^ =EKNO^._V-[NZ\?>"_#7AKPW\5(_'-AJ?BOX=
MW7PJN_ FA:7\,IQ:Z!'!I\MW'X<778KK5+O^OAL<$DC!SQGG /'';&?Y=37Y
M.?M.?M__ !X_99\0ZJ?B+^S3^SKX(^&%[XNUKPW\-OB=\;/^"C?P1^ 5K\2K
M'2EDNK:_T[0_B%X+MCI^I76DI_:5SX:36-4U#2K7=]IF:.,S4 ?H)\#?BM_P
MNKX?Z;\0O^%9?%OX0C5+W7+'_A!?C?X-3P'\1-/_ +%U>ZTO[;J?AQ-4U@6V
MGZO]F_M+1+@WTAOM+N;>]*1-<&-?8:^8OV0_VA(_VH/@GH/Q@2T^%UD=;U;Q
M/I36WP=^//@C]I/P)$WAO7;K1!_9_P 6/AY;VOA;6+UTLT?5M-M8$NM!O_.T
MF^W7-I(:^G: "HY.5< $G;D8."<$GC'.5//0\D<'I4E!('4@9.!GN?3ZT ?C
M]^UY_P $V/$7QX^/OB_XQ_#KQ#\"]*A^/?PQ^"OP8^/$OQI^#DWQ5\9^$?"/
MP(\9?$7QCX1\6?LT:Y%K>DVW@#XBZG)\4M:35]1UNVU;3K;5_!WPZ\3Z1!:Z
MOX?N&O-;X5_L _&+P[\7O@-%\4/C?X0\=_LQ?L;?$OXA_%G]E7P-I_@75]+^
M,3>+_'/@GXC_  V\/0_'#XAW_B.^T;Q5IOPH\"?%SQ_HWA^;PWX?T/4O&&J7
M>A>)O%]T]WI+6E_^M=12'"M@\G. 3MYV]O4'(R #S[YH _ K_@IA_P $_OV,
MOAS\.+/]I'P9^SUX"T/XZ77[8G[(GB:7XDV8UUM>&O\ BG]K+X3Q:[K*K+K4
MMA]LU.#4+Y)@UD]OMNI62!7$;)^_"A<DKC.3NP<_,<$YYZ]/?&.U?C]_P5\\
M3?$*P^"?PP\-:%\+5\2_#K7_ -I;]D>X\;_$U?'NB:+-\.M0T[]J[X+MX?LA
MX%O;"XUOQFGB&:2ZA>;2+^Q&D^29+E9@Q1OV!7N<G[S#GMAB./:@!3R.?\^G
MZU\"?\%(!L_9[^'^TG)_;Y_X)3]>>&_X*A?L>;OS!/Z=*^_*^!/^"D7_ ";W
M\/O^S^?^"4O_ *]"_8[I6U3[.Z[IZZI[IV;5TT]7KJ[A]X+:11;RB@;P!@#'
M.<=><9R,GKW.2.8#90<J8U9B&9B2">>A(Z<-SD@\#ZUH^GM_GU_QIC LO&&.
M#R>,X#;1TX&['TZCD5C*E!QBN6_+>WO3T;:TO[2]NOO.5KW5DFFDVE)*^JUO
MUWZ[Z7Z->7<_.+]O7_@G7\(OVY_ WASPSK]OX9\$>*-%^+GPB^)EW\2K/X<>
M$O$OC#7-*^%GB5=?/@C4=3U2VAOI=!\0VB/IE]'+>SV\5E(\4EG<VTLMM)[G
MXG^!7@_POX=^(VN_!#P[IOPH^)NJ?!CQA\./!OB3P+HNDZ<OA3[4?$?BC0+W
M1?!L\,?@:74M*\<ZT_B1)[_1675;Z..WU6:ZT\&)?J'RF"AC@N-JCKD;2<J2
M2,@')4C!^4<U'+;F5=CQPL)-RF-Q@%&7;(AQU5A]X#&4XX->UCN*^+LPR;A_
MAO%<09MBN'N%L=BLPR3(\;C<7BLIP=;,,9DF*S2"P6(QF*P]:AC:?#^#PRPU
M:A5P^'H2K4L#2R^ECL;2Q4*C0A4JUE1BJU>$85:L(Q522A&<(6DHQFU%U')O
MG3E:\W-Q@X_*'[!WQ)\??%W]BO\ 9"^*GQ3NQJ/Q,^)/[,_P2\<_$74/L5KI
MWVWQWXG^'?AS6/%MV+&P2/3[07&NW>H3-;6")91%B+8"$(!];B8D,?E.,'@@
M@8&XJ>^Y@#CMD=<\5^=&FZ!X2_8+\0_L^?"'X*?"'56^"GQL^)=C\)K_ %/6
M?V@OB=XOO/A7XC7P?XAU7P3I_@_P=\5-6\>>7X%_LWPC?Z?+H'@[7O">E: W
MV.:#1[I/,\K]#HR<$X.X,21R22 H!W$=0#U8D\+G)!-8Y]&$\SQ>;8*G'#Y/
MQ!F6>YMDM&*P=#ZK@I9]F5.>6RP.%QF,67O*:^*I993PE7$2FL+AL!7I.6$K
MT71JGI"-.4N>K3ITH59)NTJBI0;DF]6JBA*HF]^:=[2-*B@<@45YZ>NZ;O9;
M[-+;?IJVM'Y6*"BBBK **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M73(8M5NAHFA#P"-%\-O]CD\/V.F-IUEY/[W*NW/NQ/?H23@9/J?IR<"@!U?
MG_!2+_DWOX??]G\_\$I?_7H7['=??=? G_!2+_DWOX??]G\_\$I?_7H7['=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?7M0 N "3CDXR>YQT_ >G3DGN:;(=J,PZ@9&" >W&3D<].:^<?VF/VLO@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#\K?^"@'_ "=7_P $B/\ L]SQU_ZQ[^T=7ZI5^5O_  4 _P"3J_\
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M]FY;!R,CH>112#Y0H^@ZYZ#U[]*7O[<?US_2N%.]G9V:OZ>36]_\F6%%%%,
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M>/EO+./P;XF_H/K^>C_@J[XS^%G@[]J[X+'Q;^V?\-_V(_$VJ_!6TUF'QO\
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MZ23NCLZ*P->\2>'?"^F76M^)M<T?PYHUF-UYJ^OZI8Z/I5JIY!N-0U&>VM(
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MI\6GOXL\76NI^)_B>L][X<DBM-?+WFC:9>1PW$]OJYN=-TO3KK5K']CO#?\
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M;"HZ<<3F*PT.5Y9*&'Y*U2O'"T.+&X>O/*L%AJ^!KXW%4J5/#5*WLH5X49/
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MZKK?IK;T;;6GIROYBT445L,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MM!3C&6\:M*5"<9*%*3C*%1N324U:=E&::G%6:+OE9SC!YYP.^,=#C.#R.?\
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M(?$/ !X/[1O[2O!ZXP?C >XX]  !Q@5Z]H'[,OP=\-_"[Q7\'](T/Q-!\/\
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MP5Y '!.TE5*X8_)?BG]AO]FWQCXF\1>+?$'A;QU<ZYXIUK4=>UJXM/CS\?\
M1K.XU35;F2\OI;;1]#^*>G:+I5N]Q*QAT[2-/L=-M8RL%E:001I$OHWP?_9L
M^$7P-N]>O/AMHGB32[CQ';6EIJ[:]\3?BCX]BG@LW>2W%O!\0?&OBF#39$DD
M/F3Z5%9W$P*+-+(J(JC672ARPQ6,J5W9NC4RO"4:#DN5U%+$4\ZK5N6FE45*
M7U5N=H\U.DISY"T[ZI)63NIOFO?5?PK)-/75O;U/<-CD$;9,8.T%6 P23@]"
M!GMGH!NY/*-(P*@JRL^[">6WSXY('&> VXD'))(."./BL?\ !/7]E51A?"'Q
M$ .[(/[1O[2N1NR3_P UA)))+9 ]CQ@5[)X._9N^$?@7X=>*_A=X9T3Q):^"
M_&UQJ%WXCL+_ .)GQ0U_5KJ75-.LM*NWL?%OB#QIJWC#01+9Z=:I%'X?UW3(
MK6:.2[MHX;JYN+B8D\N=_88W'5*EUS1K95@Z,%3O^]DJE/.\3-RI1_AP=*,*
M[485*N'@N8=I_P L>B5JDK^K7L4D]G?NW?2R/<<2$$^6RXW8!5CN/.,8Y R%
M.2!SC@@ F">X$$<DLF$"*'?S2J)$-I)>0DX56'9FP".!NQ7Q@/\ @GM^RJH
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M07=S.[Z1'!&]R_[:(2@/F$#YCEB< G@9&<8!Y..V< MC) ):*.O2B@ HHHH
M**** "BBB@ (!X-%%% ";0>W^?Z4  # '%+14\L5M%?=W^8"8'IWS^-+113L
MNRT ****.5=E]W?< HHHHLNR^X HHHHLNR^X (!Z@'ZT?Y_.BBBRWL@# ]!1
MC_#\J**++L@"HWC#]3@8Z=LYSGZU)11RQ_E7S2?X--?@!$L05MV2>OMUZ]*&
MB#$G.,\X 'ICKU_#I4M%3R1[?+2WW<MOG:X$:1A,X)YQ^AS_ /6^E1M",$ ]
M1MR>,9SSQSG./S]JL4?Y_+I2]G'E::B]WJHM=]G"UM-5:W>X[ON_O93^S'=N
M!7.[=D[B>N2H&<!3P.G Z8[R^0, %CQ[9_4Y)_$FIZ*F-.*73?M'5J^GP7MV
M5W9*RLE87Z*R]+WMZ7UMW(_+&S9GJ<Y]^O Z=!T^IIGD#^\>.>@J>BK]G'M?
MUL_EK%V7EMY#3:V9&T888)/X\TT0@$'<>#_D5-11R1[7];?_ "(7?]?YD;QA
ML<D8SQUZ_6D2((<YS[$"I:*/9Q[?E?[^6_XB\B-H]Q)W$;NHP/3'7K2+$%.0
MQ_3^?:I:*.2/;7OI?UORWOYWN.[V(3""3R1GM@?Y_P#UFG)&$SSG..OMG_&I
M**.2/;YJR?GJHIZ]>_4&V]_ZML0>0/[QX&.@_P _Y]J>(P%*Y/))ST(SCT^@
MJ2BCDCV^Y)?E%!=D'D#^\?R%2%,JJ@D;?U^H/Y^U/HH]G'M^2OZVBK_.X79
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M=^C4;;;64+-6;T::\MPW^6W]?T_,K"#!R,=O7. %'7U^7KUY-/CC*$<C !'
MQU*XX&!T7GCDG/'-344HTXQ>EFK7LE&U]G+2*N^B;3:6E[)) 4445J 4444
M%%%% !1110!^5O\ P4 _Y.K_ ."1'_9[GCK_ -8]_:.K]4J_*W_@H!_R=7_P
M2(_[/<\=?^L>_M'5^J5 !1110 4444 %%%% !1110 4444 03<%">!N )R
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M* /./BU\(OAK\=/ 'B'X6?%SP7H/Q!^'OBN*RA\0^$O$EJ;O2-5CT[4[/6;
MW$2O%(LMCJMA9ZA:3Q2Q36]W;0SQ2*Z U\>?!3_@GM\*OV</VIIOCG\!-+T7
MX6?#[5?V??$'PB\5_"CPZGB#[#XF\::A\1_"OC/1?B-J$M_KU[ILEYH&B:+J
M_AJRQIJ:D+?7KH'4&M%2U3]"J* $'  ] *6BB@ HHHH **** "BBB@ HHHH
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M<PU*]\-I=C5+30W^S1:OY$UK)J5@628 '[-45\$_\(5_P4H'!_:*_9!R.O\
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M!6T* QW5^^I 13*D4A4 _47^E%?!/_"%_P#!2;J/VC/V06#<K_QB_P#%0\8
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MCBOV0?\ Q%[XJ_\ T2= 'WM17P3_ ,(7_P %)_\ HXK]D'_Q%[XK?_1)T?\
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M_8:ZP]U'I#:N+69M-75I+*.:\CTQKP0K?O:0RW*VIE,$;R[%(!^<<7_!2O\
M9$UVS\9^)M=TKXF:+XM^#:>$?$7AGP9X\^ /CKP[\7O'.A_&/QA_PI3X:^-?
M@#X.U_0H/$_CG1/BQX_U&?X6^']0\+QP7MYK5P^D:[;Z787UN]]]D_ GXZ>
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M?0_B!X;TOXY^(=>\7_$KP_\ !5/@I^R,2\L<$@\AV)#-R#TX !.<A0 < '-
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M:G8:_P"#]/\ $%OI&B?3>E_\%2/VS/B#\;?V>OV.? OA[]EWPM^T/XH_:?\
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M\2_@+JGPL^"7[0?[2V@?\$V_V7/VX/@>WPR\-_&#4F72OBO\6->^"7BWP/\
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M,YP.A!_/(]NY[9YXZG+J* &A1DGG.<\]!QCCZ]_4YST%.HHH **** "BBB@
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9 HHHH ***:_W3^'\Q0)NR;[(=1110,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #A G # 2(  A$! Q$!_\0
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M^$AU?_H(W'_?PT?\)#J__01N/^_AH_LBI_,OQ#_6.C_(_O1[/17C'_"0ZO\
M]!&X_P"_AH_X2'5_^@C<?]_#1_9%3^9?B'^L='^1_>CV>BO&/^$AU?\ Z"-Q
M_P!_#1_PD.K_ /01N/\ OX:/[(J?S+\0_P!8Z/\ (_O1[/17C'_"0ZO_ -!&
MX_[^&D_X2'5_^@C<?]_#1_9%3^9?B'^L='^1_>CVBBO%_P#A(=7_ .@C<?\
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M!.3J-Q_W\-=T<OJ-:M(XGCH)Z)GM5%>*?\)%K'_01N?^_AH_X2+6/^@C<_\
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MN<27$:M].3_05\]UV82*Y7(SK/6P4445VF 4444 %=%X'T4:[XJMH)8C+;0
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MR#W('>O%P-=0;A+J?9XRBY)3CT.#HI2I4X((/O25[!Y(4444 %%%% !1110
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M_P *F\(?\^,W_@0_^-=A]E'_ #VG_P"_AH^RC_GM/_W\-:*I):*1+BGT./\
M^%3>$/\ GQF_\"'_ ,:/^%3>$/\ GQF_\"'_ ,:[#[*/^>T__?PT?91_SVG_
M ._AI^UG_,Q<B[''_P#"IO"'_/C-_P"!#_XT?\*F\(?\^,W_ ($/_C78?91_
MSVG_ ._AH^RC_GM/_P!_#1[6?\S#D78X_P#X5-X0_P"?&;_P(?\ QH_X5-X0
M_P"?&;_P(?\ QKL/LH_Y[3_]_#1]E'_/:?\ [^&CVL_YF'(NQQ__  J;PA_S
MXS?^!#_XT?\ "IO"'_/C-_X$/_C78?91_P ]I_\ OX:/LH_Y[3_]_#1[6?\
M,PY%V./_ .%3>$/^?&;_ ,"'_P :/^%3>$/^?&;_ ,"'_P :[#[*/^>T_P#W
M\-'V4?\ /:?_ +^&CVL_YF'(NQQ__"IO"'_/C-_X$/\ XT?\*F\(?\^,W_@0
M_P#C78?91_SVG_[^&C[*/^>T_P#W\-'M9_S,.1=CC_\ A4WA#_GQF_\  A_\
M:/\ A4WA#_GQF_\  A_\:[#[*/\ GM/_ -_#1]E'_/:?_OX:/:S_ )F'(NQQ
M_P#PJ;PA_P ^,W_@0_\ C1_PJ;PA_P ^,W_@0_\ C78?91_SVG_[^&C[*/\
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M:?\ [^&C[*/^>T__ '\-'MZG\[#V-/\ E1A_\(-H/_/J_P#W]:C_ (0;0?\
MGU?_ +^M6Y]E'_/:?_OX:/LH_P">T_\ W\-'MZG\[#V-/^5&'_P@V@_\^K_]
M_6H_X0;0?^?5_P#OZU;GV4?\]I_^_AH^RC_GM/\ ]_#1[>I_.P]C3_E1A_\
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MD\S;^["EO]H\5'F[_NP?]]'_  IV%<GI& 92IZ$8-0YN_P"[!_WT?\*,W?\
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MH,W?]V#_ +Z/^%&;O^[!_P!]'_"BP7)Z*@S=_P!V#_OH_P"%&;O^[!_WT?\
M"BP7)Z*@S=_W8/\ OH_X49N_[L'_ 'T?\*+!<GHJ#-W_ '8/^^C_ (49N_[L
M'_?1_P *+!<GHJ#-W_=@_P"^C_A1F[_NP?\ ?1_PHL%R>BH,W?\ =@_[Z/\
MA1F[_NP?]]'_  HL%R>BH,W?]V#_ +Z/^%&;O^[!_P!]'_"BP7)Z*@S=_P!V
M#_OH_P"%&;O^[!_WT?\ "BP7)Z*@S=_W8/\ OH_X49N_[L'_ 'T?\*+!<E\M
M" -BX!W 8[^M.J#-W_=@_P"^C_A1F[_NP?\ ?1_PHL%R>BH,W?\ =@_[Z/\
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M\*3<GN-<JV)J*A^U1_W9?^_3?X4?:H_[LO\ WZ;_  J;,=T345#]JC_NR_\
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M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445AZ[XDCT6[L;7[+-/)=3)'N5<)&&;&2W3/H*J,7)V0I245=FY17,
M+XL:;QC+H4%O;LL+!9)'N55^5W':G4XS4OB3Q+=:"QDCTB:ZM(8O.N+CS BH
MN<87/WF[XJO92NEW(]I&S?8Z*BN5'C16O+ZV6Q<O"0D*[_FD<L%"D?PY)R/8
M$UU(S@9QGOBIE!QW*C)2V%HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@
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M8<LKH****S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^E0/K"V\LWVE!'$N=F"2S\XX['.>QX[T7"Q=\J?_ )^3_P!\"CRI_P#GY/\
MWP*J?VW:;=X$Q3;NW",XZ$X^N ::-=M/W9._;(5"D+T)SU].E%PL7?*G_P"?
MD_\ ? H\J?\ Y^3_ -\"J\>I!]6DLMH 5<A\_>/<#UQ^E0?VVL/F-=1^6H/R
M*N2S<X^A^H.*+A8O^5/_ ,_)_P"^!1Y4_P#S\G_O@53?7+<)NCCFD!("D)@,
M3@X!]<'-2PZE'/%(T:.=B;BVW"YQG&?6BX6)_*G_ .?D_P#? H\J?_GY/_?
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M0?W1GD_F.]3'2;=E*EY=H8L@W?<)]/QYJ&70;>3YA)+YNQEWENI/4GW_ $H
M<\NCSI"KM RG<8P>/K]/I4)71;F1%4PAIG# +QYF*L?V-;G[TDS;O]9E_P#6
M'.06X[9[8J9=-MUD,@W[B5/WO[N,?RH J&31(Y6)-N)%(B/'3';]*5)=+B2Z
MBA16CAC9ID09!'?ZGBGQZ':122N#*3*&!RW0'.?_ $(U)'I4$8F :4K*A3:6
MX5>3@?F: *T9T=I%011@QJ)0S#ID9Z^N!_*B,:+;P?>A*K)@L>N[_.?:I6T:
MW"[8P0&D#ON.> 2<#\\?2GMI,)3:)9U 8E</]T'JHXZ&@"O)<:-%%)"3#Y?F
M?. /NMZ_IVJ1I='CBDC8VX1 -PQQSP/KUIT.CP1-N9Y&PQ* MP@.>!^=)#H5
ME;SF:-6#'!ZCC'Z]J &;M'5E5%A9@H "C/#$#\?O?K0E_I(#QK-'L9264 [1
M@\_J>E2#1;4'[TNT<A-_ /&2/<XJ$>'+(0M%NF*GDY8=>,=L<;10 Z=M*2='
MDAC+,K7(D"\'&,G/KT_*HS<:-;Q&58T#H!+L"_,"<8_'I]*M-I%HT4,95@L*
MA5 .. <T+I%NC[@TN .%W<*>,D>YQ0!3F_L0D9\KF4Y51P6P>"?3K[5*9M*@
MDAE\E$:X!8-MQ@*.2?2G)H%E$)!&'7>VX[2!Z\=.G)JR^FP/#'$=X6-2JD-R
M,]_KQ0! DFD@B:/RMT2&0%1R%Z5&HT^29EFL?+>4D-O ]-W8G&<9]>*M0Z;;
MQ1RI\[B88D+G);KS]>348T:W\N97>:1I2NYV;YN.G(% %))='5FD\M0[ 1K$
MP&X+MSD#T([U+$FF-;GSK);=(@LA64#&#T/!(/>KDFF6LN[<F"S;LCJ/EV\>
MV*C.E(+26$3S,T@5?,=LL .@'% $9N-'2?[67@\W&[S,<C/'X9P?RJ.5]#02
MJRP-DKO"C.,D<_F0>*LC28 A"RS*Y8,9 _S;N>>G?<?SID.C012[RSD*X:-,
M\)C'_P 2* (@FD(3(!$_G' QV&T=/08 J2*?2%'FP-!ETV\'&Y>G]*!HL!,@
M<G855%"G!  /7WY_E21:#9Q* &E. 0"6[$Y(X]3C\J );.#3I8V-JJ.@)4X)
M(';O4S6%HTPE:WC+CN13;/3H;%I&A9_WC;F!(QFK= %3^S+'RO+^S1[.N,4Y
M+"UBD\R.%4?CYE&#@=OI5FB@"JFG6L1S%&$RX<@'J0<_S.:EFMX9\>;&KXZ;
MAG'(/\P/RJ6B@"JVFV3L6:VC)*[2<=J/[.LRV[[/'G9LSCMTJU10!573;- H
M6VC 7I@5+!;0VJ%((UC4G<<#J:EHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# G # 2(  A$! Q$!_\0
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M!3_3 HBYZ8&.:4:5>1:G'/'Y31M9"VDR2"I'<>M;U%3[>?\ 7HE^A?U2GO\
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M"Y;48UC,WD %6W>9C=MVXSG'-.D\6Z#%;VUPVI0^5<J7C89(*@X).!P,\9-
M&U160_BC1$U3^S6U&$7@D$1C.>&/(!/0$]O6J5KXVTIM,@N[^9;-I3(?+8ER
MJI(R;B0.!\O4T =)16._BK0TU(:>VI0BZWK'LYX9AE03T!(/'K5*R\<:-=V,
MEW)*T"+<R6RJZ$L[(<$@ 9]Z .EHKF)/'6CP:NMI-<Q);26B745UORKJS$=
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MZGM4*:I9R:C+8),#<10K,X'0(20#GIU4T 4+WPVESJDE_;ZA>64DZJERMNX
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M9XFVLH88R#V-5_#VBP^'= LM(@FFFBM8]BR3-EFYSR?QH TF944L[!5')).
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MQI*TR@@\.QRQSGN>HZ5T.F*$O8%0 *I  '0"JU7=*0OJ$9[+DG\J .FHHHH
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MFNJ_X0[0/LGV5=.18O-:;"NP.]AACD'/S=QW[U:;P]I+0W,7V*,1W*1I*BY
M98QA!@= !Z4 <:_B_4DOY=-L+5C.;FY<O';O<?(C!0-NX8R3R<X'I5P>,=5$
ML=G/8);:C=_9FM8) 20KY\W=SSMV-^8K<N/#NA74_P!EDML3;GN04=U8%SAS
MN!Z''(S^%71H6EK>65V+*(3V,316S@?ZM" "!^5 ',>'/%NKZUJ%I*VFS?V;
M>;]K?9B@@ SM)<MA\XYP!@UV]8JZ/H6ASR:KY*6Q!)+L[;$+G!*KG"Y)&<#F
MM-[RVCNH[5YD6>1"Z(3R5'4_AD4 3T5E0>)=%NIIHH-1@DDB4NRJ<Y4=2/[P
M'MFH;+Q?H&HW)M[74HY)5R67:PVX&3DD8''/- &W14-I=V]_:17=K*LL$RAX
MY%Z,#T(J:@ HHHH **** "O)/&E@;+Q%.V,)/B1>/7K^N:];KEO'&CG4-(^U
M1)F>V^;CJ4[_ .->CEU94JZOL]#QLZPKKX5\N\=?\_P/+*DAMYKABL,;.1R<
M=!]3VI;>$W%PD0(7<>6/11W/X"J^B:[;:KX@O(9U1=%M;.:2.)XO,#%<8D9<
MC<WMGBOH\3B/8K179\KE64RQ\FV[1CN_T1<%A<.2(Q'*P_ABE5V_('-5R"I(
M(((X(-+8Z9HFK6TNHQPAPSW/V=;6,6I)CB4C &6SDGC)%4- UB37+2:WO&+7
M]LGF)*?O2QC@AO4KQSZ5ST,:YRY9H]3,.'51HNK0DWR[I_I8NT4JHSN$12S'
M@ #)-:T?AG5I%W&U\OVD8*?RKNG5A#XVD?+TJ%6KI3BWZ(R**N7FE7U@ ;FV
M=%/1NJ_F*IU491DKQ=T1.$H/EFK/S"BBBJ("I((GGGCBC&7=@JCU)J.NN\!Z
M.;S5#?RK^YMN5SW?M^77\JQKU51IN;Z'3A</+$5HTH]7^'4]&L;9;*PM[9<8
MBC5./858HHKXAMMW9^IQBHI16R"N<'@O3DB1(;B^@9&E*213[65)&W/'G'W<
M\^H[&NB/0UY9'XLUR'0+?4?[7AO)KRSNW,2PH!;M$"588YX( .>,GM2&=H_@
MS2"I$230,!"(GADVM"8@0A0]CACG.<]ZL0^&K*.>&>22YN)8HI8M\\I<N)""
MV?R[8 KC[_7/$EO>/8VUTTTEK8QW9FD:")96?/W]^/W8QCY>>>35WQEJ-U?^
M%Y81'?:?+'/;%K@*OEOF500K'.1S^E &C_PK_2#%Y4DU_)&+5[-%>X)"0MC*
M+QQT'/7WJU%X.TV,JTDEU<2++%())Y=[8CSL3I]T9/'?/-<Q>>(->MHKJ6.\
M>;S=8;3(E"1((4!^]N88WGH,\<CBEF\1:Z+2.RFN'BO@\[ PO;EFBC"_-(Y/
MEJ06P0!D^U '7:7X<M-(G#6UQ>&% RPVTDY,4()R0J_XYQVJ"_\ "&G:CJ=Q
M?3278:Z$:W$23%8YE3[JL/2N#C\3:JL#>)1<F6YET&VD^S@*(@S2LI?Z#KUQ
M^%;,6M^(4FBTVZN1;QW%W'$M[(\$DL:E&8@A/D!)4!21_%T- '1:?H+1^+=0
MU^X%N))8EMH%A).(U.2S9_B/ X[**-9\(:9K5Q/-<RW47VF-8ITAFV+,%.5W
M#N1_^O-9/A*YFA\(:Y<B[2YFBO;UA<*!M<JQP0.G:L^>_P!2DT2RN9;]KB\M
M=*?5GD:-5"R-'MC 4#& 2YP?2@#KO^$:T_\ Z:_\?YU#[_\ RU(Q^7/2J?\
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M\T\$NO3VKVIB7#Y4G=NZAMR]N.<8H ["7PII<VI:CJ#I)]IU"U%I.V_^ #'
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MV/?H1N7AAY$8X]:Z.B@"EI%A_96D6MAYGF>1&$W8QG'M5VBB@ HHHH ****
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MN9KEXPJOL.3P.!6?JSW6OWZ1:?;RS01 K&54_,>[>W_UJ]4DLK:7:)((W"]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'2@#U>D5U<91@PSC(.>:\NU'Q-XBMM?L+6V74Y$M]@N7EM J3)Y;.S;0IY.
M/O#!XQ6;HUSXOTVZTG2K>%[>)A!.2T1VS&5B\Y?Y3TSCJ,'% 'LE%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5:RT^UTZ.2.T@6)996F<+_$['+,?<FK-% !56TT
MZTL9;F2V@6-[J7SIF&?G? &3^ %6J* "BBB@ HHHH *I6^D6%I/>3PVRK+>-
MNN')),G&.2>WMTJ[10 R**.&)(HD5(T 5548  [ 4^BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHK(&N1#4;FW;:4B4E2.I(^]_/]#0!KT5D7.O1
M6T[JZ,5'R@ <EL_RI@U_]ZQ^R2?9QDB3(R1M#=/7F@#:HJK97T=]:+<(&0,2
MNUQ@@@X(_2H8+]YEL3A<SYWX[84F@#0HK,N=2DBU(62(,N$(D8?*N2>OOQP*
M='K,,DBIY4JAS^[9@,.,XR* -&BJ<E\/L4=Q&!\Y7 ;T+ 4Z\GFC,,4&P23,
M5#/T7 S^- %JBLG^UWMY_+NHP551OEBY53D]?RIJ>(K>2'S$MYVQDL O(4 $
MG\C0!L45EWNJO:7AA\M2A@+H2>KYP%_&K*74CZ2EUL7S6A$FTG W$9QGZT 6
MZ*PQK,\&T3Q;V!)D5$*LH"YY!_&IO^$@M?M$L7ER_N^=VW@]N/QXH UJ*S)]
M5#:/->VJGY<!=RYSG';\?TJF=7O"%0* ^YE8B%B3@ CY<Y'6@#?HJK<W+VU@
M9MH:0 <'Y1D\<^@J%;V6V)CO#$TF"P,7H!GD'I0!H45DMKT*(TC6\PC 9MV!
MT&!_,XI!KT3QJR6\Q!')QPIR5&?Q% &O15!=35;.&::)D:2$S%,YP !D?K59
M_$5K&)MT4H:-P@4K@L>>WX&@#8HK-NM:M[6SANF21HY1D!5Y [Y%-&MQEBBV
MTY<G$8P/WG)''/L: -2BLU-5/V*WE:!WEFW$1H.<#KUIDVMQK DD$32[W"@=
M..,G]: -6BLW^UU,2.MK.QD/[I<#+C&<CGTIAUV$DF.WG=,9#JHP< $]^P-
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MVW!^4XX4>Y[=: -"BL0ZXXMY2(6DF4,P5!P .Y_2GCQ%;$3 1S.8AD[4SNY
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M\@C:[$*P)( ^;OD\5)!8Z9*'F@AA<2?>9>0><_SYJ :(%7:DJ*A@$3?N@2<
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MTYW<@#&/H/RJ"30(V4".;RR%(RJ#G))_K3K?27L[%(8Y1(Z3^</EVCW'4^]
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ME X'R].>#\O7WI%T QR2O'<J"S[U5HMR#KG()YZ^U %F2TTAWVR);;HP"06
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M MEB%V0X?<)-K$@8QQEN#^GM0!JP:;:6T3QPPA4<89<G!JPJ*F=HQDY-*!@
M=:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &4 U(# 2(  A$! Q$!_\0
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MB_\ HZ7C-MUXXP:_^!W?K_3/SQ_X2+_@I?\ ]"3^RM_X5WCS_P"5]'_"1?\
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M#^5'^NG_ %17AU_XBV)_^C$/^(6XS_HZ/C-_XG&"_3P[/SO_ .$B_P""E_\
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M?ASK_P!4MB?_ *,/(:\+,7_T=+QE^?'.#_\ I=GYX_\ "1?\%+_^A)_96_\
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MCX,56A2UTPZ=\0O%A9#$7FEDOX)],"&.7$8C9&+A6D1PC*ITSHG_  4A//\
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M/EP;EB_'^U _XA;2_P"B]\7_ /Q9&<__ $/'P-_8?_!2#_H?/V4__"$^)/\
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MA[_92_\ "%^)7_RXH_L/_@I#_P!#W^RE_P"$+\2O_EQ7WS]F;_GE_P".Q?\
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M^//_  3%\>_M?_MV^._V6M=^,_\ P1KU.^\>_'SX>_%3PC^SYXS^(?BVQ_:
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M,_CQ\5?^"LG[0NI?MI_'?XF>--(^-O[&<VJ>'?B%\/[+Q&EQX_M_$WP(U?\
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MTI1K.*G^<^-2CA>#L-Q#13CFG"7%_ O$63UJ<W3KQQD>-.'<AQ6$HSC&3?\
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M2E65&<;NZE*GBJD%"2CR7G2H^T4VW&U6%TG[I_3&0W!5F^8A1M7Y2WS#! [
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M>$O_ !%_PC_\T]?H+Y/_ $S7_OK_ .M1Y/\ TS7_ +Z_^M1_KCF?_0NX._\
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M' ?_ -# ?\0>X/\ ^JK_ /%E^*W_ -'A^<O_  S#^V!_TD,\:_\ AA_AW_\
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MP'VO:RX6OU26FKLE=M)M^#W!JU<N+%LO^3E^*NC>FO\ QG;ZWTU>FW;\[?\
MAF#]K_C_ (V&>./_  Q/PYZ?^%'USWZ=1CO2?\,P_M?\8_X*&>.,X'_-"/AU
M][U_Y&3IVP.??O7Z&QB-@W *A1R"P8$$#@@D#.0/I\QS@@N*QJI8<Y/=0N"1
MSUX. ,C. ,8!YP5_KYQ+M;AR^FBX%X%;2DI--K_5-/51>EM_=^+0G_B$'!C3
M:EQ6TD_^;G>*/2ZDFUQ]RJUM6Y63W:V?YX_\,Q?M?]!_P4,\;CT_XL3\.^#Z
M_P#(R8]<].O4=P?LQ?M?]_\ @H9XW([#_A1'PZ&,],_\5*02.<XP#G@#O^AC
M(H21\*%5 >"HQT'<[AG[W)4@Y!!R*6%%9$+!1DY+9!ZY'J/EQSR026!/44?Z
M]\2;*/#O9_\ &"<#[VNTG_JFUHO[T7OHF+_B$'!=[<W%=[<__)SO%%63V;3X
M^4[=I*+@VTHS=TY?GE_PS%^U]_TD*\;\?]4(^'>3CKC_ (J4]>V>?ZG_  S#
M^U_@?\;"_&W& 2?@1\.\G&<G_D90!GC'&![YK]#"$V*<J&<X''7KCTZDC?@$
M@#.T%>9UC1WP$4G)..=H(W<$D Y4K@CD$$%<8%'^O7$E]N'?GP/P+';>W-PM
M&]KJ]O).TG8<?"#@R6SXM5DG_P G,\5'I):;<?2WNGOK'WH\T;M?G9_PS#^U
M]_TD+\;#_NA'P[_^:7'Y<4G_  S#^V!_TD,\:_\ AA_AW_\ --7Z,_9P2<1H
M1G^_@= ,#Y22,#/8Y)^I7[/Z1)W_ (AZGU0GVH_U[XDULN'79VTX(X$_^AC^
MGH5_Q![@VUT^+/GXF>*K_+CP_.7_ (9A_; _Z2&>-?\ PP_P[_\ FFH_X9A_
M; _Z2&>-?_##_#O_ .::OT:^SG_GFG_?0_\ C='V<_\ /-/^^A_\;H_U[XE_
MEX>_\0C@/_Z& _X@]P?_ -57_P"++\5O_H\/SE_X9A_; _Z2&>-?_##_  [_
M /FFH_X9A_; _P"DAGC7_P ,/\.__FFK]&OLY_YYI_WT/_C='V<_\\T_[Z'_
M ,;H_P!>^)?Y>'O_ !". _\ Z& _X@]P?_U5?_BR_%;_ .CP_.7_ (9A_; _
MZ2&>-?\ PP_P[_\ FFH_X9A_; _Z2&>-?_##_#O_ .::OT:^SG_GFG_?0_\
MC='V<_\ /-/^^A_\;H_U[XE_EX>_\0C@/_Z& _X@]P?_ -57_P"++\5O_H\/
MSE_X9A_; _Z2&>-?_##_  [_ /FFH_X9A_; _P"DAGC7_P ,/\.__FFK]&OL
MY_YY)_WT/_B*/LY_YYI_WT/_ (W1_KWQ+_+P]_XA' ?_ -# ?\0>X.[\5_\
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M655'(;)R1D#1'#'_ '>.GKCW[#UQC'<FF&%=H4*#SSVXQSMY&.>0"< \^M3
M8 'H,5\PE:W9*W>_G=ZW?6^GSN?H:C9+Y;7Z+NVV[MMMMWNWJURV****HH*1
MB0"0,GL/6EHH!E5VEP#MR.#TZ' SZ\@G@$ $^F#CY4^!6O?M/ZK\0?CA9?'/
MP?X+\.^!=*\92VGP4U'PO=QW-WK?A)+[6H[2]U8IJFH7%P\FA1>'KN[GU"QT
M6ZM];OM4T^&PEL[6"X/UBQ.,8R2<  GC@$D]CMZ]<'ZUEC:"#\^<@8 /(95#
M9^5<%CQT!7!W +G;TX?&4\/A<QPDLNR_&3S&CA*%/&8O#U*V,RN6&QU+%2KY
M35CB*,,+B,9&+P.+K5*6)A/ SJ4U"FVJJ\3,<HK8[,LBS"GG6<Y?3R7%X_$U
M\MP&*HT<MSZ.-RRKE\,)GM&>#KU<5A<#5J+,<!3P^(P<X9E2I5*E2M2YJ$KL
M0DV,-RDG=@@9XXQT'.% YY)!&!TS_,Q_P4K\:V7P/_X*]?LY_M6:EJC:3H?[
M)O[#5[\3?B7?(AO$TKX#^-?VQ/AM\'/CAK]QI:SQ/=P^'OA_X^U'Q%(T<-U/
M!;Z/=W%G;O=V\&/Z:H. 0 54.5 R,' #;A@MU[\\YSA>0. \4_"/X8>.+K5K
M_P :_#GP+XPO=?\ !NH?#K7;KQ/X2T'7KG5_A]JU_#JVI^!M3GU2RN'U#PE?
MZK!#J5YX?NWETJYOH8KJ6V:>)'KEBK+IZ]7ZM66G335:OWG)OVE9*RVTM>[>
MMWK?R:_!=#^/+X>?M$?M _L\>(_VQ_CC\-(=8TCX[_\ !0[5?^"97Q8\6>(-
M/@^''Q$USX(Z7^V-\1/^"AWB+X<KI>G_ +27C?\ 9K^#L^N^!?@-X*^!W[.G
MA,?%GQAX,\":;XLM-'N;E_'CV=IH/BO[O^&?[<_[:OQ6/P"_9R\4_M$^!/V8
M?$7BKXV?M<>#M5_:[^(O@W]E3QOX[\::9^RIX3_9Y\6:#\&O$7P^^#/QT^,G
M[)W@;X^^/]2^,?Q*T_QKIOACXE:K?WGPT_9G\>>-_"G@+X6Z[XKGT;X6?T(>
M(?@E\'_%MCXLTSQ5\)OAOXFT[QYHGASPSXWT_P 0>"?#6L67C#P]X.?4I/"&
MB>);;4-.N(M<TCPK+JVIR^'-.U))[?1)-2O9M.2WENIRW.:C^R_^S?J_PWT#
MX.:K^S[\%-4^$?A2_MM3\+_"^_\ A?X(O/A]X=U.UN+B]AU/0_!]SHLF@:7?
MK=WEW.;VRL(+IY[FZE>1S=S[V,_EI_9(_:G^(OP;_9=\8ZOX+^(WPM\)^-&_
M9$_80TKPE\7O#OP&E^,^L^(/&G[0/_!2_P#X*C_#K5;'X?\ AFTUKPYK/C:]
M\2_\(Q8#X'>$?B;\2],^#/PY\8^(=1\3^+M9L_#6I^-+[5O>/V?OVY/V_/VA
M="^%_P "]&^/$WPV^*&J?\%3/BE^QAKGQF^+/P$_9SU?XJS_  8\._\ !-?Q
MG^V;=3^,_AO\#_B;\3?V=K;XP>%?%2+X=\*:[\/O&9\)R1^'?"MU\1_ US=2
M^.? FH?T3S_LX?L_3^%=9\"S_ KX/2>!_$7A31/ FN^#F^&W@\^%M7\$^&M=
M\0^*/#GA+4?#XT?^RKGPUX?\1^+/%7B'1-$EM)-/TG7O$6L:IIT$%[J-Y--:
M\%_L^_ SX<6^BVOP\^"OPI\!VOASQ%)XP\/V_@SP#X5\,VVA^+)_!4_PYN/$
MVD6^C:78Q:=X@G\ 7$_@>?6;18K^?PI<2:%+</IA-J0#X-_8S_::^,?B;]A+
MXR?$_P".WQ'^'GB7XJ?L[>.?VP/A;KWQFF\!ZKX7\$^+$_9E^(/C[P9HWQ.\
M8_#7P)<ZU?Z6VH:5X7M-9\:^&?A^[+-=C4;;PK86S7.GV4'XR?#S_@K'^V9X
M8T']HNV\2_&+2_&<E_\ LQ_LU?''X8_%?]H?X%_ GX/>$?@S;?'C]J+X??LZ
M:]\=;+P%\ /CA\1_'.H_LL^!?"/Q/N?C7=:9^T=8^!OBUI.E_#&]@U>\U/3M
M6U.31?ZQ-'\#^#M TK4]!T'PGX<T;0=:U'7M6U?2-+T33;#2]6U/Q5=W6H^*
M=1U/3K>WCM;^\\1:A>75UKES=0RS:I<W5S->M*\TCO\ )_Q!_8 _9R\0_"3X
MB_"WX2^ _#7[*]_\1/#-[X8N?B=^S9X%^&GP]^(6CV%]XD\.>*]0LK>X/@S4
M_#VN^']>U7PIHMMXL\'^+-!U[PGXOT"&Y\.>(=&O-(NY;9@#\%/B[_P4 _;O
M^#?Q-^)G[*OAC]K+P[^T_J=Q\>_V5O@9H/[1WPG^#?[(^A?$/X7V_P 0OV?_
M -HGX[>,K#4O#GQ;^,_P9_9/U/XU?$36O@_H'P\\*M\0?B5X/\):5I/B&2Z\
M*?"_QQ\2O[#\#>)O>;']J'_@H=\8?V6/A/XJ\)^)_P!J&S^(WA[XV?'[X4^-
M_%7[(/[/7_!.O]H?Q'XU\/?#N[\,Z;X2U_XZ>'=;_:;^('P-^$GC<7,^M:=J
MV@_ _P"*7C'3[[Q!8ZS<:C8>$;3^S?#FF_I;^SA_P3%_9W^!7A#XT>%?%^A^
M&?V@(/C[K/@^_P#B7#\2/@U\ /#'@O4](^'%G#;?#WPKIOPA^$?PO^'WPDTS
M1O"-X+S7K">/P8-:G\3:E=Z[J.JW5^+:6V^_/!O@OPE\/?#.C>#/ GA;PYX(
M\(>'K06&@^$_".BZ;X=\-Z)9+)++]DTG1=(MK/3=/MC-+).8;6VB0S.\C*7=
MB0#^53XO>"OCC^TM\7_@CX"_:5\2_!+4/$/@_P#8E^(/Q6\+Z=_P5Q^%/ACP
MCHFI?$*3XV^+_#'BK5A^S9^RY\:_"GPOTSQU8>#+'P%HUS\:-)^)7B'4_A#X
M!U>TUC2?AUXEU;QUJS67A_[0NB?LQ?$G]AKPO^UA\'A\.? 7QJ^%WP%_9J^)
M7Q^M?VE/CU\;O'?[;'PF^!G@7PMX.\6>!/AW_P $]?B?XYN;>?3OB9\8_!&F
M^)E^#'Q'U?PW%H_QM\5^(?"MK\3O"EGKWC3Q0W@S^NSXI_ OX+?''3]+TCXT
M?"/X9_%S2=#U!]5T72_B7X&\,^.+#2-2FA^RSW^FVGB;3-2@LKFXM6>WNI;=
M(WN;<FWF,D3%#E^)OV</V?/&_C/P?\2/&GP+^#_BWXA?#YM,?P)XX\2?#;P?
MK7BWP:=%F^UZ(?#'B'4M&N=6T/\ L6])N]&&G7=M_95UBZL/L]R/,H ]E0@M
M)G;D/@D'@\9&?<*=K<8R#@DYQ+2;5&< #)R<=SW_ #[_ %/K2YYQWY/Y8S_,
M4 %%%&1G'?\ PQ_B/SH **3(..>HR/<<<_J*7/.._7\\X_D: "B@'(R.AY%%
M !111G/3W'Y'!_6@ HHR./<X'UY_P-% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %1J^696QE0"VT''.X]>W '7!SGK3F ((SC.,'OG/'KWQV-?F=\;/#'[3W
M@;]NOP=^TQ\.O!7QF^/?P7\-?L1_'?X>ZU\#_!WQ0^#WA70KSXV^)/C]^R7J
M7@#_ (1;PO\ %'XA?#'09?&6H?#O0?C-X@U3QQXLU?\ L;3M!\+2^&+/Q#I6
MK^(M'T#Q$ ?I:TV",#@J6R<Y(!&2H[C;D@YQG )!.##+,PX(4 C!8,1MY(8C
M.-Q"G! ));!3<0!7Y-_\$VO@E^V5\(_'_P"UM?\ [4&J^*;C0/&7Q(:^\'77
MBCXD:)\0K7Q[XFC\5>/[K5_B[\.;'2-<URY^&GPS\0_#G5?A5X.T?X>>(+/P
M5KFF:YX#\07=SX%TZTN+'7-?^I?CIK7[5C^+[;1OV<-'^!^N6]CI-E?>)X?C
M/K?C;0A9R7[3)IW_  CDO@JRNWO/M)M[D:DNJ,B6WE6WV-9?.GV=& P57,,5
M'"PQ>781RC*7UC-\PI99E]/V=D_K..JX?$PH1FYP5-RHRYJCC#1NYX^?9Q3R
M'+:^9U,OSK-(T)4HO \/Y3B,\S:LZLU33PN5X3$87$8E0YN>K[.O#V=*%2K+
MFC!P?UVLX+(,*RL6Y5LX^4YW#<3@8X.!EB H )(N*PZ<=> .N"21G//0\CGG
M..,5^9'@;XX?M@>$_P!HKX0_"']H/P=^SKI^C_%G3_B#=66H_"/6OB3K>JV1
M\#Z%'JDWVJ7Q6VFV,'F7%Q:J8TT[4!<0&9(I;>XC3=^DJW*%<_-S@+^[;)QU
M)PO#>L>0X/7H379G>3XO(*N"IX[%9-B8YC@5F> Q639QA<YP%?!SQ>*P"G3Q
MU"A@X.4,7@L51G3EAZ<X2AJYQ:D>1PEQEEO&&&S*OE^#S[+ZN39M4R7,\!Q%
MD.8<.YG@\?3P6"S!4ZN Q]7%573J8/,<)B*6(C7E2J0J<L5&5.2>MD>O^?\
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M6NKNSE;K=V3;:3LE=M=?U-M):Z6TU<4M=%JY16KT2O>^EFR_3/,7.W/S;0V
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M-?6XY\Z/!!.=R\<<@<Y'7YCCWR0":E2;V2^^6W_@O^MMQ>TC_/#_ ,"I^O\
MS_73T-&BH4E20Y5@2N%/#;=V,G:3@'(/4$\ 'N,RY!P0?_KY'^!S3C+FUZ/9
MW335KIJV_P#6BV6G]??_ $OOZ[BT4450!1110 4A( )/ '6EI& ((/0\<>]
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M?BYX)E\:_'N+3=2\,7M]9_$_4+JS\+>*?$&GZOH>J+K_ (V_M'1KRRU9+-D
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M?UH_9H_9EC_9S\0_M-7FFZ_%JOASXX_&GX?_ !*\)Z.EI/!>^"_#G@']CO\
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M1V=FW'TC/MWQGCTZ]?7CUSVQS0 M%%'^?K_GWH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D(!&,#![4O3K47FCCY7.>GR\'KQDD G(QQGJ&.%RP (9B>"1GYSQTR
M> <\<X!P<?=Z9//Q%J/QF\0:1_P4)\.?L]V^EZ/)X4\;_LE^)_C'J>L3"\_X
M2"UU_P "_$WPYX+TO3;)DG6Q&D7FG>*;^XO4GM7NFNX+5H+B./S(V^VY&5F0
M#.?,Z$'' +$'KAMO.TX.W).._P"6_P :M#\3^'O^"HG['?Q7T76])A\/^,?A
MI\6/V8_%GARZTJ6YU*_LM4\&^,?C]::UIVJ&>*'33IVL?"K1+#8L,\]U!?Z@
MC;$*$^CD]&E7JYG2K>SO_8&?5L+[5S2CC,-@:>*PTU*#3C.'U/'2@[\O-923
M4U;SL?-TXX.>JBL?@XU6E=^SJU*U*2LXRT<JU&]E=*\DURW/K7XZ?LR_#C]H
M&[\&ZIXT?Q=I?B+P)-JS>&/$?@7QAK'@SQ#IT.O6L%MJUF=3TF2&=K.\BMH3
M)#(RC<F X.0?CSXZ?L5?#_P!\%OBMXXT+XE_M')KGA/X<>-O$VC2WGQ\\?WM
ME#JFA>&]2U+3YKFSDOHQ=VZ75M$\]O/Y:RQCRU\QB(S^I\>3A@!R7^8<[@%8
MD^V[J.2,$XYSCYZ_:RP/V9_C[@YQ\&?B=R"Q)"^#M7P1@_CCT'!!P1]%PCQ=
MQ/A,WX5RK"9]F=#*X<0Y!AH9?&O1J818?'<2</O&4(4\1@<:X8?%/%8GVU*%
M6-.2Q%9JE"52<I?DOB?X:< 9GD''G$^/X2R;$<05.$.)<94S=T,50QT\1EO"
M7$,<!7G4P>:Y?3J8C"0PF%A0KU,/.O&.%HQE6J1IP4+W[+>KZIK_ .S9^SYK
MVNZC=:IK6M_!#X2:KJVJ7TS3WFHZCJ'@3P_=7]_=SR'?+=WMS)+<7$K_ #R3
M2.[99C7T#$Q.W[P)V[LC;D; PX('.6)(QNZ^]?-O[(9_XQ7_ &:@ "?^%!?!
MKOT'_"OO#F1Z9X&#_M<]#7TE&3E![@C.,_<^;(]N#QW)KY?-8PAG&<0A%0A#
M-LVA"*TC"$,VS>,(17V80C3A&.R4806EK'Z5PM5G5X:X9JU9SJ5*O#?#M2I.
MI)RG.=3(.'9RJ5)-7J5)RG.<Y-MRE.<GK)WM44@(/Y X/49]1VZ$?4&D!YP2
M.^.G(XQ]<@,?P/I7)V_K8^A_X/X#J*** "HW4L ,9Y[]A[<]SSGL/RJ2B@/Z
M_K5?U]Q5=<)@X!P5QU.X@GC!QG&&]Q@=:^>?VEO&NO>!_@AX^USP?K7AC0_&
MQTF#0_ NH>,?$.C^$?#L7CCQ5J%KX;\)I=Z]XEN+'1;.XGUF_M+;2H+NY5]3
MU66QT^UBGNKJ&&3Z-<97/=1D'..1U^GMZ'GM7%^,/"OASQIX:U?PMXMT33/$
M?AO6[3[%JNC:M9PWVG7]L^':*XMG# X=%EBD 26":..6"6.9$<;8*M0PF/P6
M*Q5*-?"X;&83$8BA.G0K1KTJ&)I5ZE*=+$5*-&K":I1YJ->O1H5H*M0K5:<<
M2ZD/'S[!XW'Y+FV RW$SP>/QN59C@\%BZ=;$X:KA<5B<'7P^'Q%+$8*G7Q6'
MJ495YRI8C"X3$8C#UO8XJCAZ\\(L/5_(*R^)?Q83]G#Q]#-\:?BM%\8OA#XP
M\;ZE\3/"UGKWP?\ %OC?Q':^!?#&FVEW:_#3Q;>6_AC0Q\-=#\2>(?#7C;QI
MJNF>'M:\506UMJGP_BTVYUV_T^SU+:M/VBOVB_AC"?B%\5O$N@^)M)\9_"&'
M7/!]EH;V]UX;N+>^@\'76E?%V#PO8V%MXQ\(>"?!&G+KP\:?\)-9Z?JGQ'^(
M'Q \"_#GP79#7)])M9_T$O?V:?@%>>'/!/A>Z^$O@>?0O =]?7_A/39-$7R=
M*N-7<3ZZ6D5UN-0@\0S1Q7'B6SU>?4+7Q'=007.NVVHS6\,D7;ZO\*OAWKW_
M  E9UGPAHFI'QGX:T[P?XEEN[5G_ +3\,Z/]I.EZ%O$H%GIFF/>W=[8VFEFQ
M6VOYWU.#;J.;Q?O<3QGPWBGBX?ZN4:M''YCC<97A5PF1T:^&PN*EA)1PF7U\
M)-U:-*=2A6Q,E5]J\)2>'R?"RGAZ/]IU?PO+?";CO!++:KXYQF%QF39#D^5X
M)X;-.+:^ S''9=A<RIRS//<!CXRPV-KT:>,AET51>&IXZM4Q?$F.H?VC5IY-
MA_)?!_Q UW7/V=G\1?#_ %B3Q+XUTK0=5TJ76/C#:W?A\_\ "9^';^;3?$M_
MXRL_#<-[$;;0K^'4M072?#E\=(U&&PMM$L/$^GV,[:]9>1?LY?M&Z]>?"CX/
M'XCR^,O&?Q3^-.C^,/'&@7VE?#KQ/<^$;329=0\0ZAX;A\2^(/#^EW_A?P)I
MD.CZ7;VZ6VJ:R72/:D=S?2W5I<W/V5IW@'P9HW@I?A]IOA[2[#P6='NM!/AV
MUA:#3FTJ_BN(;^U<)*;F9]1%U<O>74EP]]>3W,]U<74MU,TK5;OP6UG\/%\"
M?#K4HOAW%IWAVR\.^$[_ $O2[+4HO"=GI\%K8Z9]CTC52]C=+86-LEM;17IE
M"%4G?S)8E<_-4\UR7V..P=7*Z=58_.Z&8X7%5:U+#XO"8&CA,53I4*V.PF%K
M8V>&CC<73QV/R_!8&AA,;1PRI2K.M'"RI_>XGAOC*.(R?-:7$CH5<HX+KY/B
M\KP6'Q6*RW,L\JX[ XG$XS"99F^-I8&&.J9?E\\LRK-,WS;$8_!5L7'$U<(L
M.\92G^<,'_!1/QEK/@?PAXE\-_"_3;R;Q5IGPY\%M<+!XSUJPM/CGXNTW7O$
M7B[0].TKP=INO>+=?\*^ _"7AC4-66ST71[WQ!K][J>AZ=)=:% FMZCI%7QS
M_P %$_'OA3P3X1U:W^$FG+X\M=(M-;^)'P\UJ/XJ6FKP+>^.[CP)X7TC1A#\
M-#!X 3XHR6DVK>!]>^,E[X5%I#=:?8:EX<N9?M]U9?9?@3]DSX0>#O@?H_P*
MU3PY;^.O"UEJ,OB35;OQ1!$VJZ_XSO-1FU6_\;7%UI@L'TS7KB_NKA[>[T>2
MPDTZT8:=:21VA>)^@U;]E[]G[6;[P]?7_P (O \UUX4L]$TWP^T.DKIT>F6?
MAK4HM;T"WM+?39;2U)T?5(4O-/:6&::VF>X6*017=TDWTE;-?#B&:35+AO,:
MV4X?,<=[&?M8?6<PP$9166JJL3F=&6%>)IU<5]9I3BJN$JTLLQF%GB*L,9@7
M\52X8\>L3E-*O6X_R7"9UC<HR95\+]2YL%D^9SO7SQ86I@<GQCQDL)5IX%87
M$.LZ684*V=9?CHX2A4P&;+S[X-?''XG?$[Q!\7]7U+P)X;\/?";X:^,_B+X$
MT/4K;6-1U'QMXUU;X=:O'I6MM::6T%MHT&G6-]I^O:3-J*W<J7^KPQ6VF0M;
M64]_>?'/PU^-OQGU=?V1?C9=?'>Q\4ZO^U+XGT.YU#]FS2-&\.-X0\._"S7=
M*U'Q#X@&@7]O;QZ]%K_P>T2UCN?%GBO5]36WU7Q!:W>AQ0">_L-*/ZM^%/!?
MACP+I2Z'X2T:RT'2!J.L:O\ 8['S6234]?U6[UK6+^62:6XN)[K4M4O;R_NI
MY99)IKFXD?(WA1YIX#_9V^"'PU\6ZUXS^'_PK\#^$O%&M?:A>ZYHFA06E\(K
MV=KJ^M]/D02Q:39WMV_VF^L-&BTZTNYCYMU!)( R\.%XDX8P=;/90X>A1IY@
MX4<KPBPV48Z+P<<FQ> G@L=B,WJU<;@*F*S3$TN(,3F>0RGCZM? 8++J"P.#
MA*K4];,^!./\QH\(4ZO'%3%XG*YXG$9WF#Q6=Y;.GF53B++\VPV999@N'*.#
MRS,:.#R3 XCA3"Y)Q+"654L+FN8YG6J8_&U94:/PM\ _B[\7-?\ VDK>T\:?
M&B#Q!X4^)=W\2?%'PPC\+6_@7XD? 7XJ_"#39C>>"-3^%?BWP%K$?B3X=>,?
M"NF36$/C*W^(>F:AIWB6?^TFT/5-2DN;6Z@_6&V8$1 MD!%&W8RC*J0.6'/(
M*XZD ?>R#7A/P]_9Z^!_PQ\3ZMXK\ ?"_P $^#_$NLBY6\U?0M$MK:[%O=2F
M:[MM/8%X=)L+N7$MU8Z''86=R41YK>1H8RGOT&SRHF &"BGH.!M8CD\ ?= 8
M':>"/E(->5Q/FV5YUF5'%Y/@?J&$AE^$PE2C]6RO"<^(PJY)U88?*'5PM&G*
M"A!0GC,;5=2-:M[6-'$4\/A/JO#?ACB#A;)<7@>(\W><8W$YUF68T:U3'9]F
M=6C@\=5]I1H5<=Q![#%XFK&I[:;G2R[+:,(2P]!X>6)PU;%XZ01 G)4<DD_G
MNSU/4_E]*DZ= >_I@Y))_KC/]X>^'4?Y_P _G7S]EH^VW;[E:_W,_1/Z_J[9
M%+G!QP=KC)S@ J3SCMD#/(/IU!'P[XK^'GA_XF?M3^-]*\7)=WNG^'_V?_A%
MJ.F6K:MJEI:V-UJ_Q"^-D&L7D<%KJ%K;K)>6^CZ;'=W#HTK+IUJA?R$4#[C?
MG:/7>#S_ +#9_P#K^AQTKXL\2>$+;Q]^T?\ &SP5?7][IVG>)OV8_@IHVK36
M A-S-H]_\2_CU%K&F*UQ'+&L6KZ<UWI5VP42I:7EPT#Q3B*5.W+YU*7UZ5*3
MI2CEF+M.#M./,\*G*$N67+>SU^*TI=W?YSB*A0Q/]AT<12A6I5.),IC.E5AS
MTYJV8?'!RBIQ32ER.\9.,;IV.H_X92^$95)!I%P%E*"-CK.M!9-Z@($(UC#M
M(?\ 5^665^.2,&IC^R=\*%X;1KL @!0=8UK)(#$@#^U_F;8K9P>@+,, $^4-
M^PIH[W8FA^-GQFL=-L;1_#VAZ;I'B.?33HO@A+KX62VOA.*[AN#).8K#X3^'
M]!F\1>3;Z_<:1+=A;ZVU"[U74=5Y;P[^RCX)T#XI^$IM/_:Z^*&H:KX$\8P6
MVF?#+5_B5I>MW[ZS::C:_&E?!NJVVH:E<^(;Z^LO FHZA#I=E>12ZQ9_"CQS
MXHGO_P"T]&U?1KW1E]?QUW_MN(3NVTJKY=93>B]FTEJ[?Y62Z5P_D<HQ?]D9
M9K%-OZA0U?)1_O\ 9;M+T/?$_93^$DC,(](N9 C,C;-8UJ3:\;&.1&*:PRJR
ML-C)Q(IR'12#BI#^R]\%IEFDAM5F2S>0730^(M3E6U9))8W2Y9-;*VYCEAFB
M82^68VMY%8!HI D.E_LU^"_#$$>G/\4_B-I\7B+XL^'OBZT&G>.E\)W'BGXJ
M:#%KVO>)KF2;3/(GU;1?B!IMB=5\;^![;.A7@\+:AKD=C;-<:S</Y;9?L:>!
M[WQ)X[T*Y^,6J:WX=\4^&O!WA?XO?">PTKX>6,_B;PSX?\=?$7XC^![3Q3J.
MBZ?%XNLYM2D\<>(M,\2:U=7(U;XB:!;,NKWD[17,\9]?QW_09B=[_P 7_P"Y
M?\'S*7#^2+;*<L7_ '(4/_D]SU<?LO\ P5\Z> 6T1FM)[6UNX1XDU$RVEW>,
MJV=K<)_;A>*YO#+$MK%*$DN"R)"CB08M0_LK?"":,20:=)-$2X62#7=8F3*D
MAP'CUDH64@@CKD%>N:\L'[!_AF]TSQ/I^J?%;QWJ\NN^(?AKXRTGQ%-I7@*'
MQ9HGC7X3ZKXS\3^#/&U_XCMO#BZAXU\6Z=XW\7Q>,H]<\92ZO+;ZCX2\-6EO
M##I]K<P7/LGPZ_9H\'_"/X.V/P8\ ZYXM\,Z!I^JWVL1ZSH^K06'B%Y]2\0W
MGB&ZB%W%93V\=M*UX-.D@AM LVGPA9':=I9VJ&.Q<IPC/,,31IRDE.HI5*K@
MOYE2I4U4J[?PX-3E]EZ&&*R3*J6'KU:&0Y9BJU.E.=+#NA@L*JTXJ\:;Q-=R
MHT%)NWM*L90CO)/8HG]E#X2C=G2[H$\\:QK>!P""/^)QR1CC Z9)S2G]E'X2
MD\Z5<C YQK.M@XZGKK'(.T=.-P'<\ZB? JYQS\8?C3U^5O\ A,H.0.N3_81)
M'7)QC!Z'H'?\**N3@GXP?&H8.?\ D<H.![9T+H  3@9ZXZBN[VT+K_C),9YW
MRC.5?_R;UT=WWUN?*JGBFE?PVRI-IW2XAX3=G;354+:I>NOWY!_91^$9(QI5
MR3G! UG6CG''_08(!)'(]L<"FC]ECX10.LK:)<3")O,>-]6UMD=0P9D.[6-H
MW8PX<;=IQA@"M:G_  HBX)V_\+B^-0+9!*>,K<% _&\#^PBP8 \,0 226RN0
M?>%MQ;:;%;>;<3FWM8(#/=OYEY/Y, B\Z[EP!+<3A/,GD  DD9F4 $UA7Q-2
M$J2P^<8S%^TJ14U]7QV!Y%&K1LT\2I>T4M4^1I+7FO!G?@\!1Q>'S#^T.#LK
MRA4L-5]C)8O)LV6(<\/BG-..6JD\/R)+^,Y.=[PY)01X+^QW<75Y^RE^S%=W
MEU=WMY=?L\? RYN[N]NIKV\N[JX^%_A26>ZN[NZEGN+JYGE<S7$]Q-)<3RL9
M999'=G/TLGWAU_3D@ 9QVX [<GIQ7S%^QA_R:1^RSV_XQP^ I_#_ (55X0'\
MSWY./;CZ>3[P^G^/!_'G\O6O.Q&N*QTN^-Q[MLDWF68MV2226MK622222227
MU>6*V7Y:NV696MVWIE63KK=_>W+NVW*\M%%%0=X4444 %%%-8$J0.O;ZT -;
M[H X!((('3!!YSCDG..>3CJ365$6PX0@8=STP""."1@%=HSGS-IR"",;:TBC
M_+\V<8&,9],]>F<8SVZU\K_ OX;?'KP5X_\ C=KOQ8^,D7Q*\)>-O&4NL?"W
MPY%I+V \!>'&U+5YH-$<F)$!M=)N]&TAH[9YK>ZET8ZE(R7EY,AZ\/A*-?"9
MCB:F8X/!UL!1PU;#8#$O%K$9Q4KXN.&J8? O#X>M057!4:DLQQ'URKAH/#4Y
MJC.K7:I/P\RS+%X3,LBP-#(\RS&AFN*QU#&9M@Y9:L'P]3PN7SQE'&9HL9BJ
M.-E0S#$PCEF&65T,966+J0EBJ=/"*56/U+$<+SC(#%-V 2HX' /0@#DX]<<B
MOD_]H_\ ;J_9 _9"O/#VF?M._M&?"SX*:KXMT;6?$7AS2_'?B6#2M4U70/#D
M^GV>N:W:Z:J3WRZ18WVJ:?9OJ$T$5K)>7 M()9)U>-/K!%*!EQE@S/\ +P>0
M"!_M8.<\]<8(R*_GA_X*;ZG\*OA;^UGK7Q:\4_M"?MZ_L\?'OQ9^R9X,^%7[
M*S_LW_!+4_'OPZ^-WQ#\.^.?C3X_L_@UX9U?P?\ "OXQ:_X[^*]_XL?P]J?C
MGX':PGPSM_%/@&+POKEE-XPTK0O$6K_#WC2V]WET6G;39=EU6KTLW9Z+VUV?
MKUZMOJD]K/;=OLC])/&'_!4W_@GC\/?'UY\*_&O[8/P3\-_$73;[P]I.H>$]
M4\3^1J]IJ/BVTTB_\-V<\0MF2.75[7Q#HDNG[I,3#4K5&(DE"CVK3_VPOV7=
M1U+XZ:+8_M ?"F;4/V9--N]9_: C_P"$QTJ*#X3:/8S>)+/4]6\8WD\Z6>FZ
M7H^K>#/&6@:WJ/GRV6A^*/"/BCPOJT]EXA\/ZMI=G\&^#O%WQZ_:,_:C_8[^
M!WQ]L1X.O_@%^QG\-?VX?VKO"'A*YU73_#GB+]IKXF>);[X:_ KP1<RG['+>
M^"O WBGX8?M$_$2Y\-/+(LOC3PG\,[G5+=K/35@U'\K?VN?V2=<^ OCCQY\'
M/@!/XC^.VA?!;X$_&[X_>,OA]J'PZU2]TGX4_LO_ +0_[6%Y^TC/\ _$7B#P
M_)+JGQ:\3_M%?M2_#L:[IVG6$NF:YX<_9>_9=^+7AK7DFU;XE>&M9U)C/ZQM
M!US1_$NA:+XDT#4+75M#\0:5IVN:)JEF_F6NJ:5JME#?Z=J%I(0ID@O;*X@N
M('P"\,J' !Q6L1T&>_?O@' _/!/T-?D[\&?VAOBY\6O^":G[1'QF\3>,-.U[
MQ+X>\+?MC:=\)_CIX*\/7'PVT?XN?#OX;W?Q%TKX-?'KPCHWVZ\31--\;>'-
M'T7Q/H>JZ-J=YH&I1B'Q+X9OYM$U+3)V_"7P[^T+\4KK]EGXH:E^S5^UE_P4
M'^*.N6/_  31\3>(OVQO'7QK\/\ Q>\.ZK\#_P!M2Z\5_L@S? W3_AKJ7Q!^
M%?A:Q\!_$O7/A_XY_:'U;5/ _P /+W6O#^H_#W2? ?CW7+&]M=3\,>*?%X!_
M83HGQ \(>(/%WC3P'H_B/3=3\8?#Q?#K^-_#UI*7U+PPGB_3[C5O##:I#M A
M76]-M+F[L CR>9#$S-M/RCLVY5AUX/'OC(!QSZ<=Q]:_EW_:.UGXR_ GQS^T
M=\(9?VA/VW]/_8_^&O[1?[%+?M*_&;PKXB\<_%/XU?";]F;QA^SQ^T/\2?BO
MXZ\,^*TTW6?%OACPGXE_:%TKX,Z'\;_%?PRT:\O?AO\ ";6O%>JZ/I7AG0]!
M>]T:G^SW?_&3]I?XU?LA?"V;]HS]N2V_9(\2^,?^"D_C?X0^.-3U_P >_"3X
MF_'S]GSX5ZC^Q7J7P%E^)?BC5O"WAWX@ZGX$M?%WCCXF6_PV\4:]!X;\;^._
M .E:4USJVJZ#KFM-X@ /WN_:,_;3_97_ &1!X,7]ISX^?#7X*S_$1?$1\"P>
M/=>BTBY\5+X1;0O^$HDT2V"37&H1:!_PDGA[^U)8(VBM?[8T\3LAN4)</VTO
MV3?^$3^ OCN/]I+X,W'@C]J+Q?HWP[_9V\6VGC_P]=>'?C/X]\07-S9:+X.^
M'NL6U]-8>(?$NH:E:7&C0:+:7+7_ /;D+Z&\"ZLOV,_DS_P5Q^,7A7X"_ME_
M\$^_B5XY_:O\1_L6>%(OV?O^"@/A2?XV^'_A'-\8Q<ZSKWC']@_4=*^&M]X?
M/@SQS:6(\3VWAO5_$D.K7FFVLB/X$DM8;]);MK:Y_-W6_P!GSX@?&C]F+]DK
MX:^!K'Q;JWC/QS^U]_P4C^-'[.7[1'BGX<>*/A)XV^,7Q8TK]GSXS_M)_LN_
MMD:[X5UG1_#VJ_#7Q!K_ ,>?#7@G5]*NH-)\)0:[H&AVMUH-O%I'BB.:Z /Z
M?OB_^W#^R/\  #Q)XD\&?&?]HWX3_#GQ?X.^'NG?%KQ5X6\3>*[&T\2>'?AE
MJ_C;P_\ #;2_'.LZ&C2ZGIWAJ_\ 'GBKP]X8M-3N[6*VN-4U:SAC<I(TBX?[
M//\ P4&_8K_:P\7ZIX$_9M_:;^$OQK\7:'HEUXCU?P_\/_$T6O7VGZ):7\&E
M7-_<B",11Q6NI74%C=*TOG07,BQ2QHX8#\7?^"?/B"X_:$_X*/\ PK_;[U'P
M'X[\'ZO^V/\ LR?M;:Q;:9X^\+ZAH/B3P/\ #;X4^,_V,OAOX$^'NM6EY:R2
M^'IK+Q3I?Q-U)-)FU:[M=8N9[G7]+#QSSR']&/\ @GM\3_#'P]^!\.@?$?7[
MCP_KWQ@_X*'?M_?#;X9:?X@L];6X\7^,)OVE?VH?BA#H6FO+8S)";KP1X#\:
M>*;.[O9+/2KVST>Z-M>2W5U:Q70!];?M&_MG?LK?LCKX5_X:4^/WPR^"LGCE
M]67P=;>/?$EKI&H^)3H$5K+K<FC::PEO[^UTM+ZQ&H7D%LUM:2W]E%+*LUU;
MQR>'>-_^"J__  3D^',OAZV\=_MC_ _PM<>+OAOX/^,'AU-6\3_9WU;X7^/?
M#2^,O"'CNV!M&_XIK7_"TB^(++4IBENNE;[N?RH8W*_&_P#P4QD_9Y\&_M0?
M!_XI_'W]H[]N/]E2XU'X+ZW\&OA/\3_V7/A;K'BGPWXD\;>-?B-HNJ)\++7Q
MGX,^$?QV\8CXP^+;W1= NO"OPFM_!NA1?%6TTJVL=*N/&][IMQX<M)?"GC?]
MJ#]IWX?_ /!+/]G']JC0-6\%^._C9\*9?VFOVY="@\)W_A5]=\+?!O1?"M_X
M9^#GQ \.7T,">!=0^+7Q"\6^#=5^-OPPMGFBL%\)>.?A)=C4O!FJZFNH 'Z>
M> ?VO_V7OBG\2I_@Y\-_C[\*_&GQ6M/ /A7XI7G@#PYXRTG5/%-GX"\=Z'I7
MBKPGXFO-)M[AKFVMM<\):]X>\66=K<+%J \*>(O#GB2:SAT77]'O;OUWX<?$
M?P7\6O!/A7XE?#?Q/I7C/X?>.=$L?$O@OQAH<SW.@^*_#>J1)/I/B/0+\HD.
MJZ%K=J4U#0]7LVFT[6=*GM=6TNYO--O;2ZF_G8_X*(_L<^([#X]>+]-^!_B'
MQQ\0_&'[2*_M&?M&7'P,\-:!/HVI^#-%N_V;? OP<_:9U#2?BWI:WVIV5[^T
M9X+^&W@+]G3X:Z(]I8Z[X0\:?&_QE\0/"VL-<>%]*M='^ZO^"07[0/Q6^.WP
M7\7V'C.#P+XC^&/PLF^"?@WX)_%GX8_#-_@E\/\ Q7IM_P#LW?";Q5\3OAAX
M=^$<UU=3^$'_ &9OBSK?BOX%:]IQ:&3PIXB\*:K\)/%-CHWQ0^%OQ$T'2@#]
M=6; 88.[:<<$*6QP V" <X ]R  3D5Y])\2_ \?Q)MO@])XKTA?BE=^!KOXE
M0>"3,QUY_ -EX@L_"MUXL2T"%3I,'B+4;#2))_,XOKJ-0A0%E_BO\$_M4_''
M4?V28O&7P<_:K_;X\??MAV_['G[9'Q _:Z\*_%#1OBS:?"WX??!;1/@M\6?^
M%&_%7X>ZI?>![;X?:;>-XN\'?#ZX_9H^*7PX\:W7B/XVVE_XJU[Q%+K&JW.O
MV?A7[_\ VKM1_:G_ &<?B;JOPN^!/QJ_;+\8^$=9_P""?^@_&KXH^(QXA\:_
M&WXKZ7/X]_;@^!?A?X^_%7X>Z3;>'M;M$^)G@?X W/C-O ^@>!/ TS>#=$76
MK_P1X%:_>6&[ /ZDU)VKG[V%R#C(SUS^OUP<5Y]KOQ2^'OA[XB^!_A-K/C3P
M]I7Q*^)6@>./$_@'P1?ZA#;^(?&&@_#:3PO%X]U3P]I\A$FI0>$SXV\+'6O(
M+26D>MV4S1F(R.G\K'A7X@?%/XQ>)/A_X#_9]_:=_;?\6?\ !/#XK?\ !0O]
MGCP#\$?VB-?\4?$_PO\ %WQSHWB']GG]HS4?VMO /AGXG>-O#&A_$S7_ ( ^
M"_B1X=^$>G^'/&/B#1DL]-^)E]\3_!?A/QQJ4O@_^SO"W[-_\%)/A_JGP^^
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MC_BU/@_ [9SC/ISU[5]/(#N_#)^A'_UQ7S#^Q?Q^R1^RU[_LX? 4_P#F*O"
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M+,Z/\>=.^"VG_LK?LX^(?VD_B1\5M7_:/\'ZWX6\!?&[X.?\()X"\=_LO_\
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M.QN-%GTM=(US6 #[()CXRY#8VG;(PY[Y.X;MF,\DE1R,!CE=L0(RW0EU_>,
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M#'_@J?XA'PYT[3/A=\"OVA/VQ/'FAVW[8_Q=^)\VJ^(_@;\/_%7@CX(_ O\
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MTFU9OCC5XO22>7<+JR2TS?BC6T817_-*]HW5TG9V>J9[%>?!_P"!VH-:-?\
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M7;C.13O^%5?"<@C_ (5S\/@<#'_%%^$N#[_\27D9!R1V/'I7CW_#%_[-V/\
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M/V@O&][X[\8?%#2/BK;:I8>/=/\ $>H64&@:-H>AZQI6MZAHEAX-^'N@>"O
MOA/0V@T;P9X7\.Z;;06R?F[\;_\ @F?XY\&_LR_&SP7\'/'WQU_;.^-OQ1_9
MZG_8]^%.O?MB?'GPGH^G?LY?"OQ-!-;P>-/#_B'X;_"?P9K.M:M\//$5MX4^
M(6I^+]:M?%_[0GC34_!'AR*V^*-OJ6GVM[%^WU% 'Y<:Y_P2=_9Z\4_L[_LJ
M_LTZKXH^*NE?#[]EOX*:[^SLL7@W5_"OAV3XV_!7XB?"_2/A+\=/AS\6EO\
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MMGX0T/1- M=*G\-:5IWP_P# OPFTKX:?"KX?:#;KX>\*> =-T6"SLK?[= P
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M6<ZN%J4<34HU*<&H58_T>HP#*O*D9&W)Y/?/8Y.3NZDD<XJ;'.?7CIUX/?\
M+\J^1?V,/C\?C_\  WPWKFO^)_ /B/XN^![S7/A1^T#:_#S7=,UC1="^.GPM
M\0ZK\//B9:)::?=W$_AVTU+Q7X7U;7=$\/ZN(=6TS0-0TR"\A\U6DD^MD8G[
MQX&!DC&21N_0=.G&,C-=%:C6P>)Q&$Q"M6P]6I0J).Z<Z4W!R@^6'/2J>[5H
MU%",:E&M1J0O"<6?G4)QJ0C.#?).,91O=/EE&,E=-MII-)IN_,I)ZIDA /!
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M9<GYG_ MC]#C\N*<)AC +X/L2>?0G)'X'WK\Q_\ A*?^"IXX_P"%8_LM<?\
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M?\-Y=+-I_?T:WT/U'F3UNN77_@._;5KK>ZVV5C R#Z C';!Q_A41A3(^5"
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M0TS5M-U"&.ZL;_3=0M9);:]L;JVD6:WNK=Y8;B%UECD"8:39R#G!!QU]OK0
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M5HNE>'=&M[J*XU"TUO7;V[U2^U277-3^[]'_ .2G^+_^Q6\(?^C=8KT<QJK
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M^V[#4=-?POXAUWQA<^'_  <_AW3=%^(7PM\->"9?B5JNC_$37]& /Q0\-_\
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M\0_&/PIX(M/C_P#'+]E;69O$ U'XL_"GQ1\7-*T#1!K'@76AX<^)/P]T>_\
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M'A^_^#NGZM^T6?BE\!/!OQUT?4KG7?B'\=_"'@OP-=:UX&\12_%>UN?B7?\
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M (+#^./A+\(OCW;:3^V)\.+/]I#XX_MD_&SXM_ /PS=_%/QS\4_V6/%']G^
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M+4_AM\,OA[XA_:_TNZ70?%WAR=]8\':S-J_A2+QKJ%G%=O+X+\%_@#_P46\
M_"[]D[PI\+?@G^W#\+_A;\.O^"5GP1^%O[1_@BRU_7_#?QWN/%G@;_@H)?3?
MM8_#OX ^-O$_C:^N?#?Q7\;?"ZQ\1^)/@G'I/C/1+FQ_9WU71-/^#%QX*OE\
M"Z;H_P"X7@G_ (+9? /XJ)\7=7^#G[/7[57Q7\&_!CX%?L\_'OQ9X^\.Z-\
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M /A"P?\ : L(=%UKX>^&?V5;CXQ_##QS'!XU^)O[4^J:EXZT?P;IO[[^%O\
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M#T3X&>.[ ?LQV_P8\5>%]$&B?;?_  4<^"7BOPW^W-XR_:2^)_\ P3E\:_\
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M_1M4NY1J\_V74=7_ #^^%W[#/_!6RXUOXH?M#:G\*O#GP6^)?_!5;X8?M_\
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MX.2.@R1*^-K9]">F>1R.,C)SC R,GBOP]^,?P'_;X\-_\%/]._:V^&FA:_\
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MC?%OX!?$W]BCXD?"=-"\%W_Q?^/'PFC\8ZA\(?VA_$E[J'Q"M_BWH?PKGOM
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M/X<^,4=[X$7]GRY8P?'_ .+UMIGQ!UK]EKQ=<^-?@7XN^+^C0^*QH_Q5\8^
MM0OKRPTOQ+XWT[6-3&@RQ:$UP;'3M+6Q_%7]E3]@W_@HWK4G[*W@S]H3P]^U
MEHGPEL_VA/@GJG[3_P /?%7C+P-X%T%9_!/[-7Q;T+XM_$G3?B-\/O\ @H9^
MU1\4OBEX?^+/Q?'@-_B-$]I\'_"_BS4YM+\4>%_AIHMO=^(;#2OL+_@FA^SW
M_P %-?AU^VUXY\;_ +7VH_&>6UO=0_:?M?BOXV.D?"W5_P!GGX\6^O?%ZYU+
M]F_7_"7B5OVY_'GCO1+7PE\,[;1K7P#X7\*?L0? O_A!/#<]]\.O'MQ=7NFI
MK6K@'ZQ_M5_\$^?V;OVS-9M=?^-NC>.[G4T^#7Q?_9\OY_!?Q)\9^ +;Q'\'
M_CK;:+#\0? WBFS\,ZM867B/2KV]\/Z%K6EG5;6:;1]<TJTU&PFBE5U?Q[XY
M?\$W_P!A'QMXG\0^(OBA'K_A'X@_&3XP^ ?BYI'BS2_C#XG\"^-U^*WP1_9Q
M/P.T74/AO?V&KV5YIMQ8_L^^%]1T[Q3I&E1W%IK6D1:UK6KV<TB2W4/\_P#\
M%?A_^WU\7_C)^VC\2/V<?A_\??%>J_#W_@H%_P %G/!7BCQYXK_:\T_PO\&O
MC#\)+?6?&_A/X._LJ^ M)@^*L_Q0^"?Q"T7XN1^';KPKXDT?X7>#O#_@_P /
MVUYX@T'XUZ?+KESHGAC?\"_L!_MIWOQ5^&_Q+^(?[*/[5NI_#WX3_MA:3\1O
M@CX USXQ?!FV\6_"7P#\6?V&_$/P_P#''B?1?"L?[;?Q1T'P[X/T']L&UL/%
MOB'P?-\:O'/C[2_A]JME?C2?$=YJ'B;PY  ?N'H__!+/_@GQ\8/@YXXC\.Z+
MXH\;_#;]J/X;_L>)J'CS1OC-\0+_ %/Q-X<_9%\,P0?LO?$#PCX\M/$ UFQ\
M3:'IT]MXAN?&EC?'4?&>K3#7?$5SJUY/+)-\J?%7_@B7^RKI7QFT;XG>,O'6
MM^!/V0-'^$7[4NA?%[PQK_QT^+WAOQUXR^*W[77Q?^%?BSQYK_B/XM_\)I87
ME_\ #SQY:^%]3\*>+? FN:J^G:]>^)Y(8]/O'U-IH?A3X7_L@_\ !7;PU\7/
MV+KSQ:OQTT7PWX _9._X)L^#O"7B?X;-\)?B9%\&/%/PJ^&$ND_MS_#'XT6'
MCG]M_P#9RT#1KSXK^.)RWBGQM9?!S]KJ_P#%W@EO#<?P^UOPOK_A"Z\-W'@W
MQ0_X)6?\% ?'GP#?X=>(/A'\=OB-HOC'_@G7^R5XI^,7@7QA^TE8^)&\4_ML
M_ _]N30?&/B?P_X>7Q5\84M]*^)6G_LL)XCT/PU>:??>%OAUJ>F'1=#N?%=I
MXDM8)X #^AGX2_\ !.V_\,?\%'?B7^WGX^U+X6VVDZ'^S_X,_9;_ &7?A3\,
MO".N:3:>$/A[X<NKS4-1^+'Q5U3Q%JE_:ZW\>;W2]2D^#NC:WX2T[1['0_@M
MH]AX<ENM275+FTT[I;7]@;]ASQ_^TI\;?C3X3N-=/Q97QO<1_M!^"_AY\8?%
M>E>"8_B]XQ^!&D^%+C7/B)\+M"UN/P]9_$3Q!\#?&_AN]GDOK&&74=-UC0?%
MT]I<:Q-9ZS+\+_L:? /]K[X9_P#!3'Q[XSU7X-_M&S?LR^+M)^-^K7GQ)_:B
M^(7P]T[6_A=;>)F^&]W\*OA9\-X?@=^V-\<_"W[1'A+2IM)\2Z1X03XI_LX?
M!SXA_ [PC<:M97?QB^(,VH0^'Y_./VA_V*_VS;;]KWXN_M.? ;X>_%FZ\4:[
M_P %3/@QXRTR#PM^T#;_  O\'>./V/F_X)H> OA'\7-1UO3(O&<&D6>GZU\9
M_">E>!=:UR[\*:K\1K*?P_X=UCP]I;Z5H%OJ,(!^@WB[_@C!^P?XUT_X<Z7K
M'@GXEVFE?##]GKX6_LOZ%IVA_&CXFZ%IVK_"'X(>/8OBK\'M'\;:;IOB&WL?
M&VH?#7XE1+XX\+:KXEMM0N+3Q)#;:E<BZFL[ V_O?[1'_!/C]F/]J3QGXY\?
M?&3PCXCUSQ+\1_V5/&O[%WBR\TSQEXD\/PWWP#^(/COP[\1_$WA^"ST>\M+7
M3]:N?%?A71[V#Q19QP:Q;6\4]A!<BTF,9_G-^ G[)W_!6/P=\._VD?B7:_!C
MX^>#?%GPO\<?\$W/VK?V6/V9_&W[1GAX:/\ $KXI_"C3?B]\/OVWOA-;Z_:_
MM"?M(-IFD?%7PGJMM=M<?$SQY/:^/=<N/!'Q"U;0/!-[/<>$?!W>W7[#G_!5
M?X;?M"_LYV&F>-/V@O$O@GP/\,OV-;;X<?&?X?-\-?B_<_##QOH7B;Q)XI_;
M:TGXR:=\3OVX?V2-'M++XIZYX@DTCQ)JS?!K]JAO&OPBETW1? H\'>)_"L7A
MN< _:?P#_P $FOV*_AK\==$_:'\(>!_'5MX\\-?$WQ_\7= T_4_BM\1M>^'^
MC^/?BO\ !&__ &?/BGK5A\.];U^_\(PR?$/X;7=K8^*G331-J&HZ#H%]%- =
M,AAD\@\0_P#!)G_@FC\,OA]^SQ\&CHFO_!FV\/?%GXP:5^SIJ_ACXS^.O WQ
M#?QU^T1H.O>*?BE\-?#'BVSUV+5]9TGQCX.\#ZA.O@F]DN['3O#_ ($TY](M
M[%_#ME/;_FI_P4A\-?M3?&+_ (*<_M!_"/\ 9K\+?M!^//'ME^PC^R;K?P.U
M3X9_M+:3\$OAS^S3\<=3_:A\?76C_M#_ !/\,>(_%&C?\)GX-T31?"M[;^,X
M_!?AWXB>++_PO!J/PWN? -]I?Q1D\7>"/:O$7[%G[<(33?'?PWA^(/AWX^>*
MO^"O7Q]^*\OCCQK\13XU\&_#S]GF']F[]MGX??LX_$.X\!WWCXZ#_P *;\-_
M$#XJ_#WQ!J_PK\*P66O^(X]2$6J:"MY:PG1P#]L?%_[)'P3\<K^RY'XET'7[
M\?L<^-M ^(/P)<>*O$,<^@^)O#7PY\1?"K2[[7;G[<;GQ<L?@[Q1K%K=1>(7
MOOME[<)J%RTUV%E?XQM_^"*'_!/6V\+?"OP-;?"_QE'X/^%GA+P[\/+GP?%\
M6/B0OAOXO?#GPC\5-0^-'A'X=?M$Z)%X@AT[X[>!?"_Q+U.^\1Z3X:^(\.M:
M<L=Y=:%>1S^';N\TJ;\??"G[#W_!236?A/IWP_/@/]K;X<> ]8^)'_!-'3/V
M@?!_Q,_:Z\.>/?BE\4_BYX'^/]GJ?[>_[2WPU^)?@[XS^(-2\"_!+Q5\+A)8
MG2X_$'AKQ/\ $F0PZOIOP=\"IH%KI6H_H1_P5^_9P_:_\=^'/V3/"7[)N@_%
M#Q'\!O %I\6_#7QC\ _"&]T;6/B)!>W7PTTGPG^SSXYL],\7_M??L87WC%/A
MMJX\0:G;WDG[0#7.@^*Y?#GBS5_ GC^&UN!I !^B.C?L%?L]:)\'_P!JWX!V
M5AX^?X1?MF:K\==9^,7@K4OB3XSUC2;>\_:6M/$L/QH7X;_VGJ5U)\-K+QK?
M^,O$WB&YL/"DFGVEOXFUFZU:RMK6=QM^<;+_ ((N?L$:=X6G\-6?@7XG#48M
M9^$FJ^$?']_\;?BKK'Q3^&-O\"-!UKP[\)_#'PK^(6O>*-2\1^!? _@W1O$O
MB>PL/!>B7L/AF:'Q'JJ:AIETLL(M?S#\._ C_@I!X*_:#L?CU\4M!^/FH? G
MPM^S'KOPN\>S>./C'\-O#WC>Y_:DTS]B*TTG7/V_?%7PG^&WQ,^)/P^TOP/?
MSZ/K7P1USX8^"_BQXON-.^,&J7GQL\)Z;K^G7%KK#?%/[(7[.?\ P4R^)?[)
MOP@^*7PH\&_M/:?\ /B/^S3_ ,$R?%?[1?P]\2?M:>$=?^+/[:]MHNI3^+_V
MD?$W[+GB_4?C#>7/PCO_ (@?!/7/ $4FF>/_ !=\!-0UN:SU[X07$VB77AR/
MQ'X@ /Z/?#?_  24_8W\)?$+X6_$[PUH?Q9TCQI\+;/X?:>FK6OQJ^)8'Q#C
M^%OBS7O&O@>;XQVTFO-#\3;K1];\3ZY(9O$Z73W^F:A_8=^;O1XK2RA]/_9G
M_P""=G[+G[(^I_"S6?@=X1\2Z#>?!O\ 9]NOV9/ 3:MXZ\4>)H+#X1:C\2;_
M .+-QH]Y:ZSJ=S!J>IGQGJEY>1:_>B758;1TTM+A=/AAB7^?G4_V0?\ @I[H
MWBG]GCQOHWPR_:F^(\&C?&OQ&_P=_9^^+7QS^',GPM^ 7[+-[^T%X9UKX9>%
M_P!H']H7X=?MA>!_C7X'^/7@'X7Z?XNU/QAX@\)?#;]O#X?Z_P##KQ!X8^ U
MW9?$/5- O=3CZ;QE^SC_ ,%6;KQS^T=X&T7X4_M%PZ18?%S_ (+B_$?X<_%R
M#X\?"5OAQXX\,?M=_!KQ?+^P_P"#_!5BGQO?XF:=JGA'Q7<:3IUCI_BGX=^%
MO"GPK\175D=-U^%(M0?2@#]E/&G_  23_8N\;>'M2T&]\'_$#1+J^_:.^.W[
M5EMXP\)?%7QWX:\<Z!\8OVDIKQOC3J/ASQ7IVK1:CI/A[QK'>36U[X6@8:%!
M:I;M96D,L%O*GRS\.O\ @D;^SMI?[>'QJ^(_Q/\ '</CS2]4TG]A#X@_L^_
M"W^*WQ'M/$GA[0?V*/AS:?"OPKXO^/?A@^,%TKXX:7:_$C0_#OBWP-XB\9Z3
MJ\-GXKTZ>2_GN-4^VM-^=_CK]AW_ (*B^#_$7[$FB_#J#]H&W\ ^$OV5/V8]
MOB'P-XF\%_&/XB? []M!?&]GXR_:R\<_%B7XM?MW?LTZ-XBN/'VF._AF\\1Z
MM%^U)X,OO"S>(_!WACP/X6:31KZ_^G?V\/V'/VQM?_X* ?M0?M)_LE> _%5K
MXT^./_!,CPI\"_AA\<-%^*'AGPGH?A?XQ^ _C#XH\2_$OP/KPUGQK%KO@#Q!
M\5?@K)X>\!?"#Q]H_P .O&?A7PI\0=6D\6ZK=>%I=+U?Q#0!]U0?\$?O^">G
M@+P?K\5SX$\0:'H.F_#Q/#TGB?4_BUXUTS4O .A^%?VG/BS^VOI7CGPYXO.N
MV=]X+\6>"?CS\6_'OCO1?']AJ-EK.B:=-:Z*;Y=$T]; Y.L?\$=?V ?C'X8^
M'VNWD/QB\;6,?P8UKX:6?Q$@_:8^,NLZY\6?A3\1OBXO[24Z_$;QHWC*\OOB
MEI]_\6+Q/B-H][XBN]2LXIY;.TM(CH%EING6OS%\-/V,/VG?B!^Q)_P5*^!6
MH>"?BY\.O@;^T7X"USPY^PU^RI^TQ\6M$\9?'7X6:_>? S^Q_B?<^.OB[X4^
M*WQ@T;1_!OQ<_:",OBGP5X(7XL^*M,\+Z6NLZ]>S^&]+\>S>"/"_PO\  S]E
M'_@H5X-^.G[#MQX8_9,_:F^"7PV^ %K^PQH>M:O)^T-X$\5Z%=?"?P7\(=0^
M&W[3/A'QQX7O/VR-<T7PM;WGQ*O9_$^G?#7X4_!KQL_C.PM(?B]XL^)NDZUK
M \"Z: ?M/XL_X(V?L1^+)=1N9- ^,6@7]W\5/C;\7=*O_"?QX^*?AV[\&:]^
MTE!I1^/_ (?\#-9>(1#X5\ _%_5M'L_%'C+P/ID</AZ7Q;&/$&EVVFZC%:RP
M=%J'_!*+]B@?&'0?V@9_#/Q"T;Q%X)^-?@;]IZTT2U^-7Q,TSX20_'[X:> K
M7X;Z?\<-<^&2>)T\ 7_Q#U+P#I6FZ+XV\7ZEH\VH^)[>R.HZW<3ZI=ZK?WW\
MTWQX\!?M&_L/_L6?L@Q_M,Z_\6M.\7^+O@?_ ,%*?&'QI^'E_P#M[>"OA/\
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MC!IP$A_B/T\QS_*/]10IY7M]4QVV_P#:KM_ZJ7Z?UH>RQ?7$T/\ PC7Z8O\
M.Y^>I_X*@?LNC_F _M9?^(%_MM_KCX!G'/![#OSQ1_P\^_9?_P"@%^UC^'[!
M/[;A'OR/@+@?CT[YK]"<N2 '8X_N^81UZ95 2.GX<DXS2D2'/S$'@ ;G&?<
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M_0**** "BBB@ HHHH **** "BBB@ HHHH **** "@@'KV.?QHHH 0@'J ?\
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M5\0Z/JPMW\E\??\ !;7P+\(OC-^T3'XW\-Z)XG_9^\(_$3X3?L__ +-U_P"
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MC5/@?\&OAGXJ\7>/O#7AC7_&/A1+-\S_ .?>&7;]RW;Y>V2_%6W6H>Q?_/\
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M\)GXM_Z#EY_WYL__ )%H_P"$S\6_]!R\_P"_-G_\BT_[&Q?_ #^I#_UGP/\
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M@Y>?]^;/_P"1:/\ A,_%O_0<O/\ OS9__(M']C8O_G]1_KY!_K/@?^?.*_\
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MO%K(A&NW3;ESQ%:Y8C@D_P"C=R&88.>3P1Q3_P#A,_%N!C7;MN.HBM#[=5@
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MU$]RLWUU10!'%$D,<<4:)''$BQQQQJ$CCC0!42-% 5410%10 %4  8J2BB@
MHHHH **** "BBB@ HHHH **** "BBB@#A_'X!\+:WP"?(M_;_E^L._6OFD
M1\8.X _B"<$XYP,?0\U]+^/O^16UO_KA;_\ I=85\TG^#_?7_P! KZ#)]:-;
M_K^O_32/A.)]<SPZZ?4(/Y_6:Y+1117L'S04444 %%%% !1110 4444 -/)
M_//<'/!'T!Z]^W)JM)C"X QYB ?3=+_/TQ@ XQ5D_>'X?R>JK]$_ZZ)_Z'-3
MCNO6/ZE0^)?]O>NU]_+IY:'3>(R1=:21U'AKP^/O8 4V0!)YR!D@Y[$<8 -<
M]P<<< ')!).P X. <X')!." 3UKH/$@_TC2,\#_A&=!(Z=19Y/!X..6 /?!X
M*BOC'XW_ +<7[+'[./CC3?AG\9OBC/X5\?:SX:M_&&F>%-+^''Q8^(&KW/A>
M[U";2K;6!#\-O GBU(+.74H)+*+[3)#)]H"(45I8LYX2E4K0ITZ-.I6J*G.3
MC1BZTHQA.HYN5.DG4C&G&:G4<N5*,Z4N:,9<TM\:_P#:J[:LE*FKNRT=/#ZZ
M7?VMWUZ-JS^KPP!# L,EB >-IZ[NPP06X8XX8'I3]XQD#@<$]E(QP>N",\@\
MCGK@X\_^#_Q/^'O[0?P[\+_%CX'^+M)^*/PU\:Z7_:WA?QEX0^U7^F:I91W,
MMK.VQ[6&^LKNSN[>6UU&PU&TM;ZQO(WMKBWBDQN]$2RO9H)+E+6X>VA8B6ZB
MMYGMXV0?.9[B-&B54)+.&885LG#86M))4YRIU6J,Z=65*K3J.*J4Y1ERRC*#
M<)^TBVH3@J:]G434FTXI\Z5U>SMKT;=DW?6UM+*_S?0CWCTX]00<GJ .Y)'/
M3H0>AS3<*1D#CW/(X (QCC((7!(R /3-2?8KWR([Q;.Y%HXVQW(MI_(9RVT*
MLX7R7/F$H%W_ #L#@LV5JV-%U<X TG4R"SQJ%L+QF++]]1^XR71@X9 K;2K]
MP:CFCUG!>\XVYZ3DDK^\[5>5JUFVFK7=UIJ);:.[MI9WUT[=7MM?6R=BGO';
MG@G&#D <9(QG /!(!Q@YQ32PW#.05SUR!R!QD@#H0>>/T-6H],U28%X]/U"6
M-3(#)'8W,B1M$P64$I$P!@;*2KR5/RM@D !TW4DECMVL+V.XG&^" VEP)ID
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M7 0O7;_95V,8Z<9Y[#@BL2:">VEDBGCDMYHRN^*9)$E4E58>8DH#J3&Z-M8
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M3E2J*4(RC4C/]U*,U3E&JG!P4DXNG9*+33NUJKN-[<SBI+1NVO=*[M;4]-W
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MT(ZC(/YU\=75C=V;A+NWN[5G!94N8IK=G .,JLJ(Q16#*6!(+9P>037!C]6
MP"/FZY^I&,$$'KGKFFLFYHJ4<2YII:K#S72-]'5=O>;23=[<M[.5@?%:5_\
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M\9* 5 WR ,>,/GH%.#T XZG'!P<D\UO:ME]/\)$EB3X?E)8L<G.MZD"">>V
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MMJ<Z<J$Z/L_:2ID8MVDFVG*+UGJDXTY\TE%^TM&"IR]^*5YOE;?.S\&_AO\
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MVH)9=;O@P9?NV$9YS@,%%P6!4Y.004QNRN :3_A4]H 3_;=Z0^ Q^P1GEC@
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M@67A;XSVOPMD\$Z3X3?X@:IHLWB."*Q-KK<&KQW>LV_]<O\ PJNUPP&NW?+
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MXT[Q9_P21^.NI_M%:3XM^(GQZMK37/VO?!.L:9HW[/WAWXH:>GQ#MK>Y\?\
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MVW@.S2R_LG7+I_%Z6(AFL6_H^'PEM#S_ &Y=YP"2;*'=M0G*[S<;]I89QN+
M#!.,"@?":V/RMKMTPCP$/V*,JA P"@^U85L@,2 ')&=_0CG7%&$]M7K.--3K
M8[%8ZE*-+%\F$KXK!ULOG.%%3ITL0OJF*KTE1Q7-2C44:D=)5HUZ_P!7\V2M
M&C2BM%)K&05XP:G%6BD^7VD8N5I1;LK-.,)4_P"7;X2_#S]I_P"'/[2/PM\$
M_"C]G;]H+X>^#D_;8^)/Q(^.'P$^+_@/X)_&;]ACX<^!/%GC/QYJ7C+]I/\
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MW/IV(''^/3@\X]1D\ BFX(X! &5SD9XQ@%<Y!R!T/W0.<G+,,V.G)ZXXYVG
M)(P3ZX&,\Y/)!P_$^H7.B^%O%FM62V[W>@^$?%>NV27BS263WV@^'-2U>RCO
M([>:VN)+62ZLHDND@N;66:!I(XI[>1Q.GL)2<HQ5KRERQ3=HN3<4DY6?*M79
MZ]VI6/F7IWV;6CZ+7I;3[GIJ];;>01R5(SQVVYQQ@8..65LYR01CO1E@2P!Y
MZ@$GC)Z Y&0 ,DX !X'&3_.]^R%_P50_:B^/WB3]CJPE\8?L3?&S7?V@]?\
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M_P""COB']D35/ ?P'TWPK9_M%?&'X(S_  LL].^(4G[1OPV^%W@'X7:!\0?
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MF>.@ QFK^OC.O:QV_P")G>?EY\IXSR/J#G]*S[$D7UD!VO[3&.0<RI@8ZDC
MSNR#U8$<5H:]_P A[6/^PE>>G&+B3IWY^Z<\#CGDY\E?Q8Z;T)^NF)MY>NR]
M-CIC_N4K+_F-V6ZO@6M?.ZOTWON9#9!8\=B<@?=Q@9QC(&&QG./E(Z$'R#]H
M+P+K/Q2^ 'QZ^%_AN6PA\2_$SX%_&7X;^&YM7EDM=*B\0?$#X8^*O!^A/J=Q
M#'));:8FK:U9M?W$<4KV]HLLJ1LZA3Z_C=VR<$@<<9([].Y/(!'Y&D(/U&X]
MP,\="<<?-E@#P0#D' %;P<H2IRC\5.I3JQ:5VI4YT:J35K2CST8N5-OEFG*+
MTD[<^JDWJ[J6EM5>,HMI..FEVD]F[]+/\Q_"_P"QM\3]+\:?\$9]<U2[\#7&
MD?L > OB?X8^.43:G/=2ZGJOBO\ 9 U3X'>';KP#;2:6\6NP6GQ FLM1N)KM
M]+>STN!-5@5[B"" ? 6C?\$E/VAO"_P;_9DT<W'A#QSXJ^&GP#_:=_9\^)WP
MOT']IWXQ_LS^&M8T?XT_%W6_B?X:U:/XK?"'0YO$'BWP#=1WMIX=^+?PCU33
M+73?$VDD3QRWEWI]G:G]%_CU^W]I7P ^,?[1]GXFT!-4^ W['W[*'@GXZ?'O
M6/#^FW>J_%.Y\?\ Q>^)D'AGX<^%/!5G=:WHWA@:%I/@O3==UWQ4FI1SZCJ-
M_J6GQ:??Z>FDRPZC9O\ _@I+\-K)/BKIY^!G[23^.OA!KGPOLO%GPLO/"G@;
MP[X^/A+XT>'?$?B;X;?$FTA\5_$31]!/A37K'POJ44^GW?B"V\9:5?;+34/#
M=NZ7#Q?01K9W&$\1##1E2Q:IRF^2'L>7&5,155*IS8G"K"U*E7-E6JRA.'L5
MB,NKO&T.>/-*FH^S25E2?/#EC434FHTFG*DFY-JDERS:5U+D?+S(\)\(?L ?
M'/X7:;^V^GP8\3?"SX6>*OC%^R#^S=^SW^S-XIGN]0^+J?#75O@Q\&F^'.NZ
M)KE_\3/#%WK.J^"3$9?#'AK6_$VC:IJ5QHTFG^(-9\-_;=.%@OYW?M'?L1_M
M&?!/]GG]H#Q1XYL=,\7>(_VA_P!K;_@EYJOA^QUGXM?&#]KGQ,OB3X9^*[;P
MIXIO/CA\0/'6DS^/_''AV361;ZEK.H:=;6>@Z;\-Y8_#6C:5IYTN6.Z_8'XB
M_MU^,_\ AC+XQ?M._!7]F+XDZMXH^'FG?%)K?P7\5M7^'GAW2_#%C\-?ACXD
M^).M_%CXC7OA'X@^(DN_AEH5EH(MCX<\):L_Q%\8:]=:9X8TBST*'5)O$VC?
M/'QG_;E_;A^&_P"SA^QW^U7X8^'7[,6H?"OXL?"/]E?Q)\6H_%D7Q4T[6/&W
MQ2^/1\&OXS\*?#G6M.\8#P5^S=X%\ Z'X@U#Q3:?$;X\:UXZT'4)4LO"LFIM
MJSVBZIMEV)S18BE62R]U'F&7X;_:*V&P]6=;+J6!Q=# NLZF)J4Z.(EAZ52D
MHQE0JXF.*E"$92Q%=6W)P<7&3IU5B)64I03YH.%::;A*7.E5<8\ZE*',KQY>
M5GE'[6_P5^(OP5\%?M:?MA_$'2_"]I^U7\4/VUOV9_VB_P!DKX$_!NX\9?$^
MU/Q;_9O@\*_#?PCX'7QKI_@/1[B_U_X[^#4\1V?CO5+WP=9>&="TWQ%<0:PV
MJQV<[']:OV/OV?;7]E+]EWX$_L[17\&L:G\+_AYHVD^-_$D$;1+XO^*NLFX\
M5?%WQJ\#S3M!_P )7\3-<\4ZS;P//<O;6-Q9VAN9UMD<Y?P]^/GB#6/VPOVM
M_P!E3Q?8>'+.^^"^A?!WXO\ PJUGP_'K5MJ?B/X)?%S3-4\.R-XS@U*]OK9O
M%OASXK>"?&VER7^B/IVFWGAN^\/HVEP7]E>W-U]19Y ()P-O& -N[.W/##@*
MN>,* S;I-\C>/B\75J82AA*B@U"&%K0E2]FDL,\NP-+ T^6,93C3I87#1JQA
M6K5ZGUOZS6G.51U92)M\T[J[E4G.[3UE4G.<I*SY=YNSA&,9146U))6!N^4$
M9&SKCHVW &>XP <CN<=N-[P__P A*4^NCZYZ' _LJ[QCGUP#CZ\UAG.WCID\
M=<D-VZ'#'D#CL 5R"-KPX?\ B83#((&C:V..N1I5VN<'. >AZ$[01CI7E8AM
MT:S=M8S=DG9\SBW9>KVOIHO(WP=_K>%_Z_TW?IO)]EO^9@1_ZM!C^$D<\9W,
M03P3GICL.>Q.?A7_ (*%_LK^(?VP?@[\-/A3H9T5]-T?]I;X&_$SQ[::WXG\
M1>#FU#X:^ _$YU+QMIVA^(/"D]EXCT_Q'?:1--%H=SHNJ:/J<5YLEL-7T^XB
M6>ONJ,?NXSC@*PY)P&W,-V,\D@$^Y/?I3VQD#&3CY<XP3GZ@$YY&TJ #SP0*
M[:6(JX7%4\10E*%?#UW6I34G[D[8FG%K6482M7D^>*4XMIZ\J1QPLZ:32E%I
M;ZQLN1JW9*R=O+MH_P U/B_^PQ+\-?V<M3^$?_!.ZQT_X"ZKXB^/G@#XM_%&
M;_A:7Q"T;XC?&OPWI.M0MXYT/4/VJ?&4_P 6?C9X*\?:UX?M-/T_P]\3[/6-
M0\2^$-.TQM!\(7GA:+5)[R/X\_9]_P"":?[2_P #OB+^R?\ $*:[^%/B$? [
MXV_\%,M7\8:#+\4_&NI7UW\/_P!O+PG\)=$\(>)]*\:^+M!UOQ!XR\4> ;GX
M?:L?%]EXPN(?$GBB>^L]1.M375YJ%Y;_ 'O^T!^VHOP4_:2TGX2Q:1I>J^"?
MAS^QY\;OVX?VF]1%MJ=[XZT3X2^$=>_X5?\ "30?AG9QZCI>A?\ "2>.?BE8
M>+[S6KC7YKRTM_"G@/4K*&&RU+6-/OX^2TC_ (*<_";6;+QBUK\%/VDX/$OA
MKX-_"#]HCP]X$UOP=X+\.>+/B=\#/C1XZ3X=^'?B3X'.M^/M/T&#3]%\23V4
M?B32?%>M^'/$4%K?6\^GZ5J $B+ZM*KFE3!U'&A#%T*R6(Q&)G"%6O65;VU*
ME]:Q2Q6'K5.5.K4A[55?8PGAW^XHUW W=>O1DY2<H2G%Q47&*O";HRT@XQ4'
M*-*BH222=/2%DTH_G>/^"1OQ]TGX<_LQV\LWA+XC>(/ /[%?Q>_8Q^+OPMTO
M]J/XT_LP^%[C3O'?QSOOC+HWC.#XG_!_0K[Q!\0_ .LVMU-X,^*OP9U[3[?1
MO$40\,^)8TOM;\%:,(?5/BG_ ,$O?C%XC^'7_!0GP1X-F^%=@/VE?$'_  2U
M?X+PZEXS\1ZW_8GAG]BK5_A]>?$S2_$WBOQ'H;^)I!):>%M3C\$7>K)-J'B(
MO;R:LNGW5S</7UCK?[9GQO\ BW\'M;\;?LQ_![1/A!?>#?B%I>E_%KXD_MO7
M_AFU^%7P;^$$'@/Q9XX\3_&'4?#OP9^,-QX@\>QV=WH6D^#;+PO;>+?"=Q#J
M/B1]=O;B33M(\O4?FWQY^WG^WU#^P9\!?VV? _P1_9S\-Z)JWPQUOQ]\;!\0
M;'XT^)+3Q=K\_CO2O"/PC\)?!SPCX5\1Z/XD^&?A;XS^')M0^*#?%[XO:UXB
M\-_#'PLMM!XTLH?LS7NJZ1GFM?D;G@*=2OCXX9J=>-*3QL<34S#"1JPIRJT'
M&M*=>%&=.K6FX5(4)VIJ-5$)3A:5F^2E4C!-*2A22]_2[:E))RLE%Q3E)7;E
M(W/B!_P3_P#C'XC\*_M5>"=3\"?#'XBZ7X[_ ."CUI^W+\#_ !;I'[2_Q3_9
MX^)WA2+6=(U+1KS7?!/C;P#X)U>^^'/QM^%D<.G2^#+OQ&OB/P+KD7BKQ+<W
MEC%J6A:,E[^@7[&?PV^/?PF_9\\)>!OVEOB1I7Q4^+.F:GXJNM0\66$>F7-T
MOAW4_$%]>>$M \3^*=,\*^"8OB-XVT#P[+9:;XM^)UYX6TW6/B#K45WXCU@7
M.HWD]PW.?"?]I?7_ !?^UC\;OV:/&NC^$-%E\/\ P"_9T_:C^"USX9U.YU>]
M\0_"CXK6-]X1^)&FZ_K*75YH/B'4OAM\9='BL-.\4>'8]*TOQ!X0\=>%)/[/
MDN]-U+4KK[%!).>AYR3CD9XXX'3!8 9; QAA7G8O$8OD6'Q$8051T,7%<C;4
M:^&IN,Z4W-JE'$JAS8E48P5:K2DYI1IQ2AII0LKJ*<HM)2A).+33DE::7.UH
MUR37*]4T(2-DGRCA=QZX).>O0C(.,9R,'I@&OL#1_P#D$Z7_ -@ZR_\ 2:*O
MCZ0X$I&"&1>>_.T GIG.23CKC)P>OV!HX(TK33GKI]B0,=/]%B'KR.,]N_)K
MY7.G?ZLWN_:;MOK%;R;>EK:MNR2OH?6\*KW\=_@PW_I,M_U-*BBBO"/L0HHH
MH **** "BBB@ I,#.<<]?TQ_+BEHH 0@'.>XP?3'THP#_D^F/Y=OQZTM1E@2
M0"23U"\XR!SG!V]..F3N/)Z']?=M]P;$E%,+ '!; &2>1QT;D=1@''..#SG.
M0FX '<2O0 DD$G. 0#ZX&1C'7.03F'+1.SL]+;==+O2WWB^7ST_RZ$E-8D G
M'3'7Z^F>W!SU_&F;A@ D$8/)89]%R?4CKQC)R#@&C.X#J <X.1G=\P&[IG&,
M@9SD<CI3=[62M?2[V6UO6_SUZ[AOMV?EKH^W:WZG\_O_  6R_: M+;Q5^R/^
MQC#\=_B1^SYI_P =O%'Q1^*GQD^*WP?U3XE:?X\\#?"[X0_"KQG-\/;69_A-
M:7OCF+PY\1?VA=5^'/AS59]%A\PV>E:A'.3;AXI_BS7_ -MCXL?M"?"+_@E=
M\6++XD>/_"GBGQE^Q'_P4\TKXYZ1X=\<^)]!.H?'#X'?LCWVC:IJ'C#3M(F\
M/1W'BKPWX_T>[\8:*^HZ3#J?A+6M1BO=)DL;U$G/]/R?!?X5V_QEO?C_ !>
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M0?F#P-^Q'^R%\,]2^,^J> ?V9O@IX2O/VBK74['XY/I7PY\.16_Q3TO71?\
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M%3NFE%G\KOQS_P""4/B'PE^SQ^U#9_!?QUXO^,GQN_:.\1_LRVFLZ9X9\$_
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M7_;(\,?LZR:7\+QX3T']HGXS^%HO!_Q%\21?$*T\'P_%CQ1X3N_#MN]GX/\
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MG4FE!2Y4UPM+EM]=ARK2,7AZG+%;OE7UAV;DU)VT3;L?'3O&$8EQD #:N-H
MYYR!DD COU/05]>:,2=.T\9)(TVQY/10;:$XQTS@YP?IP.MLV%F3S:6YX/\
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M^--7_9QNM/\ B_X87_A"/C'H2)J'P\U+QHVL'PM!?W&M7MWXMETNWTC5M_\
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M\="I%?7I2P].I[E-RDW*BX8>,(2C[+1Q=.LIMU:GM8U4Y;-'\ZVI_P#!5_\
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MQ"J0M&E3BJ;5-16D*DX.,Z<:LJ%><#\HO __  4W_:M_:7\66=[\&[[]C_\
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M14I;RY(4Z3D_.3I7MTNNFK?1110:!2'H<^AI:0C((Z9!%']?U;4"E,#DY(X
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M&XGI@YXSZ\#\QZYJN8BVYB06;GO@*"K '@\]!P ,#IFI3(@/;&[YB<YR "I
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M5MIGB%PD$SADAE>W)B$RQ2.CF$RH)4#(TB@G'\@/QNTCXW^![;_@NQ\/]?\
MVQM<\0_$*TTS_@G%8:O\8/B]X^TCX&>'M2TGXC_$-+7QK\'?#6J>%K>R\(?
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MJ2D(!!!&0>"#2>J_I?EZ@9DYEV.UNBR7"13-!'(X"M<*C^2DN&3Y9)%56RZ
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M\#^/[[7;R">VT>XU'2/"O"__  42_;G^#_P=_92^#WP#L="AMO@%_P $R_\
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M/;!R #CCITI])CG(Z<\=L\#],8I:^=C>VMWZJW]?/4]<****H HHHH ****
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MM\JJ2<S^3WX;? CQ/\9OV)?CO<^$_C3X'^%'@S]D;]MS]IWQ9\3]+O\ XO\
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M\ OCUXY_:,^&G@W6M-^(7C:[\=ZC;V6I>,O$6L^!O -U\6?$%IXP^+MQ\*_
MFH7TN@?#\?%/Q78V&O\ CA-!MH8=3U"QM/*6SMHOLU<A??\ !,G]FW5-;^&O
MB*[N?B8^L?#[XP?%/XW:O?6_C6*QD^,OC3XN?%30?C/XG3XV#3]$@_X3K0M/
M\?>#?A]>>%-,!TR3PYH?PX\ >%-/NE\,>&K#21Z6-S/),3*K3I82=##.A2E"
MO2R^C#%0K^PK4%!*GSTWA\/15##QJ*]7$U)U\PD[14H<>'PF845SNLJM3VU3
MFC/$U94O9^TA4N[:^UJ5'.;A>,:,(4L,DDYR?Z+1J1'&" H"!"#P5)QDD?WC
M@8 /!)(."*G'3Z9'Y'%1("RJSD!QAG ]2HZ]P.,\@>G:I0,# KY>%]KW[^3T
M[:?/JK/U]E7[M^K;;\V^_G:^K%HHHJQA1110 4444 0RD\  XZDCKW''N#@C
M(P" >@-?SQ?%/]J_]O#X9?MC_MV>&?%FI>']9T'X7_\ !,/XU?M(_L[? +X)
MZ3?:U*?%'AGQCXATOX=:KKFMZ]HUSK/BKXK>)(]-M/M]KH^D_P#",Z2MXFDZ
M?HVMS6K7U_\ T/.,E<D@'@G('?CJ0<XSTSG)]*^/_B'^Q+^SM\6_BK\1_BY\
M2O!L_C36_BW^SCJO[)_Q#T#6]7O)?!'BGX(ZYK5UK6L>&KSPW \"Q7E]<7UQ
M%)K-M<PZA!&ZBVD@FBCD3TLJQF#P57%RQ^$I8NC7PCI4HSH>VG2Q$<5EN(A*
M-3FB\+&K2PN,P];$1O-4:[IQ2564H\6,HUZJH^QKNCRUDY\M3V?/2='%PDGI
M+FE&52C5IQ:LI4E*SY>67\_GP3^,?_!1S7_V4?C9\)8_B;^W'XZ_;@^'7BW]
MG#6_C_\ #GQ)X=_9$T_X_P#PP^&/Q#^#^J>)#K7[,KZ%X@MOA9K&C>+OB6?#
M0O\ 1_BMX@M?B/X<\"6'BNS\1:+IGBF&32C^EG[ _P"W;!\<?COXZ\ ?%;XQ
M:;>?%3Q!X2\/Z7\-OA9X1TK7-4^%^L6_P/T=?!/[17Q5\*_$#3O"A\!?;O%7
M[1%K\4M!\-^$KGQ_?>(=4^&GPTTKQ_X:T:^\':U%KUS]9?L[?L ? 7]E7X<?
M$KX?? ]_B)X4U+XHZ'!X<\0?%74_B#K'C3XQ:?IFD>$V\#> K7P_X[\:#7+G
M3++X6>&UM+'X:Z.UC-H?AW[!:O\ V=>/)<-<9OPE_P""='[.'P0^,'P\^+_P
MSLO&OAN^^%7P=\-_!7P;X%B\83S?#.RT#PEX2M/ 6A^)[KPM)9&6\\?0^#+1
M?#TWB6YU1FO+:>\NKFSFU*ZN+Q_3S'-<GQSS&,,++#QFZE7 UZ.7T\/4=6K1
MPLYTJL(*4<-A%B</&CAJ:<ZU#!NK]8K3J8AU:G'A<+CZ+P[J5HU7%*-=5*\Z
MD>2,L1"$X->S=2O*E4C.NY15&55)TZ:]FK?>2R,6'3+%-W()&",@<X(*L"-H
M^4'G)'-JJRHZ[<'(W+DL<DC=N(Z\$'(P,@\U9KY>/-]JW3MV5_ES72\DF>R%
M%%%6 4UNA]<''<\\?7G]>E.IK $'/<>GH01V/(/0=>3@'FE+;K\G8"FTA;;D
MD@L/D P[ L0!UZ,#AEZC@G;T'\Z/Q5_:3_:__9-_;8N_$/Q!_:ET+XP_ CXN
M?#C]M_Q-X8\$R^"/!>B?!BT\>_ SP0GC3X*?LT_!C5?!WB'QWX^T#X[>"/#_
M (;\8^)_V@?$_P =[KP7X+^(&CW.B:7\)K36_&]KXG\-Z#_1:4VGC/R=">"O
M3)SSR3\Q.!M"J3@-BOSW\*?\$O?V+_!7[0?B']I'0?A21XYUZ_\ B5KT'AN^
M\2ZY?_"GPIXO^-NDZ9H7QM\=>"/AC/?'PIX7\8?&'0]%T;2O'^N:?9!]8M=*
MMEBAM76:6?T<HQ6786>*_M"%2O0K8;V:HT\'A<3[9NHW*/UC$+FRV34%46*I
M1FW_  Y6]GAN;CQE/$58TEAYJG.,Y2=6565+V:Y)*,_9QO"O:_+[*IRR;:E%
MZ23_  [^%/[5?_!2+QOX$\=?"3PQ\5OBW\>OB7\9?V'?V$?^"A_AG5OA_P"&
M/A!X>^,OPKT+XY?'/QQ\/_VD/A+\%H?$P\-?#[7[*V\*^%+#Q'\+$\;ZK93:
M)'I_B;2&N]>OK^UGM/TF_81_;L_X6G^T'K?PP^._QJM;?XM:[X+\!_"SX3?"
M#1-.O=9\#>*]=^"OAKQU>?'WXQ/\1/#'AN^^&EE\2OB9\4?#7QNT/PQ\/G^(
M[:GXA^#G[,UQ\3OA_P"&-3\'OKWB>?[#_9H_X)\?LX?LC:?\6[/X&:;XU\.:
MA\8='T'PMKWBG6OB%XB\9>*/#/@;P=IGB#3/AQX ^'^K>*;G4F\&^!_AG%XI
M\17'@+PUI\)T[1KO5[NZ:.[+A5POAW_P38_9K^%?QC^"_P 9O!,?C_2-:^!7
M@/PQX+\(>%$\9RM\/]4U+P?X"^*_PL\,_$_Q9X;_ +/WZ[\4=*^'GQP^+'A.
M'Q'_ &A:6<FF>.=5>?2)+V.RN;7U,PS+)L;''TX85T/:4_:83$4LMIT:M6OR
MTG4A7A2ER86A-4Z6'A*EK%4'B*CA'$R<^+#87&T7AI2K.3@U'$4YXJ=2$5>4
M8\DVHRJU%S5*GOI*527LY0DZ4>7]#%W9Y!].HP, <XR>2<_0=>:?30,'VP.O
MU;I^!P?;%.KYF.WS?YOO?S^_31(]GTV"BBBJ **** "BBB@ HHHH **** "B
MBB@!K@E<#/)&2.H'?'<G'&!D\UY3\7O >M_$WX>^)O /A[XD^,_A%J7B>WL]
M/_X6'\.VTF'QOX>L#J-M+JK>&+_6]/U73])UB_TN.ZTNUUE]/N[G2&O?[1L8
M6O;: KZQ59HCA@O )4G! ?(RW!Q]Y1@+GT&,#I,I3A*$Z>E2,TX-J+49)QE&
M4E.,H-1</AG"<6WK%JZ<RBI)QE?EDN623:O%IIQ;332:>Z:>UFC^1C]F;XW_
M !^^ '_!(+]EL_LV?$#P+I/B3Q#^WG^U)X)\8VOC?XN?!+P/\:?B3\,="^.W
M[2FH>)-!^ _B/]I[7='^%?BGXUW-YX=T'7-3L_%6IK<WWAK3_%UW8"&\5;BV
MS? /[=&M:Y^UKX8_:LU/]IOXC>+/"^B_\$0/C+\5=*T3QMX*\$_"J3X@>.="
M_:'\;>!=;\+VGPTTG5=3\)VOB2;Q9X"TCQ5>^,/AWK^KMXG_ .$ MO[!\57'
MPTD;3X_ZEM3_ &>_@9K/@"3X3:S\$O@_JOPMGU:ZUZ3X9:E\-?!>H?#R76[_
M %>\UZ_UM_!5UH<OAN36+O7+^]UF[U(Z:;ZYU6\N=1N)WN[B:9Y-=^ GP2\4
MS^#)_$WP9^$?B.;X<:;<Z+\/)->^''@W69? >BWMG;V%_I/@N34-$N'\*Z7>
M:?:6EE<6&AFPL[BSMH()89(88T7ZJ7$6%J5,;5JY7'VV-JYK*M6I1P*K2H9J
ML/*=*;K86K[2=*KAXJC6IQPRHT*E>G1A[54)4O*>75E&A"&+:C0CAW&,_;RC
MSX5U+2]V:5IQJMR4W4<YTZ?.U#VRG_)U\6_A'^S#\+OVP?V(OV;=6_:*\+?#
M+]KOX<:E^QG\3_C_ /'3XS?M.>"OAK!^SQX;\&:>^HS_ +-O[+'@76O$6D/X
MV^)O[6OCG4]<U'QIX:\+^'O$FB:9H'B33O%GQ*GNT\5>"-/O_J9_^"@'[9NA
M?&OP)XIO_C)HNN_#W7_^"YVI?\$UKCX+2_#;PA8Z0WP8\1^ /B3XH@U.\\66
ML)\97'Q!\/:MX7TVW\,7<%]8V M5^RZUI.M27#W"_P!!FN_LS?L[^*?%S_$+
MQ-\ /@CXB^(4U_INIS>.==^%/@'6O&4FIZ283I6I2>)]1\/7.M2W^F_98#I]
M[)?-<69MX?L\L9B1DZ%_@=\'Y7MIW^$?PN::R^)*_&2SFD^'_A(S6GQ=CM[N
MSC^*ML[:/OM_B3':W][;Q^.8BOB=;>\NX%U017,R.5N(\-B*6'HU\O>,E0PT
M:#EB_J=50J5,3F&)QKPLZ6%@Z&&Q'UC"4*%+E53"T\$E1J<^(K59..7583G*
M&)=)3DWRTO:*\51H4</S\]25-U*+C5JSE!*-:=63FFE%'\I7P%_:;^(/[5G[
M=_\ P0L^,7QB^/\ X.\;_%/QO\7_ /@I=KOB?]G#0M(\%Z!KG[*3:9^RK\=_
M!=K\/-9TK1KL>.8IX;7PI%I]_P#\++L(]<?Q!I&MRQ&T:2[L8_=/^"R6C?"W
MQ/\ M86]W\1_B9^SWK1^&_[&GB?Q)'^S!^VC\1/B;^S9\.=>T:Y\47UYK_QJ
M_9/_ &A_#NH6WA&T_:,\-Z;IEWX8OFN-&UC7OA^;SPUXE2ZTZTE2XA_I"LO@
MA\'M/\92_$&P^$OPQL/'L_B:Y\:W7CBR^'_A2V\87/C.\\*W?@>[\6S^)[?1
MX];D\377@K4M0\'W.O-?MJUSX5OKWP[-=-I-W-9RS_$3X/?"WXMV.CZ?\5?A
MA\.OB?8>']5BUW0-.^(O@KPSXUL]$UN)3''K&CVWB;2]5@TO54C9XX]1L8X+
MN-'*I+@X.*S_  ]+-,-C\-@ZF&P]#+\1@5AJ#PU)J&(Q57%-0G3P\(PIPA+Z
MI[2+I8_D4:[Q3K.I"NYX"I+"U*%2K&<YU_;^VE]8FDX1IQAS1G5FYSO#VO*H
MRH2G:FZ2IML_DV_:W_X+$_%3X3_LN?"KQ_\ LM>-_B;\-M<^%?[#G[-?Q[U?
MX8?M-#X17]_KMEX[\6V_A+2=*\>^*?B->VWQR_:!\4>*M T#5XI=;^%G@_1(
M8-,DM/BEXC\2V4FO0Z:?H2R^.?C[]F+]K?\ X*F?M%Z%XOTGPU\%OA9_P5+_
M &.K;]KVUUG3H=0LI_V;_B;^R9\&OA/X@\6M?)#=:QH/_"I?%/C/PQ\4;^?0
MH?,N=!\-ZNFIH^FQW(K^CSQM\$/A#\3=1.K_ !'^%'PO^(.I'POK'@C^T?&_
MP_\ "7BO4&\'>(9(+CQ#X0^VZ_HU_<GPMKD]K:3:OH E.DZG)9V\EY:SM#&R
MVKOX/?"R\L_B)IUW\+_AU=Z?\7E,?Q:L;KP3X7FL_BC%_8<'A@1?$6UDTI[?
MQNA\,VMMX<5?$T>IHNB6MMI&/L,*0+:SS*_9*E3RB4*=2-6EC'*KAJE;$T:^
M94<=.FJ[PL*G/AXTZE+"UJU.,Z52=.M)5*<*E.LH8#%*HZE7&\\E.G.FHPE"
M%.5/#2H+W/:245-R4ZT:<G"2C*,>6Z<?Y-OVA_\ @K)^V'\./V5-&^)]M\9+
M[P1\?/B!\!/B[_P4,\)> =>\(_ 3P]\.O!W[.GCKXLVH_9F^$FN:WX_O8/&7
MQ<UO1?A;_9]AK?A7X3^&=0\5W&I>(;O7?%_C/1].CT2:Z]'_ &Y/^"IO[5?@
M&']O?Q'X._:$\"?L[:]^S!\-_P!B>;]G[X,ZIX%\%:[<?M&2_M.^ O!?C#XC
M_$O38_&OE^,-3T[P3J^O>(/"WAJ[\)M/X7TFX\$:OI^N-=ZO+J$%A_3OXG^"
M/PB\<1Z+%XU^$OPM\7Q>&O#^N>$O#R>)_ 7A3Q''H/A/Q3H<GACQ+X:T2/5=
M&NQI7A[Q#X;EG\/:[HFGB#3-6T*232;^VGL)'@/PO^U/_P $L_A)^UKXFM)O
MB!X^\>:3\+[CPSX5\$^)?@QX>T;X8KX9O/ _@_7?#?B*R\"^"?%^H>!+SXD?
M"+P5X@U3PEX??Q[X6^''BS1-$\70Z3IXO+*WEM%F/5@LZX>^M83ZUDL,-1IX
MFK6Q4J=.AC5.C4KT:SPN'I5:+48O#T%A:;K<\J2G5E"K"M7J5CGK8#,53JNE
MCIU92ITZ=.#E*BW45-TW7G-3M&<74J5I1HI4ZCA34HR=."?YU?##_@H5^V3\
M0O\ @H;XL^&#>,/@CX=^&OA/_@H!\4OV4]5^ _Q ^)/P'^''BJ_^"_@GP?+=
M^%/%WPZ\&>*-?L_VA_&_Q=\52);?%FQGTK0;_P $^*/AW=7-KX7A:QTY]87U
M[_@I)\3O'WAW]M;X16VCZG<Z5I7P&_X)U?\ !0?]KCP!.]JUUI$WQY\$^#-&
M\'^#]=U#3;]6TG7+GP1H^M:CJFE6$\<WV>XU:6ZEC,,T,B_M@WPG^&K?$)?B
MZ?AM\/\ _A;']C#PX/B:?!OAT_$1- &XC04\;/IO_"3#11YD@72QJ?V%5+ 0
M#Y@?,?BU^RW\-?C)\4?@O\6_%>G03^+/@I#\2-#TLR:;HVK:9XJ\ _%_PA-X
M/^(WPW\7Z=K-A?0:EX.\36"Z;>75BP#?VAI%E*"T;7$,WF+-L"\;1KQRZCA:
M-/)\5E_LJ$%%?6*N&PM.->;A>52H_9XFE[:JHUZ4,QKQ?M(TZ?+U_4L1&E*'
MUJK6G+%T\0JE5J\:4*E23IQ22LO>I34%=2GAZ:V9_/M\'_VT?^"B7CVX^#?@
M/2OBOX@^,_Q!_:S_ ."4GPQ_;?\ "NA_"SX>?LZ>#/'/P^^*NM^.O#VEZAH?
MPJF^+WB'PK\*+[PO+X8U:2'6$^*OB69;BZL)]5TJ^M[_ %"WTU/T&_9A\$?M
M_?&'X4?M$> _VKO&G[7WP O]<3P'#X!^(/BX?L&V'CVRT.)O$=S\0;'X;:C^
MR;X\^*UGHM[J=I!I6FZKKOCNUTK5M)6^LKSP,\E[#J=S9?J?H7PB^&'AG4O#
MNM^'/AK\/O#VL^#O!MO\._"6KZ)X*\-:1JGA;X>VLB3VO@3P[J&G:9;76@^#
M;62&&:#POI<UKH<,J(Z6(= U>@M 6C*$*<IL*L R,K<,K J5=",!E92N.&&T
MD5..SJA5FG@<IP>#@IT*LY^RI3K1J87&8C$4YT;4XX6G%T/J>'G2EAY>T>$]
MI4YHU'&54,%4IQ:JXK$5FXSC[TI<CC5I4H3BTVZDDJD:M2+<XSBZLU%VLU_!
MI\5_BO\ &2+_ ((9_L]?LT>!_ ?[2 ^"OBGP1^W#\3OCS^T3\._A]XN\?>$[
M*R^'?[4OQML_A]\'_B#\3+!;K2/!.D>/O%GE>*/BYXM\5ZE:W&G> /#LT=I;
M7ESXCN/[-_=KX"_$C53_ ,%'?V$O$_A#PQ\2/!6@?M9_\$I?$MI\7_ 'Q#\-
MZUX*\0:9<_LU^.O 6I?";Q3XR\"W4KMH'C#1I?BWX^\*6E[JY>6?0/%BZ>)K
MC9IWV;]JX?A!\,;7P'<_"BW^&?PYM_A=?6NJV-Y\-(/!OAN#P!>V6MW]UJ^M
MV5UX+72AX;N+35]6O[[5-5MY=->+4=0O+F_NTEN9Y9F\[T/]F/P!H_[2VM_M
M2^5/<_$"]^ W@C]G/PG9-!8VV@?#GX9>%?&/BOQWK&F>#[.RM+9[:?Q_XA\0
MZ+-XKDNI)XS8_#_P3I^EQ:=:Z=>"]];&\4X7'X;&8>651PZKU.)<4G3J*HZ^
M)SU83DG72PU&$:E"I2IU>:E..$IT\%16%PN'G7K1GQT,HGAZM"I'%3FJ<<MI
M6E%1C"& E6;=.2G*K)5%5J0M53E)5)SG*48PY?HH*&4 '_:)XV@[F)!(XXP0
M1GH*N4T#&3GMT7M@'('X\]N:=7QD(\M^S:M\E9+Y))?-GN_U_7]= HHHJP"D
M/4'O@CVY()'KG X^AS2T?TZ4GL_1[>2\^^OJ!G%Y S;%R2C!!P07!)4>@R<C
M#8[!B*_C7_X(H7_B_P"('Q;U+PYXA\3Z7IG[6GQS_8<^->J_&K]H;X)?%;Q5
MX^^)_P (OC;%\:M6\$:U_P -A_"GQA?^)OA?:_&[PUXWN;C4/@7$VEZ/IFB>
M&O!FJ>#+;3-;\-?\>G]E[I(> 2><Y.,#DE6)&#P<'!.#@YR,@\7X?^&_@3PC
MKOB[Q3X4\#>#?"_B7Q]J%KJ_COQ'X=\,:'H6O^-M6LK?[)9ZIXOUG2[&TU'Q
M+?6EL6M[>\UJ>\N+>#]W#(B#:/2RW,U@<#FV#^K>TGF>'I4J.(511="=.-7E
ME+W).K14ZD:LL-+]WB)T*4*]J48S7%B,(Z]?"5U5E#ZM5G)P2;YXS482A;FB
ME>"G%3=Y4_:2G!\R2/Y2_AS^Q)J_[2'[%7_!27X":3\:O#VCVWPJ_P""HW[4
ME]XI^*W[4&N^*/%6F:KH&@? '4/AIJ7Q,^)OB/0O$'A>^/BOX:7/C*U_: \-
M:A<ZA9>&],\>_#/PM%<VNDZ-:076E_=O_!-G]K.?Q5^TU\0?#'CCX;^+K7QS
M^U=IVE_&?2_B-XV\3:';_$30? /A7X:>$]4^ /P=\<_"A--M_%7AUK+]F[6_
M WQ7\5>+]3N+:P/QW^+/Q6\"6^CV\WASSF_;"X^#?PMO/#?Q"\&7'PQ^'K^#
M?BV_B:7XJ^%?^$-\.KX>^)<_C.P&E^,+CQ_H\>F1V7C&?Q3IF_3O$<^OPZA/
MK=@QL]2:Y@8QFS;?";X96OQ)U#XRV_PV^']K\7-7\.V?A#6/BK;>#_#\'Q(U
M/PAIMTUU8>&-0\<0Z8GB6\\/V=P[W-MHMQJ3Z?;SLS16R,"P]#,.((9F\Q^L
MX6LUC'[7#PC6A3CAL1]5P5+GG*%*C[>,\1@?;SI*%.G&"H4HTY<KG#FH9=.@
ML+[*LOW*C&I*4)U/:TE5Q#48J=64HR5*MR<\I3FW%S<K-0?I*$'< <X)/?\
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MW=$I<LE_(W\+/V?/$W[07["7QY\5S^-_A-\"/V:OV4?VP?VHOB%X,?0_%/Q
M^,WP1^&7P9MOA#;6?B3XA?LL_$+1-1\-:GXT\;_LT^,(_%/BKX!^)KK2T\"R
M_$!M<MM)TRWTIM,9/UD_X)??M*ZCXJ^,_P"T%\'/B!\(-8\"?%WX@>)O%W[2
MWCSQ3K?B?P]>^(V\3ZUJ7A.VOO@OXL\!V&DV.O>!I/@!X"\5_"CX8Z3J^L:E
MJFG>/-;\/^.=3TBUT064]F_Z^W'PI^'%[X$M_A;=_#KP+<?#"RM-'TVR^',O
MA;0V\!VFF^'[VSU'0].M_"(T]= M;#1[[3["]TZQAL$MK.YL;62&)&B5ECT'
MX1_##PUX\\7?%+PY\-/A]X>^)GQ!MM&L_B!\1-!\':!I'CSQS8>'A+'H5GXO
M\66&G6^N^)+31HYI8]*MM9OKR'3Q)*MJL625US/B"&94\9&M@E!5Y5)8*%.J
ME+"3<\'4A.I57+/%5:U:CB<5B76=2-6M7Y$JDJ<*\,Z&7U<+4HSABI3<8Q6(
M=2*?M[1K7DDGR4E!5*<(<D;*49S<>:<HKTY3VSTSC)YQN(Z8!P, 9[TSS021
MR,,5R 6&02.<?=/&1G@@YSP<(74.N " ,$K@[2Q'!(X'7<>>@8\UFWMN]T!M
MFE@ 8OB-PFY6"[78C=]P@-C&"<%BHY'SE.S=I2MZKX?)V2U?]=6>G-M1;C'G
M?\J=F_G_ )?HT-U*V-_#Y8?9B0$!QN3(SC<J<E74-M!Z\'T-02Z<7TW[&+AU
M94,8D96))W%@LD8^8)@E2#RRX R.:L7=K)/"L"3S+PF9$8*95$9_CVG8"QR<
M8W$*/<1O9RG3TMA<7&]851KC(6=A@'EP-H[@OP,<9!)(V4Y*--1JQBXUE-+D
M4^7E=[M7]ZWQ.-UND[J]N>=-2J5).C*7/AW3<O:N*DY7O24;WC*2LO:I76UD
MXE>TT][;3)K!KALR)-F2/_ED)>08@6)\M,$*H;=EF R12Z982Z?:"W=R[>24
MS$,(A\^Z=7CC/*2-YQWYX)5,D$<OM+-X;!K<75PTC1R;9I6$LL7F  *K8(?R
MV^9"22H8C).,KIUG<6<)@DFDE7R@B"9S))N62Z=Y6D)^;SO-B4#DXB)+L"35
M5*CE&LG4B^:M&I90Y7=67M'*]HJ"?O0=^92ULD9TJ<5+#-8:<>7"U*3;K2J*
M$6E>@[O][*=KQK-*5UKW?$/X-G+N1?VK LQ#26TKR,"207=00SGJS D,V2"0
M:*E;P]XI9F87L;!F)#'4[I"P))#%!;$+GKM!(7H"0,T5ZRKXBR_X5\ M%H\N
MC=:+?S[GSCPU.[_X0LR>KU^OS5]7K:^E][=+V/4JJ7)"1R2YX17<@D@'RTW8
M;KA"4VM@?=8D<G-6_I5:X7S$=0VTE70';R&=60')QP"=V 06V\8 )'@2Z+1^
M]'FNFURN4>;S^'FVNU\C[&5^65M^65MM^65M]-[;Z=]+G\W7[%/_  6H^._[
M3%]^QAK/BSX,_LU7WA7]K_Q+)X4;X?? CX]:YX__ &FO@E)'9>+)Y/'WQ1^#
M=[X6BGT;X9Z5-X5^T^(?%%SJ-E9:'H6OZ%J=[>1RW<-C/]R77_!6']G/X@)X
M=_X9]\?6?BA8?VI/AK^S/XZUOQW\)/VAM"\)6?C;QGXRU_P=J7PY\*>+-.^&
M[:#JOQ=LKG1HM37P[+J3:;I'AW7O#/BCQ/<Z9X=\2Z3J%U^?'[)G_!#?XW_
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M=:EHE[X%F\.6^K6MSID-@VGC4S) /SY\*?\ !&3QYI_@"[N[OQW^S/X*^/\
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M\.=+M_"/[2WQ6_9<^#&L_!SQA:V2Z;XS\%?M$^)/@/\ &+XE?#[6]1>"&_\
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M>(-?TK3_  _?0O#^RACR5*8#+\ZCC.%(48 /*X# X['D'K7X!Q?\$.]%U/\
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M)2:E"T;RKI+WDE>,G=I)V%LO[6_LJ87&#J 2Y%OYIBW$H%6 R>4%B9FESM/
M*>7O^;=4.@C6?(N1JC,TAD/V87/DERH\QF):!B#$)&C\H, X567'H_3[W5)=
M&FN;FU87T270@A*&,SF- 86$3'=&6;*;3RP3*_*P-0Z!>ZG>PW+ZE;^3)&R^
M2QA>U:8E"\D>QP'7RW8*KYZ,P W*QK24*GL\6I0PMHUX1FXN-^=-M*EJN:B]
MI-)<UM;)&5&I2<\OM4QTG4P=3D=12<912YI5,4U&RQ*M[K=DGLGHCF7'C8.W
M_'Y]YO\ 5S6(CZG[@(R$_NYYVXHJ)M>\6%FS9.AR?D_LFX?;S]W>' ;;TW
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M*:!X)\+6%SJ$\MWJ=U:^'_#6G:9I5M/J%Y-)=WD\5HLUW<RO-.[R.S5W B<
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M\N]'F)W8 ^G?GVZGIVH ?149?=\J,%?C((R0,!B,>N"/7&>E.# @G/3.3S@
M<]QUQ@D?TH =13#(@ZL./_K_ .!_(^E)YL><;USZ9YQZ_E0!)13=Z<X8$#J1
MT'IGZ]J02(>C _3T!P3]!_GK0 ^BF"1"<!@3Z#D_EU^OI2>;'TWK^)Q[]Z )
M**:KJPX(XZ@$''UII<;MHD4$8!7&22>W7C(Z<=J )**C,J @;U'KDXXQD8]^
MG_ZZ42(<88'/ ]_I0 ^BF&1 <$X(SG/&/KZ9ZCU%)YJ9VYY_3H3_ $/Y&@"2
MBF&1 2K$ C'&?4X']/SI0RM]TY^G;.<?RH =13!(A.W<-WIGZCZ'D$?44[/)
M''!'X C@G\<CB@ 9@JECT'_ZJCD951W8#"JWS<9Q@@XXR,$X_&HKB:(1,[.!
M&H+2.#@JJD'(/;D8SV_6J\=Q%=J)(G$L3!TR2?F!&6C:,#=D!6SU(W!CRJT6
M>CM)QNDVNE[=^MOSU)E))\O,E-QE**?9=;=D[7([>ZANB[1NVY-JN&&[:K<@
MGDX1PI#%AR >G-16MW:3S2I;@"0)NDVQ*C2JK%"RL.74GD[CT(*D<96Q:R9)
M39!"ID_>D,ZDL"Q0$'G82&  ;;@'&5S2VL5NDTWV:$1S?*)CLD7&XALIO&UH
MY,'[A'*G!P *UM#]\G"JM%:/-;E;Y;>TM\2?36]FGVMSQE4?U=RGAVVY<\EJ
MZB2DVJ#WBU9<SWT:6I!'>63ZB]O&@%T ZB<1J 2B_.BR@!BRC!*$[2%."6 -
M,EOM.%_%;21(+MBD:S>0A\J:3"PH9" Z2,SKC:0H+[<@MDR*NGQW\AC1%O61
M@S,)0057,AC?'EF1%*^84/F $%L@BF21Z?)J,>^$&_6-9$?RYG('(BE=E'DY
MR,1.P#C!",-I-6N15/@KV]A?2334DM)6;M[*]FE;6SONS&4JGLTU4P=WBE!\
MR4HN+?\ #2Z8GE3]ZS=TV[R2DH;_ %#3+:>WCO8XWDX:-F@1_LZD[!(Y ^56
M?!RHY/(&.0:Q?:;:1Q#4($N%9B8XV@$^W8"6D"2' 49RQ'WN<Y^;+M131S>V
M45\D/VMV46J.)!N+.%1616Q*AE^6(2 JKX"J>12ZK#IDL<;:G#OC65WB95F8
MH4Y?<T*[C"!_KBQ\L@G<,9I0C2YL,Y4\59PJN482ES3U=I46FI1BI7O[RNKI
M.VC59U>3&N%7 QE&=)0]JH\M*\8-QQ;DG&4IKWJ4I+2\59M<P:GJ.F6]BL]Y
M&D]G.(A'$T*3"<E1+'LA*E<J@W@MC&"00P&&MJ&FC2/M7EH^GM%Y:Q"W5HW3
MS&MQ;"  )D.K0F%@%5E8'!'"ZDFER6.R\2,V>R(Q!/,+*JQ$(]NT#>;\L09@
MT? 0?-QD4KII3:* T4$FDF!&&P2-$8&<&,H4'GLYDV[&!\XR?-GS-VX4::A2
M;CB;RQ,DW=J+A;2,;)<M:VG-UDKV>C0Y556Q%JN"26!A)0E%1JPFXM^UJM:S
MP;>D;-024TU;0BL-1TN326N[98X-/MTE$\8ACB6-D423(T(!BS)N#G:K+('R
M"Y;A-#U+2+R"=M,MX[2.%LSQBUCM@"QD(G*Q($=)E1V5P3G!/RE3EUG%I*::
MZVJQIIPCG%PDA=0&X^U?:Q,/.,NT*TK3L7Y1A\HC(AT%M"^S7']A&,Q-/+]H
M8>:SO*Q+9EDF82*F&8Q YC$9+(.M.HJ?LL3RT\9?VT8QYFU&E"[<H5WRVEB-
MI06CE>\+:MY4I8A5L I5LMM/"5/:QIQM.M648N+P3;O'"1C;FE%.FE%Q<%:+
M7,2^(?!C22,?#\4Y9W8S_P!C6C^<2Q)EWM'N;S"=^X\MNR>315:4_#SS)-\M
MJ&WON"7.IJ@;<=P18T\M5!SM$?R 8"_+BBO24<)9?N.(-EM]9MLMOWJT[:+2
MVAX,L1C>:7^W\'+5Z.="ZU>C]_=;/S3/7CT/;@\CK7B7[2O@C4OB;^SY\<?A
MSHWB"V\*:SXZ^$/Q)\):/XHO=<UCPU8>'-7\0^#=:TO2M=U+7_#\L.M:1I6D
MW]S!?ZI?Z<QNH+"WN'CCE(\M_;OT_P ^]>3_ !C^',WQ9\$WG@&7Q)J7A?2=
M<U+1G\17VBP6TFLWOA[2]4@U:]T+3YKP3Z?:C79+*UTW59-2TW6;"ZT"XU;3
M+G2YA?"6+Q3[0^:?%OP;^,/C'QYXD\2_#[QP/AZNA?'32?$^FM?>(M3UBPUS
MP[>_!'P/X*\9R#1-!U.<65KJ\5]J&I:'X9UDZ5;6?C'PKHOCI]-N+/Q1J<FL
M_/-A^R9^UI:Z5X6^'!^->E7'@KP9\'_V9O!LF@6GQ<^*.G:]J.K?!JZ^";ZY
MJUIK=MHX\0:-%X@F\(_&9+CQ3!>Z;XF^()\7Z%8?$'4=<TC3-)L_ O8Z)^P/
MXWT&\\0_8_CSJ"6.I^+? >MB6QTK5](UGQIH?P]\%_"WX7^"+'XL74&OWEKK
MOBCP/X-^$NB^(=)\4^";+P)#JWQ$\0>)M5_L/PUILT5E+-!^P!X@N;[Q!>ZW
M\:[B<ZGX;U/2('M-$\30:GJ_C2SMX'\$_'3QU=6OCK3]&USXP67B>&3XC:[<
M^&/#?@WP:?%]V;GPWX7T748=3\0>(0#H_B5^S_\ M0^*M+\#:1'\;M*MM T_
MX%>"_ /B?0=)\3^-?AK>:]\6=&OHKWQ?XAT[QCX1%GJ$MOX]^Q>&DT'5;;2-
M$\4_#_\ X0[48=!NI-*^)7BW2TZ:_P#A+^TG=?M<6WQ*U'XD>'O^%#6$%PWA
M;X9R^+_$:ZM=W=EX,^'=EH42:(^B#0O[3T?Q&W[06JZ]K$-R^I:]HWCCP4WB
M36?%EKX7\*:'\)CX@_LBZ]XY^-N@?%C4?B-+KVEZ%XL^$7B^R\(>+;:YN]/T
MR[^&5UI+RZ5H4>GB&.TL;N\TV\\;:7=ZL=>O-/\ &_B3Q#/@V%W9+8:/PW_9
MB\=>$_C%J_Q8\1?$C3-?_M#XD7OC8:!!I6N6R71U'PAXR\&7NKW%S<ZU=V-A
MKDVA>(?"VC0Z=9Z1/';:'\.]"T^\\1ZNES8OX> *.M?!CXP7'Q+U[QUX(\5^
M%8]5'B#Q)XCLO&3:]=P^*/&7A>?2I?#UA^SQK-G;Z%J%EH'@CX=^()9?$-IK
M]G<:I;QZY9:<'\(V_B;Q%XO\2VWG/AK]G7]KFPT;5'U/XIK<>(M?U#Q#K^IW
M.F_'GXL3Z7;Z[X@T[16\3#3(+WPLD$FA^,+2W;P#X=TC0K#X>:;\ Y=%N_BS
M\-=,NO&7CZ^M?"GHO_#*/BS7[^#2O&/C?26^'>B^,/C1K=IX8T:U\1R+X^TC
MXR_'#0?C6]EX_L9=6T[3[:?PC+HLOA*T@LVUVPUZRUB_U*YCTF)Y-$G\9B_8
M.^).D?"JV^#EAXX^&/B;P+:^*AXRU70_%7AKQG!9>*M42UU?P]-;S6]GXCU#
M3?#\NK6VH1_%'4=>ETKQ;=+\78Q>QZ;-;6\.KR '40_LU_MFPZ'XCO(OVE[A
M?'^K:!XKT_2]1U#Q1XQUCPGHE[K&L_%B/1;F+P;%IFB:5)<Z7X'N_@1X;^VV
M]U97EIK'@?Q7XPTN[M?&/BSQ7XI\<=IX9^#W[46CV_B[3->^,-GKNK^(OA%X
M&T#2=7U'QKXPM=2?Q9X7U"-_%D6BZ986ZZ'X+LM<T6^OM"O/B9H_AW5OB18Z
MI?Z1XLU+5O%4UGIVC:/Q>J_L,>-?&OBFPU3QU\9OM'A;POH%_P"%_"7@?3;7
MQS=:9';WOQ,^'WCB37M>DO?'MII^I:N/!OAOQ?\ !R*W30=D7@;QIK5O-J%Y
M8:WKNAW-&Z_85^)5W\0/$WC>Z^.R7']LZKX?N=+5]"\3R:[X<U+3[?X@6&I?
M%?PQ?R^,SX>TWXN0Z%XD^&GA_0Y/$OA/QWX=-E\"O#-SKL>J7VJ^$)?@^ =M
MI7[/7QNMW\6+:?&^XL/&&N^,+#XD7\MMX_\ '>K7=A)I7P M/AQ\-=,U73+B
M93<^$-+^*/A]?%FM^&;.;0/"GQ+&CWVI^*['6KO6?%6AZA\Q>,?@Y^V9H/A3
MQ&O@S]H[PAKOQ$G@UZT2TLOC#KWAGQ+>_$*S_9PT_P *6G@6-K^+5;"_\1B>
MPE\0:9)XR_X2>ZL)+NR^(9;0?$FGQ^(V^J_$G['WBW5?$GB7QTGQR\0>(/$W
MBEKG2_$NA^-="LF\ >-O .FWGAV\\'^!O%6G>!Y?!WB!)- F\,VTW]OZ9KJ6
M$EQXB^(PB\*+I'Q$\6Z+J=74/V5_'6N>)9M0\0/\(=3TG6/'^G:UXHFMM+\8
MZ7KFN>&O!\.AW/PSCM;PW5_K&A7OAOQ387_C3Q=9V'BDZ[\1_$$.@QZC\2M"
M\.6_B3P_XH .$N?@M^UEXMTS5[OX?_M$:-+H6LGP<=,U:'XG^/O%:)I'AF^\
M40VOA3PYXFT5=%AT]=&DU?PWXN\1?$#4-%USQI\5+KP"OP[^(5SXB\)?$#69
MO#/H%E\&OV@H/#?QTTL?%*'6?&/C'7/AP]MJEI\3O%UGJ6L^$M#\4VLWQ)TV
MP-MHB7O[-UW\3_ -MX@\%:$?A?J>H'X>:]J3^.?!>M>'?$5A!>VDW_#)7Q#B
M^$_PQ^'^@?M">+_ &I?#B?7S!/X5M[[5-%N=*?3X-1\ >$H[GQ/K%]X\O/#O
MP]^)GACX<>-$N?%'C+Q-XF\8>&/#WBGX5>--;\0>$/'VMJ_#>"O^"?*^#/BC
MK_Q,A^)3WGB!M;_9]U#PGXMET;5/^$\TW2?@WXTCU#Q)I'B'7QXFA@UR?X@?
M"I]7^#=WJBVL+6OACQ7XIC>RGTG6]5T*] -N7X(_M%ZIX1UKPC9?M7B/X[Q:
M%XV\47_BFT\4:U<V>C?%;4/AKHGAGX,^+;GX36_V72[+X5^&_'MIJ_C?7O@_
M%%I7@?QBTEM8^([?Q9:3:G97'$VO[*?[2NF-XBUR^^-6KW^O>+_A[X'\!)IC
M?'?X[:%;JVE?$+Q!J6K6<4VG^((YK77K+X-SZ!\.X/B=HNKQ_%77KK0=;\?7
M?B:#XA:W?>-+GW;Q7^S7XMUJ\\:0Z;KW@-M$UWQB?'%C+XA\.^(KSQ!K5SJV
MHV=]JW@[QIJOA[7_  Y=2^ M&N-,L=;T+3-%O+74;_7M*\-3:E?6%GH5W!K_
M (_=_P#!/_5X--T^2#XO2>.=;L]0AU;Q)+\7-(\6^(++XJZA:ZY::O;W7Q(7
MPS\0/#,DFH3(E^;BX\/Q:;HL6HWL2#PU=>"+2?P'J(! G[._[8&IZ1X*U/Q!
M\7#K_P 0M)\&W>@_$7Q!I'QP^(GA7PWX_P#%%YX?\%VFMZSX=\*^$_!?A[0O
MAHDWB3P]++;_ /".:9%]BCTB_FTG3O#P^(OB[3V]#^#_ ,+_ -ISPK\1;6'Q
M-\9Y?'WA*ZNOB[XU^(&K:AJ&JZLFI>,[WXE^-;3X0>%?!T%Q?PZ9X"\#Z!\/
M-5M=+^(G@'2O"LMFGBGP9X;?1/$*7.G^*M0\:>8^+_\ @G[XZUC3;QK;]HOQ
M+XC\07_PTA^%OB'6O'-IJLNJ>.=&@N9KK^UO%EYHFMP:+;>(YM6NKGQCJ%[X
M;\(Z9:W/BR2YN]!LO"RS:7<>'J:?\$^_B'9?#GQ/X'T;X^R:!JWB27XS367B
MS0]&\3Z5=>#_ !1\5O&?QL\;7'QA\+P6/C&WU.W^)TUW\6O[(UVY/B");RPA
MUJ^36);_ %&W%J :_@+X)_MW^$;32=0UOXJZ3XRU[0?%,NM6FF7GQ<\7Q:)J
M/AG5/ UM:>)?!7B0ZQ\._$C:B_B+XNW^L?$;3?$\]MJ-S\-/#=E9> OAU8:5
MX):P^'VC=)\!/@;^T]\/_%MDWB3X\:5KOA*PTKX[R:QX3C\3^)O&=_-\0?B-
M\;?BM\38M?N]8\70WDL^GV^E^/?AM;Z5HG]@Z-%\);?P==> _!"O\.];@T>;
MO?&/[)NNZS\.M-\ >!/C?XR^#D6@>*OB]XA\-ZK\/=-MK)]$M/B!J7B+6?!F
M@Q:;=:A=6<^E_#+7M2T+5;33G":1XA'AM=*O;"WT/5+W3G\[^'_[!A\%?$KQ
M-\19OB%!J&N7WQT\5?&/0]?_ +#U>/Q1!8^++KP99R>%-9NSXG:RN[G0?!7@
MRV^'UAXA@B/V_P ,ZG<VHTG3+"V33KL R].^"?[7?A30[?3? _[0EYK&J>(K
MCPOX2?Q7XB\6ZW\4],\"WVD^#;+1?'_C6YT[Q?;64NM7^C?$N'XA>*-+\&+J
M<$7B/6=;T7P5XBFT7P+X4\->&/ U2#]F7]LBVT[3IX?CMIK>))-,N-,N[^^\
M5^.=3CT4Q^*?&FKZ6TKZCIEY>?$71K/3=?"?V)XLO($ENM;2TNC>:'\.?"^C
MZGIZK_P3_2_NXM6_X6-YVNV7QP^)OQ7TG4+GP[<A_#>F?$OXU_&GXRMH_AV"
M^U[7=#T[Q#X/U_XMZ9KVC>))_#FJ:?J_C/X<>&-7UK09]-2VTK2:%U^P-XAN
M/!6JZ;<_%==5\77-K'I^DWVJ67B671]+T5M6\?ZKK?A>!)?$-T(O#7C"\\5>
M&]=\5:7-I6H:=K.L^%8X]6T_5=/ETI-# .M\*_L[?M"CQK\??$GB7XG:=J47
MC\?"#3_ MVOBWQ1J-AHEO\,/C!\>_%,8MO!3Z!;:/X,BTCX7^//A/\-+^QT#
M4I+'XE>)_AGXC\:^*]'T/7?%.M:WXG\QUCX.?MEVOAH?#/5OVG?AU;^(?&3G
M6+'7O%/B76)[WPQ-X;D\>&[70_!M_83:Y\0M.\2Z[X@\)^.[RVO_ !KHNF>$
M'TZ3X?V,/_""^%/"VCZGZGXD_8U^(&N:1\0-.'[1OC*/_A-M9G\366GP64UE
MH6DZ[K'C:VUKQ1;F*XU/6+ZW\)7GA/PI\-]!T/PQX=N/#PT'7-)\?^*M,U*U
MOOB*B^%>V^(/[,_B7QAJ'B2TC\4>&]4\/_$'P/X1\(^*]9\?:)K7B3QKX:F\
M$V%]IR7O@"YT_P 0:5#;'QC#J]Q>:K+?W\%WH.OPZCJ[2>-+7Q"NC^'P#RF]
M_9O_ &PM<BU:VU']HO4-)MYOB4?%>GIX;\;>,=%N8M!B^%7Q7\*:=I+:J^D:
MYJ$EM;>(O$7P<NM5\/VQT;P=KFI_"S4O'S^&;;Q-XK\5/XVZC0?A!^UKX?\
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M\*/&FA>*M#\/6%MX?AL[;3K[RM.FL?$DEMH]X/B@\-K)\5-2\7Q23 <UIG[
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MO'UKJ.A75EXHT;Q/XK\06EX?BI;:=K'BWX8>*-(OO#FJV ;P\NMZ-I_PVL_
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MG@*XU+X<Q^+O$GA36%UWPK\7?"GCGQ!:CQG\/[YA!/XF\/>'FTRV\0:=MO\
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M>(_&OA[X>7-A;Z=X/T&*TL;+1IO 7A6ZU/PGJ^N:!K#:U)IMSJVO:IJN=#\
M_P!M2:QT71;CXY^'9;;=INJ77B#4]1\1:W)X5US1-?\ B=J<9TWPY?:5>7?C
MBQU >*O TT$/BCQQ;16L?@P:9J"W>DVUAH\O2:_^Q]XB\=ZS<>/]?\:Z#X%\
M8:AI(TN'PU\,-"U.U^'NB3II7CC3+#7]MU?Z;X@\0>,-&?Q=!?VGB6&3P?8W
MDFFM#=^%\30SQZ_CO]D;6_B1\;_$?Q \4_$5;_X=Z_X9\.^&[SX<S:=KIM-;
MT31Y/#EP?"OB".U\36.GZCX=MM?T#6_%-H]REU%=W7C[6--&A:/_ &?J.M>-
M #F+OX'?M'7VN^*$\5?M$'3M#O\ Q)I>L:=HV@?$;QQX6O=.TS5=0U33]-TL
MZA;@ZM$FG^#I[?X9V<MC=Z'IWQ!\2>"'^--WX<T'XF>)=?N8JOAGP3^TYX6E
M\):]XW^//@36+/P3X:\?1_$#4-/\7-H]A?>)?$.O>/7MY=0T1] \/>$;V^_M
M#_A"=*T^[\16&GW'AZ]\->*8=(U+1FN-2LO$^5X?_8.\26]M\25\6?%VW\5:
MYXS7X%.GC+4?#GB*[\3^(-=^!'B?XF^-O#_C+Q_=W/C0?VEK+WOQ"\.^"8;+
M0O[,CL_!/PI\/P0ZK'%K%CX>\$6?"/["VM^$H->\'2_$6+Q1X%\?:OI_BCQ[
MXDOHM9\,?$[4/$MG\<_C/\<-5U&WN?"-SIND'5?'.L_&"]C\0Z[I$_A,:3?Z
M?=7NC:*UCJEII.B '*)\+/VE_'9^'&CVWQJT)].L-+T#QEKWA'3OVB/'ESXJ
MGTG5-0MM4\7O-XR\+6&GZKXGTKQAJ4&E:QX%U._TPV/@2PU'5O"G@W5_#6@6
M&FVWB#K/"WP4_:3U"7XA^#O%7[3EAJ^K1WUOKNFZ'X0\6:YX7U/PW,?#?Q1@
M\'W&HV_A]%UK3_#ELFO?!K1-0\/V<'ACPOXWE^$VK?$#6_#=_P")_B'XSD\6
M^]>#O@%JW@;XPZMX\\.ZKI%CX2N]*6WB\/,-9N]1U6Z;0O"?A:WC\02:M/K-
MG'=>&],\+&ZM/&?A]M*\4>-8M:MM \:K<6WA2UU75O-]:_9#\2:QXQN;A/BA
M<6G@!OB%J/Q"O='NM*;5M=\=V_BSXRZ=\8?%7PX^(-PMUI=A<^!M)O;"\\,^
M$GT;[)?WW@JZ\$^$_%<%S8?#?7Y_BZ 4-/\ @#\=X/AG\5? GB'XCRV\'C'X
M.^"/!.AZWJ/QA^*>IZEX<\5:1I\^F>(;C3O%?_$IU'1-(U-+R15\2:?86?Q$
MU>[,,WB77_$TMOIUUIV?:? ']J-M>O+U_BKX9M]'T?XI:)XI\'Z<?$?B;5[S
M0M M?"?Q$T#7-,DGU3PQJ:0F]N_%VD7VA^'/.N?"VD6]A'<:9I6@7<%I9+YE
MI_\ P3^^)%[J_C73/&'Q?TS4O!'C>:_U*>6UC\=MXFT$Z\?#%OX]\!^'[=_%
MUIX:MO!GQCG\*OXL^*^IKI-IXBU'5?$=UI>F3C4=+_X3/4O=/AK^RCXS^&_C
MW0/%$7Q73Q38Z!X/O/"NC0>(M&\222^"/+T_Q980-X&M++QK8VT:>+E\1>$Q
M\0H_%%[XBT2[TKX'_#"PT;PK8^)%@\;^%@# \$_#+]I7P7\3OA=X?\1_$/Q1
MXA\$Z3%XID\0^,K[XCZOJ,%QX>U3P_\ %"RL/!4ND^(-&9_'?CR[\9ZQ\-?&
MEEXEU*&SU?PCI'@2^T3P_KB^&]6UKPWJ]G6/@A^U5J_B#PPFO?M%V]EH5YH&
MH:!KVG^'-4\0^$]2UN]GUCQ+<:CI^C:C:*LUGJFL^"H/ ^L_\)3H>F67BOPI
MJ_PW\36G@B^\(:!\2_'4VK><Z9^PE\4K6.&:X^-&AMJD5[\0]>TW49M \7:F
M_@S6?&'@GQ9X8N;+P0A\8:9;6EAX^\1^*K7XC_$^76+'5+.;6O!OAZPT;PZV
MIMI/C+P?Q6E_\$Z?B?-9^&[3Q!\8M'L=4\!>,/$VM^!O'GAR+QC>>/M(L_$?
MP%_:!^"/AF^T^_\ %VK^(=+\/^)/@9%\=KK4OA9-IVES:1<Z?I.L:3?:7X>B
M\4-+HP![+-\!/VIV\7Z=J.H?'VRN9-+L?$<GA&S_ .$L\<::EA>R?##QWX)T
M77=7T&WGBL?'-KX,U3Q3X>BU.#6;5M/\5:GKT/Q(\16#>._AKX EOI=8^!'[
M2NN:3H]]IWQ)AN[K2M=DUK1IF^+/CVX2W\&7OPW^*G@&S\"V\]OHUM>:GXK\
M)P>.[*5?C&GBG0?$_P 2[J&/7_$=QX?\4^&_"_BG3^A^$O[(FO\ P_\ B+I7
MCK6_']KXAM=-^"GC_P"%,6D2V6O7=U96OQ#UKX9:M;^'=*O)_$%CHT/@#X<?
M\*VNXO"NG77AJZU*_D\>:J-.D\!:=I=UIWBOS'PI_P $[%\$>&/@SX&\._$E
M-+\,_#[2OAQI/C1],T77=*E\<:+X'\0>']0\8>"UTZR\5[+/P9\;-"TBSTOQ
M[INIZKJEG:#P/X&MX-*UFQ2]BM@#M[SX-?M1/\(O$GA'QC\:/#<^NZK8?#S1
MM,N+GQ?XLL(6ELETJPU;P]I_Q)M-%T/Q3X7UGQGXL59M+^(3>'?&?B^QN-6M
MM)TNW:Y@LC'BP?#?]I34O$'B^UA^-OAZ_MK8?#K2M'\*6WQD\9QZC8W_ (8\
M2W7B.?PYXQN-%M[/6[;;X6EBT[Q+K7AO4O#WC/QY::8+_P 5W?B>S>[TK4>M
M'[$OVWX6>'O@_K7QB\<6?A;2-8D\2W=[X*1-#\27OB9/ W_"+:5K":GXEG\:
M6$=SI'B*[U?XG6<][I&H:A;_ !+M_!7C'3]0TW6_!UK>WL&C_L?>)KOQ)I>M
M^./B7Y$>DZU-X@N[/X5?\)O\.T\1>)-8\'^,M(\2>)-/O[/QG/XL^'$.J:]X
MWO;A? OA_P ;:OX&BTW2[>X-A'KVIZA?H ,\(_!;]I"SUCX<:YX^^-^F^/M%
MT3XBP>*=3OK+Q7XJ\):7J%I=R21S:A:^'K=/$6F^)H/B!?7EC?Z#\+=6U>'P
MK\+;BXCL/ 7B273+:VT?5LWXA? O]JGQ)JGB72]$^)^C6OAG7O$WQ@U*SBUO
MX@_$$7USH?C;PWK^AZ!I%]IVG6,NC?V+X?@U;1-.L/#NFZ':Z1X=AT^;Q%:Q
MS^/;<^-O$^3XS_8B\:^)(/ &EQ_$OPUJOAKX>? WP'\*(O#?BCPUXL_LGQB_
M@C6OAYJVI:5XEM-"\;:?M\'^/SX":WUY)9=6NK"VU86[Z3KEO:7UMK66_P#P
M3^U+5?%]MK7BOXC6/BC3@/ =OJ]_J^EZ[>>+==TO0S\&(?'NC/JSZW$VF^'/
MB'X9^%.J_#K5?"EO=3:"_A3QOJ5U<V\U]/XGM/&0!V/C+X1_M<Z+H'AR7P_\
M<(-3O_#5]XR:\U"XUC6=,U#5=$7PK:^!/AYI$&EW&GW^D>)?&GB.ST?2?$?B
M"]\5?;M(A^+?B[Q7K7A>QTRTAT"R7*\!_ []JSQ#\/?BWIGCSXG7>E6_Q&^$
MGQ?\&^ ?".K>,_%6M:]\/G\9>)?B,WPGL?$'CV _VW/K_P /? _B+PWINN_$
M#3(/^$^U*\MH[?6->\77GAW3M:;AO^'?GQ OO %WX-\8_%GPG\0'OOB=H_Q)
MOT\4^&/%\VC2W?AW5_@7XBU9=.L8/&OE:5>?&#Q=\&_$?B_QJYMM1L_"=Q\7
MM;TR"R^(.J:%JOC#X@_JM!DH2P92S%BK%25+ ';E>/ESMZG)!(X(  /SHN_V
M</VJ]'\*>'M(^&OQUNO"E]^[UKQ GB3QOXW^(]U;^*95\;0QG3/$/B^&^?\
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M"2PV2.,*<!L(Y&[OP0.A%5K_ "=-@)9N4M6;G[^3,2K'&2OL",]\T45TTO\
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G31117TD9SY8Z_9CTC_+'^Z?E57$5_:U?W];^+5_Y>U/^?M3^^?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Z U(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHZ4 %%'6D+*
MO4@470"U4FW#G&$&.">I)8G ');'\(Y Z<59W+G&1_D9Z].E4Y&!( (R!GKV
M)8 %O3:IY[$&DY):VYK=-;6U7;\]%N]$)JZM=J_6+2=M'HW>U]KV>[MK8K7M
M[!:VT]W=W,-G:6L$MU=75S-';V]O;PQM+/-<3RLD<$,$,;232RND4*(S2LJK
MFODZ\_;K_9%L+Z\L)_VA_AN\UG<S6=P;36+F^M5N(&>.5(;[3[.[M+D!@P$U
MK=2PN5)B=@":^3_^"Q/C/Q#X6_9C\,:%H=_);:=\3?C'H'@?Q8BC:]]X8MO!
M'Q%\<RZ66P2]I?ZUX+TB/48#B.[L1-:3[H;B2-_YG3(Q!P\V\G;\@V@8 PN"
MV",+P . #@CK7]8>!WT;LJ\4N%<1Q7G7$N:95AZF;8W*<NP63X;+)U+Y<\+#
M%XC'8G,X5(VJ5<7"&&I8:E+EI4JE2I7<YTZ4?\[_ *4_TV,\\"?$/"^'W"_!
M>1Y[BJ7#^5Y[FV9\0X[.*6&?]N/%U<%@\NPN3.C5<,-A<%.IB\7C:W-4K5(T
ML/AHQA*K/^PK_AO;]C_M^T+\/^F 1?:F,#(XYTOCC')Z\C.<BD_X;V_8^(X_
M:%^'^1U_T[4NYS_T"\=1SP""/7-?Q\!IL\R7'(')!&23@@8<@#KS@D$@8Z&@
MF8;-TER-P+8*N"4&\!EW;05?:P20%E+#!((8#]F?T+.!E9/C;C%.4N2*>'X5
M4IS3J*4(Q>%C*<XN$FXP4K*TW)0DJB_FA?M-O%&5^7PQ\/)62FTL;QNVHR?+
M%RMBI1BI2?+'GE37,XP^.482_L(_X;V_8_Q_R<+X SGI]NU(9Z=O[*[^H()S
MFC_AO;]C_P#Z.$^'_7O?:D1WSQ_99]?K]<U_'N7F7[TEQG.,9)SCE0,.#\R\
M D=0>_5GF2@$^9<DX4@=!R><'?VP1@]1D]LT?\25\#[_ .NO&-GJFL-PMJFN
M:ZM@[M63::5_+HU_Q4Y\3[Q7_$,_#R\FK?[?QML[6?\ O:O%IK5->BZ?V&?\
M-Z_L?G(/[0OP_)Z#-]J?MP!_90QTZ]_H<TG_  WO^Q__ -'"?#\?6]U,9QV.
M=+/KR/?FOY._"?PX\0>,/!GQ7\<:;?6L6D?!_1?!6N>)8KVXFAO+JT\<>,K?
MP1I:Z4BQ2Q326^J7*3WGVF>VCBLU:0,\@$;8EQX*\<VH\,BY\(>-H&\:1Q3^
M#%E\*^(XF\90SQ)-;S>$TFTY#XDBN862:WET4W\4D,L4ZN89$=O,I_1%\,:N
M*QN!CXC\2_6\MQ2P6.PU1<(4JN&Q?]FTLW>'JQKT<.O:0RJO1Q\U3=:%+"SC
M6K5*$5/V7NU_VB'CCA\!E>:5O!G@V.7YW@I9EE6,C4X\K4,9@(9Q7X?EBJ<\
M+B,4X4?[;PN(RM/$+"2GC:4J%.G6DX>T_K?_ .&]OV/\_P#)POP^ZX/^G:GD
MGIC_ )!>3CVZ8/H:/^&]OV/R0/\ AH3P!U[7NIX!'''_ !*R!M/!P/E(Q['^
M3$?#+XHDQ%/AK\5&2XTB37[4CX>>-R;C0X@&EUB$KH6V72HD9))=0C)LH4<,
M]QL(-8#>&_%8\(W7CN+PUXNNO!-B+I;GQA:^'=<N/":36<>Z:U;Q-'8OH27
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MPAAZ-?$UJN$6'HXI5*-*CAJ]25>ZH)4IKV_M8N@L:?[0[QSJX+.<QCX+<(+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7%Y=327($KRW-S=22W-S<2DDSS7$K7+N69Y-YS79D@GC&/\ KI.._H" /7
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M%^LZC83VVG>*?BAJU]H%Q,FU-0L=-TS3M+NKVW7K]G&H6T]LLP4)*;>1HMR
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ML*/+<W$\\L86%(GD8*[E2L;,O]<7_#N7]B;_ *-X\%CZ3>(R/UUWD=L'MQG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUM-;K?7[VVA%Y0P ,#^]QG<?ID <Y/MT&!U;Y/\ M#_O@?U-3T50[6(/)/\
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MOB'0JU\+B*'UC#U/[[(V' P_WD!)9<@@G=N;^+!R,!0,<8(&*TESP ./\?\
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M%UN>JW&E.+^M1(Y)^0A3@#CG(!SWQDGY0I/4$D@<T.YY&QF#' &,9((!R2<
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M@:WMZ,*T:="=;"8J/LXU\%B\//$T</6I8VAA*<\4ZE# XK-98;%2P_;EG$^
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M;2PM85+3SH"#7TV':6'I-M)*E%MO9*SU9\Y7NZU6V[J3M97UYNB[_J?S@_\
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M?3='_P""DW_!/K7_ (;_ !/^+NA?MB_L_P"K_#+X)ZEX4L?BUXQL/&B2Z=X
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MG^)/#>K6TLL:2V>M:99R,&1X?-1@[>Q?:& X&X[L X)R#D]1U7& #CAL!B,
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M*<)B:.#Q^+JQP=-Y<I9IEF*P.&JX:C[2KT,OP0^'OBS0?CM\8/AY\8=+\*?
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MNZ+\&;GPW\//AGX?\*^)]$\'C6;G1;OQ'?6VI-JUK^E'B[_@K7^Q9\'?B/\
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MO_D?/M_P8S'DYW'&W;^0X(]\Y-!0X4 C@Y)(ZCTXQQSGZ\U)11;S?WO3\?\
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MX;&[=CH>,')(!!;&<9(5NW4CL%X^O[SWV\]OJ<D8.<=\+@$XK^V?_AE?]FT
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MV\!ZW;:MI/B+P#?^,M.M9M LM;L=3&FZ7XGBU*QA^JH?^"/7P+\&:=\'M3^
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M_(NMW?U3?FY-.3=1116AH%%%%9U-G_AG^2 \*\3_ /(RZY_U\V?_ *:--_\
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MKX@>2^U!+I'@3PI<P>'[&\,<AGM9M;\1745M+"Z75C+YD;5]N):!Y8W=I&8
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MXYZC_"C[.GO^G_Q-3T4:]W_X%+_Y(.2'_/NG_P""Z?\ \@0?9T_VN?\ =_\
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M#U .#D9['U^M5MLW_P"!2_\ D@<(/>G3?K3I_P#R!7^S1]P<@?>X[GG Q@'
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ML#G^++9Q@DN-HW!L$:6 ?P_#H?\ $?0_2J[1N2,'&#\I(! '.><';GJH&-I
MQ@8QX4U>*2C>SNG:,K.TN71M)I.S:>CTB[JZ/LG?IVULM]=EJNCEW>M^B3^?
MOAQ\:=3\??$OXP?#^[^%OQ&\&6GPKUG3M*L_&OBK19].\*?$!;ZV^T3:CX,U
M":WAAU.RM7'EO-97%]&@VM/):SYM1R7[<WB_Q)\/?V)?VR/'O@S6]0\,^,?
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MVWQ,B\'Z!HWA+4?'T'@B/Q9KWABPC\/Z]J^I:2TEH_/:3_P2K_8)T3QIX_\
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M#/\ PC/B;X]^+-$\>?%R2PUOQ')HGBWQQH'A#1_ =IXP'A&\U>X\(Z#XGO\
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MQW<:F9[\^*5N;F>27Z-(##[PX))Z,.23G#9&>,9QC!8+C((-@P1DC!ZDY/?
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M_P#=A13V^OOPP_\ 9B>,')S00&'/N!]?IT/3OVR.A.5["A:WLHWW;O)MM_\
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M6/FZT<0L+*E:.%O46)>;Y#]7<;M>U>=97R*3?UV@YIU?JR!R3&S-NW*H#!<
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M_/S_ ,EC_D'U'#?\^_\ R:7^9Y)%X OV;;-J-LL>%R8()I9%((SY:R^3&"5
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M9<?W%_[Y?_&CS+C^XO\ WR_^-%W_ '?_  )__(!K_*_P_P RU157S+C^XO\
MWR_^-'F7']Q?^^7_ ,:+O^[_ .!/_P"0#7^5_A_F6J*J^9<?W%_[Y?\ QH\R
MX_N+_P!\O_C1=_W?_ G_ /(!K_*_P_S+5%5?,N/[B_\ ?+_XT>9<?W%_[Y?_
M !HN_P"[_P"!/_Y -?Y7^'^9:HJKYEQ_<7_OE_\ &CS+C^XO_?+_ .-%W_=_
M\"?_ ,@&O\K_  _S+5%5?,N/[B_]\O\ XT>9<?W%_P"^7_QHN_[O_@3_ /D
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M%I:U@))PR[<@ Y!";U'^L;/LY)1P-6KFE;,</6QF'RWA_.\U6%H8ZKETJU?
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M)JNFZEXTN_ GAG51IHGEM+<75];2P#J_&W_!5*&V\<_&;2/@3^R!^TI^U?\
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MO U_^T1??"O]EOX^_M)_#+]F7X2? _X__$'XO_"?5_A=;^#+KX&?'3X6Z?\
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M[C6=$^)^O:;=^/?%;>$KK1?B3?\ A#PWX:\4_9/#5Q =0T_49WET>7E_ ?\
MP4L^+?P__89_8,^+/CCX _%3]I?XA?&?]@OX-_M+_&KXKZ-K_P "/@E\-;+7
M-3^$_@3Q#XPEOO$OQ"\4?#7P(/'7BSQ!K]YJ>E_#/P%I<;P64GFZ?I-AI?V>
MW6[XL_X)3_%W2-;\<:E^S=^V>_P#LOVB/V>O@U\!?VM-/O?@#X=^*DOQ"N/@
MK\+8/@[H'Q1^%>H:YXST.X^%7CG5?AQ;1^"-7AU,>/-#_LJ#2-8L].M_$.CB
M]O\ RZZ_X(J^.X(/V98?#?[6/A!5^"G["_P&_8?\20?%']E3PA\<K73=+^#?
MA=/#NK_%S]FFU\<^.ETOX!?$7XB0 +K=U?Z3\1K56BTJ]OX]9&CPZ=<BAPCR
M8*G[2DZ4*BGB9UYYS/%XA4\+3I58XRI3IT(4%4Q3KU<-#+^>DZ-/#U,2EB*O
M*)RS7_:)*#YWRQH\BPRHIR<WSTU*I.=3DA[*-5UN62DZD:?/"+;^@?AW_P %
M<?"GQH^+O[,_PE^!O[,OQZ^*,_[2W[*_PS_:]T_Q3IEW\.]$T'X:_"CXB^)?
M&_@^:Z^)":]XMLM2T^Z\*^)_"%AHM^^E6^L6FHW7BC3/[(GN;6VOI8>T^$'_
M  5'^&GQMB_89L_!OPR\?OXO_;:U[XZZ/;^"+K5_",.M? R']F@:KI_QKU3X
MERKK'V2[M/!WBFPLO";6OAV74KG4M4UO2VL89X9C(G&?L5_\$SM3_8V^(_P>
M^*6I?&*W^(<7P2_X)S>%/V$H_#^E> [_ $F]\21?#_XU>(OBW9_$Z.Y_X2;5
M6M[[5]+U*VT6;P9;Z?<F'5HIKBRU^>VEBM5\(_X)E_L\^)-4_;4_;=_;$U#P
M/\8/AO\  ;4O'/CKPE^QY\/OCGX0U?P)XFT1OCSKO@WXU_ME>/O#'@;6]0?4
M/"OA+XG_ !QT'0I])O+O3-+U/7)M+U@/:6-K9?9[G&O0X<E#-JN"HN6'RW 4
MJF'Q,L9BE+'XW%8C,L-1PLH8APG3FU/+<6U0I.$:&!Q?MJD98FJBJ=3,4\*J
MKM/$8BI&I35&BUA\-2I8>K*K*4)_!+EKTM74J\V(IN,'&'N:G_!67]J/XU_!
M']IO]@?X3^ ?VGOC3^S'\,?C7X"_;3\2?%77?@#^SK\+_P!I7XC:_K7PA3]F
MR7X:VMCX.^(GP:^-.I6VFZ?+\0/%\>JW'AC1=/B^S:I]IUN=X-.TV:PV/!/_
M  4!/[,G[)W@SXQ_$'XB?M>_M]2?&']LG0/V;O!M]X[_ &</A=^S1\9]#USQ
MQX?@LM&\,V7PPT/X>? 31O$/A&Q\1^%]0O[#Q')X>N_$.K7WC6YMDU.]T308
M([#ZC_;(_8V^./QS_:%_91_:6_9[_:&\%? ?XB_LN^#_ -I?P?8GQ]\%+KXU
M:)XGL_VCHO@Q::A,^E6?Q+^&SZ=-X?L?A/<10L;R\-U+X@ADQ"--ECO^$\<?
ML._M7?'OPA\&=%_::_:U^&/C_P 1?!']M3X$?M5>%]>^'O[-E_\ "_3YO"_P
M9M=6:^^&>H:/-\8_&4LVJ>)M6UBXO[;QH-3\K1;:-;-O#NH,OVDF >02P&20
MQ]3"1]E.;S:,:U>CF-5/%9M4C.^'RAUITY47E2G6IYHI0A)4E@^6DY1==X]5
ML6L-[2SI06%DZ=.5"%11H7O*>+Y7*ZK\JEA4FTFZFJOQ1_X+&> M%\"_':X^
M(_[-?Q^^'W[0/P/_ &AOAC^RW)^R[<2_#WQ/\0OB/\7?C=H<7B;X1:9\//%7
MA;Q;J?PYU#2_&?AX:IK8UR_\2:;9Z)I&AZG?:@88WM#=_.'AS_@JA\;?A]\>
M/^"I_C?]HOX8_%SPA\(/V-/V7/V2OB[H?[*>K6WP0G\=>$O$/CRZ^*]G\1+[
M0/B-X,FN+/QI:^,H?#GAO5=)?7/B/KFD60M[FVTJTT.ZDN=/C^DOBW_P2;_X
M6GX[_; ^)MK^T!J'@3XB?'7]HG]E[]J?X#^+]$^'^GZQ<_L]?&#]E[X>KX%\
M+:AK6BZWKTFE?%;P_P"(XGU>T\2:!-_PB#S^&M<U/2+#4]-U:.R\0VWQ_P#M
M8?\ !.+]I?P=^S;_ ,%7_CGXY^.-[^V)^T#^V!^RI\(?AC'X,^&OP%M/A5_9
ME_\ !GQ/X\FTC2?AWX7TGQIXWNKW3Y/#WCK3[:"#5[W5->?6-#UC7+_4[JUU
M>TT/1_1P=/@ZK5A04:?/CJN HNG6K9LZF'GB<3PXZM/ U<1!8:A1H45GE.MC
M,7B%C*-5J%&4Z,J=1\]5YO&-233E[*GB)P=*&&E";IPQ_LXUE&:J3E4E]2<:
M5&"C+WG.2ES17VKH/_!73P!H&IZ_:?M2_L]_'3]C[2X_V:_B'^UK\.->^+$_
MP_U^Q^+'P=^%<?AZ?Q\OAI/AUXO\3WFE_$;P]I_BSPUJMS\-=>M[+Q$^EZQ%
M>QH#;W(@IZ=_P5'N=7GT;P+\7?V8?VDOV/\ 7_C[\#/C+\3/V6_%WC27X+^+
MKKXE2_"[X7ZM\3->T+2=+T7Q5XSTCP/\5M#\!VQ\?Z3X(^+FDV.E:I9V-U;7
MXNVT[5M,C\YTK_@DQXO_ &@[./5?V[?VIO%OQ_T*T_8[^(O[*WP2\*:+\)O!
MGP:\3_!WPO\ M ^'_!%K\3_B5XIUW3[[Q58>-/V@C8^#/#WA73-?MO#?A;P5
MI^FZ7J$U]X%U.ZUV9-.Z_0_^"8?Q\\:^*/AIXH_:O_;?D_:"/[-WPI^,?P\_
M9DTWP[\!]-^$5MH/BSXR?"/6?@?J_P :/CA<V?Q&\83_ !@\?Z5\.=>U/P_H
M]IIX\#:#87%]K/B*.UEUC6%;3^2I2X2C*JO:KF@VJOLZ^=2I1FO:+#/*O:T6
M\0IUX8=YI#,^6C3H_6E@O:1<%/6$LVDX.4$H.,94U*&&523?O5EBE[3EHVBI
M*@\+*I)RE%U8PE%HXGX5?\%8]5/@[]DGX7^#?@#^U-^V/\=/CK^PIH_[8^EZ
MA;Q?LY^ O%WB7P=9:X/#7B>Z^(EOHNO>!/A/X0\5)=W&D2+9>$+.V\,:KK.N
MZ+X:\/Q/?WGDUQGC#_@K)\6?BA\2O^"/7B3]E;X.>-];^"'[=>K?&W7?&'A3
M63\+M)^(7C"+X=?"GQ_!J/PLM=3\4^*'LO!,_P (O$UA<?%[Q]K\ L5\7^'O
M!%CX=\"^*M1FU#6O#&K?3/[*O_!,:_\ V:/C%^RS\5Y_C1:>,(?V</\ @F]/
M^P'-H4'@&;1'\87MS\3_  /\1$^*,%^?%6IKHMK'%X0?2CX3:RU.9VO1?'Q
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M.ZB[Z-::W=K*UW>71K[3=GJW\3?1116AH%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4$_0?1OYI4]03=OHW\UI/_/\ ])D'^<?_
M $J!4N/N'_@/_HR:OA_]B[_CQ_:/_P"SQ/C_ /\ IWTJON"XR8^!DX4_7YY?
M3(_I7P[^Q>P%C^TAGH/VP_C\<@] =7TG!?\ NAB0L9YWMQA<9/T>6?\ )+\8
M_P#87P/T;_YJ;.>RE^1^:<1.WB'X:7T_X3O%#=Q7_-(<-_S2@OQ_S/N2#_5I
M_O/_ .@)4\V1@CDMM .,]&+#CCIG.<G/ (!P33CF5$4$8())YZ$A0 W'!8#<
MH&[(/)&*E>X5\#!!W'C<>>G+?+QTP!_3-?+JZ4+:64;W4K648-I^XE;O=V[Z
M7:_17*#E)-Q=Y25N>%_XM5VLJO-?;97Z)-NS_,__ (*J_'[XF_L_?LY>';WX
M5ZS+X7\3_$SXM:+\,;CQ;920KK'AK0KGP/\ $'QYK5[H)N+.\AAU;58O <?A
MN*]5;>[TBVUJZUK2[J#5M.L&/\R;?&GXUNS._P :/BR[NS.S-\1/&19F8@L2
M1K8!+,3D[0 ?7(V_T _\%NI5D_9S^"!'"G]I[0V.6(SN^ O[00^4+Z$88GH2
MORG.1_-KD>I&>N"<DYSSVXR>?F)X'N/[5\ LFR>MP"\9B,JR[$8K%9_G4*^)
MQ& P>)KU:>$K8"&%IRK8G"XFI[.C"I45.$9PIKGDTY\R/Y'\:\US&'&WU:CF
M..I8>AE&53HT*.-Q="C2JUZ>,G6JPI4,50@JLI1BI3E"52T5&44XJWI!^,WQ
MK&?^+R?%K //_%Q?&/ /(X&N@CU;& IP#D]$_P"%T_&K /\ PN;XLYQT_P"%
MB^,CWQQ_Q/%R23@8^E>;[EZ=.Y!P205(; YZ9!;E@O7@CCO?A?\ #Z_^*'C.
MV\)6$K6QET3Q+K-S>#RU^RKHFB74VFH3< VXCU+Q(^@Z+*\K*T4&IRW,.9+1
MPWZ-QIFWA_X><(<2<=\94L@R+A/A')\7GW$.<8K)<#*CEN48!X58K&3<,HY*
MGLGC,/%488CVU24U"G2=11A7_.,BH<5<29UE7#V28C-\?F^=8ZAEV78&EFF,
M5;$XK$JK[.E!2S)N_)1J3<Y472A&#G4;I\[A;_X71\:FX_X7-\63P3@?$7QE
M[ \_VYC YXXZD#TI1\9OC9_T6;XM8(R,?$;QC_\ +T_D<'\*\MBF+#]Y&8IU
M!CN+>19%EMIXB5E@G1]KI+$ZO%)$T8V2HRL58;5LA@!\P4MM+-C@'DG SDDD
M#@>W..@^E_L/))14HY-D<HR491G2RG U*4XSA1JPG3JRR>E3JPE3Q%"<9T:E
M>$H5(2YHJI%/RGFN;+1YGF<)+W9PEF6-YJ=2,JD)PG%9E.4)0G2G%QJ*#3BU
M>=G(]*_X7-\:_P#HLWQ:_P##C>,?_EY1_P +F^-?_19OBU_X<?QC_P#+RO,G
MNHHF"NRKE=V-WS  A3\N/NJ3RV<<8&3Q4BRJR*X8%6574@@@JR[P0P&"I4@A
ML\J=PXQ2_L/([M?V+DMTXIK^R,K;3DG*-XQP,I1YHIRCSPIN<4Y4U5@I3@?V
MIFVG_"GF>M[?\*./5^5I2LWC%%\K:4N64^1M*HJ<G&,_2?\ A<WQK_Z+-\6O
M_#C^,?\ Y>4?\+F^-?\ T6;XM?\ AQ_&/_R\KS<R =QWZD#[N<YXP.F#T(/;
MIE@G0R-&""4.&YR5) (! !()##@XQWQD9/[$R/\ Z$N2M=UE&6M:.VZRZS5]
M+QE-)Z-IZ!_:N:VO_:F9VT_YF6.ZJZ_YCKJZU5U&ZU5TFUZ7_P +F^-?_19O
MBU_X<?QC_P#+RC_A<WQK_P"BS?%K_P ./XQ_^7E><%AT)QZ^O/U' P1D]CUX
MYJ&.969@#TR!C.""02PR!P 00%+!0P&<T?V'D?\ T)LEZ_\ ,HRQ7M>]KX"+
M=K-M)-I)N2A9V/[4S;;^T\TOO;^T<>]+VZ8V76ROHFWI*3LGZ;_PN;XU_P#1
M9OBU_P"''\8__+RC_A<WQK_Z+-\6O_#C^,?_ )>5YB;A"S1AL," "#\IX#'Y
ML'# 9RO7'/(Y$PD7') R0.O R.,'&"2>Q^O?%']AY'9O^Q<ETO?_ (2,L=K6
MOME\MFTGHDFTFTVDS^U<UT_X5,RUU7_"GCM4]FF\<E9ZV=];/31L](_X7-\:
M_P#HLWQ:_P##C^,?_EY1_P +F^-?_19OBU_X<?QC_P#+RO-VD !(P<9SS@#&
M.2<<+@@D_P"THY).(HIXY"Y5T8X1SAN!&P;8W5LJQ1PK@!)-A*Y((I_V%DCV
MR7)7O_S)\MZ6;T>7Q>B:;]W1-7M>P?VKFO\ T-,R\O\ A3QS3UL]5C9+1Z-7
MNFG=:7/3?^%S?&O_ *+-\6O_  X_C'_Y>4?\+F^-?_19OBU_X<?QC_\ +RO.
M=Z^O\_\ "C>OK^A_PH_L+)/^A)DW_AGRS_Y@%_:N:_\ 0TS/_P .6/\ _FT]
M%/QF^-8!Q\9?BT3_ -E&\8_TUW\O>D'QG^-9Z_&;XL@$<@?$3QCDD<8YUT<D
M\'KSC(P>/.]Z^OZ&FE@0>2<%3C.,[2K?W>I(Z<<\Y H_L/)/^A)DU_/*,M2M
MU6F7O<?]JYK9_P#"GF=[.W_"CC]79V_YCEZ?,]5TCX__ !]\/ZG8:YHWQO\
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M'B<TQ&!S+ 82IC\;B\6\?3CGV%SK'T,7C<3C89?FF:9?F,)4\+E4JN%H9?\
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M2.222 2%VX!YQV.>#CG&:%Q<0VT?F2SPQ1J 'DFD\I0S<#+OM0%F!5064YX
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M.9<O$LXN*D^5RC.<%+W?:<]J9\6?\,4S'_F[G]M'_P /3&/Y^&:3_ABF8_\
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M?NP=/XO_ (EZQ*=UQ7AHWY?AR6HE>/-RNW]H6O%2:BTDTFHII<RE_"";BT?
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M:_;8_P"B^Z[_ .$[X6_^4M?%.U3GY,<9X5SZYQE>3T^O8"D&P8(3T))5L("
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M/X7^P>??W6F:'\/]>L((YQ?+Y?V?47;<O^J0#->$?M;>/_\ @I%H'PPT:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN[ZA1117D'V(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[QM_\J:/^%O:5_T*7Q0_\-=XV_\ E31]6Q'_ #[K_=2_^6A_:V6_]!F'_P#
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MKRC_ (7%X-_Y[:U_X3'B3_Y7T?\ "XO!O_/;6O\ PF/$G_ROH^J8K_H'K_\
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M_P +.\(?\_M]_P""#6/_ )#I?4\7_P! V)_\%/\ ^6!_:V6_]!V$_P#!S_\
MF<](W1_W6_)J-T?]UOR:O-_^%G>$/^?V^_\ !!K'_P AT?\ "SO"'_/[??\
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M_A9_A+_G^O\ _P $.L?_ "'1_P +/\)?\_U__P""'6/_ )#I_5,5_P! M?\
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M2>A-11WS]/TS_C12-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **.G6JSR+N1"^TAN0&R6P!D $ L<\$CH.3R0* _KY]!MS<P0!
M!+)&I9L*LAQNP/FQGN >_P#.J&HBP: F[(2+=O#[]C;I . Q)Y*MG(!PN,Y&
M32:A:QW0A+R,I^Z#&$!<'Y2@WO@'OD$G'\)X!AU&RM[J!8Y96A2(H8Y"R;5$
M8,:[M_R!64$,#C:V2!\V!K'V<9T;SG'F;YW!)RC'^[=-7?G?T3U.6K[6<*\%
M3I3BH+V<9RM&I*5TXU%=.%.R^.^MVFK)EZ*WT_RH]H0KY:;2"Q!7:,$'N,8Y
M[T55ATZSCABC&2$C1 6EPQ"J%!8* NXXYV@#/0 44FHW?[R6[Z^;\C%4:EE_
MLV'V6THM;+9WU79]58W!G'IV'?'U[?@!43+U&%.#D@KQG;@$] 0<\CMSUJ7H
M.AX'0<GCL/>JDDA^8 ECYH0+C;GD@ '<>21MW$JIR,@$'.$IQ2=[-6=ULMK]
M?E\V>A9MJWX?=ZO[]]1=@)8!%/<@*1CG@#GCT)Z YXP0 >6"?N+DC@;6P!TS
M_7IUK\U/@?\ \%._AO\ &S]J36?V6/\ A27[2'PN\0RM\8[CX8>/_BQX&\.^
M%O _QHT7X#^,(_ 7Q$\1>#;&+QA??$'1='_X20RMX0OO'7@?PM;>,="A75=+
ME$SOI\/=>(_^"@_P<\'?M_>#O^">/B;1?&^E_%#Q]\$](^,WA3Q]<VWAZ/X6
MZG_;NN_$G2=-^'LFJR:]'KUKX\OK7X6^*=7TS3WT!K'4[*U$%E?37Z36Z>C+
M*<RA6=">!K>VAE\\UE3BJ<W'+J<%.IBVZ=:I!4J4'>K%S52G)2IU*,:D)TH<
MJQ>%<%45>GR/$1PG-=I?692Y(T;.,7SR=K77*URM2<91D_O$1J<X1>W4-D<]
ML#@>I/\ 0B@1CM&G.0,@G/\ M>A/&,=N/>OA/X0_\%$OV;?B3^SC\+?VG/&/
MCG0_V?O _P 7-:\<>'_"&F?';Q=X&\'Z[=:KX!^(7BCX<ZO:H;?Q%J6DWK2:
MIX7FU&(Z;J5VMMI>HZ9)J+6=S++;1_1&H_M!?!/1M1\2:+JWQ@^&>GZOX/\
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M*:GI5_=V^M^,M5TOPC<>---U^V9OA=I7A;4;-O&OQ!\)>(M+\7>'?#?20?\
M!8?]F+5_"OP+\1^"/ /[3WQ(UC]HCP_\>=3\ _#?X?\ P%USQ'\2[77?V8_%
M]OX%^-W@'Q7X6CU:V/AKQ=X'\1OJ5G=&\O3X3U)-$U"?1O%-_'>:%_;'5/'\
M83J0?]F>S3J5ZTJ<<OHQIR369)>UC/$R<:6&>,Q<H2J2H2C5PV$GB9U*^7X>
M4>?ZMD[4K8E-1A"%_K-9\EOJ[;C)4G*4JBHTXV4JK=.=91BH8BM*?POX7_X)
M5?';P5^VCXXU^]\)>'/B=\!_$W[=6K_MS_#_ .*MM^U/XN^$<GPG.N^ ]/\
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M/$.K:PNGZOXY\'VEC)<W>J,(/AYJ,<.H:9X>\=:WXGTS4- M?(I93FLY1C#
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M/!\_C;PK9R_'?]E7X_:3X/T76=-3PGX6UG]CWX$^&/V=/A3X,T"SFT66]M_
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M'D@_7BE^U+DKL92."3MXR2 V 2=IQE20"1V!! _#+1_CM^TWX3TSX!67Q/\
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MFE>C1O=WM&A:]W>WO[7O;RL$:N'Y8_[1G#]V.K]LF_=CJU[/1O=KHVUT.MP
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MWXN\/_$S0[2;QKH_CGX9^(_%-G\-/#2V7B/74U:*YT^UU*?QK_P61^*_P[^
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M=^(?%?Q9\6ZC\1+^63XF:]/XN@T3_A6WP]'A9O%C?$*W^(]AXF^*?@N+38O
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M].L-7\3>#/!7C3PY\.=6\$_$WXJZ)IFJ6%YJ?P:^&OB#Q;\6+6WO+=I/!F'
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M110 4A.,_08]SSQ_*EI"3G&,]/US_4#MZT?AJON6Z^:T$_Z_$\$_:@\5>)O
M_P  OBKXK\'6_BZ?Q+H_A.\FTH^ ]&C\0^+;.62:WMI=3T;1Y-(\0"ZGTJVN
M)M3G,>@:[/;6=I/=P:-J<T$=G+^0GPR^)_[9'Q*TB^TH_%OXR6GAW0C^U7XD
M\+>.O#WPHUJQU#QSH_A;X(?LM_$+X-Z?<:W\4O@OX+UCQ#HJ?$/XA?%?0M"\
M06WP^\,0?$RQ\/ZII7AQ+RPTV+5$_<CQUXU\._#GPEKWC7Q7<WUGX>\-Z>^I
M:K/I>AZ[XEU0V\9$:PZ7X=\,:;K/B/7]3N9FBMK#1M"TG4M7U&ZE@M;"RN;B
M6.)OE2^_;]_9HTO2K6_U/Q!\1['4)]8\=:)=^"YO@3\<9/B3H5]\,=#\(^*_
M'S>*/AM!\/Y_&WABR\,^#?'W@_QK>ZAK>AV%E-X5\0:5K-A/=0WENLO;A9UH
MX:M"C@E7FZM-K$\D9NG9-QI>\FHJ4(5[R?N:)R7/3IM\M:,'4C*I7E!>S:]E
MSN,97DDYVBKMJ4H1M=-WLO=E._Y@_M%?$K]K/XN?![XY_ 34W^*.D7G@+]GZ
M;]J;QMXY\$>%(K'Q?XO\"?&+PAHMK\"O@UIFAVV@ZEJ4$T'Q/@_:>B\46WAG
M3Y/'NC:=^R?X+M?$,%C9_&JSN+OHO&LG[0O@'PI\0_%7P]UWXG^+-!^-7[7/
M[97@_4_A]J/PQLO%'@VT^&\/[,?[2/QA\#?$#3-';P/<ZK-=^)OBY\,/AM96
M'B:_NYO!^MP^,6\$:9HDEYK>B-7W./VI_P!F;PE\7Y;;X;:7K/BWXB_'?XK_
M  @^'_CKQQHOACX@'PE<>(=<\&Z+=^#M&U#XJ:OX>N? $.M>%/AKJ=GXJ@^%
MNF^(-*N[:SU75;G^S+/Q5K6HPZC[1JG[8/P"T36O'FB:GXK\00CX;1>*D\7^
M*4^'/Q)N?AW9:MX%T_\ MCQKX0L_B=;^%9/A]K'CGPII:O?ZOX)TOQ+>>*(8
M+/6UM],N9?#7BB/1^BI6Q$*,J<,!4ITZRHUY1]G%*]*I2IUJG(HRE2]IBXTJ
M=)^T4_9QBHTHW;,N2FYIRQ*<J2G!+F=VIT7*FI/F49\M%RJMJ+7,[MV45'\^
MOB#\0OVT/!G@U?B'X/\ &?Q/\3>*_B!\0/VLO *>!=5^&7AVX\.?#_PSX$^&
M_P :O%7PA\2^&-*;0M!N8/$<>O\ @3PGI&A7_B[Q')X?^(UYXAL?#X6&^UC2
MFES9_&GC[XT?LM?\%8O /A+XL_M ?%:W\'^'-7\*_!C5]?\ AYJ7@;XR6$7B
M/]D3X?>.'T+PUI;_  V\#:_XDN=2\8>(-4N-(U&+PA)>7LVK2:1I,\TEG"8O
MM#]I;]I7X":'/I_P-^)?A76?BIX?^*OC/5O@5\3?".@> _&GQ!N=/CUO]G+X
ME?'VWL+OP/X1\+^(?$/C.S\2>!? 6I6\L/AVTE71TO&U'4[RR33I4DR/@Y^T
M1^Q5X!T6^\/?";Q-J%CX.6V\2>-M=^(<_A;XR>(?!6J:SH7@Z?Q[XRMO%/QZ
M\7Z+K&EZW\3_  SX&T:XU37?"'BCQO=?$#2-'T'4]&.D1S^$M9TK1G.M.6'=
M99=.E4]I1Q%.K2H4HT(PI8JG6Y9U'&=127LIT,.W"*E&52<UB(Q4*>:IKVDH
M/&>TCR2I352<W+VDL/4IKELH0:DFJM1<\K3IIIT5*3J>$?!?XT_&3Q!^T%\.
M-#L/'_QJ\9:9K'Q:^(6C>,?!GBKX/W&B_#G3?V3;'X.^.]>^$'QPA^($O@+P
MY9GQ-XL^(NE_#32EU&#7VU#Q/J7C'7/"_P#PKS18_#6OZCX;Y7XU?'S]H#PC
M\9K*RT'Q[\3(/B!=_M177@#P/\$8_AQ!-\!?&GPB;X1_$+4_ ,>O_%6'PEJ6
MDZ%?>-?B%I&DVE[XBN/B1I.NP^)K6V^''_",Z=?ZFHE^Z+S]MK]GZQTVQNKS
M5/B9:ZSJ&O:GH5M\.[KX$?'2T^,._1-#L_%.MZW=?!R[^'<'Q-T_P=HOAC4]
M*UW6/&=_X6M?"VG6VLZ%8W>K1:UKFD:7>^?^&O$'[#6K>+H_VG_#LGAZ?7-8
M\2?"F2U\:M;>.(M%3QM\?_!NC^'OAOXWLO">HB/PIH?CGQG\.OB!:^%[WXGV
MWAG3O&%EX)\4:YX:\2>)++0=0\0:=*4JRIUYXFME<W3</94X^SIRC4K\]:?+
M4DH*FZ,W5Y>6%)UI0IR5.OS.]&I1DX0HT\734KJ<G)RC)4[1C*4$I+WTHR<5
M*2C!R7-"*24OSO\ @C\1/V@?BEXT_9'\9?%?XH_&%_"/AK]H7P!!XB$GPT^(
M_A?7M"^*'C7]GCXN:+XC\!?$VU\4_L^?#RTTKPKJ7CJX\.>#KK1;"PU33_AS
MK'BW5/#NK_$B&]O-%NH/H3XP_&_XWV/[6OQ2\$?#OXA?%"_U_P %>,?V.7^'
M_P #= ^',6K?#[Q3\._&&IF__:<N=>\63>"9=.37-.^%$'B[Q7X>CU'XC>&[
MC3O$GA[P]:VMKJ,^OZ?I&K_7T/[='[.MQH.F:_#KOQ(E?Q%K6F>'_!_A:3X%
M?'&S^(?CS4=;\*^(/'.@-X"^'.H?#^U\;^,='\0>#_"GB3Q)IOB'0-!O_#W]
MC:!KM]?ZG96^B:M)8X_P;_:%^"/Q*^+_ ,<%^%GA#Q'+J]A\/OAWXZ\9_$MO
M!/B[0M'\?6UK'XQ\-:;X3EOO$&AZ9'9^,OAW=^'==\+>(/!^IFR\3^'=7CU'
M2M;T>QU'2[ZW@<JU>5:E7GEC5+"X6I"-.-.A3IR3QF'G*I4CRQ4E.52I3J2I
M<]1JI&--TY0JNFH4Z<(SIK%J52K5AS3G4J5&G["K"$(+GO&3C3YTI-ISBYR3
M]T_*WX;?%;X__%>Z^'5Q\1OB-\>9_A_X4_:5_8Y\<V_B:X^&WQ T+7=)'B+2
M?B!X;\>>%_&&IZY\!?A]IVJ:/'X]U/P1X<\?:;X>\+WGACX9:YK9T[4/%EO/
M8OJVE]]\*?C1^V!;_%KX.^ +Q]>\!:7<^(O!)T+PE>_"/QWIGA#Q_P""]8^-
M'Q0MOC7)J-MX3^!^J^&=,\0^'O!=E;75AJ&L?$SX<V?A6XB\)^)=6M/$%EXM
MW:K]$^%/^"G<FO> ]0\:7WPJ\%W%Q-^RGX\_:E\+>&_AO^T=X1^)6KG3O W@
MO3?&*^#_ (E?8_#.C+\+)?$']LZ?H&E^*]834]"&OQZE83J?L2O<^OQ_MSR>
M*?&OP5^&WPN^%-[XK\=?&WX#>*OC/9Z5XB\=:;X-M?!6O>$+[PQINJ?"?QS*
MNC^(+_3/%EI<ZIXGT[4[F+2Y[72-=\$:KHU[;)=2YM>RK+$VG?):5.C"&(46
MZE"4*+C1IU*E3WH4TZG+2<Z\Y4_WD7)8>-.M)U*W.HTVI<N.J.<G#F253VC3
M<H>S24I/E;JKV<;J2E959.,U&/PAK-]^TGJOPG_9'U;XK_%K]HBZM_&_P]_8
MQ_:%^+^JIX MM.U+X??$F?QS\-M,\8^'QI_AGX:27WAS0)4\3WTGBOP7K>G7
M^HZ5=6<FKWMWIMA97XMO>_CYKGQ#^'?[5OQFUS2OB!\</"OA#QCX8_98A\::
MGX4\"W?C+2?A]\(--NOC3IWC[QI\/HH? NNP1ZMI?BE?!NF^+-2M_P#A+;_P
MCIWC.Z\2ZMX6705BU71OM/\ 9>^./Q'^/OASQ'XK\5?"72?AAHFC^-_B9\/=
M*FT_XH1_$&ZUGQ%\(_BQXX^#_C5Y[>+PAX873]/'B/P!JE[H=Z)KV75-'O[.
M:X@L+H7%K']3!9""6RO);ACA2%&[ '8L&P?O<XX&5KS)X^=.7LZE"E)PA7IU
M*=.5#V4O;XBE5:BUA9QC.'LEK'VD4X4+I<E15N^&'C/EJ*K4UE2JPYE-22A3
MG&*:<^JJ-R33:;DGHHN/Y3:OJGQ@^*/[%&G:KX]TKXP>,?#@_:#UZ'QC:V7@
M_4O"/QJ^+/[&WAOX_P#BG2?#FN:EX$T%-#\5I=^+O@_9^$?$OB'2-"T_1_&?
MCOP1'>WH\$Z7KGBFZ^'UMX+XR^''P5^+WC+P+H7[)?P&L;3X93?%_P"&C>+I
M?B#\#/'^F_L@>)_$^E_#WXLW$DNA_!W5=(\(Z?J/B'PAHUQH=EX]^*7AK2--
M\&7OB75O"/@77/$OB/XA_#_Q%H?@']U&64'(7<2!D@XRV=H)/.,*!DCD GD#
M.8RLI X<[N<$@_=).#DGAEP0!QD'(&*FAF<J,I3IT90G&I7J4Z:K3AAW[>*2
M^L4:<;8BI1]G%X>HYTXTE4KQC&"G&,:J86$THRY7'DC"3E'FJ6@Y-*-1MN,?
M>?,E&3E:-[M._P  ?\$\_ >K?#WP)\;-"\3Z'!X%\;3_ +1OBN]\<_"?PGX=
MU7PO\#?A3XA3X=?"G2[;1_V:=/O3-I]U\%?B-X;TOP_\?8-3T.ZE6Z^(_P 7
M_B,?%^G>%/B9'XY\%>&_T(C)&5.>. 3U)VJQ_$[C@?[)X'-(HQL(3)( +<?*
M .HXY!))Z]R<FI1P/3D_S-<%24J]:=>24'.?/RJZ5W"G%JS;:BN3W5)R?+9-
MMKF>\(\L8Q3NHJR[VZ=%TZ65GT6R6BBBF6!Z'/3O560_,1SC;M#8X'W6SG&#
MG))'8)NZ XM5&R!\Y'\7!R0>5 )!'3/W3ZC([FIDKZ='H^^UU9^4K/S\Q/Y_
M=?\ S/S#_;0\1?'[2?B-';^%-7_:.\.>"V^!VN77P9E_9I^&]Q\1Y/%W[4T7
MB*[2T\'_ !VG@\$^,X?!?@A]#C\"CP+K/BJ;P/\ "K4EU?XL-\2/B%X8DT7P
MC-<Y/PHM?VM]-^)'P2\;^.?&'QKU8_$']I'XQ_#WXR?#G5]"T.?X2^!OA/8?
M SXS^+_"'B'0+:Q\'V&L^'M*A^+W@SX=>&O"?CR_\27MCK]KXD'A^9M0N?$N
MCO;?J9*C$J$!PN0V3UZ'G^\"#@C/.<'H::$;^X3D?,W R20P/K\G51SMXQ\P
MK=8Z4</+#^PI-.#IRFXJI/D:J<W+>E[BG*:J5(\[ES8>DXRIWY)8N@I3]HYS
M3O%V4G&[BXM72E9JR<=8KW9R6K:<?QF^(UE\7/ OQ.^*E[L_:A^''P?\8_&3
MXV>(]:\4_LR_"76O'GQ&\2_$%? _[/VG? M6T?1/AW\1=?NOA[KD4?Q>AO?%
M5OX=B\$1>(="TFQ\=>+O#]@+*+4JWPV\&_MS>/I_A9J'QG^*G[3'PV\3^+_C
MY=?#OXS^&? =GX"TWP9X-^'MK^Q=JGCC6/$7A.]3P%XGL]+T3_AI[P]I_AS2
M/B':^(-<T.[DUBY\'Z-?W::W87*?M*5<Y(7;@$*.V,<?CG&?;&.F*C\LM]X'
M:%*L.GS$DX(.054GIDKDYQP*T68UG'E5&DI1AR<UHMW5.$$U[2C)J[A"4VIR
M;G3IQ2@DU,^KT[2O*5G/F:;EM>]K*232O*VVDY+5[?A-\#?B1^W+J7[0G[(@
M\;_\-,6.EWC> ?#G[1_AGQE\)/%=O\/I?#M]^R9\1M7O_B)>^*8/AQHGPQ\-
M7&I?'[3O .AW^B:/XTU?XC:'XODU"#Q/X:\+^%]:L0^C_P $Q]._:I^'OP<_
M9=^'NC>%_BU=^"O G[&_['G@/XM^!_VJ?#'B#X%Q_!_XN^'O OA'0O'OA+X.
MVE]\)]'U+Q39>$O!UBT>H6VAGQ5X#7Q);P:4OCUM=AUFR@_<@QMN)"D\$$/R
M"#DD 9QSM[XX;D=:7:[$%D8X!ZG<<,!R">1DC/;OQZU5S*53VB^I89*I3<%3
MLW248MS4W35.DU53G-TE&MR0G"#<ZD4J*SIX9PC%.M5DU+GY^=J:;33BI<S3
M4D[-2A)-:**?O+^=?]COX.ZMX5^)O[)4WASX8^*]/\8> O&_Q&MOBUH__#!'
MC_\ 9@NO!?@[7-#^)%I?:YXG_:P\1^!_"/A?XUV&GZW/X?M=4\%Z#K_BP_&#
MQ!KFE^/[&VU*S\-'Q#:^Q?%SXC_MI1?M2?'5/AI#^TW:>%=&T'XY:/H?@RX^
M$?B[6OATSZ5^S-+J7PE\;> _'B_#ZV^&6IQ>*/BO80-X<T'POXT^(/CF#Q9=
M7.G>/[+PZM\/#>E?N*87.1Q@["5ZC&3D$'[P R ,] -PZ4[RY!N !V@ !<\%
M@<[A[[LG/7N>2:)9I4E5J59X:E*<J=6C%2YIJG"KB9UW-<T%&[E-N/NIJ]_:
M-Z-+!J-.,%6J1:E3DW!OE:I4X4HQY9RG:,J<%&:4O><I25I.Y^+NK?#G]L;3
M_$S:%8?'C]L2[T+P_P""_P!B"ULM?73/ MU-X@U[XD_$GXW?\-.:MK%RGPG:
MQOM6\->%G\%VNJ6VGP6&G_#?3;?PK??8;<LSWWZ#?LB0_%&W^#U_I'Q>U+QO
MK7BKPU\:_P!IOPAI/B#XCZ?;Z?XS\0?#+PE^TA\5?#OP9UW5VL]+T6UU:'5O
MA)IO@J^TCQ);:7:Q^*-$GT[Q#FY;4GNY_IS:RGA#N*YQQQD]SCKR=Q')]"#Q
M-$" <KMS@D8&<\C!QUP H'HN /2L*F+J5Z4:$Z<$OW<E4C"$9Q=-R<K2A"#?
MM(SY)MMJST6B-84(PJ.HI3UYDXN4G'WHV:LYRT32Y>W+%WW<H_*/W@P4X!!(
MR",8.<]!MQCH1M'8$$,9^4[P,9P"  23P><8QDC'KSWJS16/*NRWOLEW^3>M
MFWOIO:RVM?SOO?7_ (&G331[6ZP>4ORY+,"#D8.&)P 6QR, #KT[]ZE10HP.
MF20,Y !.0![?UR:=124$FGV<FM[WD]6]7?K_ , ?]?T@HHHJP"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **8[A2H(;NQ*@G 4$\X'0],>M59K
MVW@"F9Q'N)"9)RQP0,  ]0<\\ ?-R!FBS;LDV_)7?G]V_P"8FTE=NR\]/SL,
MO;R*U1))-P#'"A%+NWREMH R ,9W$X '0\BJT]U;_93<2$/!*(U52C/YK,PC
MC3RSDEBW&T<DG'?(??M9O$&O"%B0JRN6(/"EF9<#+?*3E1G(SD=ZBE%B;0B0
MI]D,:8)(">6K*RD'IG<H*'J&&1R*N,86I)JJ[U+.2O[UND6TDY*^O+JDMM=.
M:<ZO-6BI4.5493@IM_%T=5+6--WLYO1K3N+#<VC6KS(!'9QI*'79L\L+CS59
M!R"!][DY '/45!875C-$[6BK!'"7\Y1"L11MA;,B!GQ\AX);!SC=D\S0BP%G
M^X,1LMKF1@RF/RMC^9YAP&^3&Y@S$C ].(--73! WV JT/F-O(8OEP"OS^9\
MX4+GY3M78'8#"M32IM5GR8A256"7O>ZHJZ]^_P#R\:ON[MM7>Q*=5SP]YX5Q
ME0J<^BY^=+W?8I;T7_R\^RE%?)FF7NEW,DRV*)&Z-O<>4D7F@L=KCYLR*&)!
M/+;C@#=BHK34=*FU&>*UC07O[WS)1 D7G+&Y$@28',X1QAR1V(SFG:8FBJ]T
MVF-$SA\7#1NS%0KLP5%?G9NW,NP;68$#'6FVD6B#5+LVCJ=2#2"50[Y0L0)7
MB1L*#N.)3$,_>+8).=9QI.6(2AC%:E#ELVY)W2?M;)-0;>CV2[HQC[?EP:O@
M/>KU%5Y%%Q22E)+"]ZNEJBC[R7,]TDXC?Z.NKI:F-!J0*P"Z\E<!]A"PK,&W
MAA$< >7MP,;\X%&IZCHT.I6T%]&)+TB,PW#6Z.EL9&*Q>9*6#1AF)P0K !-Q
MQ\I8== 76E<F$:L1G;N?*LJ,8RL0!@$PB&=O^M"%6P<@U'JD'AU]0LCJ;0C4
M"(Q:AVD7.V0&(2E%\GB0 PF9E$I&$SMXI*DZM-J.,2EAY2;BWS<ZBTO9I?\
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MH[%5-R)]$LKO4HCM56M+>23/RFBW9O\ -;WVZ!_7Z]^YVA&?S!_(YI ,=N@
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M_#^GI.LDVL:1H+Z*FL:E8%,QSV=@WB/0O.F5]NW5+1TWK)D%M_-W>F_]=]]
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MUUN 49Y'7G]/K111;6_]:_UVOY]P****8!1110 4444 %%%% !1110 4444
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MMND>1*'5>(R7\SS&RJ[22P;E2I#'C&&:A8B^M8H!,T2PLKJ6 ;=LC=/G0X#
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MX5ZWX#^'VN^,["U.OG1[.X\+_;8O#<%U87WZQD#:>!_'V]S2#D@'D?O>/HX
M_(<#TH _* _L5?$/6=,E>33])\$VNEV'C*X^$_@#PQ\4/&VGZ)\$9O$OQ:\%
M>(M*T+P;>^'+O0H-,D\/>!M&\76WA[5- M=/A\ VWCGQ!\.OAY_8O@*^NM.N
M>V\8?LB>(M3^"G@CX?)X5\!^++OX8?M"?&;QW\.M"\0W8N=+\&?#7Q;KOQDT
MKX6:7X-OM8LM1'AB7X:>"O'7@V'1O#VFK8Z=H&F^&8O#OAXVEIIVF01_I6W
M&./F3I_O ?RX^G%12<*,<?)GCCD,F#Q]3^9]: /RWUG]A_Q-XGU'0=:\6KI?
MB#6H_B)=-XEO;_QQXRG35/@^/V-/^%:V_@&2!;^*WF\.7G[3F@^ /BOK'A!X
M5T+5/$WA'PY\3=2MKOQIX;T;4+/=_9]_93^+?P^^/]S\5OB%XP\3ZS<M;^*U
MU;6[?QWX9U'3?&_A_7]/TJV\)> _%VE7?PS;XE>*X?AA):,/#5YXM^*=_IOA
MZ^M;S5?",-E'XS\6:5?_ *8$#(X'1NWNM-7[\@[#9@>F1DX],GD^_- 'Y(6?
M[#WC36?$FC3^-O"'PYU>PT3QSX'\4>-=5UW7KSQQ+\=?%6A?'[PKX]MOC)XA
MT7Q)I-Q%H/C?P/\ "&Q\=_##2)'DN=:UW1/B=J7@^[O?^$-\'>$+*T]Y^,_[
M,_C#XK_%*WU74YM.U;X8WOQ#T#7_ !#X3U/Q!K,>G:]X:TG]EW]HSX6W.CZY
MX>MV73-;TVX^)?Q)^'^KW>@:FMSH^HVVCOK%]:S7.BV*M]]8'H*,#T''3VH
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M2MU]/P^7]>0!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0G )]
M3QR>/;O2TW^(_P"ZO\V_P% $+2.?]7^)8#)!Y!';C!'.<@YZ\UC-:3C45N_/
M**#B10S[BH7 A"_="9.[(P1R22*=;22-?7:&1RJ[]JEF*KAL# )P,#I@<4TR
MR'66B,CF+RB?+WMY><CG9G;GD\XS6D>:$FDXZTFW>-]XN6E]FK:/O9G-4<*B
MCSJ7NU8RCRS<?>C=QYFM7&^\=GUV&7ME<W-[;SQW&Q8TBSEF#0X9R[HH^60R
MY56\QL )@#)R&ZK97-[Y M[@QF,G=$&=5)+ +."G#LN<*K _,1@9YJ6^D=-1
MTQ$=T21W#JK%5< $@.H(# 'D @C/-0ZS+)$EEY<CQ[[]5?8[)N7>>&VD;AP.
M#D<"M:<JE\/*,HJ]-N%XI\L;/F4MKMN[35K-WW.:K&CR8OFA4=W2G.U1J\I<
MNL=?=2TT[7V%U2SN+RTBAM[DQO&T9?YW19\+M?S&C&[&[+8 PQ&&! -%UI]S
M)HWV-+IA<>3&/.+M\^Q_F1Y!F01NI,;-U^8$X)(IVM221:7-)'(\<@DM '1V
M1P&F@# ,I# ,&8,,X.3G.33-0ED71)IED=95M2ZRJ["17*+EE<$,&.3E@03D
M\\U--U90H6E!*-64TG!.]1/1RLK2A=ZP=TUZ(NI1HSJXOFC-MX:-*?[QV=*:
MC=15_=G:WOWNK::-W2UT^[@TJ2RDNF^T-%.J2AB_V9Y!MC1&<[C''P"01E3(
MPP%7$6B:9<V%K-!<78D9W9HU61I4A&"A8.X(WECOY7Y2 <Y%7+"6632(9'DD
M>0K(3([LSDJC;27)+$CL<\=JSO#4TMSIV^XEDG<SS*6F=I6*A.%W.6.!V&<#
MM1*I6<*UY0M.M3E)*FOCYG9QT]V*M\*TMIYB5&@IX62592IX2M"D_;2Y52DH
M\ZG':=1JRC4>L;>EHM"TB]TZ6\DN[T3+< [$6260N59F%T_F9'FNI"LJJ!Q@
MY!Q3=/T?4+/6;R^FO0]M.TK(GFR[[@2$;?,0_NX_LRAEC9 2P93ZFI]!FFF?
M4A-+)*$OMB"61I B;F&U=Q.U<<;1@8XQ4&FSSR>(]:ADFE>&)HQ%"\CM%&"8
M 1'&Q*)D$@[0,Y/J:WG.MSXM.5*\J$>=JE%)Q=DE%?9E9-.5V];HYH8?#1IY
M>E&MRT,74G03KS?+5Y)7E4;?[R%I/E@[I.SZ$3Z)J1\2+JO]HDVR&-MA>8.T
M?E,ILVA5O(,#2'S=S#&[DH9/FJ'6M!U'4-8L;ZUU$P06ZQ JTDH:!DDW3-#'
M$RK*;E0R.2P!Z$XQ5MKB?_A+Q;>?-]F_LM9?L_F/Y'F\CS/*W>7YF !OV[L
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B6T5[V\CIA@LOY8VHXBW+&U\;BF[<L;7?M]7:UWU=WU/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>atnm-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 20:21:20 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://actiniumpharmaceuticals.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:atnm="http://actiniumpharmaceuticals.com/20221231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals" id="atnm_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statement of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets" id="atnm_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>008 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipment" id="atnm_r_PropertyandEquipment">
        <link:definition>009 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Leases" id="atnm_r_Leases">
        <link:definition>010 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue" id="atnm_r_OtherRevenue">
        <link:definition>011 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="atnm_r_Equity">
        <link:definition>013 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxes" id="atnm_r_IncomeTaxes">
        <link:definition>014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent" id="atnm_r_SubsequentEvent">
        <link:definition>015 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>016 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="atnm_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables" id="atnm_r_PropertyandEquipmentTables">
        <link:definition>019 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>020 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>021 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables" id="atnm_r_IncomeTaxesTables">
        <link:definition>022 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable" id="atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable">
        <link:definition>023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable" id="atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable">
        <link:definition>024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="atnm_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>025 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable" id="atnm_r_ScheduleofpropertyandequipmentTable">
        <link:definition>026 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable" id="atnm_r_ScheduleofdepreciationexpenseTable">
        <link:definition>027 - Disclosure - Property and Equipment (Details) - Schedule of depreciation expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>028 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable" id="atnm_r_ScheduleofcomponentsofleaseexpenseTable">
        <link:definition>029 - Disclosure - Leases (Details) - Schedule of components of lease expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" id="atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>030 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable" id="atnm_r_ScheduleofweightedaverageremainingleasetermsTable">
        <link:definition>031 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah3T1Ki2MCKemJQOnFITo819XV2SZHEI0EiEoEUPiTVdpo53/UPf4KPbGQfg8/dyhoreC4upaSg/wmtLLQQWzYYSy386a+zde19o0mZ+MfUY0/DUIZcDhC8F1b4nqk2JORLCjpzK+x8Ag==] CSR-->
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable" id="atnm_r_ScheduleofweightedaveragediscountratesTable">
        <link:definition>032 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>033 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails" id="atnm_r_OtherRevenueDetails">
        <link:definition>034 - Disclosure - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>035 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>036 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable" id="atnm_r_ScheduleofstockoptionactivityTable">
        <link:definition>037 - Disclosure - Equity  (Details) - Schedule of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable" id="atnm_r_ScheduleofrestrictedstockunitsTable">
        <link:definition>038 - Disclosure - Equity  (Details) - Schedule of restricted stock units</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable" id="atnm_r_ScheduleofwarrantactivitiesTable">
        <link:definition>039 - Disclosure - Equity  (Details) - Schedule of warrant activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails" id="atnm_r_IncomeTaxesDetails">
        <link:definition>040 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="atnm_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>041 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable" id="atnm_r_ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable">
        <link:definition>042 - Disclosure - Income Taxes (Details) - Schedule of difference between income tax provision and U.S federal statutory rates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails" id="atnm_r_SubsequentEventDetails">
        <link:definition>043 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfDepreciationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDepreciationExpenseAbstract"/>
  <xs:element name="ScheduleOfComponentsOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="OtherRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfRestrictedStockUnitsAbstract"/>
  <xs:element name="ScheduleOfWarrantActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivitiesAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract17"/>
  <xs:element name="FinanceLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseCostAbstract"/>
  <xs:element name="CashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashFlowInformationAbstract"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract18"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract19"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract20"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract22"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DeferredTaxAssetsAbstract"/>
  <xs:element name="LongtermOperatingLeaseObligationsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
  <xs:element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
  <xs:element name="SalesOfSharesOfCommonStockNetOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
  <xs:element name="RightofuseAssetsObtainedInExchangeForLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities"/>
  <xs:element name="AcquisitionOfEquipmentFinancedBySecurityDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit"/>
  <xs:element name="LeasesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesTextBlock"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="NatureOfBusinessPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NatureOfBusinessPolicyTextBlock"/>
  <xs:element name="GrantRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantRevenuePolicyTextBlock"/>
  <xs:element name="LicenseRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenueTextBlock"/>
  <xs:element name="Accountingstandardsrecentlyissuedpolicytextblock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
  <xs:element name="ScheduleOrDescriptionOfWeightedAverageTerm" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRate" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRate"/>
  <xs:element name="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
  <xs:element name="PrepaidClinicalTrialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_PrepaidClinicalTrialExpenses"/>
  <xs:element name="LeaseDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeaseDomain"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
  <xs:element name="PaymentWithImputedInterestPremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_PaymentWithImputedInterestPremium"/>
  <xs:element name="MaturitiesOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MaturitiesOfLeaseLiabilities"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
  <xs:element name="EquityDetailsScheduleofrestrictedstockunitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsScheduleofrestrictedstockunitsTable"/>
  <xs:element name="EquityDetailsScheduleofrestrictedstockunitsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems"/>
  <xs:element name="RSUsOutstandingBeginningBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_RSUsOutstandingBeginningBalance"/>
  <xs:element name="RSUsOutstandingEndingBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_RSUsOutstandingEndingBalance"/>
  <xs:element name="NumberOfWarrantsOutstandings" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfWarrantsOutstandings"/>
  <xs:element name="WeightedAverageExercisePriceCancelled" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageExercisePriceCancelled"/>
  <xs:element name="EffectiveIncomeTaxReconciliationDeferredTrueUps" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
  <xs:element name="RecognitionOfDeferredRevenue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RecognitionOfDeferredRevenue1"/>
  <xs:element name="RevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueRecognized"/>
  <xs:element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UpfrontPayment"/>
  <xs:element name="LongtermLicenseRevenueDeferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermLicenseRevenueDeferred"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MilestonePayment"/>
  <xs:element name="DescriptionOfRoyaltyPaymentToRelatedParty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
  <xs:element name="AgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_AgreementDomain"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityDetailsLineItems"/>
  <xs:element name="GrantOfStockOptionsPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantOfStockOptionsPurchaseShares"/>
  <xs:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
  <xs:element name="StockOptionTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockOptionTerm"/>
  <xs:element name="VestingPeriodOfStockOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_VestingPeriodOfStockOption"/>
  <xs:element name="AggregateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AggregateFairValue"/>
  <xs:element name="StockOptionsExercisedSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockOptionsExercisedSharesOfCommonStock"/>
  <xs:element name="UnrecognizedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnrecognizedCompensationExpense"/>
  <xs:element name="WeightedAverageTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageTerm"/>
  <xs:element name="CompensationExpenseRelatedToStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_CompensationExpenseRelatedToStockOptions"/>
  <xs:element name="CompensationExpenseRelatedToRSUs" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_CompensationExpenseRelatedToRSUs"/>
  <xs:element name="ClassOfWarrantsSharesExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ClassOfWarrantsSharesExpired"/>
  <xs:element name="UnderwrittenOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnderwrittenOfferingShares"/>
  <xs:element name="warrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_warrantsToPurchaseSharesOfCommonStock"/>
  <xs:element name="ExercisablePeriodYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ExercisablePeriodYears"/>
  <xs:element name="DeferredTaxAssetsValuationAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_DeferredTaxAssetsValuationAllowances"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_AgreementAxis"/>
  <xs:element name="LeaseAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_LeaseAxis"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="EquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityIncentivePlanMember"/>
  <xs:element name="FinanceLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseLiabilitiesMember"/>
  <xs:element name="OperatingLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingLeaseLiabilitiesMember"/>
  <xs:element name="TwoThousandNineteenAmendedAndRestatedStockPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>atnm-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 20:21:20 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_SecurityDeposit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20221231.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah3T1Ki2MCKemJQOnFITo819XV2SZHEI0EiEoEUPiTVdpo53/UPf4KPbGQfg8/dyhoreC4upaSg/wmtLLQQWzYYSy386a+zde19o0mZ+MfUY7LBDh0RUuZ7QstC5a6n0F3vuuvqyUs6Vg==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_SubleaseIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20221231.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_PrepaidClinicalTrialExpenses" xlink:href="atnm-20221231.xsd#atnm_PrepaidClinicalTrialExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="atnm_PrepaidClinicalTrialExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>atnm-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 20:21:20 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PropertyandEquipment" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_IncomeTaxes" roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_SubsequentEvent" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PropertyandEquipmentTables" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_IncomeTaxesTables" roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofpropertyandequipmentTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdepreciationexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofrestrictedstockunitsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_IncomeTaxesDetails" roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_SubsequentEventDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20221231.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20221231.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit" xlink:href="atnm-20221231.xsd#atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20221231.xsd#atnm_LeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_LeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_OtherRevenueTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20221231.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_NatureOfBusinessPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20221231.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_GrantRevenuePolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenueTextBlock" xlink:href="atnm-20221231.xsd#atnm_LicenseRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenueTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:href="atnm-20221231.xsd#atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20221231.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20221231.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_PrepaidClinicalTrialExpenses" xlink:href="atnm-20221231.xsd#atnm_PrepaidClinicalTrialExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="atnm_PrepaidClinicalTrialExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah3T1Ki2MCKemJQOnFITo819XV2SZHEI0EiEoEUPiTVdpo53/UPf4KPbGQfg8/dyhoreC4upaSg/wmtLLQQWzYYSy386a+zde19o0mZ+MfUY72WvCoKd7+rRZi+v7QbqsvXcdUZI8uW4A==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20221231.xsd#atnm_NonCashActivityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="atnm_NonCashActivityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20221231.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20221231.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20221231.xsd#atnm_LeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeaseAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain" xlink:href="atnm-20221231.xsd#atnm_LeaseDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain_0" xlink:href="atnm-20221231.xsd#atnm_LeaseDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20221231.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomain" xlink:to="atnm_OperatingLeaseLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20221231.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomain" xlink:to="atnm_FinanceLeaseLiabilitiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20221231.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_PaymentWithImputedInterestPremium" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_MaturitiesOfLeaseLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfStockOptionActivityAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable">
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsScheduleofrestrictedstockunitsTable" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsScheduleofrestrictedstockunitsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="atnm_EquityDetailsScheduleofrestrictedstockunitsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingBeginningBalance" xlink:href="atnm-20221231.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="atnm_RSUsOutstandingBeginningBalance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingEndingBalance" xlink:href="atnm-20221231.xsd#atnm_RSUsOutstandingEndingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="atnm_RSUsOutstandingEndingBalance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20221231.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_NumberOfWarrantsOutstandings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageExercisePriceCancelled" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageExercisePriceCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_WeightedAverageExercisePriceCancelled" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_DeferredTaxAssetsAbstract" xlink:href="atnm-20221231.xsd#atnm_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="atnm_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:href="atnm-20221231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_RecognitionOfDeferredRevenue1" xlink:href="atnm-20221231.xsd#atnm_RecognitionOfDeferredRevenue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_RecognitionOfDeferredRevenue1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20221231.xsd#atnm_RevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_RevenueRecognized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20221231.xsd#atnm_UpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_UpfrontPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20221231.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_LongtermLicenseRevenueDeferred" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20221231.xsd#atnm_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_MilestonePayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:href="atnm-20221231.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20221231.xsd#atnm_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_AgreementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain" xlink:href="atnm-20221231.xsd#atnm_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain_0" xlink:href="atnm-20221231.xsd#atnm_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20221231.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_AgreementDomain" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:href="atnm-20221231.xsd#atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityIncentivePlanMember" xlink:href="atnm-20221231.xsd#atnm_EquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atnm_EquityIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantOfStockOptionsPurchaseShares" xlink:href="atnm-20221231.xsd#atnm_GrantOfStockOptionsPurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_GrantOfStockOptionsPurchaseShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:href="atnm-20221231.xsd#atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20221231.xsd#atnm_StockOptionTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_StockOptionTerm" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20221231.xsd#atnm_VestingPeriodOfStockOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_VestingPeriodOfStockOption" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20221231.xsd#atnm_AggregateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_AggregateFairValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_Dividends" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionsExercisedSharesOfCommonStock" xlink:href="atnm-20221231.xsd#atnm_StockOptionsExercisedSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_StockOptionsExercisedSharesOfCommonStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20221231.xsd#atnm_UnrecognizedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_UnrecognizedCompensationExpense" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_WeightedAverageTerm" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20221231.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_CompensationExpenseRelatedToStockOptions" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToRSUs" xlink:href="atnm-20221231.xsd#atnm_CompensationExpenseRelatedToRSUs"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_CompensationExpenseRelatedToRSUs" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ClassOfWarrantsSharesExpired" xlink:href="atnm-20221231.xsd#atnm_ClassOfWarrantsSharesExpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_ClassOfWarrantsSharesExpired" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UnderwrittenOfferingShares" xlink:href="atnm-20221231.xsd#atnm_UnderwrittenOfferingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_UnderwrittenOfferingShares" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_warrantsToPurchaseSharesOfCommonStock" xlink:href="atnm-20221231.xsd#atnm_warrantsToPurchaseSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_warrantsToPurchaseSharesOfCommonStock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ExercisablePeriodYears" xlink:href="atnm-20221231.xsd#atnm_ExercisablePeriodYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_ExercisablePeriodYears" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="32" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_DeferredTaxAssetsValuationAllowances" xlink:href="atnm-20221231.xsd#atnm_DeferredTaxAssetsValuationAllowances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="atnm_DeferredTaxAssetsValuationAllowances" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_DividendsCommonStockStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>atnm-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 20:21:20 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By/Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20221231.xsd#atnm_LeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeaseAxis_lbl" xml:lang="en-US">Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueAbstract" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueAbstract_lbl" xml:lang="en-US">Other revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueAbstract" xlink:to="atnm_OtherRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfStockOptionActivityAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfStockOptionActivityAbstract" xlink:to="atnm_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingBeginningBalance" xlink:href="atnm-20221231.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl" xml:lang="en-US">RSUs Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingEndingBalance" xlink:href="atnm-20221231.xsd#atnm_RSUsOutstandingEndingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_RSUsOutstandingEndingBalance_lbl" xml:lang="en-US">RSUs Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingEndingBalance" xlink:to="atnm_RSUsOutstandingEndingBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20221231.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl" xml:lang="en-US">Number of Warrants, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl0" xml:lang="en-US">Number of Warrants, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract_lbl" xml:lang="en-US">Schedule Of Difference Between Income Tax Provision And USFederal Statutory Rates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash &#8211; current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $487 and $335</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract1" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract1" xlink:to="atnm_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other revenue deferred &#8211; current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract2" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract2" xlink:to="atnm_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20221231.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract3" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract3" xlink:to="atnm_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract4" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract4" xlink:to="atnm_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 25,674,823 and 22,143,974 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract5" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract5" xlink:to="atnm_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Other Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract6" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract6" xlink:to="atnm_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract7" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract7" xlink:to="atnm_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract8" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract8" xlink:to="atnm_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract9" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract9" xlink:to="atnm_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract10" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract10" xlink:to="atnm_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share - basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract11" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract11" xlink:to="atnm_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Other revenue deferred &#8211; current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract12" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract12" xlink:to="atnm_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Used in Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract13" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract13" xlink:to="atnm_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20221231.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl" xml:lang="en-US">Proceeds from sales of shares of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract14" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract14" xlink:to="atnm_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract15" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract15" xlink:to="atnm_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract16" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract16" xlink:to="atnm_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit" xlink:href="atnm-20221231.xsd#atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit_lbl" xml:lang="en-US">Equipment obtained in exchange for security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit" xlink:to="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of diluted net loss per share anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PrepaidClinicalTrialExpenses" xlink:href="atnm-20221231.xsd#atnm_PrepaidClinicalTrialExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_PrepaidClinicalTrialExpenses_lbl" xml:lang="en-US">Prepaid clinical trial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidClinicalTrialExpenses" xlink:to="atnm_PrepaidClinicalTrialExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Office equipment and furniture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Total Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20221231.xsd#atnm_LeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract17" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract17" xlink:to="atnm_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseCostAbstract" xlink:href="atnm-20221231.xsd#atnm_FinanceLeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashFlowInformationAbstract" xlink:href="atnm-20221231.xsd#atnm_CashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashFlowInformationAbstract_lbl" xml:lang="en-US">Cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashFlowInformationAbstract" xlink:to="atnm_CashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract18" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract18" xlink:to="atnm_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract19" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract19" xlink:to="atnm_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20221231.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract20" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract20" xlink:to="atnm_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20221231.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl" xml:lang="en-US">Schedule of weighted average discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20221231.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20221231.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted average remaining contractual term (in years), Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price,Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price,Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price,Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term (in years), Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract21" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract21" xlink:to="atnm_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Number of Warrants, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">RSUs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">RSUs, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Warrants, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Options, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageExercisePriceCancelled" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageExercisePriceCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageExercisePriceCancelled_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageExercisePriceCancelled" xlink:to="atnm_WeightedAverageExercisePriceCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract22" xlink:href="atnm-20221231.xsd#atnm_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract22" xlink:to="atnm_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DeferredTaxAssetsAbstract" xlink:href="atnm-20221231.xsd#atnm_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeferredTaxAssetsAbstract" xlink:to="atnm_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development/orphan drug credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Capitalized research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of difference between income tax provision and U.S federal statutory rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred true-up</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:href="atnm-20221231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl" xml:lang="en-US">Deferred true-up percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development/orphan drug tax credit percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision for income tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income taxes percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development/orphan drug tax credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment and Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20221231.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20221231.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20221231.xsd#atnm_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Current annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RecognitionOfDeferredRevenue1" xlink:href="atnm-20221231.xsd#atnm_RecognitionOfDeferredRevenue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RecognitionOfDeferredRevenue1_lbl" xml:lang="en-US">Recognition of deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecognitionOfDeferredRevenue1" xlink:to="atnm_RecognitionOfDeferredRevenue1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20221231.xsd#atnm_RevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20221231.xsd#atnm_UpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Other revenue - current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20221231.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20221231.xsd#atnm_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:href="atnm-20221231.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl" xml:lang="en-US">Description of royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate value of common stock (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of common stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantOfStockOptionsPurchaseShares" xlink:href="atnm-20221231.xsd#atnm_GrantOfStockOptionsPurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantOfStockOptionsPurchaseShares_lbl" xml:lang="en-US">Grant of stock options purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsPurchaseShares" xlink:to="atnm_GrantOfStockOptionsPurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:href="atnm-20221231.xsd#atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20221231.xsd#atnm_StockOptionTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockOptionTerm_lbl" xml:lang="en-US">Stock option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20221231.xsd#atnm_VestingPeriodOfStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_VestingPeriodOfStockOption_lbl" xml:lang="en-US">Vesting period of stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20221231.xsd#atnm_AggregateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AggregateFairValue_lbl" xml:lang="en-US">Aggregate fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Dividends_lbl" xml:lang="en-US">Expected dividends (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Cancellation of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionsExercisedSharesOfCommonStock" xlink:href="atnm-20221231.xsd#atnm_StockOptionsExercisedSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockOptionsExercisedSharesOfCommonStock_lbl" xml:lang="en-US">Stock options exercised shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionsExercisedSharesOfCommonStock" xlink:to="atnm_StockOptionsExercisedSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20221231.xsd#atnm_UnrecognizedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnrecognizedCompensationExpense_lbl" xml:lang="en-US">Unrecognized compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageTerm_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20221231.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl" xml:lang="en-US">Total option expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock units shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xml:lang="en-US">Fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Grant year</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah3T1Ki2MCKemJQOnFITo819XV2SZHEI0EiEoEUPiTVdpo53/UPf4KPbGQfg8/dyhoreC4upaSg/wmtLLQQWzYYSy386a+zde19o0mZ+MfUY7nV6gkbVT8nuyVuMfdTMeg9WxMN5KIx2g==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Expected term year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToRSUs" xlink:href="atnm-20221231.xsd#atnm_CompensationExpenseRelatedToRSUs"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CompensationExpenseRelatedToRSUs_lbl" xml:lang="en-US">Compensation expense related to RSUs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToRSUs" xlink:to="atnm_CompensationExpenseRelatedToRSUs_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ClassOfWarrantsSharesExpired" xlink:href="atnm-20221231.xsd#atnm_ClassOfWarrantsSharesExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ClassOfWarrantsSharesExpired_lbl" xml:lang="en-US">Warrants expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantsSharesExpired" xlink:to="atnm_ClassOfWarrantsSharesExpired_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnderwrittenOfferingShares" xlink:href="atnm-20221231.xsd#atnm_UnderwrittenOfferingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnderwrittenOfferingShares_lbl" xml:lang="en-US">Underwritten offering shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnderwrittenOfferingShares" xlink:to="atnm_UnderwrittenOfferingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_warrantsToPurchaseSharesOfCommonStock" xlink:href="atnm-20221231.xsd#atnm_warrantsToPurchaseSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_warrantsToPurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_warrantsToPurchaseSharesOfCommonStock" xlink:to="atnm_warrantsToPurchaseSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Common stock per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ExercisablePeriodYears" xlink:href="atnm-20221231.xsd#atnm_ExercisablePeriodYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ExercisablePeriodYears_lbl" xml:lang="en-US">Exercisable period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExercisablePeriodYears" xlink:to="atnm_ExercisablePeriodYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense related to warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DeferredTaxAssetsValuationAllowances" xlink:href="atnm-20221231.xsd#atnm_DeferredTaxAssetsValuationAllowances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_DeferredTaxAssetsValuationAllowances_lbl" xml:lang="en-US">Deferred tax assets, valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeferredTaxAssetsValuationAllowances" xlink:to="atnm_DeferredTaxAssetsValuationAllowances_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign_lbl" xml:lang="en-US">Federal income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Net operating losses, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl" xml:lang="en-US">State income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xml:lang="en-US">Federal research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Orphan drug credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStockStock_lbl" xml:lang="en-US">common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockStock" xlink:to="us-gaap_DividendsCommonStockStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20221231.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20221231.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenueTextBlock" xlink:href="atnm-20221231.xsd#atnm_LicenseRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenueTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenueTextBlock" xlink:to="atnm_LicenseRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:href="atnm-20221231.xsd#atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20221231.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:href="atnm-20221231.xsd#atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl" xml:lang="en-US">2013 Amended and Restated Stock Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:to="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityIncentivePlanMember" xlink:href="atnm-20221231.xsd#atnm_EquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_EquityIncentivePlanMember_lbl" xml:lang="en-US">2013 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityIncentivePlanMember" xlink:to="atnm_EquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomain" xlink:href="atnm-20221231.xsd#atnm_LeaseDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseDomain_lbl" xml:lang="en-US">Lease [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseDomain" xlink:to="atnm_LeaseDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20221231.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20221231.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsScheduleofrestrictedstockunitsTable" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsScheduleofrestrictedstockunitsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsScheduleofrestrictedstockunitsTable_lbl" xml:lang="en-US">Equity (Details) - Schedule of restricted stock units [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsTable" xlink:to="atnm_EquityDetailsScheduleofrestrictedstockunitsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems_lbl" xml:lang="en-US">Equity (Details) - Schedule of restricted stock units [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomain" xlink:href="atnm-20221231.xsd#atnm_AgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementDomain_lbl" xml:lang="en-US">Agreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementDomain" xlink:to="atnm_AgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl0" xml:lang="en-US">Accounting Standards Recently Issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit_lbl0" xml:lang="en-US">The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit" xlink:to="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AggregateFairValue_lbl0" xml:lang="en-US">The amount of aggregate fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl0" xml:lang="en-US">Exercise price per share or per unit of warrants or rights outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ClassOfWarrantsSharesExpired_lbl0" xml:lang="en-US">It represents class of warrants shares expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantsSharesExpired" xlink:to="atnm_ClassOfWarrantsSharesExpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CompensationExpenseRelatedToRSUs_lbl0" xml:lang="en-US">The amount of compensation expense related to RSUs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToRSUs" xlink:to="atnm_CompensationExpenseRelatedToRSUs_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl0" xml:lang="en-US">The amount of compensation expense related to stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl0" xml:lang="en-US">Description of royalty payment to related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl0" xml:lang="en-US">Percentage of deferred true-up.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ExercisablePeriodYears_lbl0" xml:lang="en-US">Exercisable period years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExercisablePeriodYears" xlink:to="atnm_ExercisablePeriodYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GrantOfStockOptionsPurchaseShares_lbl0" xml:lang="en-US">Grant of stock options purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsPurchaseShares" xlink:to="atnm_GrantOfStockOptionsPurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl0" xml:lang="en-US">The amount of operating lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl0" xml:lang="en-US">The amount of long-term license revenue deferred.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl0" xml:lang="en-US">Long-term operating lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl0" xml:lang="en-US">The amount of present value of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl0" xml:lang="en-US">Nature of Business policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl1" xml:lang="en-US">The number of shares, outstanding beginning.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of maturities of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl0" xml:lang="en-US">The amount of payment with imputed interest premium.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PrepaidClinicalTrialExpenses_lbl0" xml:lang="en-US">The amount of prepaid clinical trial expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidClinicalTrialExpenses" xlink:to="atnm_PrepaidClinicalTrialExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl0" xml:lang="en-US">RSUs Outstanding, Beginning balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RSUsOutstandingEndingBalance_lbl0" xml:lang="en-US">RSUs Outstanding, Ending balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingEndingBalance" xlink:to="atnm_RSUsOutstandingEndingBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RecognitionOfDeferredRevenue1_lbl0" xml:lang="en-US">Recognition of deferred revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecognitionOfDeferredRevenue1" xlink:to="atnm_RecognitionOfDeferredRevenue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RevenueRecognized_lbl0" xml:lang="en-US">The amount of revenue recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities_lbl0" xml:lang="en-US">The amount of right-of-use assets obtained in exchange for lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0" xml:lang="en-US">The amount of sales of shares of common stock, net of costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently Granted, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockOptionTerm_lbl0" xml:lang="en-US">Stock option term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockOptionsExercisedSharesOfCommonStock_lbl0" xml:lang="en-US">Stock options exercised shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionsExercisedSharesOfCommonStock" xlink:to="atnm_StockOptionsExercisedSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UnderwrittenOfferingShares_lbl0" xml:lang="en-US">Underwritten offering shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnderwrittenOfferingShares" xlink:to="atnm_UnderwrittenOfferingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UnrecognizedCompensationExpense_lbl0" xml:lang="en-US">Unrecognized compensation expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UpfrontPayment_lbl0" xml:lang="en-US">Upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_VestingPeriodOfStockOption_lbl0" xml:lang="en-US">Vesting period of stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WeightedAverageExercisePriceCancelled_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Cancelled.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageExercisePriceCancelled" xlink:to="atnm_WeightedAverageExercisePriceCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WeightedAverageTerm_lbl0" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_warrantsToPurchaseSharesOfCommonStock_lbl0" xml:lang="en-US">Pre-funded warrants to purchase shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_warrantsToPurchaseSharesOfCommonStock" xlink:to="atnm_warrantsToPurchaseSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementAxis_lbl0" xml:lang="en-US">Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Anti Dilutive Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl1" xml:lang="en-US">Payment With Imputed Interest Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateFairValue_lbl1" xml:lang="en-US">Aggregate Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseAxis_lbl0" xml:lang="en-US">Lease Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Grant Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="atnm_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract18" xlink:to="atnm_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract19" xlink:to="atnm_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract16" xlink:to="atnm_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract17" xlink:to="atnm_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityIncentivePlanMember_lbl0" xml:lang="en-US">Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityIncentivePlanMember" xlink:to="atnm_EquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl0" xml:lang="en-US">Finance Lease Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract21" xlink:to="atnm_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract22" xlink:to="atnm_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract20" xlink:to="atnm_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantOfStockOptionsPurchaseShares_lbl1" xml:lang="en-US">Grant Of Stock Options Purchase Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsPurchaseShares" xlink:to="atnm_GrantOfStockOptionsPurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">Non Cash Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract10" xlink:to="atnm_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract11" xlink:to="atnm_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract14" xlink:to="atnm_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract15" xlink:to="atnm_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract12" xlink:to="atnm_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract13" xlink:to="atnm_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueRecognized_lbl1" xml:lang="en-US">Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ClassOfWarrantsSharesExpired_lbl1" xml:lang="en-US">Class Of Warrants Shares Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantsSharesExpired" xlink:to="atnm_ClassOfWarrantsSharesExpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract2" xlink:to="atnm_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract1" xlink:to="atnm_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract4" xlink:to="atnm_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract3" xlink:to="atnm_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl0" xml:lang="en-US">Deferred Income Taxes and Tax Credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_VestingPeriodOfStockOption_lbl1" xml:lang="en-US">Vesting Period Of Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0" xml:lang="en-US">Research and Development Arrangement with Federal Government, Costs Incurred, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract9" xlink:to="atnm_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract6" xlink:to="atnm_UnlabeledAbstract6_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract5" xlink:to="atnm_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract8" xlink:to="atnm_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract7" xlink:to="atnm_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">Other Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockOptionsExercisedSharesOfCommonStock_lbl1" xml:lang="en-US">Stock Options Exercised Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionsExercisedSharesOfCommonStock" xlink:to="atnm_StockOptionsExercisedSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl0" xml:lang="en-US">Two Thousand Nineteen Amended And Restated Stock Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:to="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockOptionTerm_lbl1" xml:lang="en-US">Stock Option Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl1" xml:lang="en-US">Maturities Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseCostAbstract_lbl0" xml:lang="en-US">Finance Lease Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Restricted Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl1"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl0" xml:lang="en-US">Restricted Investments, at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0" xml:lang="en-US">Schedule Or Description Of Weighted Average Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeferredTaxAssetsAbstract" xlink:to="atnm_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementAxis_lbl1" xml:lang="en-US">Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PrepaidClinicalTrialExpenses_lbl1" xml:lang="en-US">Prepaid Clinical Trial Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PrepaidClinicalTrialExpenses" xlink:to="atnm_PrepaidClinicalTrialExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US">Nature Of Business Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RSUsOutstandingEndingBalance_lbl1" xml:lang="en-US">RSUs Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingEndingBalance" xlink:to="atnm_RSUsOutstandingEndingBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl2" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnrecognizedCompensationExpense_lbl1" xml:lang="en-US">Unrecognized Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl1" xml:lang="en-US">RSUs Outstanding Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockStock_lbl0" xml:lang="en-US">Dividends, Common Stock, Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockStock" xlink:to="us-gaap_DividendsCommonStockStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DeferredTaxAssetsValuationAllowances_lbl0" xml:lang="en-US">Deferred Tax Assets Valuation Allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DeferredTaxAssetsValuationAllowances" xlink:to="atnm_DeferredTaxAssetsValuationAllowances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl2" xml:lang="en-US">Number Of Warrants Outstandings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Dividends_lbl0" xml:lang="en-US">Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenueTextBlock_lbl0" xml:lang="en-US">License Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenueTextBlock" xlink:to="atnm_LicenseRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl1" xml:lang="en-US">Description Of Royalty Payment To Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="atnm_DescriptionOfRoyaltyPaymentToRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities_lbl1" xml:lang="en-US">Rightofuse Assets Obtained In Exchange For Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnderwrittenOfferingShares_lbl1" xml:lang="en-US">Underwritten Offering Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnderwrittenOfferingShares" xlink:to="atnm_UnderwrittenOfferingShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl0" xml:lang="en-US">Other Restricted Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashFlowInformationAbstract_lbl0" xml:lang="en-US">Cash Flow Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashFlowInformationAbstract" xlink:to="atnm_CashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl1" xml:lang="en-US">Accountingstandardsrecentlyissuedpolicytextblock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_Accountingstandardsrecentlyissuedpolicytextblock" xlink:to="atnm_Accountingstandardsrecentlyissuedpolicytextblock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CompensationExpenseRelatedToRSUs_lbl1" xml:lang="en-US">Compensation Expense Related To RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToRSUs" xlink:to="atnm_CompensationExpenseRelatedToRSUs_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:to="atnm_ScheduleOfWarrantActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageTerm_lbl1" xml:lang="en-US">Weighted Average Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl1" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:to="atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl1" xml:lang="en-US">Compensation Expense Related To Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0" xml:lang="en-US">Schedule Of Weighted Average Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ExercisablePeriodYears_lbl1" xml:lang="en-US">Exercisable Period Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExercisablePeriodYears" xlink:to="atnm_ExercisablePeriodYears_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit_lbl1" xml:lang="en-US">Acquisition Of Equipment Financed By Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit" xlink:to="atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RecognitionOfDeferredRevenue1_lbl1" xml:lang="en-US">Recognition Of Deferred Revenue1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecognitionOfDeferredRevenue1" xlink:to="atnm_RecognitionOfDeferredRevenue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesTextBlock_lbl0" xml:lang="en-US">Leases Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDepreciationExpenseAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDepreciationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDepreciationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDepreciationExpenseAbstract" xlink:to="atnm_ScheduleOfDepreciationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageExercisePriceCancelled_lbl1" xml:lang="en-US">Weighted Average Exercise Price Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageExercisePriceCancelled" xlink:to="atnm_WeightedAverageExercisePriceCancelled_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_warrantsToPurchaseSharesOfCommonStock_lbl1" xml:lang="en-US">warrants To Purchase Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_warrantsToPurchaseSharesOfCommonStock" xlink:to="atnm_warrantsToPurchaseSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl1" xml:lang="en-US">Sales Of Shares Of Common Stock Net Of Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl1" xml:lang="en-US">Longterm Operating Lease Obligations Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UpfrontPayment_lbl1" xml:lang="en-US">Upfront Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl0" xml:lang="en-US">Operating Lease Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfRestrictedStockUnitsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfRestrictedStockUnitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfRestrictedStockUnitsAbstract_lbl" xml:lang="en-US">Schedule Of Restricted Stock Units Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfRestrictedStockUnitsAbstract" xlink:to="atnm_ScheduleOfRestrictedStockUnitsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl0" xml:lang="en-US">Sublease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl1" xml:lang="en-US">Longterm License Revenue Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl1" xml:lang="en-US">Effective Income Tax Reconciliation Deferred True Ups</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US">Operating And Finance Lease Liability Maturity Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>atnm-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 20:21:20 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PropertyandEquipment" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_IncomeTaxes" roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_SubsequentEvent" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEvent"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_PropertyandEquipmentTables" roleURI="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_IncomeTaxesTables" roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofpropertyandequipmentTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdepreciationexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofrestrictedstockunitsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_IncomeTaxesDetails" roleURI="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#atnm_r_SubsequentEventDetails" roleURI="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20221231.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20221231.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="LongtermOperatingLeaseObligationsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20221231.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="SalesOfSharesOfCommonStockNetOfCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetsObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="RightofuseAssetsObtainedInExchangeForLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionOfEquipmentFinancedBySecurityDeposit" xlink:href="atnm-20221231.xsd#atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="AcquisitionOfEquipmentFinancedBySecurityDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTextBlock" xlink:href="atnm-20221231.xsd#atnm_LeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="OtherRevenueAbstract" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEvent">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureOfBusinessPolicyTextBlock" xlink:href="atnm-20221231.xsd#atnm_NatureOfBusinessPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantRevenuePolicyTextBlock" xlink:href="atnm-20221231.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GrantRevenuePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenueTextBlock" xlink:href="atnm-20221231.xsd#atnm_LicenseRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenueTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Accountingstandardsrecentlyissuedpolicytextblock" xlink:href="atnm-20221231.xsd#atnm_Accountingstandardsrecentlyissuedpolicytextblock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="Accountingstandardsrecentlyissuedpolicytextblock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20221231.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOrDescriptionOfWeightedAverageTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfWeightedAverageDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20221231.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidClinicalTrialExpenses" xlink:href="atnm-20221231.xsd#atnm_PrepaidClinicalTrialExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidClinicalTrialExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationExpenseAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDepreciationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationExpenseAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cah3T1Ki2MCKemJQOnFITo819XV2SZHEI0EiEoEUPiTVdpo53/UPf4KPbGQfg8/dyhoreC4upaSg/wmtLLQQWzYYSy386a+zde19o0mZ+MfUY3RwQGg/7tMjW17LOcgPGdXtyOkAH06hSA==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCashActivityAbstract" xlink:href="atnm-20221231.xsd#atnm_NonCashActivityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="NonCashActivityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashActivityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="WeightedAverageDiscountRatesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20221231.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20221231.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LeaseAxis" xlink:href="atnm-20221231.xsd#atnm_LeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeaseAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitiesMember" xlink:href="atnm-20221231.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="OperatingLeaseLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilitiesMember" xlink:href="atnm-20221231.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="FinanceLeaseLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentWithImputedInterestPremium" xlink:href="atnm-20221231.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="PaymentWithImputedInterestPremium" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturitiesOfLeaseLiabilities" xlink:href="atnm-20221231.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentWithImputedInterestPremium" xlink:to="MaturitiesOfLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitsAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfRestrictedStockUnitsAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofrestrictedstockunitsTable" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsScheduleofrestrictedstockunitsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitsAbstract" xlink:to="EquityDetailsScheduleofrestrictedstockunitsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsTable" xlink:to="EquityDetailsScheduleofrestrictedstockunitsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RSUsOutstandingBeginningBalance" xlink:href="atnm-20221231.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="RSUsOutstandingBeginningBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="RSUsOutstandingEndingBalance" xlink:href="atnm-20221231.xsd#atnm_RSUsOutstandingEndingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="RSUsOutstandingEndingBalance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofrestrictedstockunitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivitiesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings" xlink:href="atnm-20221231.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings_0" xlink:href="atnm-20221231.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20221231.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceCancelled" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageExercisePriceCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="WeightedAverageExercisePriceCancelled" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="atnm-20221231.xsd#atnm_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:href="atnm-20221231.xsd#atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:href="atnm-20221231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="EffectiveIncomeTaxReconciliationDeferredTrueUps" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="OtherRevenueAbstract" xlink:href="atnm-20221231.xsd#atnm_OtherRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="RecognitionOfDeferredRevenue1" xlink:href="atnm-20221231.xsd#atnm_RecognitionOfDeferredRevenue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="RecognitionOfDeferredRevenue1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueRecognized" xlink:href="atnm-20221231.xsd#atnm_RevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="RevenueRecognized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontPayment" xlink:href="atnm-20221231.xsd#atnm_UpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="UpfrontPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermLicenseRevenueDeferred" xlink:href="atnm-20221231.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueAbstract" xlink:to="LongtermLicenseRevenueDeferred" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="atnm-20221231.xsd#atnm_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfRoyaltyPaymentToRelatedParty" xlink:href="atnm-20221231.xsd#atnm_DescriptionOfRoyaltyPaymentToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="DescriptionOfRoyaltyPaymentToRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="atnm-20221231.xsd#atnm_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="atnm-20221231.xsd#atnm_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="AgreementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomain" xlink:href="atnm-20221231.xsd#atnm_AgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20221231.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:href="atnm-20221231.xsd#atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandNineteenAmendedAndRestatedStockPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityIncentivePlanMember" xlink:href="atnm-20221231.xsd#atnm_EquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="EquityIncentivePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantOfStockOptionsPurchaseShares" xlink:href="atnm-20221231.xsd#atnm_GrantOfStockOptionsPurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="GrantOfStockOptionsPurchaseShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" xlink:href="atnm-20221231.xsd#atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionTerm" xlink:href="atnm-20221231.xsd#atnm_StockOptionTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockOptionTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriodOfStockOption" xlink:href="atnm-20221231.xsd#atnm_VestingPeriodOfStockOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="VestingPeriodOfStockOption" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateFairValue" xlink:href="atnm-20221231.xsd#atnm_AggregateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_Dividends" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsExercisedSharesOfCommonStock" xlink:href="atnm-20221231.xsd#atnm_StockOptionsExercisedSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockOptionsExercisedSharesOfCommonStock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedCompensationExpense" xlink:href="atnm-20221231.xsd#atnm_UnrecognizedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnrecognizedCompensationExpense" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageTerm" xlink:href="atnm-20221231.xsd#atnm_WeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WeightedAverageTerm" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20221231.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CompensationExpenseRelatedToStockOptions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationExpenseRelatedToRSUs" xlink:href="atnm-20221231.xsd#atnm_CompensationExpenseRelatedToRSUs"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CompensationExpenseRelatedToRSUs" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantsSharesExpired" xlink:href="atnm-20221231.xsd#atnm_ClassOfWarrantsSharesExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ClassOfWarrantsSharesExpired" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwrittenOfferingShares" xlink:href="atnm-20221231.xsd#atnm_UnderwrittenOfferingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnderwrittenOfferingShares" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="warrantsToPurchaseSharesOfCommonStock" xlink:href="atnm-20221231.xsd#atnm_warrantsToPurchaseSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="warrantsToPurchaseSharesOfCommonStock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisablePeriodYears" xlink:href="atnm-20221231.xsd#atnm_ExercisablePeriodYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ExercisablePeriodYears" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsValuationAllowances" xlink:href="atnm-20221231.xsd#atnm_DeferredTaxAssetsValuationAllowances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsValuationAllowances" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/SubsequentEventDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsCommonStockStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_DividendsCommonStockStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="atnm-20221231.xsd#atnm_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975832832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,729,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,589,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-52446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">275 Madison Avenue, 7th Fl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum llp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston, Texas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974344608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 108,910<span></span>
</td>
<td class="nump">$ 77,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash &#8211; current</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">110,942<span></span>
</td>
<td class="nump">79,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $487 and $335</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">302<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,341<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">114,192<span></span>
</td>
<td class="nump">80,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">10,130<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other revenue deferred &#8211; current liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">10,628<span></span>
</td>
<td class="nump">6,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LongtermOperatingLeaseObligationsNoncurrent', window );">Long-term operating lease obligations</a></td>
<td class="nump">2,083<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">47,711<span></span>
</td>
<td class="nump">6,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 25,674,823 and 22,143,974 shares issued and outstanding</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">355,220<span></span>
</td>
<td class="nump">329,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(288,765)<span></span>
</td>
<td class="num">(255,748)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">66,481<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 114,192<span></span>
</td>
<td class="nump">$ 80,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermOperatingLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term operating lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermOperatingLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975983344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,674,823<span></span>
</td>
<td class="nump">22,143,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,674,823<span></span>
</td>
<td class="nump">22,143,974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975925072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Other Revenue</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">23,135<span></span>
</td>
<td class="nump">18,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,999<span></span>
</td>
<td class="nump">8,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">35,134<span></span>
</td>
<td class="nump">26,108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(34,104)<span></span>
</td>
<td class="num">(24,964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income - net</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,017)<span></span>
</td>
<td class="num">$ (24,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic and diluted (in Shares)</a></td>
<td class="nump">24,141,545<span></span>
</td>
<td class="nump">20,568,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974332976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; basic and diluted</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; basic and diluted</a></td>
<td class="nump">24,141,545<span></span>
</td>
<td class="nump">20,568,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975252304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 292,275<span></span>
</td>
<td class="num">$ (230,974)<span></span>
</td>
<td class="nump">$ 61,319<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">17,532,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in Shares)</a></td>
<td class="nump">21,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">35,296<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">4,588,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24,774)<span></span>
</td>
<td class="num">(24,774)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,271<span></span>
</td>
<td class="num">(255,748)<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,795<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in Shares)</a></td>
<td class="nump">19,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">23,154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">3,511,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,017)<span></span>
</td>
<td class="num">(33,017)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 355,220<span></span>
</td>
<td class="num">$ (288,765)<span></span>
</td>
<td class="nump">$ 66,481<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">25,674,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975998880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,017)<span></span>
</td>
<td class="num">$ (24,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,795<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Other revenue deferred &#8211; current liability</a></td>
<td class="num">(998)<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(272)<span></span>
</td>
<td class="num">(342)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided By/Used In Operating Activities</a></td>
<td class="nump">8,644<span></span>
</td>
<td class="num">(20,866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Used in Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SalesOfSharesOfCommonStockNetOfCosts', window );">Proceeds from sales of shares of common stock, net of offering costs</a></td>
<td class="nump">23,158<span></span>
</td>
<td class="nump">35,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">23,109<span></span>
</td>
<td class="nump">35,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">31,387<span></span>
</td>
<td class="nump">14,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">78,221<span></span>
</td>
<td class="nump">63,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">109,608<span></span>
</td>
<td class="nump">78,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">2,605<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit', window );">Equipment obtained in exchange for security deposit</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of right-of-use assets obtained in exchange for lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SalesOfSharesOfCommonStockNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales of shares of common stock, net of costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SalesOfSharesOfCommonStockNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975707072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business - </b>Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular
level precision to treat patients with high unmet medical needs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.
All significant intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in Financial
Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash and Cash Equivalents
and Restricted Cash-</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
cash, cash equivalents and restricted cash at December 31, 2022 and December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,221</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases of corporate office
spaces.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Property and Equipment
-</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to five
years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years.
When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is
reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets are recorded at the
lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful life of the related property
or term of the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term. The Company entered into a lease for corporate office space effective June 1, 2022 and paid a security deposit
to the landlord. A certificate of deposit was provided as collateral for a letter of credit issued with this office space during 2022
and at that time, the security deposit was returned to the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Income Taxes -</b> The
Company accounts for income taxes in accordance with ASC 740 <i>Income Taxes</i>, which requires the asset and liability method to calculate
deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income tax bases of assets
and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be
fully realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 740 prescribes guidance
for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meet a &#8220;more-likely-than-not&#8221;
recognition threshold to be recognized. There were no tax positions for which it is considered reasonably possible that the total amounts
of unrecognized tax benefits will significantly increase or decrease within the next year. The Company recognizes interest related to
unrecognized tax benefits in interest expense and penalties in operating expenses</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly to basic
loss per share because the impact of all potential dilutive common shares is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">For the years ended December 31, 2022 and 2021,
the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units and warrants,
have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,112</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,164</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,474</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Subsequent Events </b>-
The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent
event disclosure consideration.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s
Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard did not have a material
effect on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB
issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022,
and the standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Issued Accounting
Pronouncements &#8211; </b>In October 2021, FASB issued ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets
and Contract Liabilities from Contracts with Customers</i>, which provides guidance on accounting for contract assets and contract liabilities
acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606
to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring
the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial
statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods. Early adoption is permitted, including
adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future business combinations the Company may
enter in the future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681977572880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Prepaid Expenses and Other Current
Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and other
current assets consisted of the following at December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">874</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,636</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,478</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140682062850688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment consisted
of the following at December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lives</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">476</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office equipment&#160;and furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 7 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(487</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(335</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">604</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">340</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation expense consisted
of the following for the years ended December 31, 2022 and 2021, respectively:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">88</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">152</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">105</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981108496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 - Leases </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines
if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the
right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed
to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company entered into a lease
for corporate office space, effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration date on July 30, 2027
and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance, utilities and maintenance.
At December 31, 2022, for capitalization purposes under ASC842, the Company has this operating lease and a finance lease for office equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2021, for
capitalization purposes under ASC842, the Company had an operating lease for corporate office space that expired in 2022 and finance leases
for office equipment and furniture located in the corporate office space. In addition, the Company has auxiliary corporate office space
that it rents on a month-to-month basis; this rental was accounted for as an operating lease with the same term as the Company&#8217;s
office space.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">584</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">372</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flow information:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">377</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">85</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflect the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Maturities
of lease liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">606</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,877</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,577</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981144752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Other revenue</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s ability to terminate
the module. The consideration is recognized to revenue over each module and revenue of $0.9 million was recognized during each of the
years ended December 31, 2022 and December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had a grant from
a government-sponsored entity for research and development related activities that provide for payments for reimbursed costs, which included
overhead and general and administrative costs as well as an administrative fee. The Company recognized revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Other revenue recognized
from this grant during the years ended December 31, 2022 and 2021 was $0.1 million and $0.2 million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#8211; current liability at December
31, 2022 and $1.0 million at December 31, 2021. Long-term license revenue deferred was $35.0 million at December 31, 2022; there was <span style="-sec-ix-hidden: hidden-fact-46">no</span>
Long-term license revenue deferred at December 31, 2021. This deferred revenue will be recognized upon European Union regulatory approval
of Iomab B.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981151952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed antibody. Upon commercial sale
of the drug, royalty payments of 2% of net sales will be due to FHCRC.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981110928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 - Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company entered
into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which the
Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of common
stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. For the year ended December
31, 2022, the Company sold 3.5 million shares of common stock, resulting in gross proceeds of $23.9 million and net proceeds of $23.2
million. For the year ended December 31, 2021, the Company sold 4.6 million shares of common stock, resulting in gross proceeds of $36.5
million and net proceeds of $35.3 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2022, the Company
entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;) with JonesTrading
and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies the original Capital on Demand&#8482;
Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2019 Amended and Restated Stock Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the Company&#8217;s
2019 Stock Plan was established. The expiration date of the plan is October 18, 2029 and the total number of shares of the Company&#8217;s
common stock available for grant to employees, directors and consultants of the Company was 333,333 shares. After a number of amendments
approved by stockholders, the number of shares authorized under the plan was 5,833,333 shares. At the Company&#8217;s Annual Meeting of
Stockholders held on December 30, 2022, its stockholders authorized an increase in the number of shares authorized under the plan, resulting
in the number of shares authorized in the plan to be 9,333,333 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2013 Amended and Restated Stock Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013, the Company&#8217;s
2013 Stock Plan was established. The expiration date of the plan is September 9, 2023 and at the time of approval, the total number of
shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan was
91,666 shares. After a number of amendments approved by stockholders, the number of shares authorized under the plan is 758,333 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>2013 Equity Incentive Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013, the Company&#8217;s
2013 Equity Incentive Plan was established. The expiration date of the plan is September 9, 2023 and the total number of shares of the
Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan was 15,000 shares.
In December 2013, the shareholders of the Company approved the plan and increased the number of shares authorized under the plan to 33,333
shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
stock option activity for the years ended December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.51</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(333</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18.78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">12.45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">12.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,396</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.85</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">15,204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">804</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7.58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,432</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2022, the Company granted
its employees and members of the Board of Directors options to purchase 2.1 million shares of common stock with an exercise price ranging
from $4.96 to $13.54 per share, a term of 10 years, and a vesting period from 4 to 4.2 years.&#160;The options have an aggregated fair
value of $7.7 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 1.5% to 4.3% (2) expected life of 6 years, (3) expected volatility range from 78.8% to 81.1%,
and (4) zero expected dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2021, the Company granted
its employees and members of the Board of Directors options to purchase 881 thousand shares of common stock with an exercise price ranging
from $6.02 to $9.25 per share, a term of 10 years, and a vesting period from 4 to 4.2 years. The options have an aggregated fair value
of $3.9 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 0.65% to 1.28% (2) expected life of 6 years, (3) expected volatility range from 79.8% to 85.1%,
and (4) zero expected dividends.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2022 and 2021, options to purchase 60 thousand and 333 thousand common shares were cancelled, respectively, upon the termination of
employment. During 2021, 1 thousand options were exercised for shares of common stock. There were no exercises of options during 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31,
2022 was $10.0 million related to unvested options, which is expected to be expensed over a weighted average of 3.3 years. During 2022
and 2021, the Company recorded total option expense of $2.5 million and $1.5 million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company issued 325 thousand
restricted stock units (&#8220;RSUs&#8221;) to employees during 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">325</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.96</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.9 million, was determined based on the stock
prices on the dates of the grants and is being recognized over three years. The unrecognized compensation expense at December 31, 2022
of $1.7 million is expected to be expensed over 2.4 years. During 2022, the Company recorded compensation expense related to RSUs of $0.2
million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activities for the years ended December 31, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20.55</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">50.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(669</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,443</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">16.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,440</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">15.95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2022, warrants
to purchase an aggregate of 0.6 million shares of common stock expired. These warrants were issued on August 2, 2017, when the Company
completed an underwritten offering of 0.7 million shares of common stock and warrants to purchase 0.6 million shares of common stock at
a price of $22.50 per share and related warrant. The warrants were exercisable for a period of 5 years at an exercise price of $31.50
per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2022 and 2021, the Company recorded stock-based compensation expense related to warrants of $6 thousand and $16 thousand, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981623888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Note 8 - Income Taxes </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income taxes reflect
the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities at December
31, 2022 and 2021 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,405</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,213</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,536</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Capitalized research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,426</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,093</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,599</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has recorded a
valuation allowance of $76.1 million and $62.6 million against its deferred tax assets at December 31, 2022 and 2021 respectively, because
management determined that it is not more-likely-than not that those assets will be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For federal income tax purposes,
the Company has $178.6 million of unused net operating losses (&#8220;NOLs&#8221;) at December 31, 2022 available for carry forward to
future years. NOLs of $118.4 million generated prior to 2018 will begin to expire if unused in 2023. NOLs generated in 2018 and later
years of $60.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1,
2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For state income tax purposes,
the Company has $271.1 million of unused NOLs at December 31, 2022 available for carry forward to future years. These NOLs will begin
to expire in 2034 if unused.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has federal research
and development tax credits of $3.4 million at December 31, 2022 which will begin to expire in 2034 if unused and orphan drug credits
of $13.8 million which will begin to expire in 2028 if unused.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Federal and state tax laws
impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership change for tax purposes,
as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize these carryforwards may be
limited as a result of an ownership change which may have already happened or may happen in the future. Such an ownership change could
result in a limitation in the use of the net operating losses in future years and possibly a reduction of the net operating losses available.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2022 and 2021 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,943</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,202</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(373</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development/orphan drug tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,711</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,898</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,494</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,425</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981131344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; "><b>Note 9 - Subsequent Event</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Since December 31, 2022, the
Company has sold 0.1 million shares of common stock under its A&amp;R Sales Agreement, resulting in net proceeds of $0.8 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975984784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business - </b>Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular
level precision to treat patients with high unmet medical needs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.
All significant intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in Financial
Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash and Cash Equivalents
and Restricted Cash-</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
cash, cash equivalents and restricted cash at December 31, 2022 and December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,221</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases of corporate office
spaces.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Property and Equipment
-</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to five
years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years.
When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is
reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets are recorded at the
lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful life of the related property
or term of the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term. The Company entered into a lease for corporate office space effective June 1, 2022 and paid a security deposit
to the landlord. A certificate of deposit was provided as collateral for a letter of credit issued with this office space during 2022
and at that time, the security deposit was returned to the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_GrantRevenuePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LicenseRevenueTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Income Taxes -</b> The
Company accounts for income taxes in accordance with ASC 740 <i>Income Taxes</i>, which requires the asset and liability method to calculate
deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income tax bases of assets
and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be
fully realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 740 prescribes guidance
for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meet a &#8220;more-likely-than-not&#8221;
recognition threshold to be recognized. There were no tax positions for which it is considered reasonably possible that the total amounts
of unrecognized tax benefits will significantly increase or decrease within the next year. The Company recognizes interest related to
unrecognized tax benefits in interest expense and penalties in operating expenses</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly to basic
loss per share because the impact of all potential dilutive common shares is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">For the years ended December 31, 2022 and 2021,
the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock units and warrants,
have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,112</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,164</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,474</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Subsequent Events </b>-
The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent
event disclosure consideration.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_Accountingstandardsrecentlyissuedpolicytextblock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s
Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard did not have a material
effect on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB
issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022,
and the standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Issued Accounting
Pronouncements &#8211; </b>In October 2021, FASB issued ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets
and Contract Liabilities from Contracts with Customers</i>, which provides guidance on accounting for contract assets and contract liabilities
acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606
to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring
the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial
statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods. Early adoption is permitted, including
adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future business combinations the Company may
enter in the future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_Accountingstandardsrecentlyissuedpolicytextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Standards Recently Issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_Accountingstandardsrecentlyissuedpolicytextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of Business policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975993584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,829</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,221</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of diluted net loss per share anti-dilutive</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,112</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,164</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,474</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681977536736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">874</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">543</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,636</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,478</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681977566304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lives</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">476</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office equipment&#160;and furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 7 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(487</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(335</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">604</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">340</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of depreciation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">141</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">88</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">152</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">105</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681980491424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">584</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">372</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flow information:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">377</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">85</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm', window );">Schedule of weighted average remaining lease terms</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfWeightedAverageDiscountRate', window );">Schedule of weighted average discount rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">606</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,877</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,577</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOrDescriptionOfWeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681980219808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.51</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(333</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18.78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding, December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">12.45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">12.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,396</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.85</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">15,204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">804</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7.58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,432</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of restricted stock units</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">325</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.96</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20.55</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">50.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(669</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,443</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">16.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable, December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,440</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">15.95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981124256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,405</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,213</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,536</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Capitalized research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,426</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,093</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,599</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of difference between income tax provision and U.S federal statutory rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,943</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,202</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(373</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development/orphan drug tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,711</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,898</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,494</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,425</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975831152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Schedule Of Cash Cash Equivalents And Restricted Cash Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 108,910<span></span>
</td>
<td class="nump">$ 77,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash &#8211; current</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Restricted cash &#8211; long-term</a></td>
<td class="nump">302<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 109,608<span></span>
</td>
<td class="nump">$ 78,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975595968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,164<span></span>
</td>
<td class="nump">3,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,396<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">325<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975978480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Schedule Of Prepaid Expenses And Other Current Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PrepaidClinicalTrialExpenses', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">$ 1,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PrepaidClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PrepaidClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974057520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of property and equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (487)<span></span>
</td>
<td class="num">$ (335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment and furniture</a></td>
<td class="nump">$ 776<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment and furniture</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975983376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of depreciation expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total Depreciation expense</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total Depreciation expense</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total Depreciation expense</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981212832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease description</a></td>
<td class="text">5 years 2 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Current annual rate</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975942800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of components of lease expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfComponentsOfLeaseExpenseAbstract', window );"><strong>Schedule Of Components Of Lease Expense Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfComponentsOfLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfComponentsOfLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681971471712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information related to leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract', window );"><strong>Schedule Of Supplemental Cash Flow Information Related To Leases Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NonCashActivityAbstract', window );"><strong>Non-cash activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">2,605<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance Leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonCashActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NonCashActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681977626048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average remaining lease terms<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Leases</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681981211360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average discount rates<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageDiscountRatesAbstract', window );"><strong>Weighted average discount rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageDiscountRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageDiscountRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975263360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">$ 606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">2,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of present value of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentWithImputedInterestPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment with imputed interest premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PaymentWithImputedInterestPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974293760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RecognitionOfDeferredRevenue1', window );">Recognition of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Other revenue - current liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LongtermLicenseRevenueDeferred', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermLicenseRevenueDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term license revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermLicenseRevenueDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RecognitionOfDeferredRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RecognitionOfDeferredRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975873232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
<td class="text">Upon commercial sale
of the drug, royalty payments of 2% of net sales will be due to FHCRC.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfRoyaltyPaymentToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of royalty payment to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfRoyaltyPaymentToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681969904336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Aug. 02, 2017</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_GrantOfStockOptionsPurchaseShares', window );">Grant of stock options purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_StockOptionTerm', window );">Stock option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Expected dividends (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Cancellation of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_StockOptionsExercisedSharesOfCommonStock', window );">Stock options exercised shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageTerm', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_CompensationExpenseRelatedToStockOptions', window );">Total option expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_CompensationExpenseRelatedToRSUs', window );">Compensation expense related to RSUs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ClassOfWarrantsSharesExpired', window );">Warrants expired</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UnderwrittenOfferingShares', window );">Underwritten offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_warrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ExercisablePeriodYears', window );">Exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense related to warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember', window );">2013 Amended and Restated Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,333,333<span></span>
</td>
<td class="nump">5,833,333<span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atnm_EquityIncentivePlanMember', window );">2013 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_VestingPeriodOfStockOption', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.80%<span></span>
</td>
<td class="nump">79.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_VestingPeriodOfStockOption', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.10%<span></span>
</td>
<td class="nump">85.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AggregateFairValue', window );">Aggregate fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock units shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Expected term year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate value of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,900,000<span></span>
</td>
<td class="nump">36,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="nump">$ 35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ClassOfWarrantsSharesExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents class of warrants shares expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ClassOfWarrantsSharesExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CompensationExpenseRelatedToRSUs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation expense related to RSUs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CompensationExpenseRelatedToRSUs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CompensationExpenseRelatedToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation expense related to stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CompensationExpenseRelatedToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ExercisablePeriodYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercisable period years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ExercisablePeriodYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrantOfStockOptionsPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant of stock options purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrantOfStockOptionsPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockOptionsExercisedSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options exercised shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockOptionsExercisedSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnderwrittenOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwritten offering shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UnderwrittenOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_VestingPeriodOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting period of stock option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_VestingPeriodOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_warrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_warrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.6(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611133-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Footnote 11(c)))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atnm_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atnm_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974008448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of stock option activity - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfStockOptionActivityAbstract', window );"><strong>Schedule Of Stock Option Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding Beginning balance</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding Beginning balance</a></td>
<td class="nump">$ 12.45<span></span>
</td>
<td class="nump">$ 21.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), outstanding Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, outstanding Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance</a></td>
<td class="nump">3,396<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding, Ending balance</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 12.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years), outstanding Ending balance</a></td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
<td class="text">8 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, outstanding Ending balance</a></td>
<td class="nump">$ 15,204<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">7 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 2,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Granted</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Cancelled</a></td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="nump">$ 18.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently Granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974712512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of restricted stock units - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems', window );"><strong>Equity (Details) - Schedule of restricted stock units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RSUsOutstandingBeginningBalance', window );">RSUs Outstanding, Beginning balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share Outstanding, Beginning balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RSUsOutstandingEndingBalance', window );">RSUs Outstanding, Ending balance | shares</a></td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance | $ / shares</a></td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs, Granted | shares</a></td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Grant date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">RSUs, Vested | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RSUsOutstandingBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs Outstanding, Beginning balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RSUsOutstandingBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RSUsOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs Outstanding, Ending balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RSUsOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681975695344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of warrant activities - Warrant [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Warrants, Outstanding Beginning</a></td>
<td class="nump">2,112<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Outstanding Beginning</a></td>
<td class="nump">$ 20.52<span></span>
</td>
<td class="nump">$ 20.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Beginning</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Warrants, Ending balance</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">$ 16.58<span></span>
</td>
<td class="nump">$ 20.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Ending balance</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Warrants, Exercisable</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 15.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Exercisable</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Warrants, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="num">(669)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageExercisePriceCancelled', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">$ 29.01<span></span>
</td>
<td class="nump">$ 50.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfWarrantsOutstandings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares, outstanding beginning.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfWarrantsOutstandings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageExercisePriceCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageExercisePriceCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681977624896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DeferredTaxAssetsValuationAllowances', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 76.1<span></span>
</td>
<td class="nump">$ 62.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesForeign', window );">Federal income tax</a></td>
<td class="nump">$ 178.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Net operating losses, description</a></td>
<td class="text">NOLs of $118.4 million generated prior to 2018 will begin to expire if unused in 2023. NOLs generated in 2018 and later
years of $60.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1,
2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal', window );">State income tax</a></td>
<td class="nump">$ 271.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet', window );">Federal research and development tax credits</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Orphan drug credits</a></td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DeferredTaxAssetsValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DeferredTaxAssetsValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in foreign income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974170256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses carry forward</a></td>
<td class="nump">$ 44,233<span></span>
</td>
<td class="nump">$ 36,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Share-based compensation</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development/orphan drug credits</a></td>
<td class="nump">17,247<span></span>
</td>
<td class="nump">14,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized research and development expenses</a></td>
<td class="nump">13,210<span></span>
</td>
<td class="nump">10,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(76,093)<span></span>
</td>
<td class="num">(62,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974743008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of difference between income tax provision and U.S federal statutory rates - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract', window );"><strong>Schedule Of Difference Between Income Tax Provision And USFederal Statutory Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income taxes</a></td>
<td class="num">$ (6,943)<span></span>
</td>
<td class="num">$ (5,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income taxes percentage</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">$ (4,863)<span></span>
</td>
<td class="num">$ (373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes percentage</a></td>
<td class="num">(14.70%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred true-up</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps', window );">Deferred true-up percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development/orphan drug tax credit</a></td>
<td class="num">$ (2,711)<span></span>
</td>
<td class="num">$ (1,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development/orphan drug tax credit percentage</a></td>
<td class="num">(8.20%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">$ 934<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 13,494<span></span>
</td>
<td class="nump">$ 6,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance percentage</a></td>
<td class="nump">40.80%<span></span>
</td>
<td class="nump">25.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income tax percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of deferred true-up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140681974424096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockStock', window );">common stock, value</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>f10k2022_actiniumph_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://actiniumpharmaceuticals.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-05-16</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2013-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-02</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2017-08-02</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">000-52446</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">275 Madison Avenue, 7th Fl</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">10016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">677-3870</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" unitRef="usd">119589361</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">25729370</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0">Marcum llp</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">Houston, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">108910000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" unitRef="usd">77829000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">396000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c4" decimals="-3" unitRef="usd">392000</us-gaap:RestrictedCashCurrent>
    <us-gaap:SecurityDeposit contextRef="c4" decimals="-3" unitRef="usd">50000</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">1478000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">110942000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">79749000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">487000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">335000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">604000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" unitRef="usd">340000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" unitRef="usd">302000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">2341000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" unitRef="usd">241000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">3000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c4" decimals="-3" unitRef="usd">58000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">114192000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" unitRef="usd">80388000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">10130000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c4" decimals="-3" unitRef="usd">5535000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">998000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">494000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" unitRef="usd">245000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">4000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c4" decimals="-3" unitRef="usd">62000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">10628000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">6840000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="c3" decimals="-3" unitRef="usd">35000000</us-gaap:DeferredRevenue>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">2083000</atnm:LongtermOperatingLeaseObligationsNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" unitRef="usd">3000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" unitRef="usd">47711000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="-3" unitRef="usd">6843000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">25674823</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">25674823</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">22143974</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">22143974</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">26000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="-3" unitRef="usd">22000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">355220000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" unitRef="usd">329271000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-288765000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" unitRef="usd">-255748000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">66481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">73545000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">114192000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">80388000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SubleaseIncome contextRef="c0" decimals="-3" unitRef="usd">1030000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c5" decimals="-3" unitRef="usd">1144000</us-gaap:SubleaseIncome>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">1030000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" unitRef="usd">1144000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">23135000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">18031000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">11999000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">8077000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" unitRef="usd">35134000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="-3" unitRef="usd">26108000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-34104000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-24964000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="-3" unitRef="usd">1087000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c5" decimals="-3" unitRef="usd">190000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">1087000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-33017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-24774000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-1.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-1.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">24141545</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">20568373</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">17532893</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c6" decimals="-3" unitRef="usd">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="-3" unitRef="usd">292275000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="-3" unitRef="usd">-230974000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c9" decimals="-3" unitRef="usd">61319000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c10" decimals="0" unitRef="shares">21306</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c11" decimals="-3" unitRef="usd">1694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c5" decimals="-3" unitRef="usd">1694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c10" decimals="0" unitRef="shares">4588875</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c10" decimals="-3" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c11" decimals="-3" unitRef="usd">35296000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="-3" unitRef="usd">35300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c10" decimals="0" unitRef="shares">900</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c11" decimals="-3" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c5" decimals="-3" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" unitRef="usd">-24774000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-24774000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c13" decimals="0" unitRef="shares">22143974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="-3" unitRef="usd">22000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="-3" unitRef="usd">329271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="-3" unitRef="usd">-255748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="-3" unitRef="usd">73545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c16" decimals="0" unitRef="shares">19639</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c17" decimals="-3" unitRef="usd">2795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c0" decimals="-3" unitRef="usd">2795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c16" decimals="0" unitRef="shares">3511210</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c16" decimals="-3" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c17" decimals="-3" unitRef="usd">23154000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="-3" unitRef="usd">23158000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="-3" unitRef="usd">-33017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-33017000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c19" decimals="0" unitRef="shares">25674823</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c19" decimals="-3" unitRef="usd">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20" decimals="-3" unitRef="usd">355220000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c21" decimals="-3" unitRef="usd">-288765000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="-3" unitRef="usd">66481000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-33017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-24774000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">2795000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">1694000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" unitRef="usd">699000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c5" decimals="-3" unitRef="usd">524000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">158000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="-3" unitRef="usd">161000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">4595000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="-3" unitRef="usd">1195000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">-998000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c5" decimals="-3" unitRef="usd">998000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">35000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c0" decimals="-3" unitRef="usd">-272000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <atnm:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c5" decimals="-3" unitRef="usd">-342000</atnm:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">8644000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">-20866000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">366000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" unitRef="usd">133000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-366000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">-133000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">49000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c5" decimals="-3" unitRef="usd">85000</us-gaap:FinanceLeasePrincipalPayments>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts contextRef="c0" decimals="-3" unitRef="usd">23158000</atnm:SalesOfSharesOfCommonStockNetOfCosts>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts contextRef="c5" decimals="-3" unitRef="usd">35300000</atnm:SalesOfSharesOfCommonStockNetOfCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c5" decimals="-3" unitRef="usd">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">23109000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">35221000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">31387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="-3" unitRef="usd">14222000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">78221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c9" decimals="-3" unitRef="usd">63999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">109608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">78221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <atnm:RightofuseAssetsObtainedInExchangeForLeaseLiabilities contextRef="c0" decimals="-3" unitRef="usd">2605000</atnm:RightofuseAssetsObtainedInExchangeForLeaseLiabilities>
    <atnm:AcquisitionOfEquipmentFinancedBySecurityDeposit contextRef="c0" decimals="-3" unitRef="usd">50000</atnm:AcquisitionOfEquipmentFinancedBySecurityDeposit>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and Summary
of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business - &lt;/b&gt;Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular
level precision to treat patients with high unmet medical needs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.
All significant intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates in Financial
Statement Presentation -&lt;/b&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash and Cash Equivalents
and Restricted Cash-&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
cash, cash equivalents and restricted cash at December 31, 2022 and December 31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,221&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#x2019;s leases of corporate office
spaces.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Property and Equipment
-&lt;/b&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to five
years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years.
When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is
reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets are recorded at the
lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful life of the related property
or term of the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term. The Company entered into a lease for corporate office space effective June 1, 2022 and paid a security deposit
to the landlord. A certificate of deposit was provided as collateral for a letter of credit issued with this office space during 2022
and at that time, the security deposit was returned to the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;
(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements&lt;/b&gt;
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -&lt;/b&gt;
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Income Taxes -&lt;/b&gt; The
Company accounts for income taxes in accordance with ASC 740 &lt;i&gt;Income Taxes&lt;/i&gt;, which requires the asset and liability method to calculate
deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income tax bases of assets
and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be
fully realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 740 prescribes guidance
for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meet a &#x201c;more-likely-than-not&#x201d;
recognition threshold to be recognized. There were no tax positions for which it is considered reasonably possible that the total amounts
of unrecognized tax benefits will significantly increase or decrease within the next year. The Company recognizes interest related to
unrecognized tax benefits in interest expense and penalties in operating expenses&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share&lt;/b&gt;
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly to basic
loss per share because the impact of all potential dilutive common shares is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"&gt;For the years ended December 31, 2022 and 2021,
the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock units and warrants,
have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,112&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,164&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,474&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Subsequent Events &lt;/b&gt;-
The Company&#x2019;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent
event disclosure consideration.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Adopted Accounting
Pronouncements &#x2013; &lt;/b&gt;In May 2021, FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts in an Entity&#x2019;s
Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options&lt;/i&gt;, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard did not have a material
effect on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2021, the FASB
issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance&lt;/i&gt;, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022,
and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Issued Accounting
Pronouncements &#x2013; &lt;/b&gt;In October 2021, FASB issued ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account for Contract Assets
and Contract Liabilities from Contracts with Customers&lt;/i&gt;, which provides guidance on accounting for contract assets and contract liabilities
acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606
to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring
the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree&#x2019;s financial
statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods. Early adoption is permitted, including
adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future business combinations the Company may
enter in the future.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <atnm:NatureOfBusinessPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business - &lt;/b&gt;Actinium
Pharmaceuticals, Inc. is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular
level precision to treat patients with high unmet medical needs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</atnm:NatureOfBusinessPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.
All significant intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates in Financial
Statement Presentation -&lt;/b&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash and Cash Equivalents
and Restricted Cash-&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
cash, cash equivalents and restricted cash at December 31, 2022 and December 31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,221&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
certificates of deposit held as collateral for letters of credit issued in connection with the Company&#x2019;s leases of corporate office
spaces.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,221&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">108910000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" unitRef="usd">77829000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">396000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c4" decimals="-3" unitRef="usd">392000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">302000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c3" decimals="-3" unitRef="usd">109608000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c4" decimals="-3" unitRef="usd">78221000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Property and Equipment
-&lt;/b&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of three to five
years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years.
When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is
reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assets are recorded at the
lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful life of the related property
or term of the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term. The Company entered into a lease for corporate office space effective June 1, 2022 and paid a security deposit
to the landlord. A certificate of deposit was provided as collateral for a letter of credit issued with this office space during 2022
and at that time, the security deposit was returned to the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;
(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements&lt;/b&gt;
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <atnm:GrantRevenuePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company had a grant from a government-sponsored entity for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:GrantRevenuePolicyTextBlock>
    <atnm:LicenseRevenueTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</atnm:LicenseRevenueTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -&lt;/b&gt;
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Income Taxes -&lt;/b&gt; The
Company accounts for income taxes in accordance with ASC 740 &lt;i&gt;Income Taxes&lt;/i&gt;, which requires the asset and liability method to calculate
deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income tax bases of assets
and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be
fully realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 740 prescribes guidance
for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meet a &#x201c;more-likely-than-not&#x201d;
recognition threshold to be recognized. There were no tax positions for which it is considered reasonably possible that the total amounts
of unrecognized tax benefits will significantly increase or decrease within the next year. The Company recognizes interest related to
unrecognized tax benefits in interest expense and penalties in operating expenses&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share&lt;/b&gt;
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly to basic
loss per share because the impact of all potential dilutive common shares is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"&gt;For the years ended December 31, 2022 and 2021,
the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock units and warrants,
have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,112&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,164&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,474&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,112&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,164&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,474&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c22" decimals="0" unitRef="shares">3396</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c23" decimals="0" unitRef="shares">1362</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c24" decimals="0" unitRef="shares">325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c26" decimals="0" unitRef="shares">1443</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c27" decimals="0" unitRef="shares">2112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="0" unitRef="shares">5164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c5" decimals="0" unitRef="shares">3474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Subsequent Events &lt;/b&gt;-
The Company&#x2019;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent
event disclosure consideration.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <atnm:Accountingstandardsrecentlyissuedpolicytextblock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Adopted Accounting
Pronouncements &#x2013; &lt;/b&gt;In May 2021, FASB issued ASU 2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts in an Entity&#x2019;s
Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options&lt;/i&gt;, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard did not have a material
effect on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2021, the FASB
issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance&lt;/i&gt;, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022,
and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:Accountingstandardsrecentlyissuedpolicytextblock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Issued Accounting
Pronouncements &#x2013; &lt;/b&gt;In October 2021, FASB issued ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account for Contract Assets
and Contract Liabilities from Contracts with Customers&lt;/i&gt;, which provides guidance on accounting for contract assets and contract liabilities
acquired in a business combination in accordance with ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606
to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring
the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree&#x2019;s financial
statements. The amendments of ASU 2021-08 are effective January 1, 2023, including interim periods. Early adoption is permitted, including
adoption in an interim period. The Company will evaluate the impact of ASU 2021-08 on any future business combinations the Company may
enter in the future.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2 - Prepaid Expenses and Other Current
Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Prepaid expenses and other
current assets consisted of the following at December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid&#160;insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid&#160;clinical trial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,636&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,478&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid&#160;insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid&#160;clinical trial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;543&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,636&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,478&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c3" decimals="-3" unitRef="usd">684000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c4" decimals="-3" unitRef="usd">874000</us-gaap:PrepaidInsurance>
    <atnm:PrepaidClinicalTrialExpenses contextRef="c3" decimals="-3" unitRef="usd">887000</atnm:PrepaidClinicalTrialExpenses>
    <atnm:PrepaidClinicalTrialExpenses contextRef="c4" decimals="-3" unitRef="usd">543000</atnm:PrepaidClinicalTrialExpenses>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="-3" unitRef="usd">65000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" unitRef="usd">61000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">1478000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment consisted
of the following at December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;476&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office equipment&#160;and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 7 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(487&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;604&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;340&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation expense consisted
of the following for the years ended December 31, 2022 and 2021, respectively:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research&#160;and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;152&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;105&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;476&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office equipment&#160;and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 7 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(487&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;604&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;340&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c28">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c29" decimals="-3" unitRef="usd">776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c30" decimals="-3" unitRef="usd">476000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c31">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c32">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c33" decimals="-3" unitRef="usd">315000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c34" decimals="-3" unitRef="usd">199000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c3" decimals="-3" unitRef="usd">487000</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c4" decimals="-3" unitRef="usd">335000</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">604000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" unitRef="usd">340000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research&#160;and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;152&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;105&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Depreciation contextRef="c35" decimals="-3" unitRef="usd">141000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c36" decimals="-3" unitRef="usd">88000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c37" decimals="-3" unitRef="usd">11000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c38" decimals="-3" unitRef="usd">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" unitRef="usd">152000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="-3" unitRef="usd">105000</us-gaap:Depreciation>
    <atnm:LeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 4 - Leases &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines
if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the
right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed
to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The lease term for all of
the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company entered into a lease
for corporate office space, effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration date on July 30, 2027
and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance, utilities and maintenance.
At December 31, 2022, for capitalization purposes under ASC842, the Company has this operating lease and a finance lease for office equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At December 31, 2021, for
capitalization purposes under ASC842, the Company had an operating lease for corporate office space that expired in 2022 and finance leases
for office equipment and furniture located in the corporate office space. In addition, the Company has auxiliary corporate office space
that it rents on a month-to-month basis; this rental was accounted for as an operating lease with the same term as the Company&#x2019;s
office space.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;584&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;372&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Supplemental cash flow information related to leases
are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cash flow information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;377&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#x2019;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflect the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Maturities
of lease liabilities are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,877&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,577&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:LeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0">5 years 2 months</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseCost contextRef="c0" decimals="-5" unitRef="usd">600000</us-gaap:LeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;584&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;372&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;57&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" unitRef="usd">584000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c5" decimals="-3" unitRef="usd">372000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" unitRef="usd">55000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c5" decimals="-3" unitRef="usd">81000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c5" decimals="-3" unitRef="usd">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">57000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="-3" unitRef="usd">90000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cash flow information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;352&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;377&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" unitRef="usd">352000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c5" decimals="-3" unitRef="usd">377000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c5" decimals="-3" unitRef="usd">9000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">49000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c5" decimals="-3" unitRef="usd">85000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">2605000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <atnm:ScheduleOrDescriptionOfWeightedAverageTerm contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:ScheduleOrDescriptionOfWeightedAverageTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P1Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <atnm:ScheduleOfWeightedAverageDiscountRate contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</atnm:ScheduleOfWeightedAverageDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" unitRef="pure">0.08</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,877&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,577&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c39" decimals="-3" unitRef="usd">606000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c40" decimals="-3" unitRef="usd">4000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c39" decimals="-3" unitRef="usd">618000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c39" decimals="-3" unitRef="usd">630000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c39" decimals="-3" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive contextRef="c39" decimals="-3" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c39" decimals="-3" unitRef="usd">2877000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c40" decimals="-3" unitRef="usd">4000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <atnm:PaymentWithImputedInterestPremium contextRef="c39" decimals="-3" unitRef="usd">-300000</atnm:PaymentWithImputedInterestPremium>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c39" decimals="-3" unitRef="usd">2577000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c40" decimals="-3" unitRef="usd">4000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:OtherRevenueTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5 - Other revenue&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#x2019;s ability to terminate
the module. The consideration is recognized to revenue over each module and revenue of $0.9 million was recognized during each of the
years ended December 31, 2022 and December 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company had a grant from
a government-sponsored entity for research and development related activities that provide for payments for reimbursed costs, which included
overhead and general and administrative costs as well as an administrative fee. The Company recognized revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Other revenue recognized
from this grant during the years ended December 31, 2022 and 2021 was $0.1 million and $0.2 million, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 7, 2022, the Company
entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB (&#x201c;Immedica&#x201d;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"&gt;The Company&#x2019;s contract
liabilities are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#x2019;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#x2013; current liability at December
31, 2022 and $1.0 million at December 31, 2021. Long-term license revenue deferred was $35.0 million at December 31, 2022; there was &lt;span style="-sec-ix-hidden: hidden-fact-46"&gt;no&lt;/span&gt;
Long-term license revenue deferred at December 31, 2021. This deferred revenue will be recognized upon European Union regulatory approval
of Iomab B.&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <atnm:RecognitionOfDeferredRevenue1 contextRef="c0" decimals="-5" unitRef="usd">900000</atnm:RecognitionOfDeferredRevenue1>
    <atnm:RecognitionOfDeferredRevenue1 contextRef="c5" decimals="-5" unitRef="usd">900000</atnm:RecognitionOfDeferredRevenue1>
    <atnm:RevenueRecognized contextRef="c0" decimals="-5" unitRef="usd">100000</atnm:RevenueRecognized>
    <atnm:RevenueRecognized contextRef="c5" decimals="-5" unitRef="usd">200000</atnm:RevenueRecognized>
    <atnm:UpfrontPayment contextRef="c41" decimals="-6" unitRef="usd">35000000</atnm:UpfrontPayment>
    <us-gaap:DeferredRevenueCurrent contextRef="c4" decimals="-5" unitRef="usd">1000000</us-gaap:DeferredRevenueCurrent>
    <atnm:LongtermLicenseRevenueDeferred contextRef="c3" decimals="-5" unitRef="usd">35000000</atnm:LongtermLicenseRevenueDeferred>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 6 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed antibody. Upon commercial sale
of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:MilestonePayment contextRef="c42" decimals="-6" unitRef="usd">1000000</atnm:MilestonePayment>
    <atnm:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="c42">Upon commercial sale
of the drug, royalty payments of 2% of net sales will be due to FHCRC.</atnm:DescriptionOfRoyaltyPaymentToRelatedParty>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 7 - Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the Company entered
into the Capital on Demand&#x2122; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which the
Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of common
stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. For the year ended December
31, 2022, the Company sold 3.5 million shares of common stock, resulting in gross proceeds of $23.9 million and net proceeds of $23.2
million. For the year ended December 31, 2021, the Company sold 4.6 million shares of common stock, resulting in gross proceeds of $36.5
million and net proceeds of $35.3 million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 28, 2022, the Company
entered into an Amendment and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R Sales Agreement&#x201d;) with JonesTrading
and B. Riley Securities, Inc. (&#x201c;B. Riley Securities&#x201d;). The A&amp;amp;R Sales Agreement modifies the original Capital on Demand&#x2122;
Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2019 Amended and Restated Stock Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2019, the Company&#x2019;s
2019 Stock Plan was established. The expiration date of the plan is October 18, 2029 and the total number of shares of the Company&#x2019;s
common stock available for grant to employees, directors and consultants of the Company was 333,333 shares. After a number of amendments
approved by stockholders, the number of shares authorized under the plan was 5,833,333 shares. At the Company&#x2019;s Annual Meeting of
Stockholders held on December 30, 2022, its stockholders authorized an increase in the number of shares authorized under the plan, resulting
in the number of shares authorized in the plan to be 9,333,333 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2013 Amended and Restated Stock Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2013, the Company&#x2019;s
2013 Stock Plan was established. The expiration date of the plan is September 9, 2023 and at the time of approval, the total number of
shares of the Company&#x2019;s common stock available for grant to employees, directors and consultants of the Company under the plan was
91,666 shares. After a number of amendments approved by stockholders, the number of shares authorized under the plan is 758,333 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;2013 Equity Incentive Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2013, the Company&#x2019;s
2013 Equity Incentive Plan was established. The expiration date of the plan is September 9, 2023 and the total number of shares of the
Company&#x2019;s common stock available for grant to employees, directors and consultants of the Company under the plan was 15,000 shares.
In December 2013, the shareholders of the Company approved the plan and increased the number of shares authorized under the plan to 33,333
shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
stock option activity for the years ended December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;18.78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;12.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;804&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;15.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2,432&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During 2022, the Company granted
its employees and members of the Board of Directors options to purchase 2.1 million shares of common stock with an exercise price ranging
from $4.96 to $13.54 per share, a term of 10 years, and a vesting period from 4 to 4.2 years.&#160;The options have an aggregated fair
value of $7.7 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 1.5% to 4.3% (2) expected life of 6 years, (3) expected volatility range from 78.8% to 81.1%,
and (4) zero expected dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During 2021, the Company granted
its employees and members of the Board of Directors options to purchase 881 thousand shares of common stock with an exercise price ranging
from $6.02 to $9.25 per share, a term of 10 years, and a vesting period from 4 to 4.2 years. The options have an aggregated fair value
of $3.9 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 0.65% to 1.28% (2) expected life of 6 years, (3) expected volatility range from 79.8% to 85.1%,
and (4) zero expected dividends.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended December
31, 2022 and 2021, options to purchase 60 thousand and 333 thousand common shares were cancelled, respectively, upon the termination of
employment. During 2021, 1 thousand options were exercised for shares of common stock. There were no exercises of options during 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31,
2022 was $10.0 million related to unvested options, which is expected to be expensed over a weighted average of 3.3 years. During 2022
and 2021, the Company recorded total option expense of $2.5 million and $1.5 million, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company issued 325 thousand
restricted stock units (&#x201c;RSUs&#x201d;) to employees during 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;325&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#x2019;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.9 million, was determined based on the stock
prices on the dates of the grants and is being recognized over three years. The unrecognized compensation expense at December 31, 2022
of $1.7 million is expected to be expensed over 2.4 years. During 2022, the Company recorded compensation expense related to RSUs of $0.2
million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activities for the years ended December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;50.17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;29.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,440&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 2, 2022, warrants
to purchase an aggregate of 0.6 million shares of common stock expired. These warrants were issued on August 2, 2017, when the Company
completed an underwritten offering of 0.7 million shares of common stock and warrants to purchase 0.6 million shares of common stock at
a price of $22.50 per share and related warrant. The warrants were exercisable for a period of 5 years at an exercise price of $31.50
per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended December
31, 2022 and 2021, the Company recorded stock-based compensation expense related to warrants of $6 thousand and $16 thousand, respectively.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c43" decimals="-6" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c44" decimals="-5" unitRef="shares">3500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c44" decimals="-5" unitRef="usd">23900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c44" decimals="-5" unitRef="usd">23200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ExcessStockSharesIssued contextRef="c13" decimals="-5" unitRef="shares">4600000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c45" decimals="-5" unitRef="usd">36500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c45" decimals="-5" unitRef="usd">35300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c46" decimals="0" unitRef="shares">333333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c47" decimals="0" unitRef="shares">5833333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c48" decimals="0" unitRef="shares">9333333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c49" decimals="0" unitRef="shares">91666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">758333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c50" decimals="0" unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c51" decimals="0" unitRef="shares">33333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;120&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;18.78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;12.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;804&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;15.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;2,432&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c9" decimals="INF" unitRef="shares">815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c9" decimals="2" unitRef="usdPershares">21.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c5">P8Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c9" decimals="-3" unitRef="usd">120000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c5" decimals="INF" unitRef="shares">881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c5" decimals="2" unitRef="usdPershares">6.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="c5" decimals="INF" unitRef="shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c5" decimals="2" unitRef="usdPershares">6.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c5" decimals="INF" unitRef="shares">333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c5" decimals="2" unitRef="usdPershares">18.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c4" decimals="INF" unitRef="shares">1362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">12.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c5">P8Y8M8D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c0" decimals="INF" unitRef="shares">2094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">5.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="INF" unitRef="shares">60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">12.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">3396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c0">P8Y10M6D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c3" decimals="-3" unitRef="usd">15204000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c3" decimals="INF" unitRef="shares">804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">15.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted contextRef="c0">P7Y6M29D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c3" decimals="-3" unitRef="usd">2432000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <atnm:GrantOfStockOptionsPurchaseShares contextRef="c0" decimals="-5" unitRef="shares">2100000</atnm:GrantOfStockOptionsPurchaseShares>
    <atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight contextRef="c52" decimals="2" unitRef="usdPershares">4.96</atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight>
    <atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight contextRef="c53" decimals="2" unitRef="usdPershares">13.54</atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight>
    <atnm:StockOptionTerm contextRef="c0">P10Y</atnm:StockOptionTerm>
    <atnm:VestingPeriodOfStockOption contextRef="c54">P4Y</atnm:VestingPeriodOfStockOption>
    <atnm:VestingPeriodOfStockOption contextRef="c55">P4Y2M12D</atnm:VestingPeriodOfStockOption>
    <atnm:AggregateFairValue contextRef="c56" decimals="-5" unitRef="usd">7700000</atnm:AggregateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c54" decimals="3" unitRef="pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c55" decimals="3" unitRef="pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c54" decimals="3" unitRef="pure">0.788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c55" decimals="3" unitRef="pure">0.811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:Dividends contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:Dividends>
    <atnm:GrantOfStockOptionsPurchaseShares contextRef="c5" decimals="-3" unitRef="shares">881000</atnm:GrantOfStockOptionsPurchaseShares>
    <atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight contextRef="c57" decimals="2" unitRef="usdPershares">6.02</atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight>
    <atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight contextRef="c58" decimals="2" unitRef="usdPershares">9.25</atnm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight>
    <atnm:StockOptionTerm contextRef="c5">P10Y</atnm:StockOptionTerm>
    <atnm:VestingPeriodOfStockOption contextRef="c59">P4Y</atnm:VestingPeriodOfStockOption>
    <atnm:VestingPeriodOfStockOption contextRef="c60">P4Y2M12D</atnm:VestingPeriodOfStockOption>
    <atnm:AggregateFairValue contextRef="c61" decimals="-5" unitRef="usd">3900000</atnm:AggregateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c59" decimals="4" unitRef="pure">0.0065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c60" decimals="4" unitRef="pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c59" decimals="3" unitRef="pure">0.798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c60" decimals="3" unitRef="pure">0.851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:Dividends contextRef="c5" decimals="0" unitRef="usd">0</us-gaap:Dividends>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c0" decimals="-3" unitRef="shares">60000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c5" decimals="-3" unitRef="shares">333000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <atnm:StockOptionsExercisedSharesOfCommonStock contextRef="c5" decimals="-3" unitRef="shares">1000</atnm:StockOptionsExercisedSharesOfCommonStock>
    <atnm:UnrecognizedCompensationExpense contextRef="c56" decimals="-5" unitRef="usd">10000000</atnm:UnrecognizedCompensationExpense>
    <atnm:WeightedAverageTerm contextRef="c0">P3Y3M18D</atnm:WeightedAverageTerm>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c0" decimals="-5" unitRef="usd">2500000</atnm:CompensationExpenseRelatedToStockOptions>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c5" decimals="-5" unitRef="usd">1500000</atnm:CompensationExpenseRelatedToStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c62" decimals="-3" unitRef="shares">325000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;325&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c69" decimals="INF" unitRef="shares">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c69" decimals="2" unitRef="usdPershares">5.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <atnm:RSUsOutstandingEndingBalance contextRef="c70" decimals="INF" unitRef="shares">325000</atnm:RSUsOutstandingEndingBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c70" decimals="2" unitRef="usdPershares">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c63" decimals="-5" unitRef="usd">1900000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c64">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <atnm:UnrecognizedCompensationExpense contextRef="c64" decimals="-5" unitRef="usd">1700000</atnm:UnrecognizedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c64">P2Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <atnm:CompensationExpenseRelatedToRSUs contextRef="c0" decimals="-5" unitRef="usd">200000</atnm:CompensationExpenseRelatedToRSUs>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;50.17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(669&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;29.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,440&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <atnm:NumberOfWarrantsOutstandings contextRef="c71" decimals="0" unitRef="shares">2113</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c71" decimals="2" unitRef="usdPershares">20.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c72">P2Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c71" decimals="-3" unitRef="usd">362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c72" decimals="0" unitRef="shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c72" decimals="2" unitRef="usdPershares">8.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c72" decimals="0" unitRef="shares">-2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <atnm:WeightedAverageExercisePriceCancelled contextRef="c72" decimals="2" unitRef="usdPershares">50.17</atnm:WeightedAverageExercisePriceCancelled>
    <atnm:NumberOfWarrantsOutstandings contextRef="c73" decimals="0" unitRef="shares">2112</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c73" decimals="2" unitRef="usdPershares">20.52</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c72">P1Y9M3D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c73" decimals="-3" unitRef="usd">276000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c74" decimals="0" unitRef="shares">-669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <atnm:WeightedAverageExercisePriceCancelled contextRef="c74" decimals="2" unitRef="usdPershares">29.01</atnm:WeightedAverageExercisePriceCancelled>
    <atnm:NumberOfWarrantsOutstandings contextRef="c75" decimals="0" unitRef="shares">1443</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c75" decimals="2" unitRef="usdPershares">16.58</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c74">P1Y3M29D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c75" decimals="-3" unitRef="usd">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c75" decimals="0" unitRef="shares">1440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c74" decimals="2" unitRef="usdPershares">15.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c74">P1Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c75" decimals="-3" unitRef="usd">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <atnm:ClassOfWarrantsSharesExpired contextRef="c65" decimals="-5" unitRef="shares">600000</atnm:ClassOfWarrantsSharesExpired>
    <atnm:UnderwrittenOfferingShares contextRef="c66" decimals="-5" unitRef="shares">700000</atnm:UnderwrittenOfferingShares>
    <atnm:warrantsToPurchaseSharesOfCommonStock contextRef="c66" decimals="-5" unitRef="shares">600000</atnm:warrantsToPurchaseSharesOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare contextRef="c67" decimals="2" unitRef="usdPershares">22.5</us-gaap:SaleOfStockPricePerShare>
    <atnm:ExercisablePeriodYears contextRef="c0">P5Y</atnm:ExercisablePeriodYears>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c0" decimals="2" unitRef="usdPershares">31.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="-3" unitRef="usd">16000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;Note 8 - Income Taxes &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred income taxes reflect
the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets and liabilities at December
31, 2022 and 2021 are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,233&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,405&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Research and development/orphan drug credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Capitalized research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,599&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has recorded a
valuation allowance of $76.1 million and $62.6 million against its deferred tax assets at December 31, 2022 and 2021 respectively, because
management determined that it is not more-likely-than not that those assets will be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For federal income tax purposes,
the Company has $178.6 million of unused net operating losses (&#x201c;NOLs&#x201d;) at December 31, 2022 available for carry forward to
future years. NOLs of $118.4 million generated prior to 2018 will begin to expire if unused in 2023. NOLs generated in 2018 and later
years of $60.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1,
2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For state income tax purposes,
the Company has $271.1 million of unused NOLs at December 31, 2022 available for carry forward to future years. These NOLs will begin
to expire in 2034 if unused.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has federal research
and development tax credits of $3.4 million at December 31, 2022 which will begin to expire in 2034 if unused and orphan drug credits
of $13.8 million which will begin to expire in 2028 if unused.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Federal and state tax laws
impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership change for tax purposes,
as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#x2019;s ability to utilize these carryforwards may be
limited as a result of an ownership change which may have already happened or may happen in the future. Such an ownership change could
result in a limitation in the use of the net operating losses in future years and possibly a reduction of the net operating losses available.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; "&gt;The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2022 and 2021 are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Federal statutory income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(6,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(373&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development/orphan drug tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,711&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,898&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,494&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,425&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,233&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,405&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Research and development/orphan drug credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Capitalized research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76,093&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,599&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">44233000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" unitRef="usd">36405000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="-3" unitRef="usd">1334000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="-3" unitRef="usd">1213000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c3" decimals="-3" unitRef="usd">17247000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c4" decimals="-3" unitRef="usd">14536000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c3" decimals="-3" unitRef="usd">13210000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c4" decimals="-3" unitRef="usd">10426000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="-3" unitRef="usd">69000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="-3" unitRef="usd">19000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">76093000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" unitRef="usd">62599000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <atnm:DeferredTaxAssetsValuationAllowances contextRef="c3" decimals="-5" unitRef="usd">76100000</atnm:DeferredTaxAssetsValuationAllowances>
    <atnm:DeferredTaxAssetsValuationAllowances contextRef="c4" decimals="-5" unitRef="usd">62600000</atnm:DeferredTaxAssetsValuationAllowances>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesForeign contextRef="c0" decimals="-5" unitRef="usd">178600000</us-gaap:IncomeTaxReconciliationTaxContingenciesForeign>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="c0">NOLs of $118.4 million generated prior to 2018 will begin to expire if unused in 2023. NOLs generated in 2018 and later
years of $60.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1,
2023.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal contextRef="c0" decimals="-5" unitRef="usd">271100000</us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet contextRef="c0" decimals="-5" unitRef="usd">3400000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c0" decimals="-5" unitRef="usd">13800000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Federal statutory income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(6,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(373&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development/orphan drug tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,711&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,898&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,494&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,425&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" unitRef="usd">-6943000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="-3" unitRef="usd">-5202000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="3" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="-3" unitRef="usd">-4863000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="3" unitRef="pure">-0.147</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="-3" unitRef="usd">-373000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="3" unitRef="pure">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="-3" unitRef="usd">89000</us-gaap:DeferredTaxAssetsNet>
    <atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps contextRef="c0" decimals="3" unitRef="pure">0.003</atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="-3" unitRef="usd">562000</us-gaap:DeferredTaxAssetsNet>
    <atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps contextRef="c5" decimals="3" unitRef="pure">0.023</atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c0" decimals="-3" unitRef="usd">2711000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c0" decimals="3" unitRef="pure">-0.082</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c5" decimals="-3" unitRef="usd">1898000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c5" decimals="3" unitRef="pure">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">934000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c0" decimals="3" unitRef="pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">486000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c5" decimals="3" unitRef="pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" unitRef="usd">13494000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" unitRef="pure">0.408</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" unitRef="usd">6425000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="3" unitRef="pure">0.259</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; "&gt;&lt;b&gt;Note 9 - Subsequent Event&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Since December 31, 2022, the
Company has sold 0.1 million shares of common stock under its A&amp;amp;R Sales Agreement, resulting in net proceeds of $0.8 million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DividendsCommonStockStock contextRef="c0" decimals="-5" unitRef="usd">100000</us-gaap:DividendsCommonStockStock>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c0" decimals="-5" unitRef="usd">800000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <dei:AuditorFirmId contextRef="c0">688</dei:AuditorFirmId>
    <us-gaap:SecurityDeposit
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenue
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c5"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">-1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="hidden-fact-14"
      unitRef="shares">20568373</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-15"
      unitRef="shares">24141545</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c10"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c12"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c12"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c10"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c12"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c10"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c16"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c18"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c18"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c5"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c5"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c5"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:RightofuseAssetsObtainedInExchangeForLeaseLiabilities
      contextRef="c5"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:AcquisitionOfEquipmentFinancedBySecurityDeposit
      contextRef="c5"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherRestrictedAssetsCurrent
      contextRef="c4"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c25"
      id="hidden-fact-37"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c5"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c5"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="c40"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="c40"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="c40"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="c40"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:PaymentWithImputedInterestPremium
      contextRef="c40"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:LongtermLicenseRevenueDeferred
      contextRef="c4"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c4"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-49"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:RSUsOutstandingBeginningBalance
      contextRef="c68"
      id="hidden-fact-50"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c68"
      id="hidden-fact-51"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c69"
      id="hidden-fact-52"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c69"
      id="hidden-fact-53"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c72"
      id="hidden-fact-54"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c72"
      id="hidden-fact-55"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c74"
      id="hidden-fact-56"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c74"
      id="hidden-fact-57"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c74"
      id="hidden-fact-58"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c74"
      id="hidden-fact-59"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c5"
      id="hidden-fact-65"
      unitRef="pure"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001388320</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M((A_5K*5;G]O!P  O#   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MF_]OVC@8QO\5BYM.FU1*OO!UUR+14&[<5H8*V]3[S4T,1$UBSG%*^]^?G4!"
M)N>%2.:7E82\3Y(/MO,\CG>SH^PEWA#"T5L81/%M8\/Y]G.K%;L;$N+XFFY)
M)+Y9419B+C;9NA5O&<%>6A0&+<LPNJT0^U%C>)/NF[/A#4UXX$=DSE"<A"%F
M[W<DH+O;AMDX['CTUQLN=[2&-UN\)@O"?VSG3&RU<A7/#TD4^S1"C*QN&R/S
M\]@>R(+TB)\^V<5'GY&\E6=*7^3&U+MM&/**2$!<+B6P^/-*'!($4DE<QW][
MT49^3EEX_/F@/DEO7MS,,XZ)0X-?OL<WMXU^ WEDA9. /]+=%[*_H8[4<VD0
MI_^B779LN]U ;A)S&NZ+Q16$?I3]Q6][$$<%MEE18.T+K-\*S*HSV/L"^]R"
M]KZ@G9+);B7E,,8<#V\8W2$FCQ9J\D,*,ZT6M^]'\G=?<":^]44='XZIFXB?
MD:-1Y*'[B/O\'4VCK#W)WZ6)?BS&Z..'3S<M+DXGBUKN7OHND[8JI$T+/="(
M;V*AZQ&O+- 2UYE?K'6XV#L+5!P3]QK9YA6R#,M27) #ES]@EI?;BO(Q7/Y/
M$HER0W7VTMW8.7H[U;-/H3_F_4T<A*:<A+$*>";85@O*(>)SO,4NN6V(,2 F
M[)4TAG_^87:-OU2P=(J--8F50+9SD&U(?;AOMH]D[<><84%TAD.BX@?KC)SE
M=#;]\8#F7T:/#R/G_L=RZHR^+:[0=.9<JQ"">G41:A(K(>SD"#O@K2\9]OQH
MC1;OX3,-5.C@^M%R]J "!%;5!:1)K 2HFP/J@C>8=];E^U;9M.!RTVA^5?$!
MJ^KRT216XM/+^?3 &W02QB2>B1^[.$!/!#,Y["/Q4%+B@M6:3=-JVJ:*&%A8
MEY@FL1*Q?DZL?\ZHY= P%./^@E/WY0HM-EB<"7U/>,QQ)+ND"AXH7/<QD(EU
M4C'I$E^'5J=G#>R><=-Z/8:EZ:PE6(,<UN <6//D.?!=- DHYBHPH$A=,#K%
MQIE8]XBR:0XZ_8'=-7/,)3*F43@X QY[Q;CDI6/3),#*]G)"8(6#6-5)';BN
M+@)=:F5,1T;7/*N_"5!,C%!3X4G?T%?RK@0&2QF&8=K]OFT92FI@<6UJFM3*
MU*R"FG46M?WP_DBVE/'4*7#,$Z5)/:'X1%15#EQ5FYHFM3*UPMF;H-\]4/M)
M@R3B(DZ+QV) F)H6K#2C2EA:O;LNM3*LPKV;9]GW%!%RA%]84Z;NE;#.C$9-
M[+I$R @1+Q-4TM-JVW6IE>D5QMV$G?>>WB\2!,V7B.Z$E2 XII$ ,(WC1$G@
M[H1F1:/3:N9UJ96Q%7;>/-//SPGSJ0=ZU5-2AUF)RFD)6* VN4OX?+,P^B;L
MS7-RQU9_(G:JAS=8K)*85INO2ZU,K##Z)NST?R>V;W+5S&"YR9.2F,Y0,-:E
M5B96N'WS++N_"'$0H+LD%E_':E2P#F>)VMAJ]?:ZU,ISHH7_MV#[OH=U'Q*V
MEL[L;Z' -S)8;G&D?)">$*S, W!=76RZU,K8BCQ@G94'%AOQY 1AP3+5L+3&
M %UJ95A%#+!@TSYU)H]HE'@^IPR-."<QS^:KJR+G";UJ:EIC@"ZU,K4B!EBP
M>3]ZN1(E8N#/TI,2%RQ4-8[!9;5I72('6$4.L&#_7DRQ,AS%?MJ\ &*P6'4#
MTVK^=:F5D17FWSK+_,ND@V9)^*QV^R=$#,-H=JQVNZO$I=7TZU(KXRI,OP4[
M]?S]IDN9:%?I"':5SF00),8UAXJTSN24K*?, 2?4Q_=*@%J]ORZU,L#"^UNP
M7=\#7.(W-/5$5_57OIL]!X#6!TOVVDUKT+6[QD!)3VL.T*56IE?D .NL&?^1
MYPGU^.KP(7OG^SU2MSE8TNIUT /V?!'XT>B51 FY0CUA_B:J=W@.+%:;YB4R
M@E5D!.NLC)#3=.26Z,5+NHN4)&&Y&=FA)\I>E-RTQ@5=:N5%!T5<L,^*"SFW
M?/B;,_KJ1ZZR&9[0G"DC*5Q4>X7!)>*"7<0%^ZRXD&.;4V&! _2OOZU\7IQ0
M- W#5#YSX;K:W"Z1'.PB.=BPTT^[Y8@17(T)%OC8;7=5JX\<N*XVIDM$!?MH
M+1#L\+_1=&9H0R/(R9T0Z?9Z3;O?4[Z5@DMKT[I$5+"+J&##[G[I<^%XZ0J9
MUL?G3VA!W(2)=J9$!BOM7[_'V>OW+6;H%0<)01^,:]$]E2"U!@A=:F6018"P
M8>]_((?NW]P-CM:D<NG4":'9TT)I?^&RVK0ND1_L(C_89^8'3EBV8%6^,\"'
MMZ-*;+!BQ<M0N*HVM4N$!KL(#3;L\ _31I4M"RY_P,Q-0A0$6R4IK0%!EUJ9
M5!$0;-C-'TC)AX%,54I:L,07*M<,BU2[)&]8W;:TA@!=:F5B10BP8==^(#;Q
M68BF8R4P6*';[RLI:;7\NM0R2JVCY=YRTC]=-A\C5TY?9"N_\[WYTOQ1NB"]
M51R>K>L7G6OM1S$*R$J4&M<],<"R;*E\ML'I-ET\_DPYIV'Z<4.P1Y@\0'R_
MHI0?-N0)\O^P,/P?4$L#!!0    ( ""(?U;HA:20]P4  !<:   8    >&PO
M=V]R:W-H965T<R]S:&5E=#(N>&ULK5EM;]LV$/XKA!L4&^#$(O7JQ#&0IBLZ
MH$.#IMT^,Q(=$Y5$EZ2<9+]^)*U(ED0Q3N8/;23[[O@\1QZ?([UX8/RG6!,B
MP6.1E^)RLI9R<SZ;B71-"BS.V(:4ZIL5XP66ZI7?S\2&$YP9IR*?(<^+9@6F
MY62Y,)_=\.6"53*G);GA0%1%@?G3!Y*SA\L)G#Q_\(W>KZ7^8+9<;/ ]N27R
MQ^:&J[=9$R6C!2D%927@9'4YN8+GU[ZG'8S%WY0\B+UGH*G<,?93O_R974X\
MC8CD))4Z!%9_MN2:Y+F.I'#\JH-.FC&UX_[S<_1/AKPB<X<%N6;Y/S23Z\M)
M,@$96>$JE]_8PV=2$PIUO)3EPOP/'FI;;P+22DA6U,X*04'+W5_\6"=BSP$&
M(PZH=D"'.OBU@V^([I 96A^QQ,L%9P^ :VL533^8W!AOQ8:6>AIO)5??4N4G
ME]>L%"RG&98D Q]PCLN4@%L=3H!3\./V(_CMY'=P F@)OJ]9)7"9B<5,JI&U
M_RRM1_FP&P6-C/*1I&? AU. /(0L[M>'N\.N^TSQ;4BCAC0R\?PQTA7GI)3@
M2@C%\]S&9Q<@L ?0M74N-C@EEQ-5/(+P+9DLW[^#D7=A8W>D8!VN?L/5=T5?
M7F.Q!FK60*H?R*^*;G&NR%MG<1<J,J'T!K!=0B^90V\QV^[S&9K%<8+FC54'
M:-  #9Q OQ$A.4WU.C10W[]+$(07J@C,9-G@[@*&>SC\>=3#:K-!=J1A@S1T
M(KTE"A.53VJ[V#!!K="<$>Q3#FQ+)QS #ST[^JA!'SG1WW"RP30#Y%%)@2#"
M+ XFUX0_IQI@4Q<V6M$ #HS\?LHM1D&<V%''#>K8B?H[DS@'W<*U 8R'8T-O
M'J >Q*%9/(^#D16<-!B3%S*KU)6K=:$SJBMMH_1.3D&IU)BME&*E55'E9J=5
M*X>3E&(C9>J[DR")C=N)[X<V7LD <.0%/5)#&S\862SSAM+\3469L_(>2,(+
M&];Y$(?7GP#GL ?51X</]%J]\YR,OJHI4FE7\'.BY!]PK?.G;'5:J9?QA5]'
MW2>%_ #V6-FL]HRZD/<D&CHA?Z*ED64#6!R,& ZGH0]W:!*.U"ELM14ZY:RN
MU/$*K=V[)1K >7^%6.P2ST_&\+5Z"/V#Q/\+Q7<TIY(2>P< G;KZVA;@6-&Z
MI%MMA6YQO4I35BG1!QO\A.]R8O8:M2'QBK1*8,W"4#^A!_U^1V Q"T.]DUGG
MJA5:Z%;:KT:6.-F2LB*Z.R=J[K)^:P#R>BJ?K R.)<5PJ,7S^=AR;-48NN6X
MMQ^) TD--3:8]_7 8H2"L3EIA1BZE;BW&QT&=ZBW [!#DVBD3X.M($.W(G>[
MAKV*MX(<ZB?T(I3T@5JD.!G36=@*+70K[1>EJ*=:454F4UV.@V5OQ6S1VM#S
M!N5Y9+E%K=PBM]RVM%A/>-E=3N]- V2=#6214B_I*YA[]#<0:T49N46Y);;:
M+X@7:3FCOF(W0BYY[W+:.Q8?(MTOE D:ZG(0Q[#?"EG,5)F,06S5&[UPG&5%
M0:7NJW<'EY25>DV1,AV#^P;AM2?\_P?J<F[%&P7.CN56LO3GFN49X<)(7WP!
M_E#'"_EDO[IPM@*OOKLX4K0N][8#0.X.0)U6:]$7.@M3<.*=>1Y4?0P'6YQ7
MY *$WE3M>/H?$&O,]8FVDFO&Z;\DFX+F0RJ$;G;,:;>20JH'M7"L"3Q6QW"$
M0-VTM5T%<G<5NDS4R7(T9_ Y9?:T70 43J,XF";(-QE#: H#?ZK.R&](IZ4-
MZ5\9V&Q&U!^UG0IR=RI764;U1JSV-'WC<4I+=8C=4+7'66$.&Q _#!'J:ZG-
M#LU1/'+,0VVS@MS-RE7G?F!%4_O-$AKV'Z<H2>(H[ .U&89A'(STK*CM59"[
M5]GIQ/BV9(4][%2B*$@&LC$TB_UPK&OUVS[$=_<A VDS*_=U%.HA.M>CMI.K
MQ<YV<IWMW=KKGTS^POR>ED+U$2OEYYW%*@E\]RO$[D6RC;G(OV-2LL(\K@E6
MV+6!^G[%F'Q^T;\--+\%+?\#4$L#!!0    ( ""(?U9>X#\F/ ,  .\*   8
M    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK9;?;Z-&$,?_E14]58F4AE^V
M<5(;Z>+HU#Y4LLZ]]J'JPP;&9I5EE]M=[+O^]9U="(4$QTY4/Q@69K[SF6$6
M9G&0ZE$7 (9\*[G02Z\PIKKU?9T54%)]+2L0>&<K54D-+M7.UY4"FCNGDOM1
M$,S\DC+AI0MW;:W2A:P-9P+6BNBZ+*GZ?@=<'I9>Z#U=^,QVA;$7_'11T1UL
MP'RIU@I7?J>2LQ*$9E(0!=NE]S&\787.P5G\P>"@>^?$IO(@Y:-=_)HOO< 2
M 8?,6 F*ASVL@'.KA!Q?6U&OBVD=^^=/ZI]<\IC, ]6PDOQ/EIMBZ<T]DL.6
MUMQ\EH=?H$UH:O4RR;7[)X?&-@D\DM7:R+)U1H*2B>9(O[6%Z#F$DR,.4>L0
MG>L0MPZQ2[0A<VG=4T/3A9('HJPUJMD35QOGC=DP81_CQBB\R]#/I"LIM.0L
MIP9R<D<Y%1F0C973Y&)-%0A3@&$9Y?J2_$2^;.[)Q8=+\H$P07XO9*VIR/7"
M-XAB!?VL#7O7A(V.A+V'[)K$X16)@B@:<5^=[QX.W7TL0%>%J*M"Y/3B(WH;
M@_EC<QHBM^03$U@%1CE92\U<L_WU\4$;A2WW]UBJC?9D7-ONPUM=T0R6'FXT
M#6H/7OKC#^$L^'DL\?]);%"&N"M#_)IZNE;X>E#F.\&'2N!KS2I;DRLBP!6&
M9EE=UMRU2@X8'XODRG.!S7 O.:=*7XX5J(DZ<U'M>V6?3N;)PM_W\WYI$\?3
MSF:0SJ1+9W(B'=B"4DB+VRA[)!559$]Y#7U@@AD376"GCZ(W$9(>5G =!.$S
M^%-6 _QIAS]]"_Y50ZD)K4TA%?L'\C'@1G/:0YD&S>\9\QF& ^Q9ASU[%S;3
MNAY'GKT@><[ZFL4 ,ND@DW=!XH=.&^Q^)G9CI,E)TM<L!J3SCG3^*NE*EB5N
ML?=W\/RL#CYE-6"_Z=AOSF8_LWUO7M0O#(+Q!C[+=, =!O]]%8.WDQ_OX%:M
MSQ)-9\ED'L7/H,<LHW 2WR23(\R]+WGX=N83#=U*G@,^8CD.[O>F$3L*_D;5
MC@E-.&S1-;A.4$,UTU6S,+)R \J#-#CNN-,")U)0U@#O;Z4T3PL[\W0S;OHO
M4$L#!!0    ( ""(?U8,\\/I'00  #@/   8    >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&ULK5=MCYLX$/XK%E>=6JE=,!!(]I)(W>SUKE)?5IOV^MD+DX *
M.&>;9._?W]@0\F:XE2Y? B;SC)_'8\]XICLN?LH,0)'GLJCDS,F4VMRZKDPR
M*)F\X1NH\)\5%R53.!1K5VX$L-2 RL+U/2]R2Y97SGQJOCV(^937JL@K>!!$
MUF7)Q#]W4/#=S*'._L-COLZ4_N#.IQNVAB6H[YL'@2.W\Y+F)50RYQ41L)HY
M[^GM@L8:8"S^RF$GC]Z)EO+$^4\]^)C.'$\S@@(2I5TP?&QA 46A/2&/OUNG
M3C>G!AZ_[[U_,.)1S!.3L.#%CSQ5V<P9.R2%%:L+]<AW?T(K:*3]);R0YI?L
M&MMXY)"DEHJ7+1@9E'G5/-ESNQ!' !KU /P6X)\#PAY T ("([1A9F3=,\7F
M4\%W1&AK]*9?S-H8-*K)*QW&I1+X;XXX-5_P2O(B3YF"E"P5/C!&2A*^(E\W
M()A>:TG>D>_+>_+ZU1ORBN05^9;Q6K(JE5-7(0?MR4W:^>Z:^?R>^:A//O-*
M99+\7J60GCIPD7RGP-\KN/,'/=Y#<D,"^I;XGN];""U>#J<#=()N00/C+^CQ
M]PA;J&JPK4P##.U ?5YOY88E,'/P0$H06W#FO_Y"(^\WFZHK.3O1&'8:PR'O
M0QH'@79:Q";O__LY43;JE(T&E7U5&0@RH*^!CPQ<I\CMG'J!-W6WQ^0M1C0,
M.Z,39E''+!ID]HTK5F#B[&46O829Q:B76=PQBP=W?)LGJC6!9ZPN$N2MC5]\
MS=U_)6<G>L>=WO%_['X)3"09P0R(%6.+I7"CD^9;4F'9Q<0I("^?:B&;5&I;
MB_%%&/R !J.S8%U:T;$74'NT)AW[R2#[/Z#"<!6&/$NQHN12Z?!MK9MJ8MDO
MD\GDC.BEU=B+8SM/ZATJD_>"'<\O=I>UZ'@7%((1#<(SHA8S/Z+>N(?J41&E
M@U0_<2G)2O!R3Q>+II4FO9C_71!2[X*GQ<X/)U'/2:7^@:@_?%9-?LNKA)=@
M/:4M_DK']%K>3M4>2C$=K(+SCY4"]*M:P7B-P1-J51U8DN<X/H^*Q6KB]83D
M4$OI<#%MM_E18*P,PQ<QM%CU,CS41#I<%+]@6BMPAUMY-=#H9$<''KU@9K'S
MPSCNV]&'LDB'Z^*>',&#1W#U2NP-9,:$CC;>[_.D2=-Y4>L;[FN\O=[SHF"B
M 1C+-U9AS;3C8\+T)KC0U9A-3LW\'E6'DDH'*]C\AVD_D##;8CY9PXDRO)W7
M2BK4I=-BG\RE,;5KBR_38$A#.@K/2Y#-TAM%XR .SB2Z1SU("6)M6C.)O.M*
M-9?Y[FO7_KTW3<_9]SO=%IK>YN"FZ2D_,['.L1LI8(4NO1O=A(FF36L&BF],
MI_/$%?9-YC7#UA:$-L#_5YRK_4!/T#7+\W\!4$L#!!0    ( ""(?U;R24S8
MJ (  *<&   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK55-;]LP#/TK
M@CL4&[#&WVG0.@::=$-[Z!:TV'H8=E!LQA8J6YZD)-V_'R4[;A(DP0;L8DDT
MWR,?+=+)6L@750)H\EKQ6HV=4NOFRG555D)%U4 T4..;A9 5U7B4A:L:"32W
MH(J[@><-W8JRVDD3:YO)-!%+S5D-,TG4LJJH_#T!+M9CQW<VAD=6E-H8W#1I
M: %/H+\U,XDGMV?)606U8J(F$A9CY\:_FL;&WSI\9[!66WMBE,R%>#&'^WSL
M>"8AX)!IPT!Q6<$4.#=$F,:OCM/I0QK@]G[#_MEJ1RUSJF J^#/+=3EV1@[)
M84&77#^*]1UT>FR"F>#*/LFZ]1VB<[946E0=&#.H6-VN]+6KPQ; 'QX!!!T@
MV =$1P!A!PBMT#8S*^N6:IHF4JR)--[(9C:V-A:-:EAMON*3EOB6(4ZG4U$K
MP5E.->3D2>."GT@K(A;D:P.2FEHK\GY&)9I+T"RC7'T@%^0=<8DJT:P25V,B
MAL[-NJ"3-FAP)*@?D >!=(I\JG/(=PE<5-#+"#8R)L%)QEO(!B3T/Y+ "X(#
M"4W_'NZ?2"?LJQI:OO (WWV=B0K>ZDE^W,R5EGAG?QZJ5DL6'28S?7RE&IK!
MV,%&52!7X*3G9_[0NSZD]#^1[>B.>MW1*?;T"XX=+I0B>'4(EJ#"1K67A)R?
MC0+?OS8MQS)"ZYSDC"_U_L=OZ]$&&=D@9@RMT@M_$%XF[FI;Z$&OH'?:$1#W
M N*3 IYMVV,KT!5>_@)V1&!7++72F#RKBW]3U$:-MW(-(C_RXRC>$W7 T8N'
MH_ RW!/F;O5\!;*PHU!AOLM:MWW36_MI>V.'S)Y]@E.X'9IO-.T(?Z"R8-C]
M'!9(Z0TN,2W9CL7VH$5C)\M<:)Q3=EOBGP2D<<#W"R'TYF "]/^F] ]02P,$
M%     @ ((A_5N4=U"3[!   QQL  !@   !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6RU65USFS@4_2L:VNFT,W5 XCNU/=/8=#8/NY-IVMUG!62;"2 7R7'Z
M[U?"!!N0Y9!E7V(^[CVZ.O=*NB=,][1\9!M".'C.LX+-C WGVVO39/&&Y)A=
MT2TIQ)L5+7/,Q6VY-MFV)#BIG/+,1);EF3E."V,^K9[=E?,IW?$L+<A="=@N
MSW'Y^X9D=#\SH/'RX'NZWG#YP)Q/MWA-[@G_N;TKQ9W9H"1I3@J6T@*49#4S
MOL+K"(;2H;+X.R5[=G(-Y%0>*'V4-[?)S+!D1"0C,9<06/P\D07),HDDXOA5
M@QK-F-+Q]/H%_5LU>3&9!\S(@F;_I G?S(S   E9X5W&O]/]'Z2>D"OQ8IJQ
MZB_8U[:6 >(=XS2OG44$>5H<?O%S3<2) [3/.*#: 74<D'_&P:X=[*[#N9"<
MVL%Y;4AN[5!-W3S,O2)NB3F>3TNZ!Z6T%FCRHF*_\A9\I84LE'M>BK>I\./S
M!2T8S=($<Y* >RY^1!5P0%=@L<'%FC"0%N(YC1\W-$M(R3Z\"Q#TOX#HUR[E
MO\$$_+Q?@H_O/X'WTO+'ANX8+A(V-;F(3HYAQG4D-X=(T-E(\IS68RF\%WKO
MKTF2RLK#&;C#:3*Y+< ";U..,P76\@)6'._R7591LB2K-$ZY B32@_R@O;%-
MD9LF0:A)$*IPG#,X-SC#14P YB*6^ K8\#- %K)4!!^0O I)[A!/<QA,S:=3
M%OLF*$3(=]MFR[[9!-E6Z#MMNZAOYT$;AHU5:\IV,V7[55/^*$MO@TO"/KUJ
M^@=4]W3ZOFNC(+0[)&B'EUOS-=OBF,P,L?<R4CX18_[A'?2L+ZI:&A,L&@FL
M1;O3T.YH::]6WD3NN@F(:2Z.(H;EDE)1K452QPE4B]KII\P+.T6V'&FPZ,)@
M+=+<AC3W3:2=%J^*0+<7"X*VY74*53OVT$(=$RP:":S%N==P[NDYQQF1)U1\
M.#&83,%G4)#JV**K%2G38BW>,JX\AKS>GM4IN(772X[MHK"3G*4VR %EJ1K-
MMBQU7?H-1_Y8'%TJ5;\7G^,&0= ],Q;:@(86ZYA@T4A@K40$32(";2)N&=M5
MIUDG&6!5TAR09U+&*:O>'A[3K=P^E(6K'6C IAOT$MHM[9%&BG0CM=@,&S;#
M_X/-2R4>]N(,3Q;@@35M8$/+>TRP:"2P5D*@=100EC8E?XD]):-,W?%K70>4
M[%A RQKH--43Y/B]QO:R79NN$[T%W]+/0R5]L-^MHTY9UC:MXT.T]#[L+&F%
MW02YKN\$W9GW#7W;==PS$S_J&/@Z(:/IZM4DH'ZKA*!C]\3(0A_ T"4Z*EHT
M%EJ;_*.B@GI)-:2WUT,-6;1]08;\L"LUQQHNNC1<F[JC*H)ODT67SA2HD!NA
M9X?=HGV#NM$4[9AHT5AH;>:/T@I>T%;_K<^OT76-/E3(,!NZ70&JCW-(B:K'
M"\[4Z%$0P=$4T<6R5<D1"!'L]D/ZD 87[IAHT5AH[70<M1?4BR]M2_0&,:+>
M74<"6L*^P)O8M@7];F-PT:Y-UU$A0;U$.M,2(25]0;\EZO[71&%CNRY"5G=9
M]^TF2 A;S^W.O&_H>4X STS\*&:@7LV\HB52D]#7*\CU1"N'NO_IU <P>)&.
M*EO&0CN0;YY\ Y&?N/[$Y3H5RB\C*P%O7?F"K?+PU>APP^FV^BSR0#FG>76Y
M(3@AI300[U>4\I<;^:6E^78W_Q=02P,$%     @ ((A_5@91(1^*!@  D!P
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M0P%%\?FK.%%\;[X@W7&E>&H.=XQ&3&@#^'W#N3J>Z!M4'R%7_P-02P,$%
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MO84F8'QFP7_IA12T/_V=_P]02P,$%     @ ((A_5LL<M8^3 @  808  !@
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M<FMS:&5E=',O<VAE970Q,"YX;6R555EOVS ,?O>O(+QB:(&N/G,L2P(T;7<
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MVI_V2MR;K)#Y$TCJE05WE(OT5DB$@K4RWRG$EA?:"2E2VB0DWO)8%10N(TC
M5+U5<@CM5*ZL3%,2B:R0.('!PU[YO;("/QW!L<D?U),3WO!4#0;/D:50H0FL
M\1:<IP4E$!C $UO]J!(AG4-*0M;!2*&L-@G->B0$@!3J,=[32;P 4IQ.@"P
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MZH15V[2^ +/1VT8YF!+-#3=;5,*0(X":_@5($>=YI]!%A'9;0QO^,DA]0MM
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MT0:\GTAIZ@<2T/P?#6?_!5!+ P04    "  @B']6!MS-X,4&  !N$   &0
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M-K@I =4B8X!15TI=.6S*6R(R5QQ+*;"F%!6- DB5CDC+195W(>^J/3Z=!:M
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MM8R9,O1O D\-?V8"I&UKBXZMYIF%W)]OBV*GG^U1''));*D:@R[,$<%*0+4
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M7KQK"]$@?&1/J&#\D:UJ5)<S7Q.TV> 7>YC; 2;Z 4P8P0?1ZDK!KVV)Y;<
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M33W,#BOZ:$!I-M#[M1#Z>6(<'#Y#%E\!4$L#!!0    ( ""(?U8F$O!WRP(
M ,<'   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*U574_;,!3]*U9
M""0@'VU#"VVDT@YM#].J=FS/;G+36#AVL)V6_?O93LC2$CHT[<7QQSW'Y]Q<
MV^,=%T\R U#H):=,3IQ,J>+6=66<08[E-2^ Z964BQPK/10;5Q8"<&)!.74#
MSPO='!/F1&,[MQ#1F)>*$@8+@629YUC\N@?*=Q/'=UXGEF23*3/A1N,";V %
MZK%8"#UR&Y:$Y, DX0P)2"?.U+^=A2;>!OP@L).M/C).UIP_F<&79.)X1A!0
MB)5AP/JSA1E0:HBTC.>:TVFV-,!V_Y7]P7K77M98PHS3GR11V<09.BB!%)=4
M+?GN,]1^!H8OYE3:%NWJ6,]!<2D5SVNP5I 35GWQ2YV'%L#OOP,(:D#P44"O
M!O2LT4J9M37'"D=CP7=(F&C-9CHV-Q:MW1!F_N)*";U*-$Y%<Y"Q((5-*4_1
M?2EU@)0(LP2MJC]KYE=DPTA*8LP4FL8Q+YDB;(,6G)*8@$3G<U"84'F!KM!*
M5UI24C"X&,OLTK8(GDNRQ128JM@%2"5(K""IUJ_0XVJ.SD\OT"DB#'W/>"EU
MG!R[2OLT:MVX]G1?>0K>]11?HYY_B0(O"#K@LX_#_7VXJ[/;I#AH4AQ8OMX[
M?$T^OJ5H9IS:YE,K'5.=CN6?=-CUZ5J/=9%WV:_VZW?O9\[]K2QP#!-''VP)
M8@M.=';BA]Y=5S+^$]E>:GI-:GK'V"/KU!3#885TN:ZH0DME+J=MY'O#D>^-
MW6W;S]NPFYMA,&JB]H3V&Z']HT*7!\5Z=C(,?/].GU AM-XNN17AH*6C-PH/
MM';%!-U*!XW2P3\II9QMKA2(O$OKX*T.+SC0>G3;[CI!1THD;/R$?RV1C]T@
M7<;"CIH9A=[PP-O;,%TRYO#O_0FW=<V:)^XK%AO")**0:IQW?:-3)*IGHQHH
M7MB;=\V5OL=M-],O+0@3H-=3SM7KP%SFS=L=_0902P,$%     @ ((A_5B7N
MN1MX P  > X  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULS5?!;N,V
M$/T50@46+="-+,F6D]06$#LI=H$&->+=[F'1 R.-;2(4J9)4G/Y]AY0L6[8C
M- L=<HE%:M[3F\<),3/92O6D-P"&O.1<Z*FW,::X]GV=;B"G^D(6(/#-2JJ<
M&ERJM:\+!31SH)S[X6 0^SEEPDLF;F^ADHDL#6<"%HKH,L^I^G<&7&ZG7N#M
M-A[8>F/LAI],"KJ&)9BOQ4+ARF]8,I:#T$P*HF U]6Z"ZWD068"+^(O!5A\\
M$YO*HY1/=O$YFWH#JP@XI,924/QYACEP;IE0QS\UJ==\TP(/GW?LO[OD,9E'
MJF$N^3>6F<W4N_1(!BM:<O,@MY^@3FAD^5+)M?M+MG7LP"-IJ8W,:S JR)FH
M?NE+;<0!((A? 80U(#P&#%\!1#7 .>=7REQ:M]309*+DEB@;C6SVP7GCT)@-
M$_88ET;A6X8XD]R"3A4KG*5R16:EQ@"M"149659':_>7;"W8BJ54&'*3IK(4
MAHDU64C.4@::_'P+AC*N?R$?R1)++2LY6%S&>&D@(P(+DDOD+0!K:$,5X!<,
M^^C>XSDBS.WJB6\P*ZO-3^L,9E4&X2L9!"&YE\)L-+D3&61M A_M:#P)=Y[,
MPD[&6T@O2!3\2L)!&)X1-/__\*!#3M0<4>3XHE?X;M"HQJ<EI*5BQGI^]Y+R
M$C,F*R5S,I=Y41JZ.\@[J@2>D"8+-'SI#/_^!Q*3SP9R_?<YFRL5P_,J['5R
MK0N:PM3#^T*#>@8O^?!3$ ]^.V=13V0MPX:-8<,N]N2+-)2?R[""C1S,WF_/
MR2B(AQ/_^5#Y:5 T'.^#6HI&C:)1IZ(_W3^8)M_O(7\$==;^3H:WVM\362O9
MN$DV?A?U&O=I6$]D+</&C6'C'ZO7\6DI1E?Q4;V>!@51')ZOU\M&T66GH@?0
M1K'4WMQ+(],G\E4PTUV^G81O/8V>R%JY7S6Y7[V+\KWJT[">R%J&!8-]#S'X
ML0*N<:T*#D='!=Q-?EX\Z=)]T/L$G;J_4:6P#>DN[&Z.MQY47VSMC,-]QN&[
M*.Y:1E^F]<36-FW??P6=W4I'>4>G=^]P&!W7]VE4& 3'-[1_T,/GH-9NM-'$
MM=I5Z]KL-N/3C1L:CO9G=JQRL\&>IIK)[JE:,^Q".*R0<G Q1DFJ&G.JA9&%
MFQ0>I<&YPSUN<#0$90/P_4I*LUO8#S3#9O(?4$L#!!0    ( ""(?U813M=Z
MG (  (8'   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*V576^;,!2&
M_XK%JJF5UO)-HHX@I<FF[F)JU+3;M0.'8-5@9IND^_>S#6%I0JI(VPW8^+PO
MSSD<['C+^(LH "1Z+6DE)E8A97UKVR(MH,3BAM50J96<\1)+->5K6]0<<&9$
M);4]QXGL$I/*2F+S;,&3F#62D@H6'(FF+#'_?0>4;2>6:^T>/))U(?4#.XEK
MO(8ER.=ZP=7,[ETR4D(E"*L0AWQB3=W;6:3C3< / ENQ-T8ZDQ5C+WKR+9M8
MC@8""JG4#EC=-C #2K61POC5>5K]*[5P?[QS_VIR5[FLL( 9HS]))HN)-;90
M!CENJ'QDVWOH\@FU7\JH,%>T[6(="Z6-D*SLQ(J@)%5[QZ]='?8$;G!"X'4"
M[UR!WPE\DVA+9M*:8XF3F+,MXCI:N>F!J8U1JVQ(I;_B4G*U2I1.)@L.-289
M^O*J^D* 0+C*T(,L@*-9PSE4$DV% "G0Y1PD)E1<H6NT5,V4-100RU'=.<"^
M S,.:>> 6X=K]+R<H\N+*W2!2(6>"M8(%2QB6ZI,-(^==M1W+;5W@GH.Z0WR
MW4_(<SQO0#X[7^Z^E=NJ?GT1O;Z(GO'S3_CUY7C(T5%!IZ<*.ET)R54;#Z7?
MOB\8?I_^LV]%C5.86*KZ O@&K.3C!S=R/@\5XS^9O2F-WY?&?\^][R]2B8;C
M*H6A;%N+R%CH;6>31.,@MC?[21S'C$=_8]ZP!3U;<!9;JA9(BBF2G*CKKI&'
M2%O#<)]B/#H@/8X) W^8-.Q)PW=)V_XY^T\;(@^/J*+P 'P@Q!WFCGKNZ%WN
M)R950?^).SKZ[F[D1P?D T'!:'S ;N_MDOJ$^H[Y6K4EHI KF7,S4IGS=M=O
M)Y+59N-<,:FV83,LU$$)7 >H]9PQN9OHO;@_>I,_4$L#!!0    ( ""(?U:#
MC^9!P ,  *<2   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;+5876^;
M2!3]*R-:5:V4! ;\F;61&B=5*S5:J]GL/E3[,(:+/2HP=&:($VE__,X QI#@
M<=*2%YN/>P[G'NYEKF:V9?R'V !(=)_$J9A;&RFS<]L6P082(LY8!JFZ$S&>
M$*E.^=H6&0<2%J DMEW'&=D)H:GESXIK2^[/6"YCFL*2(Y$G">$/%Q"S[=S"
MUN["-[K>2'W!]F<96<,-R-MLR=697;.$-(%44)8B#M'<^HC/%WBB 47$WQ2V
MHG&,="HKQG[HDR_AW'*T(H@AD)J"J+\[6$ <:R:EXV=%:M7/U,#F\8[]4Y&\
M2F9%!"Q8_ \-Y69N32P40D3R6'YCV\]0)334? &+1?&+ME6L8Z$@%Y(E%5@I
M2&A:_I/[RH@& (\. -P*X#X&# X O K@%8F6RHJT+HDD_HRS+>(Z6K'I@\*;
M JVRH:E^C3>2J[M4X:2_Y*HBN'Q ) W1U<^<9NH=2?3^$B2AL?B 3M&-*ITP
MCP&Q"&7-<*C#3]'MS25Z__8#>HMHBO[:L%RH"#&SI=*HGV0'E9Z+4H][0 ]V
MT35+Y4:@JS2$L$U@J^3J#-U=AA>ND?$2@C/DX1/D.J[;(6CQ?#@VR/%JP[V"
MSSMB^ E:QD19U_;]^U<5CKY(2,2_7>:5W(-N;MWRYR(C <PMU=,"^!U8_KLW
M>.3\T95X3V0M&P:U#0,3N_\5A#A731SD21X3":'J/?68@!+=W5VIEWRC@D]_
MG.[\T\%D/+/OFBEU!'G>L YJ21W64H=&J<O.FC]!*<@NG<,G$D;.X)',,F;8
MB/$&3K?*4:UR9#:4K)IU= W)"GAG#1EY7EI#/9&U4A[7*8]?L97&?=K0$UG+
MADEMP\3XYF\%1'F,8K4<=GYPS>@A>@#"NX +(_ 7DYK624V-LOZ,(AI 8XG1
M+S?*>4IESJ$KS>F3OAN/1X_Z;OJD[P:-F)90[.Q74.<Y4J]:4C_MI!I;T<S\
MTB+LBZWM0V.2P*_8CA5Y7U;TQ-:VPMU;X?9<O15ALWP]/'Q4OAU!>#H]4+_[
M@00;%_KGUB_Z#UW3E"9Y8B[I7D>4OMC:UNR'%#QXS9(VCD OMJ(GMK85^R$(
MFZ>@8ZO,$;AW>)DQ(W\UL?W<A,V#TPO*G]P?+_]>IZN^V-K6[.<K_)H#%NYU
MPNJ+K6W%?L;"OS=D'8&/#>7?ZYAE-[8"$N#K8H=$H(#EJ2QW!>JK]2[,QV+O
MP=Z'EULXUX2O:2I0#)&".F=CU:>\W!4I3R3+BHV%%9.2)<7A!D@(7 >H^Q%C
M<G>B'U#O3?G_ U!+ P04    "  @B']6<-U@5PL#   N"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6RU5EU/VS 4_2M6AB8F;>2CG[ V$E"V(0VI
MHK ]H#V8Y+:Q2.Q@.RW\^UT[:6B[4 TIO+2V<^_).=?'\1VMA'Q0"8 F3UG*
MU=A)M,Y/7%=%"614'8D<.#Z9"YE1C5.Y<%4N@<8V*4O=P//Z;D89=\*179O*
M<"0*G3(.4TE4D654/I]!*E9CQW?6"]=LD6BSX(:CG"Y@!OHVGTJ<N35*S#+@
MB@E.),S'SJE_<NY[)L%&_&*P4AMC8J3<"_%@)I?QV/$,(T@AT@:"XM\2SB%-
M#1+R>*Q G?J=)G%SO$;_9L6CF'NJX%RDOUFLD[$S=$@,<UJD^EJL?D EJ&?P
M(I$J^TM65:SGD*A06F15,C+(&"__Z5-5B(T$O_]*0E E!+L)W5<2.E5"QPHM
MF5E9$ZII.))B1:2)1C0SL+6QV:B&<;.-,RWQ*<,\'4XE.D+J9T)Y3"X>"Y;C
M'FER. %-6:H^D2]DAM:)BQ2(F&.!T"P1HW8+X G-I !#;F<3<GCPB1P0QLE-
M(@J%<&KD:F1HWN-&%9NSDDWP"AL_(%>"ZT21"QY#O W@HK1:7[#6=Q;L19Q
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MQ8S,HT\D#N/X+3Q ZY/_>/(?>[[Y!;ZGZP:7YQP.C,EY1G<+EJ9E!604V]R
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ME3XL81LR.U&\*%N4.5>ZX2F'F>YA09@ _7S!N=I-3(*Z*X[^ %!+ P04
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MQE$T58DR%6![X/81F@N T@(HC4)I(93&H#2.HJD:E!D#VYPQ&-L^0C,$4%H
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M%S2] *517[-7L79:>>AK]AGPM7M?0VO(4315.3(MX)O3 K^*<H1NH!D *"V
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MV3G.P&LT='O0CH!WH \JZ(,/$^=[B Q:U?4;+ 8'Q+M# ]KU_FS_<F$>IG<
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MJ.T\2(+]Q0>^+JV[B!:SFJWQ%NW'^D;3*>I0<EZA-%Q)T%C,@XOD_&KJY+W
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M.!S3_-/MUM0>K*K]XK%2EM88_UC2HHG:"=#[0BF[/S@#W>JZ^!=02P,$%
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MK$%6SJ'E0M"L&.6V5,C!L+@,Y>P.3!G(YSM*Q>M"O:#^;\#B7U!+ P04
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  @B']68I;?-ZH#  !F'0  #P
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M]SOUCNE:A?CL>:SQ^>^D.MWN#<_'WY>/DYVW]XZS@W]1BU]02P,$%     @
M((A_5B[2^,"N 0  RAH  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9G-;L(P
M$(1?!>6*B+&=TA\!E[;7ED-?P$TV)"*)+=M0>/LZX4=J1:,B*G4NL1+OSHR]
MTG?)]&UGR VV==6X651X;QX8<VE!M7*Q-M2$G5S;6OGP:I?,J'2EEL3$>#QA
MJ6X\-7[D6XUH/GVB7*TK/WC>AL^NU,TLLE2Y:/"X+VR]9I$RIBI3Y<,^VS39
M-Y?1P2$.G5V-*TKCAJ$@8F<=VIV?#0Y]KQNRMLQHL%#6OZ@Z5+%MQ9S?5>3B
M?HDS&76>EREE.EW7H25VQI+*7$'DZRK>BP[[G7VX8=H_^=7^G4R?8:A<6&U<
MF)BER^V.(VF[1R8(D?5E_Q%/CD'ZZO-1.^V,LE]ZA^O]T';5S<.Q;KG^CK_.
M^*1_80X!DD."Y$A <MR Y)B Y+@%R7$'DN,>) <?HP1!(2I'02I'82I'@2I'
MH2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M (:M (:M$
M(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"ED3%+(F_TG6
M=ZU7?_UWI5WC6I7-T9]UO[#FGU!+ 0(4 Q0    ( ""(?U8'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ ((A_5E9I34[M    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ ((A_5IE<G",0!@  G"<  !,
M     ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  @B']6
MLI5N?V\'  "\,   &               @($,"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ ((A_5NB%I)#W!0  %QH  !@
M     ("!L0\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M ""(?U9>X#\F/ ,  .\*   8              " @=X5  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  @B']6#//#Z1T$   X#P  &
M            @(%0&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ ((A_5O))3-BH @  IP8  !@              ("!HQT  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ""(?U;E'=0D^P0  ,<;
M   8              " @8$@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  @B']6!E$A'XH&  "0'   &               @(&R)0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ((A_5G-)G1'U
M"@  !AP  !@              ("!<BP  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( ""(?U;+'+6/DP(  &$&   8              "
M@9TW  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  @B']6
M7]TKL_\"   5!P  &0              @(%F.@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( ""(?U;';4*UF @  /<6   9
M      " @9P]  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ ((A_5F>YS9YT!P  9!$  !D              ("!:T8  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  @B']6\X=@LV0#  !J!P
M&0              @($63@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( ""(?U:BRKD;G@H  -T@   9              " @;%1  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ((A_5@;<S>#%
M!@  ;A   !D              ("!AEP  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  @B']6"1H!96,"  !#!0  &0
M@(&"8P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ""(
M?U;G.:#))PP  %$F   9              " @1QF  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ ((A_5G:=817^ @  , <  !D
M         ("!>G(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  @B']6FC0<Y'H"  #?!0  &0              @(&O=0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ""(?U9,YW>3Z0(  /4&
M   9              " @6!X  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ ((A_5H,F)E(9!   HPL  !D              ("!@'L
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  @B']6_N,Y
MV94#  "_"0  &0              @('0?P  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( ""(?U97M*VMS ,  )((   9
M  " @9R#  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M((A_5B82\'?+ @  QP<  !D              ("!GX<  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  @B']6)>ZY&W@#  !X#@  &0
M            @(&AB@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( ""(?U813M=ZG (  (8'   9              " @5".  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ((A_5H./YD'  P
MIQ(  !D              ("!(Y$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  @B']6<-U@5PL#   N"P  &0              @($:
ME0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ""(?U9X
MO,V^.0(  "$%   9              " @5R8  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ ((A_5MFD)VC> @  Q0<  !D
M     ("!S)H  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M"  @B']6_2(]-PT#   2"@  &0              @('AG0  >&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ""(?U8W)H)^$P(  -T$   9
M              " @26A  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!
M A0#%     @ ((A_5B]]T,(/ @  G 0  !D              ("!;Z,  'AL
M+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  @B']6]Q\8_3L#
M   <#@  &0              @(&UI0  >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;%!+ 0(4 Q0    ( ""(?U8[V7.P"P,  "$+   9              "
M@2>I  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ((A_
M5E=JC_A^ @  K04  !D              ("!::P  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  @B']6 %'U&,(,  !VF@  &0
M        @($>KP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( ""(?U;3GQU)G00  *04   9              " @1>\  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ((A_5JSN/48! P  ) H
M !D              ("!Z\   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  @B']6"]%1)X@$  "J%   &0              @($CQ
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ""(?U9]K'Z&
MJ0,  ,8*   9              " @>+(  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ ((A_5NFFF&<B P  < D  !D
M ("!PLP  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  @
MB']6494?#"L$   9$   &0              @($;T   >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ""(?U9XH[(T.P(  !,%   9
M          " @7W4  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ ((A_5@MVC6A  P  )A0   T              ( ![]8  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  @B']6EXJ[',     3 @  "P
M    @ %:V@  7W)E;',O+G)E;'-02P$"% ,4    "  @B']68I;?-ZH#  !F
M'0  #P              @ %#VP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ ((A_5D<<8+FD 0  FQH  !H              ( !&M\  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ((A_5B[2^,"N 0  RAH
M !,              ( !]N   %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ #0 -  C#@  U>(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>76</ContextCount>
  <ElementCount>283</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>21</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statement of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PropertyandEquipment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Leases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Equity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Property and Equipment (Details) - Schedule of depreciation expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of depreciation expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Leases (Details) - Schedule of components of lease expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable</Role>
      <ShortName>Leases (Details) - Schedule of components of lease expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average remaining lease terms</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average discount rates</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenueDetails</Role>
      <ShortName>Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/OtherRevenue</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Equity  (Details) - Schedule of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable</Role>
      <ShortName>Equity  (Details) - Schedule of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Equity  (Details) - Schedule of restricted stock units</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable</Role>
      <ShortName>Equity  (Details) - Schedule of restricted stock units</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Equity  (Details) - Schedule of warrant activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable</Role>
      <ShortName>Equity  (Details) - Schedule of warrant activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Income Taxes (Details) - Schedule of difference between income tax provision and U.S federal statutory rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of difference between income tax provision and U.S federal statutory rates</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2022_actiniumph.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/SubsequentEvent</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_actiniumph.htm 7529, 7531</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f10k2022_actiniumph.htm 11303, 11304, 11305, 11306</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="f10k2022_actiniumph.htm">f10k2022_actiniumph.htm</File>
    <File>atnm-20221231.xsd</File>
    <File>atnm-20221231_cal.xml</File>
    <File>atnm-20221231_def.xml</File>
    <File>atnm-20221231_lab.xml</File>
    <File>atnm-20221231_pre.xml</File>
    <File>f10k2022ex23-1_actinium.htm</File>
    <File>f10k2022ex31-1_actinium.htm</File>
    <File>f10k2022ex31-2_actinium.htm</File>
    <File>f10k2022ex32-1_actinium.htm</File>
    <File>f10k2022ex32-2_actinium.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="424">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2022_actiniumph.htm": {
   "axisCustom": 2,
   "axisStandard": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 424,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 76,
   "dts": {
    "calculationLink": {
     "local": [
      "atnm-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2022_actiniumph.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atnm-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 385,
   "entityCount": 1,
   "hidden": {
    "http://actiniumpharmaceuticals.com/20221231": 6,
    "http://fasb.org/us-gaap/2022": 60,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 69
   },
   "keyCustom": 45,
   "keyStandard": 238,
   "memberCustom": 5,
   "memberStandard": 13,
   "nsprefix": "atnm",
   "nsuri": "http://actiniumpharmaceuticals.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://actiniumpharmaceuticals.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:LeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://actiniumpharmaceuticals.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:LeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Other Revenue",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenue",
     "shortName": "Other Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://actiniumpharmaceuticals.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://actiniumpharmaceuticals.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://actiniumpharmaceuticals.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://actiniumpharmaceuticals.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://actiniumpharmaceuticals.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "menuCat": "Details",
     "order": "24",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "menuCat": "Details",
     "order": "25",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "menuCat": "Details",
     "order": "26",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable",
     "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment",
     "menuCat": "Details",
     "order": "27",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable",
     "shortName": "Property and Equipment (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Property and Equipment (Details) - Schedule of depreciation expense",
     "menuCat": "Details",
     "order": "28",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable",
     "shortName": "Property and Equipment (Details) - Schedule of depreciation expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Leases (Details) - Schedule of components of lease expense",
     "menuCat": "Details",
     "order": "30",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
     "shortName": "Leases (Details) - Schedule of components of lease expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "menuCat": "Details",
     "order": "31",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable",
     "shortName": "Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms",
     "menuCat": "Details",
     "order": "32",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable",
     "shortName": "Leases (Details) - Schedule of weighted average remaining lease terms",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Leases (Details) - Schedule of weighted average discount rates",
     "menuCat": "Details",
     "order": "33",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable",
     "shortName": "Leases (Details) - Schedule of weighted average discount rates",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c39",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "menuCat": "Details",
     "order": "34",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c39",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RecognitionOfDeferredRevenue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Other Revenue (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails",
     "shortName": "Other Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RecognitionOfDeferredRevenue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c42",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c42",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://actiniumpharmaceuticals.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Equity  (Details) - Schedule of stock option activity",
     "menuCat": "Details",
     "order": "38",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
     "shortName": "Equity  (Details) - Schedule of stock option activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "atnm:RSUsOutstandingEndingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Equity  (Details) - Schedule of restricted stock units",
     "menuCat": "Details",
     "order": "39",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable",
     "shortName": "Equity  (Details) - Schedule of restricted stock units",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c70",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "atnm:RSUsOutstandingEndingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c73",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Equity  (Details) - Schedule of warrant activities",
     "menuCat": "Details",
     "order": "40",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
     "shortName": "Equity  (Details) - Schedule of warrant activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c71",
      "decimals": "0",
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:DeferredTaxAssetsValuationAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:DeferredTaxAssetsValuationAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "42",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Income Taxes (Details) - Schedule of difference between income tax provision and U.S federal statutory rates",
     "menuCat": "Details",
     "order": "43",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable",
     "shortName": "Income Taxes (Details) - Schedule of difference between income tax provision and U.S federal statutory rates",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DividendsCommonStockStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Subsequent Event (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DividendsCommonStockStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Operations (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Consolidated Statements of Operations (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statement of Changes in Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statement of Changes in Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_actiniumph.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 21,
   "tag": {
    "atnm_Accountingstandardsrecentlyissuedpolicytextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Recently Issued.",
        "label": "Accountingstandardsrecentlyissuedpolicytextblock",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "Accountingstandardsrecentlyissuedpolicytextblock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_AcquisitionOfEquipmentFinancedBySecurityDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Acquisition Of Equipment Financed By Security Deposit",
        "terseLabel": "Equipment obtained in exchange for security deposit"
       }
      }
     },
     "localname": "AcquisitionOfEquipmentFinancedBySecurityDeposit",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_AggregateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of aggregate fair value.",
        "label": "Aggregate Fair Value",
        "terseLabel": "Aggregate fair value (in Dollars)"
       }
      }
     },
     "localname": "AggregateFairValue",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement Axis",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital On Demand Sales Agreement Member",
        "terseLabel": "Capital on Demand Sales Agreement [Member]"
       }
      }
     },
     "localname": "CapitalOnDemandSalesAgreementMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Right",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "atnm_ClassOfWarrantsSharesExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents class of warrants shares expired.",
        "label": "Class Of Warrants Shares Expired",
        "terseLabel": "Warrants expired"
       }
      }
     },
     "localname": "ClassOfWarrantsSharesExpired",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_CompensationExpenseRelatedToRSUs": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation expense related to RSUs.",
        "label": "Compensation Expense Related To RSUs",
        "terseLabel": "Compensation expense related to RSUs (in Dollars)"
       }
      }
     },
     "localname": "CompensationExpenseRelatedToRSUs",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_CompensationExpenseRelatedToStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation expense related to stock options.",
        "label": "Compensation Expense Related To Stock Options",
        "terseLabel": "Total option expense (in Dollars)"
       }
      }
     },
     "localname": "CompensationExpenseRelatedToStockOptions",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Abstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DeferredTaxAssetsValuationAllowances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Valuation Allowances",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowances",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_DescriptionOfRoyaltyPaymentToRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of royalty payment to related party.",
        "label": "Description Of Royalty Payment To Related Party",
        "terseLabel": "Description of royalty payment"
       }
      }
     },
     "localname": "DescriptionOfRoyaltyPaymentToRelatedParty",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of deferred true-up.",
        "label": "Effective Income Tax Reconciliation Deferred True Ups",
        "terseLabel": "Deferred true-up percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationDeferredTrueUps",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "atnm_EquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityDetailsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsScheduleofrestrictedstockunitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of restricted stock units [Line Items]"
       }
      }
     },
     "localname": "EquityDetailsScheduleofrestrictedstockunitsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsScheduleofrestrictedstockunitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) - Schedule of restricted stock units [Table]"
       }
      }
     },
     "localname": "EquityDetailsScheduleofrestrictedstockunitsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "localname": "EquityDetailsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Member",
        "terseLabel": "2013 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_ExercisablePeriodYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercisable period years.",
        "label": "Exercisable Period Years",
        "terseLabel": "Exercisable period"
       }
      }
     },
     "localname": "ExercisablePeriodYears",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_FinanceLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities Member",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_GrantOfStockOptionsPurchaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant of stock options purchase shares.",
        "label": "Grant Of Stock Options Purchase Shares",
        "terseLabel": "Grant of stock options purchase shares"
       }
      }
     },
     "localname": "GrantOfStockOptionsPurchaseShares",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_GrantRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Revenue Policy Text Block",
        "terseLabel": "Grant Revenue"
       }
      }
     },
     "localname": "GrantRevenuePolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LeaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Axis",
        "terseLabel": "Lease [Axis]"
       }
      }
     },
     "localname": "LeaseAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Text Block",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_LicenseRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Revenue Text Block",
        "terseLabel": "License Revenue"
       }
      }
     },
     "localname": "LicenseRevenueTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_LongtermLicenseRevenueDeferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of long-term license revenue deferred.",
        "label": "Longterm License Revenue Deferred",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "LongtermLicenseRevenueDeferred",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LongtermOperatingLeaseObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term operating lease obligations.",
        "label": "Longterm Operating Lease Obligations Noncurrent",
        "terseLabel": "Long-term operating lease obligations"
       }
      }
     },
     "localname": "LongtermOperatingLeaseObligationsNoncurrent",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MaturitiesOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of present value of lease liabilities.",
        "label": "Maturities Of Lease Liabilities",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "MaturitiesOfLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_NatureOfBusinessPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of Business policy text block.",
        "label": "Nature Of Business Policy Text Block",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfBusinessPolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_NonCashActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Activity Abstract",
        "terseLabel": "Non-cash activity:"
       }
      }
     },
     "localname": "NonCashActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_NumberOfWarrantsOutstandings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares, outstanding beginning.",
        "label": "Number Of Warrants Outstandings",
        "periodEndLabel": "Number of Warrants, Ending balance",
        "periodStartLabel": "Number of Warrants, Outstanding Beginning"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandings",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of lease liabilities.",
        "label": "Operating And Finance Lease Liability Maturity Table Text Block",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_OperatingLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Member",
        "terseLabel": "Operating Leases [Member]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_OtherRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue [Abstract]"
       }
      }
     },
     "localname": "OtherRevenueAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_OtherRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Revenue Text Block",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_PaymentWithImputedInterestPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment with imputed interest premium.",
        "label": "Payment With Imputed Interest Premium",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "PaymentWithImputedInterestPremium",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_PrepaidClinicalTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid clinical trial expenses.",
        "label": "Prepaid Clinical Trial Expenses",
        "terseLabel": "Prepaid clinical trial expenses"
       }
      }
     },
     "localname": "PrepaidClinicalTrialExpenses",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_RSUsOutstandingBeginningBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs Outstanding, Beginning balance.",
        "label": "RSUs Outstanding Beginning Balance",
        "periodStartLabel": "RSUs Outstanding, Beginning balance"
       }
      }
     },
     "localname": "RSUsOutstandingBeginningBalance",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_RSUsOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs Outstanding, Ending balance.",
        "label": "RSUs Outstanding Ending Balance",
        "periodEndLabel": "RSUs Outstanding, Ending balance"
       }
      }
     },
     "localname": "RSUsOutstandingEndingBalance",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_RecognitionOfDeferredRevenue1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of deferred revenue.",
        "label": "Recognition Of Deferred Revenue1",
        "terseLabel": "Recognition of deferred revenue"
       }
      }
     },
     "localname": "RecognitionOfDeferredRevenue1",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_RevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue recognized.",
        "label": "Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueRecognized",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_RightofuseAssetsObtainedInExchangeForLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of right-of-use assets obtained in exchange for lease liabilities.",
        "label": "Rightofuse Assets Obtained In Exchange For Lease Liabilities",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightofuseAssetsObtainedInExchangeForLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_SalesOfSharesOfCommonStockNetOfCosts": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales of shares of common stock, net of costs.",
        "label": "Sales Of Shares Of Common Stock Net Of Costs",
        "terseLabel": "Proceeds from sales of shares of common stock, net of offering costs"
       }
      }
     },
     "localname": "SalesOfSharesOfCommonStockNetOfCosts",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Abstract"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfComponentsOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Lease Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfDepreciationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfDepreciationExpenseAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Difference Between Income Tax Provision And USFederal Statutory Rates [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDifferenceBetweenIncomeTaxProvisionAndUSFederalStatutoryRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Anti Dilutive Abstract"
       }
      }
     },
     "localname": "ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfRestrictedStockUnitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Units Abstract"
       }
      }
     },
     "localname": "ScheduleOfRestrictedStockUnitsAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfStockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Abstract"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWarrantActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activities Abstract"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Discount Rate",
        "terseLabel": "Schedule of weighted average discount rates"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRate",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Discount Rates Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Remaining Lease Terms Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOrDescriptionOfWeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Or Description Of Weighted Average Term",
        "terseLabel": "Schedule of weighted average remaining lease terms"
       }
      }
     },
     "localname": "ScheduleOrDescriptionOfWeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently Granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), outstanding Ending balance",
        "verboseLabel": "Weighted average remaining contractual term (in years), Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_StockOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option term.",
        "label": "Stock Option Term",
        "terseLabel": "Stock option term"
       }
      }
     },
     "localname": "StockOptionTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_StockOptionsExercisedSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options exercised shares of common stock.",
        "label": "Stock Options Exercised Shares Of Common Stock",
        "terseLabel": "Stock options exercised shares of common stock"
       }
      }
     },
     "localname": "StockOptionsExercisedSharesOfCommonStock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Nineteen Amended And Restated Stock Plan Member",
        "terseLabel": "2013 Amended and Restated Stock Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenAmendedAndRestatedStockPlanMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_UnderwrittenOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten offering shares.",
        "label": "Underwritten Offering Shares",
        "terseLabel": "Underwritten offering shares"
       }
      }
     },
     "localname": "UnderwrittenOfferingShares",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_UnrecognizedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized compensation expense.",
        "label": "Unrecognized Compensation Expense",
        "terseLabel": "Unrecognized compensation expense (in Dollars)"
       }
      }
     },
     "localname": "UnrecognizedCompensationExpense",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_VestingPeriodOfStockOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of stock option.",
        "label": "Vesting Period Of Stock Option",
        "terseLabel": "Vesting period of stock option"
       }
      }
     },
     "localname": "VestingPeriodOfStockOption",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_WeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Discount Rates Abstract",
        "terseLabel": "Weighted average discount rates:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageExercisePriceCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Cancelled.",
        "label": "Weighted Average Exercise Price Cancelled",
        "terseLabel": "Weighted Average Exercise Price, Cancelled"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceCancelled",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "atnm_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Lease Term Abstract",
        "terseLabel": "Weighted average remaining lease term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average term",
        "label": "Weighted Average Term",
        "terseLabel": "Weighted average term"
       }
      }
     },
     "localname": "WeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_warrantsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants to purchase shares of common stock.",
        "label": "warrants To Purchase Shares Of Common Stock",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "warrantsToPurchaseSharesOfCommonStock",
     "nsuri": "http://actiniumpharmaceuticals.com/20221231",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r199",
      "r288",
      "r295",
      "r309",
      "r310",
      "r322",
      "r323",
      "r329",
      "r358",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r199",
      "r288",
      "r295",
      "r309",
      "r310",
      "r322",
      "r323",
      "r329",
      "r358",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r198",
      "r199",
      "r222",
      "r223",
      "r224",
      "r287",
      "r288",
      "r295",
      "r309",
      "r310",
      "r322",
      "r323",
      "r329",
      "r354",
      "r358",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r198",
      "r199",
      "r222",
      "r223",
      "r224",
      "r287",
      "r288",
      "r295",
      "r309",
      "r310",
      "r322",
      "r323",
      "r329",
      "r354",
      "r358",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r44",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r328"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r349",
      "r350",
      "r351",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation expense related to warrants (in Dollars)"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r85",
      "r101",
      "r117",
      "r150",
      "r153",
      "r157",
      "r162",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r252",
      "r254",
      "r260",
      "r328",
      "r356",
      "r357",
      "r394"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r96",
      "r102",
      "r117",
      "r162",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r252",
      "r254",
      "r260",
      "r328",
      "r356",
      "r357",
      "r394"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r98",
      "r311"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r27",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r20",
      "r26",
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r20",
      "r76"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r12",
      "r81",
      "r89"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r47",
      "r166",
      "r167",
      "r305",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r349",
      "r350",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r328"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 25,674,823 and 22,143,974 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Orphan drug credits"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Other revenue - current liability"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred true-up"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r66",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r66",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r65",
      "r66",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development/orphan drug credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r66",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r24",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Total Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r24",
      "r42"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r75",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r50",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Expected dividends (in Dollars)"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockStock": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in stock.",
        "label": "Dividends, Common Stock, Stock",
        "terseLabel": "common stock, value"
       }
      }
     },
     "localname": "DividendsCommonStockStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r110",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r133",
      "r135",
      "r137",
      "r138",
      "r139",
      "r141",
      "r258",
      "r259",
      "r290",
      "r293",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r110",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r135",
      "r137",
      "r138",
      "r139",
      "r141",
      "r258",
      "r259",
      "r290",
      "r293",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share \u2013 basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Provision for income tax percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r118",
      "r233",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal statutory income taxes percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r385",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r385",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r385",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development/orphan drug tax credit percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r49",
      "r93",
      "r106",
      "r107",
      "r108",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r142",
      "r163",
      "r195",
      "r227",
      "r228",
      "r229",
      "r241",
      "r242",
      "r257",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r284",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Shares of common stock"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r269",
      "r275",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r271",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance leases current liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r270",
      "r278"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance leases right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r269",
      "r275",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-to-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r281",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r280",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r234",
      "r235",
      "r239",
      "r243",
      "r246",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r119",
      "r131",
      "r132",
      "r149",
      "r232",
      "r244",
      "r247",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r230",
      "r231",
      "r235",
      "r236",
      "r238",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal statutory income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesForeign": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in foreign income tax contingency.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount",
        "terseLabel": "Federal income tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingenciesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in state and local income tax contingency.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Amount",
        "terseLabel": "State income tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingenciesStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r21",
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Other revenue deferred \u2013 current liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income - net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r112",
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r282",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Current annual rate"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r117",
      "r162",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r253",
      "r254",
      "r255",
      "r260",
      "r319",
      "r356",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r80",
      "r87",
      "r328",
      "r348",
      "r352",
      "r390"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r97",
      "r117",
      "r162",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r253",
      "r254",
      "r255",
      "r260",
      "r328",
      "r356",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided By Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used In Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Used in Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r20",
      "r22",
      "r25"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided By/Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r14",
      "r25",
      "r82",
      "r90",
      "r95",
      "r103",
      "r104",
      "r108",
      "r117",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r136",
      "r150",
      "r152",
      "r156",
      "r158",
      "r162",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r259",
      "r260",
      "r320",
      "r356"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment and Furniture [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r150",
      "r152",
      "r156",
      "r158",
      "r320"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r276",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating leases current liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r272",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flow use from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r281",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r280",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r30",
      "r36",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r328"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other revenue deferred \u2013 current liability"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r343",
      "r353"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestrictedAssetsCurrent": {
     "auth_ref": [
      "r302",
      "r304",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.",
        "label": "Other Restricted Assets, Current",
        "terseLabel": "Restricted cash \u2013 long-term"
       }
      }
     },
     "localname": "OtherRestrictedAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r328"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r312",
      "r321",
      "r353"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r61"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r46",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r43",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Office equipment and furniture"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r45",
      "r88",
      "r292",
      "r328"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $487 and $335",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Costs Incurred, Net",
        "terseLabel": "Federal research and development tax credits"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r62",
      "r92",
      "r402"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net of reimbursements"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "negatedLabel": "Research and development/orphan drug tax credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdifferencebetweenincometaxprovisionandUSfederalstatutoryratesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r339",
      "r347"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash \u2013 current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r303",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash \u2013 long term"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "auth_ref": [
      "r91",
      "r301",
      "r302",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of all restricted investments.",
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Fair value (in Dollars)"
       }
      }
     },
     "localname": "RestrictedInvestmentsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r50",
      "r86",
      "r299",
      "r300",
      "r328"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r93",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r163",
      "r227",
      "r228",
      "r229",
      "r241",
      "r242",
      "r257",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r151",
      "r154",
      "r155",
      "r159",
      "r160",
      "r161",
      "r196",
      "r197",
      "r289"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r109",
      "r117",
      "r147",
      "r148",
      "r151",
      "r154",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r260",
      "r291",
      "r356"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r279",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r279",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate value of common stock (in Dollars)"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock, shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of diluted net loss per share anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of difference between income tax provision and U.S federal statutory rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of depreciation expense"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r55",
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdepreciationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Expected term year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance",
        "periodStartLabel": "Weighted Average Grant date Fair Value Per Share Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Number of Warrants, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable",
        "verboseLabel": "Number of Warrants, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Cancelled",
        "terseLabel": "Number of Warrants, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "RSUs, Granted",
        "verboseLabel": "Number of Warrants, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, Ending balance",
        "periodStartLabel": "Number of Options, Outstanding Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, outstanding, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, outstanding Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Exercised",
        "verboseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Cancelled",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "netLabel": "Weighted Average Exercise Price, Granted",
        "terseLabel": "Weighted Average Exercise Price,Granted",
        "verboseLabel": "Weighted Average Grant date Fair Value Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Aggregate Intrinsic Value, outstanding Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, outstanding Beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Grant year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), outstanding Beginning balance",
        "verboseLabel": "Weighted average remaining contractual term (in years), Outstanding beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "RSUs, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofrestrictedstockunitsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r13",
      "r49",
      "r93",
      "r106",
      "r107",
      "r108",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r142",
      "r163",
      "r195",
      "r227",
      "r228",
      "r229",
      "r241",
      "r242",
      "r257",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r284",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r142",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r1",
      "r2",
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Cancellation of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Sale of common stock, net of offering costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock units shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r49",
      "r50",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock from exercise of stock options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r49",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r40",
      "r328",
      "r348",
      "r352",
      "r390"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r68",
      "r70",
      "r93",
      "r94",
      "r107",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r163",
      "r195",
      "r227",
      "r228",
      "r229",
      "r241",
      "r242",
      "r257",
      "r261",
      "r262",
      "r266",
      "r284",
      "r297",
      "r298",
      "r348",
      "r352",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r52",
      "r116",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r277",
      "r327"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Other Revenue"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Net operating losses, description"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r143",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates in Financial Statement Presentation"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Increase",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r134",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r133",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r331": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r332": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r333": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r334": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r335": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r336": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r337": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r338": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.6(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001213900-23-025597-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-025597-xbrl.zip
M4$L#!!0    ( ""(?U8!+<.>'Q(   :\   1    871N;2TR,#(R,3(S,2YX
M<V3M7>MSVS82_]Z_ J>;N6FG=21*=ORXV!U9ME,E=NQ:<M*DT\E0)"2AH4@&
M("TI?_T!X$-\ 21EQT%Z_)#6(O'X+7:QV%TLP!>_KA86N(>8(,<^;FG/.BT
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M.R 3UNIMD!4V=H+];Q6'84L**DSO=V$Z1S_(YKB-4J-X2V.6&*7B>-1 745
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MO$ML9H5(YI00CDM(*(@#_KTC-QE$.M6 H@9N2FKWO8YP;5(LQ1J(YI55-6Q
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M@C3V78A3MADJQGGT:%'*/)2,52#:U  2P75UR)PPW\.)K*?4^V!G..C&D$*
MY;#.&6[BV^2>1(^$,./)+P.,$N:PK%W^8,J(N9O.B<,LD1=&; ]' 7T&LG,
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MUG:\%0^6DZ"(W-Q+L)8F5-N8J[!YN)8\[36L/?"EVK3X*HBPME +LH[M'G<
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MANV9^U1HCMJ3>56CPJ@;JMCL1)O3/9RRZ3 N=TTV:^*7&5[/X]N,JL3F]Z0
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M9>6306MG=7DHK_H5K<>)\C8@&:P6MS$'=KYA0M)EX"\B0I>7KLTO3IL#)B5
M2K=;0)B+I4MI>QL#I-+=#?@#)\%RZ49)_;[E.^G-9\%N6F[Y1J$W>&<+>U*%
M[8:< 3%M<!VZS^)1PJUIP3^Y'@FCP"<J-GSG(X-MP'0$M%'YW=7#>QR%.\OU
M_#9XMKSH.4,W"VZ)QV[KSHU%HV<IULM#&ZM,%/@UT M*:2Z<<C1C=[3<9?VX
MLJ:TGOI/E>_#N\!J!H[)T+ 9'X9U^NV,$)-@X3;YIV:%G8>%Z;!ZLJ D ;\[
M'*R!R^4O$!G<.N6K15<VS*ZL$7J.5QE'W?BN-DX6!S\9F,C5K B[+)2>NM6=
MA]5Q6_)<-# \2YV'4@.RM/HTQ?>AZ[@6?9Y:_!%@RN>!8LS^:\2#I\@0-D&"
M3U@UF05$5]:2_7%&+3_D1WO@H\S]DT"(%@N1FP+8IJPEB4FP3\:Z(\D.?#Z@
MI/3,3@N$%:#DV$"]D!=UUU;Z:)EW=KQU0PS3*$0U<)=)CEU8C3YRG'DW]AG[
M"L4R"E%A9FM(F4497:T75AWC8.=!RN $-X6MXC)H B&%)3LV54EB(8U^N^4Y
M6+*FCGU0$ K[VU8@95A(SC:$':LL&KK&;0->?@JM#%=[F#LK-$"UJE)BI_R0
MV2[\E#,@BAPU8"-D^8EW&_PV#5[E3B@U EY49:F5S?AM ORW"?#?)L K2.?&
MLWQ^@T0P8B70:)* -%IE9K26"7?A-XIIJ@ W&Y"JTZPZ9N/>K<I8P,U.#<>-
M&APUIJ/<D8K/R+Q71F#_+N_9*^97E.&;;$PO]#R*$JAA"WS2PHFU<B/+N_9/
MR=+R'1XM##>O)G72:'@2DH%C+BVJX:EP\TXDQ04<LW-+PHBZ?,I<(ND[GQ>>
M3^]0-H(8E\%L=?E'FDI[!Q'KX#?+[#&8/00QSSZ[<GT2$>)/EDG^R,1W.#56
M3@NWG@J[1PNP22-6[YQL]I,>H^ %ED^5X@7:[IHH2J7Y:Z/SD%IX+U@S]-6
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M;$.9]=?OV(*'5<#X4)),E(YV:"1,HG&^TP(.EY\6<-CCL@P-^T GB3W_/'G
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M']RT/!NN5_<XW,7X8@VN-?@/+ L/00RP  3W:5;<X&S#7&W,* %5"^;:[1,
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MYY:1SFJN3?<:>,R?U'LHP85OFZ(A+Y4")2# %)WL3]=K#$'_N+)C7@4%OL*
M%5F.JI>.[(L6H'@U,@Z'U\32&)%9,TQ$"MWBX@O&"8J8=1QD>INE#U%.,S7(
MY?OYFVNTQB%Y[L8H+X)B1QC^A,CC%WL^-Z<0+[%-TI+FMC[?>I76"M6/^5N,
M/[Z.BC/&C>N2&2THYW+\3 *;>VU@4O@E.^NLMSOJS>399#^+: D=4Y/1UU*3
MD0 ""V%P*9#!<?7-Y+GP0U=?S$:002B[1.!SB7A[]J0.X[N!#"M)8RFE)C>+
M(Y$=!8H'E6@,O,;2C+:8P$W>WW>^(V2FD)2FD(\FGZUVTWMC.'A7\L>D=].#
MR2,RV^']W791%EC3UV+SB3C8(R\0R)8P5JL1 GW>FO4X&CJGXX2*@> 9BH[H
MS'+MV+=D9N7NMZ',"(NHV0./^Q#F<D19 N'<LF\'YQBO%!@AF&=*>!\O]#:6
M"\S0>UA"S1$"3PW%1ZL5V3[-Z*KC'=E4R=37L68Q#Q>S&B*5;\#W\\:,<4T!
M,\#55I4SD5VZ?/6CY.Z\P)O\DNUB#P>H$IQ%'J4JB%62*GFZ+/6T-)&3H>>F
MEG0C3E")8G)\#TD"YTE/-X8 ?Q8V$\?I%T@,=6-R&@*0:W_;>)!ED0-T!O*2
M1P_E$!248WSOANDDQ\!H-926]MX]DPWI;W=,#=TBKXJ9-\[S,H:-W$]ST'N*
MZZ;M0)GK#NFLXC6CJPV+1' O*Q_U.LT:)MQE>-O$3!,>WP)LK0-KQ3(,^<E1
MLB/Z$ ]:3Q,WO@3APNX]7^; #92U91LG5&S7'WQ2\MA6JMS=YO@?.T*MTP>H
MCS9;H(]T'1]1/#)@9/ZHZGM$!W@MZJAC6"MT1HFHK;F![#LB>\73)2%2 >G5
M_]A%U%A8FCAVFUT,!;I.\#;#*W9'3RQ/=C!,>7^:UR*S@E4BBA]PGG^/@GH,
M"AN#?#^I1DE&4W#M239=]LOL;R'3]XUS@;5_MS#Q5#[VE^!(-7MZ#'E.S/52
M=QM5. 5$/JH]3@"W50SA,[/M6L013D592_6T]+.1*^"D=DJ>)^1^6.')&YGI
M5G-??UH#T33.7-^B:\CDIEB:T&6$"76SC=,GC!N]_3[B9A/[J8Y;Z3H^XOAD
MP,B<6ZS($OHK^^IO/A]%6H:UCC0EHK:7^575$Y/.^QDZ8EY=?YY%;M1K.3>)
M*\&1'U%E"U$Z"-%1?6'R=R3IN=DYD#0TF,%V:]"M4 N7J**UA#E?0:.TK_^)
M>?325DWA!>-GV>SMN7UX %H0R,JB\I+YBY$.(4N:TM#'RD<WT1X4HOW(/Q+0
M]ED0=DR_S<KP,X\"UIG=A]K5!D%F5PEN4?7E,N1 PIF6IB7 S5:_NEBOHQ6>
M5QS$:[B.QA%"(5/"Z;<-T8 7W]DN2V@WA<4<QDKFM8(DI;@//T+RK/C[QRB)
M-KN-N;2000U)(?^JI:0_G\/CHK>X1"#X-]XY+R4^<%N,C$54!ITH>)R6Q:WY
M7+.XN;B,Q>R;9;!81/R*Q3UD1@3>B"T^/$ICKE>V=D4/"H,!6 /-@B))6HP9
M4,AAO2FP3P];Q>,'G(!MFTQ_%&[(H07E3L$@/J?HF:WI/F3'""Z)]/&Q*&B-
M7(CL#6)R4_K,*3+0M$#3[^IJIC@@G*FS1D12)\F]U,WA2KTU 49J:B[KU])A
M0B.#Z\Q*0]94F90FF ^.7: SGT4)N*)'B(AZ!K>]JI2PR)RT;(Q".IR+AQ%3
M*N'0(VW9">_H+L.T5<;18V26JMT>X=+<V%]>VDF%?X/^"E]Y\3S)J5LQM8^*
M=< =0?]3L,%])HZ/HVM./;E"$2MTB>;*L@!?\B\$WW09[2>X3<"%5LQ:%R'K
MVH]9]!"PF(NR;_%5E/\Z _>52\VP]U7RH()%6G&A'(+J,1X/A2$<; >::5"W
M[R*SN\VC, JRI^L *NA1Q]<,@B1?9_H7LDJ(I'#((KL#5GB1N3E[IXR?^HDZ
MGG4CO.4(VUXX1ZM5NH-$@[O+-(Y61!41MV49+3>*A29^EZBD1@Z%3 .I!J!R
M!!$>/L;KT:/G7%-Z-(C;N^T@#ACC]IOG!.>K+-K.D R@6\VU!T<#CS1VFGR&
MPOH[O^J.(0N;XF2"]QB9"J#Q13[U&53/ZSQRJEI:E@;,BH.@($F@J2P4]_4M
M%!T>M-G?Q,:VS3;$%M\E$:T;474AN\(/.-GA3O=DR1-6/8-;<X82%JF=OAK3
M:C^7L6'^VH09L:9Z_^I1MS1J\#GX_+_5S> U4M$=Y;C*7 \ *?OI=X3=Y8<^
M.2XA=8/+(JQL-__G+5D\*7@S5R.^=H:XW=[MQ24,Y1^A+?O*F[E*3-R*DP)<
M["_KSGZ?IZ"99!%_O4W:@"BK0O'#'.VC%;_DRW:B3[X?H&K>B3+D!'C;N+L^
MI,D=H?7F0[0"YQF?M5S$Z#303.&Z+:@:'-E#@ S:AU%$).BP2EA*5<#;$6+&
MH>I(,4#?1DX^1C'.BS3!0^Z)WB"GCL_NZM+P+?Y9[[+PX<22T;GBKQ K.R]F
MXYUXL;Y*GX*X>.*SWJ17F"9[7P99\63$;//9G$J!,5A2@W<U'EX&&9M!("NN
M)64P]QH-A8>0Q-X07EM'C],DCT)>/(7HK3AZP.%%<I,%21ZL9C!/#5O;1SV4
M(0!*G;)W&<UGI=G_U*B^2C<;(J@YM:U_%27H)(WC(,N_]ERUS$H66D;WP?2R
M-<0W5OJT@V  \@]H@)N?Y_D.A^=NI%:_M'/+V1#H-+Z?IICNH9S.XC6SPH;I
M$O$TH\V(L%R:<(W#_(Q@ --#&,O%^IB2E$(P=;R"=CT?&7):J&0QD5F:Y]#7
MC8Z6GI&>2OF8,;93ML> #M:7N'#ZC(D[Y(QTE<-YI*V]H/.33P^31-@^X4(O
M:DN1-"%7M:+6)\.89A2/4$J"BFWS^)Q8Q&2K^#C&)+#([D_Z2?<&]7UN:;C6
M2D]4H&O_T("9W@<Y#LFQ!S'@K$0.I,3>T6C ]T_U)_RA<P1MT-M7]=&NN$^S
MOG-CO%HW.7RNO>N38R [+^GG(-],)T1!-<)S@]6Y1*RE1,Y"94N/WP^04,Y5
M6EYWYI+(U3U9FRUC9!32S^(\W%D+DE1QA'H ()KT<9WR6CQ;/K;WBG%N$#+F
M6&4(,B.%54NSXSC(\XLU+TQPD5U%=_?%Z2/.5E&.+[,(E-2R@ 7_K9% V<SK
MU-YH :!$X,I!1(.$A/.&^@@U\)B\>7NSC&5R)8.V]+(S>3=$_09G&R.1ZXYQ
M[=#JK"]MX%F?2@@<0#Y3<21DKI@N0LG&*_43SFDD)<ZB-&P=9$:<50QW>F;(
MX9 PFP^ <X",Z%Y*'N\@/4,J&= @;;>_*Y/X61!E4#L6&PF"8)B'-*PN#%JS
M_YI\R6W_$N."^_0L&?T;.5I"/*W-];9*<[7\$7F";ICV<Q+E-#K[+,TNT[QX
M8"):%C&;H5N$:^B?S</1#C^9#Y</[$;S/JN7Y#AYG>2=.8(I]F%M%)1;/;2W
M)M!"C0"H1@A:Q\$<>WD>0'TXJ&?#1OK<8=^@.%I[#KF?7^1ZVW$^2B_B8BW!
M^BF-R300<3E#*7T7$+OWNL^/E&Y#/E1?+R =QJ%8SG9G*M@PPGEV$CU$(4["
MR3/6JWF="W^UM$Y$P_+#13GT>QQI!7*W<!O!=_IR9GZTDUU6/:F9!;=5>;TT
M[D+9A,E?,I90^%!M[$"5)0R"&SR.@S)"M.4>\/W8&"<:K0-P!-&L/ A-KT1I
M#^;+*:*=]#9<]60>C;M*P RLOCG"Y02E^U0>*.#1(FS$39&I6$\@&QORYZ3.
M^FO>[;R<G)%XZ>9P:DW6 "/+F&N, J&IAA&IHN.6$+\TA&%UDIT!/>RLS3]C
M<$?A\.@!9\$=-O8HB<:Y3:(40"#K,L"_1 '[M.-;<LU\!<DKALN0LXR$$,@,
M3Y*X29NGDYG_VG0RUQ>1*6 2,;E)BR NW8^Z$\.]HWH@"VOO]!"JV/8#5FE6
MG08J]$E)0YA=JN]R(-R;0ZS@U'=$8EK[CC;=\1G),XU0&"ON:HJ-JQW.)SY/
MP"< ]I#\J)"X92=LSR59SGV"N@XD66%5K4_7<^<G-3_%S9\4%+ ]-&V-YN04
MCUCJ&-L'2W$"]>#R$8T^&?3*&,HG'&3-T_5/_WM_'_WUYX\_O?G;7_]KM=T]
M_I*\>1?^]O;A[I>GY//)[LL/;[-W;W\\_._/-T]Y_/9A]=O+^#^*%\4U_H_?
MWK[Z]?%@]:%X^9>SL\/K'U\\/+X__N7E0WB=W;Y)\IN_G!W</^;GYZ^NB[/#
MY&-P%N'#G_][=WN3X(_WY\7[+^FGW8_;GWY]_]]XNSOYX2__\?!R=_0+(=G!
MP4ET]7CVY?K'[\Y_>K.YNGOX8?WO7^+WV_M5^/+ZQ;M5</_JYN#'Z/#C\8]X
M\Q__>9&<G=^DWQV\^Z^?#J__\N^GYR]/H]/T]/-E=/-3N$W?O'KQ^7+]^L?+
MVQ_^<WWWW8OPZ3[-\/'KW3:XOGOQ95-\^/"?__GS;[_\<OWTZKMO@__[6X@/
MWJ4O-W_YOQ_7GW]YF_ST[=VOMS_=?)?LGG[:?5R'-Q_QW;N?'S]^>O/C^>/A
MW9___#=T?'VUO__<'&:RW3B)?TPHE.ZS#.C_M:*=9O$\3P7:LPD1$0"O<Q/0
M"A^=X^=9.;$4LC2)MTI&TQF>SM#9<O23F4[BN*B8#AZ9GT!D4\O80%2D"(8N
M)8S/E&]&[^2*)K85RMHAXCEW.<#A;EBA2#F!\T!/%32Z5I^8?>:M&)$)*R2A
M_0)$K?Q"GY,09U^RJ"AP<K%>8WC2#LA(4@QW;*67P2$UT-<#4,I'=&T5[FWQ
M.F8TS/!*A.TL\%^X;-VD[<2EX1Y"LYD<7S5&0.G.#'*W=)+4Y'Y!U_(SB'^5
M*)F394Q815W2@Z8A$76(KC*U[BY;QF=]EQ8D<GVF+C54):09I*GY+>\BY*6D
ME$N?#+8J#/=<![<Q9FKU+^018G9A288Z/HG$4*@S%^%CGJ+D[X114[XZ4A3X
MC3A#^!G<2F<\3U895.V>^!Q1+N6QA;T0H.>8\3J$IX+>['(Z6%NDCF+Z>QX.
MTWON"P-8QK</,5O4A\29@::,I*(V1''X2^.I7NH?"WBNV\E"JR&).=5LRXRR
MVK,WP>-1GN,B!^</,TB1I;] ^*3936@TD>/BHGJ(I'5%>8N!(GA$ 1V\1_U^
M3.J"<KS7"J/FC&L4%S4DB?6Q1P[/=(/)_%  /UE%<42G)S\X3FEC'9Q 6YVS
M-,/1W=0E&@<N[MJ8/@P\F0L:A[1M<$0G P'UK+[;<;QYR%G0Q3YC$68E.R J
MCLD]\;1.,S"J?X@V44$7S2^2SY-?RV9KNH^",()+43TOK?H0QRDY3L@9*>[6
MY$4N!S&Z*8[F5+$,CS"4]VNR'CY*P@]DLMC/2=D&P;V VH I52&A*(/PU%SN
MH2D4 8NCLT\@2]&]PCEY>J_NR5PG^ ''Z99Z)VO?Y<]1<<^OJ!_2!YPE\$/H
M@9434*$=1D@.CNGCRZ8 RD.RTS20:S2%C"^"@B0D!W2U#%5N5_2D\YT*-:U8
M=<+<IJ*P;:YVJ717>Q7G!)KJEIF^A[%F.7_M@&0@R1H#9=O[($%AMKOKR:G'
M-D Z/HH: BDQM^V+7>:H-OPJ<Y08EZ_CX<24 B.1H78Q>QJZZ_FLT[)-F(<L
M1-?V1&K6BC[!MP4YX2[69=%H>O9-+$(&"WJM&RZ&R:!NN,_SR)R+LCKA"K1M
M?6F?@F*7X8OU^UT>)3C/:1_EIQO\6+R/3;W]NCF<6A$UP,ADA(X"5WXYSEL4
MB"%'*ANA"<+6YD%H#T/F"UG@KTHV1I\YRJ5\>$!4 $G$Z#(C#]9H&[.HD-8$
MOLTK)IQLGCM:[*UEZG,.+0[R(MJ01^[4-U=G<N>W5'M]6?193H^:ZC,4)>@L
M2LB)'I'W'WW\TP??)3P%DZ(M/QYD1\RQIK0(T![AZ3\.<G@ PA_0"H-H@9#L
M5&= B7_/A'3J4VD,*![T[3'P2FNRY,P60?_2&$5_V$C[A-][/^8F$)W6,3B6
MGB-T_BW.BB<H_%*0%6!V:@N9]Q8V7M:#;)O")KV<V7 JMM58KYW2AC*Y\S P
MIX:M%'X@"B7&'R"\1OTT&"UXJI7<6\ 4T,B:'M-O_7HI#+C5E" =DI9VKBHE
M^2.9F3Q-:IF<5X+,UW4=2& ,F2J-G4Z &C/XE;7!7&Y*WC""V </\(;=5ZQD
MT?QO6/UZ/AZR6JBD%3U8U_;&0*^WI3$WVPXE$^1'&$AB\I,4PBH><,--=;2B
MA;PA\W.69XGILCZ>((:P25,A&L-18[Q7X^U0/K=-*0,(8I7&1TM!<$FWL>"J
MQCO.C5" HJR#P8?XRXTPX$&[5Y@"25MK_H=HQ;*%Z<S#9$ VUGE*KP00F=[-
MON[SWZU:9$+^BOTJ#&U?:N+ "1YP/LL=9++B8F)T6F#)*YC5@3>-L8BZV7Q;
MM@8P6!]0TR>'K=PUTQMXE0)*KKF=16:K.K?_&P*F:DF\3]-&$*\DXCO4:R!_
MVWJ/.2U&> NJ6)UY14ZZC',9DT$B$2KV.:+!3#Y5:!V?A'&R$\O*:9 E1-_.
MRSSD>45&MYIK.Y0&'D7\S(<TSQ$9AGBB.AWN4Y@,&=EJEVZ _8C.6KO;'/]C
M!W?K0^T"FE>^S-9T;STW@DMV!59C$1OLN]K!$+ZV2A\8$\&FT'YM.\@+HJX&
M69AGF+PJBO@IHN5IMW2A@BQT:_P$'#RI^[Z> R&4:OIL##H*TRVXKNMYT666
M)N3OJX[-R?ECTI;#=6]0&UK9/@,^X2\-<U:+A"Y.PL'+^[###P52)[RL#K6)
M['HY.6U%HGF(6I',+K/^.-A&11!?)"=X0[8+5*[)C^XR3%?[B#>W.#,Z1$WF
M<=Z/0 ^3-/B'CD1$YV-C$1V,JM'HKVS\WWQV,1G N[J@GB%-;&[GFR_IS7VZ
MR\F\GZ($%Q@G1V3:$(='20C!0T%9)!ZB-P8(E]7$CBWX-C!*I._PY<$KQ =7
MT6:T< BK, (3+$( QS"\DDAKPED7TOK'+BJ>R%N;2'ST@ ?*HGRTZ^--"HE*
MK-@@5(V2"9/S&ELZIM1EMI1HCVF@PAJQB&1AFMXHK?D]O$^[,"C+&+$/1<>,
MKU8F(O;TNI3T\+,4""9E8,M-$R)H)^DFB*8N!"->8V+S6*R0""$ LL)J[."H
M/D9_99__S:L]3,6EEA5,BND(VU>9L7 #)?\F/S!:DT]M;5=)17MI5:$*I@G3
MS[R*@9@3[;.AA].H=KE\M@]$83DG?YV^E59O@1F>[D9"4$&@%P3X%-%O_^;;
M;2SGD% JVDC:5U,D&DD8Q3O02Z[Q:I=%183S3\$&SW)_:)>;7,=028P.&HG\
M-(>A>MP>@I']2\:3/)ERME45T80@MOKJZAZ'.Z@R+%[E]'$5[\@3"O*GX=;;
ML72ZBW77'33+W34M<*Y/ODFAEYV:?!%(B)3L %0NA$ 446,IFD7)%Z/N2;I<
M[R+V=/+.(IFM4WMZ!DU\XAM#,)?^,!E8"[A!AD,][*89OL]$>LYB[B1[V=/?
M79:LL+SCI*E^-V3P+ J5R8K36_E46\( (EF$<)K<[7\@[ O1#?EY!(7T:35=
MH4ZUI"S0/GN-$D [%!GJTLVSXN]7D*-@;O\C0QI21?Y52U1W-D<Z3&=9Q9,M
MRHMH%<3-S#K?@B'A #!?A-=HS5DN2;/JQ)IEW9XOIF!IDLOWJ!NA:.>8]Q52
MK^JH&;O%BJ8!<2:O>#"7;FBPH$MKHQX<.]E;B))FSEZC2TY@J!H3/EX;P.!C
MHLK-HE:IUW(I;$I(U('DM9VS'"6Z+[T%F&LXV8\R5Q%AC&F\.C.O\1U,?X6W
M:09Q3.?).LTV=*GW3_R7\]ZTYA X]+E9@&=@0^*?HVHRU)AM#]T^55\LZU(>
M+"3B^WD8*4>X_.3KS.8*,EG2I?P:P",36)60RMQ'/L1S )=;\FA*&LM6V+1F
MC>B&EN4V-[YW("'=-54E@P1WI_.TY3XUZU3E#A9VL;6LQM )+H(HSLO#*EUO
MH'0IM:>EZQ@^B:/@-HKI3P07HHJY-I,[E00+ )65IM!7?,*OT3YJ7H#UM/ O
M.C%JS"QPCGB1MQ'2T!9.6\(ZDV3)?3B=-'><%(L5:MVM.%:PA=?F,Q!NX54Z
M#9%M38/"[H7-6CQ$F:R^X9GJ1]!WB?X?&*#)6QW>[+.%?,P"HM/@LAD0D/G[
M8 ""$0MYJ<\I7RT]="X:CXNX[VWHK*HG2QM?[)*H&*  #9[4D0_&"CAUT*WL
M;JBGXSW4Z80^(S)'L;L3XC^0>E8EQ :L-$RAL9K82;2%-7C3RJCXM>\K\<1.
M FP$=C(+_G$<Y/G%FO<&O\BNHKO[60RJBH4<VIWD4,AR.&$ 2" ?@M(,T4$+
M"933\Z]554B-OKU)4SCQ7,9,S6)N?=]J8$RE2G:0+46BE!9+ Q)87:M51O$
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M=;C&*QY)<_H(+T<<LCZ]F^VN[+M0MK(DH%,]B,4VR+C9G!S5LZ-R^K()<K4
M[-*J$2A9@VF6HA *#TR?A%0BP9B0!PY.9<C(."40@SGQ\3PD9P]MM &P,159
M&E-#!U%ULCV,OR3\G,!:=)H<,\3=62(0@^4H#,FD.31,#^*_1-OC-)0^N3D3
M^) ]Q 8A,@K!,(_90')<Q!R08^T^S" [P?DJB[9L@W8\A&7^AS+S[B)#C3F$
M18,Z.2_>O%=:9.7>*T,ZN<H\ZN?X:>(U1<F1/;^B:\9(L>CQ08.OBWT#^_<D
M7>U 9[TA,TLIS;]!\)$7DT(7TNXIU,?"K>96&1,_DK?H+L.U1\C0E=;H6MR8
MPLR'YD'],L97I&(-))9CIV@5/VWF%&_T:%]>J1L)+F*;B@)MMYOI$_[2*+Z1
MI0GYZXKUE1NTI\@\K?(EK9F,MI8'E@U%7L1+.P*Z87+SM&9)Y.SE?49^)C>%
MEQ<03YKG5:CI&%\N*24BLOM)@K&C(Z[6UZF'.:!)%2=!$6A:$O!W2F,05"L(
M>OT(O#Q2Q*B(GRDJM!W:4*5!)'6_H'&Q-ZTF2LN/NQ&@/2CV1DHV5V^7H[L,
MLZ)1CY$TPZ_Z",%77@LFM.#MO4P$V+@+0;W,\#:(PF/RBX@<E3=9%,3<O2>E
M+!^#RD&(CBK=HQYS)U7(],BNQ]QI' G9;2N,PQQ,GF HA]S"7E4MR<E$!S*#
M<CD4K,GB@F-^3B(U;I+CQX0@#M,L/D&V+8'A_2Z/$FI^ZZEUHNW"AH%9JQR(
M>CJPU^-)@U=OYQC1P;'3S3;'@;8!I1_7+>!GJE90+\45:L]NUZE()O3W3<N/
M9R),/.3\8E?D!5$0R6O0,&'F4)E(-5&1C 98@B(9\FRJ9RJF]LR85*#'RH13
M):19TZ",BN;(7"15R(]118>]*NR\$D@BMM4<?H7*#$^A,74 A3R<6KU4&.OD
M(MXMOM3JO59<$F(FW:42&KB,.#8N@M(R9PO;+WNU8ZO"KQ2%3T8D>_)76?D0
M.TK"?MUWR\3/05-[2-<? I]!/FCY2B_GHYGZPI8!BTK7MQ$ 0:KH8&*Z,\??
M9 &H ==/F]M46H2'?X385QY#4UK0=LV\ E1\Y@#4(<IIGA\'6?:T3C-0PH8%
M_3>"OLD\J#617[UE ,:B(WLPP1P:5ZZN/S>5Y%/Z_^^#&+0MV>L(QC2?-8B-
M0GR8/T.D"IG>H:7'W+4A4FSV'^DC47KKE^0>L7.*N'>%:*J2M:J0-?I,CR_[
MUJGRUFK.O> JNS*"B-AL15/GQ<*8;4'=T8(7!N.UP_N-4CU9=;K@"U]S8AR=
M5A+O5WWJE'SJUH!J?"F[MN"SO5XEK;UN&:T]NL6ZM;4:(WP7)1]#&Q&_)R"V
MZ^(ONHJZN::D+JV4E)]S8[>NJNZAI84X-S41,W @E[%,/'KFQ92GH[^YN6E&
M]KL\^LK' N^;J'U!\>\6D0+-85&]@5IHN8NWD!G_J34-S/XZBZ'"<<-J?M$"
M>(OHJFR,:^])-)!*;@WMU:.Y&2TB[)=:V1%ZH3$>]D8/;-'ND.#FS!H*ESI4
MJCE+,_:.R%DA'UINXKX9P=XO>*[;.51]@LFA(PA_IN2HG)_\!9$5FND PLKP
MR]A:4]"IM^NF([[K"CR8T VTPQ-RJ,<I?8]S 58WXBR'4DV[,;@N];',J'4#
ME$6[VYA2SI(XRT!MI@!I6KE58>D\'KW?QLU3/'H+^JZ-7('B2%^9JON#I8_,
M:$IGS=$&@67@$M,T_5C&T6['7X$+S)AH3D_KG@\"4M/8NRF.TR^ET=O865,-
M1]5XGR>S 7I&GAD959;A"OB<X_4N_A"MI;S2U"IE$R"88:%>@!K%06Z +F4<
M%I-V'J&6*VU2$Y1_;[KV!@0L>GEF^>)!_P+P)0<NC5.B,#RNQPZ-3NP&N/DY
MAQ0(B<X?+?Z..WQF ,@)9G^>)X:VPW(@^JH<^C78GN4F14_>1#5V$O^A"4D\
M&:ZHV)2%^_36*[YCR@%^V2%&0FG+$J#KS*#5.4(A=1(L*^!7UQJL>E=>.9JZ
MY<7/%<\V7B%^.O.N@BAN-TBWNMC[((]64L>ZH%8;'>#5 R)$0;0[%+@Z=J(J
MK5*VECNO3%!B--@PYSR@J--$5!BW+FJ5ZB547=P=58J*>]ENA"M 3H6Z]$,O
M!*0>XENBA7A(A%F!<RW'MJ6 ^\T>YJ\%K%C3<=,1 Y!,Z@'+6T@*TE#\%@76
M\UM2%5A#(5=F[,])AE?I71+]UGZ2-XYW4918<UC;C.+SBC/!J*?O&5' ?3VD
MHR39!?$5WJ:9O.IAZ7-B'R/VM<=\#!'P,I=3'T''UQ]4:XAX!Y D;#5)EGKI
MZR%4MVL-\GH'*I 1'41:W)V]03L)!N_Q790D%MD5U<!^@H7O#(LN3KTCR(@&
M;E^;2J5?'=2M>_T(XKR7]@R2AWT;T\6OW_(3'E(JEVCRF"I>*G_E,G+*"*!&
M+LJ* 'Y*?A^3OUYD-^D7:8[[::?>-XQ :89@C.^"ZSTDNG>X$E>'QH!&P25E
M/[-FL:FJ7P7K^. [3Z&#@>RR[F/I6%LZB1ZB$"=AWH!&6?JK&K"'VN1OE_SR
M<:C(4!&>+&J\W083@F7Z8OTYQ_20N[@M@BB! ,C3Q]4]>%#/TJSI?-,61:$3
M[J?K_<_0AQGF1.6DX.LJIT5K<C"U7)3"6BE^[G%;F@AO]W$$]N5DKL#0V_ Z
MCN9&QS"1,<^WLUF F,[A+*6%H_-27,^_'S$U).M?I)?Y2K SQJ_WRC$GBCMK
M"U-D?DKC75($V=-9%.-,GH3,5+;J:\0^]UORN .[6%,3(NBJJP0#@:Y\'!3X
M+LVD]Q&G,/T6E1][BZ 6 "XFKP WMX9W7:J?+-./G)$LL*KL2YT7&37.Y65^
M7SAC\3^R^CY/_>;F_08 >U4R9^A;Q9B3O$(OP>SL=%H,8&3('P<=ZG,8AOP=
MS%@GM<I&;H#U/ZA@I04SI!+N0R;<13R77:E_#C*:1]VP[TI#DWGC;N@QQD<U
M3=P>:Y>KD.GI>7K,G5Z.5@V"SZ('J3%I?/MEF-US9(HM481Q+.,H[/(R8@\/
M&6?9;_URAL$@(G,3=N>10C0N6!L46GZWD#B-+MABAXX(-9?&@H_D]9 7:5)&
M <LT[NJ[\G3QEDG2A;AW!8A1<OVLY_X)&G1SD5UFZ4.D2.#K.F18(;$T0^7
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MC1MN-H3FL?(%+G4C=/,)C[-1:PS6"3=Q/_JT9][I&PZ6O1'K?82/_USHY='
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M2J'9=3O382+E]A:\ ([4:+F? 7H4*$!X::=$BE+T?PI](C)X8&@4-8"'-VI
M 3?DE@@R15 !:%5"0,IY+]V\33.OSMGVS9GT!A< ]'JR$OYY7XQW1ACC3!1[
MY+U.4AM6WF>WO!:'N[P0I0!];^Z/'3]L\G\?149B;^9!MK4V.^XYZ0X'21P?
MS/3)9*<0$2993D>:&MRY'E/4B7F$&96$R)SN)*@]V8+8?8'%@)91G\!:\5J6
M[[RIWN/X+_Q_GK@!Q1/_ E!+ P04    "  @B']68D;D^?,S  "$50, %0
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M=L+4:.8[9U2)XNW%WB76"5J*P.74TLM2Q-QP]N$E):Y$-GF.";T).CGA#"Q
MA0'?#!2W%]@E=!ZKQ C"')MGW1/OQU=)]'IE69M?=SGFZ^6Y2PTNO>-Y-T'D
M,LIG]]1/H 25.<P(C2BEO%1C:47WO%XC@W?(6'](O#C*/^'"X()00GFHMYPT
MCIH'5<W0WXQC1W!1]K.P3+P5VCDQ],>2X.O5+]EO'&YX\O^U_>!Z.YU9AL%:
M3XAQT,FM(*0G[H^OWK 2*+J:U$&Y3!G=2BTGE5Z[(L)_4U> +!5/MQ;[XVP?
MR)O%)]3EV](3X)/E)018H'(X<]\81\1"Q2[*5)*!4#+6$O+M[@+"R,P6!2S4
M9AR8NU1:A"WLR41VA+$MY\1F]W?JY&R878$^$2K0=_[)R 55XTHFHN/>N^I
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M%3H#>21RV''-HD8G%57NCL-)Y='P]]0:.,5BMN(2LJ;M0E,*J1VZ!$VL\0Z
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M[.%'OU"0%_W;7E9E6..HQY _TRJ<&#Z OR- ?@/)" ,Y^]6H8"5^5[; KMI
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MPO%NNCE>6QW@"QDE1M]M*,E^G#U,EN)RY2NCU.GJLE!+0"I[RDR0O07).#=
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M15Z03X%>39BBJ0>^?8F!O4]5".^7$*T_,'C%&2R8/G;#T6F'E8F$:;!1% T
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MUV;_42^$M7NMQD6-@^@_E3YE@;=XTSI=<>SMS+A)KG/-BE7=L5>K"2JAGI9
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MNT<@&[-P.$6Y-T_>_W"X?S0T>Q28C(OIC0MGI%Z 8B9?8ZE-O[]M;8=SS(C
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MQ&A''= ,U+F@%;1'4ZK6^\,K7]/N61,5IHOIVMFZ.@BD+"IC&=K:4T0I/6E
M/!+,/PQV.WX5G1,7=J6AP3_&&_?SL"*U@V16<^-8Q>B@%9!B0!93R[H;,6\*
M&XP0C,OO,\-OMKK72;VT=<?S@S.U8HQZH59FLJ>[P!(O.O6"Z"[J- SW%UAA
M[B>X22;W )6*:P?KA?%EMS==(AWQHS#"@AT2&93B0Z:V25&_.CPUS(F!]HFM
M,\Q7AVAV4Q<)WVLFRWKA:\;HZSP#3-*% .$CP$/2>GBF0%1FY/))\D/"CFJ2
ME\NR4O/ 742=D>C(@$C%2C./E:%HVBG6NF8N.OM(836=8A2JHD6:+RF0SE@N
M6![DGTH=-1[DQ5F4:8BO]4 P_N[Z3_1RT!<2A10\$+N]#).7 -\[Q_\QH6#T
M>@G0(XR*X#TAWM<MN4X:)'DM>1^?P@ FB#F,J>F5X>=SR(^U%X^)*GX),]^5
MV/BL@#1K*4S9042$ZHFD;%PJHDOY0TLD!6.4-<:/-?D81R>,88:G[BSBY;.G
MR?"*KLB)=W0\6<;-D&6VXF^#,P&3H$NP8E7<#.-J3>%/+"'3,2H;D[$J1:$E
M!R^9Z*@#UL/ #!.#-V %HP6/SPTE?ERG63#PESFW#5IE;A[X(^OF=W8CP-"D
M:#OU#6#S-W]^_0/A_^[1RGV>NKK+B[Q^73AOBB=*6CO^NK&Y03^7BVBB?[[R
MD"^2N)KA1S<?& ^=H(EPQ)Z'^E\;C0Z8+6T:5UM>RJ,'3Q:?6IHL7M(]\?(O
M7E^?Q[__U[.=W6<OW&Z?ES5R-!OW#8?$QMQ^&Y$&(0D:-!IK8" <R1/KW[58
MU^):KH/2['FHS4_/.]:%/V^'EU6S>+E"I NT>24+U'G/+#VA8>EQN';\:G$)
M*9ZKS%&?:&=]Q%Q<7M!-\E$9VFEM)#DZF72O+HIQ;WR&\6!5%#7T8"/!]_)D
MV\"K7,*M#/>U83ALT ,)0->4I"NO1@7> VZ?IB' #3;CG-%-*(QF831&=;_%
M#K=C^YWG*?:Y<<#PEGA3%EE72*V01?P.J_-N 7L,4WZK(F.65<2K72FXI36U
M0,E]DV1N>ML^SPT4BD'B9?VB-'<+MG!A$[ZVX=-F<2(T<E#[D6]N43-Z6E-L
MSVLSM/I)<@/BZ+U5T3E6PU!\><48R325BPUM1>_^!Q-"QVHRD0&3P7+@TN2M
M:Y&E8C7[.@S @'(ME5=S*G8E55)J4Y$RS\V2LUYK[V*OU^PMO>"^TW"N% G?
MO8^$2R3\R7TD_-[BN[?XKLOB&PKY_[J:GW(-2XT3]'BNK:_0,[_(H\:[-K4%
MR&Z2U>/\<%MB8 7;EQ'N4+!&F'PL>\]X*1.P]=><,3;0)C=2+CP\7"/9G*8
M9-T<,N67=0)YI1B+H+1D-N*5ZG*:K&6CL=9QQR>^CL/MW0=^N=(,:ZKC<!HE
MV"#.H4FA"[T]94)I>%Y:R9ZLF$E-MIJ0V6H,1"K3N0OXD_-2&889WCJ.1.1P
MV7[V(!0:&L.I6,W 0EUV<<@ZJH<D#YJAAN-3Z\O5G$)T+D(G0TI7[U'<RMA$
M' #[O!R:?2+,+-IDTMNU 3-'<YT"8QEF@"P]0*F*<UVJ[967>\DGGWZ0<,)>
M=$9,LT@[+-KPT@3Y?O0?ON"F&:9U2@6X!'X 8=-A(DS[,+>/21OJV*Z3.=3&
ML!->E5.FJ3$<:W::YQ7VI:XXQ$=P836/^.0UP$TNM,9%\U/9A^-HF!C8CVM0
MWM^?/\_]N6]K(_0AY$@XX^! 6];D\:+?1V'R9 JBL9P0^%>W"E]S@YH;T=XJ
MY9JR%^F!912Z5[+CA.+7AVW<: W!L!TZ2Y<)RH'OZ<(%&AY\[7#OI!,.W\(]
M]@;^<_2&5<?AH4?=ZOC'?FD)+]LJCPNR?91B%3!<VCBT5%S"%Z<2/5HJ]7$E
M%T'::1:AH4!]U'GA=+""8 ]%FH"2P@0(USH8C8B#D*HW>]-1ZI[7F /^V]L=
M 9M7^72J/7PWY@(7 )HU#,[779F; Z?^P3I)@UQ&L!IT)><<$J.]EI"<QCMZ
MD,35F8>D*/#)\^A3,L<@D?!M"J7"#^Z]WRO;GT?9OC84;(XUXJ0$IW"F)S-D
MY!M[O0]M;84NFFA)#GI*&!5#:[D#EX R[(>XB1,:$1>@81)7L;V%*4(LC1(F
MJA+U<"-]*747Z^IN>N$)'%<J[LBY6*A-6S?=@SDR)#<JS1CY8\HIG&Y#8ZP7
M&G<1-8Z4E"ZU0Y<#XZM=VB3X:KB#'2H3M^K5+3+U:EMTCE98VUB]Q[I?DKFQ
M'#.S;<.6VBCV*?)0,;)TX"OL&+U;2\C'B#C#%X]F8KNQ22OE-GBC1[8!B>D\
M4C*7*.(+;%GG@>4114XH%3>[UM&*',(6T$\G:0XR^#M5@>%8I+N)\*Z;&M"3
MWT<CCSW=\F3I(/TE7BJ1+3.#R"4Y$G*&A'+2\" V?*A*"K )VB;/XE5#/:Q^
MP OF_H;Y^6Z8MVX>3Y-_@KW$BDFC'VP1!J<A\PO=UDFB:>O1)>C-VX17N29U
MZ57<$03%&Y":3J7G_6=?:!QSUC5>HJC5%UE/.<;QF+73\A?%7[-"^7&S!DF\
M)N(1,M).*#2CG2:_J*!B"'1E*JE\EM &)RI=I.^<M=.[M:8<I,C'6,<BK)R6
MTY/CB T^3X?'4W^CG<?3#^SA&"II;N2N-NW58'-KET=\\-YYO[1T%6)1[0;*
M2TGFI9DS[&0]C285TF$)&SDC1F&?<TQ1\J)B=23I-21:[\[RBQ]007];X ZX
MEA^56G@DGA;((S!*O]C7EB];QRZ8)D59Z4*Y6NK F',6_EUR>UY08N;,N4E:
M!Y\E04$2D@GX@WY:/N=G>35*\N5&ZVEUA8@%2XZXBQH$5@G>V$0].<ZO@XEK
M8ZOC9=#H8]#@#T7'NI4AU.T&83+F)K_0\E+/7&^:/X%)&R#RT]5"E.I 5O72
M!;6MIKK7*\+&R)B<SE6_'M]G8% ?B*+X?'!U%1NKZ2BDFT97USHKKQJ@0@IG
MW,L)(E B4U1@\<"]X _B=K.OCY<9:)4)PB(0=HC>572>(ZG:4L,1K6Q:0>+
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ME)@6%1Q>I;Q6<CIFK;+8-#5J78]X1/V^^T\W0S#$&'ME^7+<1W!,Z]T)DU?
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M.!_YQ?C7K.:TBUYB#"G@3A(42;+S@BMADJV&V!LG7<D<1.D2&X:",YV2#YQ
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MAIG3:$@U0:_  ,J3"<F&0N&71_NHM=IM+(1BJ8[=!$+!Y,KOA#N-U,4EB<B
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M9]K V2*/:.O(4O7S#Y"Q>=/ I>I3\\AZ-[.!!E?H114OV57 #JDS3BS\[-X
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M,!)Y/[X?!)8^2<>\YA9NY_0=&28<B9/\+#USBZ.=KWVF!NVS^A8V*YA7E*P
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MV:$S/RI"?P>"V%RZ/L5AH=J">!-CR3XF,S%ZW^9!%6VQK1PD73.<216O3;,
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MJ2L7JV4HYG/I>V_43"(_ZA8)%42Y/^32)0651+6=N%6<B"1[#Z!IA#E3$O-
M+@Z1#W$YQH,NQKLK-?=/B4>B@^$4OX#_MK'-W\@4UQ]7>GD#/IHWDEIV.R$5
M8I[;EI_7TO+S&1 4GQN^(12.JP7!P*@)64W06<N2NL>I$DPI!+>K)J-]4CNX
M1H!HHQ7-M+N':FQBV;:YV7W)>99EEQ=4?W>;QA+,LXLU8&E<K*<_TF[@YR/
M8",<@.3H(SR= 3W_ZB:V+RK&/&2)@75$D+&2VK8FW*U5]5OZXKC*KGI+%WW0
M2S$%%AD7NKL/NNB]WTO>1GK6 8DU>$^KWB6 /7=+W]8G9#;CD#90$7C<O Q2
MF7<U$"0L")W8.OZ)X"&8[9)59@E J*HI_@ 8N2-@&,1\.F=Z,\]=:JD[M,6B
M\YQN\0<2 A2K?M'%MW('3=LM &&-!BE">-R>51G5V;&ZJ/S$24YG,,1P3XI[
M:C>LAPNJ=Y19J3CX/JW+4P%<3*4O^3\K ERP+NANHX,C-'%V1XN_9G+J>*&
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MK76,9%.U&AYYM,-*=<C+R=$3K#Z K@8PB4$*=P0OU?" ^\*2=ET)B;E-6(H
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MK+3'8&=/-3 M"U)PRYC$/TOK5IT:U=PIF[.J:QMZ48(_:[^6.)C8TDZIBM3
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M?9I=G%99]7RR.?*:F=7V2J@*H:W:94/,,8J1XRDH!_%YGX1&#8V>I"U]RE/
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MV7_P7V"';SLO?FGL*1!-K99 9W(?:^ (02HASA]0@.0[-;5)<\HI&H@%%J#
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M=X52%)FBV/ XFX7\M6?XT%@/%YF5-?H,P*_ROJ)(QL4YE!PT%.2="RN[0CG
M&3@L]TRXA9\H/Y3AQ-[+F.H?OBE]\N6/NSY5#O=;;;/W'I*;MI6V'[SVR2VG
M[:=LHAL3H&((O1_+1U2H38%;J>HG7:F8*+K.#\J4]S00C#6%X%I[9O%''^MF
M>B$;1X]GJN296)A_9GD_<F6!%(;_D8<@[!#A-.OR+&^6GVBMWP#CQ\*W<,+
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MR2:W9M*N2A:UVN/IF%*;]9-!V6ZU:FLR73\_.KEDB<MDJG\F9F.(/1XF$<@
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MH"JN4?483")T8%+1+S,FCF-/\B85#Z;X:C[_,Y99-ATS^"<J$=PCBKAB$#*
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M3P'HQ>6VYR0(3H)@AX+@?($@:+WY\"=-$T&#87V(1* +@UB'$2Z59%C"'[&
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M]$[*%($39,."(ILJ,'T8!VRXV(.[@SFC,I/#,9/8[2>^B:FD6B1Y%)I]^,1
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M&/ P] )6P^%@XXHYD8'B]K2S??T3W7$(8\+!<AU#I%4DC&J%(:!D-$Q&)K4
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MB)6^XM]:T#1 $!9L)3"COH"SA[ +EF8D&K.G@*54\@&)L$T(UL!XV5F?-@@
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M5A&KS[YHY<2$$IW:[J0A78O.78L,XXP.U)?Z$;75Y,I@*4CI,ZV(V;![C*%
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M*3Y,^'HJ.!QI5=UW?4GZ#E/^.Q#Z,.+!&:VVT %:6DW*T3AVXIJ_JBUPS6_
M^S[+^[N;9I6%>T5FE9")P_I-;C)]B4<7[D<KK>&?TSIRLQKA>@*YI*37W3Q%
M"%^OUI8@_.&VXBDM(-;E"1 K#Q"K?@+$*A<@5KT(?F-]QP".G7@.YJ&A8Q[&
M\X$(!105(<,J8"KY((QMN@@(B'F/6:P+@A^<P$><A"DL@$ZX A"A#FRCX*06
M@"5F9B+QAM1*K2S K!L\>U$8R#2-%/8*T4(BM^]+ %LBNDZ4ES#Q'<;/0B"3
M48BSQO_PE Q"^P 9ED2,W>C!:CZZE#X49P@D9OHRJ2=*0$QZM<" ++Z#A]HJ
M;(F[6@2]KM[<@%DR:8E\$COS#0A]&!;)/'LD>\ZVG)>T$R.EW=Z^D;)"ILQ*
M?7ET3^HZ22USCO"]&Z&RH[RGE8;F/AT"_T++9<WF/;^4S[;9:(_XU;=ICBVS
MY":UJXM+4A;NS.$:/VM(DB)(C"!NMN5C_,,>)1$#<>>EBFX3,VJ'DGTQA<]7
ME]6*V74"1[]1*C8D:#P^[/J2B7DL426;FRLOJS]0)NK^ZDFNL?$2@HW5KZA]
M%R^F H(ON>*]='44&R."./#;(L$^<[X;M4;S(/2TJS5"WGGXMHIQR>RU3XE[
M&WP#=@._P'O[_26<UT1^&BUVY03E<E.^M4ZRP>8IOQ2JUBY30^ FM?:J(N_^
MACQ%[AR$A8OZ8IMF3XE$A1,%Z@>2%@*'[_QU';[/81+-.7O-54RU<IV]QM;/
M7L&3=?'*3I;W/(^KM9H'?[*:!\'59JK_V$>@D.:]<2"D_*W80DOB71SZ3A_,
MG\+GOME>'H^EE&!6F]S#HA>N-?/"E0AD2H.'8XBI;*QP3ZG..[D*\Q*;VP5J
M4?>0ZKIWDVT=$^T@Q P2 M, $FYCP<D!!\^SSC9_V\A!+$[&G][HZ99IIDIB
M(W?@)0/]O,0P(QA^2L;4-BACIM!J#FZK"HN7\T,0+QF0MAR9<Y^?JK($+NE!
MPNFM?N/2J-9=/\.EX9-Y NV\@$ [P1RN)$/7V)?%0G,#:(=+AG^W$@.=FU8X
M)S0Y'6Z^PT9KW]QG%S[-B7;.BV;F/;FMI$,8M_OA:SARS7.S8M*KS8C?_=NO
MW0][CC;KQV&=V/_\S= K7!9MV\[;H<J,P[1;->7^&;*A'\6@NR&W-8Q%JT-L
M*18Y(,BBT9@2"/!CD2L:]\(AB3!LR'U1N^ TR\PPIOT8N8Q>Y<7<-CX9XB.#
MQ!]Y0]\U!R'FQL6&AI2)/>O#!!N9Q6"O]U2]/#"6B1:%N$:O[V$6FHE-O;E-
M*W$P3.C16MEC7F44/L,3Z;"Q&SU[/=%V'DN0[=Z3P?.A*N27)Z_WE$G6C-R>
MZSW#$X,P<$?<L2V(85!>+<].IUC/!KH^A=CBGF?0<V&R1%I\FUB]29T/@[0?
M*[5C34EGCZC)+*9K9@F@>JW'\JK1Q#-#4_[H*+*I_MJ';><LTK2U.K;*Z2'I
MQ1/<P+9JBK-+7?#BI(<SQP"_V##98E5K]Y[ 9OC49I?OS:,;]&3>"1 ]])^I
M03HBG,78XE,DRFKT4KFYP@[+-*DEHO#;Y4G3:,\=<=5<1J&B""U4)PGGY(HO
MM]&/DYCO-YX,UZ!]<OMN%+F.H&E]=H/.)3!-MC^96C4/]F5&^U!*&M>VP 'U
M ,X+49ZWVN#VJH03.EW82/LRU17R>!H-SA<(S<*B8\=E SJ_H5:;YF-D U-"
M."0#_L#K18GO%>H3&V*>.K)EN+W(.5(F#KOKP)K\D/MH2H:?,G=.19=L&A^6
M3CDQDC?H)A'FKXNNL\R@)62B@3-Y<JD;J&,"\P'.X',;6 =K!9 )4FMA>AHS
MX5Y<X%7<%7/B)WUW%J=-60?A01$M:#!O)&4/3$6)%FY;2GTY[2A"W 'J.6MV
MXCCL>40 T:I,\DGUGI<G-\#%81=AQ[3CV:04(U2S6I<VEB&:<<,L>//$W42.
MNOA.XC6DR[TU3DGS_::F.X\A33<K4?P'YSI_BFOPSR6F.(T.)Z=H43=E[G#M
MCU\+:VL59FW-W;*VN\#L#"/062YE#VI-V3,FFY?#?0Y$14^,H.-C34,[PP=1
M>VG4WG\1/^S(;^GS^ONWK/?=#H!!>#W;O'^RX?"9G8_FF7A2?B4?L+#]<9S
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MRY(_R[>\3^+).]'//HGL<G21ICDJF51]/&\GZFMLUZL97.DJO=PD'@:XU&T
MEZH EPX;P*4G4F%?3[E?09+TCT]BP_^_[0[V'OO1_WF5$Z4I77P]_^B>M-RS
M?YQ^^N7\RKWXY)Y^>N>^N[@Z_>7+^?G'\T]?K]P_+K[^PST].[O\[=/74_C
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M;+UKK1>Q'KX$L2I=O2&X96^L?Q,,W4_!8!R'*69I?!ZO'\4=O0#%?1#^T+T
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MEOLVB-66>=HV43OK5.YL%F.MF#176E2T@6<6W@&AV-O:MM?:K=E36JR9H+T
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M]M^8$T*<0C)>&>E,NG>FDBJD+VL4L'0!/AGT<T94PZTY:AN/(XL1=F+HY>(
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M. WC":OF-,(I]58  J'8%DYEYF5>00P7OJ2<RO#Y/P0,:W311;["/!B?GN'
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M#2I%69RFOON+B(3U$JVA!K.:,SD(K)"DG>RD#F=@&U4#LW7D72P4OV T5&5
M'WFEC:SP-L[;.!_S5D%1N'.*]A5E \)+;LAXVD-_NN<.*%&0&Q%>SW!"7<_
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M,"48JV!*%CYF750<'(DY;=).0&-&O6"+Y)OJAUN$IL5&M]MXM2T@S@1K:F_
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MF&>T@Z2B$HX39A8I19>T7JT$P_?^E&T\/3X;AM1(K^-$)E;2!/4$/+F3F.^
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MR!VCU.P0BS7X2P&%TMPB2E5=,WH>@F@"MK5#$\7]G=NQ'%OU#(4$M<*L,ZH
M4E%Y11)J;,Y[52U#.&74Q8^"$?:FR%Q<KU6QHZ>J4]&G" Z$RFUX9] KK(:\
MM /P58?CBG/GCNV,J&HNB'+A6K4-BVQ38&TT67!$V4$RR"?<!HFK..WBE9$0
M0\QYWWK-YP]AM8OA2TW)%K.&U4_N3F?7O8*=%.D87IN-Y8DN N:Y@QG4MWAQ
M1H+BP92-#)=\$2$$>BVQW[/S2RYRVNG"1#*!XTMB_!#GUV,PP=64<!;OM:]2
MSF+K#_MK><>=NAU/19;*:DB?C-A<5R_62B[4"(>S9\\I )_.+U//!L7SG>*P
MQ#S& ?"3&/XC9*OP\$ZQRNI7PJBZ7$:+)%/AO XG_OR*W27Y^A2 ^XQ:\YG9
MYL:K=H\TL6>ECZHO=33]H1M3?&,5!(>6-?Q6=6FY/LLS2<J$2*]I$4.P=S.J
M%G% 7<_--<EL_5L"U',(0X>=4L">904'%7Q@G:D?RLB&K/(&965LM;@'^4R5
MS;K,OV8<]%B!RNICN:&$IXAM"G+**HX6O"(:4\2'BM:TYKNM:=C:C!_$8>A/
M4[!BU4]-G&/%8/Q9AGU(I3N5*BX,D NE(I"'7PSMKC+;T_J\H<P7HTS5=!2K
MK./(5V7'=B&NYM@J''#+<-Q<,9,):0CV\R D"S:,H^L]]"FX",LC5(JT!?%"
MEB;C$?NIK%:$R6)2-O<65C7<)E0O^PK+MZ9-(*IZ"A<&X;Q85>[TI8J*6?DW
M"LZQKF6SG2)!!Z<0?%C\*F08S'HP2'S3L0]ZP4#D=$'Q(6SDIKP8 9F]LEVT
M_AL<)RSUF\@H3F"1CL1TT @!<9YA5ZU4PLX0GL@$:#9G6D$"3 6Y$#@/GR::
MD+.6J(W3-##HA63JE&E4*>Q*RR&-!$%7"BH4ZREF+*#@ *T\_*8I9]"Z"9U
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MBE-27GFQT%\AP>TD6B 8$YS>G%+&B_662E\5>X**HQ?<''(ZF!:3QGH#I,5
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M-7==@FVH,G;?BWZ2XW%RL2>\HO")5Y@2-GED>BG2,_!G1RCHI\(^4*]&U>$
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M?\,Q%D8"J!BP2L6]?[;O$;V/, _<<T(6*D^]<IXRG&)/H%B@MPE+)V[.2V>
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MFF%-5<.=5H6A2@W\SA)4S46<W%N6CI^Z(QC5O =(=(8JT#DFP@^8'E-'LTP
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M$[JB,!*@4B..,_0,P>)L.P93[C+68ZST"$Q3\3G:)Q=GM&E 'QL^931'H1F
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M.@%UA,()+@</H&T(N]&M"!-/R!KW:C)SANZ997!CO$H#^%HWC(N 0@[J-:Z
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MA.=,8C+%P&(-<#N(SW@5GFU?P6^H,CC^4C4D*E6V9;"0FN-7IT76!.&+"?K
MB6PSA 2M5GB  AJ!3G#74M=MPM5^4%D6)>F @#U#':0=64)7 QI2;RS< ''&
MJD8\5K@-X/9,K0;BUVJ ,.H4!:F+6X<MK$$V+(Q@<(G?+?L'_/8=_5ZI65OA
MSQ2 8FL=-/ =;PU< '7B@-\9_#9WLH"7AF=9SJHS"-QQ31Y#8*7GCP1S<?B0
MH6>)"=".(^TC)N@:31"O$5\ZN(^:F2.-XZ:?WP*,8.7Y;P?RP9(!TV*-#"L(
M5>^O _OH6.B'"H3_[:L0_TNF2/CO)U$MPC_"I>OQI:>NTZ_TCRY@;NFKWL^,
MI\V0LF4A"@_;#8YO0DL32*^0WV36< >37 <N%S_VJH;'7GWEM#8Y,Q])SB##
M<\XAAQ19N_$3&MW/%D_77,<L90#RYCP6Y^4E?V8=.'E#XC9/<MOW@W>R6*_*
M2KLJ-QKO%Y[2:C5_FN<$@PP!K,_@>:K$$$[H_7U2^P5Z_*>EQU/#I](F2-<-
M_BN=V"L^KJ1JLX.W,[46PI,V$SLU5@CXF[7F6I#_M"X?I)\_6^.0Y;*UK63>
MK ,6")A\16R%3>?@,(\CD3C@(6)XJJ6 J"L4,)N(R.*1^X![XHS ;+JCG!?;
MD.4JZZ"Z:K7LU&:NH,@U<348:ZND3>0FA2(+[N/-%2%24ZFV&UEHH^1-F^V=
MOXWF.?YG[@#LR\C:'V0XM,E4^%833D<04%:%S[6S6L[H5#K5CM3(0-CZGK#Y
M"?69^D!UX0H\3?"4,>5W,\J?]'6EVFA+&4C?V)-^4YGN_D5=H5\3^B/B8L'P
M3N@J5ILM.0-=FWNZYB?2MQ@VVKK0 ^*[A)KPAYLWX;%O9!8CW=H3/IM 9PI;
MNH:QX- ]W\3\B)N8PKMFD$'/&_GM!O!!.XM-;^<-BE++H(=BCO1\BZ'"'9O.
MJ=-0ALJ96#NBY?UR4M<+#)Y,N,ALZ"19MB?#6>0VA_XZN-]58:>HI9_FVOPP
M5LNEN\W.&U2]9K;A^?;LC).LTUIG9^T$ZVDY]2Q3D!O5EMRI*BTQLNVL\40Z
M;T Q5T<P*SJH!$4'X0;!VV:WS9NF<09+Z4":<P^U)4R6*SAW(\) B&R_@T]A
M@0M)'4&6&Z)P2W2AC_OT]XYP9E/<3K\$UOM*[K&SQ=57H=V1E$9-. E*P],J
MO\)S#7WL^.(!ETC*1V'(6KQ<D('MJ?:4P='TBV<" 4@IK=# FZ'\5%!=:E9%
M,2HM<P4:82D&WT413M4)=0&D"P^["5S>".\0+EG\A7_/ /"?85](O[RO"BVQ
M796:K95SG.$!!JJY@CPW3W2:Z",7LQFDEEQM1%?! 8G.$M3=?;9KP6+<D8UI
M.#S@TKOM\G,4_G$0K,SR3!=&5AK+\!,;(ICD1D4HJ<K ^,9.M?#Z&F=B>?RD
M]@P._P2'*:CW]S;P!#\=(S?%#29F<[ "GN@,-09'9.5X5AV/#2PJ,6PVJW6Q
MN6ANZC@>TU/L])9?T<6 _A;45BW@&RXHL-I.L]IL;F6".8[@;13""B\LOHJ4
MKJE"O=;I_,2 2"WB9-V ^!CQ\B\A5OX5/U2E LAC7K-I6G,@NU&(="\XU[,2
MB@BY=.H$IT<6U)[RYH&SRKX,C0'?D#$KD>\D[])WN@:!(Q.7,%9'DR&+4KW*
M. \WCMC)?]9GDK?>XD64T=X$C(D+_@]X@XJRR!M\Y'U)9@(+9IH?A?YOJ:W4
M.B+*/'^Y)@"Z DLK2&V&K48&;)4!26&SB;BURXPML56KQ['5A>\- 9$$J&JN
M0E49\!3MRR'%;=@<KK#962JF&IU:*XXH7O>,L@>(:BU E%_#7#8T)1R;.MXW
MMS;:ZE(2;7]XX-)*7&^UY[%6!BPM5:V"HBQ37 OQQ*\\3T64S!#5F2&J#$A:
M:8.$1MQ1SH8HO- VKJ^\>^Q;P!$EBPQ19<!1-F,-DM*IBDUY;4SAA84Q3,W<
M!IXVD:IEP%-VQT90)+$JM=?'%5Y)E2I\#$WR:T-36VY5E0V,8#TF?+@7$YXL
MLDOA5T8"2]:&Q[RO0:B_XD13N,AE%K*!GD5]H8EDK9'P.$X9L.1?1(#'2OBQ
MM495:4L+EE9[V>3KSH^,2_LCXRE'QN7]D?%]DB77)(NRXR3+M>9:H:\4Y SB
MI:!IL=Y<KF5I/+ D-&\HR<@I+3+/"% EM%LPN)1K"+P,HDJ:)=TL9,H86J9!
M4UGA'E7;.89P<8 J64* C3"4,5;:!*(&QB3KLU"FF&1C+(FM:KVY"9J6._^;
MPB,WFM6ZLD'.)$:V)>YI);M[*C7E:K.UD&2A>YKT_20(J19A]85]O[T97=^,
MUG=L1KG1@HC35\IGME]QGR%0C>X/5];*:]?JTG+;L#4PGF40UH&B'3$"V:'(
M8@3RAR*;XE\'#J"ATI V0,<*9;\.#"VY*C4B*K6RE33*LW,4E85&@)\_R6P#
M=J'<"W'SY*M6^(T=*_R4W584JO"\318EHRB5G'8SUP2E$BM1VF*LM!M(,H1)
MNP$DJSE<!Y)V;G'1;B#);A;7@67.-&XQ#EH7CGGS6$!S6%>J<H:,?3(D6DSK
MY3;S&48S;B(RYG+WAG1[AK2Y8T/*65IN1PT&/]J88^A43[&A*?9B.W \VUAD
M!B/?X"EG,+*;B<R Y!D^908B;B J+V,@TI-FE?7CI9F!:#5:FQF(?<ZLB)J_
MM6/-?T8T7[C9N1!)X=4=P<GF+/)=;38;BV*HQ6I7E&IBUNK9[-!4-ME/R5Z;
MN@8@^45SNX$D:SUE[H!D+EA<ATMRW>7*'Y+LNUOKP))7-+<N',6/YNI@K)=L
MM2^.YJ1%VV*[S(#&K<C>?F_/?K=W:;]#ODKS,-OU5E59[%+B>;56M=-:%#&]
MN/>X\VH[>5]MEU)MI^RK[9Y]04MGJQ>T+-!WX:TM2BV\G^7V_+)[U[N^PGM;
M^-TL[)/SL\K=;?>JWSUE7U;9-V>]V_/3N^M;H7=U=GYS#C^N3L]WV*\]5TTP
M.+X#E\/A]_KYUYS=$H/=>W##V_>4Z:Z:-3O?7%GF6[H!D]$[Z-S$;KO#N]A0
M;17V^H$=@G!A^0?&+<=#QP#=6IM=THO7;[ +#BG[&*2#739B16Z>C^"RRF^0
MC]P:PV\U9,?=_0MUPZX,X5VR"]H !U<=$^$CWJIHXITWK Y._B7\JI+X*I7&
M-;_M0TYZ),][+-@$(*R'>(\M<6GL=L97K*&NTZ^<9*=8''@=>,D$O&@1O(0W
MQCI5_QJAN3O"^3VI>.,PY;>;L.N%D%/I>$QTO!087X#XT9VB<^QQ1O2O3)R]
MBIT;   V4:V"K1]F$\_/B&.GK(&'@Y:A"_PV8N)BAHN:>,6S&EQ0RR2(]:G
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MNNH)B\7L#C:RU$^#UETP4'?6L0NL??B(C]'NHVKKZ!:X4[Q4P&8=EAQFCN]
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M&1-^:K/9(Z>]T^9SKBZP/8M8E[F*=I6*(HG+ W/H7#IB7 L7/01#SA/AU%B
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M!.Y]F!"^H8#Q,E847]/8Y?29A8?U0C]:)(BD$@/LA-$881!6L8\4%G',0N2
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MNIJY0C:;(CZ@[,9U&A0SV\DO@@VPA@M&(J7,FW37&%,9L-EL$KMWJC:)([-
MV8_P(R:A&J$)ZT> ^"0FR9.9D*A5,HR5">J0C35CYB1T0$&B3_,X"\'D(_D<
M&(>KU0;PN_T.Y+#$&19,_P26(5. &!@J *K0$.FFBJS]S)Q8C#\SN(O##YI4
M'RMG$GU ,FU XT?F2AQ'!8,#FE)H;&V2'/[%D+Q/T%8SB0+#^##]$S'&I@FU
M+%,PC"%_L\!G^D<'6J$(_A1!S/_5Z<%3KOF$AC@KAX@+_0D9%3Y73N8?+!FW
MOIK_VU*.WCWFOA[9/M&$/4!_I*]=B5RMN_8%AVRC_OWL&K^$C&*9\7*Y1C\Y
MZ_3#)5=7$^#%/-EZCL01_);8]F7F*JWCIBC (.?#4%]5R'@4ZO43+J33D4C-
MN72APQ2C>P0(Y]T-*;0BLS)G+*Z=GD^]MXCZ/;03]09**E0&$X".27IH][(U
MCF^QF==RWI[=4J9"@-.U ;H&<KJ7W+/5AI5X#3\_8]+<V% 'P#E0/"D*M?^Q
M9J1:(]NX6PRLM^&E(ZR(1%OVO=/,SNQ06,3N E#=($<9C>_BE5T)-*?AI,#8
MGAO:G4A1] H])UF7"TFD- Z146^Y$!J[9[+3S51W0<K(*D2)UB!MJOH,&$I?
MB@B1TK"5_G$X JK ^H&ID)N3J Y7Z\JH$'1:G3G\:':WP:"(XJ##HX>/[.WL
M4]];IWN];I HYX=>S\]V1AH5*J/3D%!'<=<XT"XUT/#YN2I'>;G! EU9YVJ5
M]8K1TC.I*M$3%<=<5>TD&"XG2UW*UR\AJ!44P.9W7X[T+.G"-,>*G Y^R/@!
M 6W-L)K-',),3L,@'0B,!+L$+@*_!4B3<V'X-F'?*A_0?OW GNES3YI'(PL4
M-2R>#=?H#'C:C30>, J^:3R]+P]]3/.@5<-VJT8_0J^//N/*A1A4V[T.G"HL
M+XL>NJHS@+0?S: '[WM_C!Y9UWI_V)]@/>9B8OG3_7!H_M;U(B'7"<UEOVBA
M*+TO?.P87&>'$N?X)/T'/LX5RYYB(HY'?T(RLYF%5O#P03L[]V?/2#%/69E*
MT372)WZO<U9*>C%:+N1M?:K\5>HUNY#3JVH6:M?*&Y<U"G,2%#7\\]U[- [^
M?NUQ'O\9-X61M@4_@&Q167';R<EWP*?:^E3J@MWC2XQ*>Z^GF2&$MA\^8#41
M1P_BU#U^"/_*Q^,#PLA]HI:G<F/&<$@S4FE+2/5A\GD)>W/(_ZD_N%,$P!X*
M*A&7;;?/<29P^SN,60>9M4M<"/]=.*X45 ]=&DKR.0;B:0BQN2UB/$NY%#0[
M]T2J4!JT8DI;CT6\/?SZYT8;$]_M8.3S['7Y KT0P;' I(H@(@R,XNPUX?&(
M+(!M+4,7=\$D<7Z$?>B\'PMJUE"BZ"B&/]E6W'/D2J' LN*LW;@.Y>W3F8T^
MVO*5*R$> 2H6P3?S$A-/#!UNWC#U/8.$^72\/S5Y^];50*' ] *V@"F;J&C
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MN. L3VXYX#HAB-#6I+)"G"+VY:2T>/^1U7?>+!]P.CP\+.R4[.7<A4^,C<#
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M4(Z>RIZY^]5<R,O^2[S"/PL)[9K1UFC(807BQ!I#+Q%IL*CIVGM;5O=6OL*
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M4^@B=[9/L*ZR2SMVDIA5U/*>H;@9/G81!@HDD.IGD Q"W TN)$4'(3B%^1&
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M=M*:[Q\)D0Q=V60\8GU%)!!IJ%]=*8 +%_*6G\3A8X:FPZ,0O92X381(VRT
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M,F]AV]-IJSH(X(^\0_B?-HZ)_UERER*V;74>/Y2+Y:TT."BG_=H,/_-''UT
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M0LOW$)L&<LC3NY^\-MW!>=NQBYW)V86.HL'N8*(9E&1>UM97%#&[04>FXX_
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M]B5P<!8RI546CP%EDEME^!:"!_,4GQZ95\PYR:Z<R] *S1K )-6B4EK5GU&
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M.5-_6!BG)@%'5]Q 7-A+[-CQ%V:R"(3;S];Y1")__'^X[XRY;A'"JHB)Y%O
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M*D]WYF'36P T(A9=IY(_]NFVYMZ>V2_6?E3C5L,%@S:V_G65Z] -.6[M'MT
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M:,^*4F:FCM:!4\E(\/[[FQM6*L9GP^9F&XY6]-TJ=&X^A/G%[1)M=>0K8C8
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M_ $$!VDW/'0APVFDQ1!CRXF@5IJ=)5#OGZ&M)4QW\CM5/Z4&W\W9'!<26K&
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M&T!\2U^"<BD7A7^%@_%$-4.!-AN"1\JA8+*834Z1?^;R/)P\>5>!*!945:
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M&2\@ZY:5E%=JWBL6WCGAV=[Y:>2!9^<=@4E")'SO"6-A14&N^+OX'9+,MNA
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M<_W$"8]2O,+"Z<7,_OI&Z5]UY$X8[B7B@[+E;I/?-JS%&%7_)]>  #]X!^R
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MIA4\?A*3P27Z6JQ\#[8/)T+IK!^\4=8G[%["?TY)@/8![:"@/^QL!W(W6_]
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M0)59'_@Z=[58LUFP$P[_'0[B,.-%.QXT\R+6'B>'\ QVB"_EB^"&20GF%^5
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M-@#685XI7XFW4A\D&\#]^<=AH@W\2NB"%[@4^OE /GNHK13%I[U3.EV(LD?
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MW83:\N/(NVM2!9XV&F_G:(;!I9&,J[,2S,"U$WDPC=_L(GZTC<8)C]6WD(N
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M&D<02<+O2+3E!*YOAF=$C$7C@H;"-C;L0\,CH$_2QJI/0./X/_KE")LS8-G
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M<F YPH\A]0Y 5W[$\1;KE@JE89A+=:N@%![.VEL3>J^V^V%UC$=64MF8=TU
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MS$AGZ#M,Y]"T80_R_0\4<8= 3$K!FXSC30>:XNZ'U5!BQ6L&':5)S[FZ@QO
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MJ=L7C36&31UD!(,<4D#7SRG:4#OU@ JUP!76O$TU4MQ3&E!M('4N0Y_J#->
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M_2_RWC.JJ:[M%HX5J1'I-2HJTD4Z!G); *F1WH3<BDH3$0$)$!*E]P@(>(.
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M@QV-V&$KG<"D"'XP^*\ V$#N .ZP[\?G"Z:C5V*_N(=; 8J]?XPO&:W]&OM
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M#]>MQ.$KBB5+<B18'FS"1DJU%P/9"^2CIIQ16=W8L^,Z2'YWT.)<2I$(&N4
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MQSD@JU]>BX%?GJICH<>;(U.*DM9<P,CN'5PR\96V4>15_/GQ#IT=D5W(_G_
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M94YBA-8.%8=6Z+P=(ZC=8HYR>/_L4-\!K;GOJZ",7@\T0;JP@K;BC ($.)K
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MH%!:26T\*89T$SG%I(+<89'40GRY"8/^&B?,D4+K3OMW^CLUC< / ,']\G)
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M63+?Y,%35GW)J?L]4C-D9]W[]8]P$9NQ(5S$F"5S -I<1H1.9T+;UNZE\*6
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MXX()Z1T5Y:SGZ1*LL )ZW\".7IRY#4LG<68"8(L(,6A3*;EL24X&X#! I(A
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MA@<OQ\5I$6H&^UZ5,PLC2KO4HE^=>^3Z2N,+[(/SA&Z KXP2"I2+AM8<A:@
MT@W:,T9BFJ+!@YW'('&0Q*JH9S15R@;A]ZR>P>M74Z>??JFZ.'27M2F)CA4
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M.%F"1M.8%CVSF]FP'O",?HY@LMOV[-O[["Q?)'+XJWL[[?IV._[\[IHIJW%
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MO[9!DQA4V9</17+*##B,MMW&=@/B]3/:>Z&[H%VC> 6PHPQT''*W[E-M]-P
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M:@MI%S@^/DD7_>7:# Z[$U3\W3T,K08Q\H0W$0I*EC%T7]I9W#;$_.C\7M8
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M;9'!&:KYO>LG16;0=N%MHBF$!_,%^Z$<'F7XTA!W*8IQJ7MXR JZ" @Y^\M
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MXJ&OQ[XU%<L-K8_Y8&-TY:?F^/EM6;B.X"%DSMW1(I2%!S)-&A3Q ?V4^RO
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M7_L=&8I=2D[H+-:H2W+LG*'; 'O?,53P3F6SQ7K@1&,>CZH74;QC"&_,-56
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M%\:QEF7EHI@!*2Q21H\YG'4$JW&\]G #1_-BL040MYJ%4I^1*#9"\4_F)3N
MMI_00X#?K45/!0W:@:['&]J@AU.<33V"#./2(NVU7ZF5PP@?R,JH/R3OBW7Z
M";MZ$3G(0""1)]?I,5K7B5&O;_ZV@MZ*QQ9,Y;[ [XT$*>V%HIH]A)T?D!A*
MX.B9N80.VNU)7-5(9[)ARF//D9JM+W+^KFH,22_7>IF]\337;*N%?_>.W0ZZ
M1QZ_>->17;;O\#FUW7+WSUZV]N\3 NWG9KQ/1?C=19[QM6S4/EB23,WN9)?D
MUE9/57N5+>YW54[K/))OM;]:5;X*9^6AG-+)?:YT,/]EE?>CZ2V7B>7"=/PT
M8V*> Z5_1[@8,M#B0Z@OA]'!'N9^O1CA$ /P,94<7:,*KQ&G6LBBIVU6G]">
M&"71'KY@5OP"[OD_YHJ\?F\M1'2?R$ZV6?M\*?*;X7_GKQ"1_1;S\GI$^UFC
MKM_5,)IHJL%'%4P($_/] '^2#*8QQ)'6#FL_$?=!*4QT5V\;!P.-+L=*8:WP
MSF"*C.,WVD,Y0!D7NV %UG41->GRLXCZ].1I*2PUD9N%OH':V<)>GI#CD3KA
MVG@OF;>@=N B@X8M3A6X?S"_"CVHAEP]AY#V\5O!&5^;I.ZJ_(*\T:ZPRS^5
MA>IX.$F %+>A+S#2I; &M$@E3R(_#7CPFA;EN)@<K9Z%!G!5L =EGN<-H+-%
MZX 1SR&) 7X_E/)$Y)0:AVNH7KK9PLKTY7=+=K01-Q\_3_KSV</ O#.T%D *
MFQM93 ?CIS"=Q$R,(G&J$+%=!J+5@FPI+(T&H',L.)D2#6#\-)/+29'"8**#
MYKYF^'-04;7E\_)(/=V!"U">%+995EBD7#%S9SP2SGL91O\0IT&S+PUOB2X#
MG!8* &V!KUA6WQ3E$!X.NJ<+ST$/^>FWZ'(16O$+EX6.DF&$&E5B!FGW(.#F
M0;M=0;\>= JY3OPV/,&-<F.%F-9(+4,Q*/.-A>0,"[??QGV:4TZQ8Q.K3].\
M.7F#IPEZ[R[Y[..78+1OO*NS<"0-:W=.^6P^>^E^2W"/;8=GAU=[B.&YZJ]&
MRO<N>+^[=/ RQ=TZP8SJ.G?Y4EP,TD1?I6P_+@'ZVZAB8L\,#X&<ZW]DD-+I
MWMKI7;0EUB[?;/.S>V="#=]?\:P4KA,&_T,,)8Z97_]3UJ8&X)\Z:_"-\_X;
M_DHH_E.S>^$'ZS*@(#GNUXX1[F'(Y,**TH?Y6V+J=<0+QJ(6; JO#)7:*).@
MTKCB@S=Z+N%8R"W?4.NDL#<*D)$4=OXAMT=2LJ9[;>E79@LMXOSDH=G&,2DL
MV\"T?Z+-A^R+KT'\1'Y<$IH_B%J3POKZ^H(%?BMSEXF-9-$#UF*(%':A'Y2Q
MLT]8YKQH<<0X>D<2?TL%ZT@ <ETW#DVJM:8N^XJ?F?<Y!8KSB.%B%:<7S8,K
M26&_\EJ4SP9$/;H0V.;@-8C2Q)4.O^T>WKOA34Q\S(%+]AI?OMP^=>5/]+1G
M]+PQ[9 C[_CG-"O'$_=B]VUYA@0<UMV^?:<\P6\&I>*"]F9Y7VVT@DT.NY\.
MR)2?RXNYJY49C?QV*#MH@A28=6_^K_H67,)XJ['1$W;$R?@OA5>S[Q;36LJQ
MPPQ=PA"Y+KX;FU;(6A#RT=OQ+M U+GJ'2%Y\*S8&#&.BE7:#R;,RG4V\8+H1
ME_<GB+U!WXW;1-R!P_B#)*:;(_]T\E*[#2E]Q= ]CW^>U#EB:1:>W^U\6*9V
M&Z2P#@]MD;+X"4H)BD9HB1_Z_IHC<9XXFCC5DX'T+F'",PF&@1(66;F6YLTC
MZ^#=)'U#*U'H#@._%X-+-2(+[D\+M_B%0L7\]"<3DWM_!/F'$Q]H'IZ*?<TG
MX;\K_0$_<OEUU_K=SV=[O%D$I8/S'Z>O>]BOWGT9:5J^?[O'#GYZIX.F>UZG
MY)MUA6_'J4J_B0['4EQJ,G.@R,+WU+W-AMZI6X].6^-%=3I'"XQR]GPR<.OS
MPL\]&L)5$9>,KS#G+70NL!^NAEI9;70G5J-U&9%+-Q J-$_AM>#'=.20Z*#P
M&"Y2(K_(Y6R8G2^?F"D<II1)WNO901@>/+MP3T J?S(0VO\]2)M)-R)NPDP^
M;@F:K+NL^C';+;8W?L$7W>BT$#IU%5QD,/N\NYPI^#_%%5+862KI4@>GK@X7
M@ND7_2ZTE0R-(;H1&C+Q3#"9(ZM*C$1^T"IX8>05J\H1Z<'KA6B&Q.J+EQ%R
MK+,5.-:9IBQ01>Z?:ZB?/2&SV6KS')VD];?9C U7Y.=B;N?BIF&?0P9]5:U=
MC:O=[VGZ=%?%<AT+*3JN.9H'[+9:ZCVB("K?1I^Y'^&=E_.HL**Y;']Q?T/A
MN;:O?$>OPH2WR5]3[H4/%4ZOL0G+3QXZVPK-'T^FSTYW<L9"!%']2 OA*:L.
M5VH&4=O"=%Q=<!,PZ&*IX>#\D1N![1)5 )XJ6@<:=2%4:FEHGANQG;RCUH*D
M.Z]W8-AB'*LPLUJ\_2706>C!O/CMK\&5-D2G$?:O3^0T8@1K=)J)J%OJHLJ=
M(?0BX U85<('QC::/$5T#/+A8C4E'Z0P);KFC"P2$A1&R3N@+1*X]FF\-QTJ
MN,Q73.31FZKFM1I3*-"8AP*K=";@:$M?>=N"94LLHT@*LV(XI+S:O;MD95KG
MG\./IZL)=FLA&J]>L8[(?[N</>*#TGUU)/MB<\A<ER_SG XENUJ^;VKV[+ZI
M69_3F$K/1_N\V\]ZW;VT/&_(G76Q&+SG[/O@PNEB JX'WK= <;UWLE0\=J=Z
M?]6ABGF7+4^K3UV)>B_O[!V[IW9DCIPCA?U-O8[>3M@#<;KH>P%2#OXPUW2,
M+?  FMH98T1G(&1.;Q?HQ_3((2JN)-E*5%>[,+!@'!]3A[FU9I?:=$.B%S0W
M9E+'&]>FJH0S_1]VQE_!%2NT8I7QSB"]5W!A *G-1<B)-@RC=HN.@T_5489#
MLF>A("/M/!3V[_QP0$WQ@W"NZ7J< ?<?$)LYS7Y*.S2\5EOV%"KSCPP*\QVR
ML%Z<2ISX/<HXUG3SY^^VRZ_M6G1NY.*L=Y.#8?*Y91LN$>Z_OT1Y-/UA9;H<
MF_+FTL_82N1>_/GP@9/![;R(Q"T,7\JMLI33MQ(1X;ZG+@V5I26OO0M/W*]Q
M++AX5_GFX5R+RSZ1E54?2@Q,0A=]M(=(R(K!I[.F4>YW=1,&DVK\7^Y_'E?=
M?;?$A?H\?0C12.Z2PC:)<.(RI ]H^VK[7![.SQ=(;^]3>AL4Z5K@-!CPXY44
M)H>7G\JYY'K6[#70:<&"1[A>_/(I*$!</'<H:\]9>JF,ODRFB.V.='DI[&,S
MB)6-GN=;NS 2QO3[R.\C9 >.;OIS_@:]X]V;B%O$)WZ5?DH&0&+*@>>MM_ 6
MX!5_%\>%YW\RMHJ<Y5\6_?-'IK(Y<"0T[^]S_E.DJS]/ZFW](>^QON-:K5+*
MPY+4-P?K*VURW:.W,??U%'ME1R_<&V_XO' G2E?#IHY:.#5_ZLMT96Z98853
MOF'+IY%,6HVN>=M8P.'P&*'7!^+G>) AQD%H*<QY)>#[TK@V!F)Q,:/:@B>@
MTP+_R60DNMXT30H+0^>T2&&OBG:[]]>(CE7,D366B6ET_4&"9O@8,7WI]Y?U
M(]0E?#BV--!_9N226U35F3>J.9U>#K:5*[H*<CUZUHL/X7*?X[JC&H*MD7&B
MMLM!X\I-L\G6?Y_?YG3B\NU7+#NXJHCI,W:*3;__]_X$.RUF.]H.<7N-H"ML
M,*4('0V(!XX=6S.#)L7W"&A"!V8]30%P$F3]RI)UD37F(9#9-SD32I?(YX%"
MP4U(#/@QR;JH@Q*VGJ*XA+ ';R0NKF>HSX^E+TYSR6H8D<L@80O4RV1HQ;IR
M-HL.8#<[ 9%=7KC>SE6,PM._&X*V2&%,PC;,SA2!6%S%B&3($;I41.=EQ-W:
M7:PEA:47$MLWHW9?;"$S&1H$EIH4IHRWX#%R)59@6AD8S\5VHC<2WJ,1$I,<
M Z[Q>RHWTBU^Z@11=1F]7G2RY8.QR*\<?_S9B,7BIK%OO4)G8)I)39<H#>-]
M>*:;(>UVNBHHE]NPN0&K/4_7!NCI)9&H0T-_%7[#Q:%5(UJ"<LI7;\5M_L)@
MW+'M"TYLO7EG#1S^<\2LH*L.,@;BW5\D6;E#'D"O!_LQ=$.NJ^#9"UE$-/[[
M(:^H?**Q)!(\6'-VX,XF*"62&!J6B.6;(41[3@8'!)[IJ<CX-X.-"IU>=17E
MD@J%(S_)-S" ^]*8R;@@22;0XD4>0F=</V$_[CV'F_M 1L):(*'2E.EV; EE
M=&8\G-&8ON@4CJV 0CH#RAN;U&Y77@0?)MDC@ZK](Q(P-Y^:SR*=*T<GP@O-
M :M.#!"UNFCQK\CP5X:8BU(89.#7C<FZRE%&1]1XNP%^G0_'9?3%T:0I@$X"
MVQ%9)\1LE"C/JDVB(#.^HA./=4MT#302I(K_K>>HS!%W,,+=_)AT+4LX#[$Q
MPFJ-GC,U8X[5)\X+F7HJ ",Y-I*H!)DR"^$WD>CPF*K@L1F4>G_]$GRF<;7P
M:W5B[7S\I?  M[;R;"N;[N;*")OWE9=WR%N65$>HM^2,]\;'( ?^PJ&Y3AU+
MZ?D!A(<RGN8RKN,5*.%F\U8V/NDI>&TN1V%TM@"U*S$<;Q]#";R8D'17S7O^
MA?_HFQK7*!UL54/Y<T9DWH9CKE1T"^8SPF*5^@.=*X6-_^ 9M,.W$_K)@$^\
MF"8*2KHF_%,FV$PAVSCA%M'F7_]16_4P  ^R',Y!X#4BV8Z+\6X4_\L(C;K*
M]".NQ[M#(U6BXW7@U3K>:EZ'%*:Z,LZX-:D)4#LF'(X#Q05(O1UM,WAM66/=
M%S>NP#4([R5P8"\K'6G%+3(2G).YS7F\QP>DD= 7[RHN$*'YV+$F9W&5YH*,
M 8(/0VV@:S>GSB,3[\03V[HW%'1P%&548BP#?+6L&)#A?@^U'T?T&!!YAI;Z
M2V'!=%/H+##.4^2DK< 1>#O -->4IEMA6</5YFA #DR)?BO06#'@_VZ,E&X2
M5ZTPNFPK('L\>[ 4VVP<'1"I?7CK]7'[+Y^&:>NGB-MQZ1UT$U ]!6_ @ZM"
M:E&.T^UZ^T:05F5S]%U 7/?SO_,#:)(=PTM/IP=%MI;585H!$8<NKOI>"1[?
MU7YIP+'$/FYZ%?T=_I]^W*MT3V:!0#&]'I-KP\@PP7L \SPBTY8(&3F)=LC"
MQ@1W:91Q'++2*^*1E2%;032@WKF429:+&_?("#"]A<6[QH/NB>+U]M!EM8<4
MR-U-O;-0IR5V),%X).LK;<0"^X0QE4$&O.!C/8(IT.T-Q.4MW0A& J;9Z%#3
M5'+]'A6<=C>Y+HG1B4Y%J.%#>6T.KJ 3<S-=%:\!?0&Q/?G$3><&INN:@/1;
MJ,,SDULA1@G4VH$Z"% Z@TSL I(.31#Q41(5D7%]:P.C 8H$UH8E/=UCK,YJ
MHW'B1BA:NQ5]:W)WVARG,QA=WTQR<ZZA15''.<'C\\%&&2-!@U.MS9EK:UR#
M^RARFLR\V(V3N(>>0'P*?B_7V*&[<)&5B0]-XI(5+[8H<K+PGKB#UW@>*I]F
M?7WKYEO$'_><F5M[W!3_(]DW_)/*G7G6MX*?<GU)\R+6EY_HOQ"CJ'&)TA^#
MM-_P"+ZVZ089'P'N'HJ_[A#]76\ _0"_U">A!?4I N'((H>OD^_'V7'^V<O,
MX7%G]N\/7Q5F^Z&W].54/'\)A(3_^!38MQ(O4DZ7;-D(]@K8$$GH![GR*=VL
M=(EM Z10,2NSS';)5BC4E.DM/"G28DN,\*' \*]@M'' VW/@*WL%*Q//6GQ@
M.&L*KCB+4*!AJ#AXA]8JDZP1%!&U9](2>/1&6),XA=DPE_!E*6,%(8?SDL(Z
M6PI2+P#Z)3QMCM*L>L*O;"'?3/<.FB U$ZL]+JZE3J<:#!H4KV&5/IVADXP_
M?__4]J#0*<;I"!0*<#I&6O0I7%*Z1 Z8+.=2Y=J!'\R6W!M<W?5.] \HQ-BG
M\<DQ2/MH*WO!>'H CXBZ%AD5+Y?V]YZF#[SFIN389_[G'$^--061G23V/S )
M4IC9RX)O,A%^XA/A3[\O2Z(=KA+/$+!7\@:>AEXQ ,H)_[YV]F:7;4VZW'-X
M/B5W=&KE-[J&N)*@!%'Y2POK0 <NXL:YS.ENPD'(Y!GDU7'MW\8L7U"/I)I^
M*S9)_MNW\K3A7B%!"G-*=PPZ\O5HP_/$%5IS:+*F8D+S,9?8Y]>2$NZ<+'>R
M>3LW]+#_R*/]S>^QD8X'W=W&WNA/9C1\#0DQ;/F0^?7N]T]_[\S_?K>MT#F\
M-1'QZHG]V5Q(O)X]E^3@-KB<Y.K=']=FYMEO,:'B1>]OZ%,(>-8RL%($]V>;
MA+Z0?1YVHBU7>\+*ATT]F\\^R:;N3/OV]IMA5.TN9\^YVM.)XAV/$O7(O1;B
M< (VP=B:Q<G.\\XN,S!T/'E7AV_M<BB[;-^;;L^[H>K[WAI+? ;VOY\U9[^(
MG"P&KWS-ZI_=J_X9E7F!/T-<DE%!E^?+-83PLQ0&GEH02F&?7TAA.T>:ODA"
M9IY$H](E/]$B'VU2B11&]Y#%SF-DHB@?\UE+(&*\2]K1UR/C?8Z!%)99=GD9
MO?I&"N-5U"U)87=Z12G!G(*?I-('_[/N_ZY+3390?O<G_A,Y_ET*.[CL;85P
MD,+P9,G^G/]962F+(7$U_:Z82,!\_7^\3O]5*>Q-J,2>BNT5]0RZR_NNARWN
M1%PY^#);;]WAW8_X% .33TEP\7=BCXCWSV>!W?-NM,[*-"=U)NF(GYOMFP#/
M>_P^M9\!5UO\_!J*U^Q2&A^:KS0YS=?FS'RC/5CS *F2+:I@!)^)V(C2([#0
MZK20*<PZG*O  S("LKH%"=B;2 27I&+0"=\2;C4<;!NDP#,$/C-V+)HG/G'3
M&S-:@D,C3L\'#PQ_>V]KO8"UV&=J19>7C" V(^7Y+,A KX%GY]!U&1<O\(4<
MP.EVXK::IS3;I(1"TUMT_2"1C\TINAI[.XXWM&O0&.D\!<45.;B=MFP_=SOH
M0-;CKJV(@C-3Q0Y7K.6:-TA0HK!!OOF"'AK%)[L7R;,,*I"?IT923'1Z];0T
MCO<+3HT,MY4'>*;:K'S)+KE_=OY4IX_ K-+W9,D#7XK]&T:HA>81PYB8JT^9
M.ZIL<EVP^=DAFD(@N20X)[9,Z>+W2IKY;I2?VJ>'4:.!*_."O\647RG$;NKI
M0!9/W0QRS#UTH,0I Q)]&VZ2&03ID7?0O.5R:)%<CUO#+90,/!J4O4LA&C Q
M-_PF=X(6-5_2F=ADLF(L=H=3Q41=I* I(+J)G_BSF:$E&>+4.66BPU1*H4RF
M'\0 TT:XV [$9F@=8:>$)5D'A'61?\.-< <@]]%HPFX"FZ- \^/VJ? -.A!*
MX<6(H7J& B[0$_) 9XJ<*',!>PLRP]C?=H_$4405[5.QRZA'?^6.L@R06_EY
M73JK<GDW7J\*7J^OD+/F#S1SMH0.="9%QSU?,6H9G&MV53$)?7/XO?G@L%[1
MQ0_3U=:#%)<VDX3]YFSV_=$+]^^Y?MSW(5O5D'WFKLG#1V>5XN5YNE9[RMX_
M)!V*FJ/&K!0(BL1U*'F1-U"PB."ATUK*)3?X\+%2#_FF;+J6J_ @SLA^Y&_T
M<YI?&50LZ.4Y+<K!.R<\14EG__UTD61Z/8ZT%7)AG^'$E0?.K5TE76RAC$H.
MB_,(QCBSJ9$LPL%YND62NS9&Y]<R+-,.Q2UN1FYYIYKS9(ILNT@C%KVU';?K
M?*+;P0;]D*2*UULM+Z?>XYU]*Z*;]>B<)RH=7GF%?H#B?WSH$4V;MLNU#1N4
MPK;9I0?'C*:]_L/ZQ"8#D\?52)1!WEABP%N?\Y5<X#ZN?2A7"S7]K/WLC'<T
MJK_<U\>@QCS$3_=634::";YXH.CGJ;/6U8=]\P)&*G<\ E4J>*4UEI^?CG\5
MRT/QH*G@V @^7*@#>?"'1G)KT6&DT>FIO5T<DLBN#/([-5B+C!$>Q;%[BO="
M.7RR4OF]W)+("L1ZYPI<%E/+A,%3?=E 5)DE*H4!XNS+,RW=14^M"B2CG.TT
M!!C/2RO@D^7QX:!ZMU$B6<F!"RU8F-YHY-3]VA!+&1?(+% ,G_)(Q6S%RU,@
M:I=-$N4&_G#IIPD'BA,6Z:=\O";^:7#DV+?JJH@!44[*[7^<-5@4XKMDHDYB
MH3<YYM4>@MTSZYXCG [4WSJ^=P]EH[35/;1U'"V]RUR57<RK_ 0O(\\]U\CV
MW?7B"1#]U&BX^E9>YZG4@.BGX6<K70O3=#UCO#6]8O<>.06(:F,OS%58^^:5
MN!=I1?O8T<Z^T3CB=?+N894BYRLQ?6\D?3(0D$-_%CV1PE[(@:92F)<';'5I
MA;KX&^,.'+*2PJ9(.2M4$F,;XV+^P-)3@B;.C/NU 7@_WFGE&Z-/YF%T<=6!
MP%=*3,E%/_=*52$4Z/CA/ U$YK/V#=1:1/W6'2H\)NX8)08&LOX5$[L9F\%=
M;?MI/O[>CR[,_'5)(^(3]>'H2+E[7:6+.[)_.KTAN= +7^MB,N!F2N/><M<\
M9?=81V=^Y-&I^FC%@>P+5$'8&P.YJ^7:SI:%>TM+)Y/DYB7F6%3*B@PJ(!F\
M-TMAMY?1O_#]?__4A":9_J\1_%# ?N/I#P0&W_''#!H#ELJ B?@_F/__(R=U
M@NJBZQ9+PO41C#6'O9'_5:0;5%#Y-Y(AV#2$7D[# H@:G\.FD:X2^H",Z*:_
MH$W-]DMA'955$EWW:DF2S\*H7[MLL#/"821=$^I2F)L@CFTP@2#]L'B'<UC?
M,:END(V+/_890'_6O9BP%F( U.9=T[F\)H61?BYVJ9K7^,[*G)KJ*(5]60E^
MDVI\UFTBW!V1;<C8];_^I,J6'T+R3RW1R"3C78%(XL/CP*2P,'(*X\4JT\YJ
M:ND5:9/#%")=RY'!)^T(IVNE^(-J;;JU;>#N[A89UV&T,+447@WFS#!9&-D=
M;# 2E]]8X'GG_2N.MJ+)9*]K4_V+E%$KLKWLNG*T_].!LO[3R/_@?WVA: V*
MD\(VE,MDTC7\7O&_&$$I%"?<C[< J-V?AVGVO"A$E]KN3C\M@Q2:)^\CC:0*
M57.GF6T.9UJA<&"D2T\_ZPLH=TNTC@M7C P8W=M@),S?FS-.A/9212IK;,&_
MZ$:?I@4&(# =,Y)L3R3I4G+60]DS?XB<:,G#DZN\&FH'NU9F]/)ZJ/EJX]55
M=;3J(EX1WNF_U-]@B#^Q=K/NS)O5[O_8J>S:,H(*]?_?1,\.R8A,OI,^3@L6
M!^E:D>@&JPY;\JTU5OM'?%04P/)G$_:* J&PIS@7#@^IAV@$:6HVE ZL'DY-
M\A6M' @%'DE>B=/.>O7/J$84[=8WJB\_&W02;2=*Y/F\)9A,M_A5$7KI&Y[)
M+(+"87C89)0*#MUADYZ-7U^*BVDG:T5-I_!6;\9I8W^#R,ST[F -Z*%Q7W<E
MOV9]#YSG9M2EM[,8NWU.4$#8>6_%4BS_?^JN9C^R3LD:P)'8;M> P[MBXX1H
M<;&INL@&4@5Z.ET?X_T@_K^69262=_G%ZFQB&$=%_0-=/_Q% !X#H<L@,^:8
MW'6)W<>VIA[=]<RK!<$Z]5!:BQKUZ>Q:^B"YKFFA#3 5> #1S< /01*P!ZTD
M4N&A;^D=@LJKH*LCP:!OVU^3AZ$;%?HUO,5@IF1[7WPP^5CCL(6YU5+)Q3NS
M$D1]:_[7)+1+_9UOLT]6B_Y?O9%3HXX9^"_]] ;NT4D\>,;M34^GHK5 ;]L(
M_$L-%-SJUJ.Y5/QJZD?NXY!"7NTA//&)WF'@:B/!6PKS9&S-5N)OV(YJB"V:
M"$((VQ+Q97))2V%)YC\UAB)7,0)EAZ6O%3AB\O)M/N,&1A6E,9JS;>[JVLCB
M.J!TKK?+UZHP-T6WBY6)# DM<>;E&#@.+=L%_' 8IEG4XHC!#'9L&]%Q<,E<
M\;Q32/7L2)U]O/H[Q#/6PA<JWACLR:8Y)9JV&Q[ &Q)!!#=N :T42\K1ND -
MJ;'*JB=M5TBT1L: O3QTNKD4IM!89.Y=I+_Z)[GKV00+:\'(S"49G?XD_AV4
MZV"HTS7Q]B.$@W@%X-L#T, 9;"C.0W0C;K2DWUH0Z59#6<' 8G:"90J(YJ(S
M+>[059Y#MR2:36R9PC15@+XFJ3.##P/3Z4B%R^%\XKJY8 5Z>@\J<8JE26"_
MF-,JRDT'T'S=M+)JUX3G\\1Z;(84=D$,YRZE%'X>LPGR4'_%T!4=!5=)IK&O
MC8\5W4H>F!SQNQ$PMMH9<.:.HJ?9F2:_@)E[O'%VGWX.&U\[X#M177/UA]_W
M;PGJV<C#?,2M!,IB8 @PC<$HX-[^X'K<E(DO[RZWN*3035E\5P\EW%*W98%9
M1.$IL[F$R/#O>)_^T)>#]=7A#4'Z1K=6%"T-L8N+9ZE*-,A-B ]?+1Q$;\4G
M CU<S@VU\X-(36#5$USL(5T8<*\5K!8;]5N@-:%Q 19$WZI9*#CY<K@6N2.*
M&K=HU%XPHG;2J6Q^<MW ,BG=AOB)K(341C"7%/3S+E?VUD:J%XS(HEJFR",F
M2C&U)X/F4W,":]%V-=":4F0NC,S*_V[>9Q%-1;^(38RR=54O./+:PP!GLCO4
M1/-$TM',M]ZPJ3O"Y]?MY2B$CWL25NX,CWB2@\F;#0-_)B&,QM^\%GW+F\(N
M%O#V8:,D^_#^P&HG8JMN9(<*FIECUN4&O.WI3% L[^EJ,^CR;2)O(VB)M(""
M7)I=9>/#6I$>V/C0KOSK<\I<\#[ E\'M9",-*1&6DIV$D%/089F6-VP91JI7
MCA-DF@GNQ3ZB52-H?=QC<OO);%,+K1!57G*ZMB@<OB"^5A&AY?1Q)5+8&X3N
M1NT>YK(MLK!;Y]6?SX^LZ9 CQ5:!]Q]LS=CU^OH_09H!=J]"KU_JNI22MJ!D
MOQ,\7N!Y(I5WQ^K/_ZN][PYJJMOZCAT5!02D*B H'42DESR"= 'I'41 "! #
MA-ZB]!) NG05 E(CO1,A%.G2!830$:2$%@()R8OW7N_<>>Y]WSOS?O]\WS=W
M)B=S9B7SVZOLM=9OSSG['!=+"2/S^,R7RISLL.P_"B [#AL8% H2C@2?F_(X
M%+,HK'V):^DYE.V:PX2WW/7V:J4&H1B:;%MD=\HGFJS]/)!*D'?34S$W"!T-
M_9C@_48E['90TQF[Y1^SU*F*(RM[1/FI((RB=VWZ1 273HF%[\<HD2$5F"5^
M$&:]_[G#(&KW<H5U-E.R-T1P")=Y]AS]\S/LNRR,DI<2>)^WU+X5"3-^\>T;
MY)[QTI2+ZK7RC&N=%)+L2QX78Y!Y54.SHB,U.]QIXM4QRY[)"TCP1GV#1\77
M*AH5I5LB!XNLQSN=6II0W'%E=XD5*&SZJA.=[@GBJN3=E)DHU2NOX@@[RZ'V
M-P1TMRAZSCDJ!9S?O*/H>GZ0[7J\:H(L.$&$71G*U%/;LT[%.+?*B&OH,S)M
MWDIF5;^0KG*_/O:QNPW;FX3'Z^]\(*R)YUGK;.@^SIMR9EE?XAD+',QJRT@
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M=]_[OYFY]\ZL._-AJM?^=,ZJKEUU:M?>=>J\_GG= . HR0/E 7!P<("/?W^
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M,2W5N:^]8ET:AC+5T,'PU$D%5\]#.)\6'93_]BAV+.A .^(5\&8A?WYW->!
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M&TW*0ALF1XR&!"C5G?0R_C$=&-@]'V.AL+9?=L;9X\>1GY^A*4>0^?N_;YV
MXG86+WE9343%C^$J [[H6(%M:!9?59PP5W(?MC0,J84U[T(O\A50Q[[=W*C)
M4>[>C^L)D?P9$.8DKZV>)N[GP9-'R@]1=9@^61S/NAM*5L;WLTZWG'&XH@C!
MD]#O,NGJBG\%U-Q%=')3)IR!?+F[%ACW'%KV26#XUU3[I02]![^!Q4J+JKS*
M :PN61OYF?%UU[7R,_P><P60?K8C8?C[B+)20S3NP#'G[D67PUR/8S=(LG?
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M@'GKR[V;)S;5<0>WT2*MO7;?H%3OD $Q,+6E2^UEXXS"L#=()",S"** @WV
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MM&QMT6<CV^ZKR3\_GH&5J4OL- 2[#\V?9Q:*@;[+IXI;ZVISKX!F]&BCJ>:
M.A-.>-BNX_,/#!/7G!VG03?IJLW-Z)V90".CLR9,3&)0D;"D,V;/T_H7[)F.
M:@6-")6FM^/U$H>$3-M1;I>BY"S!1^JU!-F2X*KJ;8S;K'"MM^*]OE3\C9_
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M([!249QS&_O'WRO^I.MQ[N9/B\RSC*C+;<?NBW_:6?0VU+G[1/P%]M+]IK1
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M(G,961U2K<D0F>&FM*+]W&0D^J?SBN0&>G/'M:BO+V$%H:YML:/B>*LA10[
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M=J['(Q0(T2OAJ*4_CVY$4VAB"\3,"9\"<5C(*+_#Y'J4U>1VM8O_/XW0_I\
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M,N"JL;Z1/N#"A0N 1^<OP-D<0._?J__4\>]-_K/WN'#6!6"[?"'WHA[-A>N
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M<KJDT]:-P!2FZ9&EINQ^4X=EUJU3$@^>^K+(DWI]"L13YG&49:^*\@^&ED'
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M;*?I>?(3Q=::'ENQO$N1];(NKO?A[%^U*K?I>QSX#'S"Y:C/WEYFPQG5O&+
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M!TW$S++X<8+I%!_W-T>8S1^^9VH_EWI#.>L_:*,.H\@")=2QJ$LZM.,4;Y(
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M;Y6LJN*-6?B+=FVW\O6<DK@>/7^7<L_IJ6F;D*P0[L.];G^F.B-VD,^K_<@
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M5P,/0X,=?5BR7,3X.N]SUG%FR15GZBX:/^B5:N\<J0@HX3WY(_$*XZN2IE<
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MI4W/XTAAN5BWDJAE  RG3<?1U;+B@!1.D\.&,T"T'(7KM% 6Q'420?F';$"
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M>WROD470?$6+=<#>+R--NYS4B<,F1?6PB509&05_\XJXV$*QA#C[2BFO;:N
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MH46,T%RUELF%:SF[\&'=G^X#\"9J_L<(&#GF1),B]AT4B0=RDJ,G(.1TPAE
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MS<>.N.U_SHFZ@N7^_N_\+>KG!M*?_QLQM7R)-4=%[@R Z$0R<@Y\4<&=-\+
M\_."@'L%*K'%]ZAE?# $]O1*NE,?95?;/VD;T73Z7^]/$0%U\0E;3W^ULJGF
MF%$V3<L\/X&&V71WI;?W1=^V<"1364 <#^F9<(I W<2(C)%]XES5:/Y5FZ#,
M)Q&?XL(LNP++1VV*.^OO%Q_L<(B,\Y2(8J.72/YW\X9I]I89S*0Y7+Z90_D?
M^ZO350EQ+7U+/^]()9W0S4M55%$Z$+M:3V0%X)JG:C+<"]Y+.\HM_6VJ49JN
MP7^5NE7L^=PW\>365Z1]:.G@_F>FH]J7A+>%*R !4"&,6M<%8U7<3":6MU%-
M,2]PH\4+[5>"W(Q:ZA):9EW!_D!SWTACD2RW-*%BY%MH_Y'[?A)2S=@/HKQ\
MU^J<TH+$G$68B112U<;#9H6<J*W#5TSG;_U?2\O_',JVJ GQH&,SSJ3V+_?Q
M:WP/@'7)S;;B>^+K2&K[T)IN^KHG'T?R%D5&[BC9438JK;>\-6(N^S#T473\
MMNW?+AK7-7NN__EZK6$"PA1_VW4L1H;<5+DX^DEK[<A!4K=MJ4'/^R8"XWT%
MM;T3.=%^?2Z/FR3N@4[!+^ZEVOD$]E:67ODAG.ZYD$!-*,E2R0X=O7GXWZ'9
M4 WP6O7 )D<JPE]#9D/9\4_\$DRKDA2DI5!RN^7T<6GFJGM_CFRF)>_K/?;B
MWLC:D_<&7,/7%&XY>6O#&_.[F(GUZW)6ECDZ7+[EM6B+YOKG$V<WWGQU=JNU
M(AIZ#O"E'1Z"A:X,!YJ17!4RLL 9L2>K<:8B]?V7[SE)%<[WAA;G[0M,H0WZ
MO^#U]JF>G4@@]G^=]*N_XG? H"NF3'WSN/7^)\>VAH;.L;^:L&J1[_(K.R;+
M_Y\[I?ZO75/K^-\_L__BY&W=XKM%P?X]=_NJN00;)%R@J!$L8AZE8AD2&9E%
M(,]@YG2!CO 2K/9QSPPF>I":Q5Q,3>1F<A;S;6E,9?*85&D7T>YT1$5:-&H_
M6T(X=9*U&\1J:Z6WHR!S_^Y:C??!VM>]]+C&![)0UAF]_S^S]IHR@,]_',,\
M^*S_>&FW\LH"1=K_X$M0G<Z1T6WC"5ND*@TU#4#T[X!C#M&"OEO_P%T^8*Q]
MT,T[HLH6&T.WE9S++C#Y NB[!V(#PY5N%34JDXC]X#SV0UKB=VGH-*]]ZJWD
M:_;N+H)O&:HV2D$W4()?<*5SY.CSNGAAH:WS/_%'AO?] Q[R;U.O(!N. 2'/
M:=;[VW;?<S!Q%OIO:-V;M'$I?=N2SZ-M),>MI>$EV(&NZZO7]1>OSTV,/1JR
M_L]SP5P;=^7^!Y^(<7N__)D2<F>HX^=KG6NL_(6A9IW.EX$.6H2+ALVJAS__
M$*.[,;*AE6)"WP5R-$E@]8AT/^1P)#Y!Y9*J\KU$WZ;BSH6=V:I[#V2. R>?
MLX1\U\(1)Z=1\A+7O*K8\(0AS@5]!N,?T@O*V*3.GN84 27KW.!-$J+%K_L_
M&WE0.C?&)JI&%1@W-(-I]RI,5XH7RN,SOK5YO7]=YNLRE*8DF0Z/SVWZZ+$B
M\>6WK.[3IZF.]_][H?];<&(& ZTU1_HX0*!X(%F%&T-M@#&RB-GB!!\!^9.D
M^$#OU@H5=@']"'2B>OB<C$ZJ 8I'AQF6*V<PK0S+UP#E,AQ<_.'PB&SH^=/#
M4$5;X6I G.8 :%\IO'&C<:ME@N0Y#S8G&/S9+&,$;6\6_K#MG;WT^59BA]W7
MC541!@'8G/O-84*Q5:;0^:?;^PWOJ1NJ7S1^N)O;N7E](ABR:8I5'G1U6=P?
M)R;S#Y;MY-TZO-74T@VI"4U<5;&O;'CGDQ<?YYG(_BS5Q/;04K9<Z"WU+ZW-
M*KO]-:=I>&WLD27SQ(9?EF]L/W/C3V:V]20\?:#.YMN9]ZF36R<Z=I[YL:UE
M^@UEKMVKQ"D7$X^I ^?#SLM/%_H5#;LD>"7V-1'/WA[O_W3+:.WCLMF/[UQ:
M<NZ6,LS:Y2?]2=F<9>G.?N\7G=QI]*@\SGK6Z@7[=\]_>_W%O:6K_EBV:-/F
M?P&RH_=2 Z@&M+]MV)J3VD8"]J9WIW]&\#.8M&+FR4^VRJ\5<YRXN!R!(=I)
M?NYDR%$@LN4L@,-K=Y$7T3<T@-CKC.4T7?.[)S&R_FQE4[BX36!2>Z$NXK5.
M8-5V#C$*5N4$:+]+23&XG,;0.COV9<(14-Q, K;+H35][VL8C>0,W@[05_LW
M)%5B9\]@6G:3XIRVA6];.1I>TT/W4[H8MS-K<%?@$\ 0Y5K^R0J%(,/>/>\0
M=+&2=JRU<'DM>XH4CEIK'[IC/TF1ETP" FB,#?38;I[QQ:>Q0VOYT+<G<>%S
M&]I?P4E47<#P#*8NM%C]5YV?VTE@LK"IDKZOYIYJ),+.\L- [-39&<RQBU=^
M&&]UT3ON0 \:!9L >6D"18' "':LAB0^$/KI'"68 N^&SBB6"I26.8RU]-\E
MC*70.Z4\ UE)#P:#_E;J-[=*B0X]DZ1K49X0NZI%&2 WIIWKX&\%0RLNJ#G8
MT<:(P6&/2S@\W08HY( XQ#@'[#@$O K<K$R&S?.0!9\ G#8(F,IPF?C@IK?R
MARIT@31)&#10U:DL!3XUY;+C[3.!".6X<!OV$'#OV9';>](. OR*1S$IYPO*
MJI!'_U7HCM.FE'FMGXXAIA'Z*L0I%F="7 Z[HDUT7'R5 P2-7\[CX[M.@@U7
M."K690).)<YA. /$NH??98F(;3_![Q$BY5CSS5!_W/\HE:DF93 \NA]=W/VS
MN?%D7JS;#.8%R4*@N./EFRN(PU_GU,I%S$%O[8 ^OUH0^Q=L8*59!\@5N-9Q
M0QJE90:SY 1T#)C!D"&*<ENP7]\DES7D $X)*6:>E]TJL*;Q]BY0B$J\$'H:
MGQIAYRN:YJ;3=Y5\&-7"H;?1>._0W^61=+.0?AQ QF%'!8MY)."^M@EZI1[/
MX9/ -9E,Y2#3XKO])C YDV>F,EDL%^[]]+V!OTQ22YYWD+X18BI37;;6>GKU
MWWQT.&HT[!QT.Z*/OF.MX?\H.,$)RH"WU@+-=2Q]L?XJ;X5N"[P+!:LWNI.Q
MN)IO8YUJ\M49S+/BJ1;.54H=5G-9Q4FGF+*SB9LBZ <@X32)E9#$9GDR#(#H
MUA#](_Y:^9LG'SCSH6^MLD39#.;J"NA^4GG8-\,VYN4.)45S"%W.'2!/R(10
M21)2H374S"3!X#DM34+$(ET"+!K,].D\32 7W@1$LUQ@BBZ YJBB"O&7[)?U
M\HZ QL*4AA8Y%N(V<RSH5-!0U=%J-WM(W'J3 OOW5_Y@K!D]$ZBWHB?]JEW:
M.>T=" L8* 5MX[)H;5X?D8#\0]S\&BH XK7]0$,FSTY!D6T6,<VJ/_>K..$%
ML+MBD)0AR\VY^&BD'C&7TE=[7E)WUW%-8L^?O_TB;K&XPC&7OAX]M#.TN854
M3QF;P>@NTO?KGPE.,67)VCMZSJ JI#J[&CX'?KLR23&DT*)55D*V%;R".O\[
MR11V4C#G0S[*_KS2&+[S[=;DM!9+F]^'UH"=M?PUH,67R2%NQ?T;6#%UX)UR
M:DP Y&(A/!:VF K1<XASL%GR.:1XZN \YN4AEQZ^+>PM*0'Z2L<N X:! +&T
M&G;C@?9Y%U7LN6A:Q& YXA1!/]S[M=_Y%-&5OOTU9<D'*,7%L55V\4<#ZKF-
M!$>_(RYT,W0MJU'%,2>DEM,$RHZQ[E2=-32(&)GIDF!WX-LUP@DEQ0R^T.LF
ML(:]0&(V@-T'X@N*:0)1(;:?%,/,Y3N"I6V<^4.QX2:3A7\__IY/$:'$"VUN
MC[($A@2/$*$</;PUP:0,MM$W,:/CQV5,[;5>XGR&G&15Q[Y.= ;F/>$8X9V)
M9O%$ B1)!?/4]G>!IWJBG>AIQ+# 8HW@=DMCSGAFM;N>N0/0UW/*:,PP"3WD
M.'_Y_6'L8#*R0 RHM?U]Q#FP#S-38".()LELM4=!RRH5]A*S-GGL/]4@V9@>
M"%@T9(U-Z+T[HDP%V5$27J 2;TLG@3_^?A+K1<TA.*CDV)'^_,[TJO:_3C.?
M37(7Q]I\,/Q*;J,,G-.&ZW.8BN=,P+]$?PVQA<RU,=!-W?9A0=VWM!E,C" =
MAZF]:*X4B,19\AK?RPRCD:C-M5+$ =X*#-TLA3R<! ;P2;03%E,,H8RW+L:M
MTY.:3_JK]Q"G6B"]"+)J9BKNDYY%CQ7HCD-AVC8T)5S&1X8I\$UCK,3)G+0O
M],\9+O!< -L>2?$%K9HI::2:TBN\L#+ZLAKP'Y+1CU.UXBNEJF_785N NCNM
MC6G-K:;_F5]ZF6]/7]O/VZK&FXZ8T]Y.A>JS]?DDQ5\44\%)SA(X&D)'@?%]
M-;M=/.BC9E]RA.)5[,%@=4F-DKR,?@15JRO*W"'J0LB[V7XI2Y@?)L3/I3D(
M&W\4%$&5-%\_ --#.,0=MCF%>-L[UDEJWP68=@@Y !F?48@.L2M4/&Q.:B;B
M06XZWVH&(W*CL;1QMSNZWQ2/1A'N^X*<]$D\EO:M_3BMI".BZRAHE74:WJ&R
M.QUA&^F$F'V:_3/4(VJ9Q*T)%]B=.+@(VTJ%5C=HY/BQ%:B 5.@O\6UE#)$
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M_5O+TD:CGR8@'U"F,-3, EYK3T,Z!>5:**ZNH3EBVS$1PP+R>423-C/G\<R
MGTKR)4*84GQ-&[4>Q+/P='\""A,+=K7?OF  Y0)T#Z";_0E9C ;<FW2,:<]L
M686L8K:@)Z)J;$B9@CJV)DRW(7 &,Q<#=>NB8R7R=^!/A;:\G&;Y32UH\:8,
M'&LEK@<C6?"Z2!_M1> .,@NZ",B%Q-D@Z3(/IPH!L"RZG6I?&<WZ5*TQKAN7
M)@ "J ;,%@+]A"X,^<@TI9-UH8R/,YC:L%;!0/P!@-6*GT._ !4HQ?:T0>T]
MD'+Y6Q_OT,,!COD(8BNI=+MXKK5Q]WTE-8UA 7RJYL2B+2-$3+K=3!R#@']N
M54D.SV#<AC9"3CIGQD?<[ F4W==@8?,.;0X:M/LT%1E'CX<B3W"1%GL28-5*
M64!'"?-*)(U(SLX!R6KDE6X[[9TJ68B]&LYNW6:@,.'?!7&H=J,">Q7QT!<1
M#N&O\5T_0AXXK RU3"IBFH)C'GL)=XB^7G]CDIQ+FB-0?$3+E9Q-/P-:[0+J
M2X%L-16VP&N?O0*869-R0WKLLXNIPK AI^[:48%5A \3=&H^2Q.KI)K+:FI&
MX:8^--I7CO36CHJM!J!CK><1CR[8VS)ORC"=/X_107KN"5O^%!9:ZV_RY]*L
M%"%Y8QJT*N*@-V" -KV+83DL8Z:/\9=#:\;5U,MNY/3\\Y7]7M<[U=2L_)#Q
M2SQR!?2ZC6FF.47PJ8B9EEZ>;(IO'W)]=:5=CJZP+LI2ST*L:,>TTM?ZEPGN
MY$5^H*E4&P TC!U3L!=8231T:P4^+<H>RB:UF01)=]75U-3WUD7,8!9#)21L
M8%*R*E5S/M)&OOV*6/1S^,^1\-HP;XZ)X#A[ ;Q%7S:#B1/+*I#%%#,HKTU>
M%\WB&]#P4<![KFE:O!(WE^:IP*43_!Y"YT2(;6U/8H5QYPGW*DH[L@ETK:F@
MO==%]2-]W ;6Q+M.DLB&<;]D^RR(A:Y=]BN!R!M2G7B,2M*,H[6Z'(H&)-H&
M?8E 411EPM)F0P.@MWKNG>GVVT :FLQ<M\B=4TJQ$#^@'8_ZVYT[\!.U=//Y
M5O%>)W.H3VD^E+1V#UE[X52::B'?"N"([' M) -X,;01C-#^DNACS)8M# O8
M NK0$9#>(6=]/N+$Z!+4^J(Q_/!-.P9*,TWOZTX@*(,N0-S@,,A81Z*Q5)XL
MGJU]GLJX@CH[HN$R@03\QUA-WR(AVD707ES$^H&?2OY^-&S%7P(ZCG[*@Q?A
M%"4WE4PS1%R(TU?/8$Z339!FOC-86*=JHB(+](_@/[HK&7-W/8%*P[-;&:L@
MOX>TM_CY^ [R G@).*_^=M0H"0MO WV"=(GYTLSJW*?YI5GN3?NGQJBR<\@"
M%I"L?L_2;<6E,Q<A;HQV'(HEQR/GX0V0]W)+YG'QT@CZ-BF,!?Z20?ZB?9#=
M4RCZ0 ^\ ]!U".;5I5)90_.L"@W0@5*7NG05<"]O'F?;O;M,58 )W0 P5J8A
M_V,:$Y>BJG*,Z!*%-#=^@\U3M1PH%4V7'ES-T:!&;XX$U-Y4L*\)GH6U53EM
M[X:9R;HMC"Z^E81@K"";T,)4Q?5U*B8V7F!,=>=DR'YM2G=//5,&?1R"HE +
MGW)G!F,^/BVW8@A)"P31.,C1%UYLJUT(E+9@T_EFT&O=148W"0ABSV9\W SY
M[ +.YX$XU;<TQ&#X%B)%!6>7]!K] O#-E]7.QTMXYM4TPQ )?:OZ_H(?*X$"
MON"$OE1M@M\C'7>_Z#,YN!--^T;8D'QE!E-/%<DS24M_@1AN*9-*R1@%:K09
M^DJB$R39+N5[4&BDWWOJ"C:W#-D"[@7L]%I.!@[+<U2D]W-7]Q#<E4Q6O4=*
M;4X\+IO2&CJ]^TJC[U,Z$3W\J9A&+'L&<P2;15J"(@XEAX-#EB/-1'M]T00[
M?<@)RB481#^E51S0%R5*@7L5*JIMIT(P'_HCZA/DH*3_1.']WLW2XHPK;NG/
M^NMR\,&@:\&\FNVX0OEL-#QI'"!$,#B%&,W5[6$,4$SHZW3;Z:OUF<R8U/$/
M!MKMD#E(^TA[IQ0(FRA*J0AG-"JOG<&TWD=U3RJ(APZI*(O@>)#32E[P<9CH
M ;K>Y$+O@KKH9LH$^X"+1N/-A=9-N$<X() Z0-5&Z>^Y461L$>YY:=M%4CMI
M%N&0;C_M6^MS& ?4OWY(8Z,]./8&C)/L CHRD(WP<F!W\9./<3:YV?$)JL[Y
M\>%2T>BG/0=A4C^W>L(%M[-[3>!^)\16/04OSNU01;>)LYE61 -$1JEGC>U@
MZGQ]BP-TNVD4;124J=SF*"29\T**H'!)\SWYDMI4+([FV&'%F<]WC83,R=TP
MOA*:4JZ6IU77=0 -Z820\H$ ];:53+,12B+RCE/C*R1_F%*01-R!=XK3:>?0
M*\V@+)RX7^#M4]>;Y%1 /=Q+G2PXMA=TS*('J@)3]/FCAT'2=4)$Y2CB!.ZN
MP _(4)VJL_VKRD55:$S;3K(@4(#7S23@  5R9FDV @Y:#M#4@"*N#[+@!$#5
M'N4#TK$OZE3-[F]*9JX@'B\K\@.Q;<8X=I030,Q+X=M =ZVN$$V_V["%GQQ%
MS"4)=133F&$5T_SC<)3E*W9;>$FYXSM<O>%8'8#5GNAEK$,ZY4 0-W<#'2.9
MP2A*9S -Y+%('19!_YO/P(P2;7MXWCK<QQ$^!BH% U3R'.)2*%4$R'%7!18,
M3W@><("XB&B=:HLU=657'HJ;\K)[V=B=A.*>F"&1 X%5F]7,]@JY+$#1H2&A
MM=0Z@['GD14F.&58&\4.>6^_ DB)G<'8\.V@_;K@/GA!*1P(.+:RY]-&6[S8
M68A]7'A] ^XR8TVL5Q!;W>DD(JX ':_BW5_+38<.'1Q>ED@!=H\/;$ Z]B,=
MP2,"N^J$KU W5N.#UWB? :G[.5H14R8;C*B5)J#S!.(3WI3F!&'9H=+^T!L1
M4+_)^J6#OFDZZ]JK/37'MAA^Q<%+V,B"%MU"I)DTBW1T/!/WW$I(,F1TRNOE
M0O&@@]83<M'90.-*GK9P+E0$2CKD2Y -D*.R(Q=5^&/@"^9)SO5\<BOI<B?H
M@:K.<WJXU"J +QE+^E^2RWD<%LIK'5H&^E*5[ ]%2BMXR6O$V!&=0&;0H"ZP
MI8)^!#+0V7]@O&&^P K'T\(: >IE>R*(EMT*G,8%-!6IIM+I6X_$*\>SSY.,
M&"MA?XGKA#Q#OJA.;#4<GIP%!ZLJ*-<*C7/MO%LL4Z*_XYK'H54<=,K,H9^'
MSNCV,GHXM63-:AT-3H6L2N(:/<=^JG&R^+9"FSST2[.=X5TGMI5F35)8<A.B
M#8W2;#\[KR/*5;<7;>ILE>/U1,X2B)^:8-QRX^#(>7-:P)[&M&'*0)[6"1",
ME2ODLC ?B*J6VP2HQF5L;2ZDT073?JI<:PS3?TPV>:LZVI6ELL[R[U$XI,W>
M.$O<,DUF\1Q+8L(/R QBPSFPPYLRZ-:[8$&?>UXOAI1/@AP=QYQTV#C2,ZI&
MHZ,B/6B<>#A0K/V]B[\-'16!R#I&^PP&0XA4[09]6SB79S OR!EP?'E$G(_2
M,6.RXAK#FF:KHER?%*2%W^6SP;26E/:*Y,>0OUC4T?QK YE7XU2N,WZ+''6(
M&-<93"QY0(R8_ *_L_1HZ&[E",.XGV@,21 C!S 49PS_#EJP6P.XOX)CUE*&
MB"G8":I-3(52G,F?U_.UBQESGYW1X\&JH$7X=]%=E%1S-(*(4]\D;BZ4&M:
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MH57@;PR[)C )BLCQD$;5=+M'4OU[,=O46@TTJ2 /L+7;(1V8I\)?XZ^!*#L
M^25W.QMI,.1PI"2.8_,$Y+0NJ.+;T[?V$!<.,Y;W3(YC/\$1((Z-<E"5H?)N
M0Z9;3H (M?H^N\AF+7A64>^!&8PUKB%L3*(D#10A"\K!G?]B(<^B/5#R7/:E
M]]G1NA,P$P5*@SA. S%=MX>F:[TWM BZ ++)O?PEPZ3%B#,] KPCL*+O4H[;
MH;!L]P3>";BR5:^?]!)<HA6?;)M_=IPDU7$'#;1^T#;=648G.O<$)SCLE---
MY? &J*(D-C3EGT(K<.YX.B'D\:C],G#>337.D"82$9=+K"."0%P:+_YA#-&I
MY]Z_TA! KWU4Y'-$M<T@"IC\4?%HA'0[:C,:^_DQ%&L5%.&H<4?]E"7ZP36&
MQ),S&SX'E*+$.&^,X00' W.&%@#)F?PEM"+?_MIQRQ'B?.";* <;"$ZU1E)\
M:D''*TGX:X)%I2 ^BYQ!H%;/QR_O7X/T7C?03BD]6?0 )3:#:0H[JO'FG6J*
M%>J#HK# MRS>D3.K/_^$N*TICJP)O6<$Z/PSSM/*\^?A^.F"NJ$JMZF:P'-X
MF>3]RY=W5Q62?ROKV7"]-?K;J@</)K8N_?;@UC\!)S)/+;8(L?3__WK_:-:I
M!.OEKF.W=BS'5%[$[IQE^+SE,\"\3_[U(&F!X@G.@*DH06MN!A-#'3#4GM>C
M0!V+2[>DU(A9/%O025D91>JO9$8S+>7O5,QED1',8U#JGKZ$*C?!-<3F19_K
M%]05WV_EVX(YU?G3_7\GEPQ?<I^L8_J=6U@V>F-@Z?2&;;.0Q;LWBG>\X7Y%
M/206VTH93$:,(I4":$W5-XTYJ@FI^H):W(=WA_1/B"N_"^;#^XIIE':.7=(@
MUYZL_(LPKR%O>O=#_(KZ'N>P8(K)2'WA&N!+>WH)U'"P%][\-'!NI8S:]^?Q
M8X2OKRO("\+FDIW^L3_Y'**?Q)L$S-VB*)-6+",:52W;];O_P0>$/[/2Z01E
MU-G*$:';MRW0P.=7?]X9W]_D>NJDI5LQZ\Z1K:J(UM3U^^_N"2DI"W+[.GHN
M./Y3<>HGQQ^4&CF\)  QN@!ZJZDB+$M@*5#<LM\ X0%Q&]^IOIL0"YZ=P:CZ
MVAM.*.PL ^+_.RG]D<B&PJ9C!5<6*&KJ_QT,KC\T]TWCA95S_Z!\VG+AJ&)A
MPVZC15N$<.N\!/V\!5MQF\JWQ"$^Z 3C9I&6\JTIJ+B]'%H%D-KM+DZ(90X*
MWU;\E1F,!6+P2<\Z!$BO\;"6>:609#]TM?^YC^'UTW4NIH@ZX!79/*[Q7M$Q
M)0LHN2+S Y!L+CVDA[B:&:G]?//>W,/E[W>REAH] ?XQQ82L\,-@?#P.])XY
M;XQ-;U4X7FD^\5^"S8?#25M\G*;ATM"#SF*KM(J%]!KG4(\G3CMIM,80B]A]
M54&\2&MW_\J"+^[Q[PL.2N_&#@@/]Y7N?%(5>M?H1A M94M<:N 045Q /+'5
MK[:O>/1&RC>'>IKXOV\D_Z0-Q[8:;C6LWW1V$Q-'];](YU$3J-6-Q4F)M>>[
MZZKDP?W_:DH_+MFW:\/_]:J>!1VD;[!N7Y2+SH].02DH6C @5XL[Q(LZF*Z7
M 9)"W(:[;O,Y)>1J2GW)M*^(;!#/=^O-"^HYV21YU(?/%^_Z^]3$<)WQ4J[K
MPC_]+L151U\W&)@JQ7G]NXEXY'_JFV*'KU$7.\J*4CY?OW[YEN&6.3<6=.RX
M(7(T^$+]\8"YC&*$&*/)V%]+AE96H_0[UQ5"<65NE+Z8*HC#II-J#-G,TYQT
MILF87)E;KO.,I\P?3\1",7\Q[) N&Y,9C$@?WRZHQ:&6'WB3U(GW ^=5J<6F
M4*KR&,01$HT!9GIEHH!EU3B>RQCH1@@,*04(P\L\I$I<,X7-]]1?)1VCI E>
M?!L3@[Y:+NC8<A!>P=21:3,8M53# I@!T'_ J(+;,GX]:BO@F%V+JJ&W,DQ4
M<*PY?"J;L3K&?@DJ.TD7 P[S@;^ZN+5<BX@XXGP,<F/JD<%"0T9SKNE9VQ\W
M-NTY\L#IS(TS*DK--XTQP-$^A&+C09:"E57%.P.\G<&T,1?SK(N@=N$"97>=
M/DSIVTI90G<"+XZS?CAFK'@*G<59TS:WAC-R5,9G]/>YPUJ/Z2'VF;*8Z9R,
M1V=@!7P0JM!1&!V%BU"UK6<(Y6:"4UPVR6H"?YD)!&7\FM:,-YRZ!!0/3&OE
M@[[-4?-?]B%K::FM@GGTB^K[XZRS-*>.W60K>.W+"')6J+V1A)>JY,ZEY;5*
M;7"9M=A%G<!7_-6ADTF47\_'GT]2_"5_SA&*#1D2YE+Z+MU.9"!97I,G?!WH
MHV:PU7A9FK)T[$A)..S91US)Z"59"*(I Z^5J$\SI.\ \9?Y2V5Q1(?&+L:R
MD7OAW"QWSJ(X],K8[.IQ&*^LBB?OQ8ZJ_]S:\GZ^(:;0K^/(_PRO^&(RYN14
M7?UISBD(,C6=O]SNG[]6)7KWW?A6M"[X?RL%.>(,9D,"1\B4!6OW-.G_(BF>
M"(!]W,&*-E(M27,""%;(-0$ 7LO7WV:LHI$5=5.B&4P.LKH1H&82-\"6?76X
M 7/%^S3=YD/P2C ZNPCL9RLXIC3QWB[WJGEVYLUY78=IT:+,,U@I93;/3G>6
MV?([*N9<:!TU:VP&<YK-QKT(&S-1X@:=]ND+^>@\4LS]?%Z.XQU1B0>*E..7
M$#MX1S_1AGX4*E5<9 HIAL0Y(R2+6F_NXKA[.&."V:\]I7AV'3DKRA ,RZSM
M-!>:?:3]8S"]#!*#3*6@&9=.,F-LH?\!!G*N,"SHJX&P:\@*^DXP05]25+;C
M(<U7F'_B/;=:7G*WZ,-(^-#S9+OTVNZ![RF6]\OCISL_WXA-67._;*3A_'DK
MXCF57!8@&K) ?<DQ54*#B)F+;)7PO6BE2JMT'EXI8)$6$,AJ]E+H#(+/CO^T
MN55NGKC-U%KS:\]+2TIDV_L*T+.#N*'7C;.0MEY,OB7[@40&7?0D"Y!=Q*UQ
M3&M!@AA:*1[; 1BKHS7>NNWT$+Z^3*"H],*.F3V&CP-FT(7B@T@W9\Z$0!:F
MRF K.=DXR\EWU#F0D+D,<O*#7(!SD6!T!ARAV!:P3Y+$OA;.O,H[!\Y#1\#J
MW,RJN$"=>SFIE7)) .S%0ZNFQN8",QAMH;Z,X1%!H[9P&CPU/KH@B*NVROG!
M6 [[0.E "0G[D>:H=&_HN#^#,4*#98_E W>85D2GSA+ZUK[3B9VXWX VN5!L
M1/LC)IR=Z=YI''+)8(KA$8*A%QD1QT-78+SW'; DO?YSQ][1+S>L8H6P6A>!
M],I1[?IU?^:GZM?-\[^@? J+8J("WH[4HS@#(TX@H^8I)&TGXB"F$HNE443U
MDHAWE:,H6+*S$NT,_9]9+7*6IMQQ(G0UBS?-8#PXM13-!8"BFM*8Z/QC<#BF
MXA6NUE.80%+FM6^C-G/FSV!.DJ!5>9?I*'5%*),S$E\&BP+*8":4HY />*O)
MN8@#;:HU+/_WO"&7[ELC$N6X4&"UAJO$SH\/;^OMUG,Z>5MU87"(OHET?!Q:
M36IF7B=9XM0#^J>HUWTVY/0,X+8&<-/_I%D=T%<+CC A1TZ;W(Z^OX^_'-X/
MV3V.!6-M3G*X([B%!#27V[NH$_*Y3*%58GY8%GV'4G^DUN2L[B &Z7A\NW/'
MFG[;NX>.W?7PLX=Z?!8^/>]V=LOR=\N>7!KCO3PL[22]$&CB :ZV&9"W86WH
MR]/:V4I2NMR.OPX1YQ4Z@)1T/.Q>1).TS6 ,)_^B>ZNQB^'- MZF"$BM; &-
MHV)LR#F)?\N$NL-=\(['! _9O;2+"59)NAWTHUV":.HEIBU"A$KP=1!5D2PD
M9>*6TG=077JUN]6[H7B%/KK=*[TH,CPVO[COQ<>![[>%:QIZZB)N].2ED7LY
M>GOJ9Y;VHOZF0/&0\UP FU%:Y U<F&"N#KM,)-$Q^D+>.5T,E*S]LQOV5A1$
M:(^#U=DJS;$V2FUR#FRM.P#YAO3@5(8=^"R!Q01^*<0F@\EMZ_BK:+[[H03N
M:",97AD>,E0$?!6UVD"&VFN15EO_\+C^G# 7I[%/VU:3\ZDFX.4?A33M*F#S
M)<P;PH3U*F#>#HM?NWCFKM#7NFELA?+G.-8D%EI;*D)13R :ET7O>07*VTQ\
M=G0G,%8A4L03./E*\<G"#9LNJ"FY78;"_64E>WYU:3E-M+=>2MP29[^4O 2*
M;Y4YIOE>.N5NXK.WOS8?%NDY D69O87^#C,&GV.#!FZ0HWVC%Y".,S-PSPPU
M.-U).!Y@:^3 ZU:B$?0)F&K'+4CBL@I-H,AXH$+%;95?8=9(,Y/&%]+/@/,J
MAV9)8-?"12 YC>ZI^JNT?XY'"K]!Y;*SV4"W]N1^KPS<NO;=2Q=[J%<9O%2L
M>V_\1W09]V^^$]+'-&9@Z33]7X*3J$'A+);#8?JJ24I62K(PTF%[EVW(BTAO
M!?>*58=\,3U,I8G0>-Q#;(%V5DGD=YM@RC->(7,1Q!$U)I5PSI[^L:H6#@2F
MQG[M&/I3_Y!YH@"G%?:3%&6<6E(+&UJ;G$.T/@1'0,$Z3QI5.27"H]/RF5QH
M$M 6R@:-19P:;!M^0-[&,:D;MX.$XR*/PK7]?'-:MDJ*ENWH#&8QP3MY!C,?
M$:@B<1UY3&.-&W,QS4I3AY[. CJC\V2V['?F;X09P /.8F0UHT4 ^%/,1J;Q
M8QH@Q2Y>%<JUTK!TY!&1"M^J,5>^?X@LEKC"GD60@_:HO@#>I9K!7.-83R88
MJ7=+F-%-O@=!RK5:#O:-,I6-A2X93,= /T%N,ZXFN862-8/!\=?'!0^33)"%
M= +XZ[V@MO*!P;K)"7L;("KS C<N.D!R]U$">?^KAF<>LI,%U%5GY7&WP\-;
M#2)/UB-FL&\/<0/=!8H'4WUZX$"E'JOBB.1SZ;NZ)_"VWY/M+<&2[&)(+9(Q
MT0'ET&Z_M"GY-0H_;CJ7T"'QX2[7J( "QY"LGX&%?E$#AV<PCH(&4@;S%'<I
ML\6!OJ,2WJLOF<1G"NH=8<L.U=18-F"ND(K$!K3!*$ ^5@ 8BTCV=,H3:'P/
MY DD[W@FF?2.$"^4TQ< 4]D3@AR<.?UWJ9>\==O24:NP\,Z),__9;]0UM"%&
MOW;Q*/)G,+7<,0O0($S?2'1'>DFHZ3HED)7NT>>08G"7<.:\C8!4*)_#V_P4
MW@'Y@-[M."/Z1=T:&KF%@:MYI;]/V J4'H8HR4^&8)?[AZ!\N1E]M<K8Q2D,
M/%]0#87+6_-O&$YXOCH[3WF[*_KV]6_V+UM@]J.BE!M[EE_:L^KLK/T^"W,5
M5TJ[+P?_7!CVLTE9@9/-8! CD<Z?(96&>VHXH$"[ >6P"\@_ FN>CVX=O ;X
M-E;(GP-=T/G"Y_4/&4:=)<-R&[XS)%=C<QGV<-#+'F3Q=_[&7D(PH!/:FP,I
MLN$9S**5W9HDRJ)8^Z6]/*MMXESB"2A3=P[YP*DAP>8=B+$38*"V:HM,UJ;I
M2TE'Q!:T"&VD_@$I9AP3.\7 0)] M \2L"RFJ97VN+3.#M>2;R$[3*=!D67P
M\>X>]4$@BE5*RAVG>Q9_<!F'5QN$0>6J2]B1,:_;EW80SGS,>#]_TG#A#NNE
MH5O_#WMO'M3DTZV+1E$1$"(RC_$G*#+&@9F0./P0 2$B,@L1%!$0$0&)$A*5
M>5814*:(@,AD9%8,! B#H( 0!D$E)$'F2*(07LG B;N^_=V[[]W[UMEUZM:M
M.O?[HPLJE4IWKV?U6L_SOMVKVTQ-H*_,;]P$?^QRC8GY=6AOZ&"@P$5(B@9C
M42S'C,\K[8@:42:"'2803V)G]N ;K!,1U\"?&9QPMM8RA45Q8'D_Y"IC_F8E
M="$5)X&3=),.R#:>!AL<9X#5$1*=5SDT+[L>[(%,1F0:QJZ29\\VN$?S7%$@
MQ& D(VE,(1MH@[MR;81T%(G1X)["?L8W9+1#DB"LLY#)%0Z$G_5'[:6XXNK6
M8U<AGSTY;D /G9I.56V%8A"4U6R Q,"I"H:519>_L[ED;Q K\BYVOY#)\8Q9
MXV3(CI-EBX*CE/!*JC2:KJ(/#P'CKH)P*)4$7[#I4O=-5]#T_>/G=B[NG).;
MIJJ3 B"Q^+J(#++$8(KW?C@$H0PWXQWDY\,5/W]Q0RWFYJ2T&F"NL/6P*BS_
M^/HEW9V7<ZZ*5:!C+HSLOZI7CY1 XU#CT+ETBOUCD^\9/&D<IY4]SMR-;R"T
M%X31K;M")D_2$I;?L2UH/Y*X9H)QE I\%_!NVKH+ET;= =?"(#*ZE/WC6@^B
M=;NFM@'1D71($G4K\7@I.H:&2\$>\0!".HH9,/-;"8QJN_8[^_EKW65T7"%I
MN@Q5NPE*)05# =T>GDS,]*TD[GGL"!X$4YH&3U YQ?P7Q"M8432Y RZ:0\[-
MN/N#I\5*:(.; (A77AA#=LL//-O?<[35/! K#^3@&#71T_,":;>) !*8SII+
M,5K9\Q5X(,(A=.,:,CJHVP4CFZ =B$MYB3"O:MX5@,9BT'.ZJO<,=K2JO!TG
M"L-Y DKL.TN KP#JZ.E-/M"GT_JBG9/4I/!-D!@ \1RI^F(SCD')3JFD"]2\
M&:=K1UL+3CRK^7KXJUKR^<S>MK/';YXT9JQ_YE6@"=])[L!?7!OL)(3E'C*9
M0T9L%2*DAOU(%1&R-?SG)LXU?KS 0/#ICJ8"8C<B )5XIZE+EQG%26 WQ;1N
M!59Z!/*M@#NKKL=C/6$- K)C+]&_;J Z0Y);E48Q,BQ_)]:W?!-ULV9\.]RJ
M[(__"2P%G8@:$R:S;$KPR=N _X)GPXH4B-?=W@1M&^4GPRT$0U2P$4X)F(KV
MC39ISX%([P-ZGO/460,%C(S4'$3=:$M9-V%W%UU2M.W7$E[>"+%C8F%*M?[=
M4$,:A-R\5W2-T7),2R-]IVK^6O<.AQ6K;J3/:<W4?-%S-UU?SJ1>!E^X?C;T
MTP/S?%?VX6I<^TD]G'\ 1HU[7#!(8IU' MK^S 6NG35;@V:<PT[@> !\[AZ>
M%X#C&@B&2%(P3T:&%-J:L2..5=PAC7V/ES*$3&AUYXHFK"D E:Q?/2Z(W1@G
MJ0SH70)Q^TO O\=XRG+4D(NGA"A-"#[C&M=Y<A3./+\0JXX=)\D+"2IR0HMS
MB9^'\R/%0?:L"'8N!A7S_LX0HNU3(?CDN GJJ(6;#//LIJD2F'-C/$C5O(NW
M#L LN^HQ*63)$?%/61^0K.#U5)@KM!.2, T9REYC%'K^2)^[>U/T'$A#\X8%
M8\>#YIL26^Z]R9\.[K;YUM:V369PR^/\Z\*<<Y#:8,(49361J?5:&3@_7#J"
M=0&1(<S%6 7!1^HN@21@THX0(?GT6Z" :NXM(3>?4F=-Y?DS4*F;H(;![@(9
MSB6 0F]Q[<X5U-"#\B#2/#T@JF0";2 A34.J"0FEU-+8>J/K!06A?@2T2=W0
M/[>WJ9&F7^-4](2Q+T28A.NU8DB7$2I I3"#_[DG :+.TX+L(ET-=G)G*Y!)
ML5A15@E5#F-2+5PI$>[$"%88 ]S5#[%E*W1"%-!@<JO!R*G,EP"EL[%PW[CR
M8A<(00A>:/MJ?CEL)/21Y;%M>Z*V*D[O/CW<_?8K[8:81?I.B?JZB[\:3FK?
MXE9(N=WKQQW$U>>0\<#!)MZ>%8XF(-0HV\% P[^1Q^>XJ\AT:IW?W/)3&F*R
MAQ/)-MH$D761$R@ZJ0.GPG-AA;0+60,/QGH1%\(:X'8?XGDUA"1B(>F_.*5L
M0AK,BX%2#!2HLU'I!X;"0^G1"NUP&:[P)Q -E8+^/Y6U((#N:!-3ETUVJ>7G
MM<H+^JDU)&;(=#2TN[E_1%FK?66'W30B"26)U5Z ["):1$7>-&)J=&&A@/L+
M=()C)MEEC/F29\-.X.U+*EN$[QUA7FD!\4E?Q31@Z3TQ:TJ+YC]-IU-GE#UX
M/<)LZDI@JC%6)NB_..7\<J(](U%P0##AK4_B%]5#[\/_&FO]0@N9B)IN2F*X
M8;=BQ%G7TZ0RGQTO"516Z#"%[:_B(=\1A_1@5E6\<^,P3VAB_UAQX/@1;/Y_
MOS#DS?++;:8S_F;M:NWMHJ)?3$WW>QT_)8@0,I.F.]:\/3]^N0+:5=@)/ 2N
MB1V U%^)\ZO^QE,&,KEP-W2F"T#VH9FI."6HZU!@)C2$DA)<U1-H]6L=(A">
ML\:$R(G9MQ;[3(?(+IP-+#1I(/'?\XNP1^8A=:1V< I$C>=>BL[T8C6U4Q,*
MH4 .75^EO?'.K2+Z-U<K83J/(BS>P<57&:6YGAPF&'UX9Z%TD1*\IN9O6Y>]
M>'J,<;8AL;Z2=Y%W6FC.)D$'UECX-PM]E,,<%2Z?215Z4ZSH\E Y=A"K!P2S
M0Z;GVE+>;8) 2]G>1^$ZK)YN:.R1#VQ$C[+Q.WH2#U$.4&@OWCT+<L6!?P@#
MMQ1 .MLZ3(R.+%OR&(SWYUX7[0N#>?NX'FVGU=UY_)-G;.14GDD_].3"*0WU
MUR.'98\T)/:8T5["@HU<L.,R<9VT_!L_LJS%L^9+?_&.IW9\(I,E/=R002D%
M!TM3XNX\*(UW*E?^'*>\IPP:),;=;U/Q.J?%*6M^\,\9!<<E$NOOD%A40TB'
M-EQ&,(*K5V!J<YV6EDR$_GVWB:34J@AP;5@KY"5]E,WHZLHR'N2&ZR .K8:(
MVR#BKS<,@EO+*M$Q9U^_'C;R"D,.5?$0ZF\K#A3QTZWORQZ<?+;]2UKIC8HO
MMC]WO[RV35.N!W3_M" $YT<%]%:$N931Q)1CX:;'.TB?BQFNY#\<?@_,WY]&
M$D5_\ )$N&9 R"G6CSK][*((J:+RH"E%H*D:G6'3=']L@&[R9FBUP.'[KM=5
MAVXC;UX49- LC^RT/-V[-RQ[\HG*,<ODRAJE"-'D.<9;W\K9SX$ 3S[R?J6G
MB&N6_YNO)!6/%AWG"[ZL%>W2DV(QY+,W"TSLAU.JS08<PS!,%ZME>7GBC88;
M#<7*K-EL*<7$X=F9D@HC5?O ->^F=7Y978#UH\..D?5/M;34>M0./TR-DA+,
MM<"?W&4\0CI]6M6,%!JA?N/W3B8GG/+-7C_'NH)Z)>J;5\&/E>^4$"CPEY6L
MTW\XJD[HH0(&Z4415;AV<^P^GMBG'_51(<K8SS@YTA7J9W+;$GW[N,_0[*@P
M<&8(@[14JW+0L%>0A_S#5S:TVZN$A.:F--CQ$B#3<3@B^JC]V&J:(?(9\.(V
MDZC]"MNNGJ 6Y9K&\^+C6\&8VSFT,W^J@$B4 LS6G3P4B]!#BAL*DEG4#:(A
M4P2BE 8^M$/=-+ZOCS-,<1HAFH30HZ]$'_CBD7".<FW-K-KHS;4<]^'P%.YN
M,#DD"<="#@(Z@TP;5HY0KR%1DT&,P>52\++D\Y/3A.V\J\!O5BN#L4IJ7&$B
M62DTXQ::I5U'JSQ[1PJ]<@&VG973M0F2725)6!?S<.RLA,Z,Q!ZWT9"U-!2Y
M^?(=J5+<=![U&5Q#T$MEG:5.K'"Z^,6D0 B@-5#-U>2=8/DSLX)9,2[ ',N?
MTS0.AP)2W':(#'RGD.C17.XQD#%"%2!4H"$]0:'/ &J;,BYA=4410'1CY=[F
M.8S#C%X$%:J,Z^NO"1T;-5GB1;R8_O;#]3G+#*?"DOP]#@[N^91YD=]X8$)(
M3D[PG\/UL6W"N.T$%@$&.9DLZVXP<!#)D_W@!,C1\<D(>8QU$9!):VJ#BDX*
M!@5'6?@D@0)/2IBIO;0%?P5-:I&1\<WZ9:E$71I!\6M $Q;*/AID?NL=O>6(
M2MZMQB;N24XM_R'B.F+2FH9:#N6>!*"=U#KK=B$K(2S["U/>)DB.J!04%L%&
MT%V7L^B9C)7MP#L:LI,:,_77R&4*48V]![P#\S=PFQ 0',W(@XHB4GE'RP.:
M<I%Q= I]=):MW[0<)[L%F& 5<T*%"[\,X\0O)4IS[;#""=9#.W!Q0E*L0",H
M>? ,^$)M[YNACO&L!4S8.3U3^X=F*56\VUQGGA][, YFQ  KS6]H-^=Q16EQ
M"60O)-G\5$T9^E*W6)3N)##848A@DGSPGTF<^_P,W/03!41=>A$#)P9P.>]'
M,=I<6V"]"R++Q-C0H5(+<"B_1& )?*'[=ZEXA70B9&=98V\9U5;U"&G@RPE6
M]2:HJ_]D>VY&<H0^E"POT$6)>/9S4*(>@E=#QR #+\J%X+SF5PA V#X\RYJT
M!=MMS?$=:SV*:S>*:#G9I6[T"6Z$;J*/Q\+W8*S9KIVH>Q!IV'9V5*<R-!&C
M2T,FJAO:K&4D(?; K!FZDN8K=L.&$SXCA[=YJ,6ED>(O\\58N.4L]BD4H#W.
MW,X-1--7VF]!I-8@$Z(TK>4\UM:>O]GP%CHB,< GF(&7QS@#@_1O5RAG60D)
MAM!8Q\!6/2+K5%P9VK]C8["3P@@*V38_9<(&)V*,;ON5 5I(_K[G=Q%/"1-<
MCHP0DAE!'[6V.H<G,SCMVH, M%P3L.+ 7[#;TU0A'HT1@W%P4P\L11X"A@73
MP;N!+)YK! M\>I@!6(%[="6#NII?E8*3H=C]Z)A31&)]S'FVH;<VV^M'-;W?
M:6P3=%%(Q/9#NO$3XW0P3T;D+% ,:7M+%.K_;5Q^?*L9QN1M2OO4/K9)4H/D
M)4XKOP032OLMT.(=9Z$2(DCQ ED*$?%B45V<@G%") KT+J"3<<KH)6<@C8Z4
MF@)$K5XK"#39HJMR5J _Y[*VP_AY\*/""/9Z4,@_)L*F4:GAB(16,^ WK5^%
MEK6>UL ,N?#I3^K#P-G0%!@B@.T]BP2LPZ-#SK%E%B&[K)-7-::;S WR&'^/
MJI ]"$D8LQ>!D1XM9;.()"%;R".QSN$F<3141\AG44X7@.="OOS9(X>57X1(
M&>*3A$Q92:%;!349QB$"GBR-\T,A0@\P9P\F&/5#K8 @UHD/78Z /_E.1D\P
MLLU;DVTY6TY7.^+#ZL<HT-Z-#3T7I!U\!NY"3D9RCO-)Q#\;P\60P$'(LCX=
M,7&2+K<)2A<R>"A8T">,8*UB@G%MMDC';B"(7"C.7DG"[I^''P6LV'FTG'A8
M%#UM[]+&>J++ERZ\U"RK,8\6-;'Z!F95\0V=YQHBB;@+O\#"\:2YG!9^$4^H
MA+;O8U-YLB2&R?)OMD07K@FZ[#^-FO"DC0LILS]N%[ ).M7 SUG55^F$2$?P
M+[4C)(D6C'=4YA(UGH5N7J(1NKX\,<J &&Z"I&&X2]4!4]#A:8I><(0]:L-!
MZ&TB*X@K8$!OG:GBSVKBW.)7P?4$G21)DA]A%Y#9UIS10THBU1:V<*T"4/5E
M3",:)*[P &L\T9"4<$OYVH8U.6,7=E"@!/1"$GX(NTB=ZX ?91OQT[->!<)5
M6!&]K*_-\?A*O@;W"*[=$M]!;>CAR19SB/QBH@PKJDM@S*_E!15A#%B[;JU/
M-G59NI[DI_"V"RD95H32JHJ.\6(38GG[?6@IR!3LWD]K2!6>#7"<!ME%1?M.
M;8!W+0@T@"1V( H,X"ZP-D&+[+V7S&88199)<Z#IB^H.HM=+S@?#KM[X>'QU
MY\P&Q^E3Q.J*_8%56WXX\ZM]:=!"U)>!WJ;K')NFZTFM"3_[(X6^'_VG"#GX
M'NXU8IE+&YP$3\NGE @=R9 4N))!527Y$Y2!' ^@B%&-H"O<(^[0>LN_RU-A
M)] *>N(,LYORK.K8D2FM"AB'/#)I]TH#) XB%AXE$1+?NI>]GDSTC*H 4"N#
M]W$U9<P6=AEG&+#A7L>UG^(AN:8 ELNQ8PUVXJ4$[TEUI.6T*I[S.%&"1I7&
M!++2"/=:M3$HH(4M0;_R<+K%J0=^A,@*'2.JT"#BGP$(DH6/-[3TL'10*F5K
MNJYO9"S_M'T4W8'<]K.J9:?HRI9/!65#,=J_L^X^RIE?YD=M_7._WH^"L7)$
M;]DOZ^G&..X^X1R=-T&7!M4%%'5I?@S/F2N%7N+<% 9C!,:-_P)F%LUUG.*%
ML=:%*7IBD.[?\^%S S[)W#C/C\7XFVT2TWH48SQ$O#9>B&!A,ZN$7*VSKK6L
M"K"^P-XU!BY>G Q1@_"DP^C^,8*MV(^0NA\QW..$KK<KN.F7 I$_)O]3MT-@
MBG%.<1HR0DSBO5C7JZ;,QGG[1=O5]J+SVNO0D3U_*OUV!(M#MB]Z&PYCM*;M
MH"(+ J,@I%I0-J%X$?)I5'87C\JO_3,+E3]/3>H'>3(YW4X7  _D/4@M4AAW
M5 44A"P,40W@NY2Q#71(4J$RX%6-MN/<RNL0R'\R?+G*]_W546C"OE7.4"'L
M#FHU'JKF65QZ#H_%Z#/2$-UW2K,SV0,%7,B?-^^(2QFIJ 8/X;]PHAU72K@.
M.;?YU0(XQI9?0;7G5[^"FP#^=/\V2#I5F51[&2AL-J2*&^*DYU$* D4OX$4W
MHV=2-,'(3* :Q!$YV\)R'Z<W-<5T"IV0.')6M(OT&K_<RP[BN )[,6+L+YP*
MH(SKQ_-E:Z43 ]A:=*UN:O*.8 -=(:=!]YRU<2+CI>#JN& @QAJP9I$Z-KRJ
MT_$TO#!,CR)H"L,&GAXCA@4(VQ@W>RW[W_@>1"V.><E'&%OB62;,459-ZY;
M35#=>"+)%R^.?8]3#L>KH\ET]11V!KF<AD_'R6"/VM 'XPO5_UPH$Q&R'7V7
MVD\/$0NP$4V"^141LH+H,D8E!_3-5C9!'B^?@?L' 2W<<A+;DW/E+;]!R.7&
MN]1EV3AA^!0::088XMI%5Y)=-WJ29EC6'=&!/1U8$0#"NC_7T[IOB'CT%5 Q
M2!LDDT0^2QX1H?$E_F8]"EJ?VL/Z46#Y(D<K$7;R]](T =#HZ5F""G-B!S1N
M_<\=85)HJ$!<C)7!669#>++C9X":D@7O(^SQ]A Y[.AD1A<A":[?2,'J(BM,
MXEKW\TZS;C6P*NG;J*(8:X;*RFOTY#BR?MB(JV+O$"*^L'&]DB\O)!3) G%^
M/FZZ&E=OTH.XBY/^L^=RTF(Z8;F?%<)!LX-S,D*$03@$T%I/$A@%:G%>L-,:
M\7?T+@$+;!Q=5D@,^H6\("'B\(OW\)U7!7)L7#PQ.B"2+A&BMIA#L:()T9/D
M0[@@;"]>#G'E6Q!G@3W>71#5[GV /<?TY][B>?.+#2U61*>6)C\*U('#T30"
MB&<&:+/646QHLF&_B7OK"$Q_F@3:O]IL5/V&U12S0K3Y4Q-RYX[AJD>"E=4K
MR2!!)%8)VXUGN6V"/H^[\%^VR@G>(W8+4V8AW!3097,YCX%>KCWZ)".#"7F.
MN3:$A6$LV*(])!DO]+ON#6@&1H+%L!Z!0=DD5];'+D.4&+#>B9<.CW81:%*@
M1EP%5GIF">_P)X$DT"L,GP#PBQ7)4>,GD*9SU V!E>EY7!#^2YY O)V-8+AV
M$28_M,L7&M2Q<8ETEOU<#W3RBQ/_1?4:HSB _H%S;WAU)0&U31^9L);WX66#
M1>5MF+1P,HID'U_2'N)A?M*A]SUO-.[>./[>%'99NJ>HG>EMQ(!.<&FBG= 4
MZ@ZL)9K2UNR:"-<7#+I0]P3#=Z$'-AA.)JV@#/J/M!(@A*ZY88"7X]W1I0(Y
MY$EY_//^BD#SB!_%ETI;2_U*+@3<"+KS,;(-\B 7OQPA7!O&_#JX(7:@3""N
MP<CXS*"M+).X>A@_X#;7=F%J"S_UN@"&0L]Q,@ ^*WG)LQD(BV1K. *O<HTS
M68SIQ@2"]U62M*>0$//TOMDN>0YEGA[#N)?;R&?1OXG05H"#HLLV--*?ATT*
M.31DQR8(S#NM/-A!B"?5N'9\%N)3*G2.9<,4R\B.7Q@=()KK#)FTX]S@%V+\
MJK_ BD^Q79DR;.E+;&0B3**".K^QC!#%0B;0FR";QJ!HNY-OW@FJC-0,*"X4
M0GWUJ4F+%HMS]6]J6NL?%IR;'?@AIO\C^/+A]PF7>C1.?2PYG!BGB!Y=FB5,
MZ'(T^5DX'Q1HD;0+<7GPOC<8V#]=$.F=TZ7\(X?F-VKPJF%EMWW0]LS W-FW
M=$D[=[94#<SXUB?WSVE(5Z*]>9]F?8UGU,5]((CCW^DE/_:RNP_?=3A287'J
MR=9#[VZ^G2KM>?++T0HD^]]LF$KN39X'.[(-^7F.(]1NPBC$U1+(D&)Q6^"Z
M/"OA6EQ[/)DMY(%BB%B83-52KA:G,2\DXI)Q<9GDB3XJ,UMZRJ/E&^DIZ,U=
M4B[>"-M'8CE!)OSI"LM=7#,TEV'-C.1J :X,2#I\*^\O=D(7;M<%3##@1=/-
MD,+8LA'D%7"0M\4G?]:+.H9[!'Z770GP@GN^)H?<7%*[:*Y[(OQ#KSI]]%L+
M12#^US1""7..'[L)N@:)QTOQ+'%TJII0Z00!0S2P*("R#?(;X9W\<P07SMZ1
M\WQ^;,=/^M@X,S>[.#38/WAN4!8>_MXO//4HX7O"LE#L;-LE3([H('R=R?+W
M2NPG:JU#*;BGWVX:VJ%OS4AK+&;7<>X.-5C@4EVI8*)))-M S<Z.E=.M"Y$(
M4/C 4%H+?S,,L_#S+PKX>2HX/.JJX1O]?:B*#PNL3N".TP!;*4W5=W!QN$@5
M+Y;#.%S73LP$>_)?%5JHQ8;7_KYD5H24/G7T<6CR^9G?MY^C/Q.84*;<VD&?
M,KO%L\[8-TL=^7YK%8_X7;;G [6<R>Y6<#]U=\-7A TF+>2+'<>4O9*XBMH!
M:'#J^;DP?P9X#]7@*8TJCD8RFH3>+HW.0(U<3K?)1 X9JJETN7HTEF%99+WR
M()\@([*UZBL-;96'JQ^CMIAJ_)C9O:--"GOVF,CW:S/;%=_O$E-"9.-VDJ:3
M$2Q[R%VJ# \L)-8FRQ.(..Q^C,GX,S;T/N^4,.=>U<=<G?RZ^X)'SYUPE S/
M8PR#*-]V?Y$&'ZQ8<&U,U?PZQMS7_6$C3W6_S5?S\EW'D$\N+VO>+;OA^ M3
M=/(PZ&&FM_SEVI>C+VH#WU;?,4@+"=9C2-SK<$F+<.<JGG._I2'G4"UV;KU,
M)SWO'%??<."K:DUMJH"$E'1PK'W.RM)U=K*!TOM:S)T-WIG^U*KR'*,04)@(
M$1'5&^;A&Z&4!OB39S'OVT1$WC*I2_@!_ 4=?G!K-M./Y!\U7S_Y<=E3=V7L
MRW99QS-;DP\^^Y]M.V>VQ;7W? SK1@LC2+:4&(RUL\>(/<YD,S(4>,;\3/AA
M])>V._Q-4!S1LVA!67;2F%2:&%_THA^1"K/PAS4*;L(\2^K?Y'XC5^Y(]S\K
ML1O\^1%#[,WEZY9U&=]:HU(Q;Y7F""):&D(2>%5-@B::U+H'Z#D!K(<5N?'V
MC5R[EMG=U+J??48@-J1_S7>T?JD [BG,S9Z!&W(##XK=$^RE[:4(?II-DG*O
M'Q)_[6J-=_0$Q_?_))[2E=2[HISM<[\RL:,C3>_O&D-MWY<#K]0-=?H,E_I:
M3!U2 _I+SSF=Q[\],"B:?.@S,40J= =X2T99%H-]6STHH>V*<ZA,.^4#.^NU
M6T7XX;JNX98+>H?6_)0?=;9'>>A(A3\NW5F6PM5!YW6J'^'G"T! 79='U<9<
M$A'),J%9)\*LJKR.6,Y6O@I2W_[)R-+)D1C>H9+WA?LEKYQ8?_[(F1F0<?*&
M.G&<9I S;2E#H]X-SXBC!*PC).M)(FA7)! 541+X$TBQ?</2STXH\P <HJ&=
M3JC%1TN3X9.RQGO<EHXLFL=.5M>D<^RX8X^_]BXX#Z:6.[PZJN*29G(JZ\PM
M\U*=(\DQQ;8O+)3.I8D=CZK_?B+-]OQ^!Y,X;<>L@R;*H?Y7[&T;=A7K%"42
M5%WVI3MGG2,DQ;F/QQ]HT:O4+TWL[&BQ4AI//]"B SP9SW4BJ/X==-ZVU"-)
M&#O#"A\X6LF"_I?:<=--D)G@_.!ARSMWMB)G=@1X>>E6UD^ZN@9<'PXVSG')
MM*N.*8Z67VEZQ9A_<3MI:66H[K=OQN%H)/\GE68UCEZJ6"^N^-'"="V<\FU&
M&4474F]L:!?Z;N"YWTD=__P>@S>T"6HKW@3U;A_'#6Z"'LK%AZXM+5!A[ ?'
M]NXF[[T<*?FWSLW0_$MWGX' H-W/F*I9YQR&^Q]-;(,^:2T3_ YA%7]$.6V"
M,$V HS -&N)8!S=!/X]'4']M@F:LA\[\4A!J JJ^0/9VRB)N)7L3) Z%S&8(
MMD,$IPW>"7"\Q/^9,4&LCOZSDUEH^2:HU9-WD(C+10"RN-][FU=^"[O4$!KA
MW[N =:TAUC_@XA0R?EEO@K9F;((T%;PV00C!W]&R@__HQ?H?PW_.%EP5YGU'
MX7#O+Y'F-D'O,YX__6<G_QR^-Z(?PA-'\!YX1?(V0;^E5YW^O1/U?PP_I>>W
M<,CWA!T^DGBU"<)O@O;!D_W_?VVDS/R#OQM_?MT0, ? HB(B6@OI:ZP5GFR0
MPZ@1]7,/(SVK**"YL*[RPM4I5?G<6VD^D>6!KI(*:3SHC8[A[FZ)O'=/_[JO
MK74Y672KZ;<9;<7;,C^4E-RV9*;F\\JV7?,9.-;6NRV?&TE0 M;9.#(>)) 3
MRJ?UE*J(;TYD[*ZZU\TC]4(VY[D0J3S:%ZC<$)^VU<US<2,[H^S,4L3+MI\2
MU:=&=IX[*=-[XZ]XI/6!SK&..3,778D3IA\=5 ZWNY(O>L9LS.[+U@6;&^X;
MP4,;"EX./O6@G/L%CTPY]/E,R*Y0>06U)R=UVWUK8>.2:1\K'"M="D5$/:%=
M3H3DT+B\;'4Y'=\+62U]@0JS5[^3+GV#<VWY.;@K3 NGFG<4(PGPA-"B:VF<
M@I<>R$LOW;P]T"+D3U\_3TUX:;JZY+@XZ7X9#( Y]@<?Z96M*;GW$)M-, *<
M&-\@=!QY92O/]E-UA(J:#!UR7RB2"]0_N,5/2@92SK"O)Y0M<8QS/\J;Y*;E
MWREH*.#7NU8&1$=>S=R1/CP;=3D]P!+R[V[B"C<N*4OO&:BZ9%O"!GX/I V'
M:\&NZT0<M#'#G-<9J);G8'LMOUC4VIX_-&'L&$\>WQA0 3_^;HHQUD5QJHPA
M.A^N^M2X1#Z&-R24"LVH-0BN\O"86OE//$.N__]P>^OR_^W]_E_!X>FLUBOX
MLXS9[=KA:F[@7TL4'CW]:O5WM3R@N/8;S]. X#=:5'WKW2J2E^!X6E%]R\ I
M:]&R,X+Z>HK]@0;[ [FCAFOV1N&4>4I _"8HY^.?XTL,N 9ZO8,JW@H!J/2$
M] BE>MPVC"DK(PESFZ'F0;4=,_J2!NUH!0]!B2?I:J>H?[,X^,J@C4Z.N4-!
M9(1\3M'"G>R:E[ 3E#.OB2VY*K<1AQ"T=2K+WNK*)BB%R< RP%P#[-A7"/UL
MV?2Y![U94V_U[A4;R)K+\Z]GN=^/V\9K>Z (!4&\BTW?OW\_Z!U__W/!E[S7
MB\8&C$?8^5.@L#;-AX_>):K@F[:['KA?K4J!]H>.[N^;1QH,W'A[_A#;<9U?
M?_BV^G7VN?)Z>+7GSH4OZS75$2&ZAXOS1K.4_)X0W^THTAW-1AAT73%XSK0U
MO? !RG&P,/'RW;>"[M)<^7U<J%5)0ED2>%F&/=Z=D!KZ9[1M:X-[>>(:XP]P
M(F,Y @A.*%V&-T'/%Q@HGM7@)&43E.^,K8E."WM09LK]G*CJ7_37D;#V&?6"
MX]/XRQQ$+H[=_ -=N)N2LX]>4E6/\<IJ^H5;/,?;L[K2QB*ZWS;)OZS<V_"!
M_+:TBD/B70X("XDZ6%TMF]%+!:(W03P9.T%*61J.K8 (0@I"SPO#TI^MC:A5
M+UC0)BCQ+=<#]RN9, :MC8+T(X!OD']TB'*G03:DV4C!_@G4)NBX[P9!;A/T
M:>Y/K>=(PTW0_ ->P28H@?IO3W_GF]'C0M$2QA'&\3DY:QY\$R00$RIT*THW
M"4C!-Y1M@DPK^+Y<K1J><*YI0QSDI=_"SU2*ER[LK2JT[C*)PG5[904M;((4
MW:)=DX6_'O801[?(Q:V>QCIL@OZS 1?_EU;,_"P(V 1US_^SM[57TIN@(HCL
M)HCNE;4)6I6'.--)&ZHS*"!]%L_? \DDL;A_RN?E\!60RL(O"?'"\^@O_XO9
MH:I0_[ 0O'<9)[0$(SS:/Q8W;]V% '+\</SM":-H@B#!3$&@\58XQ[\39E;^
M<WL(O7H3Q+*';A@4&@F->H%?C?C=Y;JD,&&9,8OG7<_X=SS^(PX^:]ZZPMD,
M6 DM\4,XSZ&_?EO\P^,"<$/A;()@WQQ3^/F 3L9_ K[S1M<_;;]<V/,+*3"Q
M'D-;"V(QPIB3=,M5B/#_&P 4_@N ?P'P+P#^OP. )C3.-*[=\.X@#XI2D6I!
M^%$G/\GT'$.VO=XR8+X13LC=! 4- CKK/)E?C/7E);8)330&BUC*+CS ?E%0
M,GF5LK0)JD,P$P*>]U@F)-8'^_J-_-!#^+>X;!S<7T\I2U7Q,E^N'U1NUK,J
MR5@?8G9>5'W=NW>W];I[^BV=QD-E*C?#4K69/U>83]F(+I((Z0HN&2_+$S5X
MJI "TRJ=;\K5:Q[#\ZLOUE+1E<>&7UD-%/Z<3$D;\XCK(*O8J^\/C^YZ(+)X
M^4FZ^NV!\[5?,Q.+G@P>:AMN0\IT_?[[ZDD5/:_M\>4N3M-E.REQ[B><51\7
M?Y#H-:SB2>EVS&Z"%@=WP^9,^]0=57,,;Y->T_([(K+=5:4,7IB;W@*>YZ7=
MODA#93XEW#G[_<[";S(7(;3X1=)T 4X"NQ.C"H30(1FMFN_&X1">-A U'>T[
M=YK_A!3$3=-AN+'PL?71(BYY]H6_IB4+.IO#IA8&)D/?UM41N2I_K[LT_CH]
MI/7Z/W<>0@O)'ZJX1)(1B/#D@#AZ\;4I;?9@!S1!_3!;PZVM\1;X%1K?OF'<
M5&%9D*WJWC'>].M:@Z_'%$)[BVXO9_ ?2R/L$OL"=&WY9N=,OKW>F<-O)M%/
MG>C+Y1WH7+>O7K S]/'MF@S8F<-[4FR\]\1,O(B\_!F[MQ"9.;@E;Z92!%:L
MG2WF3",.R&6+N[MXZ8E7Y>SIC8JXERWF@NGG.CL:3P8+_I==?USK_[*ZW.?Y
M_]LMKW_%MW\!\"\ _@7 _Q, 90*)?_LMQ"\OS#6S >ME81=8$MOW3B0C_YZ]
M$(@I(1!&-G.,P;1$RZW8#]2&5@?S1P26AJB(WNDV9Y=+=\508\A:J>F':ZD,
MZ@_"VH;ZQRBYO9@"J6/\B1YOZE[>1,V(9-N1AF2:[JL+&4FK[P(ON&<9,CC/
M\J8['Y=RKJPH\BO"9%]CG [VXX(N2X7D/#I'6_[RK9'C2'=[UYI1*,&S'B#5
MB3*#61!.!ZLI$1;)A0,?W-CX.!B4KHU1J48%0:0$^S$FN93.T !E@U9.: !.
MAOC7]#=OP5\E0<U>XYQT?-FW@&O7!1]STB)"PK8A')SMT![&O8I]#VZZFO5Q
MSIZZ<>CT1?C9]DB+[4W>EM8)61Z9'9^JX\D#-PMT%%//AS8L')\<JDZ*5Q&U
MK;;ZL&*;+B-I=]WVD#UU_M"2M+(A(Z72MG'?8=M26UEO]<>32\I'RCW.HAB5
M+KC^<\BSSY-U).__^]N>!P_,-QAL2P0\9F1:ZK1L_9CEVZ7W2DJB,>^5% =N
MFFUSG %Y66-C8]I-N\/RI<PO^BLQ<\^VY?O#&*GY-\!:SS154QE[[Q_-Y?T
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M)L%(393,V0AR(\\9XT7C'0KHU"3SZJ\W=T;4YSBQOG<QG]=/ME3/)JQ]U>J
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MQ/=40@EG>9_?3ZNF'QVYN*8%NA/Z?JTWN_+9QW>MK)]]\9,[=OKI;7EOJO7
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MQHK7I"T>VCJRS@! 8PK^ /@/# 3@RD *N0X/V#"J!Q$>N$AW,;"3WFM-Y^R
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MV0^+J.GDRYA)'I^$G=BRY#3&P/?G,91(!PFKW,N%P$2"?9L.AY4Q"PPQ27J
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MKO6A/PB_(;J/V=[<TMH$_['5=$_RJ5-3AAF?+B44G[$U[OWN$^"0P;$=/C5
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MK PU?$7'V'>HANC(OR$9;A^I;QW6*)I)_ :YAH,-9P!L.DDK=!VFUG8#3 N
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M9F=PK'&S]>82L\2MG[RB+FC_]P&2 8KY?WK3LH4^HG:Z.8O<>1(=M@X;3^I
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MN@T,MU!T"*OYC&2.!F'38^@G;SCKBBS*H*[60//^*AI)!9^[=V"]2_S3"+^
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M1\);40CHW#BB7[RK K\TV4EJ)!H!W]+Y8XI^ #5UT4"_PU 'M,HLA^+:B1M
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MAW?.U$E#R6PS_LZ.R*;^G 2.B7D;:A[*:9P+86SQR3?N\P9>)Q_/@M38UD%
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MXBWAM4#:9^O$Z&U+FA<IQ43FLIAO\"0K),2;F)K$1QM(MXM)GK\F4J!0*''
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M]'P!'[#$4$2/X.3;E9&KA#E):@OS4$H?G@>E2DG#=,($V/+(,))N BD@#B_
MED5=H/:DMHNRGK2%4I^1WVL!.61(-S11]6]"G<NU9>D/4VUWY5.U)]DU(+?O
M>WF:0.9S3]UJSR_YJ.@;RZ8NB4YZNNWY$%T+!CW\<+ !ZG8H_'!$D/NP3$K0
MN(]=_)$HG\Z;GBJ#(B>/^6:I4H(_W?*4NG%,<JSD@"<2U5XJ+9P.%<XR6%"2
MOB<J3'!6+C2P<1@K(ZYE)-0[7L\RO)(,S]51OCBC2SM4PSO^IB0)VX+5_H0E
M8^A=5/5D8SFJ'YO/&<.XBSH.S-(VZ*.CL-L!\=OS^V"^ZG$PZB/D,U)9YQL(
M#WO8\! PLV0+I"U\#K"FXCM2H"#4A0;:$I:M WCU1H3%-D.QIGLF$^*T_: I
M(L@,"!]QNXZ >6AZ\B6K''87,Y/&%9P$DV+Z47/8O"4,)?S:LY*/ *X7)GB7
M>9<&[D8TJG<C#C"MJ5Y=\_(?!UY*6Z0SS4K.DS; OG/*(]4_ \0!1_7J6Z,W
M#*M?'KS(4*=%LGF7&*),%) 60O,B<T!K2]0-[K!Z4&</:7RJF75NRK997EW^
MX*ODU:X18.OBF(XUS(PV+KV7>D[[(^IJV:KE7;Z:RB,OY:\PK/2[>A6^);ZQ
M/7CT^>'+A1Z721Z.4)78 Z(G0"= SNY:*:2K8/-T^=0BUV+5\Q(2+A^Z[.-"
MLRH_WGF9#I70B>D<-KA7894N-5)<F%3=*A<^7NYE<>+>RK"C$O' >.RW%EZ;
MZCQT \5P*_\ PS6)C'AKM^4^G/LFV8D-;5.BRE $\7$<T!W]=C$T$2-B?&0!
MF@BCGH?,$D@.,WHQ&(^ &1GZ'6Y?0)O. GI<5U1)[+)2E#_01QLDEZT+TL:L
MI?%)/RZPU?RF=CRWN_V6=:YB>3_ZXGS':^$?H!+XA8)LR'/TM,<Y5BY: 7X*
MQQ0NZL +LV5<?68PW4DW)O#^6B2,K!L".67U(L8^8[8;US017^-!6E:8+(UG
M]-V7:,2ID1 .;5H<T/76[U<*SE_/*Q Z VU;2+]?$!A\YH?I90W)+^)HS>UA
MR^O&<\4OX7;!-L$A;EOD3_9UKLV&5ADU? Z_%%(K9](4BZP'GE=(.59(&CYR
M5%&^F%V$U;+<TO_R(^N$7=Z2_?1XJ(?26?/1)PZ>8M!;%$DK6WL?]62603BJ
MBHX.$-;KJ(LF4G@JN1NQZSPO6KHE&=^2[3D%(RF8\HVDM[*:U*(_"UYE7/Z4
M;['.LZZ*O.WR(&IB-6QO.))HL,QM>3H0G@J>O+RXY?1@@=A;+7@3R^//CNS3
M2H_\L1=55BN9H96N<=ID=4F5+(:R43A(L<J9#-)//5]F8TN_5Z @[(YO*,V_
MT&Z%GI_N6C:U"AHQ@=CE75/1KG -ICM4C"[YAN4TE%GE9K(&)ZUPVBV3<.<W
MY(W=^X^G/ _A@$X7O-V97_;X-84*-P.EMQKH4PJBPL'86K_A[T_UNJV%&_,
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M2K?=9&#FN?-^GZK.*?$JSTF3'):Q'GX;\1G&MG-]]Q/ZM$AA''VSDMD^OSW
M =$&3!$!C$4,L&B*@;?#F"\,\*_9W!ZY&3WYOY-]8ND'@\(!#?(\8]1]QW%
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MI]8^43&OD7(H@2U>I5AT8=),][$J?V!GP&2)-;$*I@NKA'T$TWF4>99T39V
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MDP25OLOO-U$#VCX$:/:  RDQH4,3/8%HPB6@WJ@G05]8]#Z[=NYB@*$,-K;
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MPX..[^12]R-(E\(8=D>%4+:B^GU#.<IY/(3XB^F]F3.!V2BR9]43<#_.7>>
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M[W]O_#!/ 7137LO26O^U;'C<2CS(V58>)X$_A7Y#%'Y--\#L!_X?#,@TSX#
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MG;!OMQ3X\BPLU9\ER@6=%+%' 4<)FR?WWO@DY2=&+;TT9_ \2?<A-8?XE*;
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M:L?SO'MXQ*B>C"(?X()^YV'8][NXH)GM[Z$V8=B%;#Z>>[\&I]WLWMK!Z9P
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MDOQA3KG8%2Z )T@C93'F@?;!F2/0"'NU 99";B>B3Z]K8YKH+Z%VMT,IR31
M#OXX,7:T"C*9<N025>9AR.?V)4.H^N81/=)T $OXC,,D.,[03&A1E ZL9H&!
M4J=I:=!8DO]3K8>3/G!XNH+5)$0I7Z':2)4B(]A.=M'(4GC@E0)@3[>:9:^_
MFY]:F[D_[VUM)O98+0DOYLV!Y7B3]1_0ANOWK5AU:9NV?,@[5RRR6:[-7X79
M0Q<Y$/XPK^/6W%!]$%"CGI5MXM-"H>[WIKB=Q;SC#[7/<I\N;SO$"2EFA7..
M.W!$A%H\TKUXNBZ2VA17:HBT+EX$G?LZ6:[]Y0L(Y(->GW9X>?[K8ISW55"
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M$NF&OYEW<ZB4/V9UQU+3\._:J8%^P%J):Q?)HF^09%Y5_1D=(R6?^<&TV,J
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M%/C]T</W>#QRO&PBF2FQMF<UPD:\X]0(6<[$</*5"LW%[D#>-8!ZWAUN EK
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MY?H+,EPB[PD1TNO;C6K[L!$D?@MS;-*PYH\EVP.UT=(#M!':;T=-]L+S2!+
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M?BZ([UWG:\C7QVT#,]A$AF\"3IUW!&B6Q*.PQUOQ!B",C.O<!$7[T$&'=>\
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M'81F]: 8 8*%W4#L,[23_] K?-R0D6SM%*!W7$J-G1UDBB[+S<#\%"KZ#BD
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M#28&K.Q_SXVZ\+:X<D1*X?O.' 2#>:%MLZEH59EJI'\N4S580,DFP 4<74(
M@$Z3N/%I:?XYUX&I(Z F)5FF&\"=T*Z_W!^TKJ&/<%H WS!Z?U^$;K*L+";8
M9,]COG:OXLP,V.!%;<TEK;><59&$]EEB;G W_JT+2UVBMD_-ZN"+%X7+L!92
MNN&>[J9+])5029D?E.0$KM/-95:1CEI35>G_X.6"U#HS]HJ5WM>X@.9S;8(I
M]R;HB4)7O=+6]3"%K9=6*%X^,M71]^Z?B^:+E^\7$HRE^?)OD$.B,#2#N *O
M+<H&%V<."QB4#0&.("D NAX,S/')3+-KAB: ]8W9>;@JA&M!;04>]A*-) ?[
M)">':O#+,)9_03%=O:<VU7(&?F 056Z%Z9XSU?)R]YX\\:$L./I-"NK9\[)R
M;Q#?Y'/*P,7W'G@_TO-[B3/\6O*1PWW)N]SO(RJZEGK#3Q1!YQP?CLUE17C;
MI!1[Y?RPC=-]D/<@-YT5\@"IJM_6N[.R/D5/?6;RC 5RJ%(W:U,_;=TYE,UT
MR"G3?.4F3@KC_ BVS=#A$:M 1TY$C Y"5ZRG_P@9@\0IW@5RI+#*K&V)TD9+
M?37,A0IE&S!IYE Q+I.^"^POJ3SYE8N%Q@+ RJ7GHJY3X?WF$QA2=*ERGCRU
M")LQ+N">;/H*P# _5$#Z*D=1$>(.U^TM>"##&0HG"1Z1M-B"* ,S*Y6W=P6)
M=H(/7->>2MPLS9([/?[,[N90<E>.GWC$N!51TT"1K99GSN-T4\E^*$!@ICS.
M5?X[ZW,&R]M/ ?7\WPXTA0*7T1G+L%IT.M( =/RWIZZVG_9\P-3JT_;66'LW
M+U9,A-TG3DI4[5QL%&UK/C5;FHG2@9Q9,B.H#R0)R,P*1CI7[NHAL]>))E"%
M )[B,5&PK?>\;(?$&53]U,"41S1694&#KQE%_,QAH<S[?S5YQ266#$_NWHA:
M)=XF>QA=.*F;W)=K</+L/6 P95^UG_^^3E09N<R]Z&AV<\0"\.><&3R%4O<Q
MHBMGET_T X+5T?N@)_&+ZU#PMN0+S^9+>P7EKZ=+3)\6\)_/<6?6N>V:#^LN
M27EZ*,7>NN7<I@^UI=^_GG(SI=_7;]#,*G%5R74R49J>Z&Y)O+QOK.2*.(QP
MX&VO)+P2OAHR5*'IR5@>LK;<+P_K*BH"[5OV3M U>P3@2%51[YW#<<)_L6L'
MW8<"_]QE:K@X]&H,=8:MKA%1M4BX63W"*6",G:5Q MH,X)AV S/F)7AELPR9
M/?#S#9@N;K?KH %C'71]D)8R2T K4E#_X#G,H%5 I3\YA5]'Y3-NS._6/G O
M8JBZ#%487?K(NF'! 2MRA@+YV"&N*#>IW5 /W%XAMI-H2>\3MQ.Y*!7H=$@I
M/J-U:);%2<XC)3>9"2@K"$9W6?5GT)I0T+N(44N*,WBAXGDY/M?]"]*J=.+R
MI9,1G@XCU-5@(;_][X%]"$=%$O-*>HMH(-$"#1;;$<IXK!.8.ST .HL3^(PT
MI(FPV=K7#IZ$C >"6:2-J,WRP&-2-9\/U+:-ZO>=C_VTNR[1TBX"9!GWQ'Z]
M\HA?><),P?A^ A8GS3]_]J5ZH5/RL2C](!,SIG>)K[FKYHX$?9^(;TU X1X_
MF;2TS9 L.0>M4XLH8FTH-$76O&EJYNWRI:45YI[HO&B;LRMG<\BEI[D=M/X7
MWCO*?Q?YZAUNM+B2J!L7<>;*;.8RK(&63=S# 6M.==-5"'#(0L@=,O, OE-U
MB3L)IAD"2T,[,)>,U*P.']T"Y";W8]0A[@E@-OE[;=]\EM9<.]$42+G^9&H4
MF:AQQ,W[)#O2;C1&%STS+/8*(RK)/RE7_IEHC>]@0W:3*]\-ZP=-E1%\H*QR
MR9D:H"%I)NY>-UU[/&@[ URUJ&O&%%<%!S6!VQN*AD_51.2]KM_STEE#>Y'[
ME22Z &#2]Y#"X:MD/7(.7U>E?0J$WZ"K2*P@VPK"@:XF+*\*QV>P&$.(#AD:
M.LQ#I^FJUGV[ZM/7-BQQIK8TQGWBUS?6U>W8[N01&:?*-@=)O!(FEDQ]H=WJ
M<&F,_X.>)'9M8.&4/X%WV^,Y96S!CMAE6'K0.K AL\F"9_]I/R@D'R/_VQ7K
MIBP*, HU8&E;ZPE_]U_Q_]%3QMP8?>_54;] '7>_E)7)>R+PA$ =CGK2_:LG
MZX*JS?1V\O=:7;RWUVJGZ;_ 9-4QATV\20^/Q_NJ7W,U<[P%!/>$U$+MNV-U
M4P=]VG] Z;' ZX'K':>WI;3R7GTP_V2ABV\Z$;7.^T7MRWU/,1JI91F%J56=
MZ#R9);&;J\$(,U.6&'?1S2(TH.%V]%I39."3"82FQ+DZ\NH8"ZT!^;9?%>#3
MS=3P<@'M\_J-VPG$NDD4OBONW*U)E]-VX0-JHOJ<=Y;H8'WXL)[HZ+IX#;&+
M1-/!!8D7'S+ ?+0KL+'5U_WS]H7!7NNSUSN#-Q]X!U-;NTD!:5B"=B%VA,HL
MC$1'T0N7J&L.<HPIB/$#,)?W6]7V77+Y9^P.D:SN#$]^#_;NK0WGOP!;SEF%
M=Q610EWZVX05O=Z_AHZ7V=W)W1KEYL8(7NOQ.)QVN_4,^."7T8=H&XG;L0N[
MKM"=W8MW,2RJ/$Y'_W':D%F".OFF<[)WYR&OTA+_RD+E^^7NS\_^D-WT'5R&
M)5,*X]B2+8W 9_3$,LP5R5,KF>*6^,^OYLT8P-!+ZIICBVS9GOV9Z&9^%$&V
M<AEV#$%QQYS_V;PJN(SWV\'N\;R#0\UG6]KW]U:=!]%+BEF-L[[J4<0YJ>;3
M"Q&+R[ GZ67A#;_&HWZ4/!!<5)K7H;4QH!V4Z1+Q45D7%O"D0-MSLU"*$%=
M:>$H$2P@-_'E,*XZ*=SL[VUH1U"'J!^$GST$[2U0!SK>/"-<!.)9Z!5_L.N_
M S]IQ8[;.$EUJL?T=J8\C"^VR?EM-H*D>/Q)OZ#MX*OS'K$';DI\8SJ(+'B\
MXNY#:_1M#&1"FS87!TBBH30PMQ7 *\AYQ4P \(A) MPQ7UW_?=57^_8^4$P%
M X2S;>CA_D465R>NRJAE&:92)Z<R"C70EPJ)>NYQ4//771Y%#0K%U/;\XM4
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M[]ZG0'%22'"B +Z.'2Y@K!WWC\TK>11Z90UY?X6T(<1N/7R\1T"9H8@1$A.
MPT:K0U/"@=;0#)$/D%('&@FQ*;4,7<B1);.'/)[BCWXV*:NNH\'&A[*?"IJU
M V[_[*GEP,.=G1OZ%K+BO;_$.A@.C7GW64[Y/02F1"SI'92)Q!12 C%'H$\
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MP(RC@>.,0==VZV78JY0LAY\EA7+^4L^8_B1 #R/X*75"N.K)\0+U%Y #'Z$
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MFE?[1^[8V)?<EEDE".,&9M?@HL2!^$8N%O(5.TW>(?;8H<@ AQEON*DK3L4
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M%]6DL",+"8PDA J#CVU(/V^)3N:^FIWNXV')=P*_DLY!)W8?^D3P$^!2B9H
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M6V3YX)RHSJYAQJP,$HH"O\CV^<GZ24"I8CM-2>(NI1)MVWG#D:3KAEL&"%X
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MKTSJ=ZN#*\)]@MRO"D#0#4UI_@\6,I >$[,*W\8-8*?-=/K"GU]% +W=DV+
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M%XBTN\"M9.6A/C /5%O]W1VWH@B?'IS,?UW/5;/>YO\30SM V6+T>BNF1GL
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MQ_B6,^ZX2)S4H_.POU:HT'/&9!-%^2#]'L0#LX-<"-!&%<I"RT[=E+1G@HP
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M -K00PFE>5;-]0(6-HZBO_*AK/I.2#2D:K)^:BD2 H:*AC%PVY"3PKG,G\\
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M.XAI[V011+\.5>TUYUX.;GG["].+?4#ZX9CW[S^DI>S^QTY#CGLV^X3\)0E
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M#?EQ'@RJ'.#>GC$F/IONZ#R13EPO9)ERM '8ABZZM9__N45Y9#=Q=PWY&=J
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MFEOYDRD8A&L#%-.(8RZ=CU.1=",YN#3WPH?!VIPG!*CF%._"#,EY)(,&DT[
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M;I,# ZM^=WTRI__4XQ<"??30<B/:^AHC ^ X_G%^)[&JA4 3@&+0FD#6QB-
M3NAOHT)HB/W>+1*I;9/[*EDA;1/^5@!BP]$;M@_J[<M8BF+0]6++^,<!J8M
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MDJK )'HN)<#V%HX$P17.LR*O ,;L!-I:(@H.3FH*+J)RY9$H'=92MR$U45L
MVH%4NL2^F:O-.E7#'Q@IU_93H5N[?;'R3=*=-#H3'#8#JXP5*M5G7LH_4?Y9
MNZD&Z R,C9A]TG=.!GH+;/<C<]5#)YFV>(7]6M^N7*W^=&%\'D(\YGFZ$MC\
M=)Y!V,F!5[<*#0]6OLI6Z<L^="-,9?C4 /X:<)#"\9>>*IY^\WSA]JF9C\8W
M)57%L5W7$?9=[H]\ *2::4=[H<5 7D)Y=(=E[4[[[/<.R4>C#.[XV")FSR-+
MB!(K5W>(<H_F'OZLE-[)STI-,5@83[80D:>\TZPX;1.Z.A^(6TC6 ARWA E
MQ^7,!:!*%U<!:("IT<@>XL/6#V">$J;C?&45TA5WC:V4(LB#?V#?+54G.TR
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MHC(+">T)O>]7-7=-<.'[>8U6F$6A -MM>00356ZX<)'<4*=8^&@!B*8*^&[
M49N%^3, .X9_7,L9E 6 >,*^MVS#2T(%EB U%S.%"*@=,YHP17GJ!U6G&4O=
MZ#<Y[!7Z(('UM[M+T9 HU%D, 5B^7,?B$!GP.!!D2/W0OSWL&?ZN8 ;X.:8N
MI),P:D6B5M\T.<VJ;R6,&IGQ/O#544]&^/JSBMM9,Y%\.9^K7/</#0.I;7HM
M8L/! M ^X"/7E;76-@:)#FI6M?73NUG%#HE;#0]S83FQ;+"%J/-3L%L0X*0C
M4YV]P.AKWH"@S@&'1.-J!:!1PA1U<8&A.8;CE.'H4M%-$H6$^,VN"J/+)*I<
MB[Q7BS0@A@?._N8ONS2./&ARG2+L]QY15*GO;SJ>#[A;LH/&1@K#Z THY8*G
MZ)_7$+T9S'SATD4!.2P8?]=K'!BJSJ;0')]C[OJ/FG<)M36C#3-&GJ+$!Y%!
MWQC4!,5CO-HBH-"]E L'@ND)$Y=0]S*5%^NW447\N?YY2$??\4D ?QW7Z5#E
MK;N5>I7([N7O\MRXQSW$J\!,%9J ZMDAT4T64]:P-D4C +8A@CRZ1OL=%1"0
MQQ_E[Q1NUC[?EETL:R8_QM.=#H_=P\YWX7W4YCGLD>I8[ZGO7]%\-JDV5'8O
MQKR>+3]V2W2%=PEC1&5=(H^'<#[Q\'QUK@_@OW&%>WV0K]S-JN<X\EY!G20+
M"Y'BK;F[HS?HB*06)?X0>B^01.] [)AUOK,3Y>3/*B4%NLRV_[:6LK"2,CQ>
M /%ISIU9ASB(*C4L)+X04TY\8; JS= &C4I!9SY(SW4],9C!O0X-6IAC.(Q]
MY2NR]#H($LZD@VN&VP4@[&JC;UAT4'T#SJ*Z@1@]27O7D>"OG=XK_TWF[,[1
MIN:*\XA[:%P$W]=-I$0 ZE$&A!;AMMEO;*7GO0-PO6#^@B4[#;7M;F/7C7H9
M95]C=P.S.?R]59MO3X!1RVP/VSU=0:R/B;3COL+?.LIBQX;2&"H/4YJ<F^P'
M;:YEL (W4[#[>1]13P+UDE:Q8QD,DZQB)-$S3E.;O!N@.FY69M4NKFV(+@K"
M[9TUO%DW(FL25U3[N7*@9@,YY#)V?F>Z1>'RO?3WO(\POZ,6 E#T!]Y;+ H7
MQS_QZ^]#S,#KR![E[)"N<^3NE@,S[9/29 /6[XAL >C'T2$T:@NPBPIZB)R-
M68:-$,MNITT'Y<D^[#T[O-,N\6A+WK,,-:6=SJ?(X@8ZA4NGOCCZ?=0E+[?@
M]\VLJEPOAJX9YEBFJ5C:I?MGZITRK#U^8N"KTJ%O!A^=]SUW>)EX9&>7Q'HB
M_R>N[D47QF=I3(3"M\3$Q<#+6Q>ZX8@>46;/AM<*K#:$"7IT&<8.@IH%M I
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MY<W;$3/K'*U85BY9*K9UB/.#.Y^AH;=SMLE&LC3]MOY5@HU^DYJK6.VQ>;N
M-*\O!7FKHEP]96;A^*8MB,WP?3!QE4/)X#$#A=-ARQ099:X>A(D7ZHKKQCD,
MC<S6$X"..?:J@*:6>Y:6(KIO+E/E'W^SJ R'V?%UAGDYZ0+0]WIU 8CT "$
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M+51,VR^ @(^Q&8ANQ1Z;KZH1=Z[DR8M^/[\Z9W-7F6>VLFS _5[D&O@[0^^
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MZ[ SKT-?>'IN_9K(Y;0;&L=^.W+^_>8?-R4LT0&-T;5W"S4[0UN/1#@$-NA
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MVVP2\5:[/B#(:Z38[Q-J;6>G,+^X6W2'?4_F<08<<?IXU%7\ED _^J^%I-T
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M$\1 H(#M>8=F I6(9!W!S'.Z*L"M8NHUFAY Z:1O)]J.D0X$_1.D9__IVXC
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M?R6^Z#C$EL 4-M2+TQT'QJ3I&J\7"T8Q$BW2$I'H73-KVMD;FE'RWU34,GE
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MV7OP$+)P7806$)S\#ZCYMQ,L#(6PH0#&<V#\UZ%QFC?YCT/@9 /EPF/(A:]
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M-V,R2P*RMP3A*'G^0,9OO]G+'^6C;A^G#D3=Y=X>Y^X-I;C\  A<A*\)5#9
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M9L%S[_5M&=M.2#R1OA'\^M&R<\?RKD\7O^Q<^F&]33*]NJJY^H_!7Z\LP!3
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M&S++-9M)PUD-I/)VYEY\"^D]KNR6/ZVG@5!:DD[+;"7 RM6]OV]>'9QGZI2
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MN'D$-TC:#=PB17)@HKI:FXZ8VZB8-5NXL#"9MD71.3"&T2!.8!IW" QQ<WY
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M52*1OTZ-7]H%M)K>RQOQ#M>]D,WBO>S#%AFM.K^"[/R($J87@_MV"8(%1^X
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MK*7W[2MFQUBHZ6GP%._*N]9ON<%1OC303!(-I-WT^[4D![>46RZJ0@@?-)7
MUVD@4?D(M4S? 6 ;ZO\_OJ32?&6 K Y>D(<>G 4+('T.^=4O:F9RZ*X--Y>$
M*W:Y0O9TB&G89"RDCSS02S8<.=8ZO^??J @]^.@2A#*!NQ+FTO#RH1AN,KC<
M4Q-,6(K"#42$7"7THW'&/.ZVEDU80P:]"77Q$G?;U#J<%TL'+T^02-T[=\M
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M3K1#P^BMG2MV_M7E=MP FYUN+@S=.N0Q)S]VMRE^P+'*1]"@R,Y=J38H._(
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MA+06""/<BIC6NDWL,P?V W$;!JV'RUV>2!Y QFI<$I#)@4O0S>L!/:[WP5T
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M>7B7)6IG@,&QYH6G7Z&]S<VK\],C6/D.Q"1Z8:)]<[)MH'5.MAD0Q2+CYM2
MJ'+J$%6=F-8>YV=+^8!QDQ<$'L]I0#M$3A&,P\CN.%8$MJ!=ED7KT[A_W!\#
M'5/^(F>)L>,]."C';'.U^%(E7KY7)\Z</>T([_U[O2FW*ZL\KI\LU+NZMW#E
M]5>[UZ=NEGR6KC%^O*7\;1O!9E<H%G_EY36GNG!_LR]K6OSAG0/\.GEJ*O7?
MZZL\[Q:I[7I^QO[$EEQXX'O:<Q5F*QTADF*E=B?+%JC5L? 8WE-M]!<^4>7
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M)5V"BU#J?U%_OZ6&#@D\Z&VIYF4 12Q9,(<<\8?PDA\//0R1!Q+(6J3KY O
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MN^0L=R (3Z[00.GLBT[_;I2A/T$'D@(.#,<0IMP@Y!W/PP*2 F2[%TS:!M-
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M6XG8KRGBCE? -I+BZV(RDUOI45P%0N'BMT-,26F#9ZMSOI6ATZ.U4XD;MS9
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M?XE@UQ"*P3*<B?^.?QW[E\A?C=U(^.GB]# AE1ZD:A-"P4+$=F(\#TYH)FB
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MIG^2KD2&.;^$>_EWF7U"L4MCF;TXXNJ3I>:! :"A^U91WIS>5I=^\[3BGGH
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M/5?C*@0IG'GTH5KNY>/MXT7DJUS(B]M'D1*8#I1[SSDUO4[D?FOI5H1-JWU
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M^.3^F_)[RD<?D:V8JFP*9EQ!\=K)^'1B)3Z5,'\"=>;JK'6RNB3@]^>]Z)1
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MNF8+Y &'1?S-;N%"]AYVIX25?\.870>1X<?\77P:'VR"QM:IM)B'P3$X55D
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MM?G1V3O?,J=+WU,7:[YAB<3P?LP!+)4/P2Z5_UPX522-GU-%,<^K<\/3]GF
M!:1@_#*&;X> LC1"A^+I=(DK*[+58;COZ_A>/K&\1>//4 ?\,IKCJ\:KUM=+
MG@45C<ZP,EY2Q6]?YPO2&MF_Q$#-*T1<K_<.8$ZG?C?V&O&D\Q-@G683>S%S
M$9B64/H,9);I"$6RF+AF#/PDY2=F3V4EA9N.TXZWE7UV.8@Z@2)8^4_/L<[
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M#LZ1;J(]XMM]6;?P\:B?BX8D>)*C#<+/C.)6]D6.S_'^.8>/Z]^A3B-J?*/
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M%_U$@,GX6YQRPZ&Q-BE^$09[-O,O018L$4?SDCJ[VE^AT9"W7OUDBFT.\![
M$V.N1<\8'5)C80LET4*S@V5QNG_44II^5T9)]C&&5CS*:6B1O2VCN:^PO;%+
MU<"!]Q$^$T6^\<U0J6<6EG>6@IR+66N.*";&]BDB&RD:M>\=&M_XN61Q=*4<
M7^#,%:QN7%E;JL +BSW%7NP/O,X+;Q.IQ]Y>XJ#:MBJM8N6SF$AX"%WRK\HI
M.-N;^\)?<.X)E52JB2S7K,^.*'DY[=V=[9V;[\YESE<__0I/QX4&WC[EZXL0
MYOR7O-+_EGU.J+-1I?<CU>V4);BKM\UT'VZQN=M3XKE8M&#9BJF"*&K<]O0]
M"Z9732'1ZF -&?US"[H$K]K&&K30ZV(>@(V;? H:!O5J0JUD20+.+1/SH1M$
M9Z9%S^-?F\,>,CV!#W<%<D#:\OG2HA7EBV5\&'UQ,O_35*YGOT%/__TA\QDT
MJOD?AW_]59%S=]B1I!$@E:PNA@+-+[B">7.'[F"75/4%"Z21KJ .Q%$^>NI#
M)(^@0:*F$8Z4OTN5^=1A_";UTJ<(QM0NVQ,*S=B+U3P%/?X2VZN]B?,\.@LQ
M&%76\=0\TB6Z%G*IDXE_B:P'G'P:MFL','J^4F'07UL%TY6WL2#V$\U#@@&-
MH<RJO.-/G;&\719Z>**^\E[K!Z?,8DFKN["RXO6S8*>:*652_HT8_O^0$M'\
M';D$+DCI:90EM6N9!$5);N +0)9Q;B!^<V+QV1'J>^E/:%&/0=6^FD]<>6;S
M\;B1^E$]RLHUZ?\,!B]]3[B_\DP&$,_B%HTR1 &=D"2;: AL90/[CO(526-1
MBBIYSU@:-W=O^X;UY15@E\+8IP)F<92WUF6*CAMQ\%/<)7ZMT/F64&7&U5"S
MPYEUG 'J+Q:K#ZD$;A+<Z2SZ@CN_'&P3FJNNOC(ZA\Q@AL9!KQHHL$\"W-?+
M38*D_U#*M[3=]?2H#"XC:H"U:U7S;;_?/ C[_YMHFS4^_Q?QEA <>O/Y_R.[
MO'&Q:%]\?\>.-1D9&1^O9DP]>WR#]-LL#ECS$2-M)1<+Q%!(< @*).@ 4^$T
M7X]T80=1QPU+C?7PHGAXU$WAF%(F2M20A4,Z3++"CJPXBE'4FTG[L@26#8/F
MG>%%5U\.6YCR>^3M9:%79#JD4^_>I8Z)^WR4T^"]E VL"A#]2"4-;%6LJ7<2
MC7%5@<Q58$)AT$Q[%LPR4'@4-'B0A"RM&@5%R%D.O)K;_ 9&O*^?['K;4>YL
M*M(9>?^,YA31D[LV\MB9?6M9'BHRTQEV;"*!'8X2'D81D_L6%J2R3)ES#4?[
MT4X(3UP%W(]E?C<E& "[QEF<0?7.IXS4/=69];+VF1T.YIN_?C7*J_\^J.Q5
M#IP^TS\@6(K%%7%."4$XP>:_\4',## @/Z>V'H)<R1QJ1 W4B25\6JB=\AQX
M_YSB'Q!"T9_%7<*G<98B%^2SN(3M?3?UOV4[E.<]D_C1_#&?^]MHD<JSO?I(
MWW2"/2V'J\.@[>V,P.%'796_8T_]@NWF-N@B/96U9J[:*%-/@E1)\),LF6<&
M_$/*;Q"G7H.63-=4G^^77>/!+?6#5FV(3LS*J@KC[;[J+[E?TG\H1Z-_>5DX
MSC&")"_F#M;BB)I 1T&2^8R[P\U[ 45U)"T*78(<*:_A]]02&.W]0J>335PN
MI5F.Q_>.7+=(/9?OY^>Q<. K+^K"4J=LZ*)=[HE4)]23+\DCE#>/=<U=&],%
M2;BD4@YBF"J=3C90W@>/5'N99T!RV.8BF$,!MSD\=JQ+A/F/8'0)N""+0DA_
M@[^1/5T1PQ'CQ(ZF?<+KRS,A/>,3BK5]9MU$*_9>9 "XJK9@A-!5A=4*015'
M9Q87(M(:B1/)Q(BAHTRSD:")Q?G=9W^5,L(D20TV[I(T7N*DCI_0]W/&97OZ
MRM%LRU3B>N%C$8VNT\U1X$)\,A<->5=1;Y"J*+UX5%L+6S6J?H=:@U():6Q4
M4>\1+2?<M*]*NZZ2BF[7$I #P$=6["6\5M]5H" DVO.3B2OAQN;D\%N2FC>U
M=T)7G1'1\P?[0AR7'0ARL7,?H\#',*P@7H:!^\^.RC=@&"XX6=K&6HML  0Y
MWXQAZ=-IGZ-SK<53893PM#6JP/_,MYD'7M29V\<.QT<4_[U-L$%V:N"7 CA>
MOB@W_S,D$$-O;E=X&WE[A5!@=[I>P(A^G^^>T,V/8HR3(>JN;<XM0W'VT2UO
M)XL=R1U/WK[==B0[)N%>]EM>&2^%V*'L5#_@8YN]=.Z2KPV6:20:!VQTO#'7
M>!:[#?T#(HR'HMJ KB2!,)CB7=X3L4N7#/:7!X)D:?%!N6^PR[;:L^]>YZW,
M.G5FW1_XG)NXF52ETYR4/M,$AA"#(E2K5S&!+K%5[0,DZ70CMU];VLTO[&>4
MGH:K!\U@44JUAW3EQ 33_:H3<-V+!;]?_;+35)UG<3VTI]1I']Y1P04S7J36
MY9@D*1XQOH!J12NZR6F9K,7JIQ8Z/LIH>'VYPEWFDX3XPWR9*!;Q"H5[A&U4
MGF]SNLM.*<4 6'HJ"+?#M:T\*$?X6:A>J)5/9U-.)/UY29[248]L^4^@/%=#
M6+M9?1N2M)%U&$4'VQ%7:>L%^?K"H*)OOET/?#,S"OLX)@S3F))'@;]8#(X,
M_'U W^_,@;6V<;>7GLO@GR<%[]+8C:6M^)I9W/G@\4G_]0,N[IC+\!0QS;>.
MBSW*$AQ4][I)-#'^Y8RL<4E)T38 '6P//Y!UU.!5>WBQG8>.TMWTT&K<#Q)8
M'8D8V2K9F/ENH9_$!'0U,US]CA0TBYO'7 E(+Y%?%)E/5(33:*M31<IETJ4)
M+2K+(E[(-R$H'W=_MW<F+:76$A3&M\,95R;I!OX@M:$O-S%59K//M[W,V:IU
MUQ@IF']I FPF(0:VRM>@ZQDJPJHJ%#SJX26S33'U396.6=C A 9*$M$4E%Y]
M2"-]OEZ<54]> 2;J40(L:H@Y:-J8&1PN7A+BFS:ES#4<+#BWL#7S?J$''<F;
MNTR6M8!)43\B20;XP(8BY/8.BJ#&&C_E$$"5WK[[;8-D!".PIAY=H7Z T2DH
MR>G QYQ FZD?@%=?N;G\"14US9!W.)B.=KU^&WV*OO[>SZ@&LGM.XOSR@"NJ
MI:/:&<ROX(YW*$3RI'K\"F"%06Y=?M!$KUBII_X5-61PE.:*I'H&8I[/:&!>
M >D^4LMDQ!DNH92%\"HK>$\93V1KB>O?P.6B5)=C06&R*HKN@1<W(#^Q 21Y
M1_D_[+UI6!-;MRX:146DB4HG($2E4VFR%!#I$A45D86Q!0$A2U$A1,Q"1:+$
M1$'Z)DOYA"4H41$0::+2*80$"(W-PM '@Y!NV=!$JFQ"21INY3O[[K/O.=_Y
M<9Y][_EQG_VCGB=42,U1L\9\Q_O.FG,,X%?2=<8*[T @JPM5E]-,.0(D=#L@
MWXUVT/197L"L!)])B8L"-ZLM;NLM)T=QU4:#\5=P[4T7AB?*IB*V]L?&(Y=.
MF+^]7_*9/_>7>3&S/#0\#@7\BA^U[V 88DS5[SF&,$L?31"9RG3%Z'<S\@=0
MN9A 74=&B36%?99!7B(4E[:8'+QMF$E%*7>PP4]<6LKP'/NIZ',-NMXRH2MH
M,\3UO>E5JQ?AW))XR;%J'O$+390>@0!,,["B.AKP^VR'?F0[QF+8FR#&"]S%
M0<FP_\>8'V'?KX 2MX&X;(S[%,9FP#7@S<O9";G@;86(L52(7[HF-RR+81 ]
MH+-_9"=2.C.M %RD_U;">BOLB;,4=]6=.A6^(\(#!1Q&I:O=0.TD%C8N 9G!
MN@1(Q>.50'DW!@.4ISE-5W]!U]^-F=W1ZXRN9KE$+Y[)-/VU@-M$\<Q15Y >
MQJQ!\9&M=$T:H)6:[=H<C<:=1^AQ",V&4IKYE#O;"HJ+DY)@Z;U2;0&Y2\J:
M(ZLL#6+18CJ=DB#VT6JWVL)F'$HDNT[%FH:\R#M"K-PY@!FR'=P;/X^(1D+.
M?DI#E#P2G.G IV@VQEG$6DAH[<ST"#/HN!2?%NK.G<F@.H+U]$S*@?L!$J+[
M@-)+3-.9;,KGW",TV2R<[8BP[XW]8:G%'<!'SYVN>!0V.3=,/_Y(D\P(V$\2
M<.6:@D!_P([N@17=@<,C![)GPC1A!<24#_>I'=4\\[,Y0!87JT_Q$S%-J%W!
M5KI ;GF9<M<0ZY0D4;@LFFHYX/3#Z:BN!TYIBUG=[S;FPU3;3S8-E2O7XJ.>
MJRS@RX=0M@"Y+^81VL::=%OQ2$N(QL5X@0E)E 6 .W?8RHFO](E,H!DUL?/$
MZ[W#+I5VTE0EJC_8CFQ 7G"E8I0;[_U0(!"T?'CM:W,3<:5(4ZP<]T)5K-0L
MF\B#*D&%O!'R!X4P"YD.C 6FPJ!+"G<();;OX" H_I#I(_+7J3  #OQFRD/@
M6'=;44!X8A!4(B7.+"-[.IW?^0*Z2Q"%Y0^Z\0P#RP@-C?N=\)#=C'(U6K$1
M9D@(;!3#6-W'6<ER 7CR--5]JO<;P.%7*%(TDSJ/,+4%HM(P]F1.U_X)VC+V
M*J0Y/MK\+3VA4@B%A0"E7RHD+7X=)DUNZOL)S)@D-)+01)G;E_4S1^%(3M@/
M%L@TW4*!(OWZ3H/.C4SEQH* W@L.82B9UU@8O@D*5^S>=3^$(+<Z5AU?$5A9
M9#OP('?+G\(K=]H7M2W]29>3H 1-J<P5,+&NA[KEYZ"UB><?JT=03[P]"[I;
M KAS[BD4W_N0$!81)FQS:![17>PQ\+W99\<5AP!/?J9F:P_.#$K8'FBZ?[!^
MJ9O^OK=]*]#5LMA'6HJ3H*GLOL*+'"RO )#3N$KR#[K,!71H;>)U"/4H;@,4
M-TG.B7C +MFJW*Y<XD/#]U\HXNE!P?MRZK*:B2'>_E4$.NVB_&+#IK%CPM!=
M[H./_"TR%EG]N4IZK]L^^57;JY]7-?F?[+' -LZJ209P$#NJ*Q^'O>4U)&P/
MS;U9[ @PVV;>68N\+[<T^QNDW"=;M%H9\=5;?<5%]0VU0?WUC Q=$N6)VXO"
M=MT_SYR^^?'#66=G;-71W@<IG^_]7GZ3]??"[=;T[7]X+MQFM,#V/R:_.0YE
M[6_JK_,)/OQLX/0PZ8+*X2"GMJ_Z0W2-&_%-P(::V MO+JW4O1T4NX/<_]HN
M=UARY-+0S?$@JY#W9<\<KGS0GN*=H3FOU_IIU*QZ0A--D-Y].MQ/(Z"S&4^"
MIV<5 <IET&U+]M,J]2L4HG[D 214;)E(_7#&D>*.J2T=(UI9#[,"'XV,.K^H
MBC$Q$5I]M[ ?/!TPP3* B74[MH2:3EXUP0 .,$9($C^8MSO;3WL!,_((*%"$
MSU)O@$H!OMBTBV3"NQ(/2$7!R6Q+,L82+0GN#(]W<S+XPNWBJQU9$#,6PZB
MB&VF?1"ASLL-@%5'; TY;?9DU[V5)7I+%KPUT(X=V^UG)KN3J:1J.AT>F6YL
M-*WM,.UTCK;\.* M"T!-MXG>,"V/0AQ)*4_IX(.3.,(HYEIM\#9(4S>FYK<!
MM34%F\O;^8S_(:LC6%[ ?%RJ+BTCK+2Y^.#-2@35GOI&*L$J30/4NI: EWI9
ML(B18K7^GV6TA)H,;='F,TDP7\Q@._>MZ?4.5N#(DZ-'0*?[PZY'T74IPQ^
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M87H9L>ETZ0.B>7P9LV0JR+TIXFEIC$E?!&&NN.#1J'_4(T*C/._A'^$A>$%
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MW,MV@/(.-[2PA""Z\P]J3[$.\$.@C^X,O4C_S=$[L(I,ZV1"Z[0U\]&4L\U
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MO0/4/4ISU4U:M'"A9EDWL!?WKKD]PDCU.!9V!1IDCY85*?R5NP=M5&4PY?>
MQ5J/H<B]]0<'7-)"JH#X\C=][/64 -4=&N%V?;7?T>8G$+Y*:3&HQ+JG7R#^
M.4,)$?<X[#]1^(OVK(E9\>:E%O*&;?;19R^*GY\HKT7H(.YL^$D$26J=C0WC
M&Z$>318SJ$=4,8Q/QAMR1*566_K95H&+5@H(H9_2,4@X"@0#Y3#@NR[] U/P
M:,)\II.A!Q7LR^KT/#+T%\:^I1==KU/L@=C^-\J<=A:5 =_/(9PYD?.4IEQ9
MU*E>.\ V<_K1E:R !T(;SM7)/(1M0$$!?SK%2O IPF?=66?U@K"K. 3]B\-'
MZAKXK(U\C $4%UDQ J6B5@@G(RZP5ZNR57]J<N%?U^Q+:J6ET&I)K3R]76)L
M"EY;N;:,[-)>&!UPG!:WI&BIJ6 VW;DZ]LS 43 X,WYW"XC*5/K:U@6'SB/2
M?_@$!#<=\OD[>YO/UW]/';7AYJ:C8]<0*?8V(B2E5_N6\AS$%..NX;7A#HX!
MNTJC2B!?,19FR*;*':!=.<VGI;ZZ+$_L9# ;^H)@VYRO&Q]E0CV&.0-4_OH*
M]6?J-J(F09<^K*M@'Z"UN;"TP>"N_&"YE9>JANJH)*J8K(--N968RO,7&18L
MVN,8J@'[ID?-V37]SL[4U03U<G=!^.W,]6[6\6XOB95%MTL!#N0XVUF=*'\%
MO0%<U$L)"I\8'):.):@"N$)#32I)\^C:-ICLZ,TC%,9D]Y!G?%8 L:K;H+ST
M2EH7WH3D.'WFN]/FJ8.-S07<7FZD\QVL^#B$#TZ>,P>0UU@.P$"KV@ 6^;%6
MHURU/H!*=<5I0\&^]8O:'D+GN4VQ[+R2"=#4\4O#<%!0WVW;A/R@[%>.=.OF
M)]H1R8CSQ6F,>Y897UP&?TQEQO^'];-N[LG*3=CT:@H>CG<;O,,CR\:B87)0
ML'N@%+3,IU^),Q[Z<B.JQN?%D-.%YN;TM86?]J7*'+_89GK8IP;O6N<ULP@*
M. @:Y$FF-#3I\FQGH7Y]3WZ:I&A,-X %6N6<(EN>E;G>/?=Q./Q08$-3R.IC
M;5$)>N=G2)N.NFR8C+YG@ \!@J^S_!/O36*L 5X:Q?<1.515C]?#3Q6:%%0*
MR0F'2&C/W)1+CT:/O2>8=K]*<[],R9]=M LU@]DI&#O?AC$$W=YF79'@]<D)
M'<%J"XXY,XU4+]/=.^S\W?+7Y<$'^FK<',(JZIH_K(EM'OB[X>Z.>RL124V/
MUVL5%+1A5C Z3:A;&>WJU8RN!O/(Z(:(38P=_67@D3*Z3<'F5Z6A4&K [B%9
MW3L;5G/"DR302??]>_>\)H(N<5*P^S:3P&_"U)=/S+'S*L)>13V:N%Q]JZ&D
M'"_XM=2^ON4I*Y<8UDSXARQ?1W+3_D!JD+9QR2[$)0 Z HR$DH-:R5JMPM\
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M'VIK.E-VP'(>D4G9_C!ZR[.?(<X-SV(*Y*FRH3UV7L==]![_XXT3I:"&UA;
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M^Q=-JA_$\50K6,'SB'0Y<1[QU[5YQ(KD=L:<QQW]>43&/MP\HL?O,_W_-OO
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M5F56F,PBY013%[.5 2%RX7^:Y?I&_YS/33.0X1(JULJH%JB^,FT0H"/S^;L
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MD1 B[@S"3-!?J$>FN.1V9K5HJ&>)GNIP.M:AZ-8[G1<16/K(@2!C#'49^'@
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M$!YS\!]%FANYJVHK4K&N\8@Y3^8CGZG$8ZPPMO31+KJ>5)=SP'/XV^Y'!4^
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M?P6;F1V-7/>43[0H0U-99)@N%:&Z@@5EJOX^(E)V/=,OSJ@YOU"Y=<,D,&1
M@P6:9)-5JCFV B :BW8G-HU104\F>B#E;7/6E1[VDI</0>MO]WMVGE[^'/DY
M./**4/;RT,[\LPTM+=<C;NR7\>^X%("7H](+VD]%CP8+T#KFY>P788*[I2ST
M3\S,@(-0_1@N+X8X\I_4'<6O<,\_S2KWAM?-MLTGE(KJE@)EI(QJ L[?E"#^
MTJUKS/RGIOR-4O]L\,6>Y=9'/O4U4+:/3HA[N@XII-6?[7AOU;LFI6\[B1X]
M[1_/*7X>S5?3U^*Y>U4^?>&4SP?2HHO:@"EVRL@Q<ZD^EN=*SU:ZJ.2UODKI
M(%<"&2',=T9TA/MMA]F')]E&Z0%>HY)7[CY;'LDWR;O[;&GSX,.[8QQEWP7G
MHUV@]TSFGW#-GX%RN.Q-+$!>H?$%HJ?&FNSQFV#: T")8HK/3*!P69_4%"+)
MG7-K1&I\52[VX:Q)\_/QH1KHQ1G6)VYUVIO5\#]_[O-+SR]0FN_\1M+.9=L<
MEE\/)01UPAB:]*%6X3^J8B0O?0&E-1])-A\55N*U.J^+/Z06_+J-"^R/F?A[
M)W]35LX4;< ^SN012B*63PK_0ZY+VD':7E6=KBY#O/E-O#R2&;=8)]21>9(B
MSA;7Y6U^VL'O1X#9I4P>Q6RC,(=7W0MCY6>U:]_L4\W3\/)-(^P&(B$^78^D
MQEMUP+'M/U2C+[J/9LD/?Q]0&%"(<]?US%$=W-O1Y/J8";_ 8>TM $K'>^O>
MF,9=$P_6$_.)3?\'SEWVT$#YSF1AW]2>MS>/ZJ,;$DZW,NM8(?(KG1(ST::-
M1B;1II4+@3V6^4\V"U^J?OD6U+A434^?;C0W3K.RKE9YMIE7Y?'PDGO8=U:1
MFV+^JJS"CB$SV[GFLW>ZKF]H^="Z/Q5R/LL^R\%U:OY:Z^43NC>7W"2XA])]
M.F]R#HN_:STA)E]PQ.#22+C@,6_QYP).%BX<=\143*[>58F9J;#Y:8C9R%?=
MMK6:+73[XSMEX+NX8.RY4^6RL3:W;F138ZC2?UDQU>N*XJ]*U8?.?U1IZ/TY
MQAN3<!-OL)HX1"?Z$"0.1/8'YIVZ(]2R779CXX8PN?#;6F#\IV@781][502<
MFOQ34^_  #%!=:LE0V/7_7'' 56@?;-K=UKC)M[0;.PQ6;H_?_D<5H,]Q@ >
M]_3LS*M\=:^29L]8#>]D:3MMU67"Y0.$4_*51=6]6WF\.T]YU4>O;9<JF7(;
MF1H7O\V&Q4=+C?D6\9_CB2Q0MW-VR5A(T7KZ.<PITN)N/=7-X.(/!W6!^B9G
M%WO.R,[A]JX'U_P)=TVPC\H?VMY[0$:X=D5_H'BG%XP4[+ FUXMG<K&UM4+M
M2R%V5_1%%*+Q'/[SKT[28'N=3EK#1_MNGA>0*C/SU]7P/6>8QZ]F,Q_]9.GX
M8N;$>\++1RH+,R&Q=S;I8_>Y%!(Z"F_B?H62<I,4X:*96TN[#]>%>CK]%$N?
MOU\YF+:3-Y_R_;$U-RTUE2\C_<>DPJTJP7 9;F^'?[Z9+MK,Q<GR:O5]3Y>1
M0FUF_6^T'<U\X!!49=Z]#J$^ ]S\*%+6Y*1H39?\Z=5ION!IR==_$L=VEITG
M9'-KPU:D[-\I?2S2M5MYX/S 1&U "FQ%+VP1^-VB!$B2EXS33..(X&Y;E;OC
MR(N$Z_GUH\_H$),1V6KG,4T#Q3 APTN_AG&&8V+7>Z23S%6H9Z9O>EFD\$^U
MSZO]TF +[W[DVV>DPA854($=;[^*R'(3#C]1R;%1E*?'H_ZG;,^.Y9N= H]5
MJ+#65>&1ARM?#746*KF4"$_S(=$_MC6WCR21R)"5K4X'2F5IV+,5'V<'Z:*P
MW[K%-N>PCZ^K#3CQ![<2KM6E&\E^$=_UPSHP)'<$_8^]D'@2>T0R>IY4HJHY
M'&YR9^":SZ#@;]5!;Z.3JZF]L5O*@[<LQ(R'XI5K5%C:2TU\$0+B905\RSKK
MI^IF"ZU?5RVYXI]D]-UH:SN^'^S137WOKED1G<XXFUMZZ>-TI.%<7M'==;F
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M4Z0FUGSDCPCDP<_;U7G4$!<?X7-&V1ZB.9\TEG'3;P.>'@%,#]@\LDZAW7"
M*IKJ !01<%-C4/R[YQ@V]&,YT&V"_51<!XJ]'. GP:<'=N^3!V-39?2P#%'R
MBS":'($)9Q!2A6BK@35*[>]?+"X A/",M[G]3O"OO\U%><AQ3,W?I@A]@IX:
M89SBQ9<"JCAJ*;VD10#Q@J32-4)A)8U_Q.-X$5WC(A[W :/$<W*=\ B^AJSV
MU<;O68S3FZ=O%O[^)3!<Q63EKF2KE53)4-J5?,#^1MUPD];7U6F[@OT4<AK5
ME@E,%KKM+AI?E%6>O[YZ &?TM C0W[3PH-H8)YNK?C;)9YUYAH$ N\2)CN9;
M;9M*5Z1)([3?GDBAKXAP\_B5KBMKBE--T,_++ZR0^YL1U5$[B8/S]A!&*XYL
M!08N;78- E>2VN" 9-+:'E/.4I/I"8<@_)=]W-OJTI.(0>.)/U .'&.@H;2#
MK;I1RU<*QV4+Y.N6#6]H:A$.06_M+I ?U+YXSG\.]O8/C@.AT,WWPDK(=7HP
MQ ND6<I@6R574K_1*]#X.#19#SXM1% )]FK1 &H9;'X'00B,*0:0<B!Z\F-;
MK@&-9/O;E!S[&YI*1 B_[23"%$:!8F-4+$<T%3[]3BVZ[1!$, !K>BB;4SW=
MOE);1.B9:->X<"BH2>L0=#P!>*V4U;H994\V0\\D4..8J$4RIC*%AY&V.<V[
M:W^G0>.&]+"]T(AS*AU@?E?4A8J?BPU #ABK1)X]UV1B#;@\#-ONLCN)J3DP
MS(VW1=^'D/5PD\YHX-(@C2>?BJ0GTFY?2@J@L+=-B]:3P%'[ \'O<-8K.)XF
M-%'&OBM3-FR:VMX^[OD2A[6??M[".J3$5Q4X@^,"['5>9Q)RS-#?Z3Q4'GHQ
MQO,0],J>;!DWO4N"OJ;=)..H1?0F!B]2G_[A$.28%9S%(]L5_I5VCOX>)7"[
ML)L\TZX^;_7D$DZ7 NXJ%3'\"N1W&L/XZETYD\*;;N>[*_\$BCK,)([M2E&O
MTBL/00ZPZ1=8]5+L(6@RD%3:'A<E*@0<RT48M*OGAZ$$W6^3R+*OJ4(94FUE
M(O*!6EI).DU59/K"E_>%;F18SB_E+-]WMHVM?$T\#';X@0/2E1X"Q:?@JES6
M30^@<PCG"6(W]A@Y'>&,%G2%D!. ('%*>!?\"$+<Y@ 5*?=GM/%]%>3TBO'D
MCXF[-1/%G#.WO2]L2=!>,V]# =6+J6K>I9TUZZ5647!K"11VJA2@1]9@L,'(
MXM238TT\%*D[0T@5-$6#A Y3&F1U;Q$?H['G 5:W*R:0QPAUFNS^PIE7QHJ_
M>;FDDK#LC@Z:*GZ]N8PR9A:^P#B5QN!JXFAG!JGI]#2,B_TI:V""N-FA0PY
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MHT;L"P,>1UI(/F+"*8VCBP-DDFXJA0]'/T/9"ML*83F5NAPNFFR6;IJXKT7
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M:0TA#?X4"U8[;#W>?+B]HGY,U.$VY>9.'#H&N^_O;NUN&=SQB_CW^ATL *J
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MLE_FFC8(G>BHZ>N=F"@[<#OD=SQ_-<4X:K>"85,L^<>1__K%P!9<H?C=$?$
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M91FA)$/YA]_9^N"PGG\#4$L#!!0    ( ""(?U:<:$2Q* L" (0= @ -
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M'N)"EOM]N) 4A3PNQ!!_!=>#Q X@MFZ07VAPH)LI,-:4"Q<BUK!["#<ZR_F
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MJB6"LY]O5QV]L,B%T/=2R3/D 29.DJ/)TF87<TY@QQ$2&#$:0AAC#\94L;R
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MZXFD,O3-[@50"Y>-5<; V4^L)'C^L<$< I(6GY)WM3&&H"-CQ!_, TP'.K5
M(M#/:Q>]^B6D5^>%1\4[D$_107\RTI)8035H@EV^(UV<"W%Z&9<GA@B=/RR,
MK/&?'8Q;Z5']4+]8&_3=K=JW*,8U^GHSXSQZM?D[K78IIJY'4#&RT?QZ/U73
MU<'DU#+]HJ9+^9.72[D];HT6EO9F#F)1[M%5SQB1C]8>CQR@"PV-9M<]?OGC
MA^W&(U+>C)SZN;\K:7MM!3]8>7ZWNB!D]O;@X5P#-TK\/H.*B@JV,\Y?D34&
M++-D]"G$/G(F_KEX.0 ;@(FQ7( X9CD/\M"L+T9^#/7B7BY$ F/-,&-7F"R
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MFH$=90UO/O2H98*2M@+-A *>"Y\T%O%Y%DB@E8H?$&+IT\BIBKD%-1CWL4>
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M /\9?"T@9 0^Q-_%C@[M86BHPD_NK*?B=WG/J?)>:=1!Y8!8<)PN%^7=A/U
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M+WU1A[AW93]08<T,202'8;N#<4]0@L2D5I %&'T+-T69UVRC3%Z8]URE<_0
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M$*N);:?LOX>CYB#>^0HD6+,)U4JH;4Z5N0=S'B>#.:>'$@65OJZ N\>#4-*
M>>MTXNJH#B5VNB<Z>.HD46.MLD[5UZEO"OQ[WT@5$7,/<9L@C];SCT/M)<F"
M0W,'>*_ D]/@M*%_)Q^RWP<T8"$3$=['R?M<$'B2FA.P>7UXW1DE"UC.FT_Y
M-IO2C)P[MJ[FOC(ML3Y1Z5M56/_2<>P6C.D,C3A\GC"%!$7\SFW?BZ 2*+60
M[;E?'_-BSS^UMABP&#@H ^%#XB:YVX3Q?W\5T-IZ53 >' 9[V\'H;9 \T_A&
MI/CIG:<#%]T;(JO.GGATXVU0V7"R:'FR^NB=_.NX.W8]=FF=]FS7D8-Q72><
MRI#0A J[99ERK<XO%6=0!V0#:;\6W5BP:TG?U9J>-R4CLVU(&O?3KT27#TC<
MD-__K,Q,O=+@4GK2X7X9[DF./BB8*DR09E!Y ;%PX"KY<^Z"7W U$ZW()S"F
M#6(:T8[;"^[%& #:3,.S@PG8O2RI#.I*.*XS3P;H82%H)?'8(W=/ _4F:?ZB
M':6 ]]9:^\. ZQ;*<E<+_>O0&H^@R7_[2'CX3RVP1U@+$63J:_(N["$TA:W)
MA*T^XAAC_JX8AW1H1AB?YMX&K*CD;=RS3'L0"F10??2QL+O3XT5>'//!BB6*
MG_&)#_5974YQ,1K<8]F.\?.-];4C;W!F.!H;!CFMS5$53,!J -H'Y1[@T-G2
M^@?M%7;M@ 1$[#1,$B_A&G=0Q1\@;J, M3ZF/FI2B,Z4G9:TL'E%I8JF)FD=
MVGO??KU*K1LIZ53I?=*MPJT@EBVC/LJ4R790BNT[5:$0US/485\IZE'Z7:)T
MM-.QQ/5=^U5B5(FJC0]AA\"V:N4/_(H,^\HKKELW>\)\$XFKWK85SEE3YXOU
M*J_9%:F:7(U6USTCTX5#X"2,]V.<ALAWU@ 5@=QE/*X"2OYE+42"N\&A+40$
M1I*#!OL$0@#A@Y]J6J'!$D"UR^3M&%F.&9#%#F9!XXP/<75X55Q=IA5&Q5WZ
M2?-9&G'O\R".=&W"0D?VY[K.!QQR'.8PM=)N7IB[]PQ]D&' D?K*W<O,(6T#
M&IE(1Z8_]PA9EG3*&>UCSX1V^AZTYL6;M52A!T:Z8%*^C+K$XVCL*;34[_DZ
M7C>1VJ\IL:P%%#AENJC__$Z^-0'N03%W6*[R,G#4$A'GDWR(P.H N'-M7EDO
M;N"BO"ADF["2/@H(Q[?"OX%]9*9=5<#3_RQ0P^QS@DXXFHAV/A6V141#"D66
M";*.V4EY-\I&4=,LOUB]('<YV3KY@23FZ.%+,89!2R-Y[G++#OGQN9=JCWI]
MB56O5)=MSCR3[=!8H';S1TN1C/6E8O%BN4K#M&?+O9]GQ%8K87<J;>R]!K)S
MP/-_>](C.2$KN!K-Y$.\"K@D!PYHTQ[F<O[%?C8LB6IVY,ASS8%-U@6Z=897
M,2:,N;Y%B*\C0H$/;!R3$1?GR5R(.#(*M_"I !YQ;VV%) 9QSH8,;2AH!O?^
MPD\1;)EF KVVPYB7PG7C',=^(;_W9\R*D1\;&Z//TDL2$/?XD)WHJ&O#"$_-
MF-"JF$+O:5P"*(/Y=P(KCI%'_@/,]"CJCM3Z[_$V-,HQ5LKJP2K4$Y ?]-0*
M9W3(K\E,CF:$[ [<;4U K8D6$/,7&K@85_'3UCHGGJ(/[0]X_/CI@SAPCQMS
M]SL^1*9,,!"#;^N(MU &Y-PW;I%U?$J+_B)$.:^YP?I8YL$3CW#L<.79$W,)
MUT+?YD=\^\QLN'S2W'$7<S+I0ED<6O^6&US/*\;!ATP9SE"Q3;8J_YZ6I[EB
M4[61N=]/VSH099]WQ";9,.6-FEVRJ4LW!K@TH&75;I,=30>R.,K@H"!0B[_\
M74J9^V<$ Z5+ G]/\&P?>2.(5PO99BU<0<EC)<$$[H-?$?)8X[N;BNHMHUT9
M8PG<N\!9UG%7 .<OGN]98GZ2_%C'^?/1NG#'ZW>+M@JZC&59U_F0J#O2'9HT
ME-29!&A<ZL'V(<#?U5_B.)GA%8BNUHR3:EVY[GRE_I)QN_8=J47\.]K*NC8(
M0W$0W"G>,S*U1*PA-E @D 3AR8?\SG"XD<Z+/FWLH/^-"BGT2",PM_B0"$@:
M[C824.OUN[_ AO!>"4$L? NKH@N)I=M,IAL7'R#C"UG73EP^O1PT=T"OX\Y(
M8O<M[V:K>QI*LE=SU"\Y?K<4<][SV.%((^W"CDN]C0.GU+YKE5QZ8UQMT]00
M$F-EMI=]/\C-;/T/JJ%Q[,:%A'&'@ //7GJI@@UH*V6D*.!___@AYH_HI!JE
MXT*\7*]&%Y1H4@DZZ/"U Q^_UDT<VF8O>G/;2 F-L<1 )46!>VXS(>Z@ECDH
MXC,!%P =PMCXUY02XM<_RR8W'X1&S#[Q;R![$&:46LGOQ1_3%<):^1!1W%UB
M[,,Y8=9. NVS63\['E"@^S^>'J@(+O/:MW)J[F^S^+K<W+D/A6W;*_Q#2J?R
MZ^M;Q+P_>>SY\#WG48E:;?JSG#>YC,^&Z369#!6;"MTJXL/0H:L)CGY]$WY;
M1R6:2*DM32Y$I94FU==OW"[.0@6!H.[TGV.15U3>K>/2$=MQU'SRKRP*<(3
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MGI# &,6 HXR ALG_70GG++!W I\">P+8<(_4/*U>!:V+"&H95D+X/B_V;X_
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M9YF;JX<Y.L ".PP(8/FS3_"R,'9,X_YNLG"SB8 [& ,3=-1C2NU@+%;3AZ3
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MHOW".(.@]*)(+U%ITJ57$Y47$1%0NK2 B$B3)A(@)-([* @H(!%I @+2BX%
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MEA^A1@CPL#X!Q83WB0LW?&YM_U0[<?JC0)-]=E9PJ*]?@%)ZU8_;?@K$H*"
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MIB0PBY<F^=]+"EV#R9LW3+P_O'\A5*54T&_B_=W7_WGOUGVGZ\\BFPW4S>/
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MKC_XBM5MZN-_Q$>;L1NARA3P=8IUB ,.!W]ZX5!ER^FG-<,!46?.AC)")4Y
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MM60:2TD?#I5NGF;4:RK&S "Y1Q[ X5\P*V@=$XU167"Y3I1.A Q5DKP?C]!
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MPUK..B7(T2=P&L-A<6"^".VKW'RN2C6C@..?%H921'IH##F=\^<HAF/KOB6
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M@I3PT%K.+>@VH#L>I/"@,FK87XW0%KSEH\E[VH$S?=#3'1"%G+,;E'*4AB7
M'2,4S"Y9/S@NO0CMWZ;I4\)Q=ZS-.:5Z7KN_6@+T<5D^: 6X#SY>[;8CS(&Y
M>WH0Z1[?ZR[(NO(F3I[/G#&E)'WHRJM:0!A08+I\.^6QR[)RK<()R"L",D7R
M^R-+>0R7^^N 2I]G!_H(X:8L&]^Z:;PYQ*R5U%"^W_LGH!]<N=@]O75+A<G:
M^]/M1XY/TKS=A!9".ND0FQ4?HQ]T) ?OA3'.PXR.M*C2%#1>?D@7?-;@">U*
M7@]2!,@I-*R:=3(IZE>W^H0"&P9(%7\MUZ]=3Q>UE&V)J>E)BIAV<5E:_'"
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MP=S83G-)P\**2-9Y<9/L$= 66RS3V7'W%NT+2RY+()0M:C$?W12"@_UPP)V
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MR)&?NSQ0CN%;V[GZR^%(?"*Q_C>IUZA,C>W K[ Q!L^8U-8-.'X>([)N_*:
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MM_V5<TFUVV6F(=8PWH1FG*<(DK122-P&DSN4)XL"GYNG:MKM28+3UB2ZQ(4
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MGAA.O[S,QBS#(7C4+30;)#@/KT%TJR \=J*6ZENBJ1(;]FR-:$'[!=AXWZ+
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MR]5X#182T_ZB;[5=I.L'@<HV4%_(JX)(7#1/EWAUN4K"U*W=H=R%5TK^U&9
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M/;B),>E][K.+.?66+-O_INBC\DE+=:SO&\^W1O/-(\2;,X !L :YWD-F8=G
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ME>Y()L^M<KN$,W1KW."N!%V80=T75Q:$6H%I'(A8A\"".3>"?C>5XO\"Q"Q
M^5%UNS A?Z<7DJB6=^9P^QP!PU'3EIC,,#=B9Y&4J]I?HUHR%D:H6@;1=8$#
M(<=3]BNZO@Y^=6+^.$$&58@<"3] ,[C<=1\KW'&XPE_V=%/QE6;ZW1*&\!IY
M-JOX<$L5-68&(3B]6F@ON/+&9_*XW^F%]=SK"LRGR8Q+K)J?!"A8V*V.4D/$
M"G<[$=?'J] J *X'=AQ]A@@2VHV[@J1(^%7V@61:X0.F$G7& -,EZ9U,:1UA
M"L*ROKGU1@6<&;Y2?D6SQ7LZ3C7N(T8T[IP?'+A%E,"1U([UT[+)PI1!4K8
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M,S'[ENFYM.V/219C&*KF_@5NX-#\$Z-LH?DCRQK]K_S.7\=E-*6[>KHF+;D
M+ZNB_*M6V!(%W9>T8*(?*_S>+&O;7R#?V/XMQM3 ]L[SH)%@<BT"X*)&]A/Y
MF+ZMK()SDOCL#I-RIVGTN4)*2SPUDZLG.A#_<C7:#E>]JE#A)RDRV0,]@A7@
MJ96GFP-FZ?XQB47T/V%[JLQ85X3ST%W M=BW!0Y85;*JFCB0$R1:IDB-%C&1
M?:[S'?'=VY;1G4R[04>@VWE&QOAF9W/"8%C5QNC=-NW)BWAML=/4J*M-?DLE
MX[B$]_;==@6752L3;*OM/L.;3EGSF R(E\<SQ.]UQ@82))M-<[+@?!:=_,9G
M]-0E=H3;AQF.URJO%LB+\/\=5YE9E1+N:]VM?*;@=$T5-?\FT@!]3U2HX'2>
MW$;PDS;W5?<QW&ZY+SV>&L NIL[>[:>I/<2'XT7 YYM=92+C*OJ6+UQ\Y^3H
M$:7CK,REQ"WGMW5%\Y:3&_CP3M.)!=/F'.<I5<V]#R]2[[3F*3$%Z)[4PIZV
MCNM0$CZE[ C].T%H#-. MH;&=]@^!Y]VZ%0+7ZQ[6GON<<S]\)F6F)B$&X$3
MYPK,G/.R8V8^5_VIJ&+W(@6WD9DPL? ;LB0CD$L.?0_\ IBRFM\5/]6'TV<8
M*6#82Y1:#T-,[^*-UI9H9((^,HRNUK][]O/%L[5IZ+_2S88WUK\/41XW$]WQ
MTX4T[VZ,A$_9:1!+Q4OX%.$>P+TQ?.A##>/-T%0.1 !]A2I@CP#ZZB<;EN,$
M .1#@A3*VZ89,'H<LK3*%IG0]Z<YSY\@_]M7>T4OOW,Z2>G'[X9+JE?,E/H\
M%4(.5F55QI,\+TR'BXK6FK!B!/C=1+/.V=#%HQ2;-I%JGZO<5_8KQN=R*"-Z
M*M(N>*.\C"[@,LH37_W/U8*#+S5$$GL\E_0#M,0>XNT%4FJO0OGLBLJ==W37
MVU^>;I9T^$8(]>M4I*=AGI$+^Q'Q>CII&TQH-=H!]*U$3>RX&HHU UF5"Q@!
M!S!GK>?Q2I'%F]W#+>F1KT@8PSK-VIB_Q\PS[F\$JT1DJEH51_#!]3ZA[X (
MP\YJE!,\%0/]3M=.]:0)F#D#%'K6(ZU2*020WUM9F*8E8&_AO]T^6H.^'/'*
M8<9?)S*D]TBIUIA)B++7 UBJK#[HN4#,@L&(%!SQ:)P,*$6*DQLGG$3A&<[
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M?2.?LLZ4V+L>-XH1B)-"C?R:D^H!O-B5D35@W<17FFYE2\>X_F7J.P-/^^&
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ME2+9P9<91[]S^<JFQ=8?E;NT4K+],\:SA ,1YT :"]?7]KCB1K" W2:HC'V
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M/(9EE\EOJQ=!KGI!UR@[%=;UT9H1_*8XKXZ8C2!C%M2Z!\DZ;![;??>5 P\
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M!$6PZ9!76]Z.6^Y>EZ8U+V4MS0LQVX^/JR'5RF$ FJ+?#Y%AV',D OT<0P%
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M]G G&&A<[ 3O> -9]&A&,!65X=O T.I\]1;X0(<B ZEYO;"D,J6I9ICPY:+
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M,?$L!:05X$1W#'*5=DOI$*]?P;S"YJ+TD?I *15--%.CN53G[Z@,6EK::K5
MQ!$2W:YQW]^4VQ4\Q&8A^?>&D[:S:GZ>&MWFB?ISXZ?_+AN4C&^UPY-#&O@0
M"CN/QY&*"Z7:]LPG2&[:. $M%D6Z*]V6O3C!T%=%R5'[6R1Z6SJIZ'1((Q(>
M6;?6CL*=+!*:1D*B9IZW%A1U,J8>^MBNQ^DS1(=WX%16Z@L@!LJ1V+G%EVF"
MW8.!"T=^D9 ^0&F-ESFUT/VM/IRLIOYKMW=7W^AB:\J/$<!Q$_I@ADXX>FL
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MH3F?*^ #FEU#PX!>8=W@X0"C>316] J"WQ,)3"9X$=3-2L09"NQ]PO!FX#,
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M9UQ^67>(<K3QP7+/(:.(=GIMKH?_/TNA]42;P655;7IMBLLW=W/;X:)DQ^'
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MM34@_C5RAN0&R5<FD!4KW"*X+^[/VPW$U19C,6<Q"OY-Z[$QU][7TFLFX>X
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M/$(4>G/S&:X!EQ#M>KP ,+P(2D42C+S;QY622R#Q:WZ<RK;PV%R0N+MV\+9
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M#D(I;AL<=-?:"(L@QKIJ6?]>[85%*D/.(1<BO[<26.$_N+V0AXWD0\QW;)A
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M -?5[+H+W<"\@-VU\Y'[78P^+L/?OI^HG0P3;_&$"O %P+TR;@&)YE=S')]
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M359&KMI27Y8;R/U#W'='8WWC:(4V%(PQ >^%O/[!]\$?YKM[W![]PJE#Q>Y
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M*,U!/D!O8SA1-M[3Y#PQL>=YC44MZEN6;O A>#)]WY0#0K>[P,\,@C>_F0>
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MTT[>\:3JU8;[Z9\E\4DV7(\7MVD][5)N9I9,N936_"EK:_+1@7IV&NF9P!7
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MZ@^<C/EIO@+#';JF43D!5; NFLF("SN7>(N:<G5=&1\4:GOY! !C!)MD/0E
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M]A)H:HL%T<JO+N58X#VP2:/K<ECE^073?0:M(O=+@(K 5=:=//F39B)GT:F
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MN8IJNVKFV@+[:UTQT%QZI?&P4;IBTD=S!4,A"^3.3#8GC1H29(:%K$E=9YS
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M-XY_MZ2I="J%'XR[G>#D_1=V"+P?H2F)(I\^JS-\2A0!KD!2FTZYVLZ86AA
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M]LN(COC]$FB,3^JYN\/7M!$7_A(>?;8]LL$ >3(ZTLDW4 L>M69>5UH$*51
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ML[HC)L"UC?I2439:.S\P6=]SN\_$B0Q4G^3]36(S-9;369ZSHJM;?LP>'@$
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MK#/*U/*. Y;0@4V%RO)_RY,X-H,^ "["7-$91V3XW0WUJZ\P)YX@3;"K;<3
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ML-["#4V\"_&1U4WC@*>M4L.YKR)B6_7B8"X<\7<O'^-Y<,/HL3G!KLXZIVM
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M5-T<S$G+I$J+7[?165NF9']74TTLT^VHRM(;SJ4PJ:_I'61+#;P=ALZ%D=I
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M\H_OCT^H'$5A$<I<>X:\9I*(Q(O%F3WJH#1JS;_$_DQ(IV], RS*\DIJ_"0
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M5?>#%I/'?^=DZ'Q.G4( %]$J0WR)_ZT+Q ,]N&B*:NK0VRO0&[;;X-  1!"
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M++TUD'T!(?;0DU[28%AA=F36#D5:%&C;_Y!V*PVQV#$DGC+M("E[67?-CWU
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MTG2\2Z$SP\%_MG(A5XP)3EK2:=3J[,13>LPL:ICG<&Y[DO_L[CU1-K@!YA[
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M-JU?H*4/H5II9[3,-K'/S \V"WKNI"F+=(%>IOEK=JC-F??:!:RLA6T*$2,
M)ZIWGQCZ$I#H%DI3:(PXWH^67% ?P17_.GCU<=VG9-*=&,F)=,\[?Z+=?^>'
MRN\('8X&;5S;M=XKF[1N; 3]J];<HRKZ=DO?*E.K]:ZB^W!Q3'%X\>CEZF$3
M_*5%+2^[_(R! EM8>A%2%BRS_/JKM"OG)J%N9=5V_7V"6MQ&R_]##^O_+T=^
MR!'M-/WF/]G^^=BWJL5$K5->92>,M+-7S^WX?%<):&Z"3G4&X!SCJ[W/#:]\
MJA[^O%R;C@PCI/]2KL,V\4 :B'=7(T64;185?<<[3;9_!>76=O65O/\@^@VZ
M !%X80,AJ9(<3V$JXQU/2<L[P3TM7((?;]8APYU*^OJLN&@JB6'- T'OK"R$
M1BROA&)2RPZ,R!T*R W(K56,!*,5I1QSP&LX'FC/GJRFNECV ;L6$RC@$\0*
M!ISHX$3T'H8"%=RI$8^K&.W$QI!VFQP$'*R +!H^:11>>2:6*0^1!?S:B(>!
MUW0-*0#7BMU?IM.:YVD[!H!;G3:L/>PJ"4/Y%0T<2[[,#@)J.CNP%1HM'-M1
M9X!51I[CGS=,(1W$C2>V8929L9U8"?8U((!)IGFTDA/A$MQ#*'R+!32ZP2J$
M0:)YQ,"<&#.71M%Z?V<=\3$P]?=3<[(.;Z2:0_3^ZK%EX!1HC!---@;NA4\@
M@7/](I$2,'%J-U81C09T62C2HC&3CV#CA.=L:YJ2WX6J47=F1CQ,C)%*2XUN
M,%8F?/3"0GQ6T'YY[(N,E?AJ_+X+5(6*\<%Q%TP&MED7YLXZS;[$B2-Y^,EC
MVETAHS QEJ8W5WK$%W, "&U75AAEJ]/<*PA,?/P2S/HSD-;=KNT"1-UB0A+0
MWN!X].W/ /G64'7I2MS.!T(04\@:B^3S9P;K 5M@Y3!Y>Z:VJY/:85)5A76M
MNB;@I'\HT-QX!]T0% G6I^RD1^Y!=[)N<$>@>^!N\.<9.'D,#/B$$ =,H%(H
MA^8PE\;D_"'V%5JJ'&K4N9*Q$H-6H[I(/XBA.X[H*EU<MV%<.'+%K6AL/G.J
M(,"ST#,CPS]"_X?PW=0&8>.Z)*F744U;?8H.=!);6H KTL-,W.PE^"F@#W/>
MZT)BIS09N.:^ V@]!K2%C_PH:!/Q%.#%56$2$F'&I2@<37\(?>7#E+>) G-I
M*WI=#"MTB:9N\!>'8'1[A=EDORFEJ0>L/#6)1P(G\,T0X*$"XJDU%9_TU8F,
M=FWDY#XBFCBC#6H)G.QB3KX.&>(,),Q0/K'-TFW7!CL>J!F1(6,NUGD:ST,@
MBDZ$IY_9UD%T64+_AR42)2_\#^<Y#^0]8G^Z<_,Q4)<G?;I-(THWI2D0_(^-
MD)"6H4.+(7+Q.LL1%T>4!-1HV@S234XF3(T5ZDDB1,QTKC.5AHO;$?M='Q(/
M9]#:BUO&B%+CJ#"RZ6#()()N=7ZG.-$'9DI4)@"!9SXO!A>/*I_(J.3G<":F
MG0>20'LR!#:_ 0NE;'/.ARK2_DL,E4[''X!;"[**U$X616N%\YW(F8W/=_QB
MZC3BU=F'=%B$BCAOPW!//^_2@M]B0Z^+7WX46.^F.$ %,1*[DB#16$A8<"?[
MB*&IY@Y&>O[U-$G N8MA1V%]N8:D^K7.'#YOOZ=!M3!-^ORN&U)-() ^Z-Z_
M;X;9@/:91*/8B.V_I1;-RD4O)(3Y,OS[0E)4\[H<7?<^G428-]MH=\B"GOQN
M=$M@8=77K?,GM(U6\7$RS65S=3JWL6PP?&I'A&L8L<4EKGTG2I_0(TOWPO_B
M@5<>QB+]#1II)@T!V=D.>)]+N!<2%UHEC';-!V6[_8SJLUR%1GOXK+2G!52A
M79F'YT$_9J=DOAL3E'/_K(TTHK7^4$I<S06?&HR'I9DIW.*$!C>WVUN,?/R<
M,VT1\=KO]]V)_L(=Y(/ZA4\=45Z9DT9#RRNL\9H)GV$B%1W79S]#&ETM/-N6
M5T.N$\,X;Q9OETQF<%D([JD777*",K;"AR*[(B&"T*Q&Q%'UN@F_T!IR/D%[
M!<[.8L=9GAS_ 3HHR,Z[KPGV!PL<"ML )3G\@;(/9'%%1>BD,;X1;X*/T2EE
M6XM+5(U$K)+.2IR)#A&H9-U&,;E0M@!@S5BA5I=ESH<1XO%+U>+:UX9#>"#I
MA; WN#P4TGQPN2C;<BLC^6Y8S7LA3L3+Y@[1E[DWSAXC^C2;#IC/"@4\RPTT
MQ)S"-EO#[T$3X'(8(VXW#U0=VZ+QE"Q \K;VIL!C3=39QDR_Q5'69>]QTV@&
MJZ,.TM8CHU^%D!V;1"6V3IU@#"QPA4<I:0N+=37O3M0/KA2[F#AYSZHONVU^
M"\N]M>:HV7-3^9;97JLD[Q_1,*/R+\/*^_43WB:\\F<6,DWZ<FA>K1+;#H2T
M#W^+6M_VR2J>GG[N-UYB2UK^-)Q5O"1;?;W89L.Y,6=QKL->10.C^:K ;;GO
M%XL>VDY.0E9DM.*3H5785FL!"KF-@VR5KR'0R2(HU0YE*)!.B;LS4!XB6\74
M>]K@0.&!]J'J;9B0YPWV>>-C0.*%AQN)K&D"24;VZJCD=BISZC6?6/KX91/@
M+8^(@EF#VS7B-Z? S(VA<7 ,YK KMP=:94UJ9?% <9LU:5-DM")"#A>S^A#!
MS&PY5I&R1?TL&P1DBO4@; :3<9O1W>.M\W"&=>JO"9K&(A\_!:D @G42Q6I_
MB1JD(:.Y4%2_;FW^<+D&3"\?2.TD$ \Q%5#0EM'1[9<P%<I"(PH59/[VTIY2
MI['&Z>J<LBKF1.<VDA'+%4EDN:.,-A7X"S5G2PRS%2C=R#A2A1_[ )@&70(S
M^ZY&T6Q2SV11R3&YA_^]G8.^,+ !ARQ(.ND2$C;.,5;:D.)]G->>2F6_ R>=
MG:X>SAUX.#K2,OU;P^%LSTUM.;F[*IG\X0HXL>A-_YL]=X(^VW;:[4Q!E6XW
MW_OR!".48X!9ZCX;JWX;^S7<QF"DYW!T<]V-PH4(QQSGRUX#]EZPRZ5WYRRS
MBVS*Y"U:7CO^BM>OF5Z,R"Z0^:2]X6?*7S6>VSH>VT).Q,F$^"5DSCS3P3\C
M[UO'1Y&EV.),/6IH&SZ6+-]@P$2VO>F"1W&5BYNA4H";#8 K1>$[?0<N45S4
M+!F-Z]Q3WRJ'\G\2AW18G;$._U)V'K?3D4\ XVIT^[X4-I):IK%I,;@4XC=N
M1MU*YOL@:X9J)S*JQC'GVU"P%4Z./QLV1B<U_J8,]\@@:+A![PDT=EE=EZ/C
MC"CZ_3O+J"AQ-8A&8N^OWVQD^BUILSPQ QB)01.%"^78UB:X.V1";=.#;\62
M8.X'IA2 OCRV-& 40$'( ZH=:A]^33H#LK:DS.DEMGK)_.;6E]M>N]6ZRKBM
M4N8LG"(/1,DAU>"6S*BIP*F^)7$Z$H0V ER8?9L]G#0,%/.#!]I-\C"&TJ)3
M$\JJ7*2H[9L%I5TT> +\@-N #E8,B2IHR^PM-GI8,?=&W#,?]5@_F%7[I_;)
M[N#A+OU+F1G'?8M$NP47].DGKE"/Q>'3+Q)W]>=*WVAKR962RW0HR>3^U7]D
MNJN_S"K3]OF0YI/WK_)/JSF_^/P^1S2[^HE*?/ \R\_3Q,HR1]0WM6&ACCL@
M>@H\%89CRVAO&N/. VW<7<.8XRA2)UP<ZT&2Q P0Q1G*>(8='?K4CVO"/M-_
M;^@(5@XMRK?DSZKZ $=7\>JAJFVWT08SRL.0;A^(=>KU$8\4:R.SX?)'1,F?
M),HW$]@0#,XOD3= - T>,V*RCX%=*L$R%RPY^8M25&2'-=)YL)H4X[H/\/F,
M<NW;]!SXO+B"MF ZF3(UXF#A,L_R4+A60[VD8+P\>8_U;O=PJVG";R"'_X^_
M.:7L4-8=-@C(=\M#'>^DKCPG45[DPCC);!>:$0^D/&X1E,<.9&I$<]5F,Q]G
MR<8N+7+)I8"O&E[V821V_]SBRXA,I[(WA4["?VA$$+;9A ?RM3[.1SP['Z84
M5?99@Y(W?YJI1DY^@QBS9:>;?BZ*5CC4< R/U@$"J'@0BJ_C1FHR=;-W4MG'
M'&O2\9<"J#ZMUQE#AC[5[4M#S'G-HTKK7V!2L86U7M2O6B6B&Q/M?U^6VD&D
M7S"MY6_IM^B<&,AQ?%<./MY^D5!A[P\DM8I97T1Y7!CZFX->#@I(-FA12]/T
MSQLZ9;50>^_U[36;><V6D0Z-!Q]>F__,2GHU2)B_@F-+AV]"ZSBY69NO^0HR
M[@Y#CWU&(76,BE8)9932HDD=V_"'^D7WD9&2;,&,EBC:$.F W^'5:K[A90#7
MYATRKW[Q>M$V'M$6"IY+'6O=Q %V+#O K0US#'" I^3]^\!@>\:4$),08Z**
M5@5>,_PZB7N9,3E[966)4"8T$G,2Y=:2>^1K0T+OWP'F,7ET3>J>-JUC@P7?
MH,]&28RKT'%#^B:*4XX6H?- 8QE4OTXU'B@!R[!/5<*,F @PRD:7Y$K9JLPW
M&8Q4)",C%@8O0EL!MYE6+88WXBG89,>(]II"G1Z5]B]3#\]M[OMG/$EVL*NX
M$SR7P=Z/I_@ME3)DJ;)M^+V87]#]?'J4'?."'_"KUACC@9J)1D V3LGD!/HH
M<#XSHC$'%\7&,MNKDN7]XAW;",SNCQ=*?D_\MK[K[?_(<>?R_4AR2X]6N5)^
M9(=]=Z6P0]M 9X?.W'!G?^G2EY"Y._,7[IZT+; )F8DI<9!"2,>U#;20?YVD
M%CMJEEY>:J95BE;/M4K%O#[QX_F';<_AJ@>?;B39WQ[:<BX2MGOE=C$HP#8@
MY_.[G=R7^0)JV?_>3$'-=3[*;<F9OL(ALX-XH*\?:1%YR\&G?KD??B5AJM]]
M1R#2G#*C?W!.+Q,WA60MP8%/VU>$J^J,U$K5E3+*,L=*9T=[=MA]#1G%NC$'
MTU5$A>=^K/>A[P1TAMDFR"ZGV-CLZE2Z%?4LE[VI&&3U]WA08UCP5$X$9HMJ
M[2FY<2<B:C?"H., [FZ2>XF^VBS^?OE \E9H_V9_],2"ZD+/SN;LD]BD"AB2
M47!P&VV%#]Z.@5/%1@.ZY.CD/.>9<F/U S[P$S_^@,R"(OT#)B+-OQ^5,&_&
MZS#?3=*AT9<#(?'5;.5&F!Q^=X198*!V2J>*R=N4@@ 5(DU_[MG:'0^#YN;9
M\X_V&Y3-%\[=]7W]&EQ<EXF\78I5FRAKV/'NL2#YN/"S1%[V9A@/5&E'F!G9
M62KJ$K0@+.]V>/;B=U32IER?,9%8J)D/]7^L>OCI7(HF-\!FS8[%%S@1Q7R-
M9/;?0>M[B;V>NJVDA^W1J$..;OPUFU;=DET-\S:33WKE:H1N-6FK =%-N,/_
M.\QN=?KC<OQY([1YH'QH1WJ"8UF(HZ,:/L_ <MP KO'D,9=H1EMARTAQ19%,
M)Z[(-B/(89@+QO3EJ@'Y].\-&FYT<3M::'R#YB?512JCM#4C]SAR[S@AM0'I
M_7'.=IY[CBGQ43PVA@@%,$]TX^^^\9.<1W@4CID2II18?MAF>[B7QG.R N8T
M6H>3@3G(%F6FQ+,.<SMS)3A?>" OI]3$3%+B>IF?ZR#:I;2L"KZ7N/]#5,2>
MZ ^5LL^7[3I$\*CGW7>/#>V;]9NV^?FA9&.++6.WZ0@,LMRPS7 3+2Y?!8%T
MK,%MI ,P]PB*9Y4XM VC6L%(286%:22L-SK8IT4\WIE:'ADP_USV]\W9GY57
MF9VBT@^$B(*<6C@EBU03&T\TP?PD2?[[RE$(6I79%T/R)?U*I_) BUAF&C8.
M)_F7$;W59(UMWAH9J61;]NL P4K6,"PUEA%!&)-M?:QG^+A2-;Y8;\D_,UA-
MD!S0NO[-M496_4FVUORMCT,]=^-2U/:=<?RA^RV$NG#OR;SI@<.G]Z"W[WA>
M2M.0C2G6MZQ1'1O$2-P]/7RC [&7N;]PCCJYQT;3MDB_53/H6I7[J80BU/1\
MT5#QXH?!:Q_FG7YBO1' J=&EPQYT,AB0W90#G!A!'1KY?(0PN<N7%FGL^\,F
ML'GNH4&?0N ZS=HE&+<+K<L0QS^O1FD<8=:4[ZC&38_BJTN?5"V=4W)KWCJG
M!5-UDA3A*\I$IED\]N'*F(HEP_4E(]&&DTTT8._EO"">!M(MF:^WXCYC#!?"
MX$OA;JSS7J/8?5REULWO.DC GESI$]N4KM'N8SEC-G)Y'_".K\RKE7:K>3M5
M4^%>>.!X\1*6@HPWD67B%Y$%[-- Y5TZ%CANPI>Q@M^!=X7HV\SAOF=G3)1O
MHXQN9]DS/#K%)3;5M?]]Z+6B!;F4-=M@316,[+8]F3^&];#27G#0\B39L1'\
MJT7UY&,ZL!6JBU&,[B:B["C[+E\\"Z*/<])AGJRKB +@ E<%?83S[M&ZP@GX
M0P4R&-5WBU##C'Z%W-]@D.\""$V<9TRVUR.=42UJC1<G#U5FNG]B4AU1SE_[
MBY[A3U_"QWX<RF/>R'< O^6XR69>K#;_%-A"N_L\Q7G;T^%51)+_M5+Y#8^K
M43VJ,*=77W6FK?M?>7X[>2W[_=RW2Y SM]8^?2DY%E]M9I4I]?KVE>8KG"*6
M!#H$2&99L?=\Y>3#@@KFN(H,<ON*'##1CA5H,/8LF/(TK,8MKG,/-WP%+GP"
MODTAIZJW$AH\J6IB<$77R?%$A:-?F!(YGMYW< \RGW#[[!$9_G(J BKEMR0U
MA[(]:@]%0B[@6I" :L9B#@O!%N'4D#S[E-"7&!@2924ZDQP#"Z>6F;7O9'2H
M\"E,'#,@/TWNG/1H(U?&)K"E*>#AD'V, C- @'7.PI.!6;!(-&,\U]L_7[-Y
MI,\IT;2F=I#TV'YS:4\'ZOO17;E6>V?DY)RS&0C82UQ:S]GUL[_F6B$W8XX\
M_TA=N(CR"I[KCZTI$(E OASY/&PIJC9N::]D$33UV7,TY.'@AG_(J:%\65NI
M8ENM[*-_"HL,KI1[EG9 TJRK7MT]6.X@;-!R-GMZ]?W"E_L;3?<,%C@HG2<!
MV#Y-'@B-8WS83LQ>N=['7K\(W_5R9V [D0<REEU+Y7-Q^1GS+?81'NA2\3MB
M!?+D8?D3O6>?8IMN81%KX^_=K\@U45*:F+49)/@9$3 8M'?GQM2]K1 3G YZ
MOQD\G(#L>WFM7J#CDK]0()QHWBM"^2/.V;6QHIU@N6,<4I<PWU &N*S7?\GR
M,78/+B<>(V0.AQ6'J_RS?AH7SX7;=TC$4UY&F@J?G7?SP]3.$%R+I><#]E^2
MFNQ;E9[.E "W0Z "W[D=#/VC:6#)>3<8%YRB.?3G7J/-X5:W_'L7-@3W*F[M
MC-H<'B]3=?<KH6S>].&XRCN9S2;Y\[6B'W<P@0<:G"3A'0(=3[S/F_W_T>'R
M_^6 K&W;>\8<$,B6T%X+%/,03/+?'7E^4?/G<%K 0E<G"#?],SSWU$G2<)I0
MV!TWU8^S$A)!J5?#W0[K8DK40RW*@D>6/-<L-AY+/;8NG*BLN-FXX[CI-/$X
MX]W;P2.59Q1]CKKM#XA*BA@_6:98E/7W>A?EBV#0S\BF2*.H[^\SC.$S6$ +
MSOZ'!]*;W_)=Y:YP#S@@(UMUM_C#</N]R3_PX'\$??2/WH_ZAC<0U<YM3:DM
M^?2YIZK\9QB[\>)AN^R7'131I&<_T:U)P[O80Q:,!3J!+2U&\R&S#URBX)KP
MO^19S3R0&!O!O$2)77P=P'(#C&AF'7WRP-85 ,P,:G<599JU6:D;*@6S]3DY
MQYFD=KPPJIS<,G6$08CD^\)++9F(V!"$Y,)^)RN/ D?N(+>55,6&UR 7VQF5
MFW'I33N$5J6@]CDZ7!Q8H';4/O'\.*^\"RAA9-"@B1@(VYGA-3^BI?NF_BXU
M-9XKP'P07XB*_&DFT5CH>,M[WX33L>U(C?@E. 5'JB8U=>/BE'=SXN"^+@(4
MV<51IBQ-M@T1+^_1LJ*$Z74$=T#VL7>/<L^@4FV9A+:/F#VH"GH[4:$ZL=61
MW*:.;3?1_]F@1D^&( <;#I<"J=>JON:NF*6,MT!)V/ODL5+JRF(XRYA]FI-M
M(HO SROO SP+7,<_--+*;.FNS- DMC7-./06,[4-$H?1'/$]6%- (\<1C9FR
M\>P@6M;WD:D!/TE4['5O,36K?3X^DN"!JNO9W()5_7_SZ.,_'Q4\CRH_.?2L
M,W^NS\]U4@)T%!^'I11,'?X9[/<K=+.T:F1C4NIRAB.PA^EVM3_]]O ZYUBU
MSW6V>%FOSI*.EZQ,R\Y&7ORTE9/=Z<6/TV[Z^JR@,'9#5/T'@X5L:'Z']D([
MY@F?!6U-(.@C0!E+DMN?09+&'$"?!8H#&"L4<CM"@0WWBS<!,7"I3DU3NI4
M%G_+$=7:3&]WM/D,TZ9E&:DMU'LC)&??=]ZJBIF_3&A,=JG8M4%N^F+6K!&5
M%RD,W&:L2UXZ*8BR,A>4;+ZU[[=6C)(P.&'#<)7TK'R%84=9J-=)56WIBUU>
M7KP]F?J\*K!W,?#VN_C3%MW[+?ITYU^!8HU)?2H[#TKU=\5>>+=[ZV"'1,0J
M:&<MI7 XYLZW+H%#%!:379E^S?*3W"W<VQ>%ZY32DP+*M6P#E1=J\J57?"N(
MFV,V+-^EXCX? 9OR"9_YZ@T.)*M!'(^J1(Q@SEPI (YME%Y@!K6==\6V6!5[
MWOW#;6=\&?=94;?ZE--YU\(Y+59_LC,?(LN^2(>*]?K77V 2GP?60L]=^=H+
MIG88TCZB3X&72#+F@MCV*>:9<VEBT$6LF(3-$U8!_,)@-DL(8J//57S6-?>3
MLC=@\%M[\' )8MP"9GQ2=S%#I]@)^;O?,_RUB@>FOW'S]>L,Z5.VP9SQC8(5
M^\=)#R<<AW,;UF=4[P_96;M<.5=;3G[+]YM(IA0W/L8X-3GX:BI^1_TP,[9-
M,YM]5G$W]D_(SYV]]WF@3OR%7"S'?MX)^XL_*%'8Y70(#P:'VD4M&QQ<22WS
MZ+-VXKS)X.Z)(W!QNIM\R9#WB0<"Q"'<ZUNA7Z<[VWD@R0D5KC1JB\\-] MS
M:2+?:P3=E!HE#.^] .II8B' W?1F*--I]O+6X1CU5*@F](PY>"48;ZYE,MCU
M@+[W7/86/4UDVAPDE7U'4A.I;,9Z@NG1(U=G<=OE-=JLC=IPRNM\"8K*H,$3
MUA$2%AYE#Z&0=3^Q2:<)\AQ6DFWFCCV&?PZS/^UP,L*;VGCSQ(;>X,N5F81Q
M 86:H9-#;>$A,=VYAZD?A]ON20N[>=7IG.B0*//*[2WX4VQM'PLKKWYE:YN>
MY"YEB5.MZA@N7CI><FD<=MIYWL+JS;ZD+\S 5[7N#S].CM6D.7<V\N/IQ!2\
M#XD1O+]\&.V7+S#Z0;SDZ*[H62&0Z]N6__IV!KY7PJ)/6>]GIPHX:4+"5'NB
M1 #V/WA[]W^F_S]^>$4..2SG0UB%'",Y,];1\8URSFD5$G(^#6L3H9Q63I73
M$I+CDE-)YBP).8=B!R6'92OFE<UVK<_WNGZX_H'O3_MANVW/U^-Q?]P/VW//
MUUP/OGF+*;%*5]Y_P3)>6SY@+@ZP00-S78HT/P6-MX #^12:.)0)U:%6D ?P
M=[7*Q@>CF&) 9MT7SY\H:/MGK89?)XK61QM.Q2C=_:5G'&,:>.I%\?:LFO>?
MUO9VN]JS,-5C2?4'--+.CR9?."T(&@R321WPGY'01+EIR@=.IB*<!B[(G(]1
M<W9T7N5SKB_.*B5_^AOO5R5C49+_K$!*[J(7%5@O*.?OB"HP3 W2A8O[?>,F
M*[%&?"(B/<HX*9D_K%_LW^^P;W*_YD(CGFT3R.9GH=0$LK%>Q0#^2+PB,:);
ML!-8/;^RJJ2]!^,])C8U]>S@^Z/158;7BV6@OMRB S9MFZ==#MP]C_)N2#43
MFGQHD...+>8JD!GA9GRJ*_#N/F*H(=:C_ZG.*?'Z3_U #QM$@=3FMRJ:6];[
MV2+4NOW8U^%+18DRWU0>X#JR*>F!6FX:WZX7-?_>J';&EORO[KQ*G ><4E)$
M^Y"L9,2[A45%3?,;L <6"8X02>19C;M4_&LJ9^D/$PKD%N\RO5:BWBA8:$R(
M6@L3E%R/U8GD'[4M=.8./61X^H TX</7BWRN^G_&LSCY:2M9@0OX2T#/HWUH
MS\$YRT=8\HAETFXZ2V$M5JJCK G2!TOOM6H=E]YH]NB?59";U-I1;6R!"Y;>
M6)\E#YB\S\$%EO<D=/#@#1XWJ'YL*5$E^+I&5#O6I>IGELRHVYRINS*H7UHS
ME6WU,2HOZ[K,I=&ZND_/2,_7;]1-.09JH>LTK-N>5]TVSPGQT'!+U @;^9G.
MJ;B#0VI_L@X6L-?35+"W%^H".T8FE(2?)2AH 2EEYE+DNR4 ^7SWMYR*32;U
MM+!P M><N3_C)&L&+< &W=Y*7H -;27_1A3"TQ>V[G?&$S-Y:#>36;*S8S54
M\F#'7!+21GE2N:/3[[4=NF\OJ>FM%)A>?$YBZ+'4DUJ\S<WS7(:?N/P3_$X2
M=%N2SN<>N'DLU6[(&.386)6&<Q.ZW]V;=C+KNWWKX=?]O0TR/6_&2JU,*+W.
MJU(R#>6F*N;]OA1%V8<#,Z7&O6+WB#N!:H,5$P/U)C\ >.QLFV=9)/(ZC>\:
M..U8P MD2'DLQ #4!@5_'[<Y1P;?3V<%)M%AU.);%R'EDM5,;*.9LG=;7@DA
MA#M.D?OW&7L>*S,^@7&H^R'A\RF/NH>[Q]O-FJ=P<K-!E?*4U(KH'1M$X<S>
MFO>+I;:@M:H5BL_'4,J-"(.NQSGRT91-,1\W>/EW-HCZF'EAB)DGR  ?O96R
MPSC%]8_?'O0 UR)YPKL,/J=#LE^N-O)W?U@WQCD(C/$-R[>#IV.>Y:0\C+3N
MX;Y[=YA<W8XJ_;E:C6.<DF_=;3*]NLX&H3>^_Q:MANWQ]]_Y@M;>"T<NDW!B
MB"4'">897:810AG3[\'P&.S2_?PM5 ZAZPT6.+/PXW13;O=JT*N11Q#%KG]M
MS6.#)-\W/>3AL(YPZ0>&H6:\#.-93F<1.@N@I??62_;08/=-2@Y:IL20S-X.
MF>D4FHTFW+BV(FHOG?-6_3"S.Z D@3Q7K3_AT:#MF]HE!69MG8JG>7!BI&LK
M&W0GM-1T84C?Q.5.VTF@Y()]BV9#VFNX2_7S_8')T*VX6%Q,TP\T]0GR(AOT
M_ :,VCH!^ROV9>+?OPWZ'?9.<G'<G;<8&_1(8_HP@2H0M9$E;#1FO*J"F4PV
M8CQ9&]O<T1\=M]^[_G*+"6!8<'3WVO]1D=WM/C;H=]X(&T0\#3Q@@RYV0QBE
M+3#4VU;>=B_?Y48QEB@;=#]@"ZD-.T<.$?@9SS P2P@PTE_+-1 G&')?JY'N
MN5[F$.XN3-@7NNA.Z<Y3>OA,[LB\TNUC2<8J65%Y>8/AWVP"O8DOJYI#$95M
M(=\8B:?J&08MTV;Y]+TQ10O<+R*E87+NBV?T=E=AW!K:B).&WY$DS[%!J5[,
MG?'L;;F<=-:=IL6RJ)\1UIR+C>O7_<.A_M5_7W(NGY/I.297?-O7-.V ]+%M
MI0P@CPAG2J33]8!1AO4ZY/7676@,*7-+5CL+&4C=Z/4Q>D>5>E#?Q8^\ CR@
M3O9R!O'^$C=PE189;$&MSF3:$@:"Z^ZX3BZ1^,("IK;@Y]_.GK(K&%U2PE/=
MMKZ@M!<<%^EP#$G[02/4*89F'G873WU]&P5!O-@@B,/E&S99WV*HCO"LS_,0
M?LC]PH?2OEV3I*)@ 8'%>Z\ZIQNV%-\F+T]?-0_]KAZ6WM14)R@7)3-9*"4O
M^[#;_DS1H'-ROZ&LW*N\$-L%-8LKT7+E)M%_?50$<_.;K:K4?_>=W+@V[7WK
M]U)N7GEH3/3>@'>4G4%)%YV#RN33:*+;ZL,#"D:?FWI ?OM/?O-QR?3\3' .
M(V$A'X2W4L<2DF!$P\_A%W[WLT$5$HI*.0DI*050!(X2S[B-/+R?SCJZAA9%
M03<Z9DJK,Z"^E4PH%9R"/$H<O3 (%T4I(W;=<TBDN1X6B.J:F^)$DWRE>7NK
MU;.@_7=#@]Z(QKO%XOOEE[2)'CBF!(9NWK)?T"G&N/;37(6VA>F21IZGA391
MV: ^'SD 39T;,%<&WAOF0%67%/.&6#)XP$G^?7O&]KX#<>!Q2N>5>L041;(N
MX 4BT3*O7W+7) V#KO)9)EH>>.)6=4$L?;C.K?Q!_PAO.LZF\(QS'?F4FB94
M??_F$1>_<C6MA'RU=AD5;WNMDI@"#^<JU?'3!<:]PO5DX^OY%=;.=)^)@>N+
MX5&[SF09;XI4C I]EZG$,OM()D;P&JNPQ.Q I]6MI0?*-T?;L0]UK_EGVR"]
M:0+<Z%[<\;/CS)R](T8?/B@MBDPIK;[D#BA#CO3 6M-['1[ )#L-J2G=)H4X
MTG[8 *1Y,(7AL CDG9TZT44U** V#_H<3^E#@[_3>._G FA_1";IU*>$G:UD
M/6/-);LX:VI UM;S4K%SI9YKG[+D:AC/]H4-N3X,A>[S&:]6*UO4V.C4I%3Q
MOZDM:2Y4/[.27\7W<>D;+*/T(N[F6Z4B5WN/E_8V&Q(^UM8#\]<]'5T[)E-^
M=;SW&2'Z^/^/%C0CJ-VTK(#!!9'QMP.-#G*K;W<K_C?.V.W_>%F2'2ILT FW
MER"3D'&F ,[K3H(CA0WR98,4JL8A>X>J?A>J3#5$,-1V!MS8H.YP-JB*:P1/
MU ;2$)S9O&'61 X11%->PC#GEAM.<SPFOW18ZM;OE>_(P/*WW(*_!.AAQ2K'
MCO![$796IS^R04TY=Z)8J-:CV^J\G_W*(K^NR&6=OO(HZ]J?DL./'8MFB&J&
MS4B@DA)3-8,V+PR.GDK !9B%9."B._J$IZ9JZ6IK\S:G%F,Z: X'UDW&*F@J
M)(%@!?D[!_TFD(*.)V<U6_7S]4Q>N"A\-.H/.7)Y]%TXDFCS,()"NS.IDQ,_
MOHM9(HBUE\7NR*PVQ(?>98.4+PQ5Y.B%<=':I3]Y/!BS&C<SR9O[/%<SB&*9
MA-U&0<M*XZ$*K6U:-BXUD3U.<*>>Q$=1@>CF'EA"9;4!]B8E\5N#YJM'$=57
M;.S#-MS?#0]<>C?7X>IQ%5Z]M*/T/$-#_[5)\O^M'6+/\C&:R.ZLJ!(_ E>9
MU9!<R?8'\P*S<X;JA-(WZLXIR6[J[GY169CB)FG>V;S65C?O=OSPSYVVT@MW
M].?:F4(H"ETMBW##\J>)AB_U;[I"OE-F9.3$JHKQHW-,RR#U>"R3D<XZ7,<&
M?<R")3+S.>+LC/Y[O<+* EW^RVC0$J_7XE*<_:63:CQFSQ.O5&:?6+)W^;*"
MI= ^<>X9+^X&B#S-->WT\AD7DPW".OS;-L=C9>64_?ZH*09T"(J]%E$2B_NH
M#:CA,]B@8$@:&JP_G@5OA@]B9!%!VO=8?!VT0W,]F%0X5Y<D\BK-D!/.(^+N
MQ >2';),VON_H19VSP,'B*-BY[O::<J8O@:8%6UTXK'S=#1>[.NWP#8/<7S=
M)WY>Z3&^5;,AN2R1#S(]O+2#7=#]<MAU^/P(O9QFCB'#,Y?$:25+FI.=,HU,
MW<XY<SED"+!,-=\=Q![NM$8'UP5C^;O4AJFV)$C?#M!.Q5V9)@3/F\LC;1W$
M 1O^+?WF@,K%2R0[U*F+7+__=,/;P!0'4K83@0VBH'F'Q@40U02I ?AB>P^L
MZ1.LV3"M2P[P (,<J.2AA09LGY N:3D-=7+I:OO 6VA,&+DX'RCGG]$/ RRT
MNR V2V+%O;)W?BJ<="B'$5[ V^!]&![F@?U&%$\0%HR_-6K;/TZ5&EHX#^3U
M+C=O]>/%D(;6S N$=UM-#MK]0BH6;ZB?FUH-3PMYL&Q[>')JHD/]X&J?[Y@^
M9X-Z3/!^84+,P$D4%$ 3417/@>:^)9UTDD,Z4JH:>1EH#J3R]L'$*5T0:^J+
M9=)<.OHF'S(<V]R62O-8),[T 8[+I),%U,&I@=@]Y-37<[67:KXZH U6F>)'
M]."OVBFQAM? \^.D]20^-JA<U]4QEAPJXQYPC*R">=H.2ASOGM9AB@.PHQ*:
M6 $4I$(\9/TJ4J62J_7MU\JL--;QE*7W-IUU! ?F(W#*'=A* 1+Z$P3YK;HF
M#SH,HA^N^'Q@(*$!I-?&YT,I28B88X,:-B@NE7^?6D'C,Z)^<8GBTW]:#0]Y
M6DI3RI:?#!%+ G9JE?R_,&L=%(^)Y(((7*7=!+_KKWF6_GZ,174N&"I+H#PR
M;=>7<^U:$^%^I?AQZER(5"EC9^*O96_N<P;I@YD#QX&*[I_6"Q/ 3M6LA!OA
MKG,+#1DKIYD</ MBE!FO[$7D:/R <",= 7]B-IHT^XCD\$"!B\JJ P^,'QDV
M>-J(&.DKLB\_:/<<<:V\B)-2G=K?NA18_&1^0?GW9Q@4!&U?H8T0L.@L_&%.
M)JU]0-BD/>*X3;%(W1+6!6B*AVNUBVM!C4M@AZ/=5$-PHIQ9@_*YFDL-7_UF
M%WY21LXWP&XVN!:WU)Y\2R@*:@BN#AJMCIE1J>CH2F_84DCG1'=9"_4KOQ'J
MB _21R,P&SOZ*UAJ)XL?\[>>$RA96.HKYE'L"WO<; IG$4]E(#)=DHGH@7[J
M+842LMLJ=?1"]AU8#"QV=$&_M16_#O'&2P93:B@4M7EZ#>]?9P>G::[(RA#C
M&.A!XX^_PT]_+=F1,091(YA?<=W8^5T"+U/J @'7!P<A85184M?18#S5'KQ@
M.+!\I&6PZ0$%>KT644UZMP3L#L)$6]][_\(Q@QL!#,4D>RX3Z4 V<W"9:4TM
M^A%BPW()P"V[ =^I_R6#![53+T:#F!>H<5'CO.X+1DK70'QRJR>;OP-XJG P
MIM66YD!8:;=8"G9HM2/C#MF%S^;IZK5E1YVL#15J8>2/A/J=-GF8:K"]_;H3
MI7BJ[$Q0X4G;HX_)X6*IRO>K$63?<XF!JM<IX^>=%1U+_*H.*54K)P19&F@5
M"'K=^N/RO/3P=I-(?K5]Z/;*LF)HZ_3-*G47V9829:6R-O1']*8BXQJJ#]OF
MQA0O)KBVAI"TT_$\7?*HL0NDN!X,<%)ETY\ N5=V<C*EA^0>&M;I0-L=0AV;
M9)H%$N"\7X&ZB]2U&2@704/F"M*T<IV7X>B^TX?LP"S!J"[@0PA?4C53XBB+
M;Y4:-A32$ 071BDOH+XLP'.8,M4 ;@!U=!(:7!ZX .Z5OW&*=T $$>PZ"??Z
MO-+5VA:\+^64&V)ZN?W/[:UC99.!Q,?TWCE2V.::OYZ;*_P(BV?^VUGGGIA
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M.)O$_8R8RIW@YWUMC,6XMG=<==;5C(^)IDL->FU_:G,7=D.T]KP+]83-51'
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MJA"O%E!3>XQ!F3I[O=Y3 %(T@LA:.H12S>W(S(&V=F1NH)HAHJW8_/-^$9Z
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M6D>!<:W>][OO-YQ]YL?L*Y?UWT[:B-2BH,":/6OH9SSID'GT?K6V3#C4JR3
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M<E^8'EZBS*-%(&77<HT_OZ2Z4W+%]/!D,HK^DNX'->".&\9&DI#T2&DQ,A;
M'D>H"U>$_A05]5W37*\3885OQ]>\OQ7UO2IVSBQ6 /,L!*_0_5 3.8W:]2$A
ME  S8G-BX_6?R_4\.2)_#[DC!S_QIA$SQ"_(5FCVWK\];:BPP9>VVH\!-$)
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M1C$9T-FY^+&9_L6Y<# GR\5YU'ILC;\!L@M#O_%SKRUFCAUM5[[R[E#YA]7
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MH"%>UQ; _(E2.F0J,C2>X97P%6)9Z=[/C]C";2G#S:074J]Q7SE^N"R?6<5
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MQ(DF-O'!?-_I_M]*1ZSM3?X\/W-GZ.RH6Y?XOZ##?R0VCSB):DM\Q(/B;K8
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M>YCF[BJO:Z-I4+0\!W$HQ*-"2G6)5J9O-JE%V JIY3Y3[Q-6?PQ3B\"B.%&
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MO&,]#W-WNX?MZ?/I[/WJHUGS<&2[=EV-06+\R?_&#<_7.K%6&BTIO5.=)U:
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M#M^, ]^2=3BQ:KI2R(>0@]Y9,?W^1)T56\I!.JV#US^A;D[>"+1\K1SH?3!
M3.Q V+:,50Q(?J_CA%C\ZKD6;N.PO>UY6XE^GN:]L?*[TA)2)[MK#D^0[*&:
MNXZ3]:'X#'J/Y@5#)F<HTL5GTZ"J]."#FE\>^7L;9LP/*CU]>")@KWMDEK)4
M1N];Q?N!EOW227T7OIS?/27CX>NT:;DVTLV8UU@P4O1# 5JP62H:_;3GFJ;F
M0KQEUP:E:\[<3_"9"E@J/AOS#=L1Y\-07XCCV0B'",T3KY:@&)_G@G81)(0N
M<W:NK3"KQ/P>E&IR9VW8:6>><=G!DB/L?F[3B=]*QW\=VK>8P;_3=5-Q59UO
M/<E-[>=7.''O?1@I!E^R-ML][^<;W5M>-WM[*<$!VU2,#NXN4(AX^*V@+<-F
M/_[]KXQ+^GO?A]@G\!U(,AKOC<IE5LK\\A1NU#JJ;G_\9"27:&WI\+D6=XBS
ME*43W_M" 4'](S7$SKKV8B<NG]ETEJC&=^!DRQNY(3,RG9FU[Z"I?=V=TE[)
MEL[#]9M&JP2?'6"U!-0M$>3=,=Q2M0@"/I%<D=CB#&4,K07?>SE"()K]<1)W
MS%7!XZOBWBRI**AH9V>K8XX8V"7"%)=+.YNZ6+E"W46>_:I82,)HQ[+@TR@P
MF;Y%0@11U\\J+?^T/%@(&MY:0P_VE%+F3%)M2911GP'DV_YF/@+P0JU<94?-
MLX(3"=$\<1=&>:[&+39&T17B(V$BB*K3Y 4;5/KLP[^H^&5BLHC##L%6Q+V-
MYL(!HJEN5AP<Z]NJ7L=TA7@N%CLD 0,:833[XF*8.N;HX D.CGGQ.D3*]I_7
MEBJ44?*&3@K+]"J=P#]7N@.WK$;Z]G+!!$P5[A'+^4/7^@G\RQ0ITWD1Y+ (
M,HVM$SR#+?7T!P2*(*P:^07=;TGG;KSWMUPUH%=BQ032TTD)N75,_%"\</AH
M*>X;"L33(5EV^L6Q')_BW-P!*:'T(N^HDIB5)#<+*CA22-"%O"UPXBYV>_"A
MKM]2#99E5WW6B2!#,TQRT56#U-US"Y1I61<*>"[  *P508XQ^T00N+*-#EW,
M,R)(P\P<??*<"%+Z5'A5!,F$7<8+8WO^]"#O4SA+")HAD6_CQ,WY $6H\8_H
MBKO#&Z=!*<BM'I)MC1-?>9)[1UQL<.Z]61'$'D<U*OX]R#<JCB.<'</58#9R
M@?*4%;IP'TH)]R<=95>)H[H!9X3W7F;^;BW=B;:.XP,B2,S:,]3C!<[+F^L>
M?_EG9:8-=_A#*$#O)>\+./#A_6%OQRU7-5./R"26?GXS: /\<<0Q2@G-]G*X
M'BHN=(>-<ELO?7/Z^DU,9S#K*N*?3XQ2-*G$S@!S$.3QC(0?8<^\<ZNQGY!Z
MPMVA.%4[ ]N4QLKP*3BPVEJ@BL>OHJ2ZS"JG2J+8MA=Z?%O&R@&CIU]I<VJE
M'@X1G?::FTW*'H!!/07<O:>O.+ &Y:9C:E]-/U\P#P#A5!VYQI-O?A7W6U&'
MLRRT4X@)99;, QTG=A_ON*\;??Q >TDVS ;HST1[KI.;2>N09%_.UC]=9?^
M?? T\#O9,FG?09:<"&+ 7- -9?SB1YR]M+.H/]C7R[M4J_A)7TZM%9;O1<%=
MB)]3,"]N@WS34?X0NQF!G:Y\HD:ZM?GNIQCSXG._T.Q'_6Y6<G(RS\TY3C<-
M; 2L309_LD_P)KZ=S#>]P)U."S7-_5VNV3R,.E5%JOU,& YS7AQJ:3ISW+W=
M-6!J<74T7J5$>L8F,>NA!D1X5-D5FK-/ 8IS@[I/5L$#'OCX]]FE76%FX<O8
M.D"674<&;C73VC:>(K@1N6,,UR4L_+G.Z8^XAAY62%4Y2L_ 9N9V6\@E9EEJ
MLDG$UJM0).)5^[I1#PD"T:;4%OKM\,"6*[>RW([U027(L;A[I8_3&\3DLOCG
MUMSNE^TZ.CKQ,5L4X'KQUL,SHWH%[&+%4=CR@/IQX9GDWL=WG\*8]/D5MN4C
MG5*X'7UF$O@1TC[BOX@JI>/^^>2W^P77%LHZS,#:.K5H]QU Z\!>L7/LDI0G
M-"N^M]2MALZ'G_GV4Z*ZJDGRT$]'IRT>*5*Z^YRJYV>S_:+/2'YL=B]F?\R8
M^>-^8GW:KD?_VZ/PO8KR!(3P#L;:W7\K;+=&\CG(!Z_#!KS>PVOQ3#[/X[K+
MS;QL;&E$5$ 1GOAN@L@ZNO?4W>-M-I%]EE<4T&^Z@8F[B+:WN!819%$SCG>(
M#^>DM# IFV@@FV72B\M RE""EY*FU,=:$IDDA3F8HG O6& JK[;4*]3/&CGY
M8@AC6.;;6XM.]"L=1(R:64]&&/)@QYX]'UVU/A5BFCV)Y$9.W(!+S*^A,AMV
M/@6S>4?#<,\&DU7YUO5.N&B >+0=,&NH9-86:1KU?B"<ET"?\7DNG.I(,]:L
MM^N_FN^J5GGARA[LT-1VP5VR 5\"\.!C (N>;$V^W(O"N'H'?(;QV%Z^,V>8
M"]?P@R>8D63G;^IM?0:F,KZB>EK%](4WP6C7?$;W')FX\4Y[4>OGR,D46M1"
M>7*MBV9RUOE;O:<> 6KU1P[%_HR*+RK>X7!DY<N?\+@=5E<J+<QD[@LJ+3S,
M0I=/U:L[UA+OE+L%?/#(=#KTJ]LDY[@K[TU<9J^UL\&AP;RS'20FX0Z!XR'N
M7T+(D VR'(D=#%"!*V'E,3X O@>9Y2<@I&(B6<C$*5T$E&_)F>F%;@KWPQ(9
M8HD33MC<+%!F7<IDA<MOFZ26;N-<UM,#H^H/1YID-2RNS!H'/5][R59?_,R@
M),;Z= ^JS;>?\LM.L''BP?F^@FJR_OR4]B@;B.9O)6RR4P*5#P-V-3',PV5E
MZ?VQ>4WU(-%AZ(;%2*&LJ\?(XL20N19-$[,*OP@%#9"I'6;,[.01,-!E>._T
MJ' 72#R>QF8'4^F;,)% L]#DV?./6-.Y4B,0'P[L[6=#J?7:_638\*4AX;9)
M<*0W8,LPWY,YH&MD-G]Z1: U;JA'84V\&OP,95%NW8!ISL72;^\4$,@2?$UP
MA)/8'Z#%L:LD^O.M1K$0L);)+:E 3S!;ZZ\Q9<&E%6/K'AHNF0^O_U'S*.!,
M6&S<K+O]1563](E:[RJGW><?__H2KU++4MMYK=(JK'-/\VY[:1G,,G6/5V5&
MUAZ5W7MR*QU5=YV?<RNO]/ Z--SO-(F8-]UC7L,[U!;EX/CD0<@';_R!3%T#
M"PW3/U6/ZPK2<(QJ2E-RR32E"IW8(X+H=!C4_LCW^XD/KD#G,@/*PVO0;?V%
MZND8*"-5J $>&::?[(R/9LG3[Y!WH&4&78<V=T6(]8*T6:Y8'SE\"UL_^&B(
MPBBG0_C.;#H>OFEE'G7'#T$EI*Z1TC"ZQ! [8PZF4)*8B(EGVH;-=]/H"9AK
MU0%A=_U,[MSHO#ZE0A[&&$:QK+^/F!B9H;V:OSJ.+_)1K*,PCBMI\VF,QZC=
M3KYI1X'I=_ V"9VWY#V$W1F:O]:?9G.-A4LV)R@IO_+ATCHKWU.4FV%ZLS#I
M\X7L;HN;=KO 2'8$W&&TP[ ZI/!!R?CC@D$&"33P25Z%IT2K!ZP'2E-9I)1"
M(YP.1CF85>_)#JB-BV,?XY^.9\/EQ-H-CE_B7XN.  ALMW)V7$U'$-,VG&6%
M?MD7FU<;J5=>":;(IM;[1Z_E>>XB!><"6C5645N/6U1Z%%*-#M0X='M[U#K1
MO+K?MECON9?T\\DN^,5E+Z#M95_0LX2KA(-);$L/+V,S,\WK([G)8Y:.0 9;
MA6T7XP:+$[Z#ZZISLT!Y#IMM^$.>&>_36WBI)I!%DFD9IALD\^,8=,5P/4D0
MSWSIZNJ^L888@K7B3(@3:>'UZY%PK+&E==1O:N.+_4XK6N^/&82NVGR[I7*Q
MM$>^F#L_13[$\2+UF'P*9$1W41*&YP*,@.05Q0$F7*&K/$0IG*XH-.;_,QHT
MVA$$R/;B>VA[C"G<ME2,?368WF^W^WEFW8KK'K;7"_E(.8\SC@)""CQL,&'*
MD,(9+R&&MW=VBB!I+,ZCEI;QCH/U/WRTHI:RD%1NJ=XPQAY5Y^>'>#1O845*
MQ#B5N5:%*=I'AM?/SK@^.-'TSR7.?M^8#PT[R5+0@--Q5%:I O%9+DK>K05Y
M<?J[P<XQ,PV7 @-U=76K!YT5YW\,/V&[9=H<G14$>59JS9FG175F[C[U+2UV
M;XSYXV;G6G\_Q+0)N'OD)^?W@INC$_]R.-?U"MIFOG0[FU(F/+V1XH9;$\0/
MKORPK5U6%\I<GKJ4R%-.@/(K4%P7*7V=DFAJ!>/WV[LXG8Q+%+?:/./FHF5R
MJADY:Z!VL2WPT:[':8]D=CV^]7=L>>![]VTLY-@6Q5^MAS79\/WZ5\_M.Z9]
M2Y\CQ;TOR#+C"AHH*)?LSTO,*Z1R$,\M%GLX;\S1-D"*&HY<K/D.%H@%&!)L
M9%G+&W87]E.-L4L>>1$!(UW<-60*'\8\;7;H!FH]>O_""DHVM!":<C[A WU-
ML@\WR!PD?1R[E-0(-U=Y:;[NZN%WN&:O9\Y&FL?9F]1#Q(+"%1.WL1Y(9!LL
M?.>Y8<P$][%VH? F$60AE)/+A7-\%LV8\F>X., BV0;!&G!B+O75TI5Z&=G2
M&..QYGG_.!:=?W!/51F@L-IA7#4?ZY8N/NJ;D#+(>:W2LNK/!G/T!1@3E3:U
M$PP62V!)L(#3XSB&"T;CPA"33BRG/OCGM!DVM%O@:C!D8QS-@7'18* %%:',
M5QV-0DG-<]7TK,&7G D6+OL\9YR$8Y8@?9L 54IJB^2S]HF+![!M?]SL(A:.
M>8H@QMO9&OJ0W-)H 3OQUY+<DR?/BAWKG(WY1TOKXL[=T(5 SEU[]0A*A<J!
M<&X>)YNOVL0]AN?> R<Y=+;MZM("C(>E)/ZTT\4H=8)&-M;R;7V$3UO"W]0;
MTZE_^>J^"!*6G@GE&4O\ 'Y$5(5YW"%E-02UB;T*RRD1%QZ7G7H0)#+%PD""
M,])-V;1H;$Q$X;6("W^NL>$:QRXW?W9[\A2DF:3ZR:&,!7-_N)L;;E6-:4;X
M?LE?EDKDGW:&\E67N-H/AO(L!(DX1KEB2M"YRG)P1,QY/_<^^73R?>WVRV\K
MGM66[UOWH&CEQ>,MW]%=<H^ '&<# Y*EA)3^EHOG=+X:N9XU=GY;(J>+BSA2
MI7>M_]R^F.1#1RI^+(^6R059/>T.U(>&Z]B=/V*HGACY &/*]LO<>W%LH63Q
MNZ7]C?&.]G=#S>3E7^5"Z4&>!_^FH*5C*XN23OM 8=)ET+ NL30WP&PCO+(:
M[,KTZ2ZU';LQB%_N(3K@ZEO+V>&MG!1*?$PD-[W3@F=Q*F%J:K_*=;7B=[!1
M0O/--F").9AL$P^<Z8(K8J1#F=G2(?OFS872$V3-@'F?WU5#]6QRRW/ E9)Y
MH\\=-WUL_%=_>>.S [O0#?^8_5GB0>8(,+XVSP_7Y??3!A%I<D<$"4)(8^+:
M)\CJ/P)T.$OXGS:GZ)JKZ?[A?4C-!2-68YO>(4"O/(H9?X897U44\20L,N3Z
MV6R#GCQSB^MA]18_)GH&TW";1)#+2[>LIBCAS"5=$:3[!6"-IG0)#3B$;!L+
M%B%YRKRUG9-79OZ 9:SM/KRSZ#B@EAFMNEK@NS?B"C-T*+"0]IUU_V#<Z9_N
M,AIUET)S&0*"PFB>9UJYCEV$SEK>/V Z!/@3K3!MV?PTYBB@25;*E+L$4];\
MKF*<5NZA5$1RJVC4'*D="/D0YN59H]99^'CNB<>W![[NKK\\L?.9%:,/OI'B
M3&KJBZX:.6KFF=LL+_?5?]A'W/! *F2+W(U7:N&OR;+\<QQ$'VG=CP!+CCDQ
M-(X8UFI^X$MH[1/?.2L*GEBZT[ "3+$V?-G7.';NZ/OQB>NRQ3D?% Z3_$F2
M\'F 7XC-U$I6^7^6U!OOY69?P6W^!,?#2V*6J*0_!G;66ZYC5%D?$C? 0,<6
M$]8WQKWBXE^1(ZH_Y/ZQF7EPJ/_L+;K;9Y*\H*SC?#@#?DL$T<0$WAR*T=,"
M3[,S?2L&6G=?><3Y\#C/.ROVTD]@<?&5YIN["JR7!]Y&&4Y_=I4Y]=V[_NSD
M+J+;9M<7'ZI0]QWWN9SZOMMY>_.9MHHS 0:*K)#SA^+L>B^$C93;R]\+7IWW
MJMDA<V/6_743K66/&R*D>_/]HM94"ZP(HH[KVJX>O1#,J&/#.3E@V57(H8'>
MLBUZ+PZ]Z9*RN99@N#)_0=( I2W=)5$U5<#[PK5<M9U?-A1*FRBV"K(Z]%'/
M+3YCO%@O+UV^JB=;=*P ;7G.7R,X)['&)G#E8^.>C1N//YA#;S\GEV6^\F[Q
MU8*USR2:G,]W0"K^)!Q@VVUQ>]/I;;X_MF+D=_FEGTL1FG]P0\/7L!)H6\/*
M >:,K)M%#AB40'4S.=U*TG2H1X6:F+Y84O$/+\3AS7A+<C^>HA.IWK%VQ"BF
M0&'^)/YXRWA4;?CNGZ8E>^9//7?$N[62R;[&0>0'%UU\O\<4:+]S1^:4R@D>
MX2)@ZX5#! A9BX\"3+KANG,$;9)9$IC*,602\.=02MC!0JO0WUI5^20D2#DQ
MNG?[Z WTMJS/>U&KO5GRQPT,@Y\O%+)7\;V_IW:.\'>S7.B;0F]JS:1?;C;V
M7NK1VEF#6;N47Q<^/J[\KGS69ZW"_017K3!SX2KMK/\= YY1],;XI$>J8%Q-
M&%T)'@K+PC5EI_$E>":8HX)2>!A< >,X8@:G!;(JR)HO.2)(\LJ25(B:2\4\
M6:<32%K2;:-F0^>M'#+,K?82</)+^3IY0_:0ZY>47_G*[3V WVS48_+&\/L[
MB8SDR]@@N7:O7W6GGEV.O]S>49E*]1RX6F#3>%]_<?\?!0GU@D&+TU>04<E4
M5C6IG(W!&DC?>:.'S!JHN00[VW,\2T+"YNBN2S=V3S^WBDG>@^V7-Z*H%]29
MW:QA-&$N::_3:60W#@J(\HZ/9['&V$]PW54ZK8A-[,;A<2VPA:\<J6Z8?(NX
M*VIWM^(T^?H1-7/8G4#0##[B$J UNY;VU6C$/I#TSK:3FH]U[9!XD[3O_%;8
MLU(=E-*L4'((FG:E3LRE/)A,Z#"8LGRX5<TJ.M7&*:+"D58RCK_46][<-&ZV
MJS+?%2^OXQRYF7:3(=PK'&ZO++?G(3&*8W &(3H<,&!]:*LE=F??(2C82*%8
M$0:L[WV=,?N'R-O IO[]H>/93*3B['(GN:EFTB7:(A?;YAT=:173Y,*=Z48H
M\=U!?R;A-OV96PUC4&>NU":1BVQ]V0DR\H;F8 H88W:G\M$7PPL=!^OF?F^,
M)O@TC1I'8-]>5-[1^_BP4>DE/L$S[1E&37\K\^V+2Z=OO_VZQQ<5GO)@KSJZ
M8V1O#^>GRYV!0PD-J-P+Q.Q>!KD3J6JOF/*> :SLOUZ#D'"LTI=.[W%?1@>;
M4S]^B)SSY;_3?/@DE^JHD1U>^D[V5O_X8!/&W.?>R+N#EW?8Z*EK/+V_;VS7
MQ"OG<_,?D\(":X^D&,BGUW,,$G!74+3^T^-8;;Y])X#J_GH)!L,.6="E5G&?
MV"Z<@Y,8;PXLA0&H%&ZGK4XW&^12A^@_"D_94RTFVKB-/P:"C8+\?[^3SR<)
M/U):)OI$D/7"T0!;#C&%'_4(C7,$ ]G9GW%=4ZJ@9@P3(1]FU=^?"6.?:/N%
MGNSU7OO.-V%K5')>.#P=*>K./5SEVYE,+1SU.?@!0TGA6W.(+"G^5HH<62<$
MUQ3=!U400;H.-\-IZSK<V4LT/_:1427K17.4[A1]CKQ_%&LX$&W<T,F,L.\^
M2 M-9]9LSW<]$[=Q\R?3B0/2(D@$/#SS6H<D!^"',J'K?Y0:"1Z9F8]@-?A:
M$U))1E&=*"> F$&,MW ;R_>*MPK_"COZL:*41[48EJT-EPTQWNZ<<WB__<H7
M)_N4 PLBB$$/XWGPMEZC\;SP7":GN3I()=31T.P=O"FR,*?<1S>QU/G,.KGN
M0R=FE(W@*J-ORQX&UGKT3)]\-%CZ.AQ0L] ?,+RPO#"=\8OV(B#01]6O*M0[
M*H;C._,PZ&KR<;31B<@TC9ISW]/>[0.HG*]R'ZJ@LL<;]"7VK+!]F,'4)5U,
MD*!<>  )AB-+>[A1X(X(:+=LO-6D$V>%@SD!?H/Q4/W"+;C-9V<]P91)1_ \
M\<UCT+%OY-C8PHU.3ZI6:0?M?O2,:UO*Q**&_K*^W*<-YZ /8M:=2K@*T7LH
M\6@F)Y(/8C_J;01;>)9A0FW0B</KA>G=*$)("@?MH&1!\7<0&<EZOF*2BFQQ
M; $\UN99PEK T@8NM^:3MBH?\&%NQ(/@ O &'WT.6<M[Q#5G5CP/$O _3H\6
M.0U/>N\R<QRYP1T=TC]ZN-JL6!ZKLNV13-NEH).476<E7T&@[]&D'3WG:K[]
M*9503"[U>LC4Q[_R*$]^('>TFK%OY5SC\\]QQREG^MAS7K6I_1/WS]N8FU=<
M?]M0]W1_P1I<9D:CV/_$A$1V95H67#+MP>4@OT]W?![5L@V][C]%'_LUDJ<M
M?SM9"WU956U&!K0*WY^8V/?V?M24ZDE?27VIA'(=1F#V9>X,8,F_*S8.R;=%
M$/FM8NFXTC4C5!M,7>[?+H*@^#N_L;,V.IW M*Q-;*]SOP.Y:W7O=M=KJ0VW
M;%_;K+(HV__^DN4H@0872L_/BR"R@50&Y- [="+S$#MQLGJ^.?C6*Y]A]%X*
M^_SWCAH1Y'5Z%NEG"PZ<X(?&3QPE>-7G<>$'UEQ=7;KEONZD?*OAO,"X1+/Z
M\7$5]#<M0Y.7L*14CQTYIRN.G;OC:C3\^HV.NY/>3'">\[Y[3EJ/;M[<ZN65
MKN.#YZL*RLGRPH_+&%=$8NG^1N!K=C?L3C1.AH^L__'V%QAE$TZ<M?)NJO8-
ML7I_^;*-/:J*%F[>^MNO](%9;TZ8]+5PE4'CYI>V63S79^-&)LTE;F\G/(:C
MSEB_U'7LXVYH;Z8\?9EUS,2H8?$[78<[<=(T[_?F]F<N*G7/=GLX8$.% T(E
M$,_A>?W]!GD6OIX, [4= $FBV 7U@BY,E YM'@X5JGP)X1*DA JGC^=%ZREQ
M5A=[&Q+#JR;G%4-_H2.=R*U:+<7FZMKZZJ[0Z>=:IPP9C<_N?PD_7_W]5UE,
MM\K%1HTZ<[7:V@%U"ZL;WV:D-K!E+3RC4%^#K9KG3F9<>!%L=*2P^<]C-D+9
MW8^V-_STLO\+TQRW&1H-T;^$+R2(.Y6.<# S_LDL7)DOQ4#)\]TH(ZN"G<M.
MPV;T=>B<N'I3-+%K;6!D9PDK4__(6'W14>!B>YP%7S^V@^L=F]-EO%HWX@=J
M CU=\&9DSR0N#29'H%I,;1QM65+\05-[4??#0@A+IW*%&A-[;UCRG9FOE[K?
MU:*=O#L:2Q%0=((B5S<.@6BEI=9-.^8N(X4R!AQ$KPBB)-PL?&=G =S,CV,B
M:%HP&HQAL+#*7E(2?BBDI.ZEO>/B!/5V^T #!F'1E:&-W!QFI14>B8$#L.YX
M[-(I M5GS3R_#BW1JZ60"*CW^+6EM"S)T<(5^9:\2+X%H)?*.XXYS$&D>A[A
M0+N14IAMH#-SZ9/;%#P)WH+/W&NC:I?./%.D>]/D,Q;Q.9\5?1MCRQC,MC+)
M-C:E++Q<4OHD5OC!QIUMR0NFB]B1KJ5K$;"FY#=7??GFFD-]\4C-.Y4!'I6&
M7J>F_ -2E+6M[-Z:*"+GS1H?8KSUE(B:S*L:9^-#CW>4.=B%/7^[8F!AM?^!
MQFBE#&JJ<G>=$\6>9DD)=CMYLM:QPN= C;<O]K3G] -*U>K[)^^3GUZW\SAF
MT!!]+C(WZQ$#@GX#T=G8HV)3K3GY6O*JX_XWC.)[?1J,P#_[!&0"ZV8GD1_3
M,LI7!Z#^@@:ADO"]<-V$G1+&'= 05'X'7SS!'.$0NS,-J;]%$%7*10($HQYQ
MD#'S*L84H>Y0'48V&UTE:,S];INR&&EQ@6N$8 TXQ5:XY!;HIZ7/%LQ+V23A
M!*$UN)^B\F-J]Y@-\CP@\0JK#2)9!*4 L$I7WX&CGHK=P#\TUN$<SN'9DY^W
M<;XG9]^Q.3*A3M9O'VZFV\WX9CY^66AYN3Q! >/MR'FX.] @J^J/%_.XJ;Z!
MY?$&A9(]S2/4X\<S?0.WFGD>3QVN(Q[96SQFO(LMZ P^8AH64G0].LW;2SE]
M.L.O\('!S\X1HO6O#PI(!WZ8H FKC%$&<C"'" Y@(X!DG;)RS;_3DHT74S-6
M$\QG]:?9[&!V'HE97!G ]:EA]? +6.V154OFPU#WL+;&,*W[-W\-!@7:MINV
M('P%SW'!AB9)=C+@NW*PQQ-,9E+N%'Z=21;JH:.9,TG\PZRE5#M3(.^^2=9+
M1KT^<ZRUE+RK&?!)$4&>K6YEQ<-\1U:*"'+:LO?JS1(;SDS3%3#N',I"$,\9
M.]X&;[;-3L<<9*)HLBQ$$M80LQ\<(8+Z?0'F'&+JC8<V$DRZY%G,WM$6A%1(
MZ0ZR6.:F=LC7A*C_]KN267OZT^> D#4:?=;"Q/!L/U(/C>^RBA?B6:@LI!96
M&3N*D\2J\Z\+&NVV8,+!0"".T5K)0FW 8 5W+^\5JJ,#F5/9@$]O@!2G$W]G
M]:N%@^"1_L<.1\PU9N>9'KVMPRN+AF>'@\3Q6JX:/J5=&3U0M\/O_B/ATVKG
M<T0G=2W@:O];LE;4-96GS]%]REZ[3MTOKOY8#+@=\N/4(.8?['L:ABX<RG@1
MHV_MY5FQ-.APY&:Y1V5 ""^7J(>,<<Q]X&NV]]AH\$+^*P0MF)F_J!S!0O/5
MI@P_=O@P7.KW]/2+>0>['>WBPX%22>O]YV]F5H<$4Z<V3VQ+6WL[&? T[<Q7
M;8^VG&6WT2U9W_RFG&T[NQU68#M41]5H^$?;UW<$Z]]Z>^@5W-SR2\?$M/K"
M.C8EK70?0.AWB4>PHM,IH?#;L4'$GA%./K<,+.'X], EL0;H">_G;>,4IB&(
MJ\V61ALP;Z8"AH<Y<N&5SI5HV@23F%1H_15Y:F@)1K6X^J:&D"RV_?7J;B_!
M?E[(%[[_$"XDPH=;< :Z@<A7XIT"+],U' GE&\&@1PTI]$U+&.D]:&C/U.YG
MX,_2K9W@1#Q[]^4E,Y*42Q!Q?B0L0,:W^?FS4H36BQ0#*9EYJ,RIJV.,7/2;
MZ@DTVLPJ<BW9 2&_!R!E9(:,4!F<YCG><2]#SX[Y>>R'9*L<XNZW%4\<WPXE
M7B5:Y;03%\MBJJ^[%^9F.K>\G>T.A=/\];F9'(67O,,@B7OY8[,(HANN9\51
M3VY&J*"7D(T<[Q9X#VJ3N*VY7FIO2^G83T(++[JJ3?3Y<=/>U<^2=3-_7ID9
M+KAR<;_A'H4F9G\?8@/?9P*['QW7-6%5\J&2<Y#5V=^5?4>1/NL3>_EFJ64K
M&,_AL6ZTKET<N5M(?FBS&X!W1RN&C9\[4_3B2IVTA9JRXA^ I\*7';:!\BYA
MZ73E*%P*#8<7&J ;>-Q0A"(X_>[$F+$QQJL!C>?B.-%W['8Z5_@/6 ZA%JY@
MMYSY\H5>HK0AA?9'OB-YNZ<6WQ^ ]D3?PW@+*K:#8TQZV@%L7RR1KVK=W]Z_
MN#60Z7JP_^DDF-MS /L*]ZRJ@%/D"T21;EUH!7!I=M(TON?(]#,@26O?*,8:
M5S/;ZEVZ)]%]I%G@]J'R^W._AQW>"IFQI$\,CG)R:/OUY-C5Z@EJH+YC\9Y=
MK'A28Z9-JV*MM*5WCV-3U?1"_*7FW4<JCU\].]8HL]_G[/V:#_=#GN2[[OXU
M6E2[O5*%;:!=42!0SZ06&UZ1"(]??+MI\"QG4Y>NF_,;RYU%+>4>1Q9?&_&\
MNN\]9QM</7?MI<V# (5]7T00"[JLG:P+$"?F1HB==C@-VE\K@GRJ]16T4L(^
M4X*79-'OJ$C59NLBRN<+$UQ_3MF0C2W;><E,&ZKSAN/I PJ@O2\)R5/R8!'Z
MWCO.%%+R1WB@"+*)KV7^0!:KA($\!^.8J,^1;,?;CS&7$>E3ZF+)0D O,_0>
ML(PC^W!J40)D-ZY1F,[[AQ\,XIB#B6OQ^#MF<>_B3&ZIB2 **Q1H0T'EO%J;
MUO;E :F,RM&9,52^;VY8@?P.MTCA"''/O5#'G)[C%L6U%W8/)14WIAGFH4,%
M*.<X:><^F9<>2OVG7WXL3$*]_^K(8I5)MSZN"5>5[OWH3#1\5W3O,_P'E\7P
MZ[+]-DE5XXZ</=%M?D$_62_X8O:&I@U'W$_56@9J,=8%Q' 2680DK 7&E)/?
MF[T>47T6/-BO=7[<5+;^S(GGPR;3SRP\3^>WCUQIC P3!A53G;8J>%Y\M!BD
MRA_&&(ZVU)_A/A,4"?71^DQ*IHTL.TX$H1'[II0%CY=6,YVXE8 (TA^'V(#.
M[1&K$W%9&O#<^(Y 4%N*4!:>N%J"U5W'UV68*(!QO7HPSD!)PZU2R7&^+8HX
M=1;)A3<Z):_H*O"X6Q.YUSFH?K@"=H*KMQMX(:@/!M8P(<-\ _@K31M+X'!?
M+A [TR<?S3A#@@2 ;Q%X3\RF$;Y9<'0MZ(>V69+X'*J6@VZ=\)C"F&GY.H_F
M[6]OS3PVE9.E+2]S"A#2#LT:G>W,7WJZHBIW0C]@]X5=4TH/CKWNG0[S8FL,
M32=Z)C=S<Z^0]>[[[]C><'^/S_V:YN('QNPFP1M!!2Z<@(<U[6WBE/=,[>7T
M]U)TT;5LNUJ6 /9*3PFTX$R>!8M8$1[(]>!EL*W7(MKJ2L;KRZ9?#>W7<\,_
M?S[9]D;S+<1JZ;,(PLT&HWE./[2$+8S]K ']4QS4'>WN*1N.!14N/3>U'DQE
M(!73K?T]Y U[L=!Q5@KO..'DL,GE5?\]LT>YL2E%-_+5VG*W!B%?$R:CO<'%
M2HR'N!1CP!%N EA(>%;:QJ3?$4%:O%I;@'+N"4X%17=E<&-(>]NK(A>$W"<D
MC7\!5 6TG5K:@;S')LU%$V-D[:\5SJ@(M?1:&O*+\X%XF-C)C/I?F>^CM,+N
M.*5CMV!N<H+3A5LQ!P 3,6&'X]*F)-O </9@%NTEW\Y5FUJJ1N@N1";9Z:)/
MH!&,@:ILYI(\Z.DM)@S2!A +F)4X#O+@[F/-G2X!HW^>!#V,C;&U"8S2Q9W7
MR@JK=V;.G8HIN:Q3IND"=4LDRMGH>^_+C,Z(.CN_YWCFM_H+\S;ACW*OSEQU
MS]]3NRG>VZS,LH=VO$+E29M"J$>FJJKJ[DA3^CQA>2EM=^K:76ENOPXALCA.
M(88X@5>/NC0V1JK_[<(?=,4]='<BS?Z1V9.BXNX ^5\'TAS[$=Y"7UCE&9&2
M".P)J@L.8I#U;6(;I^@L&M<;.\-M+M7)1A!\'?0T/JZ2GA4=BCJS<6#I<Y(0
MN^6 RKU3$K-6ALN)0CVF.'>K(DCYG:?PWPBA(?0CJ TO@7%^0T$#HD#' 2_<
M#%.E_$EY!!U:.W_O\)92)^3Y^95!3;$=M#;",>H(',0 XN33X3I*B+_=F44/
M8?^)1O$]\+1KJ4M1AL_K+I<I46X/'^J8KV$FN1CV*YD^^67UZ.99V"2>.P1F
M\@PP88('I@/:KVC03+(T.#W"GLD004)Y,_X7D'?@"D(H?\>P4+L_!CC(7"TM
MVM\RODC6FT-NKN<C ?U_""ZCJ_Y.S-9TE@L%NF6L^?GY=M?*EVW5L"K#;:UQ
MFX]U,8",8NRV!(82U/T-5XK(0A]:&:P4MY/-XO*K/8U^UTV[1&&;X'T"MG)^
M$H!P%_ :8,*6ZIX?T,.EV&UH GMY3N $(W]AK,XOE-;Z,H:%T/Z$I@VZ<MSJ
M6?71W7?GM"ZEHU@O(\*^!HW0PEU,_ 4$.(.(W$0V_03ZG 0FDFR">' #:K8\
M7P;([@[!;G=]'):/W-QAP7/\-!>-DZ6-PR7\P=NFT,UA Q4!75&/YK,CKA&W
MY^4KGS6@K:>^8/.'_KPQZ6J6FGUXST5R@Y+CM;E#EGJ?MO/8:;GZ)-0O0\">
M25_D ;],/C<YB&-*Q/@A;\_R3, 1)JX7E=8>O"!V[(OZ5#5<\T3R"DKZ<$U8
MJ13G9R*K,[@_&KL9) $ROX\/F>2R<,E.21W2ZHFK!3,)[SPH31])TQVKBTY"
MF2@B&N4Y6F<3S+/@!P^7B97JG2A$TM0.PN$.CDF6R65X:*8^0QD['$UIFLY^
M#,;Y$3P!\Y<&/2TNX3"-T)/P1!3&E]W#7;L=0IM%FN(*#<?=11#;CI5_L-7?
M8K,*^+;8^S[?\'@XHXZNT/*)+//N&H="7?,G]&9KAY&EQFT<KK'H&P@;^?#.
M$1M[9B;$+]QN=^G<ARZ;TU;H-K?Q?&9?.UD#>!EZLSV-]F.B_=9(78LQ0EX$
MZ?(1JIS]@H&/BE6R.7B/0WP%5^-;,)=2*?)8??0SG+0K\ZLG Y^.:LDTZ$&J
M\KWT'CSQIZ.U>CS&C)IW57"X+V3FO<V%%IR*-O<=O1_*0HG%0Q-3682I[+CH
M7\*&6X(S5=;)6W3.);C%-XZ,+O,[PX$Z7%<(5J:^/Z/R!6@/5-$=P3B&"T41
M_#![(\*.[2M.748$+MA6EELM@B3'X,IZ]&7#>SBYO5/R><C-7\/VA;0*30 =
M.^6\PS%!T59Q]%XH+8Y=R;W'VX*V%Q_26WQ;#H(E@BS&D,*YE4+S'G6J,8PQ
M@^=O990$LA2>%#;<X_!ZM20)&9C(^A\WU:Z&V.DU :T%YU$QT3=^__Y@6L H
MB.SC3F>NC!3NG5C!39R#.VYX,M ,*\K(/I'!GA=*/:\,ELU@Y_;;_M/'LBO@
M _/(!S-<$020ZLYTQVIB@CGY>/)N4 1A8@E,W6!N(5C LPKS5N3O GV8N#0*
MS":4H\UHNQ/\-]+5E]GJ"!9%?9XL 03-9&*U0JRRT\T0*8G==ENTJNIC5&@F
M7$*A6/E(!I&!RV391H[! IWM(KND/4_8@'%@+@.R5*S2"'."O([O DZR2+=+
MC<'4<^UJM=@UY!V,/@LG:TRUVSQ>:%URQ@%0QZ\67<HQ'UVH@XEKS%:X:RVZ
M57@..Y B5W;[#\)^[N M+/Z/)V:T[WIL<-4^VYA^K-VC-9]O_0D41BU6&\C*
M?HPNA7\>80DSF8H,9)((HF&W=6ZMH88!:Q9;-T/>8<PQP*('<=O.=KPYSA\;
M;^]+!F_7@ 9]V"V=G&C\Q,D)FZU,$X4O8;&LWAA<Y>Q$@"V0*)3)!*28Q(4=
M/"-,)-X9=#%8U.2YA/O=&>I0KG5BO>9OPNS@?.CO(RB2#X;?]"X,6IQ(+7>U
M9N)N-=Q *OB[QAD_PQP'\+<74(FTN<<?/.8[;E)Z=<DB"!A1VKZ.E[?I2G%V
M0/_LO)>)R99G">&IGYQ49"[F'6G@*1OFR:3]!(T*-M4=UM<?^94H/G()]6BK
MZ9]PT%OLE<F[,*X<81,+^CG_%7D3@,2OTB&A9!C01LVF%3&G"@!D5X#:T+?Q
MEI?6M1$'>P(D1@FG@?ZT%NLS9^2W3=-Y!S:MRL[\>O0;]XG'G>8L+<9=$[='
M$42V(X;3_HO.I/1 ,ZPD29D_.\QB+-+LM/FG*$ >OFP^C*PSVF(Z'"6+V,RW
M ]SN/?FA5>X0KW*S'5LI51)1<]3+TM#_=/V:Z? \N1;1=9L1#>,@X!NFXAMD
M29FEV_!N+T;YAJQ="\V#TE6E:Z@,([LM;7<ZPMFN>FM?\WX-4J>L.?[X),RZ
M:Y@ZMDMBS\B\>:.9L*U:[?O?'EABM;.(47*FAX;L14%[&]"$+JPIZ,^*1U!+
MY<!< .[\@@-/QV@SQ/)9-])A1&B,<04^5#[F.P]?[I"N?!-:-^O7F8\/;'Y9
M= RA8-Q2>?\!3\IRJV[/KJW'OE6$'"_?'XR)R-AL&?E"7^J:YRVGMQ1I,<O\
M V1U CU=9",./:'.YC2GJSE]2=[^\?SOU'*0<!S8FU@=KB4_FE_8\N1$X75_
M7_."2%;1(?KQSD)=Y_KZ(Z&_4GY73[\8-X &M-@$EAC)]%@-U=B8QISW(^N5
M'.J^'[(W]BI)QZ@6'FZ>F_%M^L5HAXV##44:*7N\?H?6I\\L.Y)'B=7;Y3+'
MJ$HWK]*MQ\V(;F:J&VJ>GZKA/?_5FOT@BO#)8\(+(.!76\'E:MA?E7L=[.ZQ
MS^TN_%HQGI]OS[IH57(/;S^^$J_>ZUQW&-"[6>0!)E>@W[E_Q#5IO>O&'QZ)
MBC\N;>V*X#IPN'B>+28>=!6?_5[:Y=@VJ@B"I\O?0,H=F=)$*:!C1WKIF["Z
MZ.!NH6[\A0FWMIS=S2B-\ "ED2L87[+[W5"K3$&NV=O'+Y&CE,N#VF@$UQ=L
M!":I9$E.*Y%E(@L.]A!DA<H625&N?B@(YBR8"9CT!<B!"$Z?O(77V+G6L8B.
MK=% ?O^:>L+JDLK#RL8(.W%P>GD[GZ6IV+5QTMET*DX3.T)HQK^"ZX+:/5BM
M(;*,6/HMI=KL8&4J4]7]R#7L2>0=/]2=BQ-1\2Z.D]_0?L/RR)XV[\*-F3NF
M*Y_$W]KQ7? ZY^)M?5C6P+[GJ>> J,F:VW7Y.W8SV6YFLV\?8+&^[DG:]]F.
MD6Z9ENWWJI\,$_W,W%LW:LA=T3OTWO1L]06F@9L']VU%-:U^ W'1P/Q!9W/H
M\^.GOE@&28^F)PT25E&?V/\ "*J)!N9,YSA?LA),IP9Z3-PPD9RG0\TH=_0V
MC42)(.H@Z56I&1!/R.)KLDS4YN$*4;,-4=!ULX6!((FYE,R7(,UI5=E$Q533
MP<)!Q O_ IS8%<K9<][U!"@\!6]7S@9LX?SB_S,VV1=K<ON*::;CY%D@H+,:
M+.\IU>"43)5L =03[11! ^_QEL-EX,$>X=8V B+Y1NV MN=PB^V>M[]TZ*!!
M].)G5O:DDQN@5LNBRX1@(;F>')_;V/T8<TY%K$FFJ8D:+(FN2.IP"6;6AWOK
M&=R:M3-JRD$HO(, N)2]1J:3)1=L75Q%D*3KO49;.CI7H7B<)B4$IX*EX=2$
M4F'FE VKI-MT.1OE*G2N/R"V6B((+)2PN<.01=*AU]'E[6#SRF&T^M_)F,.U
M4V@?MPF,%ZNH1$_73G[G6Q3T3*^R:W4[47E@/_(EOB5_AZK&<%JIWMEF1O'Y
M31;.%JA0;TQ]Y9Z<XHJ9GY--<S>TJBLW6?@4T9QWOB@6[@X9(UPJ##WSH+_6
M!"L?UBI4!25Q99C 0 #'Q=KI^\OV"@]R!E,[(IA?XXX!Y"*[7);))G3"6YX7
MOD]]S;_TGB"W"AU-C2[=^QQX=ICY3I:T>;Z06XZK_T*/$3;R;-"/E_P^1@W@
M6*L35+H2F-X+6V>"W8U^Y\UIR&6\,*XC;T*S>^E*!F3QF6*6['S[93(LEMQX
MGD&2_['?*;HZ9$KE60*;JK<-,&\35)*0?!YG22@3#Q@@/T*I<'7^?HX\7FQG
M%6>1\F03T)S>0VNE&*2;9HNY2U"U"O]<> :JU8^E!*+2_.P>W8#IGI7?8=QA
M9U0YP3>*..,Q7#;:(/9+@4GW,F=2@JY OC:VYC;O50G><80!^:1Q4D5V/]71
M#3-TO?C)V^L)/6_GZF/!&L^$%+5<HO.%_4JU;O>U*ZJ^HW_U28J=T<T(<Y)4
M^.A4\:E3)=/CC6?K^1%1'_EOQ5Q4X):OIR5(O;+MPM"@6 %H"G(J,Q:#WE\/
M+]V^YTA[BB1^^X&$@Z\W7*"<A/R,%T'VPE_!/E#VXQC$38&<WPL>!^_B&.6X
M9]%G<Z#<F3O+&2N:/S9"=)MR<&X"\=6(RFN&.RK'Z[?_=G_I/C79/U/57E1Y
MD10^>0897>OR=G'RC:2*^XF+UQN]7C-RI(X@;*[NBQD\D7!P5(M?">;^%23@
M>2*ZG#HE*RC$!2_1RKF<<;YJ+1T=UU^8O5# (0_VXA0ZM$FS^1-:-VN8DTOI
M=OLF^.J<95]@8T$<RKB46(GVH5H)/I387.^)-?YY(6>7".)= 3<Q\IQV?WXN
M\-Z',QD*(LB)<QF)_#7A$(YS$J&.-F1,I?*L^!M!'T"6JRHH;Q9!TK";.7TM
M')(G:,^A^P*5^:^"@+T5%"7L5BS5W(^?(QP009I16<-]AL8^/79JS>V 70W7
M%>D[VH)(:6]HK,K4.P?]"/T\*)1QXIQASV378V7 HFZ8)B5(!*'M_(UX,;I@
M!Q&.XA1(6'5PB5H8E80,'25U2-1HKN(D,$Y-P^67M')!6&_L8N_]XR-?)GM1
MS_[^+Z3VUXA0FAW'.\SWXJ"R5@DTH@/P.]O&C '+^/45^QJG2@DS28!#A7+8
MT=BEGL\=^N4E]E2D$ED;K6__T<:8*8]S /Q_IV(,F-FJ(60Y,+(6G.AJ]=;J
MHS!*]-;F0EN@HY1E(6X05PE1^7+[5?^[C.Q_G"4H&OV4(_L+H]#$16G68*J>
M!*@*Y/?1I6PTI:B(M"DE,)2-5.1;<(R'_6TIZ3:AY2'JOZ=T/EXQ7K@2@2(%
M=HX]2I$VY6G7N@@\+.VZ@B-1438^>]8MKLLUBMZ+0#YBY[A!11 D4.6<LL$0
M\^JGQK>-9\_=C7SU<^.Z-TNOA9XVVO_Z.U/#JLD=.X@@CR_/.^^/N0"@%CW+
M^$JY;H(R\C9LGY93MRZ2ZPPFBP$V@?9LGP2, 8<[X\C!)PFW=3&7H'XGQ.9K
MB>I_L'>-?@L3H[./[P ,4K]:G\(?'A9!SN(N$FC1+/4DH3*6QB6TM%'U 82G
M(!$>BM#@JP'J?8,RF'T1!\7$JFHC&<1Q800OKF-FJ\\39,@:H1-K5\';1#".
MW9*=P'>IXEMQ5E/N-825*A?Y#?'W/VZH,BW:!]WU$I3D%#%F^&I$;C1 Z:'(
M3?T@[P%G>&JXKG\P/H"]5P= R+9QA=V)*M%G(Q=4ULZ.6UFDVR :T+AN<^X2
M2S=T:J0KU@=?CW+]<HW>$ZE05.D4Q-MO22O8LGD?=$..0O0YN57(38,:C2V*
M8! #1IMAY"^*E:%DA)C<31)H^9FK&C92/&GA5%[I#CLS$ %8,R_?I:22#PJ[
M$.4-A7;;T8AN^N3[=\S%8W.R9>G<8??F/V:(9PWU1-GL+[.;VQG*"7\.61];
M=XSY]-C66Y8:!O?NRAO,XO(Z \1R8_ ]]#WT4PWF,)- >RF4*>&,G,QUZ!QN
M'J2AF-&]2&A8.T:=NU9^!A,J*!'JA4_0]G;D^RB?[EB3YZ9N5U-O#^O2'<@<
M18:D7@F\2:K!*H,$=E\M$,U-XPS^53.%*#Q9$WVF-P!:Q##(,BV[L!6@)YF)
M(#*T+^A2X]..E)HY*:J=-A#?4"GY[7>L8V)H)!$Y>^&#X736="RXQ&QM84.3
MZ!P? NT@4Z&Q#!WIP8E>S.:9_H"W$!(Q$41T^LEL*E:Y4Y W#:KS#J+%7)[*
MWQI5)DB(0RFZ BY. /8V*].$>K%7/JNR OEC^E+"3U@5UHIO/C')1K[*IEV
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MOL;L;>0&M#8W!7#*Q+CP#F+.<)IOTF869GD7T'"FH"W!=,#S%-X%0/5TQGF
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MB1YQGE0M>]J5A9&GMDTA8[6NI'KT]!C7@#X6G2GO3&J(^>[J4&E0FQ9QQG1
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M:J?.CO=ST9U1Z0@5@8+@/5J!AR9P] ^@>>>'!4>_XDZT@2VU/V1;C]4R8;O
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M$R,=98F!JCN&7#MYX-S34MR@H,.,!!.U6@A$;&Z#UDQ=.B+^KN<GI#C+Y_T
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M0)TTSZ&:I:LNI+YGKC(8'VN3D-6W!K9!S]SA5'!+- 6/.*SX;"RP]S3F8%:
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M%?1/'?P1;VH9M=F]  E>1R_V!1;8M!,SVE""Y+E7*!A;!]L[<PIL ^#-;D>
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M<%+MIO>T=O:JY[LLRY6Q16\_(6Y.O_$_YW)>8W+_+_:MMU_?VY^S>*#7;O-
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M^'/%Z%_VJ?>CVBFWQJ_&4QMM/MVD7Q<DEZ$S+HWA-SX9WR85[B_R"_C4$0K
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M%;"@;H_V50/#<QV)1,] 9O?8TO@.O%VJ"(R#)F3#8YPIX7ZY3O?J/7S]BQJ
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M$.'X'Q\KU7U_*AANA4P>:] 8,$<>1#))PRVOYUL#6*YC6%DTBNI$[LA#M&B
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M[5O;W07^0J81@_X7TD=U+>4]<P>SO^?4>MFGY;A<_O8]O.QK LG2KJ:,F&+
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M0T[MZBHGN[-.[8!YUDRW6MU+7@-3W<+<-:S4ZLP&%Z%+R=Y261K[AR ZTWX
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M7)<F6Q(#EZV;OCD.G, 8M9TM=D+:]>BPQ346^$M84B;C2H!(&VMKA9THQ6"
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MM#FR!&VVGF%"GD-M=H0JO]"MFMSJG%5G!'0@!1MC_=>8ND'DGN=^ ;BVC0P
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M,)]\30UU]W?]*"H7*GS^GSF'OZ%<4Q=6"PK<6A>A#L;L0;SZ>,NA4Q8D;'5
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M]M0=-Z&+D01\KD]NK9V6- WS#'_='W*/(.>P6YEB&'Q6TV[ [P34LP.H:I^
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M@/K8EM^1*7H!S(SQA+.@1XO9&BBX)!-^3+?I"<@'EDDS:9Z$N!)@K)=>H52
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M^ZO,-RJ[VOB9+>LC%)45N$2NQ".BZ8RPU(TWM0O'8B*!!!-@,3/VQZD0D>H
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MA9BJ!4Y9Z?VJU ^<B9UGC>WCA7*<^2"1[;XCTXPS""&_33AQ>N(:B87 L0*
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M <=% SY<4G@45J-JIA,KO/L$R$Q;<MC:L) B2=BO08]K5X\K>Z\T#\W\I7_
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M>I]>FG3W6,"5N'MH9R*#@ZR9L;I>85SK=Z0IU5!5GX</UR@R:]5_\[30PLW
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M' .]]&>1MQ8:+M44/^YPMAX@,VU9J=P'!JT>E#1CEBM 959-'\WMX8.DZ_7
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M$E0/_Q^UG&E44VF3QV.C(+*$?1$P( @*0E1 90TN[-(@O+)#7!H5TH@@2X1
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M'$.9%.VK"&F,M2!(\J[0[IBB-_#;B$M0T'RL8W""Q;\41+V*+'A#S15+"Q7
M=(F:-*_06;)D0[:7=V])&NP-H(DS!*NY*(4K73-&#.LI;:NR10=;*86:DHB_
MI 3>1RA#XSIGHH+H^^..&V8H<F+O?/I%UN2.I"CO*<+MD0(-@;4>O#KE /C
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MS(1!.6M69]%NM)\;S[N3I0CZ=1:KSD]65T]G/VY__^;;$XMDZKA,,*@C721
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M1]FQ05#]AMQ%5OU&DZE?B\NU[E&'=>;NB$_9H,2H!-46<;5'N78!) N%&E^
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M5)>/IIHXEJ_ZV]AJ#%_Z<#KW5X6E597V 7MGY]755<\8VWSGUY4[YWZ7*$K
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M0:?875D^;Y>L7CX[%+XXEI&"/O8,8>-M?YI<U_ZI(EPM[R&F:](Y\+"99GA
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M_G1*4^#<Q5M!&\I7/)\2T/VHWM:%<AUNVO0!H;IM/K=-LDPU>-,M?W^! %S
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M8;6G;3'YZ2CC!A9P"<MD2*83I!@!HDV0UY0BY%XM>H_>,XBRA_>K>)X;Z,
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M?[>:#:HM'OP^M5SJ=-T/>['N,>4RAB&/822RBA+!!'VTTCF-, \0_7"4*4E
M0=J\'$#'B=UY8_YOQ,0Z;!=:TYL!>9_MC&JP&VG\?%9^_BCE5V/!XICI ]6U
M&[>DLIS/=&TJ?*-LCMQ49/CQ]*]//^TDR^R/:D5K76;YOUE>^R3)75V\*<;6
M<5")EIU--H!HP'PO9N/R"X*UP!#2 _RXO115@JP3Z-E/V %D=V6KX&W [#OX
M<WSCX/O!L4XMM]!_S47@W49S/(>CVT.\G9M'!!KB2ZS]O:N-DO)#]9<W&[L@
M :93*4ID"1OP.)=X!Q7#-R3T,^5%NP7GA+EXF0I(R7-09&B6+HADD<223*;#
M&DZ#WXT1:9,'.LZ4"_8!R#XZ8F8*44 E(#ZM&"@'Y<4JI79@HU9C';VPHJ9A
M-W6]"S\C;SE/W>"M2&IK2=#) 1* GDCJHOBY1,(,LKK O$%8BE?A6^.DCT.S
MT?Q+A'^*]N9QG!Z/>?NJKL/2B,$&=\#@MG<OVX:;$=>&6<,&#RZ,NH0USWF<
M4.R]1J)(*>G4&N6T2V(,NRVFZUSP?DT$#+$;BW("I:@L$A4N$X"5]NRER#:M
MPQC>/+M6D-([ OY(+?X S)\:H@0MW5YD\W>SO#]+9X;U!W)42MN2O@\:+-CF
M?'URT.-"GQIO<]Q34@>U:/R2.>_99E06D5XQC]U([#ZQA3ZQQ!8-1A##2- >
MC"\N#-)56KC9_FN3J%!OZ1VT4R1ELP[;NPKP170Q2SBNP^J.";-FO4_SK6IG
MYZOB*JZ.#+EXUM:R5V\S;';]3-L";('1+&B^X4\SBCH_GO@N<452U\_CDLKC
M!]NFGVM7R'P\@8+7!*S%$4E8L/S0@8Z+67!D!LMT8"BA'>%<<O_LNX?JE]Z$
MO8^+&QIH;J0T=K;Q/WITCCP(+&6X.:S5A(T1VF<)F3=C,.:4,"R$Q/88?"9U
M3:D#'REA;-(F7(D-] 9(YUQA]E9C4C3E08,,DP]Z;/]43RQZZW"TM1M#;38*
M(<?0GLT;>!]GW>'AAG([]^6SHWYCT32'F. +!R@I!.U@RB:4E3@DH((JO#*8
M0LW> N5TM1W,J3!(0@_C[3B9&U=M@&L C148K:]'LQR"[B,I ^>BO6>X+2-7
MVX:Z4PG/?S[>YW>;&Y3U1LW^W8,3_TCN.=']V\Y$O?G[F7&PI\?IG5_X+=>\
M:W?#1\[&LPP?<A-]1ZW2H/9#;UN)R>#YHP676N.2ZL=?4G7^ 5N_^.KM[Q[]
MU_#)7CWCV]V7#!^_M Y29N QB=0#)D&*UZ%8^1I'"4>#LJS^P;YC)<<4=4=/
M7ZKVO'/1XZ6VHIO#CJ>[ _?UA]@,1X056GC]B@Q/S'Z'>!732T+@?81IZ[#+
M!FDDA1_]): 1QV6!#CC2,#NBX?5>L\P0D)DJTH BSX(AX_6O3BSSCX;73L[M
M-&FZO>>AS=WFC7*WXD/WZAC^=CZ$TTI(:*U<>G/+?/'^&,ISVK;@&<Z1)PW"
M%WX#*:R*'HTS9"G\-2C/#\A?A[F/$@,,4J<,.B!/C@E O!N-W30K@@,Q?4[>
MM")L K$!KTVL>/\,9^4+%.4^,QO_GFC7YF+T3BB;\71G8JNA3H2]UC[)<(TC
MUF=S>J9U=IZ='KCS"^4;<KM"'>W2J_(HKN!RXZ574>CJVX_BG[@7>1^055+)
M.!?W+IA3>>4AD!LNG]_#?J4X:W%1;R JJ.A>IH5C48UEU',/^W:'XK(M7PM&
MJM+D7Q0P\V,:,W7WJ2?8W)R=;POE>2\,?B;D-S<2//;M*TY[]5\K2?^3-LQ_
M2/#$_H<==O]%L9MT,B[XZ\"?(7.@[?FBZ'48JWYJBS!_262*-P(-:&$9F-=A
MW5@Y7#I+*16_ TCI)S7[=\=EAK$?)8 N/5A5D;K #]C<GP-^[E-U&NL)VUC;
M7HDS<@5HO20)*,=C"&7/P6P("JN9N1YTHTU16+ .LS&!D&*%MTM8@CX(%9P&
MLA/P1A?Y<0(K:.=-#B(=+0-UEXOH6, )NYTPA) C[)X4&()]>4D9HV*:>AL&
M(MD(ZE(R^7##S29*"J-IJ3M,"9?2/WK="ZH[.FSLK:_+^;@LL42$]DYW490)
M=.+KZ90.12Y1%K\+V%7/,5#'>T(M\![F1/=W$LN@)].*B^QU(G*<*+<("MCS
M@5YJ<X1=0U=!Q?Y21B8YLW36:%Z57(7"E >*$#ZZ_<PE+\%OL:FYB)/F$:$K
M? 0>#6 7J( +]T\9DSB[43R.849U81A0BPR!E#XU:Z(K^*BN"O>YUZLNJ2.X
M*BBF328OHP-[\R54X3+4>&(Y;&OQ7(,C&PL/:-,9O2$G2CRUX63$$1U_+4,N
M>8LE;V[KFOOL@XWO3L>P?F599?"S!V^AY:%V?C@5F.9EU0L?=ZCQT?@P:)X[
M3D (#D%Y7&M'=C#^8 NP2EV';<-?$%,&<S-N[R]L#D>R-VSS7'[NMWF!"E3(
M4:LQZHG%W@U;7I*!G%==VV_O#K_<8D&2IK"*,5*$_8*003+<"R?!Q=R)PFC@
MJCDQMPA;Q9*I)=%X4H]%6I3@4FXS&:N('8(]0%WO#?1?PRL%Z?/62E31?M L
MR0#ERA83;B!)3F#&(FK,HR7;1A=0^^,/D"P)G]=AK[)[7;*9:G5X3Q;E%N45
M,\MX*14M 9UCU3AR6_H-)(,?41KK%F:K!/H@*:W#/I!+2='4'UK .^#/W0P)
MY&0O(I+60A/->FJ.=V'EHL(6,R-[-?4'5AZ'=%A@V9@%%_XI.]"%=QXPZW?R
M9SO1%L;X$@)?*!,L8&&R\88U4)X[- 2VGP&1U+HTTE:R4@!)$645_VQ&I *<
M%FT$[/I)ZDR!W>BRM:-7"JW(8%"@$<E>-*.N^=#OZE^$\1"0WM_'12K:CKK*
M"\+*==@ESXCCEK<PP<3$(-7C_TA)[_MR?</XL^Q[GK//:%IQ#ZQ^NJ!;D>:+
M8XI_BO!N-A#>)6_%6T)7_$#^D5%,H!H)0>=?)+Q%:YEJ[A<V$J\AU 4'5?/2
MB$'KL*11QF-L L$8^E:'W^ES6+G)^WEQP/$N;1O@LS#+!3X^FUEQ[B:F\UU[
MY(_>U1E[<Q5TQ>S;KF>2GETDP,W@MQDEA<DC8@ 'K#!6:2$&&S_V?WO^"")^
MX,\7JH1[UP];:G*MPU>*TV 0E?<>"@,E^ML0711%@?D82H8M=&$1%^V!8*Y_
M>C3B;DN%"]"+E108O9B+5:+MUUPVOCXQ[T'<BG+G.ME1E3PCO<>]H0?O'4EN
M17J;VL)7A@_;' @\X/R@[W U5>>:IH7KJT_OU=,<VBQS<67'NHNO1%TJ5856
M15+F5>LPP(7^N5E>\0ZSOF[13L6M/4$&,*,]V7P]8NL_%IOD;K"^>@X1MMAK
M 7:)^J6IS_+A6Z&K%EJX"56S[+]?VZ;>2PKH:-F>\;(D</M+HWNF5=_NOKU^
M9L\_SQ]=G7CDG5RA&O3P3:3Z07AJ^!F]L?-#-?":8\8O^ETS]AVK">AWX[UV
M+=1V<V ,WT$BF;GO,MP6?OO6_I@-&8EQP*FPN%D1)Y2GQUH_WJQP%6+H"I[&
MER<_>XP<;/>.CYH?\JB)N_;B_]]\@4K,:C6GN_13Y,1<48Z1#B4;X6,A&[9!
M JEA'=:_I"0:CU7JR5: LGM(C6;=2Y^U>Q'UI\2*/]L57$U>=KI![2VR^I37
M-X#_NV6TP^& R7M$TM1>R 1T[&E["PB'VS[>BUIN?4T1=M91L9"NP<(J2.%X
M]E,2F7*$3:*/+>LP!91-"=X0C+D=G7T7+9;9M\OQ-_[L^8;R; ::,,HSC$'H
M,.<]*RLONA)O_VE%>EXZ/GC1LFEZ(NK#L0^7LL;H 3K7X4.(";4N9B.12D\H
MV@'0%J^ !7;0*OCQP\J;#D\0<0QXE,CB2[]W7+SZ8Y[*V-T T),%.XOG/8M4
M/TV]/SZ,POJQL!+'.?QYO6RYBMN"?7GSS\:%1MA\(N" 4)@3(84/%EB@63+*
MCD57A@RXDC12\I094)%&"<Z^BVV1K6<O[<*CH;(ZR-OS50XO$\K3F=H-WI'9
MFY]GNA;EUDQBXVHE4^[K+S7R^6>)CG\\;;#YR0>R,*26?\+86GS<J8VLC<X6
MYF]_A \!FH46R#?E_]PH.32WQ7:K9(N*A?KR=W*XL!P3;)"P#GMM=@>ES0W+
M\MV?1[6TRQ9C.QHR8+7'.9G^.CN*=P&5.*$4R90.@V<!:VB2>LM85NB51^NP
M,V^R#!IF5?63RZJ9;V5R,P;A>Z%@,7S!A22T+CXZA;4K,0S$G!PSH<OC+P-8
M*D435\TF4]CT.QAE_!5@X\^I(0XMB2POL"4?+8'&O( .?X]A=C+M76*O%R()
M%5R+\^5Z#0JT:R?/WL*+/>SFVV!>IO$Z3'S#VU':Y7A=4#(5K\+!,OQX=FV@
M9Y\>7 YR=!Y JT\&8IORNNV-T_7]J6VU99)I)LW@3D<=TT$HQIF<]?;Y8:RQ
M+E@MHMR6O1XK#Q^6A\_)$"[_^9'3=?%0.#\\;28H=%DX:4\+@X*QB2DQ%LK:
MWY!UH51$>9=L^)>?1[_>BROJB*(=,9_M@^GCM_W9X;(.RXF#XM=A_K_$QJ]L
M'3;VG$"+7IW\SYU1&U8G_[>-->IC:2CK9U#+T3&4/J=&Z01HD(QR*@TB(T"E
M%-3QLO%YKRV49_.[E%2OUA<'YZ-+-G\LK)Y9:RZ(CKQ8%9B?U/3AT7,_U&C>
MC5]'#]QEYK=5I'9$\M4)0\S7G@L30 [;OXLI2^A'(%;@*@(TD'>+K"(PQTA]
M$Y)06-;21MP25S+5I-!TK+L-!Q&K9\1SQZ3A9X"=/9 QJOHZN*WG2W!+6R$K
M>V77M0M9[\X")SZ>^H&2F(N\G]!2M/*S8M'H&7Y_*XD%SQ3M%]B!_E0[*(QO
M@S<E0W%$=ER[PCKL3@O',[N, KFRB<FBW8T4H")=[12PE/U#$(''W RY*)M2
MJ3-F.M3-"5'4SH^<R#F3A(IV4)QQ0:3TLR+/(T8T$4I9I_HN'?XWAD<PDT[L
M/I.\VP\P%QS<TH3R5=W9-]1#U;#U'3M8\_ABL(WCS^;\I$(+"^2[-]INZI]R
M FE3&54!@YW<JD"C>9,+X7.18QFL6T3WM&BWU$2YLLNVKAW:V@>W_)Q4>X&\
M_L\_$A4.#>JW;3YNG1WV>_&/T! :R[,MKE1^:V]O;SMX_H.U]2)[FTU%7*6M
M?N"/ZD?+-^9'Q*!B;5FS30SG,__=?Q#U_[))_.?5IS._O<5A"A.':;48)/\F
M3OS S:_#SJ[RLNI&=/\KP0ZNQ5O5"/Z=+*PA([T(##0*A-\Q(8Z_Y\E!S[F3
MGKRO(%&P,Y%G!M8M8@!+&N\!*-G#7TI2A=_%A_-/$3Z1%*/B+UD%!R.VE-4E
M^<*3L)*-@1U6Z/H7=2D=89QUF$I0D2:XB\1>%17!7>GNLV.)M);:^/HIBAE:
M2]3WA^_K) 5!8$J?T/LD0.K",JQX+UK&1"J?\4Y 7;\^D37=6[<31Z'=N&&Y
MEU*#5VEL !_E5D!Q7'K:2WWC0H-S$ F@'QDB'\#E4T\.-!:&]<9FD2Y># S=
MX"?:YLW=U^'"USD+71<@(#7 S U"@A3><V%!AQT+.Y'7[0+,\^(*^D@-]$4E
MT(!MD"KP!Q*[W9^$BL7K.NRN)3TI5! HFQD?5Q6D>K6L)LA#-:NA!NOM4N5#
MR/*DBU%EJ6=IXA>+TD5*%H/7.NQ*O&0761V29/M(+!!EE]=A*:H9EJM)H<:_
MPVI_-.F'H-SRD^NBN?IQO99?UXJ:.$MJP;$?FSC9*KA:OA>(25LI].S-KZV,
M-_ND #L=(:1^G#(WIYNCLHYN)@!:&7ZU1FYN<EN[510V0(E_2@6*7VL8'B]\
M2=8*P*B(Y/&AP,O8I<0\'A%@WD8K"FRA<\50CAVP)9V-8""HB%UB.=DN5N>9
M2QW8,B>VB[S 8Z##B*T'5WTOF5*[$D^TA7S8!I+C\Y:^.3'5.GPF''.YCB&6
MS"W\O_#6$$D\U0DJ0A+F C&+J82VPDESX4D$+68PVA3ZC;PKTA"$0#8 L2</
M*U,&C#R&XM#WV?"L*2T0WA_O[09NJ?"_R:F3FEG#W%H,6\;N"/*J3>!CZHT*
M2[01%1*_W=7E:C)@"DDL=<W>[?Y/69&W;*]'=DG^$HH?%"E,Z5 "IKN:F8T'
M"T ^CSG6)(YDQCJ,YS2JQF[)I(1@&=K]1-@N%T71*$;J>=N@6.^GXL,J\<8Y
M5$OL9P91!KH^(UT.Q?Z@V[\9U&Z(/SQLL"P%TS#_6F1M_W9^GKG<1S@B9@HL
M0;N[%"\/A0 ?.G: 5N?:P99%)%\[Z!YNC#JU<32:E.RKD$TEB5GHR;=$#B*K
M)B9 )/MF^%'XKH3@RM:"LZW;-E?E7;-;6ZO0^BFKDJ+9"WZ*L-3LM,R'1?]_
M)Q0Y!UE+^</>MX_^\Q4F:6VT@AS;=-.SCY[(E"9;0'JGH9M@.IN>0-##*9TA
M.9$I +8W3'JFZ!#0].-Y\22U*B!FU5*S_4I\Q8>;I7/-S8RL)Y$ZFM&9BQV>
MIDOJ R79Y[5V)/ZS7#7$,7E7B_9 ;MH8WLC=I/[3*L+REK/>HP[=UC.\,Z"Y
MP^L2+X5Z<]V50^,=J'GWNF,F0&N^>X6G3&HQZ#N8&>2>,?M1U_.;DWW?B\:%
MPOS8N<Z)_4'MONB?HW/SE;^9X@=;%!;AO?DFD#0O"9!M8A4:L%>3HET^._**
MP*5NIM2,F=<Y@)<+8/K19HFG(#%?#C8&RJ0D&_L5[SV TMN^Z_C?J83W/+4+
MBGK+Q[[ .E8^PI HN6UK/TNW?[WU[/(M&;P]$(<%W443Q.:P)!.$ B[Q+%#T
MA+4TX=Z'5@5XU55,WQF1+ 5T3@#]3H :I.0#R/8'-(>AE13 -[=Z3FY\@O$V
MNNI#3'2,R4# +GCS!9T6+=G(K(H?]XP6-O1;P:R#Q^B_I"8JY/PBKUU^05=\
M^NEM0Q5]FVW-]@.[ JD=&-\[^]UJA346=C()Q:!#2<$CRUK+.I2H7H5NZ7JJ
M3-G6+>AAU> JT[@@*78L9,+WY].%A1K%S;Q0;TEM[>=?74^@3Y7,6$X_6UD:
MS*.T(,8P@ZWNG86%^92*'&^FX,G%_Q$_+?SOR4>8,B(: 7@(39E_"ZN(?B[*
MN+A>,=#NK0<3:;%,ZM(=HC1ZA^A3"W8G?C^HB=T90&J2[*Y+ST>FB^!X-P@+
MI/-NM4,W_3CQP=T\Q#8!L4:,>8_2V7%Z1(6 V$3<[[ #7" LE?)L312+8563
MC:!SK"5&.ZL>#%LD 4R>-FA:#7@,G4OI7X<U&O1\4.)*=M6E6BKUA#'"V&%]
MD\@N#Z\M.>!QEF>?A@3'M)!+WPJ%>7:,-A+3[N.\78'-HYW%OI#'K][# ;Y[
M@4^2DQ3 OG,O8XQG M2E:4$I@!''AM[GDHK0(!^<9V0O]#V'4GK$XT1/QON
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MT3G%4/9I8,_:+%8^"I-29#RR7("0%)P8$RG.9<L^ 8\?!VQ;:N8($L.ASQI
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MYQ;$3KLSP%2_3I] .N^*$,/:9#?+2 ,ES(2O0-@6W$&8&!J*PC#W01Q\C*,
MY#/&NPF\1OHHW?H"JE]7_VKXJBEMK)EMCNRF=1-A4MY8T3L$JN* *EH<F6L/
M++K/I DC$=3Z;+KZ0LQ-$"\T3)2$,<*^9A7.N:1&'MN4/Q#=CPJ"I37-\OQ9
M^-N*E'-TMQZE0>7'Q$]#=UM7N*<YH*;=3YC[RPNP!U2V(NHLHV4,#QG%>!%B
M7@!^Q$\HCV'4-?7DDQC^*8M2EWW0-]&BERTMEK36_>03X2S#!SYC;^A]^3HO
M(Y&J$3W,D_P[&9$W/AO"$>6G$?ZVID(=!D(8-9T0093@6]2_P%.V);>;'!?)
ME5WBGAO\*Y:&>O:=>5UV^U?MYGX^P&EC0P8!;QAR#\JP*;"H^9SZ3?'XX\%_
M=-!-(5_F/\V77,2\7ES/ 3G]OWZ9^_L37Y!V;UQ<Q$ZE%0= 3N!ED7!:6E3+
M+<8VB7Q??_P9%/'&"RO.5,S0RKB<$YOP@6SM7D8.'5O)%OT5;C:M8=CRR5K0
MH/#%'1[74>&KMH4V(@NWRTT%3?PK3%HE,PJ=,KTT8[SL/.V*E8//C93:9^H_
MSU.2,/%/LK;0OC]LJ9CC65*5X]6KM9;C;5+Y *7 OL(E<?6 01KLZ++1P=W:
MOX0SD7:=@8M6;9'%'@3X<"CM8<ZY#W59;T-"O&F6;A 9E!837Z$3GTX*CSC6
M[_?>V1'_NG2"!\$JS@I%ICVC?$SK@L="3J+DZ%/AW*,Z[ "4RQ!*L^QK!(8Q
M2;-.,#KN"@AU#9KY!'I]1B3XM, 8?D3RR!B??,>J@_78>44=T4&-1D&_?35T
M(S'U!H^A":@O8#T5(_F4J+E.-H]IY^6%SCY-3KT@$#A"+]->MJ5!YX]G?:C&
M*C_S/YKBHEE\/C=VV3XH0*#Y?7%J)=&NQNQV.=3MS./.'LTLM8L5>D0A<R^A
MXHNEO#JVF;\7<8:W,^NW(QH4$YQGZL<M52 9A#K#@E4AMAYW@ #&>%'BPL97
MB6PKU 4F;Q*NY333@'4)4"I%B3/]GD%5J:_Q)Y!)_^Y+)ZH?/Q+_F^K[B1\<
M_]DTML[2X58K4%P6*J;?5ZB*?Q'@?<9Y8O<:#4(F=))Y5ZA4 OD?R(00ZS-3
ML8XFL=FHL)N',IS!Q(S#:Q&Q&3;XUD\Z6$5&YAZ(%*'9-F;_V<O)%/,^%Y+@
ME,QBZ;!LY4]^&[_IM!N@I3#R_-E<][?;(/\#\!93T/V32/F/,J'>5YUDL$X;
MA<KMH"_S&?DMP:3+!@EZRO99<O'^C2UJIK'=_GA>"?B9J$*'"\4Y"#WC1^M*
MI7 1^U3+M([9'X\4><'0BYTFF6IR[:0&(6MPW-MK0@FD\*UWRC[F172G6W9.
MJ%3A7V7]F<8CI>>^-NE\*_B47S;5()R7%@_S4)^LL=PM0\NAX(!9!%L7/5Q0
MX]=I'2T+!LSH?^^LN+.R]O<;<V3:&WL"&*S@W!YHD:E$WN1 @6:FO<'RO0J4
M+#._I(1<N$":=@Z_7<L.2%]?@0>%U@AM2TGT79)^BDTV<XO.BS2;2@YP$_-@
M0U'GJG??[+M&+Q4X7UTI:=6!ZIK6[N- NNFM/^)=SM$90IDI)6T6@)=D(4FW
M9&4)W*_,0[U;K(QR5T^;I<_N7F$MEW2>.WM]?ND 4P(JN'QF;#%@LLM(GID=
M#Q5D7IIW8SYH* /BG!KK=]_M@1X:*H]%6-CEKZO+UP]M$A+JG7Q>@J$I<XX_
M'"<=)T_S^4D'O*OT3*KLT.4$=MZ;RV64.#JH]2A(-_!'DP)<&$V$T59L0$QA
M6E\-!Z?1Z5$A(DY[O.*K;]OU33=A9FEF\=IQ\]:':6/N_(^'<49>67FE1Z4'
M?KEU?=-:O!VCU_C[7%?X)W^KC5]/=B'>Y5?()\X=2A#0V$@.:M<[]9RO[[&)
M</+SI.#3/&OS\D'=/+NT(_1R.0FZ7ALL1Q^VS^OA+#E&\7;,OHZTCC4Z 32\
M0YD *308!%@F[@O#U21F*?$2!JS0.  ]5^@IZ="1C^ *CZ^*5;H@GVQMIIBL
M[8&(X]OZ,E5)*/24NV*Y8DV(;'X%M3^>P+#C3SL!A%'^%CS 5S2*@/_H3D-4
MIEKY6_047&JKU\]RX#[^J7;NKMQU_&Y,D)2JNWWM< YMWFI8K:Y2<?QF2ZJ4
M0;ZM5>*#ENC^SKG;'FZ5_S8GZCZH^D<5:M '5,A1798%K807S2LJ.X"%!Z]^
MBB#LQ@IC2\_WBQP+*S45C*F01.Z<*'Q71C:_[54^.<VZ[356+*%"R:J^^6RH
M'C?1I=)<^FU]1W_\&-_DT[Q+1PQU>0_>?])_J";Z:1[/B<_9D>^E,R+?7+K#
MN/$SS$<ZCRY7>M6Z&RZ+NL<.67#3KJ_9S46#T#T$(2B/8HJ/%OX4T,.VX5@#
M.K1:)H]%\.[;TM)GJ-/L\QSWH;FARAF+![4C:4FJ:[[%.?<SK.KOV)5PHO<)
M\ TJ</_9"&!89W=+Z:.$^]83[AT$@:J_ TN3+R+7:0T=?I-)W6@YIA_1\"2$
MWPM"QBL-!!%$N?T4GCH?BTY]Q1S?8%<ARX&BYO"*9N1;[F@4M; AFS*#/?@=
M.9\(>,<RH+94EBT\H::E\.Q;[D=D6L=KU4<05I5'QHS,OP\<7]MTT-R3WNY6
M2+Y\')P:Z_[*+A5R(#I8XW66@$:/2&*L9(S34&%BN:16J;U5JD#+GZ;3-D]L
MX[1"X0KY)DUW<>?(%S)@1<:O9\^G@N3/GCI\B.>2GKB$S\\38)F+_E[W!$^A
MNN=XH@H!_'^Z?8?]_2]>U$AOZI\IY9RDL&B[92V69:@CNZ\PWN"G1@< ]\-O
MV;PHC=TWZ),HYP&TT3Z]#X[B%3A0QJ_<&=BA*61TMU/P6DRIQ5MDG)-D:T'"
MED[CZ+KLF'/S*S5%0K"/.6:*K6K2MS&MTFS0J+:*2/%H^%R7J>93^BP*^J4T
MLL6FQ"YVX4?4M0-11U/16C.<\4@@28KHV">GW/W?A:K@AP\D1 ,B:=*%%]KZ
MI?+N^C=^5_-[&?[HD+7O!LJI\IG=M+IZETWGW8"7]'BB7?ZUXV[B[Y5KA>D2
M?I*UQ5<#TF/.Z7X3D<HPLW1Z<BO'*\#^8?,<0K=]/D\ Z+Z6/+.AMP=:/BS7
M7*8GGY><)]3'-S^<G&85<+5?2D!:6G#BT\+%)QO7_M' OOGU_.=I>5[IL^[C
M)6C&%VGTW>0MW.LGU6'-OU7P(=NN!@9%:YF;]G4OZD;)S9^]6.BLS_:>7I7U
MNR>.)"R8'+X4I7],<#D/^VR[FS?56N5@5&!>ND"H= :V:3WYY)6M+N6?)B;_
M1J=?UC5,D."1KKKR)_;*S/Q!R6,]T;^#Y=WO&1%6V(+]4"%RG+=*?553KI4#
M(2*+Y=MO43\T&I-5L>[G4#+N5\=U.O;P=:Z>S!6(V@T#I-Z7-?V9O/LG]&UJ
MK_M /:RNS()N0*N3C]U]HM=W@0_ZQ<,U<3(2M'4W;!/JGFHF(3>>2HT-ZKYX
MH#L8=LEL<6-V/O*"D6] 3HC7UT"?W56[^L$@AZ&E=0>$XM'>Q<H,\HZ*=\E7
M[<]FBI-^]C^&A1ZWX6Q");Y^D3@H_?PR_R3O\=0;I4>L;1P,HA%Y"''>*HQ
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MC,OS0A.ICRZ%=KW?G>N]590S'_47,#95.EOC*HW1AS#VDV2/LFO+5QC6BF<
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M_/&17REN6>NP:FKM8N.LZNN;O'77N>^<[OTOVX6@M@$68ZUX<ET0K.:7\"$
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MO6VSN^;9;U5J>>8XRCFX!*'9%D2Q>PCE,AO6$]:(?%RN&<5)]6S6!,9OB"<
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MD>7:$DCH;0]=8U8/6[6.&0K'Q;3;M'MVIV24T>TY<VBNA F^\'@"_P6HP\2
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MH*=ND_^H+<A'73Y[UUX[_KD@ [FKH&S#)9T#N_&]O=O>NTJT''YZ-?;F^?T
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MZUYC@:[P@L#J5<_8Y3I:5!I;CU443?%#$S,)K22BR[2-]=M^$T^82P_?^6E
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M'=QED,-V85Q[P\Y@T-H("C\SK]7Q?L?^P$ Z5]I"J7CT55$D1Z$UH_9@?G'
MB$EU\O<N0^,2S77MJY T#W<]B7SD713D>80YI_I]Y3DLU2B[=/_4AAF9XZ$I
MO^NHK=?:#Q;Q7(5-B"KHZOF1T:."(J&"L!^U2?(1K)4\_,["A+W(),TP7H)4
M%W 3NXYAO.(^GUP)!6S.@5Z47S?1?4<1K!6!F#(GMQIJOLICCQ'NX?>]$P%W
M]9I7QBR?-.=NJE?)F[R N(;ORJVQF5GFV8$5I]E.+4$V;88&Z0]>@L1F\T$*
M)/5:&^78Z'84@/4^VUMO1.8? U68R6<_;E9@ND8;(V0#5H\3HUYA;S)F9U^9
M&!QT8T:9K[8OL&9EK<8C'H!WK 36>#E"LS$%RK!4N%<A!6B 83I%[^%+CDF#
MFI!;Q]&4^?C<2M_$1E.L*Y<(QI+!4:NAH581L XIC4W \O5XJOQ]#?U+#AY,
MR1)V!T,E#J^./3F&)5+') GB8Y/(=>S!X@+\7 HPGL.G:]V: .!]TVF?  ,H
MT#9?/FMV :XJ"#&;?M!EQM+K[WOQS^^X=7S%[H0?)KA\7KTLWMU7K(V(QRO@
MAQ&;4'Z$1*$.:,D@W,U%O KB*Q5C!^>ZF;3DQG78DJ.@&#F0)L6_^!Q$NSJM
MPYT;,G"*JS]6]@7,F6)8H'8\I/G795"%6^OZ?DCE?S7E7;*F2JY/NN^DN>_]
M ;AFDZ[&';&F]3\HV?HD< =EUHJ)WH*=. I*UQKRY86#$\WH2N)MG#?/#J<(
MDIGSI)'Y694B_A4PHP!,;!GJPQWBN,;7FS&=I *%:I\+.8T-A?S?ABR"O#GZ
M=%J2A>,-TAUW+HE17*6P$S9;TX08<6+ 9O<7X>P&\9O <KBZ'UI*N ^<H-LD
MAM5M\<_OM6DEQ<T^MV(9&%I3TO9-1^ 3HXH["I'D2XMN3B_< Y2Y?7]6UW4W
M#GTG\>5KN$BPDZ>$A7-30 S'Z12XW9!HX0K1044'1;(>Q88S=/CJ; 01J7H>
MJ\"8CS7V\#1JAC$/M>:"QTNSL"?<_<>4W@V9;'8Y2G1,#7)IU=I6.R <P*QF
M'Y$4$P'(QF^H#\O&$0(L5P1HA1#4=_YG<9>_:FGBGR.$=PG;".;N.\7V6<*^
MV_]SW_&_VJD@S6":I5/?PK(F/!B*6D"L+\66;_N!_^'3?]N^L^&(SGK?FHGC
M UW7C3I^AL.',J%; N*WF\:%OGK+_WW?QXEU5DN3JP2B^S[8$=3N?UP)2'O?
M_J^//R4+=^[C6PDO(%H@P1O_91>0=^%,^=$)5?&8Z-_77Y:1<5J7ANW::,[_
M=C/GZ>TLEJJ>N#8]!30C/T$%((;GJ:A*Q)W9&]T*N.."O$:-8PPI$[3\.;2P
M"Y(V-FWSPWWH_E=IMN_N#D^/:8-63,K&J4QNFNQHL&1:J4/4<VJD^GG!@Z\'
M*,R5F:NU$RV&PWW"#60.X218P7.&/"F6AT/-=$1RGIP%63QO83\DB>WALF W
M5P8D<\AMYMVQ]9N9B 37QDUWJ!Z<N,>]WR!9T$/&P56>7(P*8H#+AC+8:]-V
M@# Y9@[VW4R3HA$2<3FTXVE1^L8#CC#'P%\I@F0HCT"S73 C\TV$UXCDF=FU
M,D[B5A#0RK!59L7*L'920B5AC[N@NVD3;7C42^HE-K'U8#%GWB:&59B1?,/@
M\,G>F4;-R5IRT[MZG=(I[L@218&/OL@8KD0H<G)D('9CX@<)6GAQX8>Q[>!V
MMDKS"*&=$$\HA[?FCF"8@R1?-HS[AZ#(0I.,S6!TM\\K"KMJ#U%1@#\TAC":
M]#0%QD=QO#MR  XZ'M:&OE<[T8K%RX A/&KFC@IZ[KW5Y-;,5CIB0/Q$25*(
MFNTIL?;CD2O=3\=#;LW<JA>OBF;IW@'FK-Y/F<&>;Y@0S^1_%12A A'W_K&]
MRQ^-'T#)X'9%LKLA9&NEQ: EY_&:6-_VSVX!KI0-PIWXWB&\&-LIAL(PJJPK
MS[7NOPPZ,VGQZO@\IB;*N=)3Y\P3JFM$U-#P[-X5>$<[Q'C[A.TB@.TZKVG/
M">56@'5D/(2,8BC?W&$8-P3,91C&-YH/\ET85SBD5LIP!6NEU5.!>W>@K-[J
MU2=_E=;-H6WH"K4>O@MS\V'[##3G>!%G'7?1;:!@9_70!<2 ^?L-L/LRZ])5
M#>:3I&4$;R=4"_><#I%J/V"#E]*]T;7_2SC==<&3)R<<HE438[>"-5=S%4S@
MB10-$7#U'X4A]PX*E:UY3MBZCIS#H!Y/?UCX%26%U,</](+>5.'&'IP5@S?!
M=FIVND.EHC8O=<>-R7,(U+?([5 *51=P$S):#)32RWI,JNOU1:#Y2CK</\$8
M3@TW0I""V\28'PYOH56B$E#0XHW2N';@!,>W76L3^ [*\P;']@M2D"I0:M;,
M(-\3 5)X-9  :3J^YR%BHRYHR$R_O>,=':7(=\T1 <U:^NJ4&(^.S&;VDE![
MH F5;[7SZ@6M*-(I\\BP4T;]"&^[RV+V-[LDL=T VQ%FP2K*:_Y$T#]$J]&;
MC>5,\:@(I5RF"E&H@-5O0[.MYD>WL"82&S5PAAE,Z]BN;)X5J,.L(=9+A7)T
MFM1G&LVJ>Y?LLXW<:M@-(H!JZ7K^,_\8<UX2O#+!A,>-#X1MHBAY8&/LEFD;
MH:$=0]'ST7"<)<>0OK>874'/F(7Q[/T0; ?*<"B7#FK1I.L/<6).^?0VZO/=
MAAJEL#5-(D"ATM*;N;>$!1]!='A)EK._T5I[7H&PDZ#A"]RYS#%>\ZIOK(51
M:4 $ODP5MI3\PQ#8>OAFBIC.?4 L6OM!W7K?Z-#>@E.J46/O-)*"4W[7#$XC
M#5)RT.+X48HJ9#T$-UCPB@5.TIW41_GZ@H9Z(YZ\L"='##S#7F1US(@ AI,&
M3D]06D6+0TG7&\+:,,.'N0G(?6 B.Y3[!VC$B60BFF@(OUEO%DW]VS%VNZ$6
MM0!\BPUE25(8E@JKZDD7CS1MP7O5U5YWG)$>7WX/TT[[0!=;^B\[-!6?0)E0
M,(EJUFX>5O@L6D'\,_YTY7_;@+D#AA0!$VS^X<5!"&V//+T!Z;KEB5]+EG5A
MA4T"@"\9S/_TW]Z'.XP89<G<173KC+Z;S<%.A4SM%,L[;CMAUFT)4V5-T_HG
M+"7,_]L&Q8*1=UV2P2G9%5GX&Y4GQ4][6P"2Z^@RBL#^7S&._Q]L]\N/]%%:
MKOJ4W7(KO>;FBG+-!EV_/^][6NNZ:&,_?E"[_*#_P#Z?[9Z_Z\<L[HCE:>)D
MV+1HRF5T7*UKG(DNFSQCWK@!55%5,+9C:,=;=AX8SB9X@0H,TFSD2KV*ED$@
M)DZX?6"IN/L>\LO>>3T'=[HE7^X3^G3/$80,3FKMEQKX/Q$5&"+!A[*1OYU]
MMB+/C_+F%9&#IM* ,C(NF/G)#PP\ 0Y8K"!D=081+OT_,$H?7G:&&HTX,,6C
M#M[_TS&3G:6T<!@!ZAK.6.7SM4 4VX@**=C;#/AZOBR;UDH2 W<O-A$T&P_@
MD)RR%:IA$G)?OT4XQYZAEV)QBTY0!\/;D):@*XNB$&#X$AO3I&70'T:0Z;8L
MB[_3JU*1<&R5\/OQX)G0(XB#N#!!1J,&_X8@@Q_%TPM0QVG)08K!,':!;]BC
MT,(]>Q)%+;$\;'>GNREB)<;X%R/*O/,,&%P\.0*[9Z&C\<#R>>Y+,/)$\!9K
M6;M?L'8"VPXU3.4^!+TY6XX+*BPV>7-<F>C9[>QI[NG/(B @V9N*/ C&/ 5=
MVG/,!(^,*;+'Z&0%K/R(@9/C@(7<51,G5;#E7%SZX*&1]K02ZT(PSGZY>O&Y
MX-2S:*0F!\-7J..>YCSC.YG74#\=[9IFYI2P;5K=4TH89 VPKWEU):;>E6>*
M=;;8PC[6CMI8;\4(PM@/-BJ!-8PNHN+)GQ$BX/9\923G>AR3:5L_?3<=+@ZA
MBSG*!T7T6JNXY,- $6NS,Q)1/E&A+'(B7@E,.\F93[&P8FZB;1'V<IW=<6&<
M^=9/X>BA*@-O9G>*4/>\;N:K!A;BGNN8]M"/@2N9PL-?GO\QV#CY+!IER?AG
M47INI@WU$]R)[9I0V8!B%#5ADM$56O'*:1Q4QTCP(%X"A__#$+\-6LFFJJ%+
MB1WFYVO'#X[M8O?G[$ATKF63XF=*J\CP\Y,KG]5R7=;*],&'[9EZ]^9Q'DR2
M!#85+4O#=Z&E4#Y^)F5;F.A6Q*9 <\.6W-MH!0S^ %\/LVD:K\31BB\%T1WX
MC6!VL$KB#=*]6B4!*3&O?\^-)6&OG\$9I[&')V'?(1=0L&]"JG'F9Z8#Z64V
M9ZI!??835FX2ZBHB,1UIP>DF->[F7Q04H@+M">*3N9N%4N 0D];:?4^]XY[%
M,299!F?0\VH9HW9,LNK5&(W0$LE>H1_B;J]^\!1G&7E8!/2]M3J]L35=XXVV
M^ =3NOSAL _=IVX5^_W[5/;_N.TBKS@Q^&WKKGUH?!\&06&W:/A_ 5!+ P04
M    "  @B']6-0P#IE$]   240  #0   &EM86=E7S Q,2YJ<&?MNP54E'W7
M+SR$-")*"PRE-$B7@*BT@'1W=W<,(9T# M)=4M*I2'=W=W=+S9SQ?N^^>=[S
MG+/6^;[G6]\9UEZ+B_GO_NU][7W- )V"+@$>28B(BP#@X.  .K ? '06\ :
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MZ^I;6MO:.SJ[NGM&1L?&)R:GIF>65U;7UC<VM[9WCD].S\XO+G]<7?_T"PZ
M /?;ZUZ_L&%^P2,B(B B__0+#M[YYP%LQ ?D+$B/A621=6V?4+#ZH."\!F>4
M-:-2LLD=X>K9#:/A4;$O/SO^Z=HOGOU[COG^;WGVNV-_^#4#P$" @R4/ 1L@
M"+B\IBG1[B#E&?6@M$"\2KT0^E0<=>+9O4>7A4]M\'Q$V5A6V&.ST$/A6"2'
MGJ!DHH?AF*3>QP=RO%$V&.[Q3EJZSA,* (4[,A!?5^"K48]]5.[5/DITB8?X
MQ2]>_AB& E#S@D%;/+\<$BSHK75WG+J."[DRASR1>0P%#-G=0*  (L%E]F/F
M.V3FIL/CK!V[ ])Y)X&<S&]J4,"'T;:F,^)O4$!31^0/J9>24(!0[^'-K<EU
M<D-@C69D@4EI7-.?>/\B5""/:7E_4G]'C7Z]],^\?Y7Z-Y,BZM<O[R#L6$0N
M'\\F_P/L^9T[#DCJDCOO][S&R78ZS>8V'"@?;W.Q6W;^ '>5E.!'KTU%3DV0
MKBH%-=#,WZ87<G)&N7T]6::NT>QJ2=)?6<# FF_@P(.!9:LQ3BN1=!FNS\$8
M;))9SC'X:,;D/=*G^(3 [L>I,G5G.!FH"M%ABM,<9BT?B7?XJ,R'M>0]5SWU
M]@=C7U2_.RK#VIVHB RJLK-S?!IY\\-\/$)>L; :?'JZPL#K%*9^ ]X[4PX#
MM;PIA)DML@J!P!)+/@X%;%':PM*/J7PA++.A'0S<)0&N@=SX4T..(W^(.8*N
M4>9 BZVBMU2\37>(5H*'RUDW%'FGS&V"$[R"79 S=W[<5>!1U X4<(9="PM1
MP)^9?I$8!"IR ('OMB[<Z#O^HO"O;'LA:7U-CZ  E2TH@/)F^.^FROQ+L2'T
M[5# G^4R_[]MZU\YIW$%$[S((67#$-'+K.FM4@(8H@*5H8#T\,Z[6_8?MU)%
M'7;U'Z" 4..K$4A7P6WO,=$*+[\.%( P35/Z<O@6Q"I69@8.IGSIFO^B=8=O
M$H1XK/$]1HBB^TE8(>U2R.GNLME[IT3^Y.<" 4Q<V>>:O-&RPH;FB7>I_E:D
MRS42BSLKVHV+2_R[*.W=,WPI=M$A#1PFI=1-QQ-E3IO=8,NLO;(($%N_41KV
M+N+:#A?P\FC2P>XZW&R$.Y47=2MA7T$Y!-0B7 0:$MG\Q36*"<$M2OO_ HP'
M%)" OGNT-VB>V2@/><RH#_'E$KP\^ME6\,I@!?0T[>:'"60P[93L^I:/;6:K
M% ?F>ZC*3]\'8;[_66[%YFV70-/#OHMZ^O8_*P$>@<V!9]AU_Q7W*RB %:NT
MM8*_).08AHBJ2%CRH(!?X*G6"4LYZ&?*!4!]?O\?,6ITM&UFS)@^?_!'-2@%
M.'T*,0!J!QJY"^-N$HFVT7_*5CGG;ALF?=E&8'C+2W1&;_[)FG%D94&(2IJU
MB&^21.U)]MV:HUPQ6N$\W:Y;$>_S4.<"F1[U#FW@ G_@B@W]>HJZ0OU$%<\Y
M^C1&3%_[IPM2;_>'L0=0 ,%SET:TK;JV>.Q"3Q[!(>5!Q^D/(>MV;$7G7V2%
M<6=T<&2% ;C#+D!AHL.0XO0X2L9*P)P&#>%<$%O-,3<PW+XJ*\_<N5XQ]KPJ
MJ>CU.>ZSCQC<[^W]K>;&NCF+ HH]I4<UC]1V!!B^1"\@C5AP/&5SIK(&<BZH
MW*WLGV_9'KXZZ@C]O$4*K!XMZ7+O;#BQ,O"F[-GMZ5@5:#.J*P02F3OA30QU
MVI2CFR::+.A^#5B?Z1'?R7;$F5W$-W/.DH%CM(R1_M1O%C?T064JRLU36+];
M7M@S=".X4'\)OSZU9<:\CJ(VNOWP8 4;?JCC(>ZK08:%0(*"2.^BY?I&\Z]J
M*A8Z99+#U%%$KW*J/QH@!P"U5LJ>=A U_ CQM%T+/BBA9)$(2PA?I7R =JTC
M;WRL>+MHJ1@R0E"R'S>^$O HI*R@"X'D=&XCY;,S>MNT-L*,U'+@A&7IP8%\
M;[3B"6-KT$6,?Q327-&KP7=HZH.!Q<;I_*M:-;.4%>J=X5GP%'DI(5?=.CS;
MJGA>+&-%[.N5-2']FKKF#G4G@ 1]J\*&IK%3J=ICJRS'[+L E[VY*WHKJT2
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M >IK!3O];^C,FAF\^F3'U G\BV?#_U,_V=UA]TFVA\)3JU# LKS+&XB'$:R
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MU>E"CGN]<#D;EE.4GO;>Q>P0I<>+17-$ZQ $+KSP ]BYK7QE"FDJDK@!J8'
MI"V<<RL.E0WCC;*YVB61KGE"NJ94<E_G]#AC/]&@ :C)=)+'I?0E&\9+/73U
M 9C.=&HO:3;AQ6##KR<JAD#N5Z2LFY>"IC>B'U.]^E.-%I.L[,.NC7*4*NJU
MQP_D<QR-H(!"E=,KH/JX(\]ZS;!Q984D8=;)9M5;EZE<^(ZE=1_K'+-P(G50
M #[GBUD):^/1I+[P\H&32A>>08]C34\<WOZ97AV%N!KW9('(7/.H1;-^X_(>
M\<==##7OXY71D0@ *&N<#V23Q,8M]QPQ)9[2 M]73)*>(*()I:!]KE[48[M2
MSI(5K7'^ZC=5J+:)Z%#GL,N,ILXIDO,\W3@A<*&7OK(IHW.)OFC$H2*7L=L]
M+E4]V&.:./V5-&"+>Y X=:.DJI&95WJ8//&%(G&$ FDM?X6/G,) 5G29;&[F
M 8ZLL(')SW_H^>\(M\UEK/$RV""19+\-'_M!0V-EU6,Q_0&/'*HP@P@9BTEK
M80WJ;GHP]RD]J:5YCKF2%H>1[\S6;+\'D]TQN;=0!3*#ERY9!P"W:@4=N/_)
M05,)DVG9^O$%_-NR%16]AY(&!DO.')/#:KS]E?ME:"'BA0<VUQ<A$]=AET26
ME:-BLB4;RKTB8CJO:2Y!R9$7_+NY0U:ES Y!>4VAO2FA6+7R=@'DZJ;;8+](
MMY',3$6>+",%W5[Z]'_[4\\2)'7ZFS3\PN:,0<LU]-AH.877.[MM0:#-+&)C
M_@?.8TI1:<^ZDGF*7"_])N6&WRX7.6;E=F+(HKOG*,</S >P^$ !#-]Y..H>
MQLVD!3L&5Z$KX76C3<]::2"):'1]OXE& DV7Q(44*%K66*JR9$=+W) Z/_N6
MDS'/,1!K^G(KNA&;<)65+16=I8/EJ[?FO*_[9$98%.L+]Q U.F,!+__7Q#\_
MP3;T_]MBA0E6C4>YP2IADW65AP(&NZ& ;P\$G*.Y258B^Z*P8MG"THJ-M<W*
M5>?:'_FKU!>0Q42+=\ A %/X0MH/Z4!75X*7W[-ZTB!>,G='=*'F%SK?1MKU
M]4HD4J?7W$Y8Y)[7&!T%P\4@&C]U/4SKQ=%@4#O)@P+28J  #[27!5# YAIL
MLX;/!SY2^_1R*C-5)I[,HE,@30M3I7Z\V&(S@K"WD/< V>K54BJ(4KBE#:(
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M;,8RMWWH;%6TA/#!^F,TG[NL31GSKQU&]C>7<84YNBA9.NU/WNTIF\';CL:
MP6-RU75(:XHAN@W4]L\!Q*=G2S!]SO_4YROUJBHA%85*OY8N4(Z57]1.(!;1
M;4ZU+;]U'=D.OD?FTGYW'Y:3?P V:_=%D*%#A)R>B/&#%T\(E[_R$J6J#[%/
M-OIC^!FMR7<<2C#A4=T;G'"OP?Z3N2_/+DKPN9>,!3Y1XU(E]J&RFU#&7N;S
M*&Y' X 1L'16W5>/D)GJ3NP!\9MTT=Z'KJ1S1":310G9*K?3A"@$;ZF=1T+]
M0U/_WH45.*^3N5B#5E6?"K8]6A:UN%; *F)LK/#,0;1E<M*)'AS@WK-/[8R
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M;PD1G:]3:8^WG,#B]'ZTK '(C$/$FU# :PXJ-P7L8&]3B1Y_SKAEY1B?JT1
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M58)<J?:A)1\WRG'3Z_UYSVTZ5?)*?9X5MCA.RP"4O*>3H,*^#HXJ$=0.T?5
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M?KV(YY(N#.V[!KV#(<]PC4 ]L5O/P:R_NL1F^(%$HR-..,*#G+*GRJ<EL>)
M3!DEY&>65BX\6P!EU/#-3>%!A<>\D#17/4WDT18- \E5=EPJ0_3'8^G;D 'J
ML3@X%\S&EW6%/$EQDI+*A[RZX?JELM6R%5<J]5BIF>*'W$H@7,VE*6TQJ2"Z
MAGF.9IQZXDE557DGU+5R5;K.[(:6N^&+:DI2Y'1,$@;.;%,:<GRZ.#VB+B\!
M0B$N+LZ#AJ'C<)/P,G-ESNE'0_OOK9>1/R.<[<9(RVD8X2=ZQT1N"BWRAEH0
M!%IB.:X%9+'EJ#]W.*-@(4RH.BG),2#5WPFJ_.9] P*L?>;-7C\UA^ZWXD+Y
M=^,]O $)X>./;\"?DJR*L-Z6^12]Q4<7/7P2&HXG2L0!JL9C!?A5G4Y#PN:
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M-^/^_>R9QBYCVWA&*ZUJXO,X-I+]( E_Q76RT-9>T](+HPNX9>-0'T-XK*6
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MW_#V7QPGX%7;D=H3>SYP+V7+L;$8MV+F1B*9*/)^@8"V$\8WDP\@K9P%2V^
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MCH$J>GI-,70=T]80ZD< R6B(R*5!_1#1R\J&)]&&!NNF6FYR'3Y84Y#8(L?
M'[[Q>U9W3' 5G7D68Z/?BD;8A>#]3M9 +M31O0SW59P@A2'= 5CP0F6@*"XJ
MQYT.CT4&&DD+IXM3@:Y]_LP5,]*8]G'22.=;41PWM=ON9FY<6W5G;7CKCAK
MS]&^$4>9KH)Q]=5GKIHW<*^[\D!P/TY9]]HA!<UY('&&0ZK1T#<X+PUDSV,?
M64F!ZD[/_,0;NWG$-&YM1%6IV;^I:O4QG"9^ @.$' "5"J?S%#SD"!@MFKT*
MTL:\FG8R7!W%E#7&-$X-L$V<@F3;8;4@)@75WO;<QOT%P!$B8Z"/R2,PTN><
M<)/\^+5]E3O*=R(5T(<<QZM""%/J( V"."['S&_[GL0*CC \@-\ZCT1D7CM<
MG:*HY(8VBUFQ!JA&W%N\ZNN6E*53"TT;BXC+_,Y-A#?C]=^"):MO^MGM )XL
M@A@[(E_L_+A3>@]FX*=O!]_I,KJSFN,Q$A_"IOQ4_<A#+2:=F,&_LU7)PQWR
MBQ=I,@,/MD^JA#\K3M.:!N:HMH&W)]=)0'5VFL,\+*P6:7#SUI^64[HI?1GE
MLJ[94CQ;5EX=]*8@'!)O&#%YV"H/&'#V!. SZ[;3J#BADN:LV3"SZ,TA,PM6
MAQQ!1U0*#'9GOH 7 F'>L4<JI3TLK.&P1%-+U^_&B/2)71'W^;?E\\8]A<,]
MPL[=M4I)LKA509=N=@L;WHW5W<[>."6LC7I%[+Q*VZD&))(!$?WK'%CC?1D6
M6P*?50(/.9K8S9%?"'%OT;#)GUU637\!BI^"[E ,C'\!^L&?'X[]SMME%*?0
MIW;^$<WQ6U+*^<^5K'J$.B2TA\U<1IIH((F[1O3<=0*.]D);*= 2@\"8I 4)
MY]47?0<;B=?*-&[+U798)0V3@G<TWXH:ZA"1T%$KWS$NF9F*(U,HK?\L?*]1
MO* _]F,SM<F4S[,]W:+A6)QD3\;*+0&*OB67)[(,H]_8HUPK+DPXM2PYXHYY
MS-XK-CI&NIO<%]IU8W:2!/&+YI+HYM5(LCA*Y416F#=!YU,A[R6#C$KAK)C-
MH@!/[&U01<M_F=$X]B41BG.10-++%YS+;*]]<8MQP__HM' 0#9+NI'N^_DD#
M_A%\S!P2+)XMP>4[*O].H\P]V+!&082=VZB9[Y-Y!= \+_8E^?\*#.=_J%F%
M1'SQ2%T0(RQ</2]$=-FQ4WC6NG RG^(L&,6V23(YT93Q%T"\U^)("K%G-#LN
M7NI(J[++:Q>GRG)PF+A.S;G)IN!B[M8+&+LV@Z_ZW-#+"68P4.Z)6Z_D?5F2
M^D2F\"(3V3K"#1.]M4S4M'\D:!MGK'/FTHJD&?+-1WC#5SU=:<3<A#>>:><8
M7I;4MSZ=$X2[P7&9&@%O;J<J'+$P6EZ([B8:ZQ2HN[N'-=S29U, [2<U2R<1
MIH]%628[J2*W-CG Z3_05T>6S>F;:/RJZHT346!.F=1,1U"B_=79"+9LN;7V
M?7^K?_!EV31K;6.J71+>TFO9H<0;[>(8Z@@%G??SBD^<(WN4B&^F7%]WT?XY
MH#V%7+D85^\[K^Y MY)/;M=U#83$Y%_^!4C^$+.\E,+=-]F,SW$L7(SF9M+_
MXN<EO7%=)J@]VSM===HNX?GZ:>K:R>=KR&SKZNW%/W_5K'Z2%\N!D310_>OL
MIW<>7)1*%)CTDVO<X)ONI0IWN<\G9[&SS#42]6V85T42!DB*"'H9U;T_Y'AG
MG]\>\2/^$A:+,;3PFK?W+P##B1K0X87>X5[13YK>]JQK;B%CM& XTJ^< /\^
M11X$.GK(GP(C6VD"4^94J%F0-#]>8D2^H<+BA'9=53J8/=D+MO5%9T_#9A S
MJ*;J!?8O+=7H3"M,KF"U<=NZV?P.J*7=PB\"\Q]B2Q$Q,AKI(4!)HSQDJ7 F
M0@EE,-+ZG :;+.'W,LSE@FKK<S"E72JWJ,I8&:'SRR0%SOA8M^%R11#6DIZ0
MX]JAD4[3U,$1G":0NZ&$!_'EERT6B& 1^R^ (A@_\?YYR>KNU:W7Y7+I&PMG
M5HI:N?SZB&HL44D @ J0>3N&LWW/ELY8F[1;^4(A'HRV6\$ELW[<1L+66NDO
MO_M7&.Q>:2X;4VFKR_6"8F#Q/58<L@*9M@D.VX4GHU4E#GP./F?S_>[)"SD\
MF+V23<;-8BPO8BQ#821:ABL<XYLS]3N_8R7L5=UC"#W@FIV8HEXWB<UK$8#G
M>POT9797Y[4HK(4,1!S:"912K8SMS5+4()_-.P;W/;3,NI7CKQ;N(0O=W$ 3
M9,)TV>^9#>\IAC8=*&9%^/75++F6!1#PRMZO95Z!S?VB*$.$_>_=2?!TN0M[
M=,:0HR_:"C5P*E?2^GAK' L8;SUU2;4-,D_:Q%0<3>;3':P]&.7E"VVSS>8<
M68T17%3>#LV'*Z]Y*<:"#!67]+P!FA[]TM.ACK\SPATM@0\] C+SE1,W4Z1;
M0](3!H&1*X_3IJ]Q'/EVKO@TH*Y0KVVD=&X"2S_=$"]^$1=J$(#^OA4B3B?3
MT[A060.L@,\[%]3<&:J3F*V0<\$@842O[U^T\$[GJ(G(&ROQ(@+Z%BGD,/"-
M0-CA_9(S>I_:7D#7;@Y-M_RAV,(:3@&YBLI9^=A88Q8U,R7=WQUNX045AH/5
M705#Y2]0:8._=/%J<E)KGGSUR.;U%<1HS!8:9VTPBMY*EX<20K 1[A/5HX?A
M5$[F&_%?D9(Z:Q74R!<J7U7L+1UKQ^2'ORNSMCK36M?-MG]H/.DK*9S?J9T?
MLG]QE9FL.#ZHK\0\X-&%Q1@OX3'B(=Z84+8C/+O@DN-R[>&0#HE4_CDZPI!N
M@D(B1/_U!E\G *]''P=6"_WK<?5"P;^ ^HZ<K7S6&[4:DZ_\)4[F9'B]TJ\I
M=FJ750!M^);$*Y;?]>?85Q=Z+!JO^]\-T).U"R-(;\8B4]\WM@&2?_4EEN#&
M-[]]W[U&I]IK;R$TDE8S>8]V6B-H*YA.D8_U[23T"//QU\1I\2W3:(I\R;W!
MU;+. 6Z*0<NTR;P$Q'O,75R7&=I&>RZ;^D2.ZKF7FNCW#=9RB"[!%$&VL-C-
M\@!@J6PBBW'7DS8?[\F*? ]E5OO-FE=#;=8^D(@=OIDJ7]=?MY%QY>W=*&SA
M##I# MM@'F_69X\&-Y:,MA&C'K)T@?\=R./_!WT0>/*A/Y=J/83YS@21M?&0
M]UI$=+[-Y;[4X;2=Z^TI479B\9]?$E+"1OLQ[*UA+P7/9B'PCY1;[)*O)2"'
MAC4.IB_;F]5$-*9>$U7TWK**9_5FSY[!F2?I\C'BYO#!=)!1#JQ)4_D$FF4]
M*7Y(.IE\L@2=$9V;AZDC^BY0<6]O52/R:65;G-@/2GH#UA&!<K&!W\]:YVYM
M:@Z]B(RZ41Y"!2D'*IZOV154;(*%DITH=GQO9 E:$>08!U_UTOO+?.$R($-]
M-:&#*R2U GNR*\+Q%=0GH')&UP56SNO;:^WKC>XI*5H$3@EI\!"\;. ZF5G<
MA.LF<^&[TC[#R"4QR]?3&YW!_7>^7U314.=$-Q1_C+Q"ZS76.']<>@IG9B6]
ML5Z%:#.\=,Z%A+CS.\Q\DXG]G3ZQ,$B5&_SL%8(,;'[CM#0"3SR_-WT/P)J*
M!5RV<(VV"97Y5E[WU1JMEO5:/U=/ZF6FQ=:*CI: -%VR0P:D<#@K4#%"BQV4
MJ[T%2\M@[@91Y[PZ(Z=?XYP)4NFJ@?XGLI>Y)!IY;>DRY+Z%V\IP?87?S?&C
M>A(5^*&05XO,JJ2CO4C1O&V]4ZG&YN""Q7U*! +N[$C+]&JJ7[+2!PP*C="1
MDT@P!%RF<PT=WBNL)Q<K<SU4#6OY7+6:5</CIRF9R=JLYS+IGPZ@"CXD] 3Q
M:I#@<D%9:*8CU_>';N2@5O#/U_XAW*&#F?0"LO2M"E!CO^//'?6>()[LS6_H
M"!=+1"-G[[=:8[A)>2NDR1HL5O$:N$_/&MXC(MP";8Y6(L35B.5RWO7ADF;P
MM\30]O\7R@6G@I<7(8Q*P\V=:VAKIDT_E:AX:[=B(_L&/FP45X:M_&F;:@D5
M)A6GL#;?,"*@6W?BU88BUS0R,EU2U61@YLX?"$]H.X.@G,9PR]X;1Y:5F+T.
MS6\==RUJ;?V9HCNZEKN)G00@7B))>2.EY+"]-=VFY"@(O]9;"-O-67@N/SL^
M?YS&J<A+_D12,*,:,F;9#O +%,K2Q#P@?PY+CG=$2?+?7GU'<]'$N:LTL48I
M*0JOX?><M=+UP"S=-)NI?J=W3U]R>WR8LG1,]NN;N-K:4L&P"6B: /31"DO;
MV"SX96XOA$A%QIZ9O-4]#?J:KO.M9<I5Z*5"V\1 8VDUY@$P.8(U K#-ZC4B
MY+5*/U)))"Q:I&^Z'BCE8DB,A4NTG2V]U]]Y*8BQ_U4OV]?OKN?:\#&#>Z1W
M=NXHOPW*" >4T>+)]2;#CMAS"AT*.[PJC?[T&[75-W7$BWZL1\#P#,'HF$6!
M=V4P/C.78$[ Q1Y7[*20B7T 3=G*NVOB4Q7.W<D1!]4J!@PZ-.#YJ+]5Z$3S
MH@:I;^H=V[2KV?O(IZ]98_=NN-MF\&LV5649)0R:AE[3<6!-[P*G^]Z'$Z(9
MM]//#I5Z5I@;9P^XG5.U$KFO"%+A8YRJV482PF-%R2'2)UUH8,8/XS\=:BT3
MGF6^IBMLS]15Y+V'K3^>I]YHJ**+NWH!_B_^7_]KNK63AYX[&_$33V*L4PK=
M.GH.W(<#D66"FA@ZSH+[*E0N5HVAEOXE ;MIMML!&,E_,'2+_RMOK,1HEX(B
M>46#J+8<$=>RAF1%]HFQ(Q#O6A4 _!P_(EEC6;7C #HZ( !QI];._P3#^K^E
M\M!*>2&:#.^%#R]>@/? =ZNH"T&,*@4KX_UQ(_6]G5ZE00 M''562!1\71Z$
M9)_O R>SL#H33<ZF Q;R2N?-E +M$'A46&2MQN9AQ'@/G*#7*]8UHL:HK#^'
M$6PA@ASE0UGOP U,5M'\:WB)48/-[%4=M/B>?L/\X)+-=]]11_,AW3 T<XB@
M7:F[&4F-$@3$(&:,<_'JB?@9] =O+TX7Z["VP(4QX:,@AD,L\G'6'WK?6MRE
M\_ZG?K..F%0PIX-O[ HXH >159/4^9I)%CMG8 RG%YCJ7]I>L!8U]"$2<T=Y
M[Z;3K*^\8"HAOV"F]]R0E&W"380TTW9?EF*GG*\<A3,N:31'9J4M5Y[+ \4]
M+>E88VRXDZ^!NC\>9RWZ2C7=^^82.7#Q!VH+)P@=EN:D8OCP>&1ZWP>_*_3R
M_P7$#+G[IA^MGQR"=^.1.!,BLE.*$'GM;&ZS0"V+B[M))>FQPPELA\^E'1.J
ML1%@4>92;=!_Q?BN8-78CL\"GCG'Z[19#ATS#Q:(?5,E?UKVHJV'%-F/[ZYM
M>TK^[Q$T3=1T1ZD*8Q+S/PUKB74"K((:#.X5'$$9GA\BXWX]X0KKSUX-S26*
MY1+>-T0TU$7N)BG&O_\"A&+]5!!TA, Y&B=3V4EA)"ON2K1WU("IO#HM'9F/
MB)1<'[ASCV)X)G&[?;(CI/PI*ZE@ZQ('G2B:_3*7R)!+Y,Y$%;SO*$%%<I2*
MQ<.7&1_X,LKD4Y(E(FN2BKB4UPU#Z@Y+EKI>U_IGLZ/;-7Z8JES!9^!:R._U
M]);\.I/%MW1U;-?,9@)4FI1N._X;FC@5P&A)!7+=M2/&%"O1!<#:>;;2PYF#
MS2PSZNBP*!'R9? '[N9R_,^O&&4*EC+1W\^'W[]A^3+(KXCQP0TL/5\2W#@6
M@3GC?AP6$PK_\)1HM@@G1(BCO&B6:<Z Y8O2N#57EY.MZ^;[A&>]7$!$F!*S
M[*?$>+&;#O6O&'4*FHU3$3T:C)%:M/9-3:8@-"O&3"D)Z2]-E0TPTYRR5+<5
M@._X/]9Q;:I)S(P 7?UQ!U8$[?,ON#L.D)(?#QE#D7H"//< _L][P<]E*?\C
MK87\0\^APZ<4)^L^+&(H0XJ^L\&/5EZANNH%&!5XFS'YXI\M58_M3^C1?)=?
MT+;M^&SU]3(6[8.TA8:)^TMJ^?@5[T2KN>> Y[/90?_IN@S/.F$$?5LB;N2E
M9S^PDO^D:U7Q_.EL^,I%IM^(.X@5T'VJ)4M#KOLJB%$YF@L[YMG=07>*1 U,
M.\HD3H]M!NTMXMPYNF3K8_8.,)-79KP,<LKV4DV\?DN+E1RB@1#2.3HZK$Y.
MHQM"\VT73D#I6C1QLH HI<JE<COK.'53R4U\"R,Q42E(?(/(5<KAKU0$+W-@
M$=)D3WU3M%L39QD8G5XP/AU1HF-N]3*4BA8CJ:LE".A@(@<>2]%F-095JXMB
M2?TSQG' #,M@P1BQ%AT2ZBB.Z+<8*)<'498*82+W%5_)L7C>@MA,*_/0!P6
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M\,5([*9N ,D.NK<#&*DQ@^]3C&Q,6J\BL=&S5?N: G;)9.75*3PL1(GUF0"
MC-Q+UI,##2CKNK>.5U\G,<8";B5?O^J'_N_ +^]F\:S(<&\L,#S.KE!W,A4
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M$,"KX/\PGOS_ODC^SO\'4$L#!!0    ( ""(?U;N6#2N03(# (U+ P -
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MI52S7E3;#5G\2MR@( !\S"^<ASLG+@!;7?I7)V2!Z7^)H$I3P<<EU# /DCD
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M*/M!CEI% -I0#A3;5,S=0Q0G_HIQ9,+8DAG<#.)[4)WL0F8BV4\)79@W"S_
M_:@$^IT;Y:MOP8U-9,P0@2S$5,?"ABL=SE5Y!OIK6_M_ $'_!H+[#<0.+<P!
M9?>.O6"P%:8'"$."ZOX7C)[?,+#O-EE:H* 49&C^!6/A/8G-@!4D;6%%E \L
M_E3+ZW3<Y*ZY;TW[<3.[MH-BT1R$NUB%[=,#,WQX$;P:H"D6Q\W 7<<V\"#D
M1X@-6^X0$CC(=@9E0+_ P=\Q2KNL.07NTR__ H=$_^+?2(V.1N%2<GB0R\6K
MBUP4*"_XW+\^QFW6MW,DT((@PHLG?F'#N>#K>]IN@2KN![@5V"?D!L'2#K[$
MSR#HGM M96((C*UBI\Z#?*<6G$?2/?EX$).%U4=VI?Q /@\R?!.9Q"G)P2Q=
M6?I>"5;BR&DU[G&"4G0UB,&#VSK)@SR,NFYW4J$(/L@Z!BH04# ^_/F/,*2_
MPBS,8'^'@2%"$/\,LWR/D_8WF=1=)^S%_PJRVCYFEV'!A07_\NH:P2[>RN-(
M_"X5)P(</H<6MCW_25YMY$'6_XH5P%C_*W,F8.;NT&%,*%LRA9M!> _:HEWN
MF0CVTXJ_;[+IFZ7\+B6A"EZV1[YZ38B1*DQ?'@ 5H:$)OLAD7&XQ2G8$N_5R
ME-OFN]2+%ER\*#(T^2+J[@/P,@(<N=D+,M.$S'^"XT%^HX-M*?,@(7"V"D8#
M^R])7/RO)-YET5Y9O$H-EA,0HRG%_DS2VK\V/:1DTM,_S@5,L77Q]WB06U'7
MO4 7;:U+I-P% ?ZC,=;_I3%&_F+1&@WD*H.NV5?&@SS+=_J+6JK_@UJZZRE\
M2Y\OH6!Z2+:C^X^[.YYC2?"3Z)NB DKC/,@T:"^G3T3UHH5_D.>;02*#GOW&
M"9??P(B,LZ$(#A0&-BBH9;N/8+]>Y100Z6E (8@A"_$WG9E$/ZV6 K/![C[U
M>CM@ZV#7(KN+/$AB-8(:MPTS@:TKQ/YS.)"XB1GL@T/(#23J!0^2#;,$E2H:
M@/V>-(?_^Z3Q^-MQH;N.57G&F:%9_@I:*[5;]$C!?W;YI(C[D'/+<'\_"?M-
MM)S-<-QZ_YM>_&#VK/7^A5X_LS_B&>(F^-]9)#9@R8]@&[:8(01P$.WT&P-L
M!OD7$< :_F;"[QIV;7T7C?ET+:DO&.%>C.\I7EW%?K[!YD=.NL(WZVM )D5=
MXT$8(D.@?0%\0(5?0/SZ@H'E0:0=8L!>8]#A_SYZ'GP%HTA,#V*;,K> _\"$
M:VZ'=:QPWR"1WQ(].?>)BS<0/MGMHP)UB,TFPF\._R"O-BULM<+^2ET@T EV
MOOI?)0(GX>G?)4)\3>048.FI?[59%O+?AB RZ8H X9:A58GC'('.?/1=<$1%
M45%9C;S9_2O)"%#,>P 2UG\9-*[F+XOGW'XC^K4,_PM0Y[\",O]W0(^XW7\[
M^?[$+MY@EV_Q( GC=P_PJ:F*Y3V;@_$@$F!U3O @;\U>XH&,D*@ )#>=^.=_
MFW\F_YQ_Q/]9H+_))CC(1SZ@ZXFK_0M</L?_VAD\R%0'<<,U^C_F.#@)]C05
M<V2ZX%CJ(,AJ9;N=?S<2)+%_T^^LQ7_9#W;_LC<JN:U3X)B+N(YEB PC_B-?
M+QA7P7S9Q8)G_O5W^2K_VZV*.!?UZS,/DM?_>Y[^RUZ%K9R*VMKW%%Q^>_XB
M:=G_  *SVV$%AD@AXA A1GD.-L(,>,YI(]J)Q<\V<9:#-M%3[WZ3=;<0'H89
MLN@&*Y4J0W575!8UR^W;_$FR+XU87VC&_Z)"V3L17,U6Q.JG8+&-M5;+E=?D
M>.;+$8OM9O"LE3H_$;HQYJ12$6'8=/Q5!252'Z^,ZIP$9TC^S9*XA%$>I';I
M$?-R0KOW)L)*8_IW0*[\T]( P@[,6Z24Z7"4]MVY/Z;99\CZH<=2^^]0Q@>:
MI<M"I=YXAJB9CQ?>OW;AH77P(R"2=0EE];-_R[UG :<LQ,A8'65<]2M2L(7U
M$"4HK4A1H&;YR$-=6 IF[Q+)/"V^3 5%RT.T]>J<=(]\?'31+_:LW:J8)/I7
MTK.>'/(&*WM<3C%^8R3V,T*:NQMM 7P@O[!_B95$JU2@GO=:94NSE,O$DRK=
M.XR:^FN^WBW0*IY5;HQZFH3W'@]M?^ZC'Z4V'*G._,X<I2K+OPEU%^E#JQ2=
M_NIZ%;%6*IR&SC?O/J7>*#YL9%D:VFOYPBJR([\[Z'R(5.UAMU(%XYZIN! #
MG7GHX G^T%PR42QV?EK,M0.7T>E6G4$MR3;)T=#!"7*>77]M+&I(^369<]_J
M1)%0VY7TGM>>M3E#,05AT^T-]C9_\#V_=41-I/!T_XGCL Z?IB>/SAJ"?ODT
M07;PC:#LH,VVF)4_#VS%(F\CFDG9Z"LL,W9@$ZC$X0#.BX%--7NKL^+-*>;J
MK+CKAG?\S&A)L9S 2* J/:_(6Q,D479CAK,NS5'X0WE:>A-+F96S8=C'[UZ]
M\992VYO3N'EL!I*_J?1J41T2\9JJF$6 TI;>;7V$F0PS9ISE2EU+*&J>LC8T
MK7ZKT=[@!OJ30K3M8<^T"P;6\'XMFG'GH'#N<..?S)G$^!A\:#?Z3!IM=U.;
M]NF8.P:1A32&)5P\^LO9)1=CRCQKNSQ<KBBHYLQ\P],AXTHD%#?4?$&RHGCQ
MBH&U_ML&-]-&*3H@[.V-.?U-5ID61AX-5&(397F0.TS?)/P\#_(JO\TJR3I)
MI^736DPIWU:TSQ'UK4O>WRULZ":^@MOEEE;6>9#EMUX=7\QYD/,T_M JM\[-
M[@%+_IQ1S;,+BVUMI_P#S"?%X&E;B&[PB+8ZW @2T#J\R8/DV*C1[S$CQN*%
M67+8,&+6K.8ULUJ.V9VH-1MHQ4&N'N/>G*GGW&O^_+#$H(,&[;]B3(*.SSN+
M<7_2IS(>H6(=QFQLRY;:9NW2'B[)G\.5+Q4=ZX\*?;SD[W8_(KCRN'] 7Z;D
M?F;1Y2DFO5]>Y]#-JESO;="7L!:+"55.._;,<.VS$#OI0HS)C/^<QF9%)X)^
M=YABK;TQ5]E6^O%$_:R^N+Z;VF[Q0]]59M453B W,.+/O<FG:=.//UJL%5H[
M& O\84EH('VAS^N^/!&IK9%>5\P0$*=*ZK/FQXVH%\XYZ12>FHV/MG0XD#(<
M]N'P>%E@=#9F*A:A2DZ,, 1-RQ.6A#Q.(7D$Y9?<$#BI>^:['C[%^)M&FJ*Y
MC[T1"7AN]':Y*V**D%ZADYD46.!G27.7!?PHB^DV+C2<_$I':!H:1A%1\&#
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M.46=H'CCK^0D8R11V<PB#MX4FCE,WUH_F$\9:&;@*5W%M(GI>'SF1Y-BY]&
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M)O1S!0![4''?Y11S]3%3\L04-(QE0F+M E5B$LN"[034Q^G"T^WX.8VM\-Q
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M[DHW+/9>>WD]1R*-'SVXO5JM#O6S!X'#[^JRP6?BZ57HF$J QI5<[R<HH(6
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M>-GZ?>G[N"&(4)(,EQ2HR^G DK-F"=VDV77:])HY0P$YAK%&53(+QC&FZ'-
M/N,B<B?ZU#2&_V1;9?7'\_@]^YZ/=^U$L?RGUM@G**<<*=#KCFDV1K T-K1\
M>7_IMH;]QD!*'RP1V^W4^?N;,Y1V4*2M4*&IB$C]6*[@',N7N(I/HL!%V<%
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M4IN%WP?JVT+9B.O.%,:Q#;)=,?!TK!7%2I%9HP@?9V/FBE&,.\BXB:(DU=.
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M!TIC#=&<<A&^Q)1LKF%G^Q*<HPV%9%(:7:HC,K<8O93@4OY6Y6."T[?49=_
MXMJAI2)X9ZE?+KP?CG0][](_,Z!=9:A7^#%_&!; ?Q2#%;SM.5>N.2K$[=G
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MM2BW"^G@)5>P$>30\:FN)L?)@3&Y@@]-<.T"V;^,O#+/T>F#ZLU0'6V*VYU
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M'<641-=W _&>[[(PDV2AZ/%0KTQ'J!;>X,*CFX&:_+%.BQ9:C$\54UG597_
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M;C^LRE7FE-,CTNGT*/L1LEJ)PONGF3^KQG;>_88Z/=%+X4X:1'XK/R?ZO>7
M:_CEUF(%_0,PB/G#H$2MD6>)5];.P1?,=:VQ%"R)+]47V(ZY40;]OJ"H82HH
M/"_M#L8QEMXHDF/GZ$E\K'X5'?\!C^XA[@KWR2]R=KK()/I!6>>R[#W['3JR
M="-3;^D$!K  T7BV@%33PH4BX2?2)63#L.8G.$5-R0>=0^U#B!))9F;?Y07,
M>55&\@U !/<.(4BL:0D2"JL\(3IM/>&TURHB)Z&6RI]N,K*9G^RF_G!$Z-XO
M;+%+NGE <D6Z=/+/JG5/Q">E98FQX9O-0IS+H3Y=^FT"C6Z_>"K"_".['MQ,
MZ=3BV>'].EM9DFLB>0:TTRPTQKI5FZ4OQ1N+CN_">W%LN%_W*8OI?+)NUHYW
M'2Z6=.ZO%KIH5N7R+:5JT<@[]6.>D\:="\=2$KTW.%7I&=(<'O*P6:3-?5)G
M"N_=VI"$T(6U/EZ=34[DIH_,4V>ZD^4^D2!JJ-=CE%*JV/\YWN=-8L,RJ1]<
M/#])FS3-M*UJ'%;W=WYO_M?S,OZ70UWXQQ/N4\*T>8^HJ-AE.!G>>;U0.HJ#
M'YHHD_3 8.Z<*G R(<CC.*359:WS[I? EOW(%IL""[I+!6<1"<V/OVB:Q)?*
MWUL8Z_C[F!3,"]3%JDDTEU-:J"@@0[K^C-V Q#T7$),/>.'?;Z8*QHH1-,7$
M7#>97,V_G.N.738G$A8F[6.%TIS2>Y'?&]Z\SM7\9?JRFQ ?=O-UH,"%P)40
M)S;2\I^$VL>=ZM[CG8%S]N4^66.Y;Y<5.]5BTFX)_B2-/[O^()MSI,7<][CL
M?+I1[JL\(XZLZY+A\07LZMQAG8:&;Y,CC)T.^@5QS)SSC#S>%*$?WI_WZ?4_
M>UT6>0:_-Y;#?I$>_N0&O,2/-J_9O8HSK!:2^+E%UC74,771$ MUE]IX<Z2[
M,AB2WH(B/C!(,,L0\-][;34)7V]&@LG(<G[ULXD60F,YZ[<3%WH6WT..KC-D
M7=R;C%LU[I?^^V!NRN\KBYBYW!R%]2[R0W2TQ8J6(?X*N'@5>Q^D$9K 8#HO
M' [R ^VVB+T<]@[>Y0G9B#@2YK@FA[W_E)$QB* 2<K-E&4HB]"8"V9@@"R;S
M@C73N?+3I6;NHTO%1HB;G/H>5CV&]8/+G5TM.>>*^"P-\1FRHZ\+=-M1EU<'
MBKA7SYND\W8;%_'FZ4N[B-VK%PCU3AJ/WL.LP.9R0V]![%Y"P.!MDK J:@A*
M8TG&MJ-'R$%U*(T*HR"X61KCC!S*2H0=_WZ=Y-^U<CD1M3Q\I$@S4,Y_;QY1
M;ND>!^'UW^!F#78A+\;F*9\?(DGT<,7G0-DAD(Y'TUC=<5F*+ ,FT)A:FY&$
MIG @HY'D(<-_'T=>X@<5E&:8H_R%3%D^.!P,Y$%-:W6"A3C6IXK4$Y''-'<W
M5BY(:,, $9Y"R[1@,#S8$WEL:@=\@YK26&ZS: ?;;P<\@TS249(YY^W(-Z@@
M&K4>%.91.*/W:"R>'P6GT2,CK U#<2[=<>SF$.A\<5)-(+'QYCX]TN!!( _K
MA4O,UY*R[-\T\[W7IX(6C*@@6R#] !Y,8^E0.EH(>[LTFG.^$!!^1#*GB&-9
M,8?*!#29+>G_(*SKQC(E4.AX!P;$JO8CES.0LS1U3!B@-)*DMHC[E*L\-'_^
MJQG9SC='!1V64$$D!Z",IBFX@]Y_MVO#R+8;E-^0G==8+BH(%PT$_'UI5VA"
M2!9-U&5I2D,3=^Z\OQ&+_D:<AJS/TK1$"HS$7VQ&'C/2D]7^T,Q%":U2;':Q
ML\=\D"P,\2>LFOY80*83 SRFT.1O6T_K7RMHOC(VCB5O&QRM($EU_V\LXV_8
M*BKH6$"J<Q9XHLH[/TMY9JN4")8[E-FCZ19TB'(((;OG)0MJ"$38=L6G-C]_
M[;^=DCAE#[)_C40C=,D-2M4ZY(O-&=6#NA3MQ T8GOFOWGW\UC,C")3YT^(K
MDY4VJF!*T1MM1W;[5%!8)'RVQN EC+D62@4-]P3MT0D$_*-@3;2"10*3M"P-
MVAJHH#7=8S#G9AA,_<%5HWQ)[;4;O_N]^N<T";6FT\,W%7XPSK% :.HRY<Z7
M?R*G_4W6RU96B9RHR"[$O4-/PG[-85)S\;A\YB)"BG/5<>_2I)4LS6>\@K6D
MZ9,?INA@*=<\8M$!A5_GN]5M4DOD#T7\R$38-S A).G@GEU"RR[D9"BO/<P
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MWH\".DM:YQ=>QQGYM.S*]U>J=5KU3XSW[MY>T5EZB@<TA*Y=K]I^W+7+6.=
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MZF0#2P[*&-!VFK?U+-J(HMNU_WP4&Q ;KA\31RPI#56_$9?RH,+'67<XIS@
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M=@NI83^17KQL"\$SSTE#$'XK &"E5B$O+T(& I.B5BY'2V0Q1$6(SOUV8B"
MTQQH/RW=K*HA&[?R&R 65[!#UF'R+O\6.&:B#N/-3H"D3+$,Y$S5P=MWNX6H
M[Z]:AW5JRC#,-HB\UXH#H"9NN^DBPQ95(4B07XD!KUC]R5Y-LE1OJJP&A7](
MW",<)YGZ<A&P#GL[O0[[-4)R/GYBQQUMF.!G[N/'5_[6(4?T;721EN.F7/J0
M>--3?QW6<'?H4MU"SN<.=#:G"3&7+<01/U.5(*MH+B?'3VHMCT!Z)D)!3"XZ
M^W^JSHE?GD%0JYFF;<4D$B[]R\;[=(\424%!?/G6>30_IH.2=)<E<%J';<*3
M&%H&].Q(@4Q*U)$0;-<O;18<Y,Q)YBI-A.[R%N#!1=9K31)M>-M7@TFI1V2J
M^QJRNB9A UKT+KTMT# /?KO@<,TS",L3AA:9#1QZ3]R!EW<?C3+BJ$ZK3TJU
M VK#(_DDT';APF! G_QOY@*1\GYZS003@OG-;VLNAHA+XIN9SS4-JLUSRNT.
MV!8X"]Y<>J=I>/2KX!X.'.W UC6)U+36873*UJB%#$YC/AVGB^DFR9&"T3"(
M@-](=QN:H^I"N4RQ5CI*'EJU'ZH6R7!K5"4VIK-&DU5Q9C7?NYORW \Z;6>%
MN;?H.OIWPA6NN!==JS'O#I2O)$,R(,8/>L!] N>EWKH"<7!\VFTV>GX#6,=?
M2!9I<\/3;&43.]%*5!U)>!E0#"_!D^DYXF?5,"B*>"$Z"X[0>.7]<V7#!$0X
M,,YX79,JPA8KE@X3ON2MPU8$HST)K;<KX%,I*WYK:,SO-;&G)SKTM9WC]WWO
M!'?GUV$C+[!7F]!QP>9,4;W][+V#=.NEMW;6OV^662Z_F>HE;U)YTL/4N=7K
MB'THX.AO##U?.&9&]2%Q:;-A7?.[_Y<\%1*,8RT/]O4_+3[E:O_@[],\C&+3
MC8,W<F]>AY_%P/0$![_J;"7]^8W@1KH<_#Y:,C9Q:+BZH%'RTYD!Y<NKZS"G
MA=DW]>=.G/W??MO.'1LQL.C29W]OV;&$C%@XNK7U.5WJWE%NM TSW.^:#/%)
MI-].@"-8AW6LPS*)NZ%;/+-4E,U FQ<?D1SWM6@[^)-2WE'QEJU>%Q:94/[%
MN^K3?'9I2IU:D41R%#A/K*96+R?8CKH/AM>/9[Y;" MJ)'\Y7;UY\[6(HE8'
M6W )\:C&$ CJI*2BX<L<#2BWHT@>X*18TM*TZ+A)\Z'ZA,-'M%G*LP<U W$3
MQT^^/;7G7GQA987HKJJ51E-^7%)_^[?A+D;[>;T+0'-61#VXR.S-4Q'J\H*2
M<I0L>5E)M2R+G-UK3TLU\E[<[724VC><8W$O>IR^?W?71XVMR)[=XIZ*^X[[
M+KR,Y)\45 1&6]@^-,@;\KK\;BKQ_K5#$<J?VN\ORCUZ:7@V]G*%@K%_UK6"
M)<AG]>^O"NKZ-WT,I.[>>F]]=>/77^:/,T0E:_^NP[C_DK:B9/[K'_R_P[,^
MKX3+XEU)M] Z5#AN<C\XQ=#.1G=Y3EH!3(8NCH^B $T\I=P21?7O@I.)QT"S
MK&5G@Q/#5Y>K=.>K2 W;?LYZ#;CN*VE9PY)W;I&SYAUE3GSUU]]PM^-2KTQ%
MS7O.>+A8MDD 9]?Q_PO-00@M2&[JA&_O$>I](4A#OE4^D,?"Q1&4%B&H'QW,
M2:748^F4''6-K;@6QW&W#O$.*"$@4*SCT'AOS71J6R@Z(';>@)_3&"^L]%@@
MN30NXN*K4U\WC-*N3AQN^5V.\V;KN0&>8KEUV-/0=9@*[2J.1O;V>, EW\1*
M$W<0- 'R7$T"%R$'K?*#NA$Y*YQMU+W$?@[LGWECHAZT<;Q[<B?8E"G>2<"N
M/4*&5XB, -9-I(UI>0S \0#$M35C%R85PZ(HSTLEEK]2S)3EHC=  ST,F@;A
M1!7A.)3+9R5YHSL06\0?.?78S'58J)T1WY&.,S()XH\F(P.$)E 0+Z4*7.RP
MHLFVF5=,$\W!KV(#B%3V>7IRVRAA3_5TDW=#/AFYP2!#@A[Y$ARTZD=>XHYS
MM@235 GFTI1DJBZI UEOEJQEE4F 5\ZBU-9A24TKFDUKS^KG TD9<4&I!'^>
M+HXQJ0*-EA+[O=>*6L-Y%&6\&R/.9(K=D&D7*@G$._]AD:%D"BX$K[4GQN*M
MA--KCXD'"$J0O_ $P1:<FM=\.3L205 %/8J%-C@.G!2J*,\-3Q'AN%L(FNBN
M_:C]/<_Q!YDK. CQ$C)CVHYVF3CZ4D<(.V/]^6H4>MS7EA/961(<"<1"1@;T
M!1V19JZ Q<3J!'O+I#Z#T( %$\3+\VK>4LAZQN#K"0)AK8(6BAX3\/:L) <4
M>^/KNHOLAL0'0M'22Q1%?"1W-)6HU@%J=*#V 0OI#>%JOIP0JGE_5(ULO.6"
M2(VV8CU(W8['\J/%%6!W'U0CZ"X7FOD0C-&O5^=ET/.R)<1^6Q+=%\O_BI A
MG!+:L46VS1"M&!KT =0?*#7SQH^PMB3D>K\>)1PAA<1%??*0Y_W22$9S[R!T
M"/* 53<%CK04>K/'1?:@XUOX&(:GMI!CC-S))TM_AIK.KA71<.'C,BL%8#LE
M(_4F,I)'VP[%OR5I+;'8]]"I!<,U=,QVR+%;K/ZZS]($0R>:-E'.UON8#J[8
M2T)P"JI9"0(EPWQ>B/X& M\0#"0,!X.2A1&<'T1U("9[:?[@!=0.2;D>$9T2
M;O,560]&(_1$IZ%,_FS%$GDK_B;A.,H2Q&:TV;_$W^ZT>6D9G'^A.??\#D09
M108=2KFU#M-%;9$0U0D"&FS# $][.=UA_(3PK@*'!JX)YJW5.DRQ0='3$2+S
M%M+UU,$R2C$^7_)5K#MKJU[W##](GS0:J&_W/$X=K+[W<]CUP*??HV"Y6/Z<
MT"Z84X>8/P$&<?7(8"*3IBZ6%_>VU,Q+ X,\+!D="&=C>=]+P1C>SY+0*-8F
M AX(2D5Z 9Q.JC%T2VCL@V^</9/)C^FF;?29T=.$(GC-Q:-M/B_P))=1@E%"
MU=HY('-%OPD(FAL6.H@_4:W MB*#?E(P.1W=P,R,3B ='Z3\1>M'V@G/X:>Z
M4?O"=O6;F4;_5>@.E.7S%_]N^F5>/V1F[#H[=^ZOSDW0]46Q+%IX5'0"PH)6
M'5@]="AF [X56R^)0"Q! H2W(XB];.8ML<($M-L18-$Q&<[ ]\4NK*K8=-JJ
MR!+<P\I"&<QZTF10&G1+2E(T7 9OY%C;MWRCOWY[->&8T1@LH0;1939^I(OT
M&M.!4"/H /^U.],D#I!4JI%J97@Z Z$A5A=YKA40M0G[^Y>=LD\O,K&J$DPX
M0G "_T+4*QPNTAJ,BOA7PN6JQ)VI3-1>D)2&M$255T(^'8.SD[OZW%:LUDJ)
MEB+WIK7G(CC8BH'<JJ#%%1^H3@)4S5 M<)#.M,5TD#+RS^(M3H/WTTM^$(\T
MCS209"'.VX%0$'+DU]RN0D:#,LX )[VJP BS_4O[QX(;3WX@&ED=-6PS ?FM
MHA,//<<"FXY#4@+2MEFBQFO0@)'@=APTK:@HI_MHWXT6D!3P#L).U%Z@NIT'
M5X$&>@<X]'/X49=AI0I> MQU9!D.E\=L*\NNG&Z@74'<Y*A0I46J0R@X?H:S
M$M$?574PP67P;0%VCL.%I_E) R-/2G&'![Z$_DG-%$!D4)N/21/Y"A*"&)YQ
M*>U\A 86QV%3]PR953<XWXB?#_RU</:^%(^5B 4ND)*T2&\Y26@-4BA9VR!E
MF9(5%S07P L[PN-TL,8&5VY!=_FZ4H+4>2Q@ST"K(_=P=0]R>&OD+K@JX7PN
M\Q//UYO3<0>_^^VKBS\T7H<4J8V.GQ]>MC8=G:PB<26RN7:EF%LCAR\Y11&L
MIA$\^2P=2,#[B(")]@OWB0=0!R11L.-SDA>>H1FS9CK$3T7J4,!+ A;P)=-G
MS;8&:^6G-["4\=[TOYKJ0'BJ>J_XSRK#5K>H^!>+;@;M;LJD(GJ$^]LX>E&*
M9XB])(UUV"5X.CL_GWM$Z,8O1'^>6G&%FH76,P4F:1*,STYY$"'X9,]WIZ3/
M+?R47HK;DW,WNNR+-^>+7U=,V"VAHP0A5)]!8V!=USJLWI>23=V&SV46[81X
MX)'N&U0%J)^+3J/NAKRL.BD9:"6B A08KA Z@E5"&8H.@AG00L>D)62/$Z"5
MH/)3H'/>@WC_%Q?Q.(^^HET%63"$/]0CEEL0*D%.)P$'6AE^EA_4189#+-[F
M;.&Q+[/KL+IUV-RT\#@A81"E*]HR2FOPQ$"UX /J-LG= U@27:802T6 :NU?
M$5M-HA#*(:-$;="RZGNB@EAO9%O/#SC;?V4$DA?J_Z H1'.RM!8RM3@"SRP?
MWFIG/#R%HXC:(;H"PLEMX59)RRS-X")U@):"4H-BN@K$=2_QY<Y]5XW;C(+\
MR\^P5YIBRD-N_/4I5K.F!YY# DXH^G>CY=%!M%2.''4O0:<O>ATF <6-ID3Y
M8.PVD1M ZJ)J@O^]MJ.,L_+^7EQ#"(.D!>B;6#7J5FB\$[4K_SSH4%?I1;
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M-6(.OS(M+6MH+ E]S?:E&\5+QS9U(E)0FI 10.<Q.^&;V#[38CCDRT7+B=#
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MG%3=Y"?O_XJM^AKLOW^A[Y]?3__>++?_A[7VA1P,+*%ONV[Y;92K8NQ%3&%
M[$B HT8NEUB<E()-ZCQ?LOQ/C2PKK;/ZU' *8E_TM?J0#W);SQ99:+L/98=.
MCAR*4 4@S N DV*=F/SZHI],VF+,8_\(FY& A_U5;KJ4P.A@+CB<4*JE%O'E
MV)PYOJ"V8KYLRLFT)[AS&[T/'WOYVG M?GK3T<</=.YAIEKM,&Z_$PQ=GFQ8
MF$Z\=TK\AK6:2M5U_+T.0S\AK.61&R>HWW!K']=4_HBKQU2;.Y@RN*S'W(W/
M%G/&I)")TT/*P$*&6 ]/X@?-8P0)1EWO8^++(=(*"3KQ?#JOJC(T+Z_1RIO&
M,,N^@].XVX%[[CW^,C_O#ZI0=X)><KJGW+N8M%,5_H;SI&04CUR'O1I;A\W^
MT8FJR42>XLF'(XC]ZS!MI%H"*;X\9'+OVD.Q7#"[?F2C2N1A,@DT$PQY=S^L
MBM"I?>E-?3P:YSXNO:VT]!O]*.BRZ\&1Z[^'2I>G77-+]WU[V.JB-$BVZ"S?
MYY1WL:ENE%]?.L&9LLY(5L"LZ.J<V.=1ZI9^\&'O@PN1@P6-E\".#X81SONO
M'^EV,6^Y84N& LR2 ER//;LH??_?[)RZ*NG<N)NWMHP<F-^Y#O/\EN<IN'<@
MU%]H0-CGI^W0"KNIJNOO_7Z'^0[X/.E1HU&0S+_&=)C*-T6A7/#"C;VI@J!N
MG.[A[GZ17?%TBV/:U*!+)C>I!?(RJ4GBMZ9PW]MDT'GHU"7-MA-?QV=7M?YJ
MNA1>U2#?[GEN.#9<2?P!)=N'V@^=#D.OM$#%ST.IF\ L=780W03+]\BOXE#K
M0IZS12'8S3.-[)322+[V[*S9QE#;)%O?!U]=9]5)<LA(?OJ"1+@LA6$=VOOS
M1\%1TOR;I)_CIRN_C;C%F04.>+>2'MR;OHB^^\&<-*896.M,>WYV^-<Y\3HL
MH-6I;Y6Q=E^\[>3'W0.F5[9\S*Z[,/*,#=;F_'6Y@&[X^M7G]XR,Z[JJB1EW
MQ#T<Z3*O9RG#@4Y6=WP/H78-??/Q.+4G>^!;KH_15?\\S:>7S/+\<;%J-X.?
MR2KE"RTA,_I6QW)T%SJ-3?#;!=7Q%C*K-C\1E )/F!E$PV!S''LUO?I*X9E?
M!L/UV#2ML/1A0C@W_I\?GHF=[)1FW>RZBS@K^+=&;&WYK07"*4&[W)1 O:(*
MBNE":0$QR6(S@L&K :K>!18_7 $B,;'*Q-V0WF"7;4YF>1=_UJ9A/S*";V+!
M*!@>?C=,W16L_K&E_>N\VD>0@F62^@(-XM=A&NNP9E+'XOYKXI.-'ZYWK<.N
MJZ)_V[$\$:_781U86[QTO0/NU'S859Z>_M"9QOR8K,H@W#7*>#*_N>T@H['V
M]#:GV^_NE*1O-K$7&A%V%)CK:T7E_N64?$\QYL*C@\]2-PA&3JN[;ME=?<RO
MN<88\8J4$A[%4I&HVJYPW9E?L]2=$O(Q,6"XA?AM3.TJ,,@FJLQ0+4!T(C*,
MQ#\2KB0Q(ECUZ4DKD.!WD'P1O-_2UOB'G-1F&1*N8)M0]5$#]1Z870D&2)WH
MQ$;T9J14-;Z);KN9\H*#4YZU155)IZ;Y)3@QK(IVMJ3Y=@78M=T8:. ./KNM
M?;0N!$B^R[Z1=^.Y?^WUQ[N1=!6'Q\_NS^P__X)+>^1:ZGR^L@G@#GU;\4O9
M_C+7L#2UQB/%/N]RI5NIS0"]9;NQ895U97<A8_1ZR;%3K?&G:^_O;LO]_)04
M $\JN1'5^B\&B=.:E('=1O,CWF\72)6=^K1_[3YQ6V[O@^L';+KKJA)SRJMK
MWQUQ=+':\&7Q.65C=02K&Y%M1_18AR5]4#HZF[N6=$KW>D267NJ_,:)]E;FW
MB0<(H=MMUF%W/RC)-$:9WH2Y;(X3/*]>").O@=Z;%\5\L'A $A6..L9P?"B&
M%?P"3V#<T+D\ZDUJTL23^N&SC15QLZM?$6../,W=6N[O;3JDO$9R(IAKF[=L
MNOMNA;FQ !U 3CIK^X&]A]&Y=U'/:KBAT?%LQR.E>?_@B2SKB*:0[NT;&RK6
M87*[N$]HP!NJY<:Q3>5951U'1>%2PBVO_H8K'-UTS\?H3@(OK*NQ4*VI,,*F
MJ>&VE-WX[_S<WP>VM,TV7]O4I)*T:' 'IG_WT7V8\R6LBNNV9Z]^=UMHS!N>
M<$[ ZM[Z>J[2X1/R='Z]ZS#*X=YH 1!$A&]PU$C]B*ZW/F+T0<W8$NN_)_-]
M74!:))W_>##'NP*)WN4$];K$M-GLV80WFXN)B(X5[B=^](S)]XQIRL?6,=_V
M%+:VCE?4A)O^K$9I0*Y>/ZM__BPMXL]\C[WX*<*.,7 18Z09D.=X(W+I=0)O
M=.GKS<T1XS>/7(^+P)H3NQ&_0A"O6>$0$WZS7.(RDMUY&T0LHHO=FS^Q*. /
MB2P#3OU:KCFB7&VD:PI]B6]\;_4HT&1,_YXW>^24_KU3^OG#WS+&B-ZM 8^\
M)YK*W'.KFTCQUW^.7V^K/W?BV.3_U\#*^>_3=VQ7_O1)^?R\:;WI]A;= \>F
MK+\^%A2YV.9ZG5.G)^WX/YR=^5\2W?O_*3,K%S(U=['4O,N%S'V#N[K3THJ[
M3"TW*G,E)3,3#<$E]X66NRPW*C,S-2JW4@,5D,K*71)3!"USRYE2G +Q0^^_
MX/OX_C#S$\S,.>>ZKM?K^9@SYYSYO-AF6+!12_YRWM1[WL4-1KJX@^42AEU,
M2EY8OVMBF%9W=,,/1ALC@V_0JC&Q"LOG+; I>=>)'D!A?FN(Y7.@B7D] GG:
M15[0.="0<*]7[\[U-0U]T8M1V\H;$VJ_5_065!B9?)E\DPA ,N*^6[#CD8R<
MA]J.,7V8IZV06Y]KLSV@EX(G9P D/+-VKW?[L2ISCNK2NY?A+K:.3ZRK Y]@
MF._KS(/4]KQY9K/'I<OJ?I'P^8#5W4:54Y'MP)*+)=8E1"\T_/F=)P[#_[ZW
MVEUP*N-4H%)(2&[5QK-5_1T[O2D#S_60#F^4O"ZOV>6@)]>3[.BPQ-E.QZR4
MK\*B:<-RHGVM@.BN^*BTEZJ(VA1)M^AMH*H28CU!?O;IOH8COG\#D[^3RE[5
M\J:?W.1;7@].>A(APC\^LL[G15" XD&3&W&$_MEUQU,*M4^_7X4A%:YM0,R?
MGG)9ZMSPAC:5*=V$KY+L@OS%IV:Q6UN]Q/M(8XPZ#H>QE?2V3 GR%INAY_B
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MY_<.T9CBB.X;D\:6%RT9SL6>Q1'E5EWK1'T/KW4K74^E*3UWVGUQTS6?!N9
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M OX&W-N('66V&X^LM.X.8.+EVYHI'Q?Y(^6"%0GW0A#1!AH63%_JHF1<_OT
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ME1C9?EO3P';H*?&8Y7T:SDF3#_B3-\V4;8,J:43DRAV2&?'82A%**9SZO*F
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M;[[P..3]D+"C6_"UO)S .#E B[.(]1JR]8]XD+%\9" (W^>*D'J0<W^0O_H
M.3_+K.U>*,B5/8S]MG&AZ!AVP> 2D2II92[6-?G6\42]#=VG3@F:5F$$CU78
MLL*6>I3ER@LU5I#V2CEZO)2\]=*(OO4)8"A%?(!0+4#G6D3;:CX;C'+G+&0D
M=E]M=:V-L!-^%.K_'>'7>>/%C,_% #^'NCMO5:]?3R5EES^@W?D!VW :[F"D
M;;CYH.%?QI>^[_U I(G/2G1!?"?F*B\ H5SQ@B+D,N$YU(TD>\E?45@6CY;N
M@HZ?P*>3G/I:W8H0V7&EV[N]6C!*A";F=8C2+C5LU DMU^^\2QLU'3[%.M]:
M.!<K/@9EBE+3)O!I,A+S8F)52$ZD;JIF'"T#L85D0, %<..ZS)PQSS_-C"F"
M9<6R6(5#^'_I +?@4DM+\3S<JZF?>K3%T^S._-.*ZSL.+$;VE%GO8 JK6FT$
M-]W5TMA>E3;/"40[>^LX@% TH%;J\<GC9<F!2$3 U0@F/.N_W2\S*OVN?K$J
MB1"&;;1'U%P\\9"/-/^R:6NUAH7%<=6\R(O.K_J/7PB:_2).=M>%N1O=@,L(
MK671B)&8>K!<>\T:!X.KDGNGGWU7D#,.NZ?PV,[WL3/E/7S=E&GJAOD>Q&/'
MBK:/>SBOWKH4N*%*1)-@F=G[8[F8T4/#9H\?BHXN'_-'W_IXNWAFM'1N) EQ
M>9X^Q>$WP.?89%"*O?J;D4G:14@3P'-(FPG=7B M0X+YWVX6V^F!GL> T:F,
M.XJ!<7WO=N1\%(4="M(ME9[)%N[:3]%&OS"=_P<V(DOV+= ;6-N$P+==4. T
MKQ/_QJ%S\QIJJ]EBP3'.OEB.]F0PPS6V9_PZ]_GCF#;T[G:7K<$#P3"UCP2Y
MGG$QMV^<T))U<4Y%UX)Y=K=7V_B8T4S]\U<*RJ$7[STG4)^>O>]!QS'OENVR
MF3U;S/(H'"K5\'ZU[S]+4FP)Y-_N^!5?T&WU*QKE^#1$;PM'N$>Z:\+EAD/3
M[7%RW04U6L8; L.X_>A3W;6WM]J6*8YXY)W9.%C5I4NZ0&8:20=P%.A396=L
M_0\&\(2T.6YRCB,ZLS([J>'5_@U3Z2QCY]R)L%0&;B$/4<=GH0N"3*!A 4U1
M8@AT%]2O>+&#M(&FS"7=))P_UV;#N8-& #O_H2<^ZLSC;ISQQ==<JC-^/<+$
M7EKZ[J57<MO\IXN'SD<A6DQ=;MX4OY=4WM> IH68_"!Y2%[6@[J00$8QV5'"
M(];,W_PV,BQ<)T1:.,Y7@\J<7WM;2IP?-U3I&-PB5IO[)":Q.MSC%(T)%E\U
M?,31&IRP@)"TB3RJ:G)7W?G#!,W=G"\G Q!*P$?X[E-/-5T%&IZJA=RNBR[E
M6N"E9W?RV%=VG6RLR*S*ON5A>^;0#Y(_QP7=@=(*)>G$V,$118!4E5!XZ\O=
M[\%W8FAZ$S]>3A+&M"<8-?]^V#W,W1JS_I2Y1L!EA&GTR1+&*(NY8=JWW.?8
M?XRS1H5R9I]OMI%FDI6",]J\_TJ4UTL^6$4?&.,O=Y%!C5\2!G </?SON558
MQX$)9HG5G_67L\X)DD=^(I15&756+F'Z>]=@).H4D4^W),_ 18*"2_9S!!2E
M5=COV2^:F23#BK#VUD-DE\;&C_.NN-F*TCG:%=X0>G^0+70H9!6F:YIV\P5#
M8M[S@R'IB(LGHRJ_*?"*1Z2_\-+M1:&?X7(**S=4CN[5:I]+:)N< B YJ8&[
MV(S<TS[1+;%>A:FB?]VID*G<=>D[#AK\E_#3^!)"@;X]F!HL>( 1Y*D0VLNE
MV_A9<&GXF%$?_Z?%D]_3JS K??V&WC$>16J$O9I$/#3^M85\OF?V4?5,P6^L
M#+$6SXNA0[T;M1:W99""8(9KNBN)\'O_'=KP+C]30?GCP<X3P8S#*9U[X*[R
M)&*31)TFPC0I&DMW@14E:\//VFM2-[DDA>'4/GO<!A*:XIW6;>U-Z#]XC4,/
M9]TX^+RJ^QU*4M^2^GU,L3I^5.-#J[W50;=1X&-J^+E=$Q?DC7T<O^ZY<.%
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MH)+[)Z*::A^0O$3.N7(]/N7].2CYP.#O7D'36#,H[H&\KX7)0:O?I$QSL!8
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MO7 /^/B=O?R?1LL&=^\OVR]85?QAST6DKL&^IKY06Y*A8-_@.]4?CLCW+_7
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M*$C,X <^R3S<;PD2: ^99]^3<4O5H1CG:VK^#0V&U^JMI)_%84D(28M?R Y
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M(*A*LUJ03L2A8(-'LHX6QFS10WC/4C$60RH0$F=D,J\1V!@*%:,S1QDSPII
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MF"]HR!$S!FB?)-SE,OW288Z8MN81-D^[&_I15S'-.'/U4]+/M2R^5"GMD%I
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MX/6%(9@YZJOQ[H'C..>X)E3+"I:!R@!?@DF/J3AVB6PWAC66ICK^Z-8@[H$
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M@$SUU#1+I-BZG';I&XY0O@AGH@)-B*Y![S0"6Q[I?8\ZS3V&4MPJ48&9^Q(
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M='3==%1M0%\RQ99^T:2_Z%9JJ>EGJ<K/A?&:Z"8Y2/\CK0OW3,Q6A"MFGK?
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MDUDK44=98:L#@8GK=:6S),6?D:43T4A4IT]<#I@(Y,"+4[A9\ONIW+:1%":
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M$+-+MS[PO5!V5>6+VUCYT--1G[?B+U5#M7 &W@.Q$-L)!RU9W\%]L 1N>"E
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M8GWU!RRD"XX1!GT#,""M4>N7430#!@+=MQO@&+\,>/L,&"+FSKP#*@KM?[(
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MC"E+)0YD0U:P<"!&<!O:BW&1-!5'R" /8=P#_2X]:L3IP@THFH [//!.8O_
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MS(*1N4%Z*+X%TZKH14-6K5R&KI0:A3J+Y$Z-X/GPH?DY;?H%J%.SE@FQ=)?
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MG7X(FPV"[8_ )(/'&E/7[8>K*M<"&]9SOL<N3M@425()4D/'[K9]7>B\=$;
MN?*<M.,\2/ATVN$VO9-/#VM);N$E7VI#!D290KKL(^8,2^;!?_9V=1<"M"L
MM G@R-B/>,@^O$Q)B<4=#@+SNAM<&.&:ODG8I"X]'?8\_SPU&D-)>,&>!JS+
M$8X=MW#4*"?$0W/:T8F8Q/P)IP?#MX>]>[(.'YSM+Y3K%Q4I$ADM^CKA^08:
M?SQ,PS,HY%*9B?5<<XFTO:&?;Y:BI469E%219T\!S&S<O173HJ;9K7E"= @E
M??\9/*L+=?9WXRNNP8JWW]'LSPT<^"5=RZW#E2"&-A()\%+@D[I=^7(U@%6
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M))#2K>^7F (4ZV!Z6G3Y%_1UPE"0K#_G.I([B<]8H,(YY5<7IU00FO6%Q&T
M^U!EE^M]MH)RZDO6LN:6IC/_G;B/DHL0,,\*=/8OFJ%N" ?T_.'RY# Q)J*
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M9R5NHH^;FX=N]0VG#' UWI3$@'!= =0] H]A5\^@Y\>XQ<OU)K]3M\\N0K]
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M9P=;!:BG5EM0DRMGT*=(9A_&ER2X2_A4SPJ2K,?G5SJQJ%,4G4Y. :[IN4H
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M3CX=C55QV)\K(X'+"N,UJY8__MAE3P>G3;B_2Q]Z_!8\P$W\D3?1[=S<^=E
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ML[;)3/BLK@MUITO_I"4U+SHAHF@QNS7FW?(#^Q/KJW <BI<&?XJ2<^8:);B
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M;?-5G"(>^9N>B=&2>$!LZ.FN,.YN/E-;/580&5YFS+9(._+([\/][NO/K^M
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M<$:;//@>?[^I]U((DZZ\<*"&#^,.$4E!IL/IT5_\-A<@$G5VUY;RKS\(?[K
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MA7^/2?A2[07>NLDQ<>)8I//L2\GWGN_QP?BZY70IQ-<[O\"DM;<5U,^N>5E
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M.R?F(O^P\'NYZT%G/5U7)_KP8J6#CH&6@NP/K1L_-*)9HCR930@;EL8SV/#
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M\YO/)L3E[<8!'WQ:8ZU&SR&GIV&3Q-2E6&?$F?%G^<[M;U)FK@2^B=(.]I6
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MDO2YQATK5SKBEG@VTRU,NM#+@4 @-R)Y,G&,EM[E1'L&HBOA7\A';XGD.,X
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MU-'WG+/7J_-<U_OCXWHNR:(=/BIXOK3"%'S^6>DB%1T+Y%(^/%)//F-H!96
MA9;9A:$9G,^5<JNS3E 7XAOG#\X?,E+4#]XM6VB,BIG7:_$D-F6Y_VBP_U,K
M-.8NKTU(9$XF2@*!)BAA++K5A88)%,PS\WFRA-- 9'H-3C'<"I&#"(E(X+H
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M(-ZF QSE)H'!.I3(%(("/@*A.-^"ESB 16_L ]]*G#/:A(1%IA:0>ZK; \^
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M+F[/$)Y1AM]I:@P*6Q:W,",GB)[\QXC+I,EJ"JJQ)55@&8Z"\>SH8E?;8E_
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MK .-%\6"3E"YXYL0]G=" RK;++"<;ISFU0W?UU:P?%(\=AV_"=DVR*^*&<R
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M47>65^@=%!S<_>UP,J'TB=X__TF5[3P->6CG2\C3+.KA;&JJ"6#>3]RUB(6
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M'Z1[/&>TA4I./0AYC!*O@N\*:K.@LU93W,CE>6YDBK\J;GOXG": H#.G*QR
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M=-<7]+NL LBKV?8'KD]OVP@TN5J((:]>7#*JV9P.FVWB7)M$;$'<Z"3BYTZ
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M*IZB%UA)\11-$JL,2YTAI%)WBT?+Y$>Q1IASP[&$='\]GDLE>S7].V8O2 \
MF'UJM)4M&C_A^X#@^[CK F@RK3%RN3\.2'1M:2_L7R<,,)6%CMX'7[??^[D!
M65!\C[_QV&0X(OE,[C]CAD.A6AZ&3>=AN_^Y6['G^HZS6[N5K_Q3)Y_G6R1?
MJ9NK*G/W?."/K9)E!I__#1H_Z- 6\,A16?_.5'DFQ_'#1#;):YMJ0$-,N5V.
M$B?*HYJEI.L>:,LNT\VHU7:)J4 5/%]TB'ZK6Q.K=[4V^M)0Z&BIY$!7OH_K
M[5I/DZ^]WL0YAQ:/TV^.OG)TSPNMMI._\M#QN/O$/Z+S,RXNQXY9OC=^'_T*
M1L])KZS2L1FP[.'OC[Z7H[+_KL.GL:7N',8$7Z3P>[5NS<9D,Y(O]OZ_Y=#^
MUW3V)B</WCVZ1;7D+FU._<%"2IGQ4K=PL#ZL_7[KET/*-Q-91W6[-:$V$A 9
MN2+RA?O0&S=_/WA_&Z)[:G5XW\\MYY?N72SB_#AGYSUY%OJWUG_4\'-R8P?[
MO"VSE"%OFI\&M%F^6#PT\<33X4T=5MUN9799+_&=H&9Q19)9Q4 >$<2WC1C%
M+UW#6:):@Y>=!*;A-,!S]0.4WC&8BCEM6"AP#V&V:1/$%B&3-&6X_H)/' 'C
M!71VXV1B&5L7QT*+43DW#'X20;M8Y^!+72VM@- G(N7U=,[W]QR#9 0#,3W+
M]Q ]QR(PU\$4#F.Z@@U_S3;:BSFQF1&K,.?#:;.K?B**Z3N$'0#KA:9CX8^G
M!C8@V[BBXK\F8NM\!Z/"J-N*N6QQ:1 Y!$!C-R"N4T^GOIE^U+39]R_NI4UP
M-TU6:,LE[A2>G12:LPU0'!B]$Z<82H7P_-8*2F,YD;M\P=&Y,20OJ1#?LC=N
M;N$!Q]?&'-DX>:#YFB#&[);MK1=:'M(L)AX. 2,CZB]C$  .;PT+XN#V+)69
M\Y0H>)-.OR.RT?WB0Z\4E\2'QJ\VYYAV3<8^X)E5XDXT_W)]]D:OX<K4= !(
MWYO:X]9;$QNEQ"X(.+:[[*^/&-U2_3O!/BUQ>,=<BMHKZ^N*TJI>^3XGT+IZ
MBE)YU0%YUI<_FRQR="?R+]LI]DW4'AT!2\("@)A 6T<O]_^TT_,^+7Q_"Y]T
M2ZW0<2:^6>U%[%GP00B5?O73%,3Z8&YWF3F1.[6R38#&Z /F66)I\3BMV8[,
MR^6?3V'AET=JEE3BRJS '34?/@B5<9)G@2_T/N7U&ZLLY^ KP]@#8%-O\3<"
M>?'6V?"JJ0\PP*[.B:V2@@@WFJ&PM;MQ!$U3< 7PZB=":-=7"32IEE70IV-^
M(%(F3%.#=W@J4VA<B_[!F6SBRBK29W[=I86A'A1/E% /\@;OF=1I(8%3P-N0
M-BO3_/POI=4+?$3G3&0/]-Z,2K]-./=Z/D!AE^7R"ON+W7UV=O).,'H3=A02
MNDX_]WUH5Y3$"6H@7!XWZ(FY_#2Q2.;M?M]D=D#6279;#R$9M@/!-MR I-D#
M##:Q]PNOH$-\F/<$K4Z':P)/0 +J]1T)-]Z6T8@;V9^71X?V)SN-SOJ'>D+J
M]/,9F1PKU2Y#(^@^PQ,E#9?-4 4#Q[V/!@2Z2;I!U=!%KI6.7:/T,X0FTEK"
MS\HL_MH29X$=I5#J.($?JKE8Z_A\T17S]PN7@[=QWOD.-;S<S]GSNWZXC[JY
MIIT?BV%56]K>IO_^!K9LXI&DB!:#RB0J&'9MX\7QXT>M=[ V(* >Y2Z-54)5
M!).XB.D?WKS0+H Q@),"$_S,!S5/\F[B>80>JR^5B< OS\GGXS^1LJ K5/+C
M4F0(F8-26+P377I"(S(5!;A!9UJ-9B+Y0:(2L0[F%'BY/F08UV.+N('[L,I%
M]%M080O8';@,N!2H+;#$]4Z B?7^(=^79J@IP%#_*+I,K"=[!B:[I'@93!X=
MF),.UW/XU)'!_56VQ,>(REI4:..&XCV88Z_#-R"9">:#$9[KD7(A376, 2+T
M;,3.-!Z<?^=!OC"Z\NR.9Z'B_47I%1'[CCU7A.S.RL;QO41_8\*?@7@[GDHW
M,;5,:[C+BZ> S* >;ABWUG@:YIDPV,?=.ON&.P3P&R5XH<U9ON_J;JIE%?3U
MZ-<IYH7'#YQBJR+Q!^L<QN9SU'<])RV+LL+([GGJM;!0JQI3/T3HY4MQHH]6
M>0SR%ZDKP+]/7'.+23KO+^5Y/$G.B(Y*>3Q7G)N%,ICX1!*.B=^AVD@K6S;Y
MC2)ZA$4(;XJJ36B2PJ/ U'+;Y@A9@'4\*'UN'XB+B (V,1B,$IAAA['RP"39
M)$$S[84_,PRK/0Z'>8=:?29EQMCH^?"4TZK03GZ-P+?L:NC>L.^^&!Z/*Y:Z
M+ @1AHMR<3=0<F%,]4/#7>;!P$F^KNC9)CNJ7 !UV-"[,(66R*W8$5CS:KI8
M>0FN/M(,W2(>A:G/ Y1>HSU?.UKSZ\$@Z@%T[@6088YG35HK\:21;>*IUU3D
MTN,QOK^HZ$8]1LNL%#!FRV8/TIT#^\OV P@^+AES\OJ<S$17DL%'9A;%Q*).
MGZ.FC]4MYG_SNSVS)YWN'GI-<$[NN?S[K\R&R.6D\A"U^?1FZ'0M*_T)&Z<*
M7@"-^Q+,BH E^L6O<UH II@#UL"@BYX%_*VSET8,NLZV^8_I?U/VOF%Z*&/5
M1;GQ^6TC/[F#_QP-_,JMI'\OG)A/7J_:.SH4A"]WDBY^D>CX<[QFLDS-F-Z1
M;SEA:^E6YU*IY%)G32KD?L;GJUYWMGI4OSAQN\^J,=_Q=N6[/<7\BVE/?P?L
MR5MX?RDJ[PN1/36 FT5PB<NS A?QN%@.^-(.I+B!^#ITIEC26&!Z13PB/@Q&
M&=#P&.U:[%BAVFH*)G;3%Y\%"@C<UR<O4($OV38E,X/W,,K40\-"\V!.I#P8
M?6K2VCF>S>_L*!;2@(NKL_%BXU!4H_(#'I)53^)&RN!ZSC8C/\QM0/@-;>#!
M=1*=F$&5X3&7.ZN%-P1!%'HF[$%!@1EB'U4Z/$2L!J:1T.$#GIHR<!V4G'-\
M^>Q"7,)@^F'1ITQ^J*CTV6C7I6>;,"-[:$08Q<))8LQX!871K!7-;V/]FEL
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MI9S%@($")#!0F,1VJ/N(W1M*8<W*(OH2#"8F*ZLPR!%K6"(\+8B,I8O?435
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M/>K26+]BQE,BNY<=S&-5N]]JSROA6E\ANV7'P>-<8\,\JCY>/E1GJ7NIT/K
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M5W8+3O5CZ/K21[.7$<U#X7DCBN>GZA6OM(AKK$\"LVQF"D9#@DZ4 *$]97O
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M:>GD\_\]"TGT0D*7P/2O1JP6>87&N\5-T,1+HC1*.%'5T5Z_0ZE\)1])'7"
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ML>&R18/-_YH]EFI+#SY2I/7-R5ZG[QK@'GZOGZY]?6FZV\RMW$Q]-O*M5&_
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M_\ T_DBBW9:N?V=1N9-P8@_GUHJQ%N_&X?<-,T;[G:]76X<)ZL2#C;YSQR+
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M+,FD[WC*[,]40HKAH/?Y'(<3_-D8$74A@+SN)$#>1M"6XP46C:%2U.&L'[D
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MPW:UJ%LVC#!04E^YY]Z"8:_X R0+L#;PY<+*_7^"O>[4U($_I^TFF_))#1V
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MC.Z3C*>*8B6]N<8@GJ7 (/:47J"C4C"76Q7(DA92-.J^%;@6BZN,BNN D[3
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MN#2J#$:D2NE-6&3ZQ@%!;T1F\.66RWO8C;91-6BJ#^M6LE%5B85NN\MO)[;
MG\0[[T(H"EP4[Q56$XU@1F?#CX.ZC,(N:A+N(%\:HP>^9<0Z]9:IC47N0B!H
M ZO1M3K^Z:NX6[/+ZB;M0 N!G@G[/[1]^3N47_SWE"()V7>CD+(DV;>95DMB
M0BC;)&2+L69B&)3L%,DGVU3VQ&0OQHQUIE*VL80P2UF3N<MRQQB/OL_U/-?S
M#SP_G%_N^SKW=<[[O-^OU_MUKON<][^?=E9UBC2OHI+^U:*41IL-CZT%('W3
M'H-2>VJF'$QD96U\V2DF^>V8,UH2V!Z:W:L0A&8O5LP_"I&*9$+3B8K@'CHT
MKI!ZD7Q@M%OV]K;T+ W5BT^#-V944/!BOM($.W\XJWXON9'^):,GY.*ZV/ZW
M$'W[%<5<_?I;X!&4S_Z@<\M8>YD_SJYC0.SBQ%AZ8<BU'FIO;W^03D5ZK^,-
M7Z/PQ7Z3_Y K-ZP$ *?*,J,ZO WN;7"%6/*;RM&-)ZE/7_[TMPVSM:RT>UCX
M]+7%SF?^G*]>7 EF(7]\,MO/+0]&='X0K'QR_P"-?N[ $<&+%")<\%,9_K\K
MTYO1NQ#DL-7G#1)^>6M)U/;RF?][^/W_;><'O?YD#;#]?%\<H.!-OH=0V5M#
M<=$"%28"22;0VM"8^^MEKW*;4*1_MZX>H-'6U]:V=LS!0>TM7%]AK"G<V?ED
M?=,;XNIRL B)F5/\[=[F^M;V,&2?HESL;1NC><46SP^;<T67Q8=6:G9T!9<Y
MAQ[(,N7N4VIYD-C%U#.&M-!0M.SC4-Y-'ER-AJC+UEZZLR_NR-'@>_.2/[4R
MBS+/:NU"EE\<_!XHJ;C'9VV#F=$^IED7$:\>X8=0,20H\@QG;W;?)66##197
MR 9KS*RR$Q %",]W(^QZP]^M.\]2U9NC3=G3J_AUK&F<GX.2\#Y#9N:>T!Z=
M'<Y+WQA Q$;'QG&D5JPN&VNL?.>RD L^:]$?S<PTW3D5S&T@Q05A/C;57K2Z
M+ YA_Y\:V/\:? ",O0ZMA6]-^[Y*@WR+&'C)U3)CPL'$6)1UK$$?+_'"7W[<
M^KYGN+BO_V^W_],,-C[N8#] *YH4^$;V#03SF,; H6-Y6[8[4;:HY?J5G9@.
MG8,K\2W4=)^LQ:R.+?NS;5Z3UQ]7R,XK!IV'E:C(RL:&U^\C6QR^&$2;]Y-4
M.BIP1B#V@>F^-Y:UJ,MKCD#WG$L#V>KN[6+[_7+L?H<KM98'O KGJUZ>'PFU
M#4G[T1:*:;&$/T)^;JK_-1YFE"NF4Y!>=O]D[>5[[UN)?:O4:^W;Z'PA+]@U
MLY4R,:M??\<N@,97,J5LT!^4#F?9N9U34D'0LG]DVKKLX\E[S)2QN4$R[N!)
MIT;(]($^<<Y==YR@!D+&V5:!)WNPU1#97T%$VK!_BW-&/65#4MINV$(N'7;_
MPHNS:L<+$Y_$?7XXKQ!ZYF"XO5U0PI6,29Q:T7O';,0DTL?[5:3KK&(FH8HL
MV7^?42)FY!^$TS\[9QNRU980F1IU_=Z]MK2F6LO*/?@M.-><"1NYI'8LHT1
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MF.]"3J@Q-O",V8>P4R __:L.$E29C8?[(A[@1/<0P7MV8I.&6K'FZ8)F>+H
MFP\;768/@,1H1'*QZ7CX]!4$MSO&!:0P!/FPW><7.:>:6:@,KU'IH;3K[P+4
M[)[Z 6*\*D[\ULI7,IP;YO#_V=6@!RF.MO;%^[^Z.[EU,H-#>XTDHVH;[QAF
MGCKY_L>ZXJ^1PM(R.]5/DE%/@L.Z>V>$JS0#I6N?%AF)N>G:E<84<(8R\244
M/UVF?ZO_Q-1EE$8OG=2PK71TFG)D+'0@W.?WK<PEJ6P7PSOAELQ\_;@/2G88
M'\IL8U87- DN%BN*$0 $4[QR&./D%2Z&4RI1"A2TK".,1N!%T"@Z3U(-VYSY
MY9Y>R\6*KQ-^&Y.9615?/U8BG8DMU<OBCD97G2P%JD(J=B&*V,,P87068^/E
M=@PZ;,-[)XTH$X ]%($"555^CJ*8JP^2Z)$=J+0-)#=,< %97]Y:786!@2@\
M6*PY0;D.X!Y@S&O0,C8DUNCZ:H:)+@MW'G";*7D!7G08::P1_]6](#BQ"^'P
MKFY?!L51H#*L'1#<N#*F&XBD)77M+?N>',2EYMG[D0ZOSPIAM$8(*$:;J>?&
MI=$FJ]RQFA7[CE@1?0Z<"(9%T\;?-8-W.&?&*4DZ4(%>ALO"Z2MLK?C.*]4]
M<^.53]N+Y1SZ%AFB\SE#G_VN-,KK19S\)/DZC=^V\XIDOM9<M\/#'[(&57?>
MI5\L^QF,RJU0N4EN*_MU>XD^?PCN(=/ZE"G=^#=_(\BI1J:W9<>"K0WB2C%6
M+,%''(7S96!>YS..$FL:E_*=A>]Q,YKM(NJS1A.W/GNDD6'0P M (U_944NE
M-(V1P8=.QWVD>)GNIW;JB?P8&&%8/5;I"U,S21B-WWC.<OJ9QYI!B(-V6Y."
MJ;L029/[Y;UOP-N"23F+V?Y/ N1%W@^5C*[[L=TPDW>>!WK3:Z("GNW_I/2>
M$TR [E'$V$XM1G];,;8+SF^BR<+VS(B.D_QP7\.Z9EDV>[9\EHAB"![QLV<K
ML\3S@+".&1/6+J1W5=S/,5)"VB<5;P)E16$GD^C"[A.SR])C!7"R)B_EE3G_
M4^=A1 -@S.'M U*I/5&;*3J[D*]?V-ZL/W026R*/GK4B4LHV&5Z#)D[6EC%(
M7P.L=IZ%(Q]PCF.YT=@>H_7FY]7HT\R>*&CWLIQ/IU'91H%>10#-3=^>,!R4
ME+C6DGIF0L!NJ05I4+K8.EQA(QHPY""<B D2^B12D_;CJ7=R25+1J=M/E4T$
MCC$F2[\)#]_X?/7Z]3,1HNT%A16JNK*B1:H.DR$5XMD-3STE5?QW(:V8(1O$
M%L6HMJ!9ZN!.G%5U@X=_U^]!C=Y?\_8^!Q+NW/RU:7XRP*"EWPVJ%61&)B@=
MZ+?L$\G9S+2P[?S^?1,_9[41L5,4/BN$[70Q\60ANYP''NU)J(GH#3EP  CC
M'.8J\Y56FI$ -!\1X-OG.5])_.%[7,P/1KZ>*JMAYY\@L9B]@MO6F!OU]2[@
MNAR?ZQA&L49EPIO3_QM;WA9Q^(&DQX,$@6!]8='0J*-GM)^0$1!!&=T^/^\(
MUHC?[=CZ:MJ9YP_:H1ZJ6F1J!L:4MW>DL,31(%(U]Q83ZG,J6F=R\W6DAY9V
M3]>;(A6KB=MJ'C_GY@=418*K#/IRP\X/Y-IG1X?-K/CYL/-/02A_=R$&[%,!
M_<[511[GOPLM+XZEGHH72A;)YE5.<KI[4%9^'^1[A.P#\D]&B878S13;!^^^
M"P>[5$'J^)[$_V:%#![9=R>UV %O]:MMZGKQN.7TQ+3_6O3AV;&BU5%D3+AO
M[2U'I?H'N7+W#\;!NPLCY<[W&S+R/MIUY![(/!N52(.4_H:X!I\YRRN;7YQJ
MZ)@6CO>NR5UM:2_/P)N-31[,^=LX6^#8M#8VYC*]T'1/)E/T5L8+:%"!Q8?5
M!+_9^3^O4O%]3:3:_"/_6W]EMOON)^ 31+7L0KD-!E1Y3'E4XD<>(/.1C3QL
M,?V-R)U\HHY*!RF9P[OS^K2)0P0#ET3D'<;\JQ$]D<88W\,N=!H9+GJGL87E
M])"@#6A>'81VR1\#3C1$QLCE-L>7+3D9$5K>NKN<]]89T[<47'3KZ#LIZW6+
MQO5X0%(AA_-I0X$60>'Y8T[Y=_6G)L9M+T-X@>$#X.DFIVJS)BYN..X4$NX#
M^AW27V9*]J/A/=#FR%[$T6Y65[>+V_%Q![]UY%&VQ@XNB*CB.WEY(#D\J7D(
M3@]<&G>7>9_*";QRZ6=?%6W:]3KPMNB*SAF#S_;I6BA>QXB%(;N2BP*CASF3
M3?[#)3:BLI[AR]=S+5ZKLM_EN9D=?OC4O[_)X(+=B^4NK<*<L,*8,IB#Y(62
MT%#7&OOF>G^WR*2]#+H4VT!*V9-<^%1LPYW< * 2S*+5#&2L[4+VG@J7@\K
M0;C/+N20/U80 _5FXL06I2F4@\-*K(.9#15@Z(9,96-;C8W:]OLBCT<3,[XF
M*ZCX6=8UY,3LQB,J[) [V_ ]F!82#?Q! F,/Z A^\ ']%XF>);H0@M%GF6;U
MP$7 '$K^B=KF37<1UAN8#, 3[UTWKGFD>7,<)XS9YX$203 DV5D?$1-I&W([
M)02^O0R==[3I "C$Q#TD<>GBDZ'-^&3X7:S8'E#FC!.U8_N1S<@N4E:^]2S[
M%)P/U*>1DG4EV?ITI-S"C%8;E6#.+)A")<($1AJ1 KY1+0\B-&71X];C7VH&
M^!E9$V$;A)W<V&,3X,"&".@ H"ZS-I-B3U9T""9%RBM:"S+WTK\OV ZB+#+)
MN=0HKQ<ER1G,QZ>R'>A[GD1BDM*Q329J@#&EF'=L#9$2*PHB6!?I!UL2F]P$
M-.0_JFS62=D@5HI%>%+FJM4%9$0>X>W/EJAK-CV#BDAUBSD>OKXX6IWR M )
M;OSA6';DB&_7FZJQ'J?$T]+H-_X/ VR2=,2/-ZF^K3#S?Z.PU$O--:C8_M E
MG.YO/35Y/>RI;"4U2W]=Z) EA+EJ:!=6F BYE7M;4$XR,SBL.,SO]KE(U?3X
MSO7^X$,#Q\Q$?5Z0M5(S(6=H!P]Y![_[V_#D'?2J4%OF.Y/"T==_#TU4N[65
M%N3F:;=/CWB-U:[4V-MHZ+_*PJ/RIJF7BK*=7>I_OYVN?O([TY#GF^PN!'9_
MZ?[2J1%;YYLW-;*;)P.;9])&/"Z+VD-*%14>#"; C9Q/[H=KV)Q]<0MRB)DN
M&Y\9,L"\^OOO;2>E/]G3-SR+:>$?: <_DGGGHE1=[5OZ6!-!C;_R_2;\7M4W
MS[CC6,NC.NQ/JX=S%8/HE+#L^P.&*O6T>84X)QDSV3I5)@13^IA713;[D%(V
M[]^P?@.5JJK*L@\YUGX^,3JCJPTN-7I7)ITG!;<X)(GJZ+J"X*EZ&W,3@"IG
M%'I_)=U^X=6;_RF!]_^S)03SKLVE7H@AWR=C!^;/\5FK:STV/Y]5M4@A^:?D
MGX/=@GPTCO_H*KO#TU?HLSBK^SR@JF8DIZM2C.GD=;NS1=70+MCP(.*P0-C4
M3GG)B3*E ELP?VQ\:N#7<8=C4F;"3SU/-;XH&+->?+5T4>"E4LL7?P\U\8F\
MSTK/(0[J-_,D52?^GC,IE ^V2 V\XD5R44[,-[P:,.?=$I@S=_8UJ]@5K3Q2
M1#D"47E3MW2M+W;L]E')I/VN1YY=/MT-O?RICE[7S_LQ,]!.$F5'MD@Y*\DX
M>]"^Z<?D:PB9D=$6<'2/K"2D%&.=OI3+/-_F4990<[$^\7,F;W1BUCI3PG%P
M7+SD+K(A]#NFICSGY>LY^] 0&^SAV.711?&*UWT5WRY*3SWO?GSS8:9<\F,S
MSW,/ CX0]*"%^\,F<VZ.>E/%M67E_>Y['?GE+51Y]99<G+#%#S.]#=><U)QK
M8\>H\X]44DIG7CE&0)*'"LT.5WU\\H KU[9M9*-T-"*YL>ZH[Y&9NYEB1U_'
M*2K4]7$?',D]]>'VN7Y1+IM<O1^)5H=*YZ7SDDQR>BS# F0P>DZ!QN%!6Y,!
M3C\R=0FAY57]V7;AJ^M6[ZJZRICWMV^ZJ:GTA>/N?4$X95-L4K>,;_]@/SNE
M1O [E*]I?/<'E]%C1%Y75H',VS-70_V',X0BL,<(U/T?E0[D7KKSF#RL?>1=
MG,>,'A?,UB8^ U&Y?.;FU^ZH09.A;W]E%(_9%@RD?WIUX=.G1,]/[[HR:*]I
M)TMC_"?"(T;9Y5HF'ME'3L]%AG%W!5\[^5A/5MBDX<F(\DG[(%'DZ'U\:J'I
MJ\+LW +WWA-3""<)I3<X!X_^:H<ZH1L_Y*\>\3?++B^L_*,1$CA!OO8L^YKE
MNW;G<8OPG=O1-?++]GH/K8):CGDX>HI]2'$\YW%GW\R)Z1\)W-HB^PKOO&)Q
MWNO5H4)TFJM%GPT?&GCV"["Y0JBN*^6:MQ,]NZ_ITI/X!XGBZA$?@AJKUN&G
M&%:76[5/"!7*7!<QN/"?N8SKOG'^)]W*VA?&/<9>M3[1R)^H*?L[F'OK]A-G
MBQ^.EZ7\]N])$E[A$C%UHDM#D5(54WE=Z:F:_4-D8VLW><OC!WY5%J=M[^2L
MU#0KK8MWTLS:J&C>^,^H(5??TGSYM3[QM&#VVL[3XB^EDS^R)XA:[(C*U9 -
MX^M_"[YG+ZUXV2#ZCB>_K6V7%>#:?U#,@W/,&75;Y[EDT%WQXM$;Z87BCNEO
ME4(O"G>P+$V&W+\'9_] LI+T7XU/U80[LS?_XDS5/_G;(9<#+_M9NFP;"8SE
M.)+>CHTU;4WN(&YNV<L*$Z(>I'O)AD.OTG#E1M(QQQ0\3?MY[ ?HR+-C.W(U
M6% &&GK=01URDN89K.+!DZBP9JBB8MCY+2K]R!F*PM0VX>UAPE&#P[P&AIT#
M![[[&)C<KM5RJU"*.X.P33]J'L0C9TX4\#W2]E;@1J'\>UD?'E,#*0ISYB75
MN2+ 5*-/ F^V*G5B-&?\M=.RQRXD/ZHIG.HX5#&QVOK'6UL$<LX&8<H3\UZ*
M'"EL<>!WB8'";S';3O@)'ED!2Q6N$)5WBG.RV1VRA8??W;14M5!*.,R1@K^$
M5M2<.5N?+1EX0(1R[ES0B^^R19UM\D7:%\KSO-[D_$AW&/9;]E5;_E(2J#:C
MJDV86([$ZL_LR.%_4QV;@M8_^_!\5\*;%%O^/:?$0GPZ0^"O>'Q^,8,!/>(+
M4Q_21?*CJ\\-$1#T]GN? HU=]U1%\EHU?]B%T;7EIVIA%?[Y9F6H",_*&_T5
M7F-YUZP.Q+W-UK-/77A:><W*.VI_:-@?V5 K883L?+8!!7(JXMK9<P-7BTLR
M0^^;FK__L/ZRL[S0Q<[ZREEKLVO9D\'9J4_OY+XJDSI?6?J*Z95=/[:TZ>BW
M5+S52'5I_CGN(A_!VJ1G=0\\+)9H8B&Z<$G%AT!/6AM?P50[O',7(H@Y]0*M
MTC4F8?3P]_12I",1RAHK*O=SI"Y)Y%A&WC=Q3-.=_HS7^?7;6#=ROPHDHUT
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M0;6]NO+1]ZEC_.&[YP[Q]0=#)/]>V(#<&X"$Q$^6E4M);/>-\Z@\ 6."#9E
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MD&PN<B&']Z.M>O0Q52?5!VB-]%N/+^Y[U/RR/$-QQ=T95CQT/^!HBV,&]7-
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M8">!O,3YX3+6>M)/X,W$U()SXK/X?U=.*3Q#'IT,V(B4+B-$_7A6".W2XYP
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M;<\0NL\)V@OB2&Z2[TD3?8!J!15].8;Q9,J%T;NG_)_A1 AN/E4!,.%!MGV
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M+4PY\W. _'.Q\O?T:>0-UEA*3,57E7@-G>03>58HV7J_K8V:-_XA(7E8/FQ
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MW>-1A=(8+3")#-LWTB0CJ>N8=)%*T&5 ^?WV8_G\_^UP;=[$>HKA[$'+*BM
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M#.69;P;%MA0U)B)\_<CPY/(%0_5% [O%J]##5Q.C%ARK[C1;:M)L)%;74J(
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MK5#=<@UV!VTP!@6!GDT%VR"R*=/0'+(;(V^8B!TM!DF" FH9[G:[STD*ZIE
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MFHA;M@.\5*25H'N&HLV^9T4GY=:6E."R.<?!6DI=LP2-6A\6'[,KQZ/^3>U
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M[]%R/_=^=/-Q,/;9_)+SX1OM&NCCOSC\1_3SIM&HAO5P6+)I7&/C:P]>6,1
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M+Y_X*KY_L,.^\S9-:'[S4K;F#K#<,-ZQ4!2@J!'[70WB-1JHUK=R:P6$U.E
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MF-R^>AU2K#&T4\EW%RF#=JW=: =WPUNX?3WXQ'N,&+(,X5NPO=(5TWGFGS0
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M F%KMVR"W71ZB0L9^(5.K:-+N.2VPYIYK\\/GPS$%Y"1C#%E)DI\U3<83NJ
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MMY^ "&E0^1$E*_#_"+7Z?\_DH/S_=5QY,\O(_YF"X[LH)119 T;]I$RW9>0
M^L<V+*D \A6JOO;B K,"@^9VT$XD;O%U(Z:_U2Z[1J5]9EI67YM-B\_X:75Y
M+L/XP**('FSANVTZ.OUQ)X0W?:YY2#QOJ,E$P>"+]IINL&_EM&3T'2T?$<V
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M/2PM[SC-QV04[JAO/;%WZ+ZY9Z#L;5G()NOK/."7G.0-N5KQSM!D+/:/*T3
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MEE76B@B372&ET!4_=K/\KS)I3\N%O<0^BS0]OS5S]W+)NL&YR.NF*3KJM/S
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MPP,4D^+>'3]$LC)ZSWDBZ@R@WQ>IAJ483Z*+$6![(%7F$U(-)K"6W?ZR&,C
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M(LG8:="<W&*/:.TZ=/J;K/TMVQZPD[_DZ+">[9[7F)D^!UO][BERN.5Z; -
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MC6726^N:5CRH/,FDE5[3J85%U:Z(\,6L)*U0 I@+L7"0#1B0<0X3.CQ(X1J
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MPKV1APWYY_P[>S6D1FV6Z%9'5N/$/T]WXD>T.\CSX#/T9H*;797%FQ5$A4-
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M%RW'^P*OA:_0M\()7VCB2$5HJ9<F%X&.)QZF'B;,H X0Y+@G0,LG;.PCZA$
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M+>[O]H$R\=KYX=':D%,G!ME/0YJ40H95'ML2[N,-0"?X&_54\7;4(YFD8L(
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M(]-Y_#]I^UH]BW".]/^'L?<,:VKKVD;#1D2D! 6E$Y4F702D&(BZ-R @($5
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MC0KYIF+[0MWFS A,GO C8O5!ZV5G]N?O0]XU?(DIO.*PH*N .)+R-FX^[%%
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M*EW&=*#%@#(G^BM?$\@K99REY4U+RP$OW$FN$-N(D^-6=T\T#]\[D'G2T$T
M5#VC6O@Q!__ 4<J'64Q#YB"&C_  _@S+R80QK@($&M8!<$60^G!1V/^+L/>.
M:N*+WP:C*%VB(KU$!4&ZTGM$% 2$*%U:I#>1#@$"49%>HB"BM(A(%Z+2I$B
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MJ<J,==^OML6/(!YXRH:_71ZOC.\9Z225&)56VAVT?=CU% Y?O(Q8>L30H\L
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MJ?:7H0;**A'^1!=2/=\Q4>>O+?[8W;]*K2[=S"/WCTQ@S?H[=JRJ^G;/"9H
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MQ';^\7I_C.#LW^G(A !=US=^+I=&PQ'MJW! .A'WGGX1>$T!D^#KN[2'2%=
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MXH%49=J".M5^!1E]6,'0ICL"NP0T-U)Y'.H+%D.0B4M/]=615RF0Q[NK<&%
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M2L &*8/PDV]8I5XA>&1%_M&BS4\RX.D%'327;9E=B0U9+]T7?"#CLVTC<UD
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M9\[R>RVI1\ #GQ%K'R0JCV*L_<UDAS,9\"Z/VX.[MYQHA%W(%.SF82?XH,F
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M6Z.&1@$6,^O35HK:6V72$)@3NQU3_K%?RIOVQ4Q^C7-9[BUO,?X GJ+OE1E
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M]WALFI670N9P,QTM"?^:K"5$ 7M)P2;9?P5_)8H1',,3(DDW*))'PH$//VB
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M<S4P4B8Z*?;KUM(!T5HB7<X*@X%'?83)Z/EK%A?9G\[C%HG,=_%].%BTO'C
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M9\MX$4FZ["18(R9EI6BO62_UFSYF031D$J-[+Z3TH-XC0SOU[=ZI\T!_;XG
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MUSJ!#%<$.H9FJE]",@1FX":,NOO0>:.>)S)N0@W"(B]3<ML%)J8O3J*R<X'
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MD/,B[ZY<UY+T+725LN_K[Q/=Y5Q T=4>DAZ!!F]QD7>40! :B0/2%X0HCR&
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MFS,5]>GF-U,]Y7.U-17@+\;]#%1CHUZVH[*&43N*)CKBO24-40-OB557%T-
MV#?Y$@B% C2(=K&]X;L31UZ#^-[[HKGZFM"OO;0JXOB*L9D.?-Q:(E>KGE-
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MLVNYVH0$2=T[W$X*;1HQW^BR*UURGBC1RN,N143T+I7J]XP:;8QWVW_OBG_
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M,"HAVV=1B?^3O\C_W_Y8WN7I8CMV_%[,3""-:1MI?HV'-LAKRU+V8*GYN"H
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M)K0-J_1/07W8QT@QKJ7+I#2)#+E0)WO2U/=NOHR%V!36*P?"#ZWS78D?\E[
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ML2EA! I)=04PKR"145/P..##=P/3RR7>(C]BVU.1FS'\UQR!6:]FR<P=>A+
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M"KMS9ZV8\;-E4*^UE0?J4;HWM%V'0T:EW^S/&%Y<Q/Q];;P3-03"D@*2>BD
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M<<*#BY6:B-<T<P-7R8%"D&]^J+K4@?'-V//?3\)%-1QPCO7^VB;$'6 652#
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MQT [I:XW^2VT)?V3F\H+'E7WEZ=RMAL,TXNG9JR0/_17DVH=EQ1: <SPN;"
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MT<%YV/*X&IO4BC7[Z5$5QO1,,?[2P^AA!Y]EDF\0EA^(/  =6P<$#V_S)J#
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M(J[09V[".@SRILCK*R' RI;F7S ,CX+>/P !RN#$5M/E E665'ND%1U&0;T
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M9<YTFPL+>24!O7GB]UZU+&I8>]@O,M8K68O;733./Y,2<=UI4Z(;5UB'$>L
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M%F  DPW$"GB?W?QUG=U/#(DH!&J%^:>NS=<NFH4?@([163BJ7NH!2 Q[:;D
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M:RBS\R5(\"+$ND_:!O$4CW,9+(!2LL$G>N.^KP1?U'CSU]'B%ST>?F!/P_L
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MP3)(+8\PLJ+]M&WN+[(>C@JUL^+[T/!Y^14)'(38(EJ/-Z&ZGC_^[-*O?K!
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ME)%Q>D(@\^+6V/\#4$L! A0#%     @ ((A_5@$MPYX?$@  !KP  !$
M         ( !     &%T;FTM,C R,C$R,S$N>'-D4$L! A0#%     @ ((A_
M5C<OSD62"0  66   !4              ( !3A(  &%T;FTM,C R,C$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( ""(?U:T5[R==S,  -(8 P 5
M  "  1,<  !A=&YM+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  @B']6
MBS:I'NZ&  !QVP8 %0              @ &]3P  871N;2TR,#(R,3(S,5]L
M86(N>&UL4$L! A0#%     @ ((A_5F)&Y/GS,P  A%4# !4
M ( !WM8  &%T;FTM,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( ""(?U9A
M%*BKN8(" .UE$@ 7              "  00+ 0!F,3!K,C R,E]A8W1I;FEU
M;7!H+FAT;5!+ 0(4 Q0    ( ""(?U9?1EN-@P(  /D(   ;
M  "  ?*- P!F,3!K,C R,F5X,C,M,5]A8W1I;FEU;2YH=&U02P$"% ,4
M"  @B']6XSP(8FT'  #D(   &P              @ &ND , 9C$P:S(P,C)E
M>#,Q+3%?86-T:6YI=6TN:'1M4$L! A0#%     @ ((A_5K&DC35A!P  QB
M !L              ( !5)@# &8Q,&LR,#(R97@S,2TR7V%C=&EN:75M+FAT
M;5!+ 0(4 Q0    ( ""(?U9-K[P$Y ,  +P/   ;              "  >Z?
M P!F,3!K,C R,F5X,S(M,5]A8W1I;FEU;2YH=&U02P$"% ,4    "  @B']6
MPHXP4/8#  #L#P  &P              @ $+I , 9C$P:S(P,C)E>#,R+3)?
M86-T:6YI=6TN:'1M4$L! A0#%     @ ((A_5K?(N9>_:@( 5<,"  T
M         ( !.J@# &EM86=E7S P,2YJ<&=02P$"% ,4    "  @B']6Q43V
MPF9>  "/8P  #0              @ $D$P8 :6UA9V5?,# R+FIP9U!+ 0(4
M Q0    ( ""(?U;NN.\E&WT! $:6 0 -              "  ;5Q!@!I;6%G
M95\P,#,N:G!G4$L! A0#%     @ ((A_5ORGO>POE ( X]@"  T
M     ( !^^X' &EM86=E7S P-"YJ<&=02P$"% ,4    "  @B']6.SO+?V=-
M 0!O:@$ #0              @ %5@PH :6UA9V5?,# U+FIP9U!+ 0(4 Q0
M   ( ""(?U:<:$2Q* L" (0= @ -              "  >?0"P!I;6%G95\P
M,#<N:G!G4$L! A0#%     @ ((A_5MGSP5B350$ MF<!  T
M ( !.MP- &EM86=E7S P."YJ<&=02P$"% ,4    "  @B']6EJ UXBS8 0"3
M[P$ #0              @ 'X,0\ :6UA9V5?,# Y+FIP9U!+ 0(4 Q0    (
M ""(?U;Q]<\BZ@$! !@> 0 -              "  4\*$0!I;6%G95\P,3 N
M:G!G4$L! A0#%     @ ((A_5C4, Z91/0  $E$   T              ( !
M9 P2 &EM86=E7S Q,2YJ<&=02P$"% ,4    "  @B']6):ZBI?5F  !8;0
M#0              @ '@21( :6UA9V5?,#$R+FIP9U!+ 0(4 Q0    ( ""(
M?U;N6#2N03(# (U+ P -              "  0"Q$@!I;6%G95\P,3,N:G!G
M4$L! A0#%     @ ((A_5E H<A);:0( #GL"  T              ( !;.,5
D &EM86=E7S Q-"YJ<&=02P4&     !@ & #\!0  \DP8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
